Registration Statement No. 333-             

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form F-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

Advanced Human Imaging Limited.

(Exact Name of Registrant as Specified in its Charter)

 

Australia   7372   N/A

(State or Other Jurisdiction of

Incorporation or Organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification No.)

 

Vlado Bosanac

71-73 South Perth Esplanade
Unit 5
South Perth, WA 6151
Australia

+61 8 9316 9100

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

Joseph M. Lucosky, Esq.

101 Wood Avenue South, 5th Floor

Woodbridge, NJ 08830

Tel. No.: (732) 395-4400

 

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

With copies to:

 

Joseph M. Lucosky, Esq.

Lawrence Metelitsa, Esq.

Lucosky Brookman LLP

101 Wood Avenue South, 5th Floor

Woodbridge, NJ 08830

Tel. No.: (732) 395-4400

Fax No.: (732) 395-4401

 

Barry Grossman, Esq.

Sarah Williams, Esq.

Matthew Bernstein, Esq.
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas, 11
th Floor
New York, NY 10105
Tel: (212) 370-1300
Fax: (212) 370-78
89

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after effectiveness of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

 

    Emerging growth company

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standardsprovided to Section 7(a)(2)(B) of the Securities Act. ☐

 

The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

 

  

CALCULATION OF REGISTRATION FEE

 

Title of Securities to be Registered(1)   Proposed
Maximum
Aggregate
Offering
Price(2) (3)
    Amount of
Registration
Fee (4)  
 
Ordinary Shares, no par value, represented by American Depositary Shares     US$ 23,000,000     US$ 2,590.30  
                 
Underwriter’s Warrants to purchase American Depositary Shares(4) (5)                        
Ordinary Shares underlying the American Depositary Shares issuable upon exercise of Underwriter’s Warrants(4)            

US$

1,380,000     US$ 150.56  
Total     US$ 24,380,000     US$ 2,659.86  

 

(1) All Ordinary Shares in the offering will be represented by American Depositary Shares, or ADSs, with each ADS representing                  Ordinary Shares. ADSs issuable upon deposit of the Ordinary Shares registered hereby are being registered pursuant to a separate registration statement on Form F-6.
(2) Pursuant to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions. Includes Ordinary Shares that are issuable upon the exercise of the underwriters’ option to purchase additional ADSs.
(3) The fee is calculated by multiplying the aggregate offering amount by .0001091, pursuant to Section 6(b) of the Securities Act of 1933.
(4)

Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(o) under the Securities Act The Warrants are exercisable at a per share exercise price equal to 120% of the public offering price per ADS. The proposed maximum aggregate offering price of the representative’s warrants is US$1,380,000, which is equal to 120% of US$1,150,000 (5% of US$23,000,000, including ADSs and/or Warrants sold to cover over-allotments, if any).

(5) No separate fee is required pursuant to Rule 457(i) of the Securities Act.

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine. 

 

 

 

 

 

  

The information in this prospectus is not complete and may be changed. We may not sell the securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.

 

SUBJECT TO COMPLETION DATED [ ], 2021

 

Advanced Human Imaging Limited.

 

American Depositary Shares

representing                 Ordinary Shares

 

This is the initial public offering of in the United States American Depositary Shares, or ADSs, representing ordinary shares of Advanced Human Imaging Limited. Each ADS represents                 Ordinary Shares, no par value, deposited with The Bank of New York Mellon, as depositary. We anticipate that the initial public offering price of the ADSs will be between $[__] and $[__] per ADS.

 

Prior to this offering, there has been no public market for the ADSs. We have reserved the symbol “AHI” for purposes of listing the ADSs on the Nasdaq Capital Market and we have applied to list the ADSs on the Nasdaq Capital Market. No assurance can be given that its application will be approved. In the event that the ADSs are not approved for listing on Nasdaq, we will not proceed with this offering.

 

Our outstanding Ordinary Shares are trading on the Australian Securities Exchange, or ASX, under the symbol “MYQ”. On [     ], 2021 the closing price for our Ordinary Shares was A$[    ], equivalent to a price of US$ per ADS, after giving effect to the Australian dollar/U.S. dollar exchange rate of as of      , 2021, and an ADS-to-Ordinary Share ratio of -to-1.

 

The final offering price per ADS in U.S. dollars will be determined through negotiations between us and the representatives of the underwriters and will be based, in part, on prevailing market prices of our Ordinary Shares on the Australian Securities Exchange, after taking into account market conditions and other factors. For a discussion of the other factors considered in determining the final offering price per ADS, see “Underwriting.”

 

We are both an “emerging growth company” and a “foreign private issuer”, as defined under the U.S. federal securities laws, and as such may elect to comply with certain reduced public company reporting requirements for this and future filings. See “Prospectus Summary—Implications of Being an Emerging Growth Company” and “Prospectus Summary—Implications of Being a Foreign Private Issuer.”

 

Investing in the ADSs involves a high degree of risk, including the risk of losing your entire investment. See “Risk Factors” beginning on page 20 to read about factors you should consider before buying ADSs.

    Per Share     Total  
Public offering price   US$       US$    
Underwriting discount(1)   US$       US$    
Proceeds to us, before expenses(2)   US$       US$    

 

(1) See “Underwriting” in this prospectus for more information regarding our arrangements with the underwriter.

(2) The total estimated expenses related to this offering are set forth in the section entitled “Underwriting.”

 

Neither the Securities and Exchange Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

We have granted the underwriters an option for a period of 45 days to purchase up to _________ additional ADSs from us at the public offering price less the underwriting discount to cover over-allotments, if any.

 

The underwriter expects to deliver the ADSs against payment in New York, New York on      , 2021.

 

Sole Book-Running Manager

Maxim Group LLC

 

Prospectus dated             , 2021

 

 

 

 

TABLE OF CONTENTS

   

  Page
PROSPECTUS SUMMARY 1
THE OFFERING 16
SUMMARY FINANCIAL DATA 18
RISK FACTORS 20
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS 38
USE OF PROCEEDS 39
DIVIDENED POLICY 39
CAPITALIZATION 40
DILUTION 41
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 43
BUSINESS 56
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 75
EXECUTIVE COMPENSATION 82
PRINCIPAL SHAREHOLDERS 87
RELATED PARTY TRANSACTIONS 88
DESCRIPTION OF SHARE CAPITAL 89
MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO U.S. HOLDERS 104
UNDERWRITING 113
EXPENSES RELATING TO THIS OFFERING 119
LEGAL MATTERS 119
EXPERTS 119
WHERE YOU CAN FIND ADDITIONAL INFORMATION 120
INDEX TO FINANCIAL STATEMENTS F-1

 

You should rely only on the information contained in this prospectus or in any related free-writing prospectus. We and the underwriter have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the ADSs offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or where the person making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. We have not taken any action to permit a public offering of the ADSs outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the ADSs and the distribution of the prospectus outside the United States. The information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

 

We are incorporated under the laws of the Commonwealth of Australia and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the SEC, we are currently eligible for treatment as a “foreign private issuer,” or FPI. As an FPI, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.

 

i

 

 

ABOUT THIS PROSPECTUS

 

You should rely only on the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where such an offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus.

 

For investors outside of the United States of America (the “United States” or the “U.S.”): Neither we nor the underwriters have done anything to permit the conduct of this offering or the possession or distribution of this prospectus in any jurisdiction, other than the United States, where action for any such purpose would be required. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe, any restrictions relating to the conduct of this offering and the possession and distribution of this prospectus that apply in the jurisdictions outside of the United States relevant to their circumstances.

 

Unless otherwise indicated or the context otherwise requires, all references in this prospectus to “the Company,” “AHI,” “Advanced Human Imaging” “we,” “us,” and “our” refer to Advanced Human Imaging Limited. and its consolidated subsidiaries. Our direct corporate predecessor is MyFiziq Ltd., a limited company organized under the laws of Australia, and listed on the Australian Stock Exchange. On March 5, 2021, we changed our name to Advanced Human Imaging Limited.

 

In this prospectus, unless otherwise stated, all references to “U.S. dollars, “USD,” or “US$     ” are to the currency of the United States of America, and all references to “Australian Dollars,” “AUD,” or “A$     ” are to the currency of Australia. Our presentation currency of the financial statements was AUD and will remain AUD. Throughout this prospectus, all references to “ADSs” mean American Depositary Shares, each of which represents of our Ordinary Shares, no par value.

 

This prospectus and the information incorporated herein by reference contain market data, industry statistics and other data that have been obtained from, or compiled from, information made available by third parties. We have not independently verified their data.

 

You should rely only on the information that we have provided or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different information.

 

In this registration statement, any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof. Words importing the singular shall include the plural and vice versa, and words importing the masculine gender shall include the feminine or neutral gender.

 

PRESENTATION OF FINANCIAL INFORMATION

 

The financial information contained in this prospectus derives from our audited consolidated financial statements in AUD as of June 30, 2019 and 2020. These financial statements and related notes included elsewhere in this prospectus are in the form of Australian Dollar (AUD      or A$     ) and are collectively referred to as our audited consolidated financial statements herein and throughout this prospectus. Our audited consolidated financial statements are prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Our fiscal year ends on June 30 of each year, so all references to a particular fiscal year are to the applicable year ended June 30. None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States.

 

ii

 

 

PROSPECTUS SUMMARY

 

The following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial statements included elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of investing in the ADSs, discussed under “Risk Factors,” before deciding whether to buy the ADSs.

 

Overview

 

We have developed and patented a proprietary measurement/dimensioning technology that enables a User to check, track, and accurately assess their body dimensions privately using only a smartphone. We refer to this physical measurement and analytics tool as “BodyScan.” We have global customers/partners (“Partners”) who utilize our technology through a Software Development Kits (“SDKs”). Our global Partners have substantial audiences that they address, and from those underlying audiences, individual User (“User(s)”) will sign up for, or be given access to, the Partners’ software programs/apps that embed our technology components. Our global Partners currently include companies within the following sectors: (i) mobile health (“mHealth”), Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel.

 

Our patented technology allows our Partners to supply to individual Users, via our automated technology, the ability to take a series of images of themselves using a smartphone, which delivers accurate and repeatable measurements across an individual’s entire body. These measurements allow the individual to understand his/her dimensions and the physical changes that they are undergoing through diet, exercise and lifestyle modification. Further, the images that we capture also provide the individuals with an understanding of their potential health risks related to certain chronic diseases (including obesity and diabetes) and using the global standards measurements set by the World Health Organization (WHO), and the International Diabetes Federation (IDF). Once the image capture sequence is completed, it supplies those measurements to the Partner’s application, whose contract with the User then determines the manner in which it analyzes/reports the data and/or the potential health risk to the User. We are working towards globalizing our technology in order to assist individuals, communities and populations live healthier lives.

 

 

The above images illustrate the BodyScan capture process.

1

 

Recent technology advances have provided opportunities for complex mathematical problems to be solved directly on a User’s smartphone, rather than limiting that computation to the Cloud. Modern devices produced by companies such as Apple, Samsung and Google now have AI-focused chipsets utilizing platforms such as CoreML and Tensorflow to process data at lightning speeds. We see the opportunity to harness these ongoing technology improvements to lower latency, increase security and privacy, improve reliability and reduce operational costs of our core services. Our overarching technology strategy has been to take advantage of this hardware-accelerated performance, specifically by utilizing on-device general purpose Graphic Processing Units (“GPU”) found on today’s modern devices. 

 

In Cloud-based systems, data transfer/retention is a potential impediment. Data must be sent to, and then processed in, the Cloud, thus adding additional latency and disclosure risk to the overall process. On-device computing eliminates the necessity of a roundtrip to the Cloud and permits near zero-latency. This process greatly improves User experience and allows for near real-time interaction with the service.  Running directly on-device additionally negates the side-effects of Cloud-based interference. In areas where connectivity is sub-optimal, such as rural areas, having analytic models on-device means that processing results can be generated locally, quickly and securely.

 

As sensitive data does not need to be sent or maintained in the Cloud, there are fewer opportunities to exploit any potential vulnerabilities, thereby providing increased security and privacy for Users. This security is critically important in a world where data sovereignty, residency, and retention are a major concern for Users and under increased protective global legislation. 

 

By focusing on leveraging the estimated 3.7 billion devices capable of running AI inference and analysis on-device, we are able to slash the costs associated with Cloud-based analytics and inference, bandwidth and retention/storage concerns. As our user base scales, implementing machine learning on-device will mitigate the expense of expertise and time needed to implement and maintain a Cloud-based solution.

 

We deliver a non-invasive, highly accurate and privacy-sensitive healthcare and biometric solutions that generate results to the User within seconds. We leverage machine-learning and computer vision to analyze images, detect pose and joint features, and create non-personally identified data for measurement estimation. We further take advantage of dedicated GPU libraries such as TensorFlow Lite (Android) and Metal (Apple) to run prediction models, which have been trained with a substantial and diverse human data set from around the globe and which are able to process multiple captured images in fractions of a second. The result is a solution that runs on-device and does not sacrifice speed, security or privacy. Images and private information never leave the phone, ensuring security and privacy standards are met across global regions. This process allows us to produce what we believe to be exceptional results and simplify the output of useful, reliable, digital measurements and remove the human error otherwise present in traditional methods, such as tape measure or visual estimations.

2

 

Our BodyScan application has been developed over 7 years through the development of our proprietary image capturing and analysis system. We have refined this process utilizing a proprietary data collection exercise conducted by the company, which involved over 7,000 individuals across Australia, Taipei, Thailand and Malaysia. This multinational data set of ethnicities was used to train and to enrich our machine-learning protocols and to improve the accuracy and repeatability of the BodyScan system. We have further enhanced the use case by adopting a number of predetermined and published markers for some chronic diseases, set by the WHO, and the IDF. According to the WHO, these chronic, non-communicable diseases relate to 71% of deaths each year. We have developed and built the application’s patented capturing system, in line with the WHO and IDF measurement guidelines for the assessment and identification of biomarkers of these chronic diseases, such as Type 2 Diabetes. Whether it be an iOS or an Android application on the smartphone of any user, we provide our Partners and their Users with the following biometric data points:

 

  Anthropometric Measurements (BodyScan);

 

  Body Composition: Total Body Fat %, (BodyScan);
     
  Primary Markers of Chronic disease – Type-2 Diabetes, Obesity, Cardiovascular Disease (CVD) (BodyScan and FaceScan combined); and

 

Primary Health Markers – Waist-to-Hip Ratio, Waist-to-Height, Waist Circumference, (BodyScan).

 

Dermatological conditions – 588 skin conditions across 133 categories, (DermaScan)

 

It is our mission to deliver an easy-to-use, early warning and health assessment tool for our Partners to supply to individuals, governments and healthcare organizations, enabling Users to take control of and to understand the health risks which they pose to themselves, which they may be unaware of. Having the opportunity to combine measurement data with other biometric data sets widens the utility and importance of our technology through multiple business segments.

 

We believe that our technology is unique and has been independently validated for accuracy and repeatability by doctors and professors from leading universities and research organizations around the world, including  Professor Timothy Ackland PhD, Professor of Applied Anatomy and Biomechanics, The University of Western Australia, Dr. Erwin Christianto MD MSc, Physician & Clinical Nutrition Specialist, Eka Hospital Pekanbaru Indonesia, and Dr. Alisa Nana PHD, Sports Science and Technology Mahidol University Thailand. 

 

With the increased requirement of medical surveillance and remote healthcare services due to the COVID pandemic, we have strategically partnered and invested into the expansion of our information capturing capabilities with the addition of vital signs data (FaceScan) using transdermal optical imaging (TOI) and also a further expansion into a dermatology AI platform which provides information to identify and assess 588 known skin conditions across 133 categories (DermaScan).  DermaScan is a software application using artificial intelligence to perform patient-specific analyses of skin conditions. DermaScan is intended to be used as a second opinion tool for healthcare professionals to support the diagnosis of skin conditions but does not provide a definitive diagnosis. A definitive diagnosis should only be performed in a healthcare professional’s environment with the patient present. User error can potentially lead to limitations of the product as DermaScan requires good quality images of the skin condition the user is analyzing as well as a series of questions to be answered specific to the user and the skin condition in question. It is important the user provides images of good quality and accurately provides information as prompted to do so. Accuracy of services will vary depending on the quality of image presented as well as the quality of this information provided.

3

 

Business Model

 

We operate a business-to-business (“B2B”) model and revenue is generated on both a subscription basis as well as on demand-use basis. The overall mercantile business model is one-to-one-to-many, whereby our sales channel customers are business Partners who have the relationship with the end User and whereby our technology is embedded into our Partner’s application that is made available to the Users on terms set by those two parties, thereby allowing User privacy (data on the User smartphone) and agreed data retention in the Partner’s ecosystem. We believe this B2B model enables lower overhead and allows AHI to leverage our Partners’ sales forces in an efficient and economical way. Our go-to-market strategy makes our business model highly scalable without the need for large corporate overhead, which cost-saving element will help to facilitate better operating margins as we increase the number of our Partners and as they scale the number of their Users. We have a pricing model which can be adjusted downward depending on scale (User volume) undertaken by the Partner.

 

Our technology has been both designed and developed to augment Partner applications via individual Software Development Kits (“SDKs”), enabling rapid integration opportunities for both native and hybrid solutions. Through the licensing of the use of our technology, Partners have the ability to effortlessly select the appropriate SDK components and then to customize these solutions to fit their own brands and needs.  The Partner’s public cloud provider manages all of our Partners’ hardware and traditional software, including middleware, application software, and security. Accordingly, our offering allows flexibility and pricing scale reductions for our Partners as their User scale increases. AHI works with its Partners on the contractual remuneration and service basis involving a per-use, annual subscription or license fees. This choice is determined with the Partner at the time of engagement depending on the use case and User volume provided by the Partner.

 

With our technology and distribution channels now most developed, we are now entering into a growth phase. Serving as a catalyst for this growth, we now have 15 signed binding agreements with global Partners that we believe have a total of over 400 million potential Users within the following sectors: (i) mHealth, Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel.

 

We are selective in our choice of sales channel Partner, favoring companies who have a global outreach with large pre-existing User bases. When identifying a potential Partner, we take into account the current digital environment developed by the Partner and its applicability to the SDK offering we have developed. We also consider other factors such as available user base, market reach and time-to-market with the Partner’s digital team.

 

MultiScan Platform Capability

 

AHI offers a growing suite of human scanning solutions using a smartphone. This MultiScan Platform, called CompleteScan, currently includes BodyScanFaceScan, and DermaScan.

 

Our MultiScan SDKs are embedded inside a Partner’s smartphone application(s) on both iOS and Android platforms to facilitate this multi-scan approach.

 

The MultiScan SDKs simplify many actions: User authorization, registering billing events, downloading remote assets, starting a new scan, returning results, and payment registration, all from a single interface/abstraction layer. These functions ensure that scans are easily integrated and correctly billed based on contractual agreements.

 

 

The above guide images various screens of the Multi-Scan suite. 

4

 

Key MultiScan Technology Components

 

  BodyScan, supplied via our patented technology, provides body circumference, body composition (total body fat %), and specific health indicators relating to (including Type-2 Diabetes risk, as well as obesity and central obesity risk) which have a direct correlation to the chronic diseases we wish to assist our partners in managing.  The Company is currently investigating the scope and requirements for FDA approvals should the need arise. However, as we are not a direct to consumer business, we are only providing the ability to capture the measurements. The way those measurements are used by a partner will determine if they require any approvals with the FDA. We have not engaged or commenced any formal process with the FDA at this time.

 

  FaceScan, supplied by a license with NuraLogix Corporation (“NuraLogix”), provides vital signs data, including blood pressure and heart rate, as well as health indicators, including cardiovascular disease risk, heart attack risk, and stroke risk. We have a technology use agreement and a reseller agreement with NuraLogix for the sale and distribution of our combined service offerings. The Company does not intend to seek regulatory approvals for FaceScan but NuraLogix may seek FDA approval in the future.   

 

  DermaScan, supplied by a license with Triage Technologies Inc. (“Triage”), provides skin disease detection for over 588 skin conditions across 133 major categories. Triage’s software application was approved as a class I medical device by Health Canada in June 2020. In April 20201, Triage received confirmation of medical device status in the European Union (EU) and is a CE marked medical device according to the Medical Devices Directive 93/42/EEC. Triage expects to seek FDA approval for its software application in the future.  When combined into the CompleteScan platform, the AI dermatology engine of Triage will be  branded DermaScan and can be deployed to mobile devices to scan skin surface and then to assess the relevant skin conditions with simple images taken with that smartphone application. DermaScan is a software application using artificial intelligence to perform patient-specific analyses of skin conditions. DermaScan is intended to be used as a second opinion tool for healthcare professionals to support the diagnosis of skin conditions but does not provide a definitive diagnosis. A definitive diagnosis should only be performed in a healthcare professional’s environment with the patient present. User error can potentially lead to limitations of the product as DermaScan requires good quality images of the skin condition the user is analyzing as well as a series of questions to be answered specific to the user and the skin condition in question. It is important the user provides images of good quality and accurately provides information as prompted to do so. Accuracy of services will vary depending on the quality of image presented as well as the quality of this information provided.

 

Patented Technology

 

Our patented technology is the on-device image capture and data processing capability of BodyScan and each of our technology providers has its own set of patents 

 

Significant research and development (“R&D”) efforts by AHI have gone into optimizing, testing, and developing proprietary technology to work within smartphones’ confines. This R&D includes analyzing and processing phone sensor data, downloading assets remotely to reduce the initial resource size, utilizing hardware acceleration, and implementing machine learning libraries, such as TensorFlow and CoreML. 

 

The result is a software that runs on the device without sacrificing speed, security, or privacy. Images and private information do not leave the device without explicit consent from the User to the primary app provider, ensuring global security and privacy concerns are met.

 

Data Points, Health Risks, and Health Indicators

 

Each scan returns a unique set of data which is categorized into three layers based on the type of data.

 

Layer 1 – Individual Data Points

 

These are the direct outputs from a scan, such as body circumference, diastolic and systolic blood pressure, and heart rate. 

 

Layer 2 – Derived Data

 

Derived Data is a formula or equation applied to one or more data points. These are labeled “Health Indicators” and include waist-hip ratio, waist-height ratio, and a combined systolic/diastolic blood pressure result.

 

Layer 3 – Contextual Data

 

Contextual Data combines individual data points and derived data with a publicly available dataset or study used to predict health risk categorization. Examples include Type-2 Diabetes, Obesity, Hypertension, and Cardiovascular Disease. 

 

5

 

 

As part of the partner integration progress, a data review is conducted to determine what scans and data are required. Documentation is provided to partners throughout this process to explain key concepts, including validation of measurements, disclaimers, research and studies, and understanding risk categorization.

 

It is important to note that the various scans offered within the MultiScan platform are not offered as a medical device nor as a pure diagnostic; moreover the image and data captures supply individualized data to the Partner in regard to their Users. Depending on the manner in which the Partner utilizes this data for health risk assessment will determine the Partner’s requirement to meet regulatory approvals in their operating jurisdictions.

 

How BodyScan Works

 

BodyScan’s image capture involves taking multiple front and side images of the individual. This process involves entering some basic personal details, such as height, weight, and gender, following a built-in guide provided upon setting up the phone, and then initiating a 10-second countdown for both the front and the side images. Images are processed on the phone and deleted upon the conclusion of the session.

 

This process is referred to as a “BodyScan” or a “Full Body Selfie”. The capture process utilizes “burst mode” or continuous shooting capabilities available in most cameras, and smartphones take multiple images using a timer.

 

Application of Our MultiScan Platform Technology to Multiple Business Segments

 

We have developed a MultiScan product strategy called CompleteScan comprised of: BodyScanFaceScan, and DermaScan, which unlocks a multitude of biometric markers and risk indicators that enables us to generate new layers of data, and cover a full spectrum of indicators for care including, but not limited to, cardiovascular, dermatological and chronic disease identification and prevention. We have designed this multiplatform with flexibility at its core, enabling each type of scan to be implemented either separately or in combination, depending on the partner’s and the user’s specific requirements. We believe that, due to our diverse and expansive offering, the company does not suffer from seasonality in regard to its use or appeal.

 

Examples of partner-specific requirements by business segment are: (i) mHealth, Telehealth and Wellness; (ii) Life/Health Insurance; (iii) Fitness; and (iv) Consumer Product and Apparel.

 

Growth Strategy: More Partners and More Users

 

With our technology and distribution channels now mostly developed; we are now entering into a growth phase. Serving as a catalyst for this growth, we now have 15 signed binding agreements with global Partners that we believe have a total audience of over 400 million within the following sectors: (i) mHealth, Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel. We believe that our existing Partners as well as prospective new Partner contracts will enable us to potentially grow to a run rate of 4.9 million paying Users in total within the next three years. This run rate is based on minimum agreed User targets between us and our Partners, for an initial 12-month period. We are targeting a penetration rate of 1.0% - 5.0% of the existing User base within each Partner company. Penetration assumptions have been modelled in accordance to known global statistics reported in the Liftoff mobile engagement index. 

6

 

Our principal growth strategy is to leverage the ongoing and growing demand from existing and potential sales Partners for our technology, driven by global health concerns and by the various ways that the technology can assist with satisfying the need for fast, accurate and useful consumer/patient-centric data. The following factors will help us to commercialize our operations as we prepare for this next phase of growth:

 

  Contract Execution and Post-implementation Support. We have signed 15 binding agreements with various global Partners that we believe have a total audience of over 400 million. Our growth strategy includes carefully nurturing these agreements and tailoring the implementation of our technology with each partner to maximize the user experience. This process can be achieved by collaborating with our business partners to ensure that they are set up for success, including assisting them with the customer onboarding procedures and establishing feedback loops around user experience.

 

  Market Penetration. We believe that a key to our success lies in our ability to penetrate a variety of industries within multiple verticals. We intend to do so by identifying business partners who (i) are vetted for quality; (ii) fit and audience reach; who already have a high volume of paying subscribers with a need for any or all of the components of the MultiScan platform being, BodyScan, FaceScan, or DermaScan,  and (iii) who can provide us with access to such clients/Users. Currently we operate in four major verticals & markets including: (i) mHealth, Telehealth, and Wellness; (ii) Life and Health Insurance Consumer; (iii) Fitness; and (iv) Consumer and Apparel. Over time we expect to further enhance our reach into each one of these verticals & markets as well as expand into other new ones.

 

  Ongoing Investment in Innovation. We intend to continue to invest in building and licensing new software capabilities and extending our platform to make our technology as accurate and “repeatable” as possible and to bring the power of accurate measurement to a broader range of applications. Achieving this goal will also serve as a barrier to entry for our competitors, both new and established.
     
  Intellectual Property Portfolio. Our issued patent portfolio covers our BodyScan technology and provides patent blocking and out-licensing opportunities, while the partner technologies we have licensed-in for FaceScan and DermaScan adds to our CompleteScan suite of products. The company has furthered it protection by submitting additional patents for the combination of the proprietary BodyScan with vital signs measurements captured through FaceScan. At this time, we have been unable to identify a direct, competitive product within the mobile phone ecosystem that: offers our range of measurement captures and data points across a similar multiplatform offering (BodyScan, FaceScan, DermaScan). Our Platform offers solutions across the four business segments in which we operate; and demonstrates competitive ease of use, accuracy and repeatability.

 

Competitive Advantages

 

Our competitive advantage comes from our continuous innovation and transparency with regards to our data capture, measurement accuracy and repeatability metrics. We differentiate ourselves from our competitors through a multitude of factors including, but not limited to, the following:

 

  Ongoing Data Collection to Ensure Precise Digital Measurements. Regular, continuous, global data collections from multiple independent specialist organizations, including universities and hospitals, to ensure our measurement accuracy and repeatability remains the highest standard in digital measurements from a mobile phone.

7

 

  Continual Enhancement of our Technology Offering While Expanding and Refining our Patent Position. We currently maintain a robust intellectual property portfolio related to our BodyScan Technology, while technology we have licensed-in for FaceScan and DermaScan adds to our Complete suite of products.  We regularly review and update our patents in key jurisdictions to prevent competitors from copying our image capture process or innovation. We believe further enhancing and protecting our patent portfolio is a key to the long-term success of our technology offering and business prospects. The company has lodged provisional patents covering the use case and the integrated use cases of the additional captures.
     
  Independent Validation of Accuracy and Repeatability of our Measurement Information. Publicly advertising our externally validated accuracy and repeatability metrics so that they are clear and accessible to our partners and competitors. Most of our competitors do not share clear information about their measurement accuracy and repeatability publicly. Our transparency makes it easier for potential Partners to understand our metrics during their solution selection process, significantly reducing the need for them to conduct testing and verification of our solution prior to purchase.
     
  Private, individualized Assessment on a Granular Personalized Basis. We measure the end User by taking images of segmented, non-personally identifiable set of silhouettes that are processed on-device. Our solution then recreates the User from the silhouettes in a virtual 3D environment by utilizing the Graphics Processing Unit (GPU) on the end User’s smartphone, enabling that User’s Personally Identifiable Information (PII) to remain on the device. As a result, the process is more cost effective, returns results faster and allows for better security of data and personal privacy.

 

  Broad Market Functionality. Due to high accuracy and repeatability of results from our product offering, we have been able to expand into multiple markets and uses. We intend to leverage and further grow our base of Partners through the four main large market segments in which we operate.
     
  Non-Opinionated Partner Level Integration. We offer a solution that, unlike many of our competitors, can be integrated into our Partners’ existing applications to match their own branding and User experience. This way, our technology becomes part of our Partners’ environment, allowing for trust and additional functionality for the User.
     
  Zero Upfront Integration Cost. Our potential Partners can implement our turnkey solutions using their internal development team, at an upfront cost of A$0, removing the need for an upfront capital budget that can often create a roadblock for many potential Partners.
     
  On-Device Processing Delivers Frictionless Scalability.  We have adapted our BodyScan software to run on a User’s device. This feature in turn only requires AWS for the tokenization of the event i.e.; initiation of sequence to commence with all other BodyScan functionality run on-device at no cost to us. It is important to note that all BodyScan major processing occurs on-device and as such AHI only uses AWS cloud infrastructure to support its services. These services include authorization of services (AWS Cognito), App configuration (AWS Cloudfront), and Billing events (AWS Serverless Aurora). For clarity AHI does not persist User data, nor does it preserve service results on its AWS cloud services, therefore the data stored within each of these services does not contain any User’s PII.
     
  Flexible and Capital Efficient B2B Business Model. We target potential B2B partners with large existing user bases, significantly reducing the costs of acquiring new Users in comparison to our competitors. We also offer our solution on a pricing tier, based on a per User per month basis whereby as User volume grows, Partners pay us less with each tier, enabling a higher return on their investment.

8

 

Intellectual Property

 

We have submitted 22 patents globally, with prior art/inventive ownership dating back to 2015. We have been issued twelve patents, including in Australia, China, Singapore, South Korea, Hong Kong, Japan, Canada, and the USA. We regularly monitor our R&D for potential patent knowledge gaps, which provides the basis for our continued formalized patent protection, existing patent protection updates and other core know-how and intellectual property assets.

 

We utilize various practices to safeguard and protect our IP, including (but not limited to):

 

  Non-disclosure agreements

 

  End User License agreements

 

  Commercial agreements (including IP clauses)

 

  Data Processing Agreements with clauses for jurisdiction specific regulations such as HIPPA, CCPA, and GDPR.

 

  Employee agreements that include IP clauses

 

  ‘Least Privilege’ access model to restrict access to key personnel

 

  Multi-factor authentication system

 

  Regular threat and intrusion protection exercises in conjunction with cyber security industry expert organizations.

9

 

Recent Developments

 

We have focused on growing our universe of partners, expanding our technology suite, improving cash flow and strengthening our balance sheet to rise above the current global pandemic situation. During the height of COVID-19 in Australia, we successfully reduced our operating cash burn by 46%, converted or redeemed previous convertible note holders (A$1.3 million), therefore removing all of our long-term debt and received over A$600,000 in collectible cash from our affiliate, Body Composition Technologies (“BCT”). Additionally, we received A$500,000 in license fees from BCT between July 1, 2020 and December 31, 2020, as our expenditure began to normalize to pre-COVID-19 levels.

 

Some of the recent, key commercial developments, include:

 

1. David Tabb, the Company’s COO resigned from his position on June 23, 2021. The resignation was not based on any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

 

2. On June 1, 2020, we raised US$1,500,000 by way of convertible note to progress our initiatives to be listed on the NASDAQ. The convertible notes are convertible into a maximum of 1,500,000 of our Ordinary Shares. On conversion, convertible note holders will be issued shares at the greater of US$1.00 per share and a 25% discount to the price at which the Company issues shares in conjunction with a NASDAQ listing.

 

3. On June 9, 2020, the Evolt (as outlined below) application launched into its platform allowing gym members and healthcare facilities using the Evolt platform access now to the AHI BodyScan, which marks the first Australian consumer-facing app to go live with our technology solution embedded.

 

4. On August 24, 2020, Bearn (as described below) application launched, the first iOS and Android consumer-facing app to go live in USA with our technology solutions embedded.

 

5. On January 5, 2021, a Biomorphik (as described below) application launched, the second consumer-facing app to go live in Australia with our technology solutions embedded and the first app to provide users with Total Body Fat %.

 

  6. A further nine (9) partner applications are expected to launch (with our technology embedded) within the next six (6) months, to generate revenue, including:

 

  a. We signed an agreement with Nexus Vita Pte Ltd (“Nexus-Vita”) on October 6, 2020. Nexus-Vita under that agreement, has contractually committed to a minimum annual revenue of US$3,588,000 per annum (on a cash basis), from the date of the commercial launch of its app (anticipated to begin by the end of September 2021). On June 21, 2021, the Company entered into a binding term sheet with Nexus-Vita Pte Ltd (“Nexus-Vita”) whereby the Company and Nexus-Vita have agreed to collaborate and work together to design, develop and integrate the Company’s platform into the existing Nexus-Vita platform.   Nexus-Vita has agreed to pay the Company a fixed amount of US$500,000 for the completion of the integration to be performed by the Company’s development team.  We anticipate to receive the full fixed amount payment within the next 60 days, with an initial payment of US$100,000 being paid within the next 30 days.  The Company and Nexus-Vita have agreed to enter into a definitive agreement prior to Nexus-Vita’s application being integrated with the Company’s platform.

 

b. On November 17, 2020, we signed a binding Terms Sheet with The Original Fit Factory, which has developed the world-leading TRUCONNECT and TV.FIT fitness and wellbeing platforms, available through iOS and Android app stores across 71 countries. The Original Fit Factory has both B2C and B2B app solutions for users. Our BodyScan technology will be integrated into The Original Fit Factory’s B2C and B2B offerings.

 

c. On 9 September 2020, we signed a binding Terms Sheet with WellteQ Limited (“WellteQ”) to provide our CompleteScan platform for WellteQ’s personalized digital wellness and analytics platform.

 

10

 

 

  d. On October 20, 2020, we signed a definitive agreement with MVMNT Inc. Under the terms of that agreement, our technology will be integrated into MVMNT’s core mobile technology platform and our solutions will be made available to all subscribers within MVMNT’s branded digital training experiences apps, commencing with fitness-centric platforms including but not limited to McGregor F.A.S.T. and Fitocracy.

 

e. On October 8 2020, we signed a binding Terms Sheet with Jayex Healthcare Ltd (“Jayex”) to integrate our CompleteScan platform into the Jayex Connect patient engagement platform. Jayex has a customer base spanning over 3,250 locations in the UK, Australia and New Zealand and over 50 million patient interactions per year.

 

  f. On June 22, 2019, we signed a binding Terms Sheet with Boditrax Ltd (“Boditrax”) to integrate our technology into the Boditrax platform. Boditrax is an innovative British company that creates digital solutions for the health, fitness and wellness sectors internationally. Boditrax solutions are medical grade devices, programs and software to give gym/clinic operators a clinically validated understanding of each client’s body composition, mental well-being, health goals and progress. Boditrax’s technology is renowned for its accuracy and is chosen and trusted by leading hospitals, universities, corporations, Formula One, Premier League football and other elite sports teams. Clients include the National Health Service NHS (England), HM Government, BBC, Sky, Rolls-Royce, Renault, Cadbury, Kellogg’s. Body Worlds, and the David Lloyd, Virgin Active, Fitness First and Pure Gym Health Clubs. The company is currently experiencing some delays in its launch with Boditrax due to the COVID-19 lockdown restrictions.

 

  g. On April 28 2020, we signed a Definitive Agreement with Active8me Pte Ltd (“Active8me”) to integrate our technology into the Active8me platform. Active8me simplifies healthy, active living in an unique all-in-one mobile platform that incorporates all aspects of healthy living - exercise, nutrition, mindset, and tracking. Its solutions target insurers, telehealth, mHealth, healthcare providers, corporates, governments, and some of Asia’s largest telecommunications companies. Two-time Olympian, Jeremy Rolleston, has brought together a raft of fitness, nutrition and health experts including dual Olympians (Duncan Harvey, Ben St Lawrence and Johanna Lyle), together with Fay Hokulani, Nikki Torres and Jaclyn Reutens – to curate proven fitness programs and to create customized plans that users can follow to take control of their fitness, health and wellness. Their range of programs include: Lose Weight, Lean Fit & Toned, Diabetes Prevent, Post Baby, Running and more.

 

  7. On June 22, 2020, we announced that we are expanding our technology to capture measurements which we believe can assist doctors with providing cancer treatments to patients. We have developed an extension to its scanning technology into body surface area (BSA) calculation and other serial measurements, which we believe could assist with oncology therapy decisions and prevention measures. Specialist oncology physicians use BSA-based dosing as a useful way to mitigate patient size variation in medication regimens. Using BSA can help prescribers to dose more optimally to improve drug efficacy, minimize drug toxicity, and account for some changes in pharmacokinetics depending on patient factor. The ability to determine BSA accurately from a mobile device would be a significant step forward in assessing these calculations when working with cancer patients. We have been working on a number of new and innovative measurements to be included into our applications as we develop further use cases that we believe can dramatically impact existing and new business sectors in which we are working.

 

8. On June 15 2020, we announced that we have reached an agreement with NuraLogix to develop its FaceScan technology with facial scanning capability and which provides a COVID-19 symptoms assessment. A formal Reseller Agreement was signed on August 21, 2020 and on June 3, 2021 the parties entered into a License and Services Agreement. 

 

11

 

 

9. Research & Development (“R&D”) funding of A$600,000 was advanced to the company by R&D Capital Partners Pty Ltd to support our ongoing commitment to innovative research and development. The funding was an advance to the company of the predetermined government reimbursement which the company receives each year from the Australian government R&D incentive plan. The government funding is calculated at 43.5% of all agreed expenses contributing to the R&D for the company’s technology.

 

  10. We have taken a majority stake in our joint venture partner, BCT, up from 50% to 54.5% ownership. In addition, we earned additional licensing revenue of A$500,000 and a further A$309,711 in application development services performed by us. BCT provides technology to the life/health insurance sector.

 

11. On September 22, 2020, we entered into a Data Processing Agreement (the “NuraLogix Agreement”) with NuraLogix pursuant to which NuraLogix will process on its DeepAffex Engine certain physiological and physical data of our customers, including through the use of facial blood-flow OIT technology to capture the user’s blood pressure, heart rate, stress levels and emotion, to predict physiological and psychological effects. The NuraLogix Agreement contains certain provisions relating to NuraLogix’s’ requirements for the protection and storage of the Personal Data (as defined in the NuraLogix Agreement) and compliance of certain data protection regulations.

 

12. On October 14 2020, we completed a A$5 million capital raise to improve significantly our balance sheet position and to provide additional cash flow to cover our operations for the next 12 – 18 months.

 

13. On September 28, 2020, we announced that we are developing a world-first, in-device Dual Energy X-ray absorptiometry (“DEXA”) imagery capability using AI and machine learning models that are able to mimic an individual’s medical images pertaining to body composition (including body fat percentage) via mobile device image capture. While the predicated medical images are not a 100% replacement of an actual medical scan, such as DEXA, the company’s images are highly correlated and representative of the actual DEXA scans performed on the medical imaging machine.

 

14. On December 3, 2020, we announced that have reached an agreement to invest US$6 million in Triage Technologies, Inc. over a 14-month period, subject to shareholder approval (US$3 million in cash and US$3 million in our Ordinary Shares), as part of a strategic plan to expand our service offering by DermaScan. The Company announced on April 19, 2021 that it had completed its due diligence on Triage and that all formal agreements had been concluded.

 

  15. On May 20, 2021, the Company entered into a Binding Term Sheet with US based on device blood pathology company Jana Care Inc. (“Jana”). Subject to AHI completing due diligence to its satisfaction within 90 days of the signing of the Binding Term Sheet with Jana, AHI will have the right to invest a total of up to US$8,000,000 into   Jana, comprising: (i) an option to invest US$5,000,000 in cash; and (ii) subject to shareholder approval, an option to invest up to US$3,000,000 in Jana in AHI ordinary shares or, if the offering is completed, in ADSs. If the Company does not secure shareholder approval for the US$3,000,000 share investment, it has the option to proceed with the investment in cash. In May 2021, AHI  invested US$500,000 in the current convertible note round being offered by Jana. AHI has a further right for a period of 3 years from the date of the first integrated product launch, to acquire a further 10% of Jana stock. AHI will be issued 1% of Jana for every US$1,000,000 in gross revenue to Jana under a contemplated revenue sharing arrangement. In the event AHI decides not to take up the investment in Jana, AHI will still retain the right to equity at a rate of 1% of Jana for every US$2m in gross revenue to Jana. No definitive agreements have been signed as of the date of this filing, however, subject to due diligence AHI and Jana intend to enter into the following definitive agreements - Commercial Agreement; a Software Development Kit, End User License Agreement;  Support Agreement;  Data Processing Agreement and  Investment Agreement.

 

16. On May 31, 2021 the Company entered into a Binding Term sheet with INTER-PSY B.V (Inter-Psy) pursuant to which AHI agrees to grant Inter-Psy the right to use AHI’s licensed Software Development Kits (SDKs) and related intellectual property to integrate them into Inter-Psy existing platform/technology. No definitive agreements have been signed as of the date of this filing and the Company does not intend to generate revenue in the near term.

 

  17. On June 10, 2021, the Company entered into a Binding Term Sheet with Cubert Inc (CUBERT) in order to grant Cubert the right to use AHI’s licensed Software Development Kits (SDKs) and related intellectual property to integrate them into the Cubert platforms/technology. The new integrated functionality into Cubert’s FitTrack application will be called FitScan and will enable its users to privately check, track, accurately assess overall wellness and predict potential health risks -- all from their smartphone. AHI has a right to terminate the agreement if FitTrack fails to reach a minimum user number of 200,000 in the first 12 months from commercial launch. No definitive agreements have been signed as of the date of this filing and the Company does not expect to generate revenue in the near future.

 

12

 

 

Our Challenges

 

We face challenges, risks and uncertainties in realizing our business objectives and executing our strategies, including the following:

 

We operate in a highly competitive industry, and if we are not able to compete effectively, our business and results of operations will be harmed.

 

We may not reach the scale in our business or generate revenue to the level outlined in our business plan.

 

We may be unable to successfully execute our growth initiatives, business strategies, or operating plans.

 

If we fail to effectively manage our growth and organizational change, our business and results of operations could be harmed.

 

If security measures in connection with our platforms and services are breached or unauthorized access to patient’s or client’s data is otherwise obtained, our solutions may be perceived as not being secure, clients may reduce the use of or stop using our software solutions, and we may incur significant liabilities.

 

If we do not continue to innovate and provide services that are useful to customers and users, we may not remain competitive, and our revenue and results of operations could suffer.

 

The recent global pandemic of COVID-19 could harm our business, results of operations, and financial condition.

 

We rely on third-party providers for web services/cloud services, computing infrastructure, databases and other technology-related services needed to deliver our cloud solutions. Therefore, a change of contractual relationship with such third-party providers or disruption of the services provided by them could adversely affect our business and subject us to liability.

 

Please see “Risk Factors” and other information included in this prospectus for a more substantial discussion of these and other risks and uncertainties that we face.

 

13

 

 

Corporate Information

 

Our registered office and our principal executive offices and headquarters are located at 71-73 South Perth Esplanade, Unit 5, South Perth, WA 6151, Australia and our phone number is +61 8 9316 9100. We maintain a corporate website at www.advancedhumanimaging.com. The information contained in, or accessible from, our website or any other website does not constitute a part of this prospectus.

 

Corporate History and Structure

 

We were incorporated on October 1, 2014 as an Australian corporation under the name MyFiziq, Ltd. We listed shares of our Ordinary Stock on the Australian Securities Exchange (ASX) in 2015. On March 5, 2021, we changed our name to Advanced Human Imaging Limited.

 

Implications of Our Being an “Emerging Growth Company”

 

As a company with less than US$1.07 billion in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An “emerging growth company” may take advantage of reduced reporting requirements that are otherwise applicable to larger public companies. In particular, as an emerging growth company, we:

 

 

may present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations, or “MD&A”;

 

  are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives, which is commonly referred to as “compensation discussion and analysis”;

 

  are not required to obtain an attestation and report from our auditors on our management’s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;

 

  are not required to obtain a non-binding advisory vote from our shareholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on frequency” and “say-on-golden-parachute” votes);

 

  are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and chief executive officer pay ratio disclosure;

 

  are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act; and

 

  will not be required to conduct an evaluation of our internal control over financial reporting.

 

14

 

 

We intend to take advantage of all of these reduced reporting requirements and exemptions, with the exception of the longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act.

 

Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions until we no longer meet the definition of an emerging growth company. The JOBS Act provides that we would cease to be an “emerging growth company” at the end of the fiscal year in which the fifth anniversary of our initial sale of common equity pursuant to a registration statement declared effective under the Securities Act of 1933, as amended, herein referred to as the Securities Act, occurred, if we have more than US$1.07 billion in annual revenues, have more than US$700 million in market value of our Ordinary Shares held by non-affiliates, or issue more than US$1 billion in principal amount of non-convertible debt over a three-year period.

 

Foreign Private Issuer Status

 

We are a foreign private issuer within the meaning of the rules under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As such, we are exempt from certain provisions applicable to United States domestic public companies. For example:

 

  we are not required to provide as many Exchange Act reports, or as frequently, as a domestic public company;
     
  for interim reporting, we are permitted to comply solely with our home country requirements, which are less rigorous than the rules that apply to domestic public companies;
     
  we are not required to provide the same level of disclosure on certain issues, such as executive compensation;
     
  we are exempt from provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information;
     
  we are not required to comply with the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; and
     
  we are not required to comply with Section 16 of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and establishing insider liability for profits realized from any “short-swing” trading transaction.

 

15

 

 

THE OFFERING

 

ADSs offered by us   ADSs, each representing    Ordinary Shares.
     
Option to purchase additional ADSs   The underwriters have an option for a period of 45 days from the date of this prospectus to purchase up to             additional ADSs.
     
Initial public offering price:   We estimate that the initial public offering price for the ADSs will be between $     and $     per ADS.
     

Ordinary Shares outstanding before the offering:

 

  [       ] Ordinary Shares
Ordinary Shares to be outstanding after this offering, including shares underlying ADSs                            shares (or                 shares if the underwriters exercise their option to purchase                 additional ADSs in full).
     
American Depositary Shares  

Each ADS represents ____ Ordinary Shares, no par value. As a holder of ADSs, we will not treat you as one of our shareholders. The depositary, through its custodian, will be the holder of the Ordinary Shares underlying the ADSs, and you will have the rights of a holder of ADSs or beneficial owner (as applicable) as provided in the deposit agreement among us, the depositary and holders and beneficial owners of ADSs from time to time.

 

You may surrender the ADSs to the depositary for cancellation to receive the Ordinary Shares underlying the ADSs. The depositary will charge you a fee for such a cancellation.

 

We may amend or terminate the deposit agreement for any reason without your consent. Any amendment that imposes or increases fees or charges or which materially prejudices any substantial existing right you have as an ADS holder will not become effective as to outstanding ADSs until 30 days after notice of the amendment is given to ADS holders. If an amendment becomes effective, you will be bound by the deposit agreement as amended if you continue to hold the ADSs.

 

To better understand the terms of the ADSs, you should carefully read the section titled “Description of American Depositary Shares.” We also encourage you to read the deposit agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part.

     
Depositary   The Bank of New York Mellon.
     
Use of Proceeds

 

We estimate that the net proceeds from the sale of the ADSs that we are selling in this offering will be approximately US$                 million (or approximately US$                million if the underwriters’ option to purchase additional ADSs is exercised in full), based upon an assumed initial public offering price of $                per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on                 , 2021, after giving effect to the Australian dollar/U.S. dollar exchange rate of                 as of                 , 2021, and an ADS-to-Ordinary Share ratio of                 -to-1, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We plan to use the net proceeds we receive from this offering primarily for research and product development of our current products and business development and marketing, with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring companies that are synergistic with or complimentary to our technologies (including, without limitation, a potential investment in Jana), and working capital.

 

16

 

 

Proposed Nasdaq Global Market symbol for the ADSs

 

AHI

     

Risk factors

 

See “Risk Factors” for a discussion of risks you should carefully consider before investing in the ADSs.

 

Lock-up agreements:   Our directors, executive officers, and certain shareholders have agreed with the Representative not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our ordinary shares or securities convertible into ordinary shares for a period of 180 days from the closing of this offering.
     
Representative’s warrants   The registration statement of which this prospectus is a part also registers for sale warrants (the “Representative’s Warrants”) to purchase [    ] ADSs ([    ] ADSs if the over-allotment option is exercised in full) to Maxim Group LLC (the “Representative”), as the representative of the several underwriters, as a portion of the underwriting compensation payable to the underwriters in connection with this offering. The  Representative’s Warrants will be exercisable commencing six months following the effective date of the registration statement of which this prospectus is a part and expiring on the fifth anniversary of the commencement of sales of this offering at an exercise price of $[   ] (120% of the public offering price of the ADSs). Please see “Underwriting — Representative’s Warrants” for a description of these warrants.

 

The total number of shares of our Ordinary Shares (including Ordinary Shares underlying ADSs) that will be outstanding after this offering is based on 136,920,871 shares of Ordinary Stock outstanding as of the date of this prospectus. Unless otherwise indicated, the shares of ordinary stock outstanding after this offering excludes the following:

 

  7,561,958 shares of Ordinary Shares issuable upon exercise of outstanding Stock Options as of August 2, 2021 with a weighted-average exercise price of A$1.07 per share; and
     
  20,150,000 shares of our Ordinary Shares subject to Performance Rights as further described in “Executive Compensation”.
     
  up to a maximum of 1,500,000 shares of our Ordinary Shares issuable upon exercise of outstanding convertible notes at a conversion price of US$1.00 per share. On conversion, convertible note holders will be issued shares at the greater of US$1.00 per share and a 25% discount to the price at which the Company issues shares in conjunction with a NASDAQ listing. The holders have agreed not to offer, sell, dispose of or hedge any shares of our Ordinary Shares, subject to specified limited exceptions, during the period continuing through the date that is _____ months after the date of this offering

 

17

 

 

SUMMARY FINANCIAL DATA

 

The following tables set forth selected historical financial data for our business. Our financial statements have been prepared in accordance with Australian Accounting Standards (AASB). The AASB has adopted both the International Accounting Standard (IAS) as well as the International Financial Reporting Standards (IFRS), as issued by the IASB. See “Presentation of Financial and Other Information—Financial Information.” Our historical results are not necessarily indicative of the results that may be expected in the future. You should read this data together with our consolidated financial statements and related notes appearing elsewhere in this prospectus as well as “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” appearing elsewhere in the prospectus.

 

We have derived the summary statements of loss and comprehensive loss data for the six months ended December 31, 2020 and December 31, 2019, and the summary statement of financial position data as at December 31, 2019, from our unaudited condensed interim financial statements included elsewhere in this prospectus, and for the fiscal years ended June 30, 2020 and June 30, 2019 from our audited financial statements included elsewhere in this prospectus.  

 

Selected Statement of Profit or Loss and Other Comprehensive Income Data:

 

    Six Months ended
December 31
    Twelve Months ended
June 30
 
   

(unaudited)

   

(audited)

 
    2020     2019     2020     2019  
    (AUD in thousands)     (AUD in thousands)  
Revenues   A$ 887     A$ 354     A$ 667     A$ 899  
Employee expenses     (4,248 )     (2,421 )     (3,899 )     (3,824 )
Sales and marketing     (770 )     (725 )     (1,268 )     (332 )
General and administrative     (1,987 )     (779 )     (1,419 )     (1,495 )
Operating loss     (6,118 )     (3,571 )     (5,919 ))     (4,752 )
Financial income (expenses), net     (138 )     (40 )     (144 )     (137 )
Net loss before income tax     (6,256 )     (3,611 )     (6,063 )     (4,889 )
Income tax benefit     784       666       666       532  
Net loss before tax   A$ (5,472 )   A$ (2,945 )   A$ (5,397 )   A$ (4,357 )
Loss per share     AUD cents       AUD cents  
Basic and diluted loss per share     (4.64 )     (2.92 )     (5.16 )     (5.16 ))

 

Selected Statement of Financial Position Data:  

 

    31 December
2020
(unaudited)
    30 June
2020
(audited)
    30 June
2019

(audited)

 
    (AUD in thousands)  
Cash and cash equivalents   A$ 4,756       627       574  
Other current assets     677       594       30  
Loans to related entities     -       69       482  
Development asset at cost     1,328       1,374       1,451  
Other non-current assets     239       291       94  
TOTAL ASSETS   A$ 7,000       2,955       2,631  
Interest bearing borrowings     2,021       865       1,497  
Other liabilities     973       1,627       585  
TOTAL LIABILITIES   A$ 2,994       2,492       2,082  
Issued Capital     32,991       24,355       13,783  
Reserves     4,954       4,577       9,930  
Accumulated losses     (33,939 )     (28,469 )     (23,164 )
TOTAL EQUITY   A$ 4,006       463       549  

18

 

 

Certain Non-IFRS EBITDA and adjusted EBITDA Financial Measurements and Reconciliation to IFRS

 

The following non-IFRS EBITDA and adjusted EBITDA (defined below) financial measures are intended to supplement the IFRS financial information by providing additional insight regarding results of operations of our company. The non-IFRS EBITDA and adjusted EBITDA financial measures used by our company are intended to provide an enhanced understanding of our underlying operational measures to manage our company’s business, to evaluate performance compared to prior periods and the marketplace, and to establish operational goals. Certain items are excluded from these non-IFRS financial measures to provide additional comparability measures from period to period. Specifically, the table below presents the non-IFRS financial measure “EBITDA” (defined as earnings before interest, taxes, depreciation, amortization) and “Adjusted EBITDA” (defined as earnings before interest, taxes, depreciation, amortization adjusted for stock-based compensation and other one-time transaction costs such as mergers and acquisitions, financings and other extraordinary items), respectively. EBITDA and Adjusted EBITDA are intended as supplemental measures of our performance that are not required by or presented in accordance with International Financial Reporting Standards (“IFRS”). We believe that EBITDA and Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and operating results.

 

We believe that the use of EBITDA and Adjusted EBITDA provide additional tools for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other businesses which may present similar non-IFRS financial measures to investors. We believe that EBITDA and Adjusted EBITDA are useful measures because they normalize operating results by excluding non-recurring gains, losses and other items and help to demonstrate how much cash we are able to generate annually. In addition, you should be aware when evaluating EBITDA and Adjusted EBITDA that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of EBITDA and Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate EBITDA and Adjusted EBITDA in the same fashion.

 

Our management does not consider EBITDA and Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with IFRS. The principal limitations of EBITDA and Adjusted EBITDA are that they exclude significant expenses and income that are required by IFRS to be recorded in our financial statements. Some of these limitations are:

 

a. EBITDA and Adjusted EBITDA do not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
b. EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs;
c. EBITDA and Adjusted EBITDA do not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts;
d. although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements;
e. EBITDA and Adjusted EBITDA do not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of our ongoing operations; and
f. other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

 

Because of these limitations, EBITDA and Adjusted EBITDA should not be considered in isolation or as a substitute for performance measures calculated in accordance with IFRS. We compensate for these limitations by relying primarily on our IFRS results and using EBITDA and Adjusted EBITDA only as supplements. You should review the reconciliation of net income to EBITDA and Adjusted EBITDA below and not rely on any single financial measure to evaluate our business.

 

Reconciliation of Non-IFRS Financial Measures:

 

    Six Months ended
December 31
    Twelve Months ended
June 30
 
    (unaudited)     (audited)  
    2020     2019     2020     2019  
    (AUD in thousands)     (AUD in thousands)  
Loss before income tax   A$ (6,256 )   A$ (3,611 )   A$ (6,063 )   A$ (4,889 )
Depreciation and amortization     144       102       246       200  
Interest expenses     138       40       144       137  
EBITDA from continuing operations     (5,974 )     (3,469 )     (5,673 )     (4,552 )
Non-cash stock-based payments1     2,596       887       1,120       1,206  
Provision for impairment of investments2     1,342                    
Adjusted EBITDA from continuing operations     (2,036 )     (2,582 )     (4,553 )     (3,346 )

 

(1) The Company provides benefits to employees (including senior executives) of the Company in the form of share-based payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions). The cost of these equity-settled transactions with employees is measured by reference to the fair value of the equity instruments at the date at which they are granted in accordance with AASB 2 (“Share-based Payment”). The fair value of Options is determined by using an appropriate valuation model. Share rights are valued at the underlying market value of the ordinary shares over which they are granted.
(2) The Company created a provision for impairment against the investments made in Body Composition Technologies Pte Ltd and Triage Technologies Inc in accordance with AASB 13 (‘Fair Value Measurement’). The provision for impairment considers the uncertainty related to a fair valuation of a privately owned entity (BCT). When a more accurate determination of recoverable value can be made, the Company will re-assess whether a provision for impairment is required.

 

19

 

 

RISK FACTORS

 

An investment in the ADS involves a high degree of risk. Before deciding whether to invest in the ADSs, you should consider carefully the risks described below, together with all of the other information set forth in this prospectus, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and our consolidated financial statements and related notes. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be materially and adversely affected, which could cause the trading price of the ADSs 2 to decline, resulting in a loss of all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business. You should only consider investing in the ADSs if you can bear the risk of loss of your entire investment.

 

Summary Risk Factors

 

The below is a summary of principal risks to our business and risks associated with this offering. It is only a summary. You should read the more detailed discussion of risks set forth below and elsewhere in this prospectus for a more complete discussion of the risks listed below and other risks.

 

We operate in a highly competitive industry, and if we are not able to compete effectively, our business and results of operations will be harmed.

 

We may not reach the scale in our business or generate revenue to the level outlined in our business plan.

 

We may be unable to successfully execute our growth initiatives, business strategies, or operating plans.

 

If we fail to effectively manage our growth and organizational change, our business and results of operations could be harmed.

 

If security measures in connection with our platforms and services are breached or unauthorized access to patient’s or client’s data is otherwise obtained, our solutions may be perceived as not being secure, clients may reduce the use of or stop using our software solutions, and we may incur significant liabilities.

 

If we do not continue to innovate and provide services that are useful to customers and users, we may not remain competitive, and our revenue and results of operations could suffer.

 

The recent global pandemic of COVID-19 could harm our business, results of operations, and financial condition.

 

We rely on third-party providers for web services/cloud services, computing infrastructure, databases and other technology-related services needed to deliver our cloud solutions. Therefore, a change of contractual relationship with such third-party providers or disruption of the services provided by them could adversely affect our business and subject us to liability.

 

Technology changes rapidly in our business, and if we fail to anticipate new technologies, the quality, timeliness, and competitiveness of our products may suffer.

 

Our business success depends on our ability to properly utilize and protect our intellectual property and non-infringement of intellectual property of third parties, both in the U.S. and in the countries, we plan to expand to.

 

We are an “emerging growth company” and as such, we are subject to exemptions from certain disclosure requirements.

 

We are subject to certain risks associated with currency fluctuations which can impact our operations.

 

We are subject to certain risks associated with ADSs.

 

There may be a significant dilution and loss of value of our Common Stock as a result of certain outstanding promissory notes, outstanding performance rights and options which are exercisable into Common Stock.
     
 

Your rights to pursue claims arising under the deposit agreement are limited by the terms of the deposit agreement, including limited choice of forum, and jury trial waiver.

 

20

 

 

Risks Related to Our Business

 

We may not reach the scale in our business or generate revenue to the level outlined in our business plan.

 

We may be unable to achieve our expected growth or go-live with our product in the anticipated timelines, based on factors outside of our control. We have only generated very minimal recurring revenues to date as our partner releases have only commenced in late 2020 and there is a degree of uncertainty associated with predicting future revenue with a broader understanding of adoption and retention. Until we have ascertained the level of uptake with already contracted partners, this will form part of our focus and process.

 

We have historically incurred significant losses and there can be no assurance as to when, precisely, we will achieve breakeven or maintain profitability, despite our low overhead expenditure.

 

During the six months ended December 31, 2020, we realized a net loss of A$5,471,570 compared with a net loss of A$2,944,924 for the 6 months ended December 31, 2019. Because of the numerous risks and uncertainties associated with the development of our products and business, we are unable to predict with absolute certainty the extent of any future losses or when we will become profitable. While our overheads are quite low, maintaining operating losses in the future will have an adverse effect on our cash resources, shareholders’ equity and working capital. Our failure to become and remain profitable could depress the value of our stock and impair our ability to raise capital, expand our business, maintain our development efforts, diversify our portfolio of partner companies, or continue our operations. A decline in our value could also cause you to lose all or part of your investment in our Company.

 

Management’s plans include the continued commercialization of our products, current capital inflows from strategic investors and securing sufficient financing through the sale of additional equity securities during the IPO. There can be no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. If we are unsuccessful in commercializing our products and securing sufficient financing, we may need to downscale operations or worst case, cease operations.

 

We will need to raise additional capital to meet our business requirements in the future, which could be challenging, potentially highly dilutive and may cause the market price of our Ordinary Shares and ADSs to decline.

  

While we are transitioning to a point of breakeven, we may need to raise additional capital in order to meet our business objectives. Future capital raises may not be available on reasonable terms, if at all. Additional capital would be used to accomplish the following:

 

  finance our current operating expenses;
     
  pursue growth opportunities;
     
  hire and retain qualified employees;
     
  respond to competitive pressures;
     
  comply with regulatory requirements; and
     
  maintain compliance with applicable laws. 

 

21

 

 

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities could result in substantial dilution for our current shareholders. The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then-outstanding. We may issue additional shares of our Ordinary Shares or securities convertible into or exchangeable or exercisable for our Ordinary Shares in connection with hiring or retaining personnel, option or warrant exercises, future acquisitions or future placements of our securities for capital-raising or other business purposes. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our Ordinary Shares to decline and existing shareholders may not agree with our financing plans or the terms of such financings.

 

In addition, we may incur additional costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.

 

Furthermore, any additional debt or equity financing that we may need may not be available on terms favorable to us, or at all. If we are unable to obtain such additional financing on a timely basis, we may have to curtail our development activities and growth plans, which would have a material adverse effect on our business, financial condition and results of operations.

 

Our auditor’s report on our financial statements states that our recurring operating losses, negative cash flows and dependence on additional financial support raises substantial doubt about our ability to continue as a going concern, which may have a detrimental effect on our ability to obtain additional funding.

 

The report of our independent registered public accounting firm on our financial statements for the period ended June 30, 2020, includes an explanatory paragraph raising substantial doubt about our ability to continue as a going concern as a result of our recurring losses from operations and net capital deficiency. Our future is dependent upon our ability to obtain financing in the future. This opinion could materially limit our ability to raise funds. If we fail to raise sufficient capital when needed, we will not be able to complete our business plan. As a result we may have to liquidate our business and you may lose your investment in the ADSs.

 

The success of our business is highly dependent on market acceptance of our technology and timely release of our technology which is embedded in our partners’ customer facing applications. If the end consumer does not accept our product, or our customers fail to go live with their applications (with our technology embedded), our financial performance will be materially adversely affected.

 

We expect to derive most of our revenue by charging fees in connection with the usage of our applications and technologies. We must make product rollout decisions and commit significant resources well in advance of the anticipated introduction of new applications and technologies. The release of our applications and technologies by our customers (we are ‘business-to-business’(B2B), while our customers have the relationship with the end user) may be delayed, may not succeed or may have a shorter life cycle than anticipated. If the applications are not released when anticipated or do not attain wide market acceptance, our revenue growth may never materialize, we may be unable to fully recover the resources we have committed, and our financial performance will be harmed.

 

22

 

 

As a B2B company, we are substantially dependent on our customers to design, integrate and price our technology effectively within their applications.

 

Whilst we establish commercial contracts with our customers that includes: pricing charges, SDK integration audits, and implementation services, and include various options for customer to select from to integrate our technology within their applications to meet their unique business requirements and user experience in our product offering, as well as provide our own design resources to supplement customer design and product teams, we have limited control over what price customers offer the integrated solution to end users, as well as where and how our products are integrated into their applications. As a result, customers may set pricing points to high for end users, or design / integrate our application in a sub optimal way that users cannot easily find or use our products, which may substantially impact our ability to generate recurring revenue at the level that we expect.

 

As a B2B company, we are substantially dependent on our customers to release our integrated products on agreed timelines.

 

Whilst we establish commercial contracts with our customers that includes indicative release timing, we have limited to no control over when, if ever customers choose to release integrated products. Delays in customer release schedules may have a significant impact on our future cash flow and ability to generate recurring revenue, and / or significantly damage our brand reputation.

 

As a B2B company, we are substantially dependent on our customers to market our integrated product to their end users.

 

Whilst we provide marketing incentives to customers to, depending on the customer size, match their marketing spend on integrated product marketing, provide part marketing spend, as well as assist with marketing activities, including generation and monitoring of marketing strategies and campaigns as well as the development of joint marketing assets, we have limited to no control over how and when customers market our integrated products. Ineffective, inadequate, or nonexistent marketing of our integrated product may have a significant impact on our future cash flow and ability to generate recurring revenue at the level that we expect.

 

Damage to our or our customers’ reputation or lack of acceptance of our brand or our customers’ brands in existing and new markets could negatively impact our business, financial condition and results of operations.

 

We intend to build a strong reputation for the quality of our technology, and we must protect and grow the value of our brand to be successful. Any incident that erodes consumer affinity for our brand or our customers’ brands, could significantly reduce our brand value and damage our business. If end users perceive or experience a reduction in quality, or in any way believe we or our customers fail to deliver a consistently positive experience, our brand value could suffer, and our business may be adversely affected.

 

In addition, our ability to successfully sign new partners in new markets may be adversely affected by a lack of awareness or acceptance of our brand or our existing partners brands in these new markets. To the extent that we are unable to foster name recognition and affinity for our brand in new markets, our growth may be significantly delayed or impaired.

 

As a result, adverse economic conditions in any of these areas could have a material adverse effect on our overall results of operations. In addition, other factors that could have a material adverse effect on our business and operations include but are not limited to; local strikes, terrorist attacks, increases in energy prices, adverse weather conditions, hurricanes, droughts or other natural or man-made disasters.

 

Technology changes rapidly in our business, and if we fail to anticipate new technologies, the quality, timeliness, and competitiveness of our products may suffer.

 

Rapid technology changes require us to anticipate which technologies and/or distribution platforms our products must take advantage of in order to make them competitive in the market at the time they are released. Therefore, we usually start our product development with a range of technical development goals that we hope to be able to achieve. We may not be able to achieve these goals, and even though we have global patent protection, our competition may be able to achieve them more quickly than we can. If we cannot achieve our technology goals within the original development schedule of our products, this may impact the manner in which users experience our product, which in turn could impact recurring revenue. It may also provide an opportunity for competitors to catch up to us.

 

23

 

 

We rely upon third parties to provide distribution for our applications, and disruption in these services could harm our business.

 

We currently utilize, and plan on continuing to utilize over the current fiscal year, third-party networking providers and distribution through companies including, but not limited to, Apple and Google to distribute our technologies. If disruptions or capacity constraints occur, we may have no means of replacing these services, on a timely basis or at all. This could cause a material adverse condition for our operations and financial earnings.

 

We rely on third-party hosting and cloud computing providers to operate certain aspects of our business. Any failure, disruption or significant interruption in our network or hosting and cloud services could adversely impact our operations and harm our business.

 

Our technology infrastructure is critical to the performance of our products and customer satisfaction. Our products run on a complex distributed system, or what is commonly known as cloud computing. We own, operate and maintain elements of this system. However, elements of this system are operated by open source code and third party owned and operated software that we do not control, and which would require significant time to replace. We expect this dependence on third parties to continue. In particular, a portion of the data storage, data processing and other computing services and systems is hosted by cloud computing providers. Any disruptions, outages and other performance problems relating to such services, including infrastructure changes, human or software errors and capacity constraints, could adversely impact our business, financial condition or results of operations.

 

We could be harmed by improper disclosure or loss of sensitive or confidential company, employee, associate or customer data, including personal data.

 

In connection with the operation of our business, we plan to store, process and transmit data, including personal and information, about our employees, customers, customers’ end users, associates and candidates, a portion of which is confidential and/or personally sensitive. Unauthorized disclosure or loss of sensitive or confidential data may occur through a variety of methods. These include, but are not limited to, systems failure, employee negligence, fraud or misappropriation, or unauthorized access to or through our information systems, whether by our employees or third parties, including a cyberattack by computer programmers, hackers, members of organized crime and/or state-sponsored organizations, who may develop and deploy viruses, worms or other malicious software programs.

 

Such disclosure, loss or breach could harm our reputation and subject us to government sanctions and liability under our contracts and laws that protect sensitive or personal data and confidential information, resulting in increased costs or loss of revenues. It is possible that security controls over sensitive or confidential data and other practices we and our third-party vendors follow may not prevent the improper access to, disclosure of, or loss of such information. The potential risk of security breaches and cyberattacks may increase as we introduce new services and offerings, such as mobile technology. Further, data privacy is subject to frequently changing rules and regulations, which sometimes conflict among the various jurisdictions in which we provide services. Any failure or perceived failure to successfully manage the collection, use, disclosure, or security of personal information or other privacy related matters, or any failure to comply with changing regulatory requirements in this area, could result in legal liability or impairment to our reputation in the marketplace.

 

Our business operations and future development could be significantly disrupted if we lose key members of our management team.

 

The success of our business continues to depend to a significant degree upon the continued contributions of our senior officers and key employees, both individually and as a group. Our future performance will be substantially dependent in particular on our ability to retain and motivate our Chief Executive Officer, and certain of our other senior executive officers. The loss of the services of our Chief Executive Officer, senior officers or other key employees could have a material adverse effect on our business and plans for future development. We have no reason to believe that we will lose the services of any of these individuals in the foreseeable future; however, we currently have no effective replacement for any of these individuals due to their experience, reputation in the industry and special role in our operations. We also do not maintain any key man life insurance policies for any of our employees.

 

24

 

  

Our business operations are conducted in multiple languages and could be disrupted due to miscommunications or translation errors.

 

The success of our business continues to depend on our marketing efforts globally, with a majority of customer head offices in the United States, Europe and Asia Pacific, each of which may be conducted in the local language. Miscommunications or inaccurate foreign language translations could have a material adverse effect on our business operations and financial conditions. Additionally, contracts, communications and complex technical information may be required to be accurately translated into foreign languages. 

 

We may not be able to adequately protect our Intellectual Property (IP) or avoid third party IP, which, in turn, could harm the value of our brands and adversely affect our business.

 

Our ability to implement our business plan successfully depends in part on our ability to build brand recognition using our patents, service marks and other proprietary intellectual property, including our names and logos. We have patents in selected global jurisdictions, with prior art dating back to 2014. We have been issued twelve patents, one of each in Australia, China, Hong Kong, Canada, and the USA, 2 in South Korea, and Singapore, and 3 in Japan. We have nine patent-pending submissions; one each in China, Hong Kong, Singapore, South Korea, Europe, India, and three in New Zealand, and updated applications to our existing issued patents to further protect our IP in process. No assurance can be given that our patent-pending submissions or the additional patent applications which is in process will be approved. If our patent-pending submissions or the additional patent applications which is in process are not approved, our ability to expand or develop our business may be negatively affected.

 

We have established trademarks to protect our brand globally in key jurisdictions including: the USA, China, the EU, the UK, Japan, and Australia.

 

Third parties may also oppose our trademark or patent applications, or otherwise challenge our use of the trademarks or patents. In the event that our trademarks or patents are successfully challenged, we could be forced to rebrand our goods and services or redesign our technology, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands and products.

 

If our efforts to register, maintain and protect our intellectual property are inadequate, or if any third party misappropriates, dilutes or infringes on our intellectual property, the value of our brands may be harmed, which could have a material adverse effect on our business and might prevent our brands from achieving or maintaining market acceptance. We may also face the risk of claims that we have infringed third parties’ intellectual property rights. If third parties claim that we infringe upon their intellectual property rights, our operating profits could be adversely affected. Any claims of intellectual property infringement, even those without merit, could be expensive and time consuming to defend, require us to rebrand our services, if feasible, divert management’s attention and resources or require us to enter into royalty or licensing agreements in order to obtain the right to use a third party’s intellectual property.

 

Any royalty or licensing agreements, if required, may not be available to us on acceptable terms or at all. A successful claim of infringement against us could result in our company being required to pay significant damages, enter into costly license or royalty agreements, or stop the sale of certain products or services, any of which could have a negative impact on our operating profits and harm our future prospects.

 

25

 

 

We may not be able to continue to obtain licenses to third-party software and intellectual property on reasonable terms or at all, which may disrupt our business and harm our financial results.

 

We license third-party software and other intellectual property for use in product deployment, research and development and, in several instances, for inclusion in our products such as with FaceScan and DermaScan. These licenses may need to be renegotiated or renewed from time to time, or we may need to obtain new licenses in the future. Third parties may stop adequately supporting or maintaining their technology, or their technology may be acquired by our competitors. If we are unable to obtain licenses to these third-party software and intellectual property on reasonable terms or at all, we may not be able to sell the affected products, our customers’ use of the products may be interrupted, or our product development processes and professional services offerings may be disrupted, which could in turn harm our financial results, our customers, and our reputation. The inclusion of third-party intellectual property in our products can also subject us and our customers to infringement claims. Although we seek to mitigate this risk contractually, we may not be able to sufficiently limit our potential liability. Regardless of outcome, infringement claims may require us to use significant resources and may divert management’s attention. Some of our products and technology, including those we acquire, may include software licensed under open source licenses. Some open source licenses could require us, under certain circumstances, to make available or grant licenses to any modifications or derivative works we create based on the open source software. Although we have tools and processes to monitor and restrict our use of open source software, the risks associated with open source usage may not be eliminated and may, if not properly addressed, result in unanticipated obligations that harm our business.

 

Information technology system failures or breaches of our network security could interrupt our operations and adversely affect our business. 

 

We will rely on our computer systems and network infrastructure across our operations. Our operations depend upon our ability to protect our computer equipment and systems against damage from physical theft, fire, power loss, telecommunications failure or other catastrophic events, as well as from internal and external security breaches, viruses, worms and other disruptive problems. Any damage or failure of our computer systems or network infrastructure that causes an interruption in our operations could have a material adverse effect on our business and subject us to litigation or actions by regulatory authorities. Although we employ both internal resources and external consultants to conduct auditing and testing for weaknesses in our systems, controls, firewalls and encryption and intend to maintain and upgrade our security technology and operational procedures to prevent such damage, breaches or other disruptive problems, there can be no assurance that these security measures will be successful.

 

Any actual or perceived failure by us to comply with our privacy policy or legal or regulatory requirements in one or multiple jurisdictions could result in proceedings, actions or penalties against us.

 

Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, industry standards, contractual obligations or other legal obligations, or any actual or suspected security incident, whether or not resulting in unauthorized access to, or acquisition, release or transfer of personal data or other data, may result in governmental enforcement actions and prosecutions, private litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse effect on our reputation and business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable laws, regulations, policies, industry standards, contractual obligations or other legal obligations could result in additional cost and liability to us, damage our reputation, inhibit sales and adversely affect our business.

  

Evolving and changing definitions of what constitutes “Personal Information” and “Personal Data” within the EU, the United States and elsewhere, may limit or inhibit our ability to operate or expand our business, including limiting technology alliance partners that may involve the sharing of data.

 

If we are perceived to cause, or are otherwise unfavorably associated with, violations of privacy or data security requirements, it may subject us or our customers to public criticism, financial penalties and potential legal liability. Existing and potential privacy laws and regulations concerning privacy and data security and increasing sensitivity of consumers to unauthorized processing of personal data may create negative public reactions to technologies, products and services such as ours. Public concerns regarding personal data processing, privacy and security may cause some of our customers’ end users to be less likely to visit their venues or otherwise interact with them. If enough end users choose not to visit our customers’ venues or otherwise interact with them, our customers could stop using our platform. This, in turn, may reduce the value of our service, and slow or eliminate the growth of our business, or cause our business to contract. 

 

26

 

 

Around the world, there are numerous lawsuits in process against various technology companies that process personal information and personal data. If those lawsuits are successful, it could increase the likelihood that our company may be exposed to liability for our own policies and practices concerning the processing of personal data and could hurt our business. Furthermore, the costs of compliance with, and other burdens imposed by laws, regulations and policies concerning privacy and data security that are applicable to the businesses of our customers may limit the use and adoption of our technologies and reduce overall demand for it. Privacy concerns, whether or not valid, may inhibit market adoption of our technologies. Additionally, concerns about security or privacy may result in the adoption of new legislation that restricts the implementation of technologies like ours or require us to make modifications to our existing services and technology, which could significantly limit the adoption and deployment of our technologies or result in significant expense.

 

We will continue to incur costs and be subject to various obligations as a result of being a public company

 

We will continue to incur significant legal, accounting and other expenses as a result of being a public company. Although we will incur costs each year associated with being a publicly traded company, it is possible that our actual costs of being a publicly traded company will vary from year to year and may be different than our estimates. In estimating these costs, we take into account expenses related to insurance, legal, accounting and compliance activities.

 

Furthermore, the need to maintain the corporate infrastructure demanded of a public company may divert management’s attention from implementing our growth strategy, which could prevent us from improving our business, results of operations and financial condition. We have made, and will continue to make, changes to our internal controls and procedures for financial reporting and accounting systems to meet our reporting obligations in order to become a U.S. publicly traded company. However, the measures we take may not be sufficient to satisfy our obligations as a publicly traded company. 

 

Any future or current litigation could have a material adverse impact on our results of operations, financial condition and liquidity.

 

From time to time we may be subject to litigation, including, among others, potential shareholder derivative actions. Risks associated with legal liability are difficult to assess and quantify, and their existence and magnitude can remain unknown for significant periods of time. To date we have obtained directors and officers liability (“D&O”) insurance to cover some of the risk exposure for our directors and officers. Such insurance generally pays the expenses (including amounts paid to plaintiffs, fines, and expenses including attorneys’ fees) of officers and directors who are the subject of a lawsuit as a result of their service to us. There can be no assurance that we will be able to continue to maintain this insurance at reasonable rates or at all, or in amounts adequate to cover such expenses should such a lawsuit occur. While neither Delaware law nor our Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) or Amended and Restated Bylaws (“Bylaws”) require us to indemnify or advance expenses to our officers and directors involved in such a legal action, we expect that we would do so to the extent permitted by Delaware law. Without D&O insurance, the amounts we would pay to indemnify our officers and directors should they be subject to legal action based on their service to us could have a material adverse effect on our financial condition, results of operations and liquidity. Such lawsuits, and any related publicity, may result in substantial costs and, among other things, divert the attention of management and our employees. An unfavorable outcome in any claim or proceeding against us could have a material adverse impact on our financial position and results of operations for the period in which the unfavorable outcome occurs, and potentially in future periods.

 

Further, any settlement announced by us may expose us to further claims against us by third parties seeking monetary or other damages which, even if unsuccessful, would divert management attention from the business and cause us to incur costs, possibly material, to defend such matters, which could have a material adverse impact on our financial position.

 

27

 

 

Federal, state and local or Australian tax rules may adversely impact our results of operations and financial position.

 

We are subject to federal, state and local taxes in the U.S., as well as local taxes in Australia in respect to our operations in Australia. Although we believe our tax estimates are reasonable, if the Internal Revenue Service or other taxing authority disagrees with the positions, we have taken on our tax returns, we could face additional tax liability, including interest and penalties. If material, payment of such additional amounts upon final adjudication of any disputes could have a material impact on our results of operations and financial position. In addition, complying with new tax rules, laws or regulations could impact our financial condition, and increases to federal or state statutory tax rates and other changes in tax laws, rules or regulations may increase our effective tax rate. Any increase in our effective tax rate could have a material impact on our financial results.

 

Our management, board and advisors control a large block of our Ordinary Shares.

 

As of the date of this prospectus, members of our management team and board beneficially own approximately 36.48% of our outstanding Ordinary Shares. Shares and Options. In addition, two shareholders own between them approximately 19.42% of our outstanding Ordinary Shares and Options. As such, management and this shareholder own approximately, in the aggregate, 33.37% of our voting power. As a result, management and the aforementioned shareholders may have the ability to control substantially all matters submitted to our shareholders for approval including:

 

  election of our Board;

 

  removal of any of our directors;

 

  amendment of our Certificate of Incorporation or Bylaws; and

 

  adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us.

 

In addition, management’s and the aforementioned shareholder’s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our shareholders from realizing a premium over our stock price. Any additional investors will own a minority percentage of our Ordinary Shares and will have minority voting rights. 

  

Risks Related to Ownership of the ADSs and this Offering

 

There has been no prior market for the ADSs and an active and liquid market for our securities may fail to develop, which could harm the market price of the ADSs.

 

While our Ordinary Shares have been listed on the Australian Securities Exchange, or ASX, prior to this offering, there has been no public market on a U.S. national securities exchange for our Ordinary Shares or the ADSs. Although we anticipate that the ADSs will be approved for listing on Nasdaq, an active trading market for the ADSs may never develop or be sustained following this offering. The initial offering price of the ADSs will be determined through negotiations between us and the underwriters. This offering price may not be indicative of the market price of the ADSs after this offering. In the absence of an active trading market for the ADSs, investors may not be able to sell their ADSs at or above the offering price or at the time that they would like to sell.

 

The trading price and volume of the ADSs may be volatile, and purchasers of the ADSs could incur substantial losses.

 

The price and trading volumes of our Ordinary Shares and ADSs may be significantly affected by events such as announcements regarding scientific and clinical results concerning product candidates currently being developed by us, our collaboration partners or our main competitors, changes in market conditions related to our sector of activity, announcements of new contracts, technological innovations and collaborations by us or our main competitors, developments concerning intellectual property rights, as well as the development, regulatory approval and commercialization of new products by us or our main competitors and changes in our financial results.

 

28

 

 

In addition, equity markets may be subject to considerable price and trading volume fluctuations, and often, these movements do not reflect the operational and financial performance of the listed companies concerned. In particular, biotechnology companies’ share prices have been highly volatile in the past and may continue to be highly volatile in the future. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry. Fluctuations in the stock market as well as the macroeconomic environment could significantly affect the price of the ADSs. As a result of this volatility, investors may not be able to sell their ADSs at or above the price originally paid for the security. The market price and trading volume for the ADSs may be influenced by many factors, including:

 

  actual or anticipated fluctuations in our financial condition and operating results;

 

  actual or anticipated changes in our growth rate relative to our competitors;

 

  competition from existing products or new products that may emerge;

 

  announcements by us or our competitors of significant acquisitions, divestitures, spin-offs, strategic partnerships, joint ventures, collaborations, capital commitments or changes in business strategy;

 

  adverse results of delays in our or any of our competitors’ preclinical studies or clinical trials;

 

  adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates;

 

  the termination of a strategic alliance or the inability to establish additional strategic alliances;

 

  failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;

 

  issuance of new or updated research or reports by securities analysts;

 

  fluctuations in the valuation of companies perceived by investors to be comparable to us;

 

  ADS price and volume fluctuations attributable to inconsistent trading volume levels of the ADSs;

 

  price and volume fluctuations in trading of our Ordinary Shares on the ASX;

 

  short selling or other market manipulation activities;

 

  fluctuations of exchange rates between the U.S. dollar and the Australian dollar;

 

  additions or departures of key management or scientific personnel;

 

  disruptions in our supply or manufacturing arrangements;

 

  disputes or other developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent and other intellectual property protection for our technologies;

 

  changes to coverage policies or reimbursement levels by commercial third-party payors and government payors and any announcements relating to coverage policies or reimbursement levels;

 

  litigation involving our company;

 

  announcement or expectation of additional debt or equity financing efforts;

 

  natural disasters or other calamities or disease outbreaks, such as the COVID-19 pandemic;

 

  sales of the ADSs by us, our affiliates or our other shareholders; and

 

  general economic and market conditions.

 

29

 

 

These and other market and industry factors may cause the market price and demand for the ADSs to fluctuate, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of the trading market for the ADSs.

 

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of the ADSs and their trading volume could decline.

 

The trading market for the ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business. As a public listed company in Australia since August 2015, our equity securities are currently subject to coverage by a number of analysts. If fewer securities or industry analysts cover our company, the trading price for the ADSs could be negatively impacted. If one or more of the analysts who covers us downgrades our equity securities or publishes incorrect or unfavorable research about our business, the price of the ADSs would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, or downgrades our securities, demand for the ADSs could decrease, which could cause the price of the ADSs or their trading volume to decline.

 

We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of the ADSs.

 

We have never declared or paid any cash dividends on our Ordinary Shares and do not currently intend to do so for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our operations and growth. Therefore, you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment in the ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of the ADSs after price appreciation, which may never occur, as the only way to realize any future gains on their investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which our shareholders have purchased them. Investors seeking cash dividends should consider not purchasing the ADSs.

 

While we do not anticipate paying any cash dividends on our Ordinary Shares in the foreseeable future, if such a dividend is declared, the depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our Ordinary Shares or other deposited securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our Ordinary Shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution of the ADSs, Ordinary Shares, rights or anything else to holders of the ADSs. This means that you may not receive the distributions we make on our Ordinary Shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may negatively impact the value of your ADSs. In addition, exchange rate fluctuations may affect the amount of Australian dollars that we are able to distribute, and the amount in U.S. dollars that our shareholders receive upon the payment of cash dividends or other distributions we declare and pay in Australian dollars, if any. These factors could harm the value of the ADSs, and, in turn, the U.S. dollar proceeds that holders receive from the sale of the ADSs.

 

You will experience immediate and substantial dilution in the net tangible book value of the ADSs you purchase in this offering.

 

The assumed initial public offering price of the ADSs is substantially higher than the net tangible book value per ADS or per Ordinary Share immediately after this offering. If you purchase ADSs in this offering, you will suffer immediate dilution of US$                per ADS (or US$                per Ordinary Share ), or US$                 per ADS (or US$                per Ordinary Share ) if the underwriters exercise their option to purchase additional shares in full, representing the difference between our as adjusted net tangible book value per ADS or per Ordinary Share after giving effect to the sale of ADSs in this offering and the assumed initial public offering price of $                per ADS, the U.S. dollar equivalent of the last reported sale of price of our Ordinary Shares on the ASX on                 , 2020, after giving effect to the Australian dollar/U.S. dollar exchange rate of                  as of                 , 2020, and an ADS-to-Ordinary Share ratio of                 -to-1. See “Dilution.” If outstanding options are exercised in the future, you will experience additional dilution.

 

30

 

 

We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

 

We will have broad discretion in the application of the net proceeds that we receive from this offering as well as of our existing cash and cash equivalents and non-current financial assets, and we may spend or invest these funds in a way with which our shareholders or holders of the ADSs disagree. Our failure to apply these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from the offering in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors.

 

Future sales of Ordinary Shares or ADSs by existing holders could depress the market price of the Ordinary Shares or ADSs.

 

Based on Ordinary Shares outstanding as of, upon the closing of this offering, we will have outstanding a total of                 Ordinary Shares (including Ordinary Shares represented by ADSs), assuming no exercise of the underwriters’ option to purchase additional ADSs and no exercise of outstanding options. Each member of our senior management and Board and their affiliates are subject to lock-up agreements with the underwriters that restrict their ability to transfer Ordinary Shares, options and other securities convertible into, exchangeable for, or exercisable for Ordinary Shares during the period ending on, and including, 180 days from the closing of this offering, subject to specified exceptions. Maxim Group LLC may, in its discretion, permit our shareholders who are subject to these lock-up agreements to sell securities prior to the expiration of the lock-up agreements. As of the date of this prospectus, the exercise of all outstanding options exercisable for Ordinary Shares would enable the subscription of new Ordinary Shares representing approximately                 % of the diluted share capital.

 

After the lock-up agreements pertaining to this offering expire, and based on the number of Ordinary Shares outstanding upon the closing of this offering, including Ordinary Shares represented by ADSs,                  additional Ordinary Shares will be eligible for sale in the public market, all of which Ordinary Shares are held by members of our senior management and Board and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or the Securities Act. In addition, the Ordinary Shares subject to subscription under outstanding options exercisable for Ordinary Shares will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. Sales of a large number of the Ordinary Shares in the public market could depress the market price of the ADSs. See “Description of American Depository Shares” for a more detailed description of sales that may occur in the future. If these additional Ordinary Shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of the Ordinary Shares and ADSs could decline substantially, which could impair our ability to raise additional capital through the issuance of Ordinary Shares, ADSs or other securities in the future.

 

The dual listing of our Ordinary Shares and the ADSs following this offering may negatively impact the liquidity and value of the ADSs.

 

Following this offering and after the ADSs are listed on Nasdaq, our Ordinary Shares will continue to be listed on the ASX. We cannot predict the effect of this dual listing on the value of our Ordinary Shares and ADSs. However, the dual listing of our Ordinary Shares and ADSs may dilute the liquidity of these securities in one or both markets and may negatively impact the development of an active trading market for the ADSs in the United States. The price of the ADSs could also be negatively impacted by trading in our Ordinary Shares on the ASX.

 

We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.

 

Our Ordinary Shares are quoted in Australian dollars on the ASX and the ADSs will be quoted in U.S. dollars. In the past year, the Australian dollar has generally weakened against the U.S. dollar; however, this trend may not continue and may be reversed. As such, any significant change in the value of the Australian dollar may have a negative effect on the value of the ADSs in U.S. dollars. In addition, if the Australian dollar weakens against the U.S. dollar, then, if we decide to convert our Australian dollars into U.S. dollars for any business purpose, appreciation of the U.S. dollar against the Australian dollar would have a negative effect on the U.S. dollar amount available to us. While we engage in limited hedging transactions to manage our foreign exchange risk, these activities may not be effective in limiting or eliminating foreign exchange losses. To the extent that we need to convert U.S. dollars we receive from this offering into Australian dollars for our operations, appreciation of the Australian dollar against the U.S. dollar would have a negative effect on the Australian dollar amount we would receive from the conversion. Consequently, appreciation or depreciation in the value of the Australian dollar relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations.

 

31

 

 

We will incur significant increased costs as a result of operating as a company with ADSs that are publicly traded in the United States, and our management will be required to devote substantial time to new compliance initiatives.

 

Once the ADSs are publicly traded in the United States, we will incur significant legal, accounting, insurance and other expenses that we did not previously incur. In addition, the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented by the SEC and Nasdaq have imposed various requirements on public companies listed in the United States including requiring establishment and maintenance of effective disclosure and financial controls. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives, and we will need to add additional personnel and build our internal compliance infrastructure. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These laws and regulations could also make it more difficult and expensive for us to attract and retain qualified persons to serve on our Board, our board committees or as our senior management. Furthermore, if we are unable to satisfy our obligations as a public company listed in the United States, we could be subject to delisting of the ADSs, fines, sanctions and other regulatory action and potentially civil litigation.

 

U.S. investors may have difficulty enforcing civil liabilities against our company, our directors or members of senior management and the experts named in this prospectus.

 

Certain members of our senior management and Board named in this prospectus are non-residents of the United States, and a substantial portion of the assets of such persons are located outside the United States. As a result, it may be impracticable to serve process on such persons in the United States or to enforce judgments obtained in U.S. courts against them based on civil liability provisions of the securities laws of the United States. Even if you are successful in bringing such an action, there is doubt as to whether Australian courts would enforce certain civil liabilities under U.S. securities laws in original actions or judgments of U.S. courts based upon these civil liability provisions. In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in Australia or elsewhere outside the United States. An award for monetary damages under U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered and is intended to punish the defendant. The enforceability of any judgment in Australia will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and Australia do not currently have a treaty or statute providing for recognition and enforcement of the judgments of the other country (other than arbitration awards) in civil and commercial matters.

 

As a result, holders of the ADSs may have more difficulty in protecting their interests through actions against us, our management or our directors than would shareholders of a corporation incorporated in a jurisdiction in the United States. In addition, as a company incorporated in Australia, the provisions of the Corporations Act 2001 (Cth), or the Corporations Act, regulate the circumstances in which shareholder derivative actions may be commenced which may be different, and in many ways less permissive, than for companies incorporated in the United States.

 

Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our Ordinary Shares the ADSs.

 

We are incorporated in Australia and are subject to the takeover laws of Australia. Among other things, we are subject to the Corporations Act. Subject to a range of exceptions, the Corporations Act prohibits the acquisition of a direct or indirect interest in our issued voting shares if the acquisition of that interest will lead to a person’s voting power in us increasing to more than 20%, or increasing from a starting point that is above 20% and below 90%. Australian takeover laws may discourage takeover offers being made for us or may discourage the acquisition of a significant position in our Ordinary Shares. This may have the ancillary effect of entrenching our Board and may deprive or limit our shareholders’ opportunity to sell their Ordinary Shares and may further restrict the ability of our shareholders to obtain a premium from such transactions.

 

32

 

 

Our Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.

 

As an Australian company we are subject to different corporate requirements than a corporation organized under the laws of the United States. Our Constitution, as well as the Corporations Act, sets forth various rights and obligations that apply to us as an Australian company and which may not apply to a U.S. corporation. These requirements may operate differently than those of many U.S. companies. You should carefully review the summary of these matters set forth under “Description of Share Capital” as well as our Constitution, which is included as an exhibit to the registration statement of which this prospectus forms a part, prior to investing in the ADSs.

 

Purchasers of ADSs in this offering will not be directly holding our Ordinary Shares.

 

A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. Our Constitution and Australian law govern our shareholder rights. The depositary, through the custodian or the custodian’s nominee, will be the holder of the Ordinary Shares underlying ADSs held by purchasers of ADSs in this offering. Purchasers of ADSs in this offering will have ADS holder rights. The deposit agreement among us, the depositary and purchasers of ADSs in this offering, as an ADS holder, and all other persons directly and indirectly holding ADSs, sets out ADS holder rights, as well as the rights and obligations of us and the depositary.

 

Your right as a holder of ADSs or a U.S. holder of ordinary shares to participate in any future preferential subscription rights offering or to elect to receive dividends in Ordinary Shares may be limited, which may cause dilution to your holdings.

 

The deposit agreement provides that the depositary will not make rights available to you unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. If we offer holders of our Ordinary Shares the option to receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory assurances from us that extending the offer to holders of ADSs does not require registration of any securities under the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. Accordingly, ADS holders and holders of ordinary shares located in the United States may be unable to participate in our rights offerings or to elect to receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow the rights to lapse, in which case you will receive no value for these rights.

 

You may not be able to exercise your right to vote the Ordinary Shares underlying your ADSs.

 

Holders of ADSs may exercise voting rights with respect to the Ordinary Shares represented by the ADSs only in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of notice of any meeting of holders of our Ordinary Shares, the depositary will fix a record date for the determination of ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice from us, if we so request, the depositary shall distribute to the holders as of the record date (i) the notice of the meeting or solicitation of consent or proxy sent by us and (ii) a statement as to the manner in which instructions may be given by the holders.

 

You may instruct the depositary to vote the Ordinary Shares underlying your ADSs. Otherwise, you will not be able to exercise your right to vote, unless you withdraw the Ordinary Shares underlying the ADSs you hold. However, you may not know about the meeting far enough in advance to withdraw those Ordinary Shares. If we ask for your instructions, the depositary, upon timely notice from us, will notify you of the upcoming vote and arrange to deliver our voting materials to you and will try to vote Ordinary Shares as you instruct. We cannot guarantee you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your Ordinary Shares or to withdraw your Ordinary Shares so that you can vote them yourself. If we do not ask for your instructions, you can still send voting instructions to the depository and the depository may try to carry out those instructions, but it is not required to do so.

 

Under our Constitution, any resolution to be considered at a meeting of the shareholders shall be decided on a show of hands unless a poll is demanded in accordance with the terms of our Constitution. A poll may be demanded before a vote is taken, or, in the case of a vote taken on a show of hands, immediately before or immediately after, the declaration of the result of the show of hands. Under voting by a show of hands, multiple “yes” votes by ADS holders will only count as one “yes” vote and will be negated by a single “no” vote, unless a poll is demanded.

 

33

 

 

You may be subject to limitations on the transfer of your ADSs and the withdrawal of the underlying Ordinary Shares.

 

Your ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of your ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason subject to your right to surrender your ADSs and receive the underlying Ordinary Shares. Temporary delays in the surrendering of your ADSs and receipt of the underlying Ordinary Shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of Ordinary Shares is blocked to permit voting at a shareholders’ meeting or we are paying a dividend on our Ordinary Shares. In addition, you may not be able to surrender your ADSs and receive the underlying Ordinary Shares when you owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of Ordinary Shares or other deposited securities.

 

Holders of ADSs are not treated as holders of our Ordinary Shares.

 

By participating in this offering you will become a holder of ADSs with underlying Ordinary Shares in an Australian public listed company. Holders of ADSs are not treated as holders of our Ordinary Shares, unless they surrender the ADSs to receive the Ordinary Shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the Ordinary Shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of our Ordinary Shares, other than the rights that they have pursuant to the deposit agreement.

 

ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.

 

The deposit agreement governing the ADSs provides that holders and beneficial owners of ADSs, including those holders and owners who acquired ADSs in secondary transactions, irrevocably waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including in respect of claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction over matters arising under the deposit agreement, applying such law.

 

No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the United States federal securities laws. If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with such matters, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.

 

As the jury trial waiver relates to claims arising out of or relating to the ADSs or the deposit agreement, we believe that the waiver would likely continue to apply to ADS holders or beneficial owners who withdraw the Ordinary Shares from the ADS facility with respect to claims arising before the cancellation of the ADSs and the withdrawal of the Ordinary Shares, and the waiver would likely not apply to ADS holders or beneficial owners who subsequently withdraw the Ordinary Shares represented by ADSs from the ADS facility with respect to claims arising after the withdrawal. However, to our knowledge, there has been no case law on the applicability of the jury trial waiver to ADS holders or beneficial owners who withdraw the Ordinary Shares represented by the ADSs from the ADS facility.

 

Your rights to pursue claims arising under the deposit agreement  are limited by the terms of the deposit agreement.

 

The deposit agreement governing the ADSs representing our Ordinary Shares provides that ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws, to the fullest extent permitted by law.

 

34

 

 

If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waive the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.

 

If you or any other owners or holders of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other owners or holders may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action.

 

Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any owner or holder of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder.

 

ADS holders have limited choice of forum, which could limit your ability to obtain a favorable judicial forum for complaints against us, the depositary or our respective directors, officers or employees.

 

The deposit agreement governing the ADSs provides that: (i) the deposit agreement and the ADSs will be interpreted in accordance with the laws of the State of New York; and (ii) as an owner of ADSs, you irrevocably agree that any legal action arising out of the deposit agreement and the ADSs involving us or the depositary may only be instituted in a state or federal court in the city of New York. Any person or entity purchasing or otherwise acquiring any the ADSs, whether by transfer, sale, operation of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions. This choice of forum provision may increase your cost and limit your ability to bring a claim in a judicial forum that you find favorable for disputes with us, the depositary or our and the depositary’s respective directors, officers or employees, which may discourage such lawsuits against us, the depositary and our and the depositary’s respective directors, officers or employees. However, it is possible that a court could find such choice of forum provisions to be inapplicable or unenforceable. The enforceability of similar choice of forum provisions has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable or unenforceable.

 

To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, actions by our ADS holders to enforce any duty or liability created by the Exchange Act, the Securities Act or the respective rules and regulations thereunder must be brought in a federal court in the city of New York. Our ADS holders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.

 

We currently report our financial results under IFRS, which differs in certain significant respect from U.S. generally accepted accounting principles, or U.S. GAAP.

 

Currently we report our financial statements under IFRS. There have been and there may in the future be certain significant differences between IFRS and U.S. GAAP, including differences related to revenue recognition, intangible assets, share-based compensation expense, income tax and earnings per share. As a result, our financial information and reported earnings for historical or future periods could be significantly different if they were prepared in accordance with U.S. GAAP. In addition, we do not intend to provide a reconciliation between IFRS and U.S. GAAP unless it is required under applicable law. As a result, you may not be able to meaningfully compare our financial statements under IFRS with those companies that prepare financial statements under U.S. GAAP.

 

As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company.

 

We are a foreign private issuer, as defined in the SEC’s rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act. In addition, our senior management and directors are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we currently make annual and semi-annual filings with respect to our listing on the ASX and expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and will not be required to file quarterly reports on Form 10-Q or current reports on Form 8-K under the Exchange Act. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four months after the end of each fiscal year. Accordingly, there may be less publicly available information concerning our company than there would be if we were not a foreign private issuer.

35

 

 

As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards and these practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.

 

As a foreign private issuer listed on Nasdaq, we will be subject to their corporate governance listing standards. However, Nasdaq rules permit foreign private issuers to follow the corporate governance practices of its home country. Some corporate governance practices in Australia may differ from Nasdaq corporate governance listing standards. For example, we could include non-independent directors as members of our Remuneration and Nomination committees, and our independent directors may not necessarily hold regularly scheduled meetings at which only independent members of the Board are present. Currently, we intend to follow home country practice to the maximum extent possible. Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers. For an overview of our corporate governance practices, see “Management.”

 

We may lose our foreign private issuer status in the future, which could result in significant additional cost and expense.

 

While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter and, accordingly, our next determination will be made on June 30, 2021. In the future, we would lose our foreign private issuer status if we to fail to meet the requirements necessary to maintain our foreign private issuer status as of the relevant determination date. For example, if 50% or more of our securities are held by U.S. residents and more than 50% of our senior management or directors are residents or citizens of the United States, we could lose our foreign private issuer status. Immediately following the closing of this offering, approximately                 % of our outstanding Ordinary Shares (including Ordinary Shares in the form of ADSs) will likely be held by U.S. residents (assuming that all purchasers in this offering are residents of the United States).

 

The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly more than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP rather than IFRS, and modify certain of our policies to comply with corporate governance practices required of U.S. domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers such as the ones described above and exemptions from procedural requirements related to the solicitation of proxies.

 

We are an “emerging growth company” under the JOBS Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our Ordinary Shares or the ADSs less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. We will not take advantage of the extended transition period provided under Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards.

 

We cannot predict if investors will find the Ordinary Shares or ADSs less attractive because we may rely on these exemptions. If some investors find the Ordinary Shares or ADSs less attractive as a result, there may be a less active trading market for the Ordinary Shares or ADSs and the price of the Ordinary Shares or ADSs may be more volatile. We may take advantage of these exemptions until such time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of (i) the last day of the fiscal year in which we have more than US$1.07 billion in annual revenue; (ii) the last day of the fiscal year in which we qualify as a “large accelerated filer”; (iii) the date on which we have, during the previous three-year period, issued more than US$1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year in which the fifth anniversary of this offering occurs.

 

36

 

 

If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. holders.

 

[Based on the nature and composition of our income, assets, activities and market capitalization for our taxable year ended June 30, 2019, we believe that we were not classified as a passive foreign investment company, or PFIC, for the taxable year ended June 30, 2019. Based on the nature and composition of our income, assets, activities and market capitalization for our taxable year ended June 30, 2020, we believe that we would not be classified as a PFIC for the taxable year ended June 30, 2020.] However, there can be no assurance that we will not be considered a PFIC in any past, current or future taxable year. A separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status may change from year to year. Our status as a PFIC will depend on the composition of our income (including whether we receive certain grants or subsidies and whether such amounts will constitute gross income for purposes of the PFIC income test) and the composition and value of our assets, which may be determined in large part by reference to the market value of the ADSs and our Ordinary Shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this offering in our business. Our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding our PFIC status.

 

Under the Code, a non-U.S. company will be considered a PFIC for any taxable year in which (1) 75% or more of its gross income consists of passive income or (2) 50% or more of the average quarterly value of its assets consists of assets that produce, or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year during which a U.S. holder (as defined below in the section titled “Material United States Federal Income Tax and Australian Tax Considerations—Material United States Federal Income Tax Considerations”) holds our Ordinary Shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the Ordinary Shares or ADSs, regardless of whether we continue to meet the PFIC test described above, unless the U.S. holder is eligible to make and makes a mark-to-market election or makes a specified election once we cease to be a PFIC. If we are classified as a PFIC for any taxable year during which a U.S. holder holds our Ordinary Shares or ADSs, the U.S. holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements. For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see “Material United States Federal Income Tax and Australian Tax Considerations—Material United States Federal Income Tax Considerations.”

 

If a United States person is treated as owning at least 10% of our Ordinary Shares, such holder may be subject to adverse U.S. federal income tax consequences.

 

If a U.S. holder is treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our Ordinary Shares or ADSs, such U.S. holder may be treated as a “United States shareholder” with respect to each “controlled foreign corporation” in our group, if any. While our group does not currently include any U.S. subsidiaries, if we form or acquire any U.S. subsidiaries in the future any of our current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable income its pro rata share of “Subpart F income,” “global intangible low-taxed income” and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with controlled foreign corporation reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of the Code. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in our Ordinary Shares or ADSs.

 

Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of the ADSs.

 

If, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist the ADSs. Such a delisting would likely have a negative effect on the price of the ADSs and would impair your ability to sell or purchase our ADSs when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow the ADSs to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent the ADSs from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

37

 

  

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains forward-looking statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this prospectus. These statements are likely to address our growth strategy, financial results and product and development programs. You must carefully consider any such statements and should understand that many factors could cause actual results to differ from our forward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed, and actual future results may vary materially. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

 

  Our strategies and objectives;

 

  Our ability to meet the Nasdaq requirements;

 

  Our other financial operating objectives;

 

  The availability of qualified employees for business operations;

 

  General business and economic conditions;

 

  Our ability to meet its financial obligations as they become due;

 

  The positive cash flows and financial viability of our operations and new business opportunities;

 

  Our ability to manage growth with respect to our operations and new business opportunities;
     
  Our ability to make new technological improvements and developments to our products;
     
  Our ability to enter into new partnerships and license agreements for the use of our products;

 

 

Our ability to secure intellectual property rights over our proprietary products or enter into license agreements to secure the legal use of certain patents and intellectual property;

     
 

Our ability to avoid infringement of intellectual property rights; and

     
  Our ability to be successful in new markets;

 

We describe certain material risks, uncertainties, and assumptions that could affect our business, including our financial condition and results of operations, under “Risk Factors.” We base our forward-looking statements on our management’s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may, and are likely to, differ materially from what is expressed, implied or forecast by our forward-looking statements. Accordingly, you should be careful about relying on any forward-looking statements. Except as required under the federal securities laws, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this prospectus, whether as a result of new information, future events, changes in assumptions, or otherwise.

 

38

 

 

INDUSTRY AND MARKET DATA

 

This prospectus contains estimates and information concerning our industry and our business, including estimated market size and projected growth rates of the markets for our products. Unless otherwise expressly stated, we obtained this industry, business, market and other information from reports, research surveys, studies and similar data prepared by third parties, industry and general publications.

 

This information involves a number of assumptions and limitations. Although we are responsible for all of the disclosure contained in this prospectus and we believe the third-party market position, market opportunity and market size data included in this prospectus are reliable, we have not independently verified the accuracy or completeness of this third-party data. In addition, projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors.” These and other factors could cause results to differ materially from those expressed in these publications and reports.

 

USE OF PROCEEDS

 

Based upon an assumed public offering price of US$         per ADS (the mid-point of the range set forth on the cover page of this prospectus), we estimate that we will receive net proceeds from this offering, after deducting the underwriting discount and the estimated offering expenses payable by us, of approximately US$        , or approximately US$ if the underwriter exercises in full its over-allotment option to purchase additional ADS.

 

We plan to use the net proceeds we receive from this offering primarily for research and product development of our current products (19%) and business development and marketing (17%), with the remainder of the proceeds to be used for general corporate purposes, including, without limitation, investing in or acquiring companies that are synergistic with or complimentary to our technologies (including, without limitation, a potential investment in Jana), and working capital.

 

We believe that the expected net proceeds from this offering and our existing cash and cash equivalents, together with interest thereon, will be sufficient to fund our operations for the next 18 to 24 months, although we cannot assure you that this will occur.

 

The amount and timing of our actual expenditures will depend on numerous factors, including the status of our development efforts, sales and marketing activities and the amount of cash generated or used by our operations. We may find it necessary or advisable to use portions of the proceeds for other purposes, and we will have broad discretion and flexibility in the application of the net proceeds. If an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in this prospectus. See “Risk Factors.” Pending these uses, the proceeds will be invested in short-term bank deposits.

 

DIVIDEND POLICY

  

We have never declared or paid cash dividends on our common shares. We currently do not have any plans to pay cash dividends. Rather, we currently intend to retain all of our available funds and any future earnings to operate and grow our business.

 

Any dividend we declare will be paid to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders of our Ordinary Shares, to the extent permitted by applicable law and regulations, less the fees and expenses payable under the deposit agreement. Any dividend we declare will be distributed by the depositary bank to the holders of the ADSs, subject to the terms of the deposit agreement. See “Description of American Depositary Shares—Dividends and Distributions.”

 

39

 

  

CAPITALIZATION AND INDEBTEDNESS

 

The following table sets forth our capitalization as of December 31, 2020:

 

  actual basis;

 

  on a pro forma basis, giving effect to the conversion of US$1,629,655 worth of convertible notes (A$2,172,873) assuming interest calculated through May 31, 2021 of US$129,655 (A$151,873) and which includes interest for the period from January 1, 2021 to May 31, 2021 in the amount of A$85,453. The final number of shares to be issued on conversion cannot be determined at this stage, as the shares will be issued at the greater of US$1.00 and a 25% discount to the price at which the Company issues the shares in conjunction with the listing, which price is yet to be determined.;

 

  an as adjusted basis to give effect to the issuance and sale of                 ADSs in this offering at the assumed initial public offering price of US$                per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on                 , 2021, after giving effect to the Australian dollar/U.S. dollar exchange rate of   US$0.77:A$1.00  as of                 , 2021, and an ADS-to-Ordinary Share ratio of                 -to-1, after deducting underwriting discounts and commissions and estimated offering expenses payable by us

 

The convertible note was issued on June 1, 2020 and is convertible into our Ordinary Shares at a conversion price at the greater of US$1.00 per share and a 25% discount to the price at which the Company issues shares in conjunction with a NASDAQ listing. If the Company does not attain a NASDAQ listing prior to June 30, 2021, the note will mature on December 30, 2021. The note accrues interest at a rate of 10% per annum and is mandatorily convertible upon a NASDAQ listing.

 

The pro forma information below is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing. You should read this table together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited and unaudited consolidated financial statements and the related notes appearing elsewhere in this prospectus.

 

    December 31, 2020 Actual
A$(1)
(unaudited)
 
    Pro Forma A$(1) (unaudited)       Pro Forma US$(1)(3) (unaudited)     Pro Forma as adjusted
A$(1)(2) (unaudited)
    Pro Forma as adjusted US$(1)(2)(3) (unaudited)  
Cash and cash equivalents     4,755,563       4,755,563       3,661,784                                      
Total Liabilities     2,994,234       821,361       632,448                  
Issued capital     32,991,281       35,164,154       27,076,399                  
Accumulated losses     (33,939,307 )     (34,024,760 )     (26,199,065 )                
Reserves     4,953,783       4,953,783       3,814,413                  
Total shareholders’ equity     4,005,757       6,093,177       4,691,746                  

 

(1) Excludes (i) _______ shares of our Ordinary Shares issuable pursuant to performance rights at a weighted average exercise price of US$___ per share as of _______, (ii) ______ shares of our Ordinary Shares issuable upon exercise of outstanding options at a weighted average exercise price of US$______ per share as of _________.
(2) A US$1.00 increase or decrease in the assumed public offering price per unit would increase or decrease our pro forma cash, additional paid-in capital, total shareholders’ (deficit) equity and total capitalization by approximately US$____________ assuming the number of units offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discount and estimated offering expenses payable by us.
(3) USD amounts have been converted from USD to AUD using an exchange rate of US$0.77:A$1.00

 

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of outstanding options described above and the underwriters’ over-allotment option. 

 

Below is a reconciliation of the changes from the Capitalization and Indebtedness table at December 31, 2020:

 

   

Total
Liabilities
(unaudited)

A$

   

Issued
Capital
(unaudited)

A$

   

Accumulated
Losses
(unaudited)

A$

   

Total
Shareholders
Equity
(unaudited)

A$

 
Balances at December 31, 2020     2,994,234       32,991,281       (33,939,307 )     4,005,757  
Adjust: Interest for the period from January 1, 2021 to May 31, 2021 that is not included in December 31, 2020     -       -       (85,453 )     (85,453 )
Adjust: Shares to be issued on conversion of convertible notes     (2,172,873 )     2,172,873       -       2,172,873  
Pro Forma (1)     821,361       35,164,154       (34,024,760 )     6,093,177  

 

(1) In USD, this amounts to US$27,076,399. USD amounts have been converted from USD to AUD using an exchange rate of US$0.77:A$1.00

 

40

 

 

DILUTION

 

If you invest in the ADSs in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per ADS and the as adjusted net tangible book value per Ordinary Share or ADS immediately after this offering.

 

As of December 31, 2020, our historical net tangible book value was A$2.7 million (or US$2.1 million)(1), or A$ (or US$      ) per ADS. Historical net tangible book value per ADS represents our total tangible assets less total liabilities, divided by the number of Ordinary Shares outstanding as of December 31, 2021, converted to ADSs at an ADS-to-Ordinary Share ratio of 5 -to-1.

 

After giving effect to the receipt of the net proceeds from our sale of ADSs in this offering at an assumed initial public offering price of US$      per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on            , 2021, after giving effect to the Australian dollar/U.S. dollar exchange rate of US$0.77:A$1.00 as of       , 2021, and an ADS-to-Ordinary Share ratio of -to-1, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2020 was A$      million (or US$      million), or A$      (or US$      ) per ADS, equivalent to A$      (or US$      ) per Ordinary Share, in each case based on an ADS-to-Ordinary Share ratio of -to-1. This represents an immediate increase in net tangible book value of A$      (or US$      ) per ADS, equivalent to A$      or (US$      ) per Ordinary Share, to our existing shareholders and immediate dilution of A$      (or US$      ) per ADS, equivalent to A$      (US$      ) per Ordinary Share , to investors purchasing ADSs in this offering, in each case based on an ADS-to-Ordinary Share ratio of -to-1.

 

The following table illustrates this dilution on a (1) per ADS basis and (2) per Ordinary Share basis, assuming all Ordinary Shares outstanding as of December 31, 2020 converted to ADSs at an ADS-to-Ordinary Share ratio of 5 -to-1:

 

Assumed initial public offering price per ADS                   US$                               US$            
Historical net tangible book value per ADS as of December 31, 2020   US$             US$          
                                 
Increase in net tangible book value per ADS attributed to investors purchasing ADSs in this offering                                
                                 
As adjusted net tangible book value per ADS after this offering                                
                                 
Dilution in net tangible book value per ADS to investors in this offering           US$               US$    

 

Each US$1.00 increase (decrease) in the assumed initial public offering price of US$                per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on                 , 2021, after giving effect to the Australian dollar/U.S. dollar exchange rate of US$0.77:A$1.00   as of                 , 2021, and an ADS-to-Ordinary Share ratio of                 -to-1, would increase (decrease) the as adjusted net tangible book value per ADS after this offering by US$                 and dilution to investors in this offering by US$                 per ADS, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions. An increase of 1,000,000 ADSs offered by us would increase the as adjusted net tangible book value by US$                 per ADS and the dilution to investors in this offering would decrease by US$                per ADS, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions. A decrease of 1,000,000 ADSs offered by us would decrease the as adjusted net tangible book value by US$                per ADS and the dilution to investors in this offering would increase by US$                per ADS, assuming the assumed initial public offering price remains the same and after deducting underwriting discounts and commissions.

 

If the underwriters exercise their option to purchase                  additional ADSs in full, the as adjusted net tangible book value after the offering would be US$                per ADS, the increase in net tangible book value per ADS to existing shareholders would be US$                per ADS and the dilution per ADS to new investors in this offering would be US$                per ADS, in each case assuming an initial public offering price of US$                per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on                 , 2021, after giving effect to the ADS-to-Ordinary Share ratio of                 -to-1.

 

The dilution information above is for illustration purposes only. Our as adjusted net tangible book value following the closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing.

 

41

 

 

The following table summarizes, as of December 31, 2020:

 

  the total number of Ordinary Shares purchased from us by existing shareholders and the equivalent number of Ordinary Shares underlying ADSs purchased by investors in this offering;

 

  the total consideration paid to us by our existing shareholders and by investors purchasing ADSs in this offering, assuming an initial public offering price of US$                per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on                 , 2021, after giving effect to the ADS-to-Ordinary Share ratio of                 -to-1, before deducting underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering; and

 

  the average price per Ordinary Share paid by existing shareholders and the average price per ADS or equivalent number of Ordinary Shares.

 

    Ordinary Shares
(Directly or in the
Form of ADSs)
    Total Consideration     Average Price     Average
Price per
 
    Number     Percent     Amount     Percent     Per Share     ADS  
Existing shareholders                         %   US$                           %   US$                US$             
Purchasers of ADSs                                                
Total             100 %   US$       100 %   US$     US$  

 

If the underwriters exercise their option to purchase                 additional ADSs in full, our existing shareholders would own                % and investors in this offering would own                % of the total number of Ordinary Shares outstanding (including shares underlying ADSs) upon the closing of this offering.

 

Each US$1.00 increase (decrease) in the assumed initial public offering price of US$                per ADS, the U.S. dollar equivalent of the last reported sale price of our Ordinary Shares on the ASX on                 , 2020, after giving effect to the ADS-to-Ordinary Share ratio of                 -to-1, would increase (decrease) the total consideration paid by investors in this offering by US$                million and increase (decrease) the total consideration paid by investors in this offering by                %, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting underwriting discounts and commissions.

 

The outstanding Ordinary Share information in the tables above is based on 136,920,871 Ordinary Shares as of August 20, 2021, and excludes:

 

  7,561,958 Ordinary Shares issuable upon the exercise of outstanding options as of July 20, 2021, with a weighted-average exercise price of A$1.07 per Ordinary Share under our equity incentive plans; and

 

  20,150,000 shares of our Ordinary Shares subject to Performance Rights as further described in “Executive Compensation”.

 

up to a maximum of 1,500,000 shares of our Ordinary Shares issuable upon exercise of outstanding convertible notes at a conversion price of US$1.00 per share. On conversion, convertible note holders will be issued shares at the greater of US$1.00 per share and a 25% discount to the price at which the Company issues shares in conjunction with a NASDAQ listing.

 

To the extent any outstanding options are exercised, there will be further dilution to investors purchasing in this offering.

 

42

 

 

MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of the financial condition and results of our operations should be read in conjunction with the “Summary Statements of Operations Data” and our consolidated financial statements and the notes to those statements appearing elsewhere in this prospectus. This discussion and analysis contains forward-looking statements reflecting our management’s current expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of events may differ materially from those described in or implied by these forward-looking statements due to a number of factors, including those discussed below and elsewhere in this prospectus particularly on page 20 entitled “Risk Factors”.

 

Overview

 

We have developed and patented a proprietary measurement/dimensioning technology that enables a User to check, track, and accurately assess their body dimensions privately using only a smartphone. We refer to this physical measurement and analytics tool as “BodyScan.” We have global customers/partners (“Partners”) who utilize our technology through our proprietary Software Development Kits (“SDKs”). Our global Partners have substantial audiences that they address, and from those underlying audiences, individual User (“User(s)”) will sign up for, or be given access to, the Partners’ software programs/apps that embed our technology components. Our global Partners currently include companies within the following sectors: (i) mobile health (“mHealth”), Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel.

 

Our patented technology allows our Partners to supply to individual Users, via our automated technology, the ability to take a series of images of themselves using a smartphone, which delivers accurate and repeatable measurements across an individual’s entire body. These measurements allow the individual to understand his/her dimensions and the physical changes that they are undergoing through diet, exercise and lifestyle modification. Further, the images that we capture also provide the individuals with an understanding of their health risks related to certain chronic diseases (including obesity and diabetes) and using the global standards measurements set by the World Health Organization (WHO), and the International Diabetes Federation (IDF). Once the image capture sequence is completed, it supplies those measurements to the Partner’s application, whose contract with the User then determines the manner in which it analyzes/reports the data and/or the potential health risk to the User. We are working towards globalizing our technology in order to assist individuals, communities and populations live healthier lives.

 

Recent technology advances have provided opportunities for complex mathematical problems to be solved directly on a User’s smartphone, rather than limiting that computation to the Cloud. Modern devices produced by companies such as Apple, Samsung and Google now have AI-focused chipsets utilizing platforms such as CoreML and Tensorflow to process data at lightning speeds. We see the opportunity to harness these ongoing technology improvements to lower latency, increase security and privacy, improve reliability and reduce operational costs of our services. Our overarching technology strategy has been to take advantage of this hardware-accelerated performance, specifically by utilizing on-device general purpose Graphic Processing Units (“GPU”) found on today’s modern devices. 

 

In Cloud-based systems, data transfer/retention is a potential impediment. Data must be sent to, and then processed in, the Cloud, thus adding additional latency and disclosure risk to the overall process. On-device computing eliminates the necessity of a roundtrip to the Cloud and permits near zero-latency. This process greatly improves User experience and allows for near real-time interaction with the service.  Running directly on-device additionally negates the side-effects of Cloud-based interference. In areas where connectivity is sub-optimal, such as rural areas, having analytic models on-device means that processing results can be generated locally, quickly and securely.

 

As sensitive data does not need to be sent or maintained in the Cloud, there are fewer opportunities to exploit any potential vulnerabilities, thereby providing increased security and privacy for Users. This security is critically important in a world where data sovereignty, residency, and retention are a major concern for Users and under increased protective global legislation. 

 

By focusing on leveraging the estimated 3.7 billion  devices  capable of running AI inference and analysis on-device, we are able to slash the costs associated with Cloud-based analytics and inference, bandwidth and retention/storage concerns. As our user base scales, implementing machine learning on-device will mitigate the expense of expertise and time needed to implement and maintain a Cloud-based solution.

 

We deliver a non-invasive, highly accurate and privacy-sensitive healthcare and biometric solutions that generate results to the User  within seconds. We leverage machine-learning and computer vision to analyze images, detect pose and joint features, and create non-personally identified data for measurement estimation. We further take advantage of dedicated GPU libraries such as TensorFlow Lite (Android) and Metal (Apple) to run prediction models, which have been trained with a substantial and diverse human data set from around the globe and which are able to process multiple captured images in fractions of a second. The result is a solution that runs on-device and does not sacrifice speed, security or privacy. Images and private information never leave the phone, ensuring security and privacy standards are met across global regions. This process allows us to produce what we believe to be exceptional results and simplify the output of useful, reliable, digital measurements and remove the human error otherwise present in traditional methods, such as tape measure or visual estimations.

 

43

 

 

Our BodyScan application has been developed over 7 years through the development of our proprietary image capturing and analysis system. We have refined this process while utilizing through a proprietary data collection exercise conducted by the company, which involved over 7,000 individuals across Australia, Taipei, Thailand and Malaysia. This multinational data set of ethnicities was used to train and to enrich our machine-learning protocols and to improve the accuracy and repeatability of the BodyScan system. We have further enhanced the use case by adopting a number of predetermined and published markers for some chronic diseases, set by the WHO, and the IDF. According to the WHO, these chronic, non-communicable diseases relate to 71% of deaths each year. We have developed and built the application’s patented capturing system, in line with the WHO and IDF measurement guidelines for the assessment and identification of biomarkers of these chronic diseases, such as Type 2 Diabetes. Whether it be an iOS or an Android application on the smartphone of any user, we provide our Partners and their Users with the following biometric data points:

 

  Anthropometric Measurements (BodyScan);

 

  Body Composition: Total Body Fat %, (BodyScan);
     
  Primary Markers of Chronic disease – Type-2 Diabetes, Obesity, Cardiovascular Disease (CVD) (BodyScan and FaceScan combined); and

 

  Primary Health Markers – Waist-to-Hip Ratio, Waist-to-Height, Waist Circumference, (BodyScan).

 

  Dermatological conditions – 588 skin conditions across 133 categories, (DermaScan)

 

It is our mission to deliver an easy-to-use, early warning and health assessment tool for our Partners to supply to individuals, governments and healthcare organizations, enabling Users to take control of and to understand the health risks which they pose to themselves, which they may be unaware of. Having the opportunity to combine measurement data with other biometric data sets widens the utility and importance of our technology through multiple business segments.

 

We have developed and patented a proprietary measurement/dimensioning technology that enables its users to check, track, and accurately assess their bodily dimensions using only a smartphone privately. The company has directly executed 15 binding term sheets with customers/partners around the world. This physical measurement and analysis tool, is also referred to as “BodyScan.” The company has customers-cum-sales channel partners who are institutions in the fitness, mHealth, wellness, apparel and life/health insurance fields and those customers have substantial audiences that they address, and from those underlying populations individuals (users) will sign up for, or be given access to, the partners software programs/apps which embody the company’s various components.

 

Our patented technology allows our partners to supply to individuals, via our automated technology, to take a series of images of themselves using a smartphone which delivers accurate and repeatable measurement across the individual’s entire body. These measurements allow the individual to understand his/her dimensions and the physical changes which they are undergoing through diet, exercise and lifestyle. Further, the images that we capture also provide the individual with an understanding of their health risks related to certain chronic diseases (including obesity and diabetes) and using the global standards measurements set by the World Health Organization (WHO), and the International Diabetes Federation (IDF). Once the image capture sequence is completed, it supplies these measurements to the partner’s application, whose contract with the user then determines the manner in which it reports the data and/or the potential health risk to the user. We are working towards globalizing our technology in order to assist individuals, communities and populations live healthier lives.

 

When viewing the results of operations, please bear in mind all the costs that have been incurred to date, directly and indirectly, relate to the buildout of the software and to get it market ready. While we have generated revenue in the past, it has not been the mainstream, recurring, subscription revenue that we anticipate moving forward (Please see the ‘Revenue and Other Income’ policy note below).

 

To any reader of our financial statements, the implication of the above is that, in our instance, past performance may not be a reliable indicator of future performance.

  

Results of Operations

 

The table below provides our results of operations for the six months ended December 31, 2020 and December 31, 2019. Certain other non-GAAP financial measures below have been provided, and management believes that such presentation discloses relevant information to the users of these financial statements regarding our financial condition and results of operations. In such cases, management believes that these non-GAAP financial measures are substantially aligned with GAAP disclosure and, therefore, provide useful information to users of these financial statements.

 

    Six Months ended
December 31
 
    2020     2019  
    (AUD in thousands)  
Revenues   A$ 887     A$ 354  
Employee expenses     (4,248 )     (2,421 )
Sales and marketing     (770 )     (725 )
General and administrative     (1,987 )     (779 )
Operating loss before interest     (6,118 )     (3,571 )
Financial income (expenses), net     (138 )     (40 )
Loss before income tax   A$ (6,256 )   A$ (3,611 )

 

44

 

 

The table below provides our results of operations for the twelve months ended June 30, 2020 and 2019.

 

    Year ended
June 30
 
    2020     2019  
    (AUD in thousands)  
Revenues   A$ 667     A$ 899  
Employee expenses     (3,899 )     (3,824 )
Sales and marketing     (1,268 )     (332 )
General and administrative     (1,419 )     (1,495 )
Operating loss before interest     (5,919 )     (4,752 )
Financial income (expenses), net     (144 )     (137 )
Loss before income tax   A$ (6,063 )   A$ (4,889 )

  

Six Months Ended December 31, 2020 Compared to Six Months Ended December 31, 2019

 

Revenues

 

Our revenues for the six months ended December 31, 2020 amounted to A$887,000 compared to A$354,000 for the six months ended December 31, 2019 which represents a 150% increase from the corresponding period. The increase from the corresponding period primarily resulted from software licensing as well as fees earned from the buildout of our partner’s apps.

 

Employee expenses

 

Our employee expenses for the six months ended December 31, 2020 amounted to A$4,248,000, an increase of 75%, compared to A$2,421,000 for the six months ended December 31, 2019. The increase of A$1,827,000 from the corresponding year resulted primarily from a A$1,709,000 increase in stock-based payments to employees under the terms of the Company’s Incentive Performance Rights Plan.

 

Excluding the non-cash stock-based payments referenced in the prior sentence, employee expenses for the six months ended December 31, 2020 amounted to A$1,652,000, an increase of 8%, compared to A$1,534,000 for the six months ended December 31, 2019, as shown in the table below.

 

The table below provides a non-IFRS comparison of our employee expenses, excluding non-cash stock-based payments, for the six months ended December 31, 2020 and December 31, 2019.

  

    Six Months ended
December 31
 
    2020     2019  
    (AUD in thousands)  
Employee expenses   A$ (1,652 )   A$ (1,534 )

 

Below is a reconciliation of IFRS to non-IFRS employee expenses for the six months ended December 30, 2020 and 2019:

 

    Six Months ended
December 31
 
    2020     2019  
    (AUD in thousands)  
Employee expenses     (4,248 )     (2,421 )
Non-cash stock-based payments     2,596       887  
Adjusted employee expenses     (1,652 )     (1,534 )

 

Sales and Marketing Expenses

 

Our sales and marketing expenses for the six months ended December 31, 2020 amounted to A$770,000, an increase of A$45,000, or 6%, compared to A$725,000 for the six months ended December 31, 2019. The increase primarily resulted from an increase in stock-based payments to suppliers for public and investor relations services expenses. The shares were issued to supplier’s in lieu of a cash payment, with the benefit of improving our cash flow.

 

45

 

 

General and Administrative Expenses

 

Our general and administrative expenses for the six months ended December 31, 2020 amounted to A$1,987,000, an increase of A$1,208,000, or 155%, compared to A$779,000 for the six months ended December 31, 2019. The increase compared to the corresponding period was mainly due to the provision for impairment of investments under Australian Accounting Standards Board (AASB) accounting standards for ‘Fair Value Measurement’. The recoverable amount of the Company’s investments is reviewed at each reporting date. At 31 December 2020, the Company created a provision for impairment against its investments in accordance with AASB 13. The provision for impairment considers the uncertainty related to the recoverable value of a Company’s assets. As soon as a more accurate determination of recoverable value can be made, the Company will re-assess whether a provision for impairment is required in future.

 

Excluding the provision for impairment of investments referenced in the prior paragraph, general and administrative expenses for the six months ended December 31, 2020 amounted to A$644,000, a decrease of 17%, compared to A$779,000 for the six months ended December 31, 2019, as shown in the table below:

 

The table below provides a non-IFRS comparison of our general and administrative expenses, excluding the provision for impairment of investments, for the six months ended December 31, 2020 and December 31, 2019.

 

    Six Months ended
December 31
 
    2020     2019  
    (AUD in thousands)  
General and administrative expenses   A$ (644 )   A$ (779 )

 

Below is a reconciliation of IFRS to non-IFRS general and administration expenses for the six months ended December 30, 2020 and 2019:

 

    Six Months ended
December 31
 
    2020     2019  
    (AUD in thousands)  
General and administrative expenses     (1,987 )     (779 ))
Provision for impairment of investments     1,342       -  
Adjusted general and administrative expenses     (644 )     (779 )

 

Operating Loss Before Interest

 

As a result of the foregoing, for the six months ended December 31, 2020, our operating loss was A$6,118,000, an increase of A$2,547,000, or 71%, compared to our operating loss for the six months ended December 31, 2019 of A$3,571,000.

 

Financial Income (Expenses), net

 

Our financial income, net for the six months ended December 31, 2020 amounted to A$138,000 as opposed to financial expenses, net of A$40,000 for the six months ended December 31, 2019. The increase of A$98,000 from the corresponding year resulted primarily from the interest (10%) accrued on the Company’s convertible note liability of US$1,500,000 at 31 December 2020.

  

Loss Before Income Tax

 

As a result of the foregoing, employee expenses, sales and marketing expenses, general and administrative expenses, and initial revenues, our net loss for the six months ended December 31, 2020 was A$6,256,000 compared to net loss of A$3,611,000 for the six months ended December 31, 2019. The increase in net loss was mainly due to an increase in non-cash stock-based payments to employees and a provision for impairment against the Company’s investments under Australian accounting standards, offset by an increase in revenue, as opposed to expenses and income in the corresponding period. The company is constantly looking to expand and refine its technology. With this in mind we expect to incur additional losses as we perform further research and development activities and continue with the commercialization of our software. 

 

46

 

 

Twelve Months Ended June 30, 2020 Compared to Twelve Months Ended June 30, 2019

 

Revenues

 

Our subscription revenues for the twelve months ended June 30, 2020 amounted to A$140,000 compared to A$5,000 for the twelve months ended June 30, 2019. The increase from the corresponding period primarily resulted from the live activation of our technology and Software-as-a-service agreements. We also generated other revenue of A$527,000 for the twelve months ended June 30, 2020, compared to A$894,000 for the twelve months ended June 30, 2019. This other revenue relates primarily to fees earned from the buildout of our partner’s apps.

 

Employee expenses

 

Our employee expenses for the twelve months ended June 30, 2020 amounted to A$3,899,000, an increase of A$75,000, or approximately 2%, compared to A$3,824,000 for the twelve months ended June 30, 2019. During our fiscal year ended June 30, 2020, we had an expense of A$1,120,000 in respect of stock-based payments, compared to an expense of A$1,206,000 in our fiscal year ended June 30, 2019. The stock-based payments are mostly related to incentive options offered to key management personnel in accordance with our incentive plan. Approximately 63% of the direct salary costs for the twelve months ended June 30, 2020 relates to research and development. We expect that employee expenses will continue to increase in 2021 and that we will recruit additional employees.

 

Excluding the non-cash stock-based payments referenced in the prior paragraph, employee expenses for the twelve months ended June 30, 2020 amounted to A$2,779,000, an increase of 6%, compared to A$2,618,000 for the twelve months ended June 30, 2019, as shown in the table below:

 

The table below provides a non-IFRS comparison of our employee expenses, excluding non-cash stock-based payments, for the twelve months ended June 30, 2020 and 2019.

 

    Year ended
June 30
 
    2020     2019  
    (AUD in thousands)  
Employee expenses   A$ (2,779 )   A$ (2,618 )

 

Below is a reconciliation of IFRS to non-IFRS employee expenses for the twelve months ended June 30, 2020 and 2019:

 

    12 Months ended
June 30
 
    2020     2019  
    (AUD in thousands)  
Employee expenses     (3,899 )     (3,824 )
Non-cash stock-based payments     1,120       1,206  
Adjusted employee expenses     (2,779 )     (2,618 )

 

Sales and Marketing Expenses

 

Our sales and marketing expenses for the twelve months ended June 30, 2020 amounted to A$1,268,000, an increase of A$936,000, or 282%, compared to A$332,000 for the twelve months ended June 30, 2019. The increase relates primarily to the accounting valuation of stock-based payments to three corporate advisory suppliers which were issued under mandate. The securities were issued at between A$0.115 and A$0.32 per share in lieu of cash, with the benefit of improving cash flow. The Company’s closing share price at June 30, 2020 was A$0.28 per share and on April 16, 2021 the Company’s closing share price was A$2.05 per share.

 

General and Administrative Expenses

 

Our general and administrative expenses for the twelve months ended June 30, 2020 amounted to A$1,419,000, a decrease of A$76,000, or 5%, compared to A$1,495,000 for the twelve months ended June 30, 2019. The decrease compared to the corresponding period was mainly due to a decrease in consulting costs and legal fees as the Company set out to reduce spending with the benefit of improving cash flow at the midst of a global pandemic. 

 

Operating Loss Before Interest

 

As a result of the foregoing, employee expenses, sales and marketing expenses, general and administrative expenses, and initial revenues, for the twelve months ended June 30, 2020, our operating loss was A$6,063,000, an increase (bigger operating loss) of A$1,174,000, or 24%, compared to our operating loss for the twelve months ended June 30, 2019 of A$4,889,000.

 

47

 

 

Financial (Expenses), net

 

Our financial (expenses), net for the twelve months ended June 30, 2020 amounted to A$144,000 as opposed to financial expenses, net of A$137,000 for the twelve months ended June 30, 2019. The increase of A$7,000 relates primarily to interest on short-term loans and interest related to the capitalization (right of use) of our office lease, slightly offset by a decrease in interest payable on the convertible note loan facility (settled in full on June 30, 2020).

  

Loss Before Income Tax

 

As a result of the foregoing, employee expenses, sales and marketing expenses, general and administrative expenses, and initial revenues, our net loss before tax for the twelve months ended June 30, 2020 was A$6,063,000 compared to net loss of A$4,889,000 for the twelve months ended June 30, 2019. The increase in net loss (bigger loss) was mainly due to a A$919,000 increase in stock-based payments to suppliers for marketing, as less revenue generated in 2020 from the buildout of our partner’s apps.  We expect to incur additional losses to perform further research and development activities as we make plans to fully commercialize our software from around June 2020 onwards.

 

Liquidity and Capital Resources 

 

Since our inception, we have funded our operations primarily through public and private offerings of debt and equity in Australia.

 

As of June 30, 2020, we had cash, cash equivalents and restricted cash of A$627,000 compared to A$574,000 cash and cash equivalents as of June 30, 2019. This increase primarily resulted from a reduction in net cash flows used in operating activities, resulting in less cash having to be raised.

 

Net cash used in operating activities was A$2,697,000 for the year ended June 30, 2020 compared to A$3,258,000 for the year ended June 30, 2019. The decrease in cash used in operating activity is derived mainly from an increase in cash receipts from our joint venture partner, BCT, as well as a decrease in cash payments to suppliers and employees due to implementing cost controls during the COVID-19 period. The increase in employee expenses referred to above relates to stock-based payments which do not negatively impact cash flow.

  

We had positive cash flow from financing activities of A$2,836,408 for the twelve months ended June 30, 2020 compared to A$3,903,200 for the twelve months ended June 30, 2019. The cash flow from financing activities for the twelve months ended June 30, 2020 was due to the proceeds from the final four (4) payments tranches of the A$5,200,000 placement with Asia Cornerstone Asset Management Ltd. (“ACAM”)

 

On June 1, 2020, we entered into a formal funding agreement for US$1,500,000 with ACAM through the issuance of a convertible note. The material terms of the funding agreement with ACAM are as follows.

 

  ACAM will provide US$1,500,000 of funding, in four separate tranches as set forth below.

 

  The funding has a mandatory conversion upon a successful NASDAQ listing.

 

  On conversion, ACAM will be issued shares in the NASDAQ listed company at the greater of US$1.00 and a 25% discount to the price at which we issues shares in conjunction with the listing.

 

  ACAM will accrue interest on the funds advanced to us at a rate of 10% per annum, with interest being capitalized and also converted at the time of listing on the NASDAQ.

 

  In the event we are not successful in attaining a listing on the NASDAQ on or prior to June 30, 2021, we will have an additional 6 months to repay the capital.

 

  The note is not secured.

 

48

 

 

Under the terms of the funding, ACAM agreed to fund us over 4 tranches:

 

Tranche 1 US$225,000 - 14 days after the date of execution of the formal funding agreement.

 

Tranche 2 US$450,000 - 30 days from the date of commencement of the audit on our June 30, 2020 financials by an PCAOB approved auditor.

 

Tranche 3 US$450,000 – 14 days from the date that we file a Registration Statement (Form F-1) with the U.S. Securities and Exchange Commission in relation to the NASDAQ Listing.

 

Tranche 4 US$375,000 -14 days from the date that we engage an underwriter or an investment bank to provide services in connection with the NASDAQ Listing. Under a deed of variation, ACAM agreed to not take up its final tranche of convertible notes and it was agreed that it would be subscribed for by iConcept Global Growth Fund (“IGGF”). On 16 October 2020, IGGF paid for these convertible notes for the remaining balance of US$375,000.

 

On July 30, 2020, we submitted our June 2020 quarterly report and Appendix 4C (quarterly cash flow report) to the ASX, which is read as an announcement to the market, with the following highlights:

  

  We achieved A$93,000 in net cash from operating activities and a further A$462,000 in net cash from financing activities, to achieve its best quarterly result since December 2017.

 

  Cash expenditure reduces from an average of A$1.189 million per quarter over the past three (3) quarters, to A$586,000 in the current quarter, representing a 49% decrease in spend.

 

  Cash inflows of A$1.666 million during the current quarter allow us to repay A$550,000 in borrowings, with a further A$1.34 million in convertible note debt settled (by way of a share issue).

 

  In July 2020, we received a further A$450,000 in payments from partners as well as the tranche 3 payment of US$450,000 (under the convertible note subscription deed announced with Asia Cornerstone Asset Management).

 

  We have further expected inflows of funds from Asia Cornerstone Asset Management (“ACAM”) (US$375,000), balance of license payments (A$300,000) and development payments (A$120,000).

 

  The above has been achieved despite the challenging economic conditions brought about by COVID-19, with further go-lives expected over the next quarter as we gear up for growth.

  

On October 14, 2020, we completed a A$5 million capital raise to significantly improve our balance sheet position and provide additional cash flow cover. The capital raising was undertaken with Evolution Capital (“Evolution”) as lead manager. The company raised a total of A$5,000,000 at a share price of A$1.20 per fully paid share. In addition to this the participants were granted a 1 for 2 option with a strike price of A$1.60 to acquire a further fully paid share in the company. Evolution was also granted 1,000,000 options at A$1.60 in addition to the capital raising fees of 6%.

 

Pursuant to an amendment, ACAM agreed to not take up its final tranche (US$375,000) of convertible notes and agreed that it would be subscribed for by iConcept Global Growth Fund (IGGF) and on October 16, 2020, we received the final payment from IGGF, in the amount of US$375,000.

 

As we have only just moved in revenue phase, with no prior history of recurring revenue for subscriptions, there is substantial doubt that we can rely on our revenue projections with any form of certainty. However, it should be noted that we signed an agreement with Nexus Vita Pte Ltd (“Nexus-Vita”) on 6 October 2020. Nexus-Vita agreed to guarantee us a minimum annual revenue of US$3,588,000 (on a cash basis), from the date of the commercial launch of its app (anticipated to occur by the end of June 2021). Based on our projected cash flows and excluding the Nexus-Vita transaction mentioned above, and a cash balance as of December 31, 2020 of A$4,755,563, we believe we have sufficient cash to fund our obligations for at least the next 9 months based on the Company’s current cash burn and excluding any capital raised or forecast revenue.

 

49

 

 

Notwithstanding the foregoing, we are raising up to US$ _____in this Offering. We cannot provide assurances this Offering will be completed. Should this Offering be completed, the proceeds would be used to accomplish certain tactical and strategic initiatives, including but not limited to:

 

 

additional operating expenditure, including marketing spend allocation to help partners achieve their user-based targets and to cover Offering related costs (in the absence of revenue);

 

 

investment in subsidiaries, for example, Triage Technologies, where we announced on December 3, 2020 that we had taken a strategic equity stake which will complement our current product portfolio with Triage’s Artificial Intelligence (AI) ‘health assistant technology’; and Bearn LLC, where we announced on 22 January 2021, that we had entered into a joint marketing and expansion funding agreement with one of our partners, Bearn LLC.

 

  strengthen our balance sheet and cash flow reserve position;

 

  accelerate the further development and improvement of our software;

  

  pursue growth opportunities;

 

  hire and retain qualified management and key employees;

 

  respond to competitive pressures;

 

  comply with regulatory requirements; and

 

  maintain compliance with applicable laws.

 

Notwithstanding the fact that we managed to secure US$1.5 million through ACAM as well as secure an additional A$5 million in financing during October 2020, current conditions in the capital markets are such that traditional sources of capital may not be available to us when needed or may be available only on unfavorable terms. Our ability to raise additional capital, if needed, will depend on conditions in the capital markets, economic conditions, the impact of the coronavirus outbreak and a number of other factors, many of which are outside our control, and on our financial performance. Accordingly, we cannot assure you that we will be able to successfully raise additional capital at all or on terms that are acceptable to us. If we cannot raise additional capital when needed, it may have a material adverse effect on our business, results of operations and financial condition.

   

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities could result in substantial dilution for our current shareholders. The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then-outstanding. We may issue additional shares of our Ordinary Shares or securities convertible into or exchangeable or exercisable for our Ordinary Shares in connection with hiring or retaining personnel, option or warrant exercises, future acquisitions or future placements of our securities for capital-raising or other business purposes. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our Ordinary Shares to decline and existing shareholders may not agree with our financing plans or the terms of such financings. In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition. Furthermore, any additional debt or equity financing that we may need may not be available on terms favorable to us, or at all. If we are unable to obtain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, or we may have to cease our operations, which would have a material adverse effect on our business, results of operations and financial condition. 

 

50

 

   

Off-Balance Sheet Arrangements

 

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

Functional Currency

 

From our inception through June 30, 2020, our functional currency was the AUD. 

 

Our presentation currency of the financial statements was AUD and will remain AUD.

  

Application of Critical Accounting Policies and Estimates – June 30, 2020

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with Australian Accounting Standards, which include Australian Equivalents to International Financial Reporting Standards (AIFRS), in their entirety. Compliance with AIFRS ensures that the financial report also complies with International Financial Reporting Standards (IFRS) in their entirety. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

 

While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this prospectus, we believe that the accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management’s estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time, we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

 

Critical accounting estimates and judgements

 

The preparation of financial reports requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

 

Estimation of useful life of assets:

 

We determine the estimated useful lives and related depreciation and amortization charges for its finite life intangible assets. The useful lives could change significantly as a result of technical innovation or some other event. The depreciation and amortization charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

 

Capitalization of internally developed software:

 

Distinguishing the research and development phases of a new customized software project and determining whether the recognition requirements for the capitalization of development costs are met requires judgement. After capitalization, management monitors whether the recognition requirements continue to be met and whether there are any indicators that capitalized costs may be impaired. Management is required to make judgements, estimates and assumptions for the Net Present Value model which supports the carrying value of the software, its useful life and its amortization rate.

 

Share-based Payments:

 

We measure the cost of cash-settled share-based payments at fair value using the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted, as well as estimates made by management.

 

51

 

 

Going Concern

 

These financial statements have been prepared on the going concern basis which contemplates the continuity of normal business activities and the realization of assets and discharge of liabilities in the normal course of business.

 

For the year ended June 30, 2020, we incurred an operating loss before tax of A$6,062,730.

 

Impairment of tangible and intangible assets other than goodwill

 

We assess at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, we make an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.

 

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to continuing operations are recognized in those expense categories consistent with the function of the impaired asset unless the asset is carried at revalued amount (in which case the impairment loss is treated as a revaluation decrease).

 

An assessment is also made at each reporting date as to whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognized impairment loss is reversed only if there has been a change in the estimate used to determine the assets recoverable amount since the last impairment loss was recognized. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognized for the asset in previous years. Such reversal is recognized in profit or loss unless the asset is carried at revalued amount, in which case the reversal is treated as a revaluation increase. After such reversal the depreciation charge is adjusted in future periods to allocate the assets revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.

 

Impairment of financial assets

 

We assess at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, we make an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.

 

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to continuing operations are recognized in those expense categories consistent with the function of the impaired asset unless the asset is carried at revalued amount (in which case the impairment loss is treated as a revaluation decrease).

 

52

 

 

Intangible assets

 

An intangible asset arising from externally acquired intellectual property and development expenditure on an internal project is recognized only when we can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. Following the initial recognition, the cost model is applied requiring the asset to be carried at cost less any accumulated amortization and accumulated impairment losses. The amortization method and useful life of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortization method or period.

 

The following useful life is used in the calculation of amortization:

 

Development asset at cost 10 years

 

Revenue and Other Income

 

The Company’s primary revenue stream is software development kits provided to customers by way of a license agreement (for the use Advanced human Imaging’s intellectual property). The Company generates revenue at the time its customers’ end-users subscribe to the customer’s platform to access the software, or at the point in time a scan is captured by the customer’s end-users while they are on the customer’s platform.

 

We also have secondary revenue streams including:

 

  Integration fees

 

  License fees

 

  Other application development and support fees

 

i. Identification of distinct elements and separate performance obligations

 

Primary Revenue Streams

 

Revenue is generated at the time the Company’s customers’ end-users subscribe to the customer’s platform to access the software, or at a point in time a scan is captured by the customer’s end-users while they are on the customer’s platform. Most of the Company’s contracts with its customers are structured on a monthly basis, have a minimum term of 1 year and are recognized as follows: 

 

  Per user - Revenue is charged per subscribed end-user on the customer’s platform, where per user price reduces based on the volume of users.

 

  Per scan - The customer is charged when a scan is captured.

 

We have Licensing Agreements with WellteQ, Evolt, Boditrax, MVMNT, BCT, Bearn, Active8me, Biomophik, Jayex Healthcare, Nexus Vita, Triage and the Original Fit Company. See “Major Partnerships” on page ____ for the term and scope of such agreements. 

 

Secondary revenue streams

 

These services can be provided at any point in time over the term of the contract and are usually a one-time, or a series of one-time events.

 

53

 

 

Nature of Services Provided to BCT

 

The Company’s services rendered under the joint venture agreement with BCT fall under the terms of a commercial contract for the provision of day-to-day services which are billed monthly and include:

 

A charge for rent, AWS monthly fees;
     
Back-end managed services monthly fees; and
     
Utilization of the Company’s staff for research, development and other technical work.

 

The Company recognizes revenue for above mentioned services under AASB 15 at the point in time the service is delivered to BCT under the terms of the contract.

 

ii. Revenue recognition under AASB 15

 

Revenue Stream   Performance Obligation   Timing of Recognition
Software development kits - per user   Integration of the software our development kits into the customer’s platform, a performance obligation is triggered when an end-user subscribes (to the customer’s platform).   Recognized at the time of the end-users subscription to the customer’s platform, where the end-user benefits from accessing the Company’s software (on the customer’s platform).
         
Software development kits - per scan   Integration of the software development kits into the customer’s platform, a performance obligation is triggered each time a scan is captured by the end-user.   Recognized at the point in time, a scan is captured by the end-user.
         
Secondary revenue streams   As defined in the contract either at the start of the service, or as requested by the customer over the life of the contract.   Recognized at the point in time, a service is delivered to the customer under the terms of the contract.

 

Other Income

 

Revenue recognized in any period is based on the delivery of performance obligations and an assessment of when control is transferred to the customer. Revenue is recognized either when the performance obligation has been performed, or over time as control of the performance obligation is transferred to the customer.

 

Interest Received

 

Interest income is recognized when it is probable that the economic benefits will flow to us and the amount of revenue can be reliably measured.

 

All revenue is stated net of the amount of goods and services tax. 

 

Quantitative and qualitative disclosures about market risks

 

We are exposed to market risk related to changes in interest rates and exchange rates.

 

As of December 31, 2020, we had cash and cash equivalents of AUD4.8M, primarily held in bank and savings accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected primarily by changes in the general level of Australian interest rates. The Company is exposed to interest rate risks via the cash and cash equivalents and borrowings that it holds. Interest rate risk is the risk that a financial instruments value will fluctuate as a result of changes in market interest rates.

 

We are exposed to fluctuations in foreign currencies that arise from foreign currencies held in bank accounts and the translation of results from our operations outside Australia. Our foreign exchange exposure is primarily the U.S. dollar. Foreign currency risks arising from commitments in foreign currencies are managed by holding cash in that currency. Foreign currency translation risk is not hedged.  

 

54

 

 

Material Contracts

 

Triage Technologies, Inc.

 

Under the binding term sheet, which was announced on the Australian Stock Exchange on December 3, 2020and entered into on November 27 2020, Triage will license us the Triage AI engine, and the companies will work together to integrate Triage’s technology into the CompleteScan platform, which also includes NuraLogix’ FaceScan, and our BodyScan. Our team, with its ‘on-device’ expertise, intends to advance the AI engine of Triage to be an on-device, ready-to-use application for Users.

 

On March 31, 2021, we reached an agreement to invest US$6 million in Triage Technologies, Inc. over a 14-month period, subject to shareholder approval (US$3 million in cash and US$3 million in our Ordinary Shares), as part of a strategic plan to expand our service offering by DermaScan.

 

All documentation for the transaction has been concluded, including, the technology distribution license, shareholder agreements and subscription agreements. The completion of these agreements was announced to the ASX on April 19, 2021.

 

Body Composition Technologies Pte Ltd

 

Body Composition Technologies Pte Ltd (BCT), is a majority owned joint venture between AHI and Gold Quay Capital formed in 2017. Under the terms of the agreement, BCT is licensed to distribute the AHI technology to the Medical and Insurance sectors.  AHI is the majority shareholder of BCT with 54% ownership of the capital stock. Gold Quay Capital paid AHI A$2,000,000 for the distribution rights and licensing of the AHI technology.  BCT has spent A$6,000,000 to date on developing the business segment and research and development required and used to expand the technology into the segment. 

 

ACAM

 

The Company issued a convertible note in favor of ACAM on June 1, 2020 and is convertible into our Ordinary Shares at a conversion price at the greater of US$1.00 per share and a 25% discount to the price at which the Company issues shares in conjunction with a NASDAQ listing. If the Company does not attain a NASDAQ listing prior to June 30, 2021, the note will mature on December 30, 2021. The note accrues interest at a rate of 10% per annum and is mandatorily convertible upon a NASDAQ listing.

 

Tinjoy Marketing Agreement

 

On April 24, 2021, the Company entered into a marketing agreement with China-Based, Tinjoy Biotech Limited (“Tinjoy”) (the “Tinjoy Agreement”), in preparation for the CompleteScan integrated launch of Tinjoy owned WinScan Application. Under the terms of the Agreement, the Company and Tinjoy will be involved in several marketing initiatives for the launch of the WinScan Application, which will feature both BodyScan and FaceScan, in July 2021, which has been subsequently delayed until August 2021. Pursuant to the Tinjoy Agreement, the Company will fund up to US$200,000 in three separate tranches; US$50,000 on May 3, 2021, US$50,000 on June 3, 2021, and US$100,000 on July 1, 2021 (each a “Tinjoy Tranche”). The payment of each Tinjoy Tranche is subject to Tinjoy completing certain marketing initiatives in connection with the launch of the WinScan Application, including employment of a dedicated marketing resource, further training of the call centre marketers, application translation and mandarin marketing materials for distribution at pharmacy and direct to consumer point of sale.

 

Physimax Acquisition Agreement   

 

On April 28, 2021, the Company entered a Binding Heads of Agreement (“HOA”) with Israeli based Musculoskeletal Assessment company Physimax Technologies Limited (“Physimax”) for the Company to acquire 100% of the interests in Physimax in consideration of US$6,000,000, to be satisfied by the issue US$6,000,000 worth of the Company’s Ordinary Shares (the “Physimax Agreement”). Under the HOA, the Company is still to conclude due diligence to the Company’s satisfaction on or before May 21 2021 (the “Condition”). Physimax has developed and patented a revolutionary video-based objective solution that tracks and improves MSK wellness and performance by objective, data-driven analysis of musculoskeletal condition via video capture using a mobile device. Under the Physimax Agreement, the Company has agreed to issue up to a further US$2,000,000 in the form of the Company’s ordinary shares to key employees of Physimax on terms to be agreed. The Physimax Agreement can be terminated by either party to the Physimax Agreement if the Condition is not satisfied by June 30, 2021. The Physimax Agreement contains certain warranties, indemnities and limitations of liability by both parties. On July 6, 2021, the Company announced it completed its due diligence on Physimax’s musculoskeletal assessment technology and is satisfied that the technology is a viable addition to the suite of scanning capabilities being integrated and advanced by the Company. The parties are now in the process of updating the binding acquisition agreement for the acquisition of Physimax at substantially reduced cost. The Company does not believe that the contemplated acquisition would be a significant transaction pursuant to Rule 3-05 of Regulation S-X.

 

Bearn Agreement

 

On Friday, January 22, 2021, the Company entered a Joint Marketing Agreement (the “Bearn Agreement”) with Bearn LLC (“Bearn”). Pursuant to the Bearn Agreement, the Company will fund a total of US$500,000 to Bearn over 4 tranches, with an initial US$200,000 paid for the platform scale to be implemented, followed by 3 x US$100,000 payments for the direct onboarding campaign. The loan is secured over Bearn’s software and separately a pledge over the membership interests of Bearn’s founder, Mr. Aaron Drew. Under the terms of the agreements, Bearn has undertaken to use the funds advanced by the Company to deliver 1,000,000 active monthly users to the Company within 12 months. If Bearn fails to achieve this target, the loan and interest becomes repayable in 15 months from the date of the promissory note. If Bearn achieves this target, the repayment date will be extended for a further 12 months. The Bearn Agreement contains certain warranties, indemnities and limitations of liability by both parties.

 

55

 

 

BUSINESS

 

Overview

 

We have developed and patented a proprietary measurement/dimensioning technology that enables a User to check, track, and accurately assess their body dimensions privately using only a smartphone. We refer to this physical measurement and analytics tool as “BodyScan.” We have global customers/partners (“Partners”) who utilize our technology through our proprietary Software Development Kits (“SDKs”). Our global Partners have substantial audiences that they address, and from those underlying audiences, individual User (“User(s)”) will sign up for, or be given access to, the Partners’ software programs/apps that embed our technology components. Our global Partners currently include companies within the following sectors: (i) mobile health (“mHealth”), Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel.

 

Our patented technology allows our Partners to supply to individual Users, via our automated technology, the ability to take a series of images of themselves using a smartphone, which delivers accurate and repeatable measurements across an individual’s entire body. These measurements allow the individual to understand his/her dimensions and the physical changes that they are undergoing through diet, exercise and lifestyle modification. Further, the images that we capture also provide the individuals with an understanding of their potential health risks related to certain chronic diseases (including obesity and diabetes) and using the global standards measurements set by the World Health Organization (WHO), and the International Diabetes Federation (IDF). Once the image capture sequence is completed, it supplies those measurements to the Partner’s application, whose contract with the User then determines the manner in which it analyzes/reports the data and/or the potential health risk to the User. We are working towards globalizing our technology in order to assist individuals, communities and populations live healthier lives.

 

 

 

The above images illustrate the BodyScan capture process.

 

Recent technology advances have provided opportunities for complex mathematical problems to be solved directly on a User’s smartphone, rather than limiting that computation to the Cloud. Modern devices produced by companies such as Apple, Samsung and Google now have AI-focused chipsets utilizing platforms such as CoreML and Tensorflow to process data at lightning speeds. We see the opportunity to harness these ongoing technology improvements to lower latency, increase security and privacy, improve reliability and reduce operational costs of our core services. Our overarching technology strategy has been to take advantage of this hardware-accelerated performance, specifically by utilizing on-device general purpose Graphic Processing Units (“GPU”) found on today’s modern devices. 

 

In Cloud-based systems, data transfer/retention is a potential impediment. Data must be sent to, and then processed in, the Cloud, thus adding additional latency and disclosure risk to the overall process. On-device computing eliminates the necessity of a roundtrip to the Cloud and permits near zero-latency. This process greatly improves User experience and allows for near real-time interaction with the service.  Running directly on-device additionally negates the side-effects of Cloud-based interference. In areas where connectivity is sub-optimal, such as rural areas, having analytic models on-device means that processing results can be generated locally, quickly and securely.

 

56

 

 

As sensitive data does not need to be sent or maintained in the Cloud, there are fewer opportunities to exploit any potential vulnerabilities, thereby providing increased security and privacy for Users. This security is critically important in a world where data sovereignty, residency, and retention are a major concern for Users and under increased protective global legislation. 

 

By focusing on leveraging the estimated 3.7 billion  devices  capable of running AI inference and analysis on-device, we are able to slash the costs associated with Cloud-based analytics and inference, bandwidth and retention/storage concerns. As our user base scales, implementing machine learning on-device will mitigate the expense of expertise and time needed to implement and maintain a Cloud-based solution.

 

We deliver a non-invasive, highly accurate and privacy-sensitive healthcare and biometric solutions that generate results to the User  within seconds. We leverage machine-learning and computer vision to analyze images, detect pose and joint features, and create non-personally identified data for measurement estimation. We further take advantage of dedicated GPU libraries such as TensorFlow Lite (Android) and Metal (Apple) to run prediction models, which have been trained with a substantial and diverse human data set from around the globe and which are able to process multiple captured images in fractions of a second. The result is a solution that runs on-device and does not sacrifice speed, security or privacy. Images and private information never leave the phone, ensuring security and privacy standards are met across global regions. This process allows us to produce what we believe to be exceptional results and simplify the output of useful, reliable, digital measurements and remove the human error otherwise present in traditional methods, such as tape measure or visual estimations.

 

Our BodyScan application has been developed over 7 years through the development of our proprietary image capturing and analysis system. We have refined this process utilizing a proprietary data collection exercise conducted by the company, which involved over 7,000 individuals across Australia, Taipei, Thailand and Malaysia. This multinational data set of ethnicities was used to train and to enrich our machine-learning protocols and to improve the accuracy and repeatability of the BodyScan system. We have further enhanced the use case by adopting a number of predetermined and published markers for some chronic diseases, set by the WHO, and the IDF. According to the WHO, these chronic, non-communicable diseases relate to 71% of deaths each year. We have developed and built the application’s patented capturing system, in line with the WHO and IDF measurement guidelines for the assessment and identification of biomarkers of these chronic diseases, such as Type 2 Diabetes. Whether it be an iOS or an Android application on the smartphone of any user, we provide our Partners and their Users with the following biometric data points:

 

  Anthropometric Measurements (BodyScan);

 

  Body Composition: Total Body Fat %, (BodyScan);
     
  Primary Markers of Chronic disease – Type-2 Diabetes, Obesity, Cardiovascular Disease (CVD) (BodyScan and FaceScan combined); and

 

 

Primary Health Markers – Waist-to-Hip Ratio, Waist-to-Height, Waist Circumference, (BodyScan).

 

Dermatological conditions – 588 skin conditions across 133 categories, (DermaScan)

 

It is our mission to deliver an easy-to-use, early warning and health assessment tool for our Partners to supply to individuals, governments and healthcare organizations, enabling Users to take control of and to understand the health risks which they pose to themselves, which they may be unaware of. Having the opportunity to combine measurement data with other biometric data sets widens the utility and importance of our technology through multiple business segments.

 

57

 

 

We believe that our technology is unique and has been independently validated for accuracy and repeatability by doctors and professors from leading universities and research organizations around the world, including  Professor Timothy Ackland PhD, Professor of Applied Anatomy and Biomechanics, The University of Western Australia, Dr. Erwin Christianto MD MSc, Physician & Clinical Nutrition Specialist, Eka Hospital Pekanbaru Indonesia, and Dr. Alisa Nana PHD, Sports Science and Technology Mahidol University Thailand.

 

With the increased requirement of medical surveillance and remote healthcare services due to the COVID pandemic, we have strategically partnered and invested into the expansion of our information capturing capabilities with the addition of vital signs data (FaceScan) using transdermal optical imaging (TOI) and also a further expansion into a dermatology AI platform which provides information to identify and assess 588 known skin conditions across 133 categories (DermaScan). DermaScan is a software application using artificial intelligence to perform patient-specific analyses of skin conditions. DermaScan is intended to be used as a second opinion tool for healthcare professionals to support the diagnosis of skin conditions but does not provide a definitive diagnosis. A definitive diagnosis should only be performed in a healthcare professional’s environment with the patient present. User error can potentially lead to limitations of the product as DermaScan requires good quality images of the skin condition the user is analyzing as well as a series of questions to be answered specific to the user and the skin condition in question. It is important the user provides images of good quality and accurately provides information as prompted to do so. Accuracy of services will vary depending on the quality of image presented as well as the quality of this information provided.

 

Business Model

 

We operate a business-to-business (“B2B”) model and revenue is generated on both a subscription basis as well as on demand-use basis. The overall mercantile business model is one-to-one-to-many, whereby our sales channel customers are business Partners who have the relationship with the end User and whereby our technology is embedded into our Partner’s application that is made available to the Users on terms set by those two parties, thereby allowing User privacy [data on the User smartphone] and agreed data retention in the Partner’s ecosystem. We believe this B2B model enables lower overhead and allows AHI to leverage our Partners’ sales forces in an efficient and economical way. Our go-to-market strategy makes our business model highly scalable without the need for large corporate overhead, which cost-saving element will help to facilitate better operating margins as we increase the number of our Partners and as they scale the number of their Users. We have a pricing model which can be adjusted downward depending on scale (User volume) undertaken by the Partner.

 

Our technology has been both designed and developed to augment Partner applications via individual Software Development Kits (“SDKs”), enabling rapid integration opportunities for both native and hybrid solutions. Through the licensing of the use of our technology, Partners have the ability to effortlessly select the appropriate SDK components and then to customize these solutions to fit their own brands and needs.  The Partner’s public cloud provider manages all of our Partners’ hardware and traditional software, including middleware, application software, and security. Accordingly, our offering allows flexibility and pricing scale reductions for our Partners as their User scale increases. AHI works with its Partners on the contractual remuneration and service basis involving a per-use, annual subscription or license fees. This choice is determined with the Partner at the time of engagement depending on the use case and User volume provided by the Partner.

 

We are selective in our choice of sales channel Partner, favoring companies who have a global outreach with large pre-existing User bases. When identifying a potential Partner, we take into account the current digital environment developed by the Partner and its applicability to the SDK offering we have developed. We also consider other factors such as available user base, market reach and time-to-market with the Partner’s digital team.

 

MultiScan Platform Capability

 

AHI offers a growing suite of human scanning solutions using a smartphone. This MultiScan Platform, called CompleteScan, currently includes BodyScanFaceScan, and DermaScan.

 

Our MultiScan SDKs are embedded inside a Partner’s smartphone application(s) on both iOS and Android platforms to facilitate this multi-scan approach.

 

The MultiScan SDKs simplify many actions: User authorization, registering billing events, downloading remote assets, starting a new scan, returning results, and payment registration, all from a single interface/abstraction layer. These functions ensure that scans are easily integrated and correctly billed based on contractual agreements.

 

58

 

 

 


 

The above guide images various screens of the Multi-Scan suite.

 

Key MultiScan Technology Components

 

BodyScan, supplied via our patented technology, provides body circumference, body composition (total body fat %), and specific health indicators relating to (including Type-2 Diabetes risk, as well as obesity and central obesity risk) which have a direct correlation to the chronic diseases we wish to assist our partners in managing.

 

FaceScan, supplied by a license with NuraLogix Corporation (“NuraLogix”), provides vital signs data, including blood pressure and heart rate, as well as health indicators, including cardiovascular disease risk, heart attack risk, and stroke risk. We have a technology use agreement and a reseller agreement with NuraLogix for the sale and distribution of our combined offering. 

 

  DermaScan, supplied by a license with Triage Technologies Inc (“Triage”), provides skin disease detection for over 588 skin conditions across 133 major categories. Triage’s software application was approved as a class I medical device by Health Canada in June 2020. In April 2021, Triage received confirmation of medical device status in the European Union (EU) and is a CE marked medical device according to the Medical Devices Directive 93/42/EEC.  Triage expects to seek FDA approval for its software application in the future. When combined into the CompleteScan platform, the AI dermatology engine of Triage will be branded DermaScan and can be deployed to mobile devices to scan skin surface and then to assess the relevant skin conditions with simple images taken with that smartphone application.  DermaScan is a software application using artificial intelligence to perform patient-specific analyses of skin conditions. DermaScan is intended to be used as a second opinion tool for healthcare professionals to support the diagnosis  of skin conditions but does not provide a definitive diagnosis. A definitive diagnosis should only be performed in a healthcare professional’s environment with the patient present. User error can potentially lead to limitations of the product as DermaScan requires good quality images of the skin condition the user is analyzing as well as a series of questions to be answered specific to the user and the skin condition in question. It is important the user provides images of good quality and accurately provides information as prompted to do so. Accuracy of services will vary depending on the quality of image presented as well as the quality of this information provided.

 

Patented Technology

 

Our patented technology is the on-device image capture and data processing capability of BodyScan and each of our technology providers has its own set of patents 

 

Significant research and development (“R&D”) efforts by AHI have gone into optimizing, testing, and developing proprietary technology to work within smartphones’ confines. This R&D includes analyzing and processing phone sensor data, downloading assets remotely to reduce the initial resource size, utilizing hardware acceleration, and implementing machine learning libraries, such as TensorFlow and CoreML. 

 

The result is software that runs on the device without sacrificing speed, security, or privacy. Images and private information do not leave the device without explicit consent from the User to the primary app provider, ensuring global security and privacy concerns are met.

 

Data Points, Health Risks, and Health Indicators

 

Each scan returns a unique set of data which is categorized into three layers based on the type of data.

 

Layer 1 – Individual Data Points

 

These are the direct outputs from a scan, such as body circumference, diastolic and systolic blood pressure, and heart rate. 

 

59

 

 

Layer 2 – Derived Data

 

Derived Data is a formula or equation applied to one or more data points. These are labeled “Health Indicators” and include waist-hip ratio, waist-height ratio, and a combined systolic/diastolic blood pressure result.

 

Layer 3 – Contextual Data

 

Contextual Data combines individual data points and derived data with a publicly available dataset or study used to predict health risk categorization. Examples include Type-2 Diabetes, Obesity, Hypertension, and Cardiovascular Disease.

 

As part of the partner integration progress, a data review is conducted to determine what scans and data are required. Documentation is provided to partners throughout this process to explain key concepts, including validation of measurements, disclaimers, research and studies, and understanding risk categorization.

 

It is important to note that the various scans offered within the MultiScan platform are not offered as a medical device nor as a pure diagnostic; moreover the image and data captures supply individualized data to the Partner in regard to their Users. Depending on the manner in which the Partner utilizes this data for health risk assessment will determine the Partner’s requirement to meet regulatory approvals in their operating jurisdictions.

 

How BodyScan Works

 

BodyScan’s image capture involves taking multiple front and side images of the individual. This process involves entering some basic personal details, such as height, weight, and gender, following a built-in guide provided upon setting up the phone, and then initiating a 10-second countdown for both the front and the side images. Images are processed on the phone and deleted upon the conclusion of the session.

 

This process is referred to as a “BodyScan” or a “Full Body Selfie”. The capture process utilizes “burst mode” or continuous shooting capabilities available in most cameras, and smartphones take multiple images using a timer.

 

FaceScan - NuraLogix facial scanning integration

 

The company has a non-exclusive license to embed and to distribute the NuraLogix transdermal optical imaging (TOITM ) capabilities, which has been re-branded within the MultiScan platform as FaceScan. According to NuraLogix, it has developed patented technology which utilizes the visual capturing capability of a smartphone, to take a 30 second video of a person’s face to determine a wide range of physiological and health related parameters such as: heart rate, heart rate variability, blood pressure, stress, cardiovascular disease risks and much more. The underlying TOI technology uses the camera on a smartphone to extract blood flow information from the translucent skin of a person’s face. This information is then processed by advanced machine learning algorithms residing on NuraLogix’s Cloud-based Affective AI (Artificial Intelligence) Engine called DeepAffex™.

 

Our BodyScan image dimensioning capabilities have been combined with DeepAffex and TOI to provide a total health screen from a smartphone. The combined digital capabilities of the two companies provides a health screen that can be used regardless of the User’s age. The non-invasive, combined solution delivers a far greater suite of risk identification than the User would obtain as individual offerings, and all of this information is processed with complete privacy to the User, culminating in that individual being given information and/or assessments on multiple levels: blood pressure, stress levels, heart rate, heart rate variability, irregular heartbeat, respiratory rates, total body fat, waist to height ratio, waist to hip ratio, cardiovascular disease risk, type 2 diabetes risk, stroke risk, obesity/central obesity risk, and metabolic syndrome risk.

 

The resulting data provides the individual User with the opportunity to understand their personal exposure to these diseases that cause up to 71% of deaths globally each year, not including the current pandemic.

 

60

 

 

Our team, with its ‘on-device’ expertise, intends to advance the AI engine of NuraLogix to be an on-device, ready-to-use application for Users

 

DermaScan - Triage dermatology scan integration and AHI investment

 

The company has a non-exclusive license to embed and to distribute the Triage AI-assisted capabilities, which have been re-branded as DermaScan. Triage has developed an advanced dermatological AI system which can accurately identify skin conditions from a photo in seconds. Triage received a U.S. patent for its system in December 2020, with further jurisdictions anticipated to follow.

 

The Triage AI engine identifies 588 skin conditions in 133 major categories. Importantly, the application can identify all categories of skin cancers. Those 133 categories of skin conditions cover 99% of the global dermatological conditions market, and have been built and validated in consultation with leading academic institutions and dermatologists around the world, including Dr. Lisa Kellett (DLK on Avenue, Canada), Dr. Sandy Skotnicki (University of Toronto, Canada), and Dr. Adam Mamelak (Sanova Dermatology, United States). Triage was approved as a class I medical device by Health Canada in June 2020. In April 2021, Triage received confirmation of medical device status in the European Union (EU) and is a CE marked medical device according to the Medical Devices Directive 93/42/EEC. It is intended to support patients in the early detection as well as monitoring of skin conditions. DermaScan is intended to be used as a second opinion tool for healthcare professionals to support the diagnosis of skin conditions but does not provide a definitive diagnosis. A definitive diagnosis should only be performed in a healthcare professional’s environment with the patient present.

 

Under the binding Term Sheet, which was announced on the Australian Stock Exchange on October 8, 2020, Triage will license us the Triage AI engine, and the companies will work together to integrate Triage’s technology into the CompleteScan platform, which also includes NuraLogix’ FaceScan, and our BodyScan. Our team, with its ‘on-device’ expertise, intends to advance the AI engine of Triage to be an on-device, ready-to-use application for Users.

 

Triage Agreement

 

On December 3, 2020, we reached an agreement to make a strategic technology investment of US$6 million in Triage over a 14-month period, subject to shareholder approval, (US$3 million in cash and US$3 million in our Ordinary Shares), as part of a strategic plan to expand our service offering. Under the terms of a binding terms sheet, all formal documentation for the transaction have been concluded, including, the technology distribution license, shareholder agreements and subscription agreements. The completion of these agreements were announced to the ASX on April 19, 2021.

 

Application of Our MultiScan Platform Technology to Multiple Business Segments

 

We have developed a MultiScan product strategy called CompleteScan comprised of: BodyScanFaceScan, and DermaScan, which unlocks a multitude of biometric markers and risk indicators that enables us to generate new layers of data, and cover a full spectrum of indicators for care including, but not limited to, cardiovascular, dermatological and chronic disease identification and prevention. We have designed this multiplatform with flexibility at its core, enabling each type of scan to be implemented either separately or in combination, depending on the partner’s and the user’s specific requirements. We believe that, due to our diverse and expansive offering, the company does not suffer from seasonality in regard to its use or appeal.

 

Examples of partner-specific requirements by business segment are below:

 

mHealth, Telehealth and Wellness:

 

Capture patient/User body composition for risks and primary health markers including: Type-2 Diabetes Risk, Obesity / Central Obesity Risk, Metabolic Syndrome Risk, Cardiovascular Disease Risk, Heart Attack Risk, and Stroke Risk either directly with a care provider or via Telehealth calls. 

 

Capturing and tracking of obesity and patient body compositional changes, including waist circumference, waist-to-hip ratio, and total body fat changes in order to improve obesity medication adherence and engagement by enabling obesity patients to visualize the User’s body dimensional changes in real-time, in conjunction with medication, and from the privacy of their own homes.

 

61

 

 

Tracking patient/User risk analysis of their susceptibilities to COVID-19 comorbidities from their smart-phone.

 

Partner providing a patient/User with insights and virtual telehealth options where biometric markers indicate lower risk, thereby saving money for both the patients/Users and for payors, as well as helping to reduce hospital readmissions and ER visits. 

 

Capture biometric markers of clinical trial participants in real time using their smartphones, from the privacy of their own home or elsewhere, saving time for organizers and participants, and costs for trials as equipment and staff costs are reduced.

 

Track employee risk of primary health markers from pre-medical visit and throughout their medical journey. When employee results indicate potential risks, targeted intervention programs can then be provided that are unique to the employee.

 

Combine our body composition and biometric information with existing wearable and mobile technology to enable real time monitoring of personal risk factors and generate an interception before an accident/incident occurs, customer satisfaction declines, or an employee leaves an employer. For example, through regular FaceScans and BodyScans, the process can assist in identifying people at risk and assist them with targeted interventions to reduce their risk of musculoskeletal disorders, mental health issues, as well as accidents and incidents.

 

Offer health promotions and challenges specific to employee body composition, biometric information and health / fitness / wellness goals.

 

It is important to note that mHealth is primarily an on-device screening tool that can demonstrate that there is a risk related to various health conditions. It is not a diagnostic tool and while helpful in identifying markers of various indications, it may not identify markers associated with other conditions. Accordingly, other health related issues may still persist if not identified by mHealth.  

 

 Life/Health Insurance:

 

Capture a potential policyholder’s primary health biomarkers including: type-2 diabetes, obesity / central obesity risk, metabolic syndrome risk, cardiovascular disease risk, heart attack risk, and stroke risk from their smartphone for underwriting processes. 

 

Identify at-risk insureds for whom partners can provide targeted interventions in order to lower their risks, enabling them to live longer/better, and to decrease their claim payouts from such risks.

 

Offering health promotions and challenges specific to policyholders, based on body composition, biometric information and health/fitness/wellness goals.

 

Provide the required data to underwrite a new or existing policy with the appropriate cover in accordance to individual health at the point of assessment.

 

Remove the risk associated with inaccurate or untimely self-reported data and thereafter adjust policy cover risk.

 

Underwrite dynamically with direct health information via the capture suite provided through a partner application.

 

Fitness:

 

Tracking User body composition and dimensional changes in line with nutrition and fitness programs in real-time, remotely from a smartphone anywhere in the world.

 

62

 

 

Directing new fitness program customers to specific Partner programs based on the User’s unique body composition / health goals, integrated with our on-device BodyScan app, unlocking a new level of User customization and options through real-time data sharing. Understanding an individual’s current biometrics remotely never before been available with such a broad offering. This personalized information is vital in the customer journey both for the training of the individual as well as for the trainer or program supplier. Real-time access to change and results allows the trainers or program suppliers to make informed decisions on what is needed to maintain positive outcomes for the User.

 

Utilize FaceScan’s vital signs before, during and after workouts to gauge physical intensity without the need for the User to purchase an additional device.  

 

Tracking User body composition in preparation for personal health goals / competition / tournament / event in which this data plays a key role in improving the outcome.

 

Combine body composition with other data sets for new insights; for example, provide aspiring athletes with the ability to understand what the dimensions / body fat measurements are for a particular sport unique to their own body and provide training programs to help them to attain those metrics.

 

As part of health checks, provide teams with the ability to understand the key health risks of their players, including risk of CVD, heart attack, stroke, obesity, T2D, and metabolic syndrome.

 

The ability to track dimension and composition change is at the core of the fitness industry and serves the primary driver of vanity and change that invokes the expenditure of over a trillion dollars a year into the weight loss and fitness industry.

 

Consumer Product and Apparel:

 

Enable Users to capture a BodyScan from the privacy of their own home for accurate, right-fit sizing of apparel at e-commerce and retail check-out, reducing time to purchase and the cost of later returns.

 

Sizing of uniform requirements for employees and service personnel from a smartphone, anywhere in the world.

 

Enable B2B Partners to reduce the environmental impact of four billion pounds of wrong size returns ending up in landfill each year by providing their customers with the right garment fit on every purchase.

 

Increases retention and customer loyalty through better engagement and purchase personalization specific to a User’s individual dimensions and fit preferences.

 

Market Opportunities by Business Segment

 

mHealth, Telehealth, and Wellness

 

Digital technologies are becoming an essential resource for remote medicine and personalized care for individuals and groups. mHealth, Telehealth, and Wellness is a large market with a reliance on the innovative technology present in smartphones becoming cheaper and more accessible to a global audience. Global companies such as Facebook, Amazon, Google, Samsung and Apple have invested heavily into their own healthcare service efforts, in addition to those from hospitals and universities. We see this business segment as pivotal given the increasing global proliferation of smartphones and the collection of data that can be linked to digital health records. Further, this field has been demonstrated across the global markets with the heavy investment currently made into the sector looking to enhance and acquire technologies which deliver these capabilities.

 

Telemedicine is at the forefront of innovation in this business segment, and, as a result, is redefining how the smartphone is used for remote medical consultation. For example, our CompleteScan solution provides our Partners with datasets to identify vital signs, medical conditions and/or to predict the early onset of chronic diseases. Our technology may help employers protect and engage their employees, which can result in improved employee retention, less sick leave, and increased ROI. Remote preventative wellness and health monitoring plans can also be enacted.

 

63

 

 

Our products have been designed with the needs of care providers globally, who are looking for ways to remotely monitor and to assess their patients. Our technology sits at the forefront of these capabilities, and uniquely augments partner offerings, rather than compete with them, with required data features not available from any one application at this time. AHI has augmented the approach to the needs of the medical and care provider networks, by bringing the accuracy of the BodyScan together with the FaceScan. This product slate is a unique offering and a single point of data convergence across predetermined health markers using body measurements and body composition, which further enhance vital signs via the facial scan capturing sequence. This information is all captured and delivered to Users privately and accurately via their smartphone.

 

Current Partners in the mHealth segment include: Bearn, Active8me, MyDoc, WellteQ, The Care Voice, Jayex, Biomorphik, Nexus-Vita, NuraLogix, Tinjoy and Triage.

 

As aforementioned, mHealth is primarily an on-device screening tool that can demonstrate that there is a risk related various health conditions. It is not a diagnostic tool and while helpful in identifying markers of various indications, it may not identify markers associated with other conditions. Accordingly, other health related issues may still persist if not identified by mHealth.  

 

Life and Health Insurance

 

Predictive health outcomes and dynamic insurance policy underwriting create major risks for insurers. This situation is further exacerbated by a large and prevalent obesity issue that can be inaccurate or under-reported. According to Insurance Journal, it is estimated that premiums underwritten by AI support systems will exceed US$20 billion by 2024.

 

Our technology allows for the upfront assessment and early identification of chronic disease markers, along with a more comprehensive view of the individual for insurers. This information enables insurers to remove misclassification of health risk from legacy BMI-dependent systems. We have also developed and grown an extensive human database across multiple continents to build our diverse, multi-ethnic computations. This work is now leading to commercial releases and expansion of our technology globally.

 

Current Partners in the Life and Health Insurance segment include: Body Composition Technologies, The Care Voice, MyDoc, NuraLogix, and Nexus-Vita.

 

Fitness

 

According to a Global Wellness Institute report, fitness represents a USD828B (and growing) sector of the economy across global physical activity, equipment sales, and technology, which thrives on innovation.

 

Our BodyScan can reliably and accurately measures the User’s body using a smartphone, thereby offering a gateway into a consumer’s home and personal health. Consumers, technology partners, personal trainers, fitness platforms and outlets are now able to track changes across their consumers’ physiques. This data is ideal for use during the critical path an individual undertakes when trying to improve or monitor their fitness. The ability to collect and accurately track measurement data has long been a function of a weight scale or an appraisal by a fitness professional. The ability to check, monitor and track personal dimensions via a mobile phone is convenient, cost effective and now accurate. Our technology allows all Users this convenience from the palm of their hand.

 

We further enhance this data by unlocking new biometric layers and primary markers of chronic disease, such as obesity and type-2 Diabetes, using WHO and IDF guidelines for waist-to-hip ratio, waist-to-height ratio, Total Body Fat, lean mass, in real-time to track an individual’s changes.

 

64

 

 

Our data is able to converge into existing product offerings for both in-facility and for remote programs, supporting e-coaching, weight loss and nutritional plans. These platforms then use this data to create enhanced engagement with the User by understanding activity versus outcome. This connection leads to better outcomes and retention for our partners.

 

Current Partners in the fitness segment include but are not limited to: McGregor FAST, Fitocracy, MVMNT, Evolt360, Bearn, Active8me, and Biomorphik.

 

Consumer and Apparel

 

Consumer attitudes have changed with regards to purchasing clothing online; however, problems remain. Wrong-size and wrong-fit returns represent a large cost to both manufacturers and retailers. This outcome leads to discarded clothing, which often ends up in landfill, thereby escalating delivery costs, and reducing brand loyalty.

 

Our technology accurately measures a person, not only for online purchasing of clothing, but also for in-store purchases, and provides a personal shopping experience for shoppers from their smartphone. Size and fit are defined for a given user on an individual basis. We extend these definitions to the individual garment, and customize the measurement sequence to the brand without the need to look-up and compare capability-sizing charts. This process reduces the time it takes a shopper to purchase clothing that fits, and consequently increases customer confidence in the retailer and brand.

 

When utilizing the technology, custom apparel clothing lines can be created which are unique to the individual and their style. This provides differentiation from competitors in the saturated fashion market, which we believe can benefit from new sales, increased loyalty, and reduced return costs. We believe that the use of BodyScan technology has the ability to reduce return rates suffered by the apparel industry, which will also save the transport and logistic cost of returns. It assists the manufacturers in better understanding production quantities required, as they do not have to over-order to compensate for the returns otherwise expected.

 

The ability to measure and to size accurately has been long sought by the fashion industry. Our solution provides apparel consumers with an easy-to-use image capturing process for accurate assessment of their measurements when purchasing apparel.

 

Major Partnership Agreements

 

Evolt Agreement

 

On October 29, 2019, we entered into an agreement (the “Evolt Agreement”) with Evolt IOH PTY Ltd. (“Evolt”), whereby we license our cloud-based anthropometric measurement Platform and SDKs to Evolt. Evolt is the owner of the Evolt Active App, Evolt owns a proprietary device / machine-based intelligent body scanning scale technology with over 500,000 active Users (the “Evolt App”). The initial term of the Evolt Agreement ran for 12 months, and auto-renews at the end of each 12 months from the anniversary of the commencement date, beginning on October 29, 2019, unless either party provides at least 90 days written notice to the other party prior to the expiry of the initial term, or if after the initial term, 90 days after the notice of termination is received. This agreement includes fees consisting of the User Fees, Monitoring Fees, Data Storage Fees, Support Fees and Additional Fees (each as defined in the Evolt Agreement). With an initial user target of 100,000 Users in the first 12 months from launch. The Company has begun to generate revenue from this the Evolt Agreement. Due to COVID restrictions and a lack of ability to engage appropriately throughout 2020 with in and onsite facilities, the parties agreed to the automatic extension of 1 year, allowing Evolt further time to advance marketing and User engagement.

 

Bearn Agreement

 

On April 5, 2020, we entered into an agreement (the “Bearn Agreement”) with Bearn LLC (“Bearn”) whereby we granted Bearn license to our proprietary SDK and access to our BodyScan Platform, with Bearn to integrate our Platform into its own app. The initial term of the Bearn Agreement was 12 months, and it will auto renew for a further 12 months unless either party provides at least 90 days written notice to the other party prior to the expiry of the current term. This agreement includes fees consisting of Per Scan Fees (number of body scans captured multiplied by US$2.00), Data Storage Fees, Support Fees, Incident Support Fees, Measurement Support Fees and Additional Fees (each as defined in the Bearn Agreement). The Company has begun to generate revenue from the Bearn Agreement. 

 

On January 22, 2021 we entered into a subsequent agreement with Bearn LLC, in which we provided a funding arrangement of US$500,000 to assist Bearn in the expansion and marketing of the Bearn Platform. Under the subsequent agreement, Bearn has undertaken to repay the funds within 12 months and also to deliver Advanced Human Imaging 1,000,000 active monthly Users. The funding is secured by the majority holding of Bearn and its technology.

 

65

 

 

Biomorphik Agreement

 

On September 15, 2020, we entered into an agreement with Biomorphik PTY Ltd. (“Biomorphik”) whereby we are granted license to our proprietary SDK and access to our cloud-based anthropometric measurement Platform to Biomorphik. The initial term of the Biomorphik Agreement is 24 months, and it will auto renew for a further 24 months unless either party provides at least 90 days written notice to the other party prior to the expiry of the current term. This agreement includes fees consisting of the User Fees, Monitoring Fees, Data Storage Fees, Support Fees and Additional Fees (each as defined in the Biomorphik Agreement). The Company has begun to generate revenue from this Contract.

 

Active8me Agreement

 

On April 24, 2020, we entered into an agreement (the “Active8me Agreement”) and it will auto renew for a further 12 months unless either party provides at least 90 days written notice to the other party prior to the expiry of the current term. This agreement includes with Active8me Pte Ltd. (“Active8me”) whereby we granted Active8me a license to use our SDKs and Platform. The initial term of the Active8me Agreement is 12 months (the “Active8me Initial Term”), with fees consisting of the User Fees, Per Scan Fees Data Storage Fees, Support Fees, Incident Support Fees and Additional Fees. The Company has not yet begun to generate revenue from the Active8me Agreement.

 

Jayex Healthcare Ltd. Term Sheet

 

On September 28, 2020, we entered into a binding term sheet with NuraLogix and Jayex Healthcare Ltd. (“Jayex”), an Australian technology and services company aimed at bringing choice, convenience and efficiency to healthcare professionals, patients and consumers (the “Jayex Term Sheet”).  Under the Jayex Term Sheet, the parties agreed to collaborate and work together to design, develop and integrate the CompleteScan Platform into Jayex’s existing platform. As stated on the Jayex website, the company currently has over 50,000,000  patient interactions a year across 6,500 healthcare organizations and providers. The Company has not yet begun to generate revenue from this arrangement and no definitive agreement with Jayex has been finalized as of the date of filing.

 

Nexus Vita Term Sheet

 

On September 28, 2020, we entered into a binding term sheet with NuraLogix Corporation and Nexus Vita Pte Ltd., a centralized intervention, medical and health data center in Singapore. Following the completion of product integration, Nexus agreed to promote the CompleteHealth Platform to existing and new platform partners and has guaranteed a minimum user number of 100,000 active Users per month within the first 12 months from commercial launch. Nexus will pay us US$2.99 per user per month. No definitive agreement with Nexus has been finalized as of the date of this filing and the binding term sheet has been extended through August 2021.

   

On June 21, 2021, the Company entered into a binding term sheet with Nexus-Vita Pte Ltd (“Nexus-Vita”) whereby the Company and Nexus-Vita have agreed to collaborate and work together to design, develop and integrate the Company’s platform into the existing Nexus-Vita platform. Nexus-Vita has agreed to pay the Company a fixed amount of US$500,000 for the completion of the integration to be performed by the Company’s development team. We anticipate to receive the full fixed amount payment within the next 60 days, with an initial payment of US$100,000 being paid within the next 30 days. The Company and Nexus-Vita have agreed to enter into a definitive agreement prior to Nexus-Vita’s application being integrated with the Company’s platform. No additional revenue is expected until the completion of the integration.

 

WellteQ Agreement

 

On March 15, 2019, we entered into an agreement (the “WellteQ Agreement”) with WellteQ Australia PTY Ltd. (“WellteQ”), whereby we granted a license to our SDKs and access to our anthropometric measurement Advanced Human Imaging Platform. WellteQ provides a low-cost, effective wellness monitoring and engagement platform for the global wellness market. The initial term of the WellteQ Agreement was 12 months, the contract has been renewed successfully each year for the last two years, with the current term end date of March 31st, 2022. The Company has not yet begun to generate revenue from this contract.

 

The Original Fit Factory (TV.Fit) Agreement

 

On November 19, 2020, we signed a binding Terms Sheet with The Original Fit Factory (“TOFF”) which has developed the world-leading TRUCONNECT and TV.FIT fitness and wellbeing platforms available through iOS and Android app stores across 71 countries. TOFF have both B2C and B2B solutions. Our BodyScan technology will be integrated into TOFF’s B2C and B2B offerings. The initial term of this agreement is 24 months, and it will auto renew for a further 24 months unless either party provides at least 90 days written notice to the other party prior to the expiry of the current term. The application launched on May 8, 2021 and has begun to generate revenue.

 

MVMNT Agreement

 

On October 20, 2020, we signed a Definitive Agreement with MVMNT Inc. Under the agreement, our technology will be integrated into MVMNT’s core mobile technology platform, our solution will be made available to all subscribers within MVMNT’s branded digital training experiences commencing with these initial fitness-centric platforms including but not limited to: McGregor F.A.S.T. and Fitocracy. The initial term of the MVMNT Agreement is 24 months, beginning on October 8, 2020 and it will auto renew for a further 12 months unless either party provides at least 90 days written notice to the other party prior to the expiry of the current term. The Company has not yet begun to generate revenue from this contract.

 

66

 

 

 

MVMNT - McGregor F.A.S.T

 

Conor McGregor’s proprietary fitness system (www.McGregorFast.com) is looking to bring its unison revolutionary training and nutrition techniques to McGregor fans and fitness enthusiasts across the world via his new app. McGregor sees this activity as a natural extension to his business empire, given his mission to distribute his coaching on mixed martial arts training, nutrition and fight preparation to a global audience.

 

MVMNT will integrate our technology into the McGregor FAST app, which will then be promoted to McGregor’s social media base (currently 45 million followers in aggregate) and the broader UFC community of fans, who will be able to track changes in their body using our technology as they follow McGregor’s training plans. Our offering will be integrated into the app’s subscription service.

 

In addition, MVMNT represents several other globally recognized sporting personalities with a combined social media presence of over 30 million (over 75 million with the inclusion of McGregor) which will be exposed to the MVMNT / AHI integrated offering.

 

MVMNT - Fitocracy

 

Now owned by MVMNT, Fitocracy was founded in 2011 and is considered a pioneer of mobile/digital fitness. The platform has partnered with some of the top performance and fitness brands and experts over the years, including Arnold Schwarzenegger and Red Bull, and continues to be one of the top mobile apps at the forefront of improving consumer health and fitness. We will collaborate with Fitocracy to offer our revolutionary BodyScan tracking application to the Fitocracy community.

 

Boditrax Term Sheet 

 

On June 11, 2019, we signed a binding Terms Sheet with Boditrax Ltd (Boditrax) to integrate our technology into the Boditrax platform. Boditrax is an innovative British company that creates digital solutions for the health, fitness and wellness sectors internationally. The integration and release of the Boditrax application has been delayed due to the severity of the COVID 19 pandemic in the UK. At this time, the company is unable to give guidance about integration and launch times. The Company has not yet begun to generate revenue from this arrangement and no definitive agreement with Boditrax has been finalized as of the date of this filing.

 

Triage Investment Agreement

 

On December 3, 2020, we reached an agreement to make a strategic technology investment of US$6 million in Triage Technologies over a 14-month period, subject to shareholder approval, (US$3 million in cash and US$3 million in our Ordinary Shares), as part of a strategic plan to expand our service offering.

 

Body Composition Technologies Pte Ltd

 

Body Composition Technologies Pte Ltd (BCT), is a majority owned joint venture between AHI and Gold Quay Capital formed in 2017. Under the terms of the agreement, BCT is licensed to distribute the AHI technology to the Medical and Insurance sectors.  AHI is the majority shareholder of BCT with 54% ownership of the capital stock. Gold Quay Capital paid AHI A$2,000,000 for the distribution rights and licensing of the AHI technology.  BCT has spent A$6,000,000 to date on developing the business segment and research and development required/used to expand the technology into the segment.  

 

Jana Care Term Sheet

 

On May 20, 2021, the Company entered into a Binding Term Sheet with US based on device blood pathology company Jana Care Inc. (“Jana”). Subject to due diligence to be completed within 90 days of the signing of the Binding Term Sheet with Jana, AHI will have the right to invest a total of up to US$8,000,000 into Jana, comprising: (i) an option to invest US$5,000,000 in cash; and (ii) subject to shareholder approval, an option to invest up to US$3,000,000 in Jana in AHI ordinary shares or, if the offering is completed, in ADSs. If the Company does not secure shareholder approval for the US$3,000,000 share investment, it has the option to proceed with the investment in cash. In May 2021, AHI invested US$500,000 in the current convertible note round being offered by Jana.  AHI has a further right for a period of 3 years from the date of the first integrated product launch, to acquire a further 10% of Jana stock. AHI will be issued 1% of Jana for every US$1,000,000 in gross revenue to Jana under a contemplated revenue sharing arrangement. In the event AHI decides not to take up the investment in Jana, AHI will still retain the right to equity at a rate of 1% of Jana for every US$2m in gross revenue to Jana. No definitive agreements have been signed as of the date of this filing, however, subject to due diligence AHI and Jana intend to enter into the following definitive agreements : Commercial Agreement; a Software Development Kit, End User License Agreement; Support Agreement; Data Processing Agreement and Investment Agreement.

 

Inter-PSY Term Sheet

 

On May 31, 2021 the Company entered into a Binding Term sheet with INTER-PSY B.V (Inter-Psy) pursuant to which AHI agrees to grant Inter-Psy the right to use AHI’s licensed Software Development Kits (SDKs) and related intellectual property to integrate them into Inter-Psy existing platform/technology. No definitive agreements have been signed as of the date of this filing and the Company does not intend to generate revenue in the near term.  

 

67

 

 

Cubert Term Sheet

 

On June 10, 2021, the Company entered into a Binding Term Sheet with Cubert Inc (CUBERT) in order to grant Cubert the right to use AHI’s licensed Software Development Kits (SDKs) and related intellectual property to integrate them into the Cubert platforms/technology. The new integrated functionality into Cubert’s FitTrack application will be called FitScan and will enable its users to privately check, track, accurately assess overall wellness and predict potential health risks -- all from their smartphone. AHI has a right to terminate the agreement if FitTrack fail to reach a minimum user number of 200,000 in the first 12 months from commercial launch. No definitive agreements have been signed as of the date of this filing and the Company does not expect to generate revenue in the near future.

 

Bizbaz Term Sheet 

 

On June 28, 2021, the company signed a Binding Term Sheet with Bizbaz Pte Ltd (Bizbaz), a Singapore based Health, and financial gamification technology company to integrate the AHI CompleteScan Face and Body Scan capabilities into the Bizbaz application. Bizbaz offers financial and health intelligence solutions to financial, wellness, insurance institutions, fintech’s and e-commerce companies in Asia. Including comprehensive consumer and SME profiling and pre-scoring solutions, which enable them to engage the unbanked and underserved populations and organizations in Asia. Under the terms of the binding term sheet, Bizbaz will target 100,000 active users on the Bizbaz platform within the first 12 months. No definitive agreements have been signed as of the date of this filing and the Company does not intend to generate revenue in the near term.  

 

Customer Acquisition and Marketing

 

We have spent the last three years establishing our technology as a market leader in digital anthropometry. We regularly present our technology and its functionality at events, conferences, and showcases of the various business verticals our technology has been utilized and demonstrated in. We have developed a B2B-oriented global multi-channel sales and marketing strategy, specific to each focus industry. We have engaged sales personnel in key jurisdictions, including the U.S and UK., with backgrounds specific to the industry in which they operate. Our business model is flexible and driven by a low-price, high-volume approach to sales in pre-existing environments already conducive to the use of digital communications. We believe that our strategy is strong and engages our Partners in a way that enables them to have additional monetization of their activities and data flow to service and truly understand their own customers (Users).

 

Growth Strategy: More Partners and More Users

 

With our technology and distribution channels now mostly developed; we are now entering into a growth phase. Serving as a catalyst for this growth, we now have 15 signed binding agreements with global Partners that have a total audience of over 400 million within the following sectors: (i) mHealth, Telehealth, and Wellness; (ii) Life and Health Insurance; (iii) Fitness; and (iv) Consumer and Apparel. We believe that our existing Partners as well as prospective new Partner contracts will enable us to potentially grow to a run rate of 4.9 million paying Users in total within the next three years. This run rate is based on minimum agreed User targets between us and our Partners, for an initial 12-month period. We are targeting a penetration rate of 1.0% - 5.0% of the existing User base within each Partner company. Penetration assumptions have been modelled in accordance to known global statistics reported in the Liftoff mobile engagement index. 

  

Our principal growth strategy is to leverage the ongoing and growing demand from existing and potential sales Partners for our technology, driven by global health concerns and by the various ways that the technology can assist with satisfying the need for fast, accurate and useful consumer/patient-centric data. The following factors will help us to commercialize our operations as we prepare for this next phase of growth:

 

  Contract Execution and Post-implementation Support. We have signed 15 binding agreements with various global Partners that we believe have a total audience of over 400 million. Our growth strategy includes carefully nurturing these agreements and tailoring the implementation of our technology with each partner to maximize the user experience. This process can be achieved by collaborating with our business partners to ensure that they are set up for success, including assisting them with the customer onboarding procedures and establishing feedback loops around user experience.

 

  Market Penetration. We believe that a key to our success lies in our ability to penetrate a variety of industries within multiple verticals. We intend to do so by identifying business partners who (i) are vetted for quality; (ii) fit and audience reach; who already have a high volume of paying subscribers with a need for any or all of the components of the MultiScan platform being, BodyScan, FaceScan, or DermaScan,  and (iii) who can provide us with access to such clients/Users. Currently we operate in four major verticals & markets including: (i) mHealth, Telehealth, and Wellness; (ii) Life and Health Insurance Consumer; (iii) Fitness; and (iv) Consumer and Apparel. Over time we expect to further enhance our reach into each one of these verticals & markets as well as expand into other new ones.

 

 

Ongoing Investment in Innovation. We intend to continue to invest in building and licensing new software capabilities and extending our platform to make our technology as accurate and “repeatable” as possible and to bring the power of accurate measurement to a broader range of applications. Achieving this goal will also serve as a barrier to entry for our competitors, both new and established.

 

  Intellectual Property Portfolio. Our issued patent portfolio covers our BodyScan technology and provides patent blocking and out-licensing opportunities, while the partner technologies we have licensed-in for FaceScan and DermaScan adds to our CompleteScan suite of products. The company has furthered it protection by submitting additional patents for the combination of the proprietary BodyScan with vital signs measurements captured through FaceScan. At this time, we have been unable to identify a direct, competitive product within the mobile phone ecosystem that: offers our range of measurement captures and data points across a similar multiplatform offering (BodyScan, FaceScan, DermaScan). Our Platform offers solutions across the four business segments in which we operate; and demonstrates competitive ease of use, accuracy and repeatability.

 

68

 

 

Intellectual Property

 

We have submitted 22 patents globally, with prior art/inventive ownership dating back to 2015. We have been issued twelve patents, including in Australia, China, Singapore, South Korea, Hong Kong, Japan, Canada, and the USA. We regularly monitor our R&D for potential patent knowledge gaps, which provides the basis for our continued formalized patent protection, existing patent protection updates and other core know-how and intellectual property assets.

 

The following table is an illustration of our active patents and patent applications.

 

Case Ref. *Owner - Name Country Official No. Title Case Status Next Renewal Date
267194 MyFiziq Limited Australia 2015358289 Imaging a Body Registered 2021-12-04
267195 MyFiziq Limited Canada 2969762 Imaging a Body Registered 2021-12-04
267196 MyFiziq Limited China ZL 201580066271.X Imaging a Body Registered 2021-12-04
276161 MyFiziq Limited China 201910393173.7 Imaging a Body Exam requested  
267197 MyFiziq Limited European Patent Convention 15864375.9 Imaging a Body Response to Exam Report filed at IPO 2021-12-04
270213 MyFiziq Limited Hong Kong 1240057B Imaging a Body Registered 2023-12-04
279124 MyFiziq Limited Hong Kong 42020002679.7 Imaging a Body Application filed 2025-12-04
267198 MyFiziq Limited India 201737020016 Imaging a Body Examination report received  
267199 MyFiziq Limited Japan 6434623 Imaging a Body Registered 2021-11-16
272499 MyFiziq Limited Japan 6424293 Imaging a Body Registered 2021-10-26
274014 MyFiziq Limited Japan 6559317 Imaging a Body Registered 2022-07-26
211708 Advanced Human Imaging Ltd New Zealand 731721 Imaging a Body Response to Exam Report filed at IPO 2021-12-04
279117 Advanced Human Imaging Ltd New Zealand 761690 Imaging a Body Response to Exam Report filed at IPO 2021-12-04
279118 Advanced Human Imaging Ltd New Zealand 761693 Imaging a Body Response to Exam Report filed at IPO 2021-12-04
267200 MyFiziq Limited Republic of Korea 10-1894686-00-00 Imaging a Body Registered 2022-08-28
272344 MyFiziq Limited Republic of Korea 10-1980503 Imaging a Body Registered 2022-05-14
274494 MyFiziq Limited Republic of Korea 10-2019-7001317 Imaging a Body Application allowed  
287457 MyFiziq Limited Republic of Korea 10-2021-7011739 Imaging a Body   Application filed  
267201 MyFiziq Limited Singapore 11201703993R Imaging a Body Registered 2021-12-04
272938 MyFiziq Limited Singapore 10201806180V Imaging a Body Registered 2021-12-04
279063 MyFiziq Limited Singapore 10202001239P Imaging a Body Exam requested  
267201 MyFiziq Limited Singapore 11201703993R Imaging a Body Registered 04-Dec-2021
279063 MyFiziq Limited Singapore 10202001239P Imaging a Body Exam requested  
267202 MyFiziq Limited United States of America 9,949,697 Imaging a Body Registered 24-Oct-2021

 

*The Company is attending to having this change of name recorded with the relevant Intellectual Property authorities around the world to reflect its recent name Change to Advanced Human Imaging Limited.

 

69

 

 

Duration of Patent Property Matters Owned

 

In Australia and most other countries, patent rights may be kept in force for a period of up to 20 years from the date of filing of the complete application on which the patent is granted, upon payment of regular renewal fees.

 

For the patent property matters owned by the Company, the relevant date is 20 years from December 4, 2015 (i.e. December 4, 2035).

 

Broad Scope of Patent Property Matters Owned 

 

The Company diligently monitors its research and development activity for knowledge providing basis for formalized patent protection and other core know-how and intellectual property assets, and has obtained or is seeking patent protection for its key product(s) in a robust and widespread manner that covers major markets via the patent property matters owned by the Company.

 

The patent property matters owned by the Company include granted patents and pending patent applications that have with a wide variety of differing scopes.

 

Such scopes broadly include devices (and corresponding methods) for imaging a body, including receiving a first representation of the user’s body, segmenting the first representation of the body, generating a second representation of the body on the basis of processing of the first representation, and displaying the generated second representation via the display. The patents and patent applications also broadly claim the use of additional user specific data inputs for improving accuracy, user alignment strategies, and techniques for generating representations of the user’s body that are substantially consistent with a true three dimensional scan of the body. The patents and patent applications further claim methods for generating highly accurate body representations and utilizing the generated representations for real-world use cases.

 

70

 

 

We utilize various practices to safeguard and protect our IP, including (but not limited to):

 

  Non-disclosure agreements

 

  End User License agreements

 

  Commercial agreements (including IP clauses)

  

  Data Processing Agreements with clauses for jurisdiction specific regulations such as HIPPA, CCPA, and GDPR.

 

  Employee agreements that include IP clauses

 

  ‘Least Privilege’ access model to restrict access to key personnel

 

  Multi-factor authentication system

 

  Regular threat and intrusion protection exercises in conjunction with cyber security industry expert organizations.

 

Research and Development

 

We conduct all our primary research and development in-house and employ Ph.D.-level experts in machine learning, computer vision, and other research. We engage universities and hospitals globally to aid in data collection to ensure that our digital anthropometric measurements and body composition metrics remain the leading standard in the digital measurement of the human body.

 

We incurred R&D expenses of approximately A$1.8 million in 2020, A$1.5 million in 2019, A$1.2 million in 2018 and A$1.2 million in 2017, relating to the development of our applications and technologies. We intend to continue to invest in our R&D capabilities to extend our platform and bring our measurement and biometrics technologies to a broader range of applications.

 

Competition

 

We operate in a highly competitive industry that is characterized by constant change and innovation. Changes in the applications and the programming languages used to develop applications, devices, operating systems, and technology landscape result in evolving customer requirements.

 

The principal competitive factors in our market include the following:

 

 

product and platform features, architecture, reliability, privacy and security, performance, effectiveness, and supported environments.

 

  product extensibility and ability to integrate with other technology infrastructures;

 

 

digital operations expertise;

 

  ease-of-use of products and platform capabilities;

 

  total cost of ownership;

 

  adherence to industry standards and certifications;

 

  strength of sales and marketing efforts;

 

  brand awareness and reputation; and

 

  focus on customer success.

 

While there are a number of companies offering smaller components of our overall offering in singular market segments, at this time we have been unable to identify a direct comparative product within the mobile phone ecosystem, that: [i] offers our range of data points across a similar multiplatform offering (BodyScanFaceScanDermaScan), [ii] offers solutions across the 4 verticals in which we operate or [iii] demonstrates competitive ease-of-use, accuracy or repeatability.

 

Organizations working in measurement delivery in individual business cases are: MySize, with a mobile phone-based measurement function; Halo, using mobile phone capture to assess body composition; and Select Research, using mobile phone capture for the assessment of body fat. There are also other offerings in the market that present consumers with measurement capabilities which are machine-based and therefore we do not view them as direct competitors as they are either costly or inconvenient to utilize or both.

  

71

 

 

To protect our technology from being duplicated by competitors, we hold patents across key global jurisdictions on our image capture process. These patents have been issued in the USA, China, Singapore, South Korea, Australia, Hong Kong, Japan and Canada. As part of our continuous innovation process, we regularly review our patent coverage and actively pursue patent updates to cover new ideas in existing jurisdictions, as well in new jurisdictions.

 

In addition to this and the expansion of the capturing capabilities, AHI has commenced with FaceScan and DermaScan. The company has lodged provisional patents covering the use case and the integrated use cases of the additional data captures.

 

Competitive Advantages  

 

Our competitive advantage comes from our continuous innovation and transparency with regards to our data capture, measurement accuracy and repeatability metrics. We differentiate ourselves from our competitors through a multitude of factors including, but not limited to, the following:

 

 

Ongoing Data Collection to Ensure Precise Digital Measurements. Regular, continuous, global data collections from multiple independent specialist organizations, including universities and hospitals, to ensure our measurement accuracy and repeatability remains the highest standard in digital measurements from a mobile phone.

 

 

Continual Enhancement of our Technology Offering While Expanding and Refining our Patent Position. We currently maintain a robust intellectual property portfolio related to our BodyScan Technology, while technology we have licensed-in for FaceScan and DermaScan adds to our Complete suite of products.  We regularly review and update our patents in key jurisdictions to prevent competitors from copying our image capture process or innovation. We believe further enhancing and protecting our patent portfolio is a key to the long-term success of our technology offering and business prospects. The company has lodged provisional patents covering the use case and the integrated use cases of the additional captures.

 

 

Independent Validation of Accuracy and Repeatability of our Measurement Information. Publicly advertising our externally validated accuracy and repeatability metrics so that they are clear and accessible to our partners and competitors. Most of our competitors do not share clear information about their measurement accuracy and repeatability publicly. Our transparency makes it easier for potential Partners to understand our metrics during their solution selection process, significantly reducing the need for them to conduct testing and verification of our solution prior to purchase.

 

  Private, individualized Assessment on a Granular Personalized Basis. We measure the end User by taking images of segmented, non-personally identifiable set of silhouettes that are processed on-device. Our solution then recreates the User from the silhouettes in a virtual 3D environment by utilizing the Graphics Processing Unit (GPU) on the end User’s smartphone, enabling that User’s Personally Identifiable Information (PII) to remain on the device. As a result, the process is more cost effective, returns results faster and allows for better security of data and personal privacy.

  

 

Broad Market Functionality. Due to high accuracy and repeatability of results from our product offering, we have been able to expand into multiple markets and uses. We intend to leverage and further grow our  base of Partners through the four main large market segments in which we operate.

 

 

Non-Opinionated Partner Level Integration. We offer a solution that, unlike many of our competitors, can be integrated into our Partners’ existing applications to match their own branding and User experience. This way, our technology becomes part of our Partners’ environment, allowing for trust and additional functionality for the User.

 

 

Zero Upfront Integration Cost. Our potential Partners can implement our turnkey solutions using their internal development team, at an upfront cost of A$0, removing the need for an upfront capital budget that can often create a roadblock for many potential Partners.

 

 

On-Device Processing Delivers Frictionless Scalability.  We have adapted our BodyScan software to run on a User’s device. This feature in turn only requires AWS for the tokenization of the event i.e.; initiation of sequence to commence with all other BodyScan functionality run on-device at no cost to us. It is important to note that all BodyScan major processing occurs on-device and as such AHI only uses AWS cloud infrastructure to support its services. These services include authorization of services (AWS Cognito), App configuration (AWS Cloudfront), and Billing events (AWS Serverless Aurora). For clarity AHI does not persist User data, nor does it preserve service results on its AWS cloud services, therefore the data stored within each of these services does not contain any User’s PII.

 

  Flexible and Capital Efficient B2B Business Model. We target potential B2B partners with large existing user bases, significantly reducing the costs of acquiring new Users in comparison to our competitors. We also offer our solution on a pricing tier, based on a per User per month basis whereby as User volume grows, Partners pay us less with each tier, enabling a higher return on their investment.

 

72

 

 

Our Challenges

 

We face challenges, risks and uncertainties in realizing our business objectives and executing our strategies, including those relating to our ability to:

 

  We may not reach the scale in our business or generate revenue to the level outlined in our business plan.

 

  As with most new technology companies, we have historically incurred significant losses during the development phase of our technology, and there can be no assurance as to when, precisely, we will achieve breakeven or maintain profitability, despite our low overhead expenditure.

 

  We will need to raise additional capital to meet our business requirements in the future, which could be challenging, potentially highly dilutive, and may cause the market price of our Ordinary Shares to decline.

 

  The success of our business is highly dependent on market acceptance of our technologies and their timely release, noting that the SDKs are embedded in our Partners’ customer-facing applications. If the end consumer/User does not accept our product, or our Partners fail to go live with their applications (with our technology embedded), then our financial performance will be adversely affected.

 

  As a B2B company, we are substantially dependent on our customers (Partners) to design, integrate and price our technology effectively within their applications.

 

Please see “Risk Factors” and other information included in this prospectus for a discussion of these and other risks and uncertainties that we face.

 

Government Regulation

 

We are subject to a number foreign and domestic laws and regulations in the jurisdictions in which we operate our business, including but not limited to federal, state and international laws and regulations governing the processing and transfer of personal data. including, but not limited to, the EU GDPR, the Australian Data Privacy regulations, the U.S. Health Insurance Portability and Accountability Act (“HIPPA”), and the California Consumer Privacy Act of 2018 (“CCPA”).

 

Many U.S. states have passed laws requiring notification to data subjects when there is a security breach of personally identifiable data or personal data (as those terms are defined by the applicable laws). There are also a number of legislative proposals pending before the U.S. Congress, various state legislative bodies and foreign governments concerning data protection. In addition, data protection laws in Europe and other jurisdictions outside the United States can be more restrictive than those within the United States, and the interpretation and application of these laws are still uncertain and in flux.

 

For example, the General Data Protection Regulation, or GDPR, which took effect on May 25, 2018, enhances data protection obligations for entities that process personal data about individuals, including obligations to cooperate with European data protection authorities, implement security measures and keep records of personal data processing activities. Noncompliance with the GDPR can trigger fines equal to the greater of €20 million or 4% of global annual revenue.

 

In addition, the CCPA gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches, that is expected to increase data breach litigation. Further, failure to comply with the Israeli Privacy Protection Law of 1981, and its regulations, as well as the guidelines of the Israeli Privacy Protection Authority, may expose to administrative fines, civil claims (including class actions) and in certain cases criminal liability. Current pending legislation may result in a change of the current enforcement measures and sanctions. Given the breadth and depth of changes in data protection obligations, meeting the requirements of GDPR and other applicable laws and regulations has required significant time and resources, including a review of our technology and systems currently in use against the requirements of GDPR and other applicable laws and regulations. We have taken various steps to prepare for complying with GDPR and other applicable laws and regulations however there can be no assurance that these steps are sufficient to assure compliance.

 

Further, additional EU laws and regulations (and member states’ implementations thereof) further govern the protection of individuals and of electronic communications. If our efforts to comply with GDPR or other applicable laws and regulations are not successful, we may be subject to penalties and fines that would adversely impact our business and results of operations, and our ability to use personal data of individuals could be significantly impaired. In addition, non-compliance with the applicable laws and regulations may result in a breach of our contractual obligations with third parties and may result in breaches of data security.

 

73

 

 

These laws and regulations may involve privacy, data protection, intellectual property, or other subjects. Many of the laws and regulations to which we are subject are still evolving and being tested in courts and could be interpreted in ways that could harm our business. In addition, the application and interpretation of these laws and regulations often are uncertain, particularly in the new and rapidly evolving industry in which we operate. Because global laws and regulations have continued to develop and evolve rapidly, it is possible that we, our products, or our platform may not be, or may not have been, compliant with each such applicable law or regulation.

 

Where these laws and regulations apply to our business-to-business partners, we enter into Data Processing Agreements with such partners, specific to the requirements of their business and location.

 

Employees

 

As of March 15, 2021, we had 18 full-time employees and 1 part-time employee. With the exception of 1 employee located in the United States, all of our employees are located in Australia, with 2 performing sales and marketing functions, 12 performing research and development functions, and 4 performing general and administrative. The 1 employee in the U.S. performs sales and marketing functions.

 

We enter into employment contracts with all of our full-time employees. In addition to salaries and benefits, we provide performance-based incentives for some of our full-time employees.

 

Facilities

 

Our headquarters are located at 71-73 South Perth Esplanade, Unit 5, South Perth, WA 6151, Australia, with approximately 3,950 square feet of space. We entered into a lease agreement for our property for a 35-month term, beginning on January 1, 2020 (the “Lease). The Lease is set to expire on December 31, 2022. Under the Lease, we pay rent of A$7,030.40 per month (excluding variable outgoings).

 

Experts

 

The audited consolidated financial statements of the Company and its subsidiaries as of and for the years ended June 30, 2020 and 2019, included in this prospectus have been so included in reliance on the report of PKF Perth, independent registered public accounting firm, upon the authority of said firm as experts in accounting and auditing.

 

Legal Proceedings

 

From time to time, we are involved in litigation or other legal proceedings incidental to our business. We are not currently a party to any litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business, operating results, cash flows or financial condition.

 

74

 

  

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

 

Set forth below is information concerning our directors, executive officers, and other key employees.

 

Name   Age   Position(s)
Vlado Bosanac   55   Executive Chairman & Chief Executive Officer, Executive Director
Steven Richards   46   Chief Financial Officer
Bill Bradford   50   Chief Business Officer
Terence Stupple   42   Chief Technology Officer
Nicholas Prosser   43   Non-Executive Director
Michael Melby   39   Non-Executive Director
Dato Low Koon Poh   48   Non-Executive Director
Mr Edward Greissing Jr       Independent Director Nominee

 

Management 

 

Vlado Bosanac

 

Mr. Bosanac combines over 28 years of experience in capital markets, deal origination, negotiation, corporate advisory, strategy, project implementation, and private and public investment and companies. In 2013, Mr. Bosanac founded the Company, along with Dr. Katherine Iscoe. From September 2013 until October 2016, Mr. Bosanac led the “development of the business-to-business strategy” (B2B) side of the operations and in October 2016 assumed the role of Chief Executive Officer. From 2007 until 2014, Mr. Bosanac served as the founding partner and director of Greenday Corporate (“GDC”), focusing on deal origination and investor liaison. From 2009 until 2013, Mr. Bosanac founded Greenday Commodities, where he assisted organizations both buy and sell commodities such as fuel oil, Iron Ore, and other sought-after commodities. From 2007 until 2014, Mr. Bosanac served as the found partner of Fullerton Private Capital, an SPV making specific private and public investments. From 2000-2007, Mr. Bosanac served as the Executive Director of HealthTec Growth Partners (HGP) as a founding director and deal originator.

  

Steven Richards

 

Mr. Richards is an experienced CFO with over 18 years of working with fast-growing technologies companies and business transformation. Mr. Richards has served as the CFO of the Company since August 2019. From January 2019 until July 2019 he served as the Chief Financial Officer for Airscope Industries, a high-tech drone technology company. From October 2016 until June 2019, Steven worked as a Business Transformation Consultant, including Business Transformation Lead, at Ramesys Global. From September 2015 until October 2016, Mr. Richards served as a contracted Chief Financial Officer of the Finance and Business Transformation for the Government of Western Australia. From January 2014 until August 2015, Mr. Richards served as the Finance and Administration Manager at HealthEngine, an Australian healthcare marketplace.

 

Mr. Richards has an undergraduate degree from University of South Africa (B.Compt) which he obtained cum laude (with distinction), a post-graduate degree in accounting science and he has also qualified as a Chartered Accountant through the South African Institute of Chartered Accountants.

 

Bill Bradford

 

Bill Bradford, age 50, combines over 28 years of internet, digital media, technology, and leadership experience with a career spanning over almost three decades with both public and private companies, as well as being a Captain in the U.S. Army. From November 2019 until January 2021, he served as Chief Product Officer for PVolve, LLC, a digital fitness and equipment streaming service, focused on a pre-habilitative fitness method with patented equipment. He led the migration and modernization of the streaming and eCommerce services to build a scalable platform for growth.

 

From 2014 through October 2019 Mr. Bradford served as  Chief Digital Officer, Beachbody LLC - launched a full digital business on a new platform Beachbody on Demand, transforming the company from a transactional DVD media company into a Digital Business.  In that time period Mr. Bradford also  launched Openfit as a new direct to consumer streaming fitness platform. “Beachbody” has developed leading fitness and nutrition products for over 20 years (P90X, Insanity, Shakeology, etc). While there, he built the strategy, organization, and service Beachbody on Demand service, transforming the company from a DVD distribution model to a digital subscription model, growing the platform to millions of users. From 2007-2014 Mr. Bradford served as SVP, Digital Media, for Fox Broadcasting Company where he lead the transition of Fox from a leader in the 60+ year old linear TV industry to a multi-platform content distribution and monetization business. In this capacity, also served as Chief Product Officer of the Hulu Launch Team. In this capacity drove all digital products for Fox, including streaming distribution of content, monetization, and product innovation on network programs such as American Idol, The X Factor, The Simpsons, Glee, 24, and Family Guy. From 2005-2007 Mr. Bradford serves as VP, Media Products and Platforms, at Yahoo! where he was responsible for technology platform product management supporting the Yahoo Media Group. From 2002-2005 Mr. Bradford served as Executive Director, Product Management, America Online – responsible for AOL Shopping and Travel Product Management. From 2001-2002 Mr. Bradfard served as Director of Technology, Cordiem Inc. From 1997-2001 Mr. Bradform served as Senior Principal Consultant, Oracle Corporation. From 1995-1997 Mr. Bradford was a Project Manager, BDM Technologies, Inc. From 1993-1995 –Mr. Bradford served in the U.S. Army as an Officer

 

Mr. Bradford received his B.S. Economics, United States Military Academy at West Point - 1993

 

M.S. Operations Research, George Washington University - 1999

 

75

 

 

Terence Stupple

 

Mr. Stupple combines over 15 years of IT experience. has served as the Chief Technology Officer of the Company since December, 2015, overseeing the internal growth and strategy of our technical capabilities. From September 2012 through November 2015, Mr. Stupple was employed as a Subject Matter Expert at Chevron Australia. From August 2006 until September 2012, Mr. Stupple held various roles for the Western Australian Government, including acting as manager of web services where he was tasked with the responsibility of the strategic direction and content of the Department of State Development and Department of Mines and Petroleum’s internet and intranet sites. Prior to working for the West Australian Government, Terence was contracted to Microsoft UK in various roles including pre-sales support officer, licensing specialist, channel support, and complaints specialist. Mr. Stupple received his A Levels from Orpington College (UK) and a GCSE from Eltham College (UK),

 

Directors

 

The following noteworthy experience, qualifications, attributes and skills for each Board member, together with the biographical information for each nominee described below, led to our conclusion that the person should serve as a director in light of our business and structure:

 

Nicholas (Nick) Prosser

 

Mr. Prosser combines over 13 years of experience in the ICT sector and over 10 years as a founder, entrepreneur and private investor. Mr. Prosser has been a director of the Company since April 2018. He is also served on the board of director of Vudoo Pty Ltd, a video technology and SaaS platform, since January 2017. Since January 2008, he has served as the founder and member of the board of directors of Vega Blue Partnership. Mr. Prosser founded ThinkCaddie in January 2017 until the Company’s sale to a third-party in November 2019. From January 2007 until May 2016, he was involved in Canberra Data Center. Additionally, he has served as the executive director of CPDone Pty, Ltd, a financial profession compliance company, since February 2016 and as a director of Vega Blue Partnership since January 2008. Mr Prosser has a Diploma in Security Risk Management from The Canberra Institute of Technology and is a member of the Australian Institute of Company Directors.”

 

Michael Melby

 

Mike is co-founder & co-Chief Executive Officer of FitLab, an integrated media & technology holding company focused on fitness & sport lifestyle. Mike is also co-founder of Mayweather Boxing + Fitness. Previously, Mike was Vice President at New Evolution Ventures, where he invested in and operated health clubs worldwide and served as an executive at UFC Gym. Prior to that, Mike was co-founder of two technology startups (both of which exited to publicly traded companies), a private equity investor with ClearLight Partners and an investment banker with FBR Capital Markets.  

 

Mike received his undergraduate degree from UC Berkeley & MBA from The Wharton School at the University of Pennsylvania.

 

76

 

 

Dato Low Koon Poh

 

Dato Low has 23 years of combined experience in accounting, auditing and consultant, with experience in corporate finance, auditing, and accounting in various industries such as construction, plantation, hotels, property, manufacturing and marketing.

 

Mr. Dato Low has served as the director of the Advanced Human Imaging since July 2020. Mr. Dato Low started his accounting services practice KL Management Services, based in Petaling Jaya, in 2006. Mr. Low has also served the President of IPO Partners Limited, a corporate advisory firm since April 2015, and a director of Round Table Partners Berhad since 2019. Since June 2019, Dato Low has served the Executive Chairman and Chief Executive Officer of Medi Lifestyle Limited, a Healthcare and Wellness company listed in the Singapore Exchange. Prior to his position at KL Management Service, Mr. Low worked as an auditor for an international audit firm, an accountant for a Japanese MNC, plus a couple of years as Financial Controller for two public listed companies in Malaysia. Mr. Low is a Fellow member of the Association of Chartered Certified Accountants (ACCA) and a Practicing Chartered Accountant under the Malaysian Institute of Accountants (MIA).

 

Mr. Edward Greissing Jr, Independent Director Nominee

 

Edward F. Greissing. Mr. Greissing, is director nominee and will be Chair of the Nominating and Corporate Governance Committee upon the Company listing its securities on NASDAQ. Mr. Greissing has served as the Executive Director of the Center for Public Health at the Milken Institute since 2016. Prior to joining the Milken Institute, he served as Senior Vice President, North America Corporate Affairs at Sanofi U.S. for 10 years, where he was responsible for corporate affairs functions and programming for chronic disease prevention and wellness, health innovation, and health and economic policy. In 2003, Mr. Greissing founded Red Line Associates, a consulting firm focused on business, product and political strategy, and educational efforts for healthcare, finance and food services clients. Mr. Greissing began his pharmaceutical career at The Upjohn Company, which merged with Pharmacia Corporation (and then later was acquired by Pfizer). Throughout his career, Mr. Greissing supported multiple product approvals, launches and reimbursement efforts. Prior to joining the pharmaceutical industry, Mr. Greissing served as a Professional Staff Member and Research Assistant for the U.S. Senate Intelligence Committee. Mr. Greissing currently serves on the Board of Trustees of the Childrens Inn at the National Institute of Health. Mr. Greissing earned a B.A. from the College of the Holy Cross and an M.A. from The Catholic University of America.

 

Family Relationships

 

None of our directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K.

 

Involvement in Certain Legal Proceedings

 

To the best of our knowledge, none of our directors or executive officers has, during the past 10 years, been involved in any legal proceedings described in subparagraph (f) of Item 401 of Regulation S-K.

 

Although outside of the scope of subparagraph (f) of Item 401 of Regulation S-K, in October 2015, the Australian Tax Office (“ATO”) issued Vlado Bosanac, Co-Founder, Chairman and CEO of the Company, with amended assessments of income for the income years ending 2004 through 2012, alleging he was liable to pay additional amounts of tax. Mr. Bosanac disputed the amounts in question and enforced his right as a taxpayer to defend himself through the courts. The dispute between Mr. Bosanac and the ATO was a civil matter that was adjourned on August 16th 2021. At which time, Mr. Bosanac agreed to settle the matter for the sum of $USD$11,460,000  and the Federal courts of Australia awarded Mr. Bosanac until February 15, 2022 (the “Payment Date”) to conclude the payment of such agreed upon sum including principal, accrued penalties and interest. Importantly, the dispute was over incorrect assessments and is not a matter of evasion, fraud or illegality. Mr Bosanac has assets available to him to meet his obligations to the ATO which will not require the sale of his current AHI holdings to meet such obligations.  Should Mr. Bosanac be unable to pay by the Payment Date the ATO may be able to force involuntary bankruptcy.

 

Board of Directors

 

Our Board will consist of five directors upon closing of this offering, four of whom shall be “independent” within the meaning of Section 5605(a)(2) of the NASDAQ Listing Rules and will meet the criteria for independence set forth in Rule 10A-3 of the Exchange Act.

 

Terms of Directors and Executive Officers

 

Each of our directors holds office until a successor has been duly elected and qualified unless the director was appointed by the Board, in which case such director holds office until the next following annual meeting of shareholders at which time such director is eligible for re-election. All of our executive officers are appointed by and serve at the discretion of our Board.

 

77

 

 

Qualification

 

There is currently no shareholding qualification for directors, although a shareholding qualification for directors may be fixed in the future by our shareholders by ordinary resolution.

 

ASX Corporate Governance Principles

 

In Australia there are no mandatory corporate governance structures and practices that must be observed by a company listed on the ASX. Instead, the ASX Corporate Governance Council has published the ASX Best Practice Guide, which contains what are called the “Recommendations,” which articulate eight core principles (and associated recommendations) which are intended to provide a reference point for companies about their corporate governance structures and practices, and against which companies must report.

 

Under ASX listing Rule 4.10.3, companies are required to provide a statement in their annual report to shareholders disclosing the extent to which they have followed the Recommendations in the reporting period. Where a company has not followed all the Recommendations, it must identify the Recommendations that have not been followed, the reasons for not following them, and what (if any) alternative governance practices it adopted in lieu of the recommendation during that period. It is not mandatory to follow the Recommendations. We believe we are in material compliance with the ASX Corporate Governance Principles.

 

Set forth below are the material provisions of the ASX Corporate Governance Principles together with the reasons, where applicable, for variations there from:

 

1. Lay solid foundations for management and oversight. Companies should clearly delineate the respective roles and responsibilities of board and management and regularly review their performance. During the year ended June 30, 2020, we did not follow the Recommendations in the following area:

 

a. The Company did not have a formal process for the evaluation of the performance of senior executives during the 2020 financial year. As the Company matures, the Board will establish formal quantitative and qualitative performance evaluation procedures. Until such time as formal procedures are implemented, the Chief Executive Officer will assess the performance of senior executives. The Company considers that a formal process is not essential at this stage and that performance evaluation can be effectively assessed on an informal basis.

 

b. Although no formal performance evaluation has been undertaken during the year ended June 30, 2020, senior managers have been issued with securities with various performance milestones, under the Company’s Incentive Plans. An individual’s performance is measured and evaluated during the year against the milestones set under the Offer of the securities.

 

  2. Structure the Board to be effective and add value. Listed companies should have a board of an appropriate size and collectively have the skills, commitment and knowledge of the entity and the industry in which it operates, to enable it to discharge its duties effectively and to add value. During the year ended June 30, 2018, we did not follow this Recommendations in the following area:

 

a. The Board did not consider that the company is of a relevant size or complexity to warrant a separate nomination committee to deal with the selection and appointment of new Directors. As such a nomination committee had not been formed as of June 30, 2020.

 

b. The Company does not have a formal board skills matrix. The Board considers the current mix of skills and experience of members of the Board and its senior management is sufficient to meet the requirements of the Company.

 

c. The Board did not have a majority of independent directors as of June 30, 2020.

 

d. Mr. Peter Wall was the non-executive Chairman but not independent due to his holdings in the Company as of June 30, 2020. Mr. Wall is no longer serving in such position.

 

e. Upon appointment new directors will be subject to relevant induction procedures to provide the incoming individual with sufficient knowledge of the entity and its operating environment to enable them to fulfil their role effectively.

 

  3. Instill a culture of acting lawfully, ethically and responsibly. A listed entity should instill and continually reinforce a culture across the organization of acting lawfully, ethically and responsibly.

 

4. Safeguard the integrity of corporate reports. A listed entity should have appropriate processes to verify the integrity of its corporate reports.

 

  a. The Board had not established a separate audit committee as of June 30, 2020. However, the full board operates under the adopted Audit & Risk Management Charter, which is available for review on the Company’s website at www.myfiziq.com/investors (under “Corporate governance policies”), and carries out the functions delegated under that charter. The Board has established an audit committee and amended its Audit and risk Management Charter to comply with both NASDAQ and ASX listing rules.

 

78

 

 

  5. Make timely and balanced disclosure. A listed entity should promote timely and balanced disclosure of all material matters concerning it that a reasonable person would expect to have a material effect on the price or value of its securities. During the year ended June 30, 2018, we did not follow this Recommendations as we only adopted written policies designed to promote timely and balanced disclosure in accordance with ASX Listing Rule disclosure requirements for the year ending June 30, 2019. Our executive officers and members of our Board of Directors are aware of the obligations for continuous disclosure under the ASX Listing Rules and meet on a regular basis to ensure compliance.

 

  6. Respect the rights of security holders. A listed entity should provide its security holders with appropriate information and facilities to allow them to exercise their rights as security holders effectively.

 

7. Recognize and manage risk. A listed entity should establish a sound system of risk management and periodically review the effectiveness of that framework.

 

a. The Board had not established a separate risk management committee as of June 30, 2020. It is anticipated that such functions will be carried out by the Audit Committee upon listing on NASDAQ.

 

b. The Board considered that the Company was not of a size or complexity to justify implementing an internal audit function as of June 30, 2020.

 

8. Remunerate fairly and responsibly. A listed entity should pay director remuneration sufficient to attract and retain high quality directors and design its executive remuneration to attract, retain and motivate high quality senior executives and to align their interests with the creation of value for security holders and with the entity’s values and risk appetite.

 

a. As of June 30, 2020, the Board had not established a remuneration committee. The Company will have a compensation upon completion of this offering and listing on NASDAQ.

 

Committees of the Board of Directors

 

We have established three Committees under the Board: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee, effective upon completion of this offering. We currently have in place an Audit and Risk Management Committee Charter which we amended in order to comply with both ASX and NASDAQ requirements. We have adopted  a formal charter for each of the Compensation and Nominating and Governance committees as well. We have determined that Nicholas Prosser Non-Executive Director, Ken Low Non-Executive Director, and Edward Greising, Jr., director nominee will satisfy the “independence” requirements of Section 5605(a)(2) of the Nasdaq Listing Rules and Rule 10A-3 under the Securities Exchange Act. Each Committee’s members and functions are described below.

 

Members will serve on these committees until their resignation or until otherwise determined by our Board of Directors.

 

Audit Committee. Each of our Audit Committee members will satisfy the “independence” requirements of the NASDAQ listing rules and meet the independence standards under Rule 10A-3 under the Exchange Act. We have determined that Ken Low, independent director possesses accounting or related financial management experience that qualifies him as an “audit committee financial expert” as defined by the rules and regulations of the SEC. The Audit Committee will oversee our accounting and financial reporting processes and the audits of the financial statements of our company. The Audit Committee will be responsible for, among other things:

 

  appointing the independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;
     
  reviewing with the independent auditors any audit problems or difficulties and management’s response;
     
  discussing the annual audited financial statements with management and the independent auditors;
     
  reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures;
     
  reviewing and approving all proposed related party transactions;
     
  meeting separately and periodically with management and the independent auditors; and
     
  monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.
     
  review the Company’s risk management framework including in relation to economic, environmental, and social sustainability risk at least annually

 

Upon completion of this offering, the members of the Audit Committee will be Ken Low, (Chair), Nicholas Prosser and Edward Greising, Jr, director nominee.

 

79

 

 

Compensation Committee.  All of our Compensation Committee members will satisfy the “independence” requirements of the NASDAQ listing rules and meet the independence standards under Rule 10A-3 under the Exchange Act. The Compensation Committee will assist the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our chief executive officer may not be present at any Committee meeting during which his compensation is deliberated. The Compensation Committee will be responsible for, among other things:

 

  reviewing and approving the total compensation package for our most senior executive officers;
     
  approving and overseeing the total compensation package for our executives other than the most senior executive officers;
     
  reviewing and recommending to the board with respect to the compensation of our directors;
     
  reviewing periodically and approving any long-term incentive compensation or equity plans;
     
  selecting compensation consultants, legal counsel or other advisors after taking into consideration all factors relevant to that person’s independence from management; and
     
  reviewing programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.

 

Upon completion of this offering, the members of the Compensation Committee will be Nicholas Prosser (Chair), Ken Low and Edward Greising, Jr, director nominee. 

 

Nominating and Corporate Governance Committee.  A majority of our Nominating and Corporate Governance Committee members will satisfy the “independence” requirements of the NASDAQ listing rules and meet the independence standards under Rule 10A-3 under the Exchange Act. The Nominating and Corporate Governance Committee will assist the Board in selecting individuals qualified to become our directors and in determining the composition of the board and its Committees. The Nominating and Corporate Governance Committee is responsible for, among other things:

 

  identifying and recommending nominees for election or re-election to our Board or for appointment to fill any vacancy;
     
  reviewing annually with our Board its current composition in light of the characteristics of independence, age, skills, experience and availability of service to us;
     
  identifying and recommending to our Board to serve as members of Committees;
     
  advising the board periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our Board on all matters of corporate governance and on any corrective action to be taken; and
     
  monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.

 

Upon completion of this offering, the members of the Nominating and Corporate Governance Committee will be Edward Greising, Jr, director nominee (Chair), Nicholas Prosser (Chair), and Ken Low.

 

Code of Business Conduct and Ethics

 

Our Board has adopted a code of business conduct which we have amended in order to be current and comply with the standards expected of NASDAQ listed companies prior to this Registration Statement becoming effective. The amended code of conduct codify’s the business and ethical principles that govern all aspects of our business. We have filed a copy of our Code of Ethics as an exhibit to the registration statement of which this prospectus is a part. You will be able to review these documents by accessing our public filings at the SEC’s website at www.sec.gov.

 

80

 

 

Duties of Directors

 

Under Australian law, our directors have a duty to act honestly, in good faith and in the best interests of all shareholders. Our directors also have a duty to exercise the care, diligence and skills that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their fiduciary duty to the shareholders of the Company, our directors must ensure compliance with our Constitution. Our shareholders may have the right to seek damages from either the Company, the directors personally, or both, if a duty owed by our directors is breached.

 

The functions and powers of our Board include, among others:

 

exercising the borrowing powers of the company and mortgaging the property of the Company;

 

executing checks, promissory notes and other negotiable instruments on behalf of the Company;

 

maintaining or registering a register of mortgages, charges or other encumbrances of the company; and

 

adopt any scheme or plan in the best interests of the Company designed to provide retiring or superannuation benefits for both present and future non-executive directors;

 

delegate any of their powers to a committee consisting of such of their number as they may determine; and

 

appoint any person to be attorney of the Company.

 

Non-Employee Director Compensation

 

Prior to the closing of this offering, we expect to implement a formal policy pursuant to which our non-employee directors and director nominees will be eligible to receive compensation for service on our Board and Committees of our Board.

 

The following table sets forth information regarding compensation earned during the year ended June 30, 2020 by our non-employee directors who served as directors during such year. Mr. Bosanac, our Chief Executive Officer, serves on our Board but did not receive compensation for his service as a director and all compensation paid to Mr. Bosanac during the year ended June 30, 2020 is set forth in the “Executive Compensation” section below.

 

Name   Fees Earned or
Paid in Cash
    Share
Awards(1)
    Total  
Peter Wall (2)   A$ 60,000     A$ 0 (1)   A$ 60,000  
Nick Prosser   A$ 39,420     A$  270,000 (1)   A$ 309,420  
Mike Melby   A$  36,000     A$ 270,000 (1)   A$   306,000  
Dato Low Koon Poh(3)   A$ -       -       -  
    A$  135,420     A$ 540,000     A$ 675,420  

  

(1) Shares issued to Mr. Melby and Mr. Prosser were approved at our 2019 Annual General Meeting. The fair value of shares is based on the market value of the shares at the date of issue.

  

(2)

Mr. Wall resigned as a Director on January 22, 2021.

 

(3) Dato Low was appointed to the Board on 13 July 2020.

 

Mr. Ed Griesing Jr., director nominee, upon being appointed to the Board will receive annual compensation of annual cash compensation of US$35,000, an additional US$5,000 for each attendance of a Board meeting and 250,000 options with 100,000 options due at signing and 50,000 options a year for 3 years.

 

81

 

 

EXECUTIVE COMPENSATION

 

Summary Compensation Table

 

The following table sets forth certain information with respect to compensation for the years ended June 30, 2020 and 2019, earned by or paid to our chief executive officer and principal executive officer, our principal financial officer, and our other most highly compensated executive officers whose total compensation exceeded US$100,000 (the “named executive officers”).

 

Name and Principal Position   Year     Salary
(A$)
    Bonus
(A$)
    Stock Awards
(A$)
    Option Awards
(A$)(1)
    Non-Equity Incentive Plan Compensation
(A$)
    Deferred Compensation Earnings
(A$)
    Other
(A$)
    Total
(A$)
 
                                                       
Vlado Bosanac   2020       295,650       0           0           0           0           0           0       295,650  
CEO   2019       295,650       0       0       0       0       0       0       295,650  
Steven Richards(2)   2020       149,319       0       0       0       0       0       0       149,319  
CFO   2019       0       0       0       0       0       0       0       0  
David Tabb(3)   2020       191,625       0       0       20,450       0       0       0       212,075  
Former Chief Operating Officer   2019       191,625       0       0       20,450       0       0       0       212,075  

 

(1) Represents the aggregate grant date fair value computed in accordance with IFRS 2 Share-based payments. The price for each amount is based on the closing price of our stock trading on the Australian Securities Exchange on the date of grant.
   
(2) Steven Richards was appointed on  September 2, 2019 and therefore no salary was paid during the financial year ended  June 30 2019. As of July 6, 2020, he was entitled to a salary of A$219,000 per annum.
   
(3) David Tabb resigned from his position as COO on June 23, 2021.

 

2020 Outstanding Option Awards at Fiscal Year End

 

Name   Number of
securities
underlying
unexercised
options
(#)
exercisable
    Number of
securities
underlying
unexercised
options
(#)
unexercisable
    Equity
incentive
plan awards: Number of
securities
underlying
unexercised
unearned
options
(#)
    Option
exercise price
(A$)
    Option expiration date     Number of
shares or
units of
stock
that have
not vested
(#)
    Market
value of
shares of
units of
stock
that have
not vested
(A$)
    Equity
incentive
plan
awards:
Number of
unearned
shares,
units or
other rights
that have
not vested
(#)
    Equity
incentive
plan
awards:
Market or payout
value of
unearned
shares,
units or
other rights
that have
not vested
(A$)
 
David Tabb         -           -       750,000       A$ 0.10     31 December 2020            -          -       -       -  
David Tabb     -       -       500,000       A$ 0.10     31 December 2021         -       -       -       -  
Vlado Bosanac (1)     -       -       -         -     -       -       -       2,000,000       1,440,000  
Vlado Bosanac     -       -       -         -     -       -       -       2,000,000       1,440,000  

 

(1)

10,000,000 Performance Rights were issued to Vlado Bosanac on 18 December 2020, following shareholder approval obtained on December 11, 2020.

 

Agreements with Named Executive Officers

 

For the financial year ended June 30, 2020, our Directors and Key Management Personnel have been identified as: 

 

Mr. Peter Wall (resigned as of January 22, 2021) Non-Executive Chairman
Mr. Vlado Bosanac Executive Director and Chief Executive Officer (took up Chairman position as of  January 22, 2021)
Mr. Michael Melby Non-Executive Director

Mr. Nick Prosser

 

Dato Low Koon Poh was appointed as a non-executive director on July 13, 2020.

Non-Executive Director

 

82

 

 

Engagement of Non-Executive Directors

 

Non-Executive Directors conduct their duties under the following terms:

 

  1. A Non-Executive Director may resign from his/her position and thus terminate their contract on written notice to us.

 

  2. A Non-Executive Director may, following resolution of our shareholders, be removed before the expiration of their period of office (if applicable). Payment is made in lieu of any notice period if termination is initiated by us, except where termination is initiated for serious misconduct.

 

In consideration of the services provided by Mr. Peter Wall as Non-Executive Chairman, we will pay him A$60,000 per annum up until his resignation date.

 

In consideration of the services provided by Messrs. Michael Melby and Mr. Nicholas Prosser as Non-Executive Directors, we will pay each of them A$36,000 per annum. In addition, Messrs. Melby and Prosser will receive 1,000,000 fully paid Ordinary Shares for each 12-month period that they remain engaged with us.

 

Messrs. Wall, Melby and Prosser are also entitled to fees for other amounts as the Board determines where they perform special duties or otherwise perform extra services or make special exertions on behalf of us.

 

During the financial year ended June 20, 2020, we incurred no such additional costs.

 

Non-executive directors are eligible to participate in our incentive plans.

 

Engagement of Executive Directors

 

Mr. Vlado Bosanac

 

We have agreed to terms with Mr. Vlado Bosanac in relation to his role as Executive Director and Chief Executive Officer, effective 17 October 2016. The terms, which are summarized below, are included in a formal executive services agreement.

 

In respect of his engagement as Executive Director and CEO, commencing 17 October 2016, Mr. Bosanac will be paid a base salary of A$295,650 per annum inclusive of statutory superannuation (Total Fixed Remuneration, or TFR). The TFR is subject to annual review by the Board and any increase in salary is subject to the discretion of the Board.

 

Mr. Bosanac may also receive a short-term performance-based reward in the form of a cash bonus up to 100% of the TFR, the performance criteria, assessment and timing of which are determined at the discretion of the Board. The Board has not yet determined this performance criteria, assessment or timing but when it has, this will apply prospectively. 

 

Under the executive services agreement, Mr. Bosanac is entitled to performance-based remuneration of 10,000,000 Performance Rights which was approved by shareholders on 29 November 2017. All performance rights have vested and 6,000,000 of the performance rights have been exercised.

 

A new executive services agreement for Mr. Bosanac was approved by the board on 20 October 2020, after the June 2020 fiscal year end. Under the new executive services agreement, Mr. Bosanac is entitled to a salary of A$350,000 per annum, exclusive of 9.5% superannuation. In addition, the Contract includes a share-based compensation by way of 10,000,000 performance rights to be issued under a new Performance Rights Plan to be adopted by us. The issue of 10,000,000 performance rights to Mr. Bosanac was approved by shareholders on 11 December 2020.

 

The executive services agreement can be terminated by us without cause with 6 months written notice or the provision of six (6) month’s salary in lieu of notice. Mr. Bosanac is also entitled to terminate the executive services agreement with not less than six (6) months’ written notice (unless the Board otherwise agrees at its discretion).

 

83

 

 

At June 30, 2020, Mr. Bosanac held the following vested Performance Rights under our Limited Incentive Performance Rights Plan:

 

  2,000,000 to vest upon the first to occur of:

 

The signing our first commercial transaction where the party or organization has 5 million or more active subscribers/followers; and

 

The 10-trading day volume weighted average price of our shares as traded on ASX being equal to or greater than A$0.20.

 

Expiry date: 03.03.2018

 

Converted to 2,000,000 Ordinary Shares.

 

  2,000,000 to vest upon the first to occur of:

 

50,000 users or A$500,000 annualized revenue; and

 

The 10-trading day volume weighted average price of our shares as traded on ASX being equal to or greater than A$0.30.

 

Expiry date: 03.03.2019

 

Converted to 2,000,000 Ordinary Shares.

 

  2,000,000 to vest upon the first to occur of:

 

100,000 users or A$1m annualized revenue; and

 

The 10-trading day volume weighted average price of our shares as traded on ASX being equal to or greater than A$0.40.

 

Expiry date: 03.03.2020

 

  2,000,000 to vest upon the first to occur of:

 

200,000 users or A$2.5 million annualized revenue; and

 

The 10-trading day volume weighted average price of our shares as traded on ASX being equal to or greater than A$0.50.

 

Expiry date: 03.03.2021

 

  2,000,000 to vest upon the first to occur of:

 

250,000 users or A$5m annualized revenue; and

 

The 10 trading day volume weighted average price of our shares as traded on ASX being equal to or greater than A$0.60.

 

Expiry date: 03.03.2022

 

After the June 30, 2020 fiscal year end, the following Performance Rights were issued to Mr. Bosanac following shareholder approval on 11 December 2020:

 

Milestone 1 Performance Rights – 2,000,000 Performance Rights will vest, if, within 12 months from the issuance of such Performance Rights, either (1) our share achieves a 20-day VWAP of A$1.20, (2) the Company achieves a valuation that values us, on a fully diluted basis, at not less than A$300,000,000 market capitalization, or (3) the Company achieving revenue of A$2,000,000 in a financial quarter. Once achieved, the Milestone 1 Performance Rights will expire five years following their issuance. Additionally, any Shares issued on conversion of the Milestone 1 Performance Rights will carry a voluntary 24-month escrow from the date of achieving such milestones.

 

84

 

 

Milestone 2 Performance Rights – 2,000,000 Performance Rights will vest, if, within 24 months from the issuance of such Performance Rights, either (1) our share achieves a 20-day VWAP of A$1.30, (2) the Company achieves a valuation that values us, on a fully diluted basis, at not less than A$300,000,000 market capitalization, or (3) the Company achieving revenue of A$3,000,000 in a financial quarter. Once achieved, the Milestone 2 Performance Rights will expire five years following their issuance. Additionally, all Shares issued on conversion of any Milestone 2 Performance Rights will carry a voluntary 24-month escrow from the date of achieving such milestones.

 

Milestone 3 Performance Rights – 2,000,000 Performance Rights will vest, if, within 36 months from the issuance of such Performance Rights, either (1) our share achieves a 20-day VWAP of A$1.40, (2) the Company achieves a valuation that values us, on a fully diluted basis, at not less than A$300,000,000 market capitalization, or (3) the Company achieving revenue of A$4,000,000 in a financial quarter. Once achieved, the Milestone 3 Performance Rights will expire five years following their issuance. Additionally, all Shares issued on conversion of any Milestone 3 Performance Rights will carry a voluntary 36-month escrow from the date of achieving such milestones.

 

Milestone 4 Performance Rights – 2,000,000 Performance Rights will vest, if, within 48 months from the issuance of such Performance Rights, either (1) our share achieves a 20-day VWAP of A$1.50, (2) the Company achieves a valuation that values us, on a fully diluted basis, at not less than A$300,000,000 market capitalization, or (3) the Company achieving revenue of A$7,500,000 in a financial quarter. Once achieved, the Milestone 4 Performance Rights will expire five years following their issuance. Additionally, all Shares issued on conversion of any Milestone 1 Performance Rights will carry a voluntary 36-month escrow from the date of achieving such milestones.

 

Milestone 5 Performance Rights – 2,000,000 Performance Rights will vest, if, within 60 months from the issuance of such Performance Rights, either (1) our share achieves a 20-day VWAP of A$1.70, (2) the Company achieves a valuation that values us, on a fully diluted basis, at not less than A$300,000,000 market capitalization, or (3) the Company achieving revenue of A$10,000,000 in a financial quarter. Once achieved, the Milestone 5 Performance Rights will expire five years following their issuance. Additionally, all Shares issued on conversion of any Milestone 5 Performance Rights will carry a voluntary 36-month escrow from the date of achieving such milestones.

 

Mr. Steven Richards Employment Agreement

 

On September 2, 2019 formally entered into an employment agreement Mr. Steven Richards to serve as Chief Financial Officer (the “Richards Agreement”).

 

Pursuant to the Richards Agreement, commencing 5 August 2019, Mr. Richards will be paid a base salary of A$164,250 per annum inclusive of statutory superannuation. Mr. Richards’ salary package increased to A$219,000 per annum inclusive of statutory superannuation on July 6, 2020. The Richards Agreement contains a non-compete period following termination of 12-months.

 

David Tabb Employment Agreement 

 

On April 1, 2016, Mr. Tabb entered an employment agreement to serve as Operations Manager of the Company (the “Tabb Agreement”). Under the Tabb Agreement, Mr. Tabb will receive an annual salary of A$105,000. Upon the Company’s termination of the Tabb Agreement without cause, Mr. Tabb shall receive a cash payment equal to one month’s pay. 

 

David Tabb resigned from his positions with the Company on June 23, 2021.

 

Terrence Stupple Employment Agreement

 

On November 30, 2018, Mr. Stupple entered an employment agreement to serve as Chief Technology Officer of the Company (the “Stupple Agreement”). Under the Stupple Agreement, Mr. Stupple will receive an annual salary of A$240,000. The Stupple Agreement contains prohibits Mr. Stupple from competing against the Company in all countries where the Company holds registered patents for the twelve months following the termination of the Stupple Agreement.

 

85

 

 

Short Term Incentive Payments

 

The Board may, at its sole discretion, set the Key Performance Indicators (KPIs) for the Executive Directors or other Executive Officers. The KPIs are chosen to align the reward of the individual Executives to our strategy and performance.

 

Performance objectives, which may be financial or non-financial, or a combination of both, are determined by the Board.

 

No short-term incentives are payable to Executives where it is considered that the actual performance has fallen below the minimum requirement.

 

No formal performance evaluation in respect of the year ended June 30, 2020 has taken place in accordance with this process, and accordingly no short-term incentive payments have been paid or are payable to Executives in respect of the financial year ended June 30, 2020.

 

The CEO sets the KPIs for other members of staff, monitors actual performance and may recommend payment of short-term bonuses to certain employees to the Board for approval.

 

Shareholding Qualifications

 

The Directors are not required to hold any of our shares in accordance with the terms of our constitution. 

 

Stock Option Plans

 

The Company has two stock option plans, the Incentive Performance Rights Plan and the Incentive Options Plan.

 

The Board, acting in remuneration matters, will:

 

  1. Ensure that incentive plans are designed around appropriate and realistic performance targets and provide rewards when those targets are achieved;

 

  2. Review and improve existing incentive plans established for employees; and

 

  3. Approve the administration of the incentive plans, including receiving recommendations for, and the consideration and approval of grants pursuant to such incentive plans.

 

The Incentive Performance Rights Plan pertains to the offer of performance rights to Eligible Participants, while the Incentive Options Plan pertains to the offer of options to Eligible Participants.

 

Eligible Participant means:

 

  (a) a Director (whether executive or non-executive) of any Group Company;

 

  (b) a full or part time employee of any Group Company;

 

  (c) a casual employee or contractor of a Group Company to the extent permitted by the Class Order; or

 

  (d) a prospective participant, being a person to whom the Offer is made but who can only accept the Offer if an arrangement has been entered into that will result in the person becoming an Eligible Participant under Rules (a), (b) or (c) above, who is declared by the Board to be eligible to receive grants of Performance Rights under the Plan.

 

The purpose of each plan is to:

 

(a) assist in the reward, retention and motivation of Eligible Participants;

 

(b) link the reward of Eligible Participants to performance and the creation of Shareholder value;

 

  (c) align the interests of Eligible Participants more closely with the interests of Shareholders by providing an opportunity for Eligible Participants to receive Shares;

 

(d) provide Eligible Participants with the opportunity to share in any future growth in value of the Company; and

 

(e) provide greater incentive for Eligible Participants to focus on the Company’s longer term goals.

 

86

 

  

BENEFICIAL OWNERSHIP OF SECURITIES

 

Except as specifically noted, the following table sets forth information with respect to the beneficial ownership of our Ordinary Shares as of the date of this prospectus by:

 

  each of our directors and executive officers; and

 

  each person known to us to beneficially own more than 5% of our Ordinary Shares on an as-converted basis.

 

The calculations in the table below are based on 136,920,871 Ordinary Shares outstanding as of August 20, 2021.

 

Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person.

 

    Total
Ordinary
Shares Beneficially
Owned
    % of
Beneficial
Ownership
 
             
Directors and Executive Officers:                
Vlado Bosanac     5,391,864       3.66 %
Nick Prosser     6,265,036       4.25 %
Mike Melby     3,000,000       2.03 %
Bill Bradford     0         *  
Steven Richards     0         *  
Dato Low Koon Poh     300,000       0.20 %
Terence Stupple     4,250,000       2.94 %
Edward Greissing Jr(3)    

0

        *
All Directors and Executive Officers as a Group (7 persons)     19,206,900       13.29 %
                 
5% Shareholders:                
Mad Scientist Pty Ltd (1)     16,900,000       11.46 %
The Rain Maker Mgmt SDN BHD (2)     8,826,655       5.98 %
Dr. Amar El-Sallam    

8,350,000

     

5.66

%

 

* Less than 1%

  

(1) Dr. Katherine Iscoe has sole voting and dispositive power over the securities held for the account of this shareholder.

 

(2) Dato Sri Marcus Liew has sole voting and dispositive power over the securities held for the account of this shareholder.

 

(3) The individual is a director nominee and consents to be a director upon the Company’s listing on the Nasdaq Capital Market

 

87

 

 

RELATED PARTY TRANSACTIONS

 

In additional to the regular salary and bonus payments made to our directors and officers in the ordinary course of business, as described in this prospectus, we were involved in the following related-party transactions for the financial years ended June 30 2020, 2019 and 2018:

 

a) Subsidiaries

 

In January 2018, our wholly owned subsidiary, MyFiziq Inc., was incorporated in the U.S. in preparation for the commercialization of our technology for the U.S. market. During the financial years since incorporation, there was no activity in this subsidiary.

 

b) Holding company

 

The holding company is Advanced Human Imaging Limited.

 

c) Joint venture agreement

 

We have a 50% interest in Body Composition Technologies Pte. Limited (BCT), a company incorporated in Singapore for the purpose of developing out technology Platform for commercialization within the medical or insurance sector. See Note 26.

 

During 2020, we provided services to Body Composition Technologies Pty Ltd (“BCT Australia” an Australian incorporated wholly owned subsidiary of BCT), for which we earned revenue of A$420,839 (2019: A$743,614 and 2018: A$349,726).

 

During the previous financial year, we entered into a loan agreement with BCT Australia. The loan is interest free and payable by June 30, 2021; or within 30 days of BCT receiving cash from capital raise activities currently under way, whichever occurs sooner. At June 30, 2020, the balance of the loan was A$68,500 (2019: A$482,201 and 2018: A$0).

 

On July 20, 2020 (after our June 30, 2020 fiscal year end), we announced that we would participate in the Body Composition Technologies Pte Ltd (BCT) capital raising in the amount of approximately A$671,000. The participation will increase our ownership percentage in BCT, upon conversion, to a majority stake of 54.5% in BCT (on a fully diluted basis).

 

d) Transactions with Directors

 

Transactions between us and our Directors during the financial year ended June 30, 2020 are disclosed at Note 24.

 

Other transactions with key management personnel

 

During the financial year ended June 30, 2020, we paid A$26,156 (2019: A$10,676 and 2018: A$52,837) to Steinepreis Paganin, an entity associated with Mr. Peter Wall, for legal services. At June 30, 2020, a further A$10,622 was owing to Steinepreis Paganin (2019: nil and 2018: nil).

 

On April 18, 2019, we entered into a A$2,000,000 Convertible Loan facility with a company related to director Mr. Nicholas Prosser. A drawdown of, A$500,000 had been made against this facility, with total unpaid interest owing of A$28,436. The balance of principal and interest owing was converted to shares in June 2020 at an issue price of A$0.30 per share. Refer to Note 17.

 

In January 2020, we received an unsecured short-term loan of A$250,000 from Pheakes Pty Ltd, a company associated with director Mr. Peter Wall. The loan attracted interest at a rate of 10% per annum. A further loan of A$250,000 with similar terms was received in February 2020. The loan and accrued interest were repaid in full in June 2020.

 

Other than the key management personnel related party disclosure in the Remuneration Report and in Note 24, there were no related party transactions with our officers or directors to report for the financial year ended June 30, 2020.

 

88

 

 

DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION

 

The following description of our share capital is only a summary.

 

Our constituent document or governing rules is a constitution (the “Constitution”). Our Constitution is subject to the terms of the Listing Rules of the ASX and the Corporations Act 2001 (the “Corporation Act”). Our Constitution is similar in nature to the by-laws of a company incorporated under the laws of the U.S. Our Constitution does not provide for or prescribe any specific objects or purposes. The rights and restrictions attaching to Ordinary Shares are derived through a combination of our Constitution, the common law applicable to Australia, the Listing Rules of the Australian Securities Exchange, the Corporation Act, and other applicable law. A general summary of some of the rights and restrictions attaching to Ordinary Shares are summarized below. Each Ordinary Share holder is entitled to receive notice of and to be present, to vote and to speak at general meetings. Our Constitution permits the rights or restrictions attached to any shares or class or shares to be amended or repealed and replaced by special resolution of at least a 75% of the shareholders affected by such amendment.

 

Ordinary Shares

 

Our Ordinary Shares have no par value. We are authorized to issue an unlimited number of Ordinary Shares.

 

Dividends

 

Holders of Ordinary Shares are entitled to receive such dividends as may be declared by the Board. All dividends are declared and paid according to the amounts paid up on the shares in respect of which the dividend is paid. There have been no dividends paid to holders of Ordinary Shares to date.

 

Voting

 

Holders of Ordinary Shares have the right to receive notice and attend and vote at all general meetings.  

 

Rights to Share in the Surplus in the Event of Winding Up

 

Our Constitution provides for the right of shareholders to participate in a surplus in the event of our winding up, subject to the rights attaching to a class of shares.

 

No Redemption Provision for Ordinary Shares

 

There are no redemption provisions in our Constitution in relation to ordinary shares. Under our Constitution, shares may be issued and allotted, which are liable to be redeemed. Under the Corporations Act, redeemable preference shares may only be redeemed if those preference shares are fully paid-up and payment in satisfaction of redemption is out of profits or the proceeds of a new issue of shares made for the purposes of the redemption.

 

89

 

 

Variation of Class Rights

 

The Corporations Act provides that if a company has a constitution that sets out the procedure for varying or cancelling rights attached to shares in a class of shares, those rights may be varied or cancelled only in accordance with the procedure. The rights attached to our Ordinary Shares may only be varied with the consent in writing of members holding at least three-quarters of the shares of that class, or with the sanction of a special resolution passed at a separate meeting of the holders of shares of that class.


Right to Share in Our Profits

 

Pursuant to our Constitution, our shareholders are entitled to participate in our profits only by payment of dividends. Our board of directors may from time to time determine to pay dividends to the shareholders. However, any such dividend may only be payable in accordance with the requirements set out in the Corporations Act described above.

 

Rights to Share in the Surplus in the Event of Winding Up

 

Our Constitution provides for the right of shareholders to participate in a surplus in the event of our winding up, subject to the rights attaching to a class of shares.

 

No Redemption Provision for Ordinary Shares

 

There are no redemption provisions in our Constitution in relation to ordinary shares. Under our Constitution, shares may be issued and allotted, which are liable to be redeemed. Under the Corporations Act, redeemable preference shares may only be redeemed if those preference shares are fully paid-up and payment in satisfaction of redemption is out of profits or the proceeds of a new issue of shares made for the purposes of the redemption.

 

Options

 

The Company provides long term incentives to Directors and Employees pursuant to the MyFiziq Limited Incentive Option Plan (approved by shareholders on 27 November 2019) or the MyFiziq Limited Incentive Performance Rights Plan (approved by shareholders on 16 February 2017).

 

Holders of options shall have no right to vote on any resolutions at a meeting of shareholders, unless and until the option is exercised and Ordinary Shares are held. The options are to be issued at a price determined by the Board and for no consideration. The exercise price, duration and other relevant terms of an option is to be determined by the Board in its sole discretion.

 

Shareholders Meetings

 

We must hold an annual general meeting within five months of the end of each fiscal year. Our end of fiscal year is currently June 30th each year. At the annual general meeting, shareholders typically consider the annual financial report, directors’ report and auditor’s report and vote on matters, including the election of directors, the appointment of the auditor (if necessary). We may also hold other meetings of shareholders from time to time. The annual general meeting must be held in addition to any other meetings which we may hold.

 

Unless applicable law or our Constitution requires a special resolution, a resolution of shareholders is passed if more than 50% of the votes at the meeting are cast in favor of the resolution by shareholders in person or proxy entitled to vote upon the relevant resolution. A special resolution is passed if the notice of meeting sets out the intention to propose the special resolution and it is passed if at least 75% of the votes at the meeting are cast by shareholders in person or proxy entitled to vote upon the relevant resolution.

 

90

 

 

A special resolution usually involves more important questions affecting us as a whole or the rights of some or all of our shareholders. Special resolutions are required in a variety of circumstances under our Constitution and the Corporations Act, including without limitation:

 

  to change our name;
     
  to amend or repeal and replace our Constitution;
     
  to approve the terms of issue of preference shares;
     
  to approve the variation of class rights of any class of shareholders;
     
  to convert one class of shares into another class of shares;
     
  to approve certain buy backs of shares;
     
  to approve a selective capital reduction of our shares;
     
  to approve financially assisting a person to acquire our shares;
     
  to remove and replace our auditor;
     
  to change our company type;
     
  with the leave of an authorized Australian court, to approve our voluntary winding up;
     
  to confer on a liquidator, with either general or specific authority in respect of compensation arrangements of such liquidator; and
     
  to approve an arrangement entered into between a company about to be, or in the course of being, wound up.

 

Shareholder Voting Rights

 

At a general meeting, every shareholder present (in person or by proxy, attorney or representative) and entitled to vote has one vote on a show of hands. Every shareholder present (in person or by proxy, attorney or representative) and entitled to vote has one vote per fully paid Ordinary Share and that portion of a vote for any partly paid share that the amount paid on the partly paid share bears to the total amounts paid and payable, on a poll. This is subject to any other rights or restrictions which may be attached to any shares. In the case of an equality of votes on a resolution at a meeting (whether on a show of hands or on a poll), the chairman of the meeting has a deciding vote in addition to any vote that the chairman of the meeting has in respect of that resolution.

 

Issue of Shares and Changes in Capital

 

Subject to our Constitution, the Corporations Act 2001, the Listing Rules of the Australian Securities Exchange and any other applicable law, we may at any time issue shares and grant options or warrants on any terms, with preferred, deferred or other special rights and restrictions and for the consideration and other terms that the directors determine. Our power to issue shares includes the power to issue bonus shares (for which no consideration is payable to us), preference shares (including redeemable preference shares) and partly paid shares.

 

Pursuant to the Listing Rules of the Australian Securities Exchange, our Board may in their discretion issue securities to persons who are not related parties of our Company, without the approval of shareholders, if such issue, when aggregated with securities issued by us during the previous 12-month period would be an amount that would not exceed 15% of our issued share capital at the commencement of the 12-month period (or a combined limit of up to 25% of our issued share capital, subject to certain conditions, if prior approval for the additional 10% is obtained from shareholders at our annual meeting of shareholders). Other allotments of securities require approval by an ordinary resolution of shareholders unless these other allotments of securities fall under a specified exception under the Listing Rules.

 

91

 

 

We may issue preference shares, by approval of a special majority, which is a resolution of which notice has been given and that has been passed by at least 75% of the voting rights represented at the meeting, in person, by proxy, or by written ballot and entitled to vote on the resolution. There are no preference shares issued or allotted as at the date of this prospectus.

 

Subject to the requirements of our Constitution, the Corporations Act, the Listing Rules of the Australian Securities Exchange and any other applicable law, we may:

 

  consolidate or divide our share capital into a larger or smaller number by resolution passed by shareholders at a general meeting;
     
  reduce our share capital by special resolution passed by at least 75% of the votes cast by shareholders who vote by person or proxy at a duly convened shareholders meeting (and are not otherwise excluded by law) provided that the reduction is fair and reasonable to our shareholders as a whole, and does not materially prejudice our ability to pay creditors;
     
  undertake an equal access buyback of our Ordinary Shares by ordinary resolution of shareholders (although if we have bought back less than 10% of our shares over the period of the previous 12 months, shareholder approval may not be required); and
     
  undertake a selective buyback of certain shareholders’ shares by special resolution passed by at least 75% of the votes cast by shareholders who vote by person or proxy at a duly convened shareholders meeting (and are not otherwise excluded by law), with no votes being cast in favor of the resolution by any person whose shares are proposed to be bought back or by their associates.

 

In certain circumstances, including the division of a class of shares into further classes of shares, the issue of additional shares or the issue of a new class of shares, we may require the approval of any class of shareholders whose rights are varied or are taken to be varied by special resolution of shareholders generally and by special resolution of the holder of shares in that class whose rights are varied or taken to be varied.

 

Dividends may be paid on shares of one class but not another and at different rates for different classes.

 

Exchange Controls

 

Australia has largely abolished exchange controls on investment transactions. The Australian dollar is freely convertible into U.S. dollars. In addition, there are currently no specific rules or limitations regarding the export from Australia of profits, dividends, capital or similar funds belonging to foreign investors, except that certain payments to non-residents must be reported to the Australian Cash Transaction Reports Agency, which monitors such transaction, and amounts on account of potential Australian tax liabilities may be required to be withheld unless a relevant taxation treaty can be shown to apply.

 

Takeover Approval Provisions

 

Any proportional takeover scheme must be approved by those shareholders holding shares included in the class of shares in respect of which the offer to acquire those shares was first made. The registration of the transfer of any shares following the acceptance of an offer made under a scheme is prohibited until that scheme is approved by the relevant shareholders.

 

The Foreign Acquisitions and Takeovers Act 1975

 

Under Australian law, foreign persons acquiring shares in an Australian company may require approval from the Australian Treasurer prior to undertaking the acquisition. These requirements are set forth in the Australian Foreign Acquisitions and Takeovers Act 1975 and the Foreign Acquisitions and Takeovers Regulations 2015 (together, “Australia’s Foreign Investment Regime).

 

92

 

 

Under Australia’s Foreign Investment Regime, as currently in effect, foreign persons must make a mandatory notification to the Australian Treasurer through the Foreign Investment Review Board (“FIRB”) and obtain receipt of a no objections notification from the Australian Treasurer in the following circumstances (among others):

 

all foreign persons acquiring a ‘direct interest’ (generally an interest of 10% or more) of the shares in a company that is a ‘national security business’, regardless of value;

 

‘foreign government investors’ acquiring a direct interest in the share of any company, regardless of value; and

 

foreign persons that are not ‘foreign government investors’ acquiring a ‘substantial interest’ (generally 20% or more) of the shares in a company which has a total asset value of A$281 millioor more (or A$1,216 millioor more in the case of investors incorporated in the US and ultimately owned by entities and persons within the US).

 

Please note that acquisitions thresholds take account of interests held by ‘associates’ and there are tracing rules that can apply.

 

At present, we do not have total assets of A$281 million and we are not a ‘national security business. 

 

An entity is a ‘foreign government investor if it is:

 

a foreign government or separate government entity; or

 

a corporation, trust or limited partnership in which foreign government entities/separate government entities/FGIs from:

 

o a single country, together with associates, hold (directly or indirectly) an interest of 20% or more (including through actual or potential voting power); or

 

o multiple countries, together with associates, hold (directly or indirectly) interests of 40% or more in aggregate (including through actual or potential voting power) – provided the interest holders do not meet certain passive investor requirements.

 

“Associates” is a broadly defined term under Australia’s Foreign Investment Regime and includes:

 

  spouses, lineal ancestors and descendants, and siblings;

 

  partners, officers of companies, the company, employers and employees, and corporations;

 

  their shareholders related through substantial shareholdings or voting power;

 

  corporations whose directors are controlled by the person, or who control a person; and

 

  associations between trustees and substantial beneficiaries of trust estates.

 

There are criminal and civil penalties for breaches of Australia’s Foreign Investment Regime. A breach includes failing to give notice to the Treasurer and obtaining approvals, where notification is mandatory. In addition, the Treasurer may make orders, including requiring the acquirer to dispose of the shares it has acquired within a specified period of time, or imposing conditions if he considers the transaction to be contrary to Australia’s national interest or contrary to Australia’s national security if an application is not made.

 

Each foreign person seeking to acquire holdings in excess of the above caps (including their associates, as the case may be) would need to complete an application form setting out the proposal and relevant particulars of the acquisition/shareholding. The Australian Treasurer then has 30 days to consider the application and a further 10 days to notify the applicant of that decision. The decision period commences upon receipt of payment of the correct application fee. However, FIRB can request an extension of time. If the applicant does not consent to the extension, FIRB can issue an interim order preventing the foreign person from carrying out the proposed transactions and allowing FIRB a further 90 days to consider the application.

 

93

 

 

If we become a ‘foreign person’ under Australia’s Foreign Investment Regime, we would be required to obtain the approval of the Australian Treasurer for us, together with our associates, to undertake certain acquisitions of Australian entities, businesses and land.

 

Due to broad tracing rules in Australia’s Foreign Investment Regime, the percentage of foreign ownership in us may influence the foreign person status of any Australian company or business in which it may choose to invest. We have no current plans for any such acquisition and do not own any property.

 

Our Constitution does not contain any additional limitations on a non-resident’s right to hold or vote our securities.

 

Australian law requires any off-market transfer of our shares to be made in writing. Otherwise, while our Ordinary Shares remain listed on the ASX, transfers take place electronically through the ASX’s exchange process and requirements.

 

On and from 1 January 2021, the temporary COVID-19 measures that required approval irrespective of the value of the investment or the nature of the foreign investor were lifted.

 

Liquidation Rights

 

After satisfaction of the claims of creditors, preferential payments to holders of outstanding preference shares and subject to any special rights or restrictions attached to shares, on a winding up, any available assets must be used to repay the capital contributed by the shareholders and any surplus must be distributed among the shareholders in proportion to the number of fully paid shares held by them. For this purpose, a partly paid share is treated as a fraction of a share equal to the proportion which the amount paid bears to the total issue price of the share before the winding up began.

 

If we experience financial problems, the directors may appoint an administrator to take over our operations to see if we can come to an arrangement with our creditors. If we cannot agree with our creditors, we may be wound up.

 

A receiver, or receiver and manager, may be appointed by order of a court or under an agreement with a secured creditor to take over some or all of the assets of a company. A receiver may be appointed, for example, because an amount owed to a secured creditor is overdue.

 

We may be wound up by order of a court, or voluntarily if our shareholders pass a special resolution to do so. A liquidator is appointed when a court orders a company to be wound up or the shareholders of a company pass a resolution to wind us up. A liquidator is appointed to administer the winding up of a company.

 

94

 

 

DESCRIPTION OF SECURITIES IN THIS OFFERING

 

American Depositary Shares

 

The Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, also referred to as ADSs. Each ADS will represent shares (or a right to receive shares) deposited with HSBC Australia, as custodian for the depositary in Australia. Each ADS will also represent any other securities, cash or other property that may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.

 

You may hold ADSs either (A) directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (ii) by having uncertificated ADSs registered in your name, or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.

 

Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.

 

As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Australian law governs shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.

 

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR.

 

Dividends and Other Distributions

 

How will you receive dividends and other distributions on the shares?

 

The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares your ADSs represent.

 

Cash.   The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.
     
    Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. See [Cross-reference to tax disclosure]. The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.
     
Shares.   The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution.

 

95

 

 

Rights to purchase additional shares.   If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may (i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.
     
Other Distributions.   The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.

 

The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.

 

Deposit, Withdrawal and Cancellation

 

How are ADSs issued?

 

The depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.

 

How can ADS holders withdraw the deposited securities?

 

You may surrender your ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.

 

96

 

 

How do ADS holders interchange between certificated ADSs and uncertificated ADSs?

 

You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.

 

Voting Rights

 

How do you vote?

 

ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders’ meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Australia and the provisions of our articles of association or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.

 

Except by instructing the depositary as described above, you won’t be able to exercise voting rights unless you surrender your ADSs and withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed.

 

We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise voting rights and there may be nothing you can do if your shares are not voted as you requested.

 

In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 45 days in advance of the meeting date.

 

Fees and Expenses

 

Persons depositing or withdrawing shares or ADS holders must pay:   For:
US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)  

Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property

 

Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates

     
US$.05 (or less) per ADS   Any cash distribution to ADS holders
     
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs   Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders
     
US$.05 (or less) per ADS per calendar year   Depositary services
     
Registration or transfer fees   Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
     
Expenses of the depositary  

Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement)

 

Converting foreign currency to U.S. dollars

     
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes  

As necessary

 

     
Any charges incurred by the depositary or its agents for servicing the deposited securities   As necessary

 

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

97

 

 

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

 

The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account.  The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account.  The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligation to act without negligence or bad faith.  The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, the depositary may receive dividends or other distributions from the us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.

 

Payment of Taxes

 

You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

 

Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities

 

The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do so by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.

 

If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.

 

If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.

 

If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADs in exchange for new ADRs identifying the new deposited securities.

 

98

 

 

If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender of those ADSs or cancel those ADSs upon notice to the ADS holders.

 

Amendment and Termination

 

How may the deposit agreement be amended?

 

We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.

 

How may the deposit agreement be terminated?

 

The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if

 

60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;

 

we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or make arrangements for trading of ADSs on the U.S. over-the-counter market;

 

we delist our shares from an exchange outside the United States on which they were listed and do not list the shares on another exchange outside the United States;

 

the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act of 1933;

 

we appear to be insolvent or enter insolvency proceedings;

 

all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;

 

there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or

 

there has been a replacement of deposited securities.

 

If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.

 

99

 

 

After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph.

 

Limitations on Obligations and Liability

 

Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs

 

The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:

 

are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;

 

are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement;

 

are not liable if we or it exercises discretion permitted under the deposit agreement;

 

are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;

 

have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;

 

may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person;

 

are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and

 

the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.

 

In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.

 

100

 

 

Requirements for Depositary Actions

 

Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require: 

 

payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities;

 

satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and

 

compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

 

The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.

 

Your Right to Receive the Shares Underlying your ADSs

 

ADS holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:

 

when temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our shares;

 

when you owe money to pay fees, taxes and similar charges; or

 

when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of shares or other deposited securities.

 

This right of withdrawal may not be limited by any other provision of the deposit agreement.

 

Direct Registration System

 

In the deposit agreement, all parties to the deposit agreement acknowledge that

 

the Direct Registration System, also referred to as DRS, and Profile Modification System, also referred to as Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.

 

In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary’s reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.

 

Shareholder communications; inspection of register of holders of ADSs

 

The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.

 

101

 

 

Jury Trial Waiver 

 

The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law.

 

You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary’s compliance with U.S. federal securities laws or the rules and regulations promulgated thereunder.

 

Representative’s Warrants

 

We also expect to have up to an additional [     ] warrants exercisable for ADSs ([     ] if the ADSs reserved for the over-allotment are sold), issuable to the underwriter of this offering (“Representative’s Warrants”). Each Representative’s Warrant is exercisable for one ADS on a cash or cashless basis at an exercise price of 120% of the price of each ADS sold in the offering. The Representative’s Warrants will be non-exercisable for six (6) months after the effective date (the “Effective Date”) of the registration statement of which this prospectus forms a part of this offering, and will expire five years from the commencement of sales of this offering. The Representative’s Warrants will contain provisions for piggyback registration rights for a period of five years from the commencement of sales of this offering at the Company’s expense.

 

The number of Representative’s Warrants outstanding and the exercise price of those securities will be adjusted proportionately, as permitted by FINRA Rule 5110(g)(8)(E), in the event of a reverse or forward stock split of our ordinary shares, a recapitalization or reclassification of our ordinary shares, payment of dividends or distributions in ordinary shares to our shareholders, or similar transactions. In the event that the Company effects a rights offering to its shareholders or a pro rata distribution of its assets among its shareholders, then the holder of the Representative’s Warrants will have the right to participate in such distribution and rights offering to the extent of their pro rata share of the Company’s outstanding ordinary shares assuming they owned the number of ordinary shares issuable upon the exercise of their warrants. In the event of a “Fundamental Transaction” by the Company, such as a merger or consolidation of it with another company, the sale or other disposition of all or substantially all of the Company’s assets in one or a series of related transactions, a purchase offer, tender offer or exchange offer, or any reclassification, reorganization or recapitalization of the Company’s ordinary shares, then the warrant holder will have the right to receive, for each ADS issuable upon the exercise of the warrant, at the option of the holder, the number of ordinary shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration payable as a result of the Fundamental Transaction that would have been issued or conveyed to the warrant holder had the holder exercised the warrant immediately preceding the closing of the Fundamental Transaction. In lieu of receiving such ADS and additional consideration in the Fundamental Transaction, the warrant holder may elect to have the Company, or the successor entity purchase the warrant holder’s warrant for its fair market value measured by the Black Scholes method.

 

The Company will promptly notify the holders of the Representative’s Warrants in writing of any adjustment to the exercise price or to the number of the outstanding warrants, declaration of a dividend or other distribution, a special non-recurring cash dividend on or redemption of the ordinary shares, the authorization of a rights offering, the approval of the shareholders required for any proposed reclassification of the ordinary shares, a consolidation or merger by the Company, sale of all or substantially all of the assets of the Company, any compulsory share exchange, or the authorization of any voluntary or involuntary dissolution, liquidation, or winding up of the Company. 

 

102

 

 

SHARES AND AMERICAN DEPOSITARY SHARES ELIGIBLE FOR FUTURE SALE

 

Our Ordinary Shares are trading on the ASX. While we have applied to list the ADSs on Nasdaq, we cannot assure you that an active trading market for the ADSs will develop.

 

Upon completion of the offering, we will have ADSs outstanding representing Ordinary Shares, or approximately           % of our Ordinary Shares in issue and outstanding. In addition, we will have Ordinary Shares not represented by ADSs in issue and outstanding. If the underwriters exercise their option to purchase additional ADSs in full, we will have ADSs outstanding, representing Ordinary Shares, or approximately        % of our Ordinary Shares in issue and outstanding. All of the ADSs sold in this offering will be freely tradable without restrictions or further registration under the Securities Act, except for any ADSs sold to our “affiliates,” as that term is defined under Rule 144 under the Securities Act. The Ordinary Shares held by existing shareholders are “restricted securities,” as that term is defined in Rule 144 under the Securities Act. Restricted securities may be sold in the United States only if registered with the SEC or if their resale qualifies for exemption from registration described below under Rule 144 or Rule 701 promulgated under the Securities Act.

 

Future sales of ADSs in the U.S. public market after this offering, and the availability of ADSs for future sale, could adversely affect the market price of the ADSs prevailing from time to time. As described below, a significant number of currently outstanding Ordinary Shares will not be available for sale shortly after this offering due to contractual restrictions on transfers of Ordinary Shares and ADSs. However, sales of substantial amounts of ADSs or Ordinary Shares, or the perception that these sales could occur, could adversely affect prevailing market prices for the ADSs and could impair our future ability to raise equity capital.

 

Rule 144

 

In general, a person who has beneficially owned restricted Ordinary Shares for at least six months would be entitled to sell their securities pursuant to Rule 144 under the Securities Act provided that (1) such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (2) we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted Ordinary Shares for at least six months, but who are our affiliates at the time of, or at any time during the 90 days preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following:

 

1.0% of the number of Ordinary Shares (including Ordinary Shares in the form of ADSs) then outstanding, which will equal approximately    Ordinary Shares immediately after the closing of this offering; and

 

the average weekly trading volume of the ADSs on   during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale;

 

provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by non-affiliates must also comply with the manner of sale, current public information and notice provisions of Rule 144. Non-affiliate resales of restricted shares under Rule 144 also are subject to the availability of current public information about us until a period of one year has elapsed since the securities were acquired from the issuer or an affiliate of the issuer.

 

Rule 701

 

Rule 701 under the Securities Act permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, senior management or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling their shares subject also to Australian law.

 

The SEC has indicated that Rule 701 will apply to typical options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act.

 

Lock-up Agreements

 

We and our officers, directors, affiliates and certain existing stockholders holding at least 1.0% of our outstanding shares have agreed that, without the prior written consent of Maxim Group LLC (the Representatives”) we and they will not, during the period ending 180 days from the closing of this offering (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares, ADSs or any securities convertible into or exercisable or exchangeable for our Ordinary Shares or ADSs or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Ordinary Shares or ADSs. In addition, we have agreed that, without the prior written consent of the Representatives on behalf of the underwriters, we will not, during the restricted period, file any registration statement with the SEC relating to the offering of any Ordinary Shares or ADSs or any securities convertible into or exercisable or exchangeable for Ordinary Shares or ADSs. The restrictions described in this paragraph are subject to certain exceptions. See “Underwriting.”

 

The Representatives, in their sole discretion, may release the Ordinary Shares, ADSs and other securities subject to the lock-up agreements described above in whole or in part at any time.

 

We do not currently expect any release of Ordinary Shares or ADSs subject to lock-up agreements prior to the expiration of the applicable lock-up periods. Upon the expiration of the applicable lock-up periods, substantially all of the Ordinary Shares and ADSs subject to such lock-up restrictions will become eligible for sale, subject to the limitations described above.

 

103

 

 

MATERIAL UNITED STATES FEDERAL INCOME AND AUSTRALIAN TAX CONSIDERATIONS

 

The following summary of the material Australian and U.S. federal income tax consequences of an investment in the ADSs or Ordinary Shares is based upon laws and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change, possibly with retroactive effect. This summary does not deal with all possible tax consequences relating to an investment in the ADSs or Ordinary Shares, such as the tax consequences under U.S. state, local and other tax laws other than U.S. federal income tax laws and certain Australian tax laws.

 

Material United States Federal Income Tax Considerations

 

The following describes material United States federal income tax considerations relating to the acquisition, ownership and disposition of our Ordinary Shares or ADSs by a U.S. holder (as defined below). This summary addresses these tax considerations only for U.S. holders that are initial purchasers of our Ordinary Shares or ADSs pursuant to this offering and that will hold such Ordinary Shares or ADSs as capital assets (generally, property held for investment). This summary does not address all U.S. federal income tax matters that may be relevant to a particular U.S. holder. This summary does not address tax considerations applicable to a holder of our Ordinary Shares or ADSs that may be subject to special tax rules including, without limitation, the following:

 

  banks, financial institutions or insurance companies;

 

  brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts;

 

  tax-exempt entities or organizations, including an “individual retirement account” or “Roth IRA” as defined in Section 408 or 408A of the Code (as defined below), respectively;

 

  real estate investment trusts, regulated investment companies or grantor trusts;

 

  persons that hold our Ordinary Shares or ADSs as part of a “hedging,” “integrated,” “wash sale” or “conversion” transaction or as a position in a “straddle” for U.S. federal income tax purposes;

 

  S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes;

 

  certain former citizens or long-term residents of the United States;

 

  persons that received our Ordinary Shares or ADSs as compensation;

 

  persons subject to Section 451(b) of the Code;

 

  persons acquiring our Ordinary Shares or ADSs in connection with a trade or business conducted outside of the United States, including a permanent establishment or a fixed base in Australia;

 

  holders that own directly, indirectly, or through attribution 10% or more of the voting power or value of our Ordinary Shares or ADSs; and

 

  holders that have a “functional currency” other than the U.S. dollar.

 

104

 

 

Holders of our Ordinary Shares or ADSs who fall within one of the categories above are advised to consult their tax advisor regarding the specific tax consequences which may apply to their particular situation.

 

For the purposes of this description, a “U.S. holder” is a beneficial owner of our Ordinary Shares or ADSs that is (or is treated as), for U.S. federal income tax purposes:

 

  an individual who is a citizen or resident of the United States;

 

  a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia;

 

  an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or

 

  a trust, if a court within the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust, or if such trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person.

 

If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our Ordinary Shares or ADSs, the tax consequences relating to an investment in our Ordinary Shares or ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the specific tax considerations of acquiring, owning and disposing of our Ordinary Shares or ADSs in its particular circumstances.

 

Persons considering an investment in our Ordinary Shares or ADSs should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition, ownership and disposition of our Ordinary Shares or ADSs, including the applicability of U.S. federal, state and local tax laws, Australian tax laws and other non-U.S. tax laws.

 

This description does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local, or non-U.S. tax considerations of the acquisition, ownership and disposition of our Ordinary Shares or ADSs.

 

This description is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal Revenue Service, or the IRS, will not take a position concerning the tax consequences of the acquisition, ownership and disposition of our Ordinary Shares or ADSs or that such a position would not be sustained by a court. We have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax considerations in the purchase, ownership or disposition of our Ordinary Shares or ADSs. Accordingly, holders should consult their own tax advisors concerning the U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning and disposing of our Ordinary Shares or ADSs in their particular circumstances.

 

In general, and taking into account the earlier assumptions, for U.S. federal income tax purposes, a U.S. holder holding ADSs will be treated as the owner of the Ordinary Shares represented by the ADSs. Exchanges of Ordinary Shares for ADSs, and ADSs for Ordinary Shares, generally will not be subject to U.S. federal income tax.

 

United States Federal Income Tax Consequences If We Are Not a PFIC.    The description of the U.S. federal income tax consequences of the receipt of distributions and the sale or other taxable exchange of our Ordinary Shares or ADSs, described in the following two sections “—Distributions” and “—Sale, Exchange or Other Taxable Disposition,” apply only if we are not a PFIC in the relevant year and our stock is not subject to the rules described above under “—Passive Foreign Investment Company Considerations.”

 

105

 

 

Distributions. As described above under the heading “—Dividend Policy,” we do not expect to make any distributions in respect of our Ordinary Shares or ADSs. Subject to the discussion under “—Passive Foreign Investment Company Considerations,” below, the gross amount of any distribution (including any amounts withheld in respect of foreign tax) actually or constructively received by a U.S. holder with respect to our Ordinary Shares or ADSs will generally be taxable to the U.S. holder as a dividend to the extent of the U.S. holder’s pro rata share of our current or accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of earnings and profits will generally be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce, the U.S. holder’s adjusted tax basis in our Ordinary Shares or ADSs. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the U.S. holder as either long-term or short-term capital gain depending upon whether the U.S. holder has held our Ordinary Shares or ADSs for more than one year as of the time such distribution is received. However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above. Non-corporate U.S. holders may qualify for the preferential rates of taxation with respect to dividends on our Ordinary Shares or ADSs applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) and qualified dividend income (as discussed below) if we are a “qualified foreign corporation” and certain other requirements (discussed below) are met. A non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of information provision, or (b) with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the United States. We have applied to list the ADSs on Nasdaq, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on Nasdaq. There can be no assurance that the ADSs will be considered readily tradable on an established securities market in the United States in later years. In addition, the Company, which is incorporated under the laws of Australia, believes that it qualifies as a resident of Australia for purposes of, and is eligible for the benefits of, the Convention between the Government of the United States of America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, signed on August 6, 1982, as amended and currently in force, or the U.S.-Australia Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Australia Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, subject to the discussion under “—Passive Foreign Investment Company Considerations,” below, such dividends will generally be “qualified dividend income” in the hands of individual U.S. holders, provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. holders.

 

A U.S. holder generally may claim the amount of any Australian withholding tax as either a deduction from gross income or a credit against its U.S. federal income tax liability. The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Generally, the credit cannot exceed the proportionate share of a U.S. holder’s U.S. federal income tax liability that such U.S. holder’s taxable income from foreign sources bears to such U.S. holder’s worldwide taxable income. In applying this limitation, a U.S. holder’s various items of income and deduction must be classified, under complex rules, as either “foreign source” or “U.S. source.” This limitation is calculated separately with respect to specific categories of income. The amount of a distribution with respect to the ADSs that is treated as a “dividend” may be lower for U.S. federal income tax purposes than it is for Australian income tax purposes, potentially resulting in a reduced foreign tax credit for the U.S. holder. In addition, the creditability of foreign taxes could be affected by actions taken by intermediaries in the chain of ownership between the holders of our Ordinary Shares or ADSs and our company if, as a result of such actions, the holders of our Ordinary Shares or ADSs are not properly treated as beneficial owners of the underlying Ordinary Shares. Each U.S. holder should consult its own tax advisors regarding the foreign tax credit rules.

 

In general, the amount of a distribution paid to a U.S. holder in a foreign currency will be the U.S. dollar value of the foreign currency calculated by reference to the spot exchange rate on the day the depositary receives the distribution, in the case of the ADSs, or on the day the distribution is received by the U.S. holder, in the case of Ordinary Shares, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S. holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S. holder should not be required to recognize foreign currency gain or loss in respect of the dividend.

 

106

 

 

Sale, Exchange or Other Taxable Disposition.    A U.S. holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of our Ordinary Shares or ADSs in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or exchange and the U.S. holder’s adjusted tax basis in those Ordinary Shares or ADSs, determined in U.S. dollars. Subject to the discussion under “—Passive Foreign Investment Company Considerations” below, this gain or loss will generally be a capital gain or loss. The adjusted tax basis in our Ordinary Shares or ADSs generally will be equal to the cost of such Ordinary Shares or ADSs. Capital gain from the sale, exchange or other taxable disposition of our Ordinary Shares or ADSs by a non-corporate U.S. holder is generally eligible for a preferential rate of taxation applicable to capital gains, if the non-corporate U.S. holder’s holding period determined at the time of such sale, exchange or other taxable disposition for such Ordinary Shares or ADSs exceeds one year (i.e., such gain is long-term taxable gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations. Any such gain or loss that a U.S. holder recognizes generally will be treated as U.S. source gain or loss for foreign tax credit limitation purposes.

 

For a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale.

 

An accrual basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of our Ordinary Shares or ADSs that are traded on an established securities market, provided the election is applied consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S. holder realizes will be U.S. source ordinary income or loss.

 

Medicare Tax.    Certain U.S. holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their “net investment income,” which may include all or a portion of their dividend income and net gains from the disposition of our Ordinary Shares or ADSs. Each U.S. holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our Ordinary Shares or ADSs.

 

Passive Foreign Investment Company Considerations.    If we are classified as a PFIC in any taxable year, a U.S. holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis.

 

We will be classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect to the income and assets of our subsidiaries, either: (1) at least 75% of the gross income is “passive income” or (2) at least 50% of the average quarterly value of our total gross assets (which would generally be measured by fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the ADSs and our Ordinary Shares, which are subject to change) is attributable to assets that produce “passive income” or are held for the production of “passive income.”

 

Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our Ordinary Shares or ADSs. If a non-U.S. corporation owns directly or indirectly at least 25% by value of the stock of another corporation or the partnership interests in a partnership, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation or partnership and as receiving directly its proportionate share of the other corporation’s or partnership’s income. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. If we are classified as a PFIC in any taxable year during which a U.S. holder owns our Ordinary Shares or ADSs, such U.S. holder will be subject to special tax rules discussed below and could suffer adverse tax consequences.

 

107

 

 

The market value of our assets may be determined in large part by reference to the market price of the ADSs and our Ordinary Shares, which is likely to fluctuate after this offering. Therefore, fluctuations in the market price of our Ordinary Shares or ADSs may result in our being a PFIC for any taxable year. In addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from this offering in our business. Whether we are a PFIC for any taxable year will depend on the nature and composition of our income, assets, activities and market capitalization in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. We believe that we were not characterized as a PFIC in our taxable year ended June 30, 2019. Based on the nature and composition of our income, assets, activities and market capitalization for our taxable year ended June 30, 2020, we believe that we would not be classified as a PFIC for our taxable year ended June 30, 2020;] however, there can   be no assurance that we will not be considered a PFIC in any past, current or future taxable year. As a result, our PFIC status may change from year to year. Our status as a PFIC will depend on the composition of our income (including whether we receive certain grants or subsidies and whether such amounts will constitute gross income for purposes of the PFIC income test) and the composition and value of our assets, which may be determined in large part by reference to the market value of the ADSs and our Ordinary Shares, which may be volatile, from time to time. Our status may also depend, in part, on how quickly we utilize the cash proceeds from this offering in our business. Our U.S. counsel expresses no opinion regarding our conclusions or our expectations regarding our PFIC status.

 

If we are classified as a PFIC in any year with respect to which a U.S. holder owns our Ordinary Shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. holder in all succeeding years during which the U.S. holder owns the Ordinary Shares or ADSs, regardless of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S. holder has made a “deemed sale” election under the PFIC rules or is eligible to make and makes a mark-to-market election (as described below), with respect to all taxable years during such U.S. holder’s holding period in which we are a PFIC. If the “deemed sale” election is made, a U.S. holder will be deemed to have sold the Ordinary Shares or ADSs the U.S. holder holds at their fair market value as of the date of such deemed sale and any gain from such deemed sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. holder’s Ordinary Shares or ADSs with respect to which such election was made will not be treated as shares in a PFIC and the U.S. holder will not be subject to the rules described below with respect to any “excess distribution” the U.S. holder receives from us or any gain from an actual sale or other disposition of the Ordinary Shares or ADSs. U.S. holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if such election becomes available.

 

If we are a PFIC, and you are a U.S. holder that does not make one of the elections described above (and below in further detail), a special tax regime will apply to both (a) any “excess distribution” by us to you (generally, your ratable portion of distributions in any year, other than the taxable year in which your holding period in the shares or ADSs begins, which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or the portion of your holding period for our Ordinary Shares or ADSs that preceded the year of the distribution) and (b) any gain realized on the sale or other disposition of our Ordinary Shares or ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. holder’s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below) and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the lower rates of taxation applicable to qualified dividends discussed above under “Distributions.”

 

Certain elections may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of our Ordinary Shares or ADSs. If a U.S. holder makes a mark-to-market election, the U.S. holder generally will recognize as ordinary income any excess of the fair market value of our Ordinary Shares or ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of our Ordinary Shares or ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. holder makes the election, the U.S. holder’s tax basis in our Ordinary Shares or ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of our Ordinary Shares or ADSs in a year in which we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and our Ordinary Shares or ADSs are “marketable”, meaning that they are “regularly traded” on a “qualified exchange.” Our Ordinary Shares or ADSs will be treated as “regularly traded” in any calendar year in which more than a de minimis quantity of our Ordinary Shares or ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement are disregarded). Nasdaq is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the mark-to-market election will be available to a U.S. holder. It should be noted that it is intended that only the ADSs and not our Ordinary Shares will be listed on Nasdaq. Consequently, our Ordinary Shares may not be “marketable” if the ASX (where our Ordinary Shares are currently listed) does not meet the applicable requirements. U.S. holders should consult their tax advisors regarding the availability of the mark-to-market election for Ordinary Shares that are not represented by ADSs.

 

108

 

 

However, a mark-to-market election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves “marketable.” As a result, even if a U.S. holder validly makes a mark-to-market election with respect to our Ordinary Shares or ADSs, the U.S. holder may continue to be subject to the PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. holders should consult their tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs.

 

We do not currently intend to provide the information necessary for U.S. holders to make qualified electing fund elections if we were treated as a PFIC for any taxable year. U.S. holders should consult their tax advisors to determine whether any of the other elections described above would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.

 

If we are determined to be a PFIC, the general tax treatment for U.S. holders described in this section would apply to indirect distributions and gains deemed to be realized by U.S. holders in respect of any of our subsidiaries that also may be determined to be PFICs. U.S. holders should consult their tax advisors regarding the application of the PFIC rules to our subsidiaries.

 

If a U.S. holder owns our Ordinary Shares or ADSs during any taxable year in which we are a PFIC, the U.S. holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. holder’s federal income tax return for that year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements.

 

The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisors with respect to the acquisition, ownership and disposition of our ordinary shares or ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to our Ordinary Shares or ADSs and the IRS information reporting obligations with respect to the acquisition, ownership and disposition of our Ordinary Shares or ADSs.

 

Backup Withholding and Information Reporting. U.S. holders generally will be subject to information reporting requirements with respect to dividends on our Ordinary Shares or ADSs and on the proceeds from the sale, exchange or disposition of our Ordinary Shares or ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. holder is an “exempt recipient.” In addition, U.S. holders may be subject to backup withholding on such payments, unless the U.S. holder provides a taxpayer identification number and a duly executed IRS Form W-9 or otherwise establishes an exemption. Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.

 

109

 

 

Certain Reporting Requirements With Respect to Payments of Offer Price.     U.S. holders paying more than US$100,000 for our Ordinary Shares or ADSs generally may be required to file IRS Form 926 reporting the payment of the offer price for our Ordinary Shares or ADSs to us. Substantial penalties may be imposed upon a U.S. holder that fails to comply. Each U.S. holder should consult its own tax advisor as to the possible obligation to file IRS Form 926.

 

Foreign Asset Reporting. Certain individual U.S. holders are required to report information relating to an interest in our Ordinary Shares or ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of our Ordinary Shares or ADSs.

 

THE DISCUSSION ABOVE IS A SUMMARY OF THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.

 

Material Australian Tax Considerations

 

In this section, we discuss the material Australian income tax, stamp duty and goods and services tax considerations related to the acquisition, ownership and disposal by the absolute beneficial owners of the ADSs or Ordinary Shares. It is based upon existing Australian tax law as of the date of this registration statement, which is subject to change, possibly retrospectively. This discussion does not address all aspects of Australian tax law which may be important to particular investors in light of their individual investment circumstances, such as ADSs or shares held by investors subject to special tax rules (for example, financial institutions, insurance companies or tax exempt organizations). In addition, this summary does not discuss any non-Australian or state tax considerations, other than stamp duty and goods and services tax.

 

Prospective investors are urged to consult their tax advisors regarding the Australian and non-Australian income and other tax considerations of the acquisition, ownership and disposition of the ADSs or shares. This summary is based upon the premise that the holder is not an Australian tax resident and is not carrying on business in Australia through a permanent establishment (referred to as a “Non-Australian Holder” in this summary).

 

Nature of ADSs for Australian Taxation Purposes

 

Non-Australian Holders of ADSs should obtain specialist Australian tax advice regarding their rights and obligations under the deposit agreement with the depositary, including whether the deposit arrangement constitutes a ‘bare trust’ for Australian taxation purposes. Apart from certain aspects of the Australian tax legislation (for example, the Australian capital gains tax and withholding tax provisions, which are discussed below), there is no express legislative basis for disregarding “bare trusts” for Australian tax purposes generally. This summary proceeds on the assumption that the deposit arrangement constitutes a bare trust.

 

Holders of ADSs can be treated as the owners of the underlying Ordinary Shares for Australian capital gains tax purposes on the basis that they are ‘absolutely entitled’ to those shares. Dividends paid on the underlying Ordinary Shares will also be treated as dividends derived by the holders of ADSs as the persons presently entitled to those dividends.

 

110

 

 

Taxation of Dividends

 

Australia operates a dividend imputation system under which dividends may be declared to be “franked” to the extent they are paid out of company profits that have been subject to income tax. Fully franked dividends are not subject to dividend withholding tax. To the extent that they are unfranked, dividends payable to Non-Australian Holders will be subject to dividend withholding tax except to the extent they are declared to be conduit foreign income, or CFI. Dividend withholding tax will be imposed at 30%, unless a shareholder is a resident of a country with which Australia has a double taxation treaty and qualifies for the benefits of the treaty. Under the provisions of the current Double Taxation Convention between Australia and the United States, the Australian tax withheld on unfranked dividends that are not declared to be CFI paid by us to which a resident of the United States is beneficially entitled is limited to 15%.

 

Under the Double Taxation Convention between Australia and the United States, if a company that is a Non-Australian Holder directly owns a 10% or more interest, the Australian tax withheld on unfranked dividends that are not declared to be CFI paid by us to which a resident of the United States is beneficially entitled is limited to 5%.

 

Character of ADSs for Australian Taxation Purposes

 

The Australian tax treatment of a sale or disposal of the ADSs will depend on whether they are held on revenue or capital account. ADSs may be held on revenue rather than capital account, for example, where they are held by share traders or any profit arises from a profit-making undertaking or scheme entered into by the holder. Non-Australian Holders of ADSs should obtain specialist Australian tax advice regarding the characterization of any gain or loss on a sale or disposal of the ADSs as revenue or capital in nature.

 

Tax on Sales or other Dispositions of Shares—Capital Gains Tax

 

Non-Australian Holders who are treated as the owners of the underlying shares on the basis that they are absolutely entitled to those shares will not be subject to Australian capital gains tax on the gain made on a sale or other disposal of Ordinary Shares unless:

 

  they, together with associates, hold 10% or more of our issued capital, at the time of disposal or for a 12 month period during the two years prior to disposal; and

 

  more than 50% of our assets held directly or indirectly, determined by reference to market value, consists of Australian real property (which includes land and leasehold interests) or Australian mining, quarrying or prospecting rights at the time of disposal. Australian capital gains tax applies to net capital gains at a taxpayer’s marginal tax rates. Net capital gains are calculated after reduction for capital losses, which may only be offset against capital gains.

 

The 50% capital gains tax discount is not available to Non-Australian Holders on gains from assets acquired accrued after May 8, 2012 where they were non-Australian residents during the entire holding period. Companies are not entitled to a capital gains tax discount.

 

Broadly, where there is a disposal of certain taxable Australian property, the purchaser will be required to withhold and remit to the Australian Taxation Office, or the ATO, 12.5% of the proceeds from the sale. A transaction is excluded from the withholding requirements in certain circumstances, including where the transaction is an on-market transaction conducted on an approved stock exchange, a securities lending, or the transaction is conducted using a broker operated crossing system. There may also be an exception to the requirement to withhold where a Non-Australian Holder provides a declaration that their Ordinary Shares are not ‘indirect Australian real property interests’. The Non-Australian Holder may be entitled to receive a tax credit for the tax withheld by the purchaser which they may claim in their Australian income tax return.

 

111

 

 

Tax on Sales or other Dispositions of ADSs—Revenue Account

 

Non-Australian Holders who hold their ADSs on revenue account may have the gains made on the sale or other disposal of the ADSs included in their assessable income under the ordinary income provisions of the income tax law, if the gains are sourced in Australia. There are no express provisions which treat holders of ADSs as the owners of the underlying shares where there is a bare trust.

 

Non-Australian Holders assessable under these ordinary income provisions in respect of gains made on ADSs held on revenue account would be assessed for such gains at the Australian tax rates for non-Australian residents, which start at a marginal rate of 32.5% for individuals and would be required to file an Australian tax return. Some relief from Australian income tax may be available to a Non-Australian Holder who is resident of a country with which Australia has a double taxation treaty, qualifies for the benefits of the treaty and does not, for example, derive the gain in carrying on business through a permanent establishment in Australia.

 

To the extent an amount would be included in a Non-Australian Holder’s assessable income under both the capital gains tax provisions and the ordinary income provisions, the capital gain amount may be reduced, so that the holder may not be subject to double Australian tax on any part of the gain.

 

The statements under “—Tax on Sales or Other Dispositions of Shares—Capital Gains Tax” regarding a purchaser being required to withhold 12.5% tax on the acquisition of certain taxable Australian property should apply where the disposal of the ADSs by a Non-Australian Holder is likely to generate gains on revenue account, rather than a capital gain.

 

Dual Residency

 

If a holder of ADSs is a resident of both Australia and the United States under those countries’ domestic taxation laws, that holder may be subject to tax as an Australian resident. If, however, the holder is determined to be a U.S. resident for the purposes of the Double Taxation Convention between the United States and Australia, the Australian tax would be subject to limitation by the Double Taxation Convention. Holders should obtain specialist taxation advice in these circumstances.

 

Stamp Duty

 

No Australian stamp duty is payable by Australian residents or non-Australian residents on the issue, transfer and/or surrender of the ADSs or Ordinary Shares, provided that the securities issued, transferred and/or surrendered do not represent 90% or more of our issued shares.

 

Australian Death Duty

 

Australia does not have estate or death duties. As a general rule, no capital gains tax liability is realized upon the inheritance of a deceased person’s shares. The disposal of inherited shares by beneficiaries may, however, give rise to a capital gains tax liability if the gain falls within the scope of Australia’s jurisdiction to tax.

 

Goods and Services Tax

 

No Australian goods and services tax will be payable on the supply of the ADSs or Ordinary Shares.

 

THE DISCUSSION ABOVE IS A SUMMARY OF THE AUSTRALIAN TAX CONSEQUENCES OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs AND IS BASED UPON LAWS AND RELEVANT INTERPRETATIONS THEREOF IN EFFECT AS OF THE DATE OF THIS PROSPECTUS, ALL OF WHICH ARE SUBJECT TO CHANGE, POSSIBLY WITH RETROACTIVE EFFECT. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN OUR ORDINARY SHARES OR ADSs IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.

 

112

 

 

UNDERWRITING

 

We have entered into an underwriting agreement with Maxim Group LLC as the sole representative of the underwriters (“Maxim” or the “Representative”), with respect to the ADSs being offered. Subject to certain conditions of the underwriting agreement between us and Maxim, we have agreed to sell to each underwriter, and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus, the number of ADSs listed next to its name in the following table:

 

Underwriter   Number of ADS
Maxim Group LLC    

 

The underwriters are committed to purchase all the ADSs offered by this prospectus if they purchase any ADSs. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may be increased or the offering may be terminated. The underwriters are not obligated to purchase the ADSs covered by the underwriters’ over-allotment option described below. The underwriters are offering the ADSs, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer’s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

 

Representative’s Warrants

 

We have agreed to grant to Maxim Group LLC, Representative’s Warrants to purchase a number of ADSs equal to five percent (5%) of the total number of ADSs sold in this offering, at an exercise price equal to 120% of the price per ADS sold in this offering. The Representative’s Warrants will contain a cashless exercise feature. Each Representative Warrant is exercisable for one ADS on a cash or cashless basis at an exercise price of 120% of the price of each ADS sold in the offering. The Representative’s Warrants will be non-exercisable for six (6) months after the Effective Date of the registration statement of which this Prospectus forms a part of this offering, and will expire five (5) years from the commencement of sales of this offering. The Representative’s Warrants and the underlying ADSs will be subject to a lock-up pursuant to FINRA Rule 5110(e)(1); for 180 days from the commencement of sales of the offering, the Representative may not sell, transfer, assign, pledge or hypothecate the Representative’s Warrants and the underlying ADSs or engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Representative’s Warrants and the underlying ADSs except as permitted by FINRA Rule 5110(e)(2). The Representative’s Warrants will contain provisions for piggyback registration rights for a period of five (5) years from the commencement of sales of this offering at the Company’s expense.

 

The number of Representative’s Warrants outstanding, and the exercise price of those securities, may be adjusted proportionately, as permitted by FINRA Rule 5110(g)(8)(E).

 

Over-Allotment Option

 

We have granted to the underwriter an option to purchase up to [ ] additional ADSs at the public offering price per ADS set forth on the cover page hereto less the underwriting discounts and commissions. The underwriter may exercise its option, in whole or in part, any time during the 45-day period after the date of this prospectus, but only to cover over-allotments, if any. To the extent the option is exercised and the conditions of the underwriting agreement are satisfied, we will be obligated to sell to the underwriters, and the underwriters will be obligated to purchase, these additional ADSs.

 

Discounts and Commissions; Expenses

 

The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the Representative of the over-allotment option. 

 

   

 

Per ADS

    Total with no
Over-Allotment
    Total with
Full Exercise
of Over-
Allotment
 
Public offering price                                        
Underwriting discount                        

 

113

 

 

The underwriters propose to offer the ADSs offered by us to the public at the public offering price per ADS set forth on the cover of this prospectus. In addition, the underwriters may offer some of the ADSs to other securities dealers at such price less a concession of US$[   ] per ADS. After the initial public offering, the public offering price and concession to dealers may be changed.

 

We have paid an expense deposit of US$25,000 to the Representative, which will be applied against the accountable expenses that will be paid by us to the Representative in connection with this offering.

 

We have also agreed to reimburse the Representative for reasonable out-of-pocket expenses not to exceed US$150,000. We estimate that total expenses payable by us in connection with this offering, other than the underwriting discount, will be approximately US$      . 

 

Lock-Up Agreements

 

We and each of our officers, directors, affiliates and certain existing stockholders holder at least 1.0% of our outstanding ordinary shares have agreed, subject to certain exceptions, not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any ordinary shares or other securities convertible into or exercisable or exchangeable for ordinary shares for a period of six (6) months after this offering is completed without the prior written consent of Maxim.

 

Maxim may in its sole discretion and at any time without notice release some or all of the shares subject to lock-up agreements prior to the expiration of the lock-up period. When determining whether or not to release shares from the lock-up agreements, the Representative will consider, among other factors, the security holder’s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.

 

Right of First Refusal

 

We have granted Maxim a right of first refusal, for a period of twelve (12) months from the commencement of sales of this offering, to act as sole and exclusive investment banker, book-runner, financial advisor, underwriter and/or placement agent, at the Maxim’s sole and exclusive discretion, for each and every future public and private equity and debt offering, including all equity linked financings (each, a “Subject Transaction”), during such twelve (12) month period, of the Company, or any successor to or subsidiary of the Company, on terms and conditions customary to the Maxim for such Subject Transactions.

 

Indemnification

 

We also have agreed to indemnify the underwriter against certain liabilities, including civil liabilities under the Securities Act, or to contribute to payments that the underwriter may be required to make in respect of those liabilities.

 

ASX Market Our ordinary shares are presently quoted on the ASX under the symbol “AHI”. We have applied to have the ADSs listed on The Nasdaq Capital Market under the symbols “[     ]”. No assurance can be given that our application will be approved.  

 

Price Stabilization, Short Positions, and Penalty Bids

 

In connection with this offering, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock. Specifically, the underwriters may over-allot in connection with this offering by selling more shares and warrants than are set forth on the cover page of this prospectus. This creates a short position in our common stock for its own account. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares common stock or warrants over-allotted by the underwriters is not greater than the number of shares of common stock or warrants that they may purchase in the over-allotment option. In a naked short position, the number of shares of common stock or warrants involved is greater than the number of shares common stock or warrants in the over-allotment option. To close out a short position, the underwriters may elect to exercise all or part of the over-allotment option. The underwriters may also elect to stabilize the price of our common stock or reduce any short position by bidding for, and purchasing, common stock in the open market. Since the warrants will not be listed and are not expected to trade, the underwriters cannot purchase the warrants in the open market and, as a result, the underwriters cannot and will not enter into naked short positions.

 

114

 

 

The underwriters may also impose a penalty bid. This occurs when a particular underwriter or dealer repays selling concessions allowed to it for distributing a security in this offering because the underwriter repurchases that security in stabilizing or short covering transactions.

 

Finally, the underwriters may bid for, and purchase, shares of our common stock in market making transactions, including “passive” market making transactions as described below.

 

These activities may stabilize or maintain the market price of our common stock at a price that is higher than the price that might otherwise exist in the absence of these activities. The underwriters are not required to engage in these activities, and may discontinue any of these activities at any time without notice. These transactions may be effected on Nasdaq, in the over-the-counter market, or otherwise.

 

In connection with this offering, the underwriters and selling group members, if any, or their affiliates may engage in passive market making transactions in our common stock immediately prior to the commencement of sales in this offering, in accordance with Rule 103 of Regulation M under the Exchange Act. Rule 103 generally provides that:

 

a passive market maker may not effect transactions or display bids for our common stock in excess of the highest independent bid price by persons who are not passive market makers;

 

net purchases by a passive market maker on each day are generally limited to 30% of the passive market maker’s average daily trading volume in our common stock during a specified two-month prior period or 200 shares, whichever is greater, and must be discontinued when that limit is reached; and

 

passive market making bids must be identified as such. 

 

Electronic Offer, Sale and Distribution of ADS

 

A prospectus in electronic format may be made available on a website maintained by the representatives of the underwriters and may also be made available on a website maintained by other underwriters. The underwriters may agree to allocate a number of shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives of the underwriters to underwriters that may make Internet distributions on the same basis as other allocations. In connection with the offering, the underwriters or syndicate members may distribute prospectuses electronically. No forms of electronic prospectus other than prospectuses that are printable as Adobe® PDF will be used in connection with this offering.

 

The underwriters have informed us that they do not expect to confirm sales of shares and warrants offered by this prospectus to accounts over which they exercise discretionary authority.

 

Other than the prospectus in electronic format, the information on any underwriter’s website and any information contained in any other website maintained by an underwriter is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter and should not be relied upon by investors. 

 

Other Relationships

 

Certain of the underwriters and their affiliates may provide, from time to time, investment banking and financial advisory services to us in the ordinary course of business, for which they may receive customary fees and commissions.

 

115

 

 

Selling Restrictions 

 

Canada. The offering of the ADS in Canada is being made on a private placement basis in reliance on exemptions from the prospectus requirements under the securities laws of each applicable Canadian province and territory where the ADS may be offered and sold, and therein may only be made with investors that are purchasing as principal and that qualify as both an “accredited investor” as such term is defined in National Instrument 45-106 - Prospectus Exemptions, and as a “permitted client” as such term is defined in National Instrument 31-103 - Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any offer and sale of the ADS in any province or territory of Canada may only be made through a dealer that is properly registered under the securities legislation of the applicable province or territory wherein the ADS are offered and/or sold or, alternatively, by a dealer that qualifies under and is relying upon an exemption from the registration requirements therein.

 

Any resale of the ADS by an investor resident in Canada must be made in accordance with applicable Canadian securities laws, which may require resales to be made in accordance with prospectus and registration requirements, statutory exemptions from the prospectus and registration requirements or under a discretionary exemption from the prospectus and registration requirements granted by the applicable Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the ADS outside of Canada.

 

European Economic Area. In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive each, a Relevant Member State, no offer to the public of any of our ADS will be made, other than under the following exemptions:

 

  to any legal entity that is a qualified investor as defined in the Prospectus Directive;
     
  to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the issuer for any such offer; or

 

  in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares of our common stock will result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive or any supplementary prospectus pursuant to Article 16 of the Prospectus Directive.

 

For the purposes of this provision, the expression an “offer to the public” in relation to any of our ADS in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer so as to enable an investor to decide to purchase or subscribe for any ADS, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State. The expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression “2010 PD Amending Directive” means Directive 2010/73/EU.

 

United Kingdom. This document is not an approved prospectus for the purposes of section 85 of the UK Financial Services and Markets Act 2000, as amended, or FSMA, and a copy of it has not been, and will not be, delivered to or approved by the UK Listing Authority or approved by any other authority which could be a competent authority for the purposes of the Prospectus Directive.

 

This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are “qualified investors” within the meaning of section 86(7) of FSMA that are also (i) investment professionals falling within Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii) high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated (each such person being referred to as a “relevant person”).

 

116

 

 

Any person in the United Kingdom that is not a relevant person should not act or rely on these documents or any of their contents. Any investment, investment activity or controlled activity to which this document relates is available in the United Kingdom only to relevant persons and will be engaged in only with such persons. Accordingly, this document has not been approved by an authorized person, as would otherwise be required by Section 21 of FSMA. Any purchaser of shares of common stock resident in the United Kingdom will be deemed to have represented to us and the underwriter, and acknowledge that each of us and the underwriter are relying on such representation, that it, or the ultimate purchaser for which it is acting as agent, is a relevant person.

 

Australia. No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (“ASIC”), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the “Corporations Act”), and do not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.

 

Any offer in Australia of the ADS may only be made to persons (the “Exempt Investors”) who are “sophisticated investors” (within the meaning of section 708(8) of the Corporations Act), “professional investors” (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the ADS without disclosure to investors under Chapter 6D of the Corporations Act.

 

The ADS applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring ADS must observe such Australian on-sale restrictions.

 

This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. This prospectus does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.

 

Hong Kong. The ADS have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong), or the CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the SFO and any rules made thereunder.

 

Singapore. Singapore SFA Product Classification—In connection with Section 309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of ADS, the we have determined, and hereby notify all relevant persons (as defined in Section 309A(1) of the SFA), that the ADS are “prescribed capital markets products” (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

 

117

 

 

The underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the underwriter has represented and agreed that it has not offered or sold any ADS or caused the ADS to be made the subject of an invitation for subscription or purchase and will not offer or sell any ADS or cause the ADS to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADS, whether directly or indirectly, to any person in Singapore other than:

 

(a) to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the “SFA”)) pursuant to Section 274 of the SFA;

 

(b) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA and in accordance with the conditions specified in Section 275 of the SFA; or

 

(c) otherwise, pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

 

Where the ADS are subscribed or purchased under Section 275 of the SFA by a relevant person which is:

 

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

 

(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the ADS pursuant to an offer made under Section 275 of the SFA except:

 

(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section 276(4)(i)(B) of the SFA;

 

(i) where no consideration is or will be given for the transfer;

 

(ii) where the transfer is by operation of law;

 

(iii) as specified in Section 276(7) of the SFA; or

 

as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations 2018.

 

United Arab Emirates. The ADSs have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority or the Dubai Financial Services Authority.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is VStock Transfer, LLC, 18 Lafayette Pl, Woodmere, NY 11598.

 

118

 

 

EXPENSES RELATING TO THIS OFFERING

 

Set forth below is an itemization of the total expenses, excluding Underwriting discounts that we expect to incur in connection with this offering. With the exception of the SEC registration fee, the FINRA filing fee, and the Nasdaq Capital Market listing fee, all amounts are estimates.

 

Securities and Exchange Commission Registration Fee   US$         
     
Nasdaq Capital Market Listing Fee   US$  
     
FINRA Filing Fee   US$
     
Legal Fees and Expenses   US$
     
Accounting Fees and Expenses   US$
     
Printing and Engraving Expenses   US$
     
Transfer Agent Expenses   US$
     
Miscellaneous Expenses   US$  
     
Total Expenses   US$

 

These expenses will be borne by us. Underwriting discounts will be borne by us in proportion to the numbers of ADS sold in the offering.

 

LEGAL MATTERS

 

The validity of the issuance of the shares offered in this prospectus and certain other matters of Australian law will be passed upon for us by Steinepreis Paganin. We are being represented by Lucosky Brookman LLP with respect to certain matters of U.S. law.

 

EXPERTS

 

The consolidated financial statements for the years ended June 30, 2020 and 2019, included in this prospectus will been so included in reliance on the report of PKF Perth, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in auditing and accounting.

  

SERVICE OF PROCESS AND ENFORCEMENT OF LIABILITIES

 

We are a company incorporated under the laws of Australia. A majority of our directors and executive officers are non-residents of the United States, and all or substantially all of the assets of such persons are located outside the United States. As a result, it may not be possible for you to:

 

  effect service of process within the United States upon any of our directors and executive officers or on us;

 

  enforce in U.S. courts judgments obtained against any of our directors and executive officers or us in the U.S. courts in any action, including actions under the civil liability provisions of U.S. securities laws;
     
  enforce in U.S. courts judgments obtained against any of our directors and executive officers or us in courts of jurisdictions outside the United States in any action, including actions under the civil liability provisions of U.S. securities laws; or
     
  to bring an original action in an Australian court to enforce liabilities against any of our directors and executive officers or against us based upon U.S. securities laws.

 

119

 

 

You may also have difficulties enforcing in courts outside the United States judgments obtained in the U.S. courts against any of our directors and executive officers or us, including actions under the civil liability provisions of the U.S. securities laws.

 

We have appointed ___________ as our agent to receive service of process in any action against us in the state and federal courts sitting in the City of New York, Borough of Manhattan, arising of this offering or any purchase or sale of securities in connection therewith. We have not given consent for this agent to accept service of process in connection with any other claim.

 

WHERE YOU CAN FIND ADDITIONAL INFORMATION

 

We have filed with the SEC a registration statement on Form F-1, including relevant exhibits and schedules under the Securities Act, covering the ADS offered by this prospectus. You should refer to our registration statements and their exhibits and schedules if you would like to find out more about us and about the ADS. This prospectus summarizes material provisions of contracts and other documents that we refer you to. Since the prospectus may not contain all the information that you may find important, you should review the full text of these documents.

 

Immediately upon the completion of this offering, we will be subject to periodic reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

 

The SEC maintains a website that contains reports, proxy statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov. The information on that website is not a part of this prospectus.

 

No dealers, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.

 

120

 

 

ADVANCED HUMAN IMAGING LIMITED.

 

INDEX TO FINANCIAL STATEMENTS

 

Unaudited Interim Financial Statements for the Six Months Ended December 31, 2020 and 2019  
   Page
Condensed Statement of Profit or Loss and Other Comprehensive Income F-14
Condensed Statement of Financial Position F-15
Condensed Statement of Changes in Equity F-16
Condensed Statement of Cash Flows F-17
Notes to the Condensed Financial Statements F-18
Directors’ Declaration F-30
Independent Auditors’ Review Report F-31

 

Audited Financial Statements for the Fiscal Years Ended June 30, 2020 and 2019  
  Page
Statement of Profit or Loss and Other Comprehensive Income F-36
Statement of Financial Position F-37
Statement of Changes in Equity F-38
Statement of Cash Flows F-39
Notes to the Financial Statements F-40
Report of Independent Registered Public Accounting Firm F-76

 

F-1

 

 

 

 

CONSOLIDATED FINANCIAL REPORT

 

26 February 2021

 

Manager Announcements

Company Announcements Office

Australian Stock Exchange Limited

Level 4, 20 Bridge Street

SYDNEY NSW 2000

 

Dear Sir or Madam

 

RELEASE OF MYFIZIQ LIMITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 31 DECEMBER 2020

 

In accordance with the ASX Listing Rules, please find attached the following:

 

1. Appendix 4D half-year report;

 

2. Financial report for the half year ended 31 December 2020, including the Directors’ Report.

 

This ASX announcement was approved and authorised for release by the Board of Directors.

 

Yours faithfully,

By Order of the Board

 

/s/ Steven Richards  
Steven Richards  
Company Secretary  
MyFiziq Limited  

 

F-2

 

 

MYFIZIQ LIMITED Appendix 4D
  Half-year report
  Period ended 31 December 2020

 

MYFIZIQ LIMITED

 

Appendix 4D

 

Half-year report

 

for the half-year ended 31 December 2020

 

Name of entity: MYFIZIQ LIMITED
   
ACN: 602 111 115
   
Current Reporting Period Half Year ended 31 December 2020
   
Previous Reporting period Half Year ended 31 December 2019

 

Results for announcement to the market.

 

Item 1

 

    6 months ending  
Operating Performance   31 Dec
2020
A$
    31 Dec
2019
A$
    Movement
A$
    Movement
%
 
Revenue from continuing activities     887,092       354,447       532,645       150.3 %
Profit/(loss) from continuing activities after income tax     (5,471,570 )     (2,944,924 )     (2,526,646 )     85.8 %
Net profit/(loss) for the half year attributable to members     (5,471,570 )     (2,944,924 )     (2,526,646 )     85.8 %

 

Item 2

 

Dividends

 

It is not proposed to pay dividends.

 

There are no dividend or distribution reinvestment plans in operation and there has been no dividend or distribution payments during the financial half year ended 31 December 2020.

 

F-3

 

 

MYFIZIQ LIMITED Appendix 4D
  Half-year report
  Period ended 31 December 2020

 

Item 3 – Brief Explanation

 

Revenue from continuing activities for the 6 months ending 31 December 2019 includes Licence Revenue of A$500,000 (2019: A$0) and Other Income of A$356,478 (2019: A$269,911).

 

The loss after income tax for the 6 months ended 31 December 2020 includes a share-based expenditure to employees, directors, and suppliers (non-cash) of A$3,214,843 (2019: A$1,433,257). The Company also provided for the impairment of assets of A$1,342,978 (2019: A$0). There were no material changes in other cost categories.

 

Item 4

 

    6 months ending  
Net Tangible Assets   31 Dec
2020
$
    31 Dec
2019
$
    Movement
$
    Movement
%
 
Net tangible assets/(liabilities) per security   A$ 0.021     A$ (0.004 )   A$ 0.025       574 %

 

Item 5

 

Control gained or lost over Entities during the period

 

Nil

 

Item 6

 

    Ownership interest as at  
Controlled Entities and joint ventures   31 December
2020
%
    31 December
2019
%
 
Parent Entity:                
MYFIZIQ LIMITED                
                 
Joint venture entities:                
Joint venture entity:  Body Composition Technologies Pte Limited                
Percentage holding in JV entity     50 %     50 %
                 
Controlled entities:                
MyFiziq Inc.1                
Percentage holding in controlled entity     100 %     100 %

 

1 In January 2018, wholly owned subsidiary MyFiziq Inc. was incorporated in the United States of America in preparation for the commercialization of the technology in the USA. During the reporting period there was no activity in this subsidiary.

 

F-4

 

 

MYFIZIQ LIMITED Appendix 4D
  Half-year report
  Period ended 31 December 2020

 

Item 7

 

Accounting Standards

 

The financial report has been prepared in accordance with Australian Equivalents to International Financial Reporting Standards.

 

Item 8

 

Auditor’s review report

 

Our half-year report is based on the financial report of MYFIZIQ LIMITED for the half year ended 31 December 2020, which has been reviewed by PKF Perth. Refer to the 31 December 2020 half-year financial report for the independent auditor’s review report provided to the members of MYFIZIQ LIMITED.

 

Appendix 4D Requirements   Reference
     
1. Reporting period and the previous corresponding period.   Refer to page 1 of this report.
     
2. Results for announcement to the market.   Refer to page 1 of this report “Results for announcement to the market” and Items 1, 2 and 3 of this report.
     
3. Net tangible assets per security.   Refer to Item 4 of this report.
     
4. Details of entities where control has been gained or lost during the period.   Refer to Item 5 of this report.
     
5. Details of individual and total dividends or distributions and dividend or distribution payments.   Refer to Item 2 of this report.
     
6. Details of dividend or distribution reinvestment plans in operation and the last date for the receipt of an election notice for participation in a dividend or distribution reinvestment plan.   Refer to Item 2 of this report.
     
7. Details of joint venture and associated entities.   Refer to Item 6 of this report.
     
8. For foreign entities, accounting standards used in compiling reports.   Not applicable.
     
9. If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification.   Refer to Item 8 of this report.

 

F-5

 

 

 

F-6

 

 

 

Contents

 

 

 

  Page
Directors’ Report F-8
Auditor’s Independence Declaration F-13
Consolidated Statement of Profit or Loss and Other Comprehensive Income F-14
Consolidated Statement of Financial Position F-15
Consolidated Statement of Changes in Equity F-16
Consolidated Statement of Cash Flows F-17
Notes to the Consolidated Financial Statements F-18 - F-29
Directors’ Declaration F-30
Independent Auditor’s Review Report F-31 - F-32

 

F-7

 

 

 

Directors’ Report

 

 

 

The Directors present the financial statements of MyFiziq Limited for the half year ended 31 December 2020.

 

Directors

 

The following persons were directors of MyFiziq Limited during the whole of the half-year and up to the date of this report, unless otherwise stated:

 

Peter Wall Non-Executive Chairman – resigned 22 January 2021
Vlado Bosanac Executive Director and CEO; Executive Chairman – appointed 22 January 2021
Michael Melby Non-Executive Director
Nicholas Prosser Non-Executive Director
Dato Low Koon Poh Non-Executive Director – appointed 13 July 2020

 

Company Secretary/Chief Financial Officer

 

Steven Richards

 

Review of Operations

 

Operating results and financial position

 

The net loss after income tax for the half year was A$5,471,570 (2019: A$2,944,924), which includes A$3,214,843 (2019: A$1,433,257) in respect of share-based payments to suppliers, directors and employees under the Company’s incentive plans, as well A$1,342,978 in respect of a fair value adjustment of the Company’s investments in various entities.

 

Before share-based payments and provision for impairment, the Company’s adjusted net loss after income tax for the financial year is A$913,749 which represents a 39.5% (or A$597,918) improvement over FY19 (A$1,511,667), calculated as follows:

 

Table 1. Impact of share-based payments and provision for impairment on total comprehensive loss for the period

 

    Half Year 
Ended
31 December 
2020
A$
    Half Year 
Ended
31 December 
2019
A$
 
Total comprehensive loss for the year     5,471,570       2,944,924  
                 
Share-based payments (non-cash) adjusted for:                
Directors and employees remuneration     2,596,282       887,114  
Corporate advisory services     92,520       546,143  
Investor relations     526,041       -  
      3,214,843       1,433,257  
                 
Provision for impairment (non-cash) adjusted for:                
Fair value adjustment of investments in various entities     1,342,978       -  
                 
Total comprehensive loss for the year before share-based payments and provision for impairment     913,749       1,511,667  

 

F-8

 

 

 

Contents

 

 

 

Company Overview

 

Vlado Bosanac, Executive Chairman / Chief Executive Officer:

 

The Company has executed fifteen binding agreements with channel partners across multiple business verticals. and has experienced strong revenue and bottom line (refer Table 1 above) performance for the six (6) months ended 31 December 2020. We grew year-on-year cash at bank courtesy of the successful capital raise and a 150% increase in revenue. The company maintained a healthy cash position during the period under review which in turn has paved the way for a few strategic investments, including an increased stake in BCT from 50% to 54.5% (upon conversion and on a fully diluted basis), and an initial 15.19% equity stake in Triage Technologies once fully invested across the intended shares and cash tranches.

 

Additionally, we have been able to invest in the marketing and expansion initiatives of our partner, Bearn, LLC. We continue to expand our product portfolio with the development of the new CompleteScan platform. These initiatives will be an added cornerstone to our revenue growth moving forward as we execute further terms sheets with new partners and activate the releases of current partners.

 

The foreshadowed listing on the NASDAQ will bring the Company greater investor interest and will assist MyFiziq with advancing relationships with its US-domiciled partners. The Company will be providing further updates to shareholders on our NASDAQ initiative as developments unfold.

 

Our share price (ASX:MYQ) has grown sixfold from A$0.28 on July 1, 2020, to a closing price of A$1.75 on 24 February 2021, which represents a 525% increase in value.

 

 

Half Year Highlights:

 

  i. A$5m capital raised.

 

The Company completed a A$5 million placement with institutional and sophisticated investors in October 2020 and the Company had A$4.7 million cash at bank at 31 December 2020.

 

With the current partner rollouts underway and the Company growing revenue, MyFiziq is now in a position where it is unlikely to need additional capital outside of any strategic investment opportunities currently being considered and the proposed NASDAQ listing. The Company has sufficient capital to facilitate the expansion of its research and development team and to expedite the go-to-market timelines of current announced partners.

 

F-9

 

 

 

Contents

 

 

 

ii. Revenue up 150%.

 

With three “live” partners and a further twelve (12) binding agreements serving as a catalyst for growth, the Company increased revenue from A$354k to A$887k during the period under review, an increase of A$533k over the quarter, or 150%.

 

Next Quarter Planned Activity:

 

The following Apps are expected to be launched in this quarter and next quarter:

 

Truconnect (The Original Fit Factory Ltd)
Jayex Healthcare
McGregor FAST
Nexus-Vita

 

iii. 34% increase in cash flow (operations).

 

Net cash used in operating activities reduces from A$1,769,945 to A$1,171,334, which is a A$598,611 or 34% improvement on last year. Driving the improved cash flow is an increase in revenue generated during the period of 150%, supported by an improvement in the Company’s collection of fees outstanding and a stable cost base. The Company had A$4.7 million cash at bank at the reporting date, which is four (4) times the net cash used in operating activities for the six (6) months ended 31 December 2020.

 

iv. CompleteScan solution.

 

The Company signed an agreement with Triage Technologies (“Triage”) in December 2020. Triage has developed the world’s most advanced dermatological AI system, which can accurately identify skin conditions from a photo in a matter of seconds. The Triage technology is complementary to the Company’s current CompleteScan offering, with the Company now working towards the development of a new multi-scan solution, comprising of BodyScan, FaceScan and DermaScan offered on a single platform:

 

F-10

 

 

 

Contents

 

 

 

 

v. Strategic investments.

 

During the period under review the Company’s joint venture partner, Body Composition Technologies Pte Ltd (“BCT”), undertook a A$1.92m capital raising by way of convertible note. MyFiziq participated in the raising by making an investment to the amount of A$671k, which will allow the Company to take a majority stake in BCT upon conversion.

 

Although BCT has not yet started generating revenue, taking a majority stake provides the Company with a strategic advantage in that it will result in the consolidation of additional revenue in the future (not guaranteed).

 

As mentioned earlier, the Company signed an agreement with Canadian based Triage Technologies Inc. (“Triage”) in December 2020. The Agreement will see MyFiziq take a strategic equity stake in Triage and licence use of the Triage AI health assistant technology for integration into the Company’s CompleteScan offering. Under the terms of the agreement, MyFiziq will invest a total of up to US$6 million into Triage, being US$3 million in cash and US$3 million in equity (MyFiziq ordinary shares). The US$3 million cash investment will be made in equal instalments over a fourteen (14) month period, with the first US$500k (A$672k) payment concluded prior to 31 December 2020.

 

vi. Three ‘live’ partners.

 

Three (3) partners now have their mobile applications ‘live’ with the MyFiziq technology embedded. This includes the Biomorphik App which was launched on the Apple App and Google Play stores on 5 January 2021. The initial Biomorphic App release is for both Android and iOS users in Australia, with South East Asia to follow by the end of Q1, 2021.

 

In line with the initial release, Biomorphik has commenced a comprehensive B2C marketing strategy, to draw users to the new platform with the first stage allowing people to monitor their bodies closely and pre-empt issues before they become prohibitive to the user’s health.

 

In terms of our other ‘live’ partners, in January 2021 the Company entered a US$500k joint marketing and expansion funding agreement with Bearn LLC (“Bearn”). Under the terms of the agreement, Bearn will use the funds for marketing and to expand their current platform so that it can facilitate an increase in anticipated volume. Bearn will be targeting 1,000,000 monthly users, in accordance with the announcement to ASX on 22 January 2021.

 

F-11

 

 

 

Contents

 

 

 

The Evolt Active App (“Evolt”), which launched last year, is performing in accordance with early-stage expectations. We are expecting Evolt to commence with its marketing activities over the upcoming quarter.

 

Significant Changes in State of Affairs

 

Other than the transactions listed above, there were no significant changes in the state of affairs of the Company during the period.

 

Matters Subsequent to the End of the Financial Period

 

On 22 January 2021 Mr Peter Wall resigned as Non-executive Chairman on the Company and Mr Vlado Bosanac was appointed as Executive Chairman.

 

The Company intends to seek shareholder approval at the general meeting set for the 5th March 2021 to change the Company name to Advanced Human Imaging Limited.

 

On 18 February 2021, the Company signed a binding term sheet (“Agreement”) with China-based, Tinjoy Biotech Limited (“Tinjoy”). Under the terms of the Agreement, MyFiziq and Tinjoy have agreed to a revenue sharing arrangement, where the revenue will be shared on a 70% MyFiziq and 30% Tinjoy split. MyFiziq also has an option to invest in Tinjoy’s Winscan Platform and will contribute US$200,000 towards Tinjoy’s call centre training and marketing costs. MyFiziq expects to start generating licence revenue and other fees from the commercial arrangement in the future (which cannot be forecast at this time).

 

No other matter or circumstance has arisen since 31 December 2020 that has significantly affected, or may significantly affect the Company’s operations, the results of those operations, or the Company’s state of affairs in subsequent financial years.

 

The impact of the Coronavirus (‘COVID-19’) pandemic is ongoing for the entity up to 31 December 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

 

Auditor’s Independence Declaration

 

A copy of the Auditor’s Independence Declaration as required under Section 307C of the Corporations Act is set out on the following page.

 

This report is made in accordance with a resolution of the Directors.

 

DATED at Perth this 26th day of February 2021.

 

/s/ Vlado Bosanac  
Vlado Bosanac  
Executive Chairman and Chief Executive Officer  

 

F-12

 

 

PKF Perth

 

 

 

 

 

 

AUDITOR’S INDEPENDENCE DECLARATION

 

TO THE DIRECTORS OF MYFIZIQ LIMITED

 

In relation to our review of the financial report of MyFiziq Limited for the half year ended 31 December 2020, to the best of my knowledge and belief, there have been no contraventions of the auditor independence requirements of the Corporations Act 2001 or any applicable code of professional conduct.

 

/s/ PKF Perth  
PKF Perth  
   
/s/ Simon Fermanis  
Simon Fermanis  
Partner  

 

26 February 2021

West Perth

Western Australia

 

Level 4, 35 Havelock Street, West Perth, WA 6005

PO Box 609, West Perth, WA 6872

T: +61 8 9426 8999 F: +61 8 9426 8900 www.pkfperth.com.au

 

PKF Perth is a member firm of the PKF International Limited family of legally independent firms and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm or firms.

 

Liability limited by a scheme approved under Professional Standards Legislation.

 

F-13

 

 

 

Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the half year ended 31 December 2020

 

 

 

       

6 Months ended

(unaudited)

 
    Note  

31 December

2020
A$

    31 December
2019
A$
 
Revenue                    
Subscription Revenue         30,387       84,525  
Licence Revenue         500,000       -  
                     
Other Income                    
Other income   3     356,478       269,911  
Interest income         227       11  
Total Revenue         887,092       354,447  
                     
Expenses                    
Employee expenses   3     (4,248,045 )     (2,421,219 )
Consulting and advisory         (166,973 )     (78,815 )
Corporate         (209,381 )     (190,812 )
Brand development and patent costs         (87,566 )     (103,764 )
Marketing and publicity         (682,876 )     (621,712 )
Telecommunications and IT         (91,031 )     (67,371 )
Occupancy costs         (12,509 )     (53,011 )
Financing costs   3     (137,767 )     (39,726 )
Amortisation and depreciation expenses         (143,746 )     (101,827 )
Impairment of assets         (1,342,978 )     -  
Administration and other expenses   3     (20,202 )     (287,332 )
Total expenses         (7,143,074 )     (3,965,589 )
                     
Loss before income tax   3     (6,255,982 )     (3,611,142 )
                     
Income tax benefit   3     784,412       666,218  
                     
Net loss for the period         (5,471,570 )     (2,944,924 )
                     
Other comprehensive income                 -  
Total comprehensive loss for the period         (5,471,570 )     (2,944,924 )
                     
Loss per share         cents       cents  
Basic and diluted loss per share         (4.64 )     (2.92 )

 

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

 

F-14

 

 

 

Consolidated Statement of Financial Position

As at 31 December 2020

 

 

 

    Note  

31 December

2020

6 Months

(unaudited)

A$

    30 June
2020

12 Months

(audited)

A$
 
Current assets                
Cash and cash equivalents         4,755,563       627,304  
Trade and other receivables         87,809       294,122  
Prepayments         589,755       294,568  
Inventories         -       4,734  
Total current assets         5,433,127       1,220,728  
                     
Non-current assets                    
Other financial assets         37,500       37,500  
Right-of-use asset         140,793       175,992  
Property, plant and equipment         60,882       78,295  
Loans to related entities   4     -       68,500  
Investments   5     -       -  
Development asset at cost         1,327,689       1,373,492  
Total non-current assets         1,566,864       1,733,779  
                     

Total assets

        6,999,991       2,954,507  
                     
Current liabilities                    
Trade and other payables         439,392       785,939  
Employee leave liabilities         358,435       312,463  
Interest bearing borrowings   6     2,021,596       865,000  
Lease liabilities         77,042       68,144  
Total current liabilities         2,896,465       2,031,546  
                     
Non-current liabilities                    
Interest bearing borrowings         -       322,331  
Lease liabilities         97,769       138,124  
Total non-current liabilities         97,769       460,455  
                     
Total liabilities         2,994,234       2,492,001  
                     

Net Assets

        4,005,757       462,506  
                     
Equity                    
Issued capital   7     32,991,281       24,355,213  
Reserves         4,953,783       4,576,829  
Accumulated losses         (33,939,307 )     (28,469,536 )
                     
Total Equity         4,005,757       462,506  

 

The above statement of financial position should be read in conjunction with the accompanying notes.

 

F-15

 

 

 

Consolidated Statement of Changes in Equity

For the half year ended 31 December 2020

(unaudited)

 

 

 

    Issued
capital
A$
    Accumulated
losses
A$
    Equity
compensation
reserve
A$
    Convertible
note
reserve
A$
    Total
A$
 
                               
At 1 July 2019     13,782,565       (23,163,558 )     9,902,156       27,633       548,796  
                                         
Net loss for the period     -       (2,944,924 )     -       -       (2,944,924 )
Other comprehensive income     -       -       -       -       -  
Total comprehensive loss for the period     -       (2,944,924 )     -       -       (2,944,924 )
                                         
Performance Rights exercised     4,615,875       -       (4,615,875 )     -       -  
Options exercised     206,494       -       (110,368 )     -       96,126  
Options expired     -       73,497       (73,497 )     -       -  
Shares issued     2,000,000       -       -       -       2,000,000  
Share issue costs     (123,000 )     -       -       -       (123,000 )
Performance shares expired     (300 )     -       -       -       (300 )
Share-based payments     924,000       -       463,432       -       1,387,432  
                                         
At 31 December 2019     21,405,634       (26,034,985 )     5,565,848       27,633       964,130  

 

    Issued
capital
A$
    Accumulated
losses
A$
    Equity
compensation
reserve
A$
    Convertible
note 
reserve
A$
    Total
A$
 
                               
At 1 July 2020     24,355,213       (28,469,536 )     4,576,829       --       462,506  
                                         
Net loss for the period     -       (5,471,570 )     -       -       (5,471,570 )
Other comprehensive income     -       -       -       -          
Total comprehensive loss for the period     -       (5,471,570 )     -       -       (5,471,570 )
                                         
Performance Rights exercised     701,000       -       (701,000 )     -       -  
Options exercised     1,328,542       -       (342,542 )     -       986,000  
Options expired     -       1,799       (1,799 )     -       -  
Option exercise proceeds                     175,000               175,000  
Shares issued     5,000,000       -       -       -       5,000,000  
Share issue costs     (1,085,474 )     -       -       -       (1,085,474 )
Performance shares expired     -       -       -       -       -  
Share-based payments                                        
Suppliers     562,000       -       781,013       -       1,343,013  
Employees/Directors     2,130,000       -       466,282       -       2,596,282  
                                         
At 31 December 2020     32,991,281       (33,939,307 )     4,953,783               4,005,757  

 

The above statement of changes in equity should be read in conjunction with the accompanying notes.

 

F-16

 

 

 

Consolidated Statement of Cash Flows

For the half year ended 31 December 2020

(unaudited)

 

 

 

    31 December 
2020
A$
    31 December 
2019
A$
 
             
Cash flows from operating activities            
Receipts from customers     32,390       71,110  
Other income     1,149,876       9,464  
Research & Development tax incentive     784,412       666,218  
Interest received     227       11  
Interest and other costs of finance paid     (54,112 )     (2,477 )
Payments to suppliers and employees     (3,084,127 )     (2,514,271 )
                 
Net cash flows used in operating activities     (1,171,334 )     (1,769,945 )
                 
Cash flows from investing activities                
Payments for property, plant and equipment     (5,266 )     (25,168 )
Proceeds from loans to related parties     68,500       132,000  
Payments for investment in entities     (1,342,978 )     -  
Payments for application development costs     (42,458 )     (79,350 )
                 
Net cash (outflow)/ inflows from investing activities     (1,322,202 )     27,482  
                 
Cash flows from financing activities                
Proceeds from issue of shares     5,977,495       2,050,000  
Proceeds from borrowings     1,821,810       -  
Proceeds from exercise of options     175,000       -  
Payments for Share issue costs     (396,975 )     (123,000 )
Repayment of borrowings     (865,000 )     (71,008 )
Repayment of lease liabilities     (31,457 )     -  
                 
Net cash inflows from financing activities     6,680,873       1,855,992  
                 
Net increase in cash assets     4,187,337       113,529  
                 
Cash at the beginning of the financial period     627,304       573,977  
                 
Cash at the end of the financial year     4,815,776       687,506  
                 
Unrealised foreign currency losses     (60,389 )     -  
                 
Cash at the end of the financial period     4,755,563       687,506  

 

The above statement of cash flows should be read in conjunction with the accompanying notes.

 

F-17

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 1 Statement of Significant Accounting Policies

 

a) Statement of compliance

 

These general-purpose financial statements for the half-year reporting period ended 31 December 2020 have been prepared in accordance with Australian Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001. Compliance with AASB 134 ensures that the financial statements comply with IAS 34 Interim Financial Reporting.

 

These half-year financial statements do not include all the notes of the type normally included in annual financial statements and therefore cannot be expected to provide as complete an understanding of the financial performance, financial position and financing and investing activities of the entity as the full financial statements. Accordingly, these half-year financial statements are to be read in conjunction with the annual financial statements for the year ended 30 June 2020 and any public announcements made by MyFiziq Limited during the half-year reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

 

b) Basis of preparation

 

The half-year financial statements have been prepared on a historical cost basis except for derivative financial instruments which have been measured at fair value. Cost is based on the fair values of consideration given in exchange for assets. Cost is based on the fair values of consideration given in exchange for assets. The Company is domiciled in Australia and all amounts are presented in Australian dollars. For the purpose of preparing the half-year financial statements, the half year has been treated as a discrete reporting period.

 

Going concern

 

The financial report has been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

 

For the half year ended 31 December 2020, the Company incurred an operating loss of A$5,471,570 which included significant non-cash items, such as a provision for impairment and share-based payments, of approximately A$4.5 million. Notwithstanding the fact that the Company incurred an operating loss and a net cash outflow from operating activities amounting to A$1,171,334, the Directors are of the opinion that the Company is a going concern for the following reasons:

 

  MyFiziq is transitioning to “growth” phase and commercializing operations, courtesy of the fifteen binding term sheets that it has executed with partners across its four business verticals. Each partner is expected to launch the MyFiziq technology (which becomes embedded in the partner’s app) over the next 12 months and this is anticipated to generate revenue and potentially bring the Company to breakeven point.

 

  The Company had A$4.7 million cash at bank at the reporting date, which is four (4) times the net cash outflow from operating activities (A$1,171,334) for the six (6) months ended 31 December 2020.

 

  In October 2020, the Company signed an agreement with Nexus-Vita. Under the terms of the agreement, Nexus-Vita will pay MyFiziq a minimum guaranteed revenue of US$3,588,000 in the first year of launch, which more than covers the A$1,171,334 net cash outflow from operations referred to above. The parties expect to commence integration work in March 2021 with a view to a market-ready integration being finalized by 8 May 2021 (refer to the ASX announcements on 6 October 2020 and 9 February 2021).

 

The Company’s ability to continue as a going concern and meet future working capital requirements is dependent on the above points being realized. Should the Company not be successful in generating the required cash flows, there is a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.

 

F-18

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 1 Statement of Significant Accounting Policies (continued)

 

c) New or amended Accounting Standards and Interpretations adopted

 

The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting standards Board (AASB) that are mandatory for the current reporting period.

 

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted by the Group for the reporting period ended 31 December 2020.

 

d) Accounting policies and methods of computation

 

The same accounting policies and methods of computation have generally been followed in these half-year financial statements as compared with the most recent annual financial statements, except for the policies stated below.

 

Investments and Other Financial Assets

 

Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured at either amortized cost or fair value depending on their classification.

 

Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset unless, an accounting mismatch is being avoided.

 

Financial assets are derecognized when the rights to receive cash flows have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off.

 

Financial assets at fair value through profit or loss

Financial assets not measured at amortized cost or at fair value through other comprehensive income are classified as financial assets at fair value through profit or loss. Typically, such financial assets will be either:

 

(i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or

 

  (ii) designated as such upon initial recognition where permitted. Fair value movements are recognized in profit or loss.

 

e) Significant accounting judgements and key estimates

 

The preparation of financial reports requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. The same judgments, estimates and assumptions were used in preparing the half year financial report as those used in preparing the financial report for the year ended 30 June 2020, except for the provision for impairment of investments and convertible loans (refer notes 4 and 5).

 

F-19

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 2 Segment information

 

The Company has identified its operating segments based on the internal reports that are reviewed and used by the board of directors in assessing performance and determining the allocation of resources.

 

Reportable segments disclosed are based on aggregating operating segments, where the segments have similar characteristics. The Company’s sole activity is mobile application and technology development wholly within Australia, therefore it has aggregated all operating segments into the one reportable segment being technological development. It is the Company’s intention to list the Company on the NASDAQ in the United States of America. Once this occurs, the Company will review its operating segments.

 

The reportable segment is represented by the primary statements forming these financial statements.

 

Note 3 Revenue and Expenses

 

   

31 December

2020

6 Months

(unaudited)

A$

    31 December
2019

6 Months

(unaudited)

A$

 
Loss for the period includes the following specific income and expenses:            
             
Other income:                
Dr Katherine consultancy income     9,267       7,449  
Grant income     37,500       -  
Joint venture income     309,711       -  
Other income     -       1,155  
      356,478       8,604  
                 
Marketing and publicity expenses:                
Suppliers share based payment 1     618,561       546,143  
                 
Employee expenses:                
Salaries and wages (net of JobKeeper)     1,087,981       1,138,623  
Executive director salary     148,333       135,000  
Defined contribution superannuation     132,786       119,301  
Annual leave expenses     45,972       42,317  
Recruitment expenses     38,079       1,382  
Share based remuneration expenses 1     2,596,282       887,114  
Employment taxes and insurances     195,971       95,182  
Other employment expenses     2,641       2,300  
                 
      4,248,045       2,421,219  

 

F-20

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 3 Revenue and Expenses (continued)

 

   

31 December

2020

6 Months

(unaudited)

A$

    31 December
2019

6 Months

(unaudited)

A$

 
Loss for the period includes the following specific income and expenses:            
             
Administration and other expenses:            
Travel and accommodation     1,896       164,943  
Insurance     44,344       38,564  
Realised foreign exchange loss     56,355       -  
Unrealised foreign exchange gain     (210,824 )     -  
Other expenses     128,431       83,825  
      20,202       287,332  
                 
Income tax benefit:                
R&D tax concession 2     784,412       666,218  

 

1 The fair value of equity settled transactions with employees and suppliers is apportioned over the period from grant date to vesting date. See Note 8 for details of transactions vesting within the six months ended 31 December 2020.

 

2 The 2020 half-year research and development tax concession relates to amounts received for the R&D tax incentive claim submitted by the Company for the financial year ended 30 June 2020.

 

Note 4 Loans to related entities

 

a) Unsecured loan

 

During the 2019 financial year, the Company entered into a loan agreement with Body Composition Technologies Australia Pty Ltd, a wholly owned subsidiary of Body Composition Technologies Pte Ltd (BCT), a Singaporean company in which MYQ has a 50% interest. The loan is unsecured and must be fully repaid by 30 June 2021 or within 30 days of BCT receiving cash from capital raise activities. The remaining loan balance of A$68,500 was repaid in the current reporting period.

 

b) Convertible note

 

During the reporting period, the Company entered into a convertible note subscription agreement with BCT. Under the terms of the agreement, the Company issued A$670,833 unsecured convertible notes to BCT. The notes earn interest at 2.5% per annum, have a term of 2 years and can be converted into shares in BCT at a conversion price of approximately A$5,833 per share. Any amounts not converted at maturity date must be repaid to the Company in cash. Upon conversion, MyFiziq will take a majority stake of 54.5% in BCT (on a fully diluted basis).

 

The recoverable amount of the convertible note asset is reviewed at each reporting date. At 31 December 2020, the Company created a provision for impairment against the investment in accordance with AASB 13 (‘Fair Value Measurement’). The provision for impairment considers the uncertainty related to a fair valuation of a privately owned entity (BCT). When a more accurate determination of recoverable value can be made, the Company will re-assess whether a provision for impairment is required.

 

   

31 December

2020

6 Months

(unaudited)

A$

    30 June
2020

6 Months

(unaudited)

A$

 
Convertible note receivable     670,833                     -  
Less: Provision for impairment     (670,833 )     -  
      -       -  

 

F-21

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 5 Investments

 

During the reporting period, the Company entered into an agreement with Canadian based Triage Technologies Inc (Triage) that will see the Company invest a total of up to US$6 million for an equity stake in Triage. The investment will comprise US$3 million in cash and US$3 million in MyFiziq ordinary shares. At 31 December the Company had made cash payments of approximately US$672,000 to Triage and recognises this as an investment on the Statement of Financial Position.

 

The recoverable amount of the Company’s investments is reviewed at each reporting date. As Triage is an unlisted entity, the determination of recoverable value is highly subject to various estimates and assumptions. As an accurate assessment of recoverable value is not available at the reporting date, the Company has elected to create a provision for impairment against the investment, as shown below. When a more accurate determination of recoverable value can be made, the Company will re-assess whether a provision for impairment is required.

 

   

31 December

2020

6 Months

(unaudited)

A$

    30 June
2020

6 Months

(unaudited)

A$

 
Investment in Triage Technologies Inc     672,145                    -  
Less: Provision for impairment     (672,145 )     -  
      -       -  

 

Note 6 Interest bearing borrowings

 

    Interest
Rate
%
    Maturity  

31 December
2020

6 Months

(unaudited)

A$

    30 June
2020

6 Months

(unaudited)

A$

 
Current                      
Convertible notes-2018 Facility 1     8 %   30 June 2020     -       75,000  
Convertible notes – ACAM 2                 1,526,607       -  
Convertible notes – 2021 Facility 3                 494,989       -  
Total convertible notes                 2,021,596       75,000  
R&D tax prepayment loan 4                 -       600,000  
Other loans 6                 -       190,000  
                  2,021,596       865,000  
                             
Non-current                            
Convertible notes-ACAM 2                 -       322,331  

 

1

Convertible Note facility entered into with a number of professional investors who are not related parties of the Company. The notes attract interest at 8% per annum. The investors may elect to redeem the outstanding principal amount of the notes in cash on the Maturity Date, rather than convert to shares. At 30 June 2020, a total of A$825,000 principal and accrued interest were converted to shares at a price of 30 cents per share. The balance of the notes at 30 June 2020 was repaid in cash in the current reporting period.

   
2 The Company entered into a funding agreement for US$1,500,000 with Asia Cornerstone Asset Management (ACAM) by way of an unsecured convertible note which attracts interest at 10% per annum. The funds received will enable the Company to seek a dual listing of the Company’s securities on the NASDAQ Capital Market and for general working capital purposes. The funding will be received in 4 tranches, with US$1,125,000 being received to the reporting date. The convertible note has a mandatory conversion upon successful NASDAQ listing. On conversion, ACAM will be issued shares in the NASDAQ listed company at the greater of US$1.00 and a 25% discount to the price at which the Company issues shares in conjunction with the listing. If the Company is not successful in attaining a listing on the NASDAQ on or prior to 30 June 2021, the Company will have an additional 6 months to repay the convertible note.

 

F-22

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

(unaudited)

 

 

 

Note 6 Interest bearing borrowings (continued)

 

3 The Company entered into a funding agreement for US$325,000 with iConcept Global Growth Fund (iConcept) by way of an unsecured convertible note which attracts interest at 10% per annum. The funds received will enable the Company to seek a dual listing of the Company’s securities on the NASDAQ Capital Market and for general working capital purposes. The convertible note has a mandatory conversion upon successful NASDAQ listing. On conversion, iConcept will be issued shares in the NASDAQ listed company at the greater of US$1.00 and a 25% discount to the price at which the Company issues shares in conjunction with the listing. If the Company is not successful in attaining a listing on the NASDAQ on or prior to 30 June 2021, the Company will have an additional 6 months to repay the convertible note.
   
4 On 29 May 2020, the Company received a A$600,000 R&D tax prepayment loan from R&D Capital Partners Pty Ltd: The loan attracts interest at a rate of 1.15% per month and was repaid in full in the current reporting period.
   
6 Other loans are unsecured and interest bearing. These loans were repaid in full in the current reporting period.

 

Note 7 Issued capital

 

    31 December
2020

(unaudited)

#

    30 June
2020

(audited)

#

    31 December
2020

(unaudited)

A$

    30 June
2020

(audited)

A$

 
Share capital                        
Issued ordinary shares     128,383,961       114,392,923       32,991,281       24,355,213  
                                 
Share movements during the period – ordinary shares                                
At the beginning of the period     114,392,923       91,621,888       24,355,213       13,782,265  
Shares issued on exercise of Performance Rights     3,750,000       9,550,000       701,000       6,055,875  
Shares issued on exercise of Options     3,229,371       730,769       1,328,542       206,494  
Shares issued to related party     2,000,000       2,000,000       2,130,000       540,000  
Share based payments     845,000       2,700,000       562,000       556,500  
Share issues – capital raising     4,166,667       3,333,334       5,000,000       2,000,000  
Shares issues - conversion of convertible notes     -       4,456,932       -       1,337,079  
Less share issue costs     -       -       (1,085,474 )     (123,000 )
      128,383,961       114,392,923       32,991,281       24,355,213  
                                 
Share movements during the period – performance shares                                
At the beginning of the period     -       30,000,000       -       300  
Less expired shares 1     -       (30,000,000 )     -       (300 )
      -       -       -       -  

 

1 Performance Shares (15,000,000 Class ‘A’ Performance Shares and 15,000,000 Class ‘B’ Performance Shares) were cancelled due to performance milestones not being met within the stipulated timeframe.

 

Note 8 Share-Based Payments

 

(i) Options

 

The Company has an Incentive Option Plan which was re-adopted following Shareholder approval in November 2019. Options over unissued shares are issued at the discretion of the Board.

 

a) Options issued, exercised and lapsed during the reporting period

 

During the reporting period 4,166,667 placement options and 1,000,000 lead manager options were issued with an exercise price of A$1.60 and an expiry date of 19 October 2023.

 

F-23

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 8 Share-Based Payments (continued)

 

(i) Options (continued)

 

a) Options issued, exercised and lapsed during the reporting period (continued)

 

During the reporting period the following options vested but were not exercised:

 

Grant Date   Number of options
Vested
    Exercise price     Vesting date   Expiry date
31/07/2018     400,000     A$ 0.50     31/12/2020   31/12/2023
14/12/2018     100,000     A$ 0.50     31/12/2020   31/12/2023
01/02/2019     400,000     A$ 0.65     31/12/2020   31/12/2023
27/11/2019     2,500,000     A$ 0.60     04/12/2020   04/12/2022
09/10/2020     1,000,000     A$ 1.60     19/10/2020   19/10/2022
19/10/2020 1     4,166,667     A$ 1.60     19/10/2020   19/10/2022
Total     8,566,667                  

 

1 Free attaching placement options.

 

During the reporting period the following options were exercised:

 

Date granted   Number of options
exercised
    Exercise price
(cents)
    Vesting date   Expiry date
21/12/2016     500,000     A$ 0.10 1   26/10/2018   31/12/2020
31/07/2018     150,000     A$ 0.50 1   31/12/2019   31/12/2022
01/02/2019     200,000     A$ 0.65 1   31/12/2019   31/12/2022
12/02/2019     101,667     A$ 0.60     05/03/2019   20/02/2022
27/11/2019     1,000,000     A$ 0.25     04/12/2019   04/12/2022
27/11/2019     1,500,000     A$ 0.45     04/06/2020   04/12/2022
21/12/2016 2     1,750,000     A$ 0.10     31/12/2017   31/12/2020
Total     5,201,667                  

 

1 Options exercised utilising the cashless exercise provisions of the Option Incentive Scheme. This resulted in the issue of 627,704 ordinary shares.

 

2 Options exercised in the current reporting period, but shares issued subsequent to 31 December 2020.

 

During the reporting period 100,000 options with an exercise price of A$0.50 and an expiry date of 31 January 2022 were cancelled.

 

F-24

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

b) Options on issue at balance date

 

The number of options outstanding over unissued ordinary shares at 31 December 2020 is 13,065,000 as follows:

 

Grant Date   Number of options
granted
    Exercise price     Vesting date   Expiry date
21 Dec 2016     1,750,000     A$ 0.10     31 Dec 2017   31 Dec 2020
21 Dec 2016     1,250,000     A$ 0.10     31 Dec 2018   31 Dec 2021
21 Dec 2016     500,000     A$ 0.10     26 Oct 2019   30 Dec 2021
31 Jul 2018     250,000     A$ 0.50     31 Dec 2019   31 Dec 2022
31 Jul 2018     400,000     A$ 0.50     31 Dec 2020   31 Dec 2023
14 Dec 2018     100,000     A$ 0.50     31 Dec 2019   31 Dec 2022
14 Dec 2018     100,000     A$ 0.50     31 Dec 2020   31 Dec 2023
1 Feb 2019     200,000     A$ 0.65     31 Dec 2019   31 Dec 2022
1 Feb 2019     400,000     A$ 0.65     31 Dec 2020   31 Dec 2023
12 Feb 2019     148,333     A$ 0.60     5 Mar 2019   20 Feb 2022
27 Nov 2019     2,500,000     A$ 0.60     4 Dec 2020   4 Dec 2022
24 Feb 2020     300,000     A$ 0.50     31 Jan 2021   31 Jan 2022
9 Oct 2020     1,000,000     A$ 1.60     19 Oct 2020   19 Oct 2022
19 Oct 2020     4,166,667     A$ 1.60     19 Oct 2020   19 Oct 2022
Total     13,065,000                  

  

c) Subsequent to balance sheet date

 

Subsequent to the balance date 2,737,500 options were exercised into 2,694,642 ordinary shares of the Company. no options have been issued or cancelled since the end of the reporting period.

 

d) Basis and assumptions used in the valuation of options

 

1,000,000 lead manager options were issued during the half-year and have been valued and recognised in the financial statements.

 

The options issued during the current reporting period were valued using the Black-Scholes option valuation methodology, as follows:

 

Grant Date   Number of
options
granted
    Expiry date   Risk free
interest
rate used
    Volatility
applied
    Value per
Option
(cents)
 
9 Oct 2020     1,000,000     19 Oct 2022     0.15 %     130.5 %     68.8  

 

Historical volatility at the time of issue has been used as the basis for determining expected share price volatility, as it is assumed that this is an indicator of future share price performance, which may not eventuate. A discount of 30% in respect of a lack of marketability has been applied to the Black-Scholes option valuation to reflect the non-negotiability and non-transferability of the unlisted options granted.

 

F-25

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

e) Purpose of Equity Compensation Reserve

 

This reserve is used to record the value of equity benefits provided to employees (including directors) and suppliers for services rendered.

 

ii) Performance Rights

 

The Company’s Performance Rights Plan was re-approved by shareholders in December 2020.

 

a) Performance rights granted, vested and lapsed during the year

 

During the reporting period the following performance rights were granted:

 

Grant Date   No of
Rights
    Expiry Date   Fair Value
per Right at
Grant Date
    Vesting
6 Nov 2020     50,000     6 Nov 2026   A$ 0.85     6 Nov 2021
6 Nov 2020     50,000     6 Nov 2026   A$ 0.85     6 Nov 2022
6 Nov 2020     50,000     6 Nov 2026   A$ 0.85     6 Nov 2023
11 Dec 2020     10,000,000     16 Dec 2025     $0.68-$0.93     Performance based with 5 milestones
Total     10,150,000                  

  

Performance rights with vesting criteria based on length of service were valued using the Company’s share price on the date of grant. The 10m performance rights subject to performance based vesting criteria were independently valued using the Hoadley’s Hybrid ESO Model (a Monte Carlo simulation model) using the following parameters:

 

Milestone   Number of
rights
granted
    Share price
target
    Risk free
interest
rate used
    Volatility
applied
    Value per
Right
(cents)
 
1     2,000,000     A$ 1.20       0.04 %     125 %     67.8  
2     2,000,000     A$ 1.30       0.09 %     125 %     78.7  
3     2,000,000     A$ 1.40       0.10 %     125 %     85.1  
4     2,000,000     A$ 1.50       0.22 %     125 %     90.5  
5     2,000,000     A$ 1.70       0.35 %     125 %     93.1  

  

During the reporting period the following performance rights vested:

 

Grant Date   No of
Rights
    Expiry Date   Fair Value
per Right at
Grant Date
    Vesting
6 Sep 2019     1,250,000     28 Feb 2021   A$ 0.182     Subject to performance criteria

  

During the reporting period the following performance rights were exercised and converted to shares:

 

Grant Date   No of
Rights
    Expiry Date   Fair Value
per Right at
Grant Date
    Vesting
15 Nov 2017     500,000     31 Dec 2020   A$ 0.205     Vested
3 Sep 2018     2,000,000     30 Nov 2020   A$ 0.185     Vested
6 Sep 2019     1,250,000     28 Feb 2021   A$ 0.182     Subject to performance criteria
Total     3,750,000                  

  

During the reporting period no performance rights lapsed or were cancelled.

 

F-26

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

b) Performance rights on issue at balance date

 

The number of performance rights outstanding over unissued ordinary shares at 31 December 2020 is 22,150,000 as follows:

 

Grant Date   No of
Rights
    Expiry Date   Fair Value
per Right at
Grant Date
    Vesting
03 Mar 2017     2,000,000     03 Mar 2021   A$ 0.720     Vested
03 Mar 2017     2,000,000     03 Mar 2022   A$ 0.720     Vested
3 Sep 2018     3,000,000     3 Sep 2021   A$ 0.185     Vested
6 Sep 2019     5,000,000     04 Dec 2023   A$ 0.00     Subject to performance criteria
6 Nov 2020     50,000     6 Nov 2026   A$ 0.85     6 Nov 2021
6 Nov 2020     50,000     6 Nov 2026   A$ 0.85     6 Nov 2022
6 Nov 2020     50,000     6 Nov 2026   A$ 0.85     6 Nov 2023
11 Dec 2020     10,000,000     16 Dec 2025     A$0.68-A$0.93     Performance based
Total     22,150,000                  

  

c) Subsequent to balance date

 

Subsequent to the balance date and to the date of signing this report, no performance rights have been granted, vested, exercised or cancelled.

 

iii) Ordinary Shares

 

Subsequent to the balance date and to the date of signing this report, 250,000 fully paid ordinary shares were issued to suppliers as payment in lieu of services.

 

Note 9 Dividends

 

No dividends were paid or proposed during the period.

 

The Company has no franking credits available as at 31 December 2020.

 

Note 10 Contingencies

 

There have been no material changes in contingent assets or liabilities since the signing of the audited 30 June 2020 financial statements.

 

F-27

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 11 Events Occurring after the Balance Date

 

Other than shown below, there has not arisen in the interval between the end of the period and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the Directors of the Company, to affect substantially the operations of the Company, the results of those operations or the state of affairs of the Company in subsequent financial years:

 

On 5 January 2021, the Biomorphik App for android and IOS users in Australia was released on both Google Play and the Apple Store. Under the terms of the commercial contract, Biomorphik has given an undertaking to deliver 100,000 active monthly users in the first 12 months.

 

On 22 January 2021, the Company entered into a funding agreement with Bearn LLC (“Bearn”) under which the Company will loan Bearn US$500,000 over 4 tranches. The funds received will be used to improve Bearn’s platform capabilities and then towards a marketing campaign to target signing 1,000,000 active monthly users to the Bearn platform.

 

On 22 January 2021 Mr Peter Wall resigned as Non-executive Chairman on the Company and Mr Vlado Bosanac was appointed as Executive Chairman.

 

The Company intends to seek shareholder approval at general meeting on 5 March 2021 to change the Company name to Advanced Human Imaging Limited.

 

On 18 February 2021, the Company signed a binding term sheet (“Agreement”) with China-based, Tinjoy Biotech Limited (“Tinjoy”). Under the terms of the Agreement, MyFiziq and Tinjoy have agreed to a revenue sharing arrangement, where the revenue will be shared on a 70% MyFiziq and 30% Tinjoy split. MyFiziq also has an option to invest in Tinjoy’s Winscan Platform and will contribute US$200,000 towards Tinjoy’s marketing costs. MyFiziq expects to start generating licence and other fees from the commercial arrangement in the future (which cannot be forecast at this time).

 

The impact of the Coronavirus (‘COVID-19’) pandemic is ongoing for the entity up to 31 December 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

 

F-28

 

 

 

Notes to the Consolidated Financial Statements

For the half year ended 31 December 2020

 

 

 

Note 12 Commitments

 

  Under the terms of the agreement with Triage, MyFiziq will invest a total of up to US$6 million into Triage, being US$3 million in cash and US$3 million in equity (MyFiziq ordinary shares):

 

  i. The US$3 million cash investment will be made in equal instalments over a fourteen (14) month period, and at the date of signing this report, US$500k in payments had been made, with a further US$2.5 million outstanding.

  

ii. The MyFiziq share tranche allotments (for a total of US$3 million in shares) will be outlined in the definitive Investment Agreement. The pricing, number of MyFiziq shares to be issued and timing of any share issue is yet to be agreed and will be defined in the definitive Investment Agreement.

 

Under the terms of the Agreement with Tinjoy, MyFiziq will contribute US$200,000 towards Tinjoy’s marketing costs, and has an option to invest in Tinjoy’s Winscan Platform as follows:

 

  i. MyFiziq has a right to acquire up to 40% of Tinjoy’s WinScan Platform, priced at a valuation of US$10m taking for consideration to be approximately US$ 2-4 million this can be in cash or shares in MyFiziq or a combination as mutually agreed.

 

  ii. 12- 24-month option to take up the 40% at MyFiziq’s option to acquire a holding in WinScan. The option would be triggered should WinScan achieve user numbers of 5m users a month. This would trigger a 20% investment of US$2m from MyFiziq.

 

  iii. If WinScan achieves a user base if 10m monthly users MyFiziq would be required to take up a 40% stake in WinScan at an agreed investment of US$4m.

 

  iv. In the event MyFiziq exercises its option, the US$200,000 marketing and training advance will form part of the total investment outlined above.

 

There have been no other material changes in operational or capital commitments since the signing of the audited 30 June 2020 financial statements.

 

F-29

 

 

 

Directors’ Declaration

 

 

 

The Directors of MyFiziq Limited (“the Company”) declare that:

 

(a) the attached half-year financial statements and notes thereto are in accordance with the Corporations Act 2001, including:

 

(i) complying with Australian Accounting Standard AASB134 – Interim Financial Reporting, and the Corporations Regulations 2001; and

 

(ii) giving a true and fair view of the financial position as at 31 December 2020 and of the performance for the half year ended on that date of the consolidated entity.

 

(b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

 

This declaration is signed in accordance with a resolution of the Board of Directors made pursuant to s.303(5) of the Corporations Act 2001.

 

Signed at Perth this 26th day of February 2021.

 

/s/ Vlado Bosanac  
Vlado Bosanac  
Executive Chairman and Chief Executive Officer  

 

F-30

 

 

PKF Perth

 

 

 

 

 

 

INDEPENDENT AUDITOR’S REVIEW REPORT

 

TO THE MEMBERS OF MYFIZIQ LIMITED

 

Report on the Half-Year Financial Report

 

Conclusion

 

We have reviewed the half-year financial report of MyFiziq Limited (the company) and controlled entities (consolidated entity) which comprises the consolidated statement of financial position as at 31 December 2020, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information and the directors’ declaration of the consolidated entity comprising the company and the entities it controlled at 31 December 2020, or during the half year.

 

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of MyFiziq Limited is not in accordance with the Corporations Act 2001 including:

 

(a) giving a true and fair view of the consolidated entity’s financial position as at 31 December 2020 and of its performance for the half-year ended on that date; and

 

(b) complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.

 

Basis for Conclusion

 

We conducted our review in accordance with ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity. Our responsibilities are further described in the Auditor’s Responsibilities for the Review of the Financial Report section of our report.

 

Emphasis of Matter

 

Without qualifying our conclusion, we draw attention to Note 1(b) in the financial report in which indicates that the consolidated entity incurred a net loss of A$5,471,570 during the half year ended 31 December 2020 and had negative operating cashflow of A$1,171,334. These conditions, along with other matters as set forth in Note 1(b), indicate the existence of a material uncertainty which may cast significant doubt about the consolidated entity’s ability to continue as a going concern and therefore, the consolidated entity may be unable to realise its assets and discharge its liabilities in the normal course of business, and at the amounts stated in the financial report.

 

Independence

 

We are independent of the company in accordance with the auditor independence requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

 

 

 

Level 4, 35 Havelock Street, West Perth, WA 6005

PO Box 609, West Perth, WA 6872

T: +61 8 9426 8999 F: +61 8 9426 8900 www.pkfperth.com.au

 

PKF Perth is a member firm of the PKF International Limited family of legally independent firms and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm or firms.

 

Liability limited by a scheme approved under Professional Standards Legislation.

 

F-31

 

 

PKF Perth

 

 

 

 

 

 

Directors’ Responsibility for the Interim Financial Report

 

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with the Australian Accounting Standards and the Corporations Act 2001 and for such internal controls as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

 

Auditor’s Responsibilities for the Review of the Financial Report

 

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the consolidated entity’s financial position as at 31 December 2020 and its performance for the half year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporation Regulations 2001.

 

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

 

/s/ PKF Perth  
PKF Perth  
   
/s/ Simon Fermanis  
Simon Fermanis  
Partner  

 

26 February 2021

West Perth,

Western Australia

 

F-32

 

 

 

 

 

 

 

 

 

 

 

MYFIZIQ LIMITED

 

ACN 602 111 115

 

 

 

ANNUAL FINANCIAL STATEMENTS

 

FOR THE YEAR ENDED

30 JUNE 2020

 

 

 

F-33

 

Corporate Directory

 

 

 

Directors   Auditors
Peter Wall (Non-executive Chairman)   PKF Perth
Vlado Bosanac (Executive Director and CEO)   Level 5, 35 Havelock Street
Michael Melby (Non-executive Director)   West Perth WA 6005
Nicholas Prosser (Non-executive Director)    

Dato Low Koon Poh (Non-executive Director - appointed 13 July 2020)

   
   

Company Secretary/

Chief Financial Officer

 

Share Registry

 Automic Registry Services

Steven Richards   Level 2, 267 St Georges Terrace
    Perth WA 6000
    Telephone : +61 8 9324 2099
Registered Office   Facsimile : +61 8 9321 2337
Unit 5, 71-73 The Esplanade    
South Perth WA 6151   ASX Code
    MYQ
     
Principal Place of Business   Website and email addresses
Unit 5, 71-73 The Esplanade   www.myfiziq.com
South Perth WA 6151   admin@myfiziq.com

 

Securities Exchange Listing

The Company’s shares are quoted on the Australian Securities Exchange. The home exchange is Perth, Western Australia.

 

Company Information

The Company is domiciled in Australia.

 

F-34

 

 

Contents Page

 

 

 

  Page
Statement of Profit or Loss and Other Comprehensive Income F-36
Statement of Financial Position F-37
Statement of Changes in Equity F-38
Statement to Cash Flows F-39
Notes to the Financial Statements F-40 - F-71
Certification F-72 - F-75
Independent Auditor’s Report F-76

 

F-35

 

Statement of Profit or Loss and Other

Comprehensive Income

For the financial year ended 30 June 2020

 

 

 

    Note  

Year Ended
30 June
2020
(audited)
A$

    Year Ended
30 June
2019
(audited)
A$
 
Revenue                
Recurring       139,858     4,645  
On Demand         32       -  
                     
Other Income                    
Other income   3     527,293       893,820  
Interest income         14       91  
Total revenue         667,197       898,556  
                     
Expenses                    
Employee expenses   3     (3,899,432 )     (3,823,885 )
Consulting and advisory         (87,924 )     (299,472 )
Corporate         (332,583 )     (296,899 )
Brand development and patent costs         (215,297 )     (263,810 )
Marketing and publicity         (1,052,672 )     (67,934 )
Travel and accommodation         (317,265 )     (233,943 )
Telecommunications & IT         (140,710 )     (120,694 )
Occupancy costs         (63,956 )     (133,882 )
Financing costs         (143,582 )     (136,603 )
Realised foreign exchange losses         (1,135 )     -  
Amortisation and depreciation expense         (245,645 )     (199,570 )
Administration and other expenses         (229,726 )     (210,668 )
Total expenses         (6,729,927 )     (5,787,360 )
                     
Loss before income tax         (6,062,730 )     (4,888,804 )
                     
Income tax benefit   4     666,218       531,642  
                     
Net loss for the year         (5,396,512 )     (4,357,162 )
                     
Other comprehensive income         -       -  
Total comprehensive loss for the year attributable to members         (5,396,512 )     (4,357,162 )
                     
Loss per share       Cents     cents  
Basic and diluted loss per share   5     (5.16 )     (5.16 )

 

The notes to the financial statements form part of this Statement of Profit or Loss and Other Comprehensive Income.

 

F-36

 

 

Statement of Financial Position

As at 30 June 2020

 

 

 

    Note   30 June
2020
(audited)
A$
    30 June
2019
(audited)
A$
 
Current assets                    
Cash and cash equivalents   7     627,304       573,977  
Trade and other receivables   8     294,122       25,427  
Prepayments   9     294,568       -  
Inventories   10     4,734       4,761  
Total current assets         1,220,728       604,165  
                     
Non-current assets                    
Other financial assets   11     37,500       37,500  
Right-of-use asset   12     175,992       -  
Property, plant and equipment   13     78,295       56,083  
Loans to related entities   25     68,500       482,201  
Development asset at cost   14     1,373,492       1,451,148  
Total non-current assets         1,733,779       2,026,932  
                     
Total assets         2,954,507       2,631,097  
                     
Current liabilities                    
Trade and other payables   15     785,939       345,996  
Employee leave liabilities   16     312,463       239,346  
Interest bearing borrowings   17     865,000       1,496,959  
Lease liabilities   18     68,144       -  
Total current liabilities         2,031,546       2,082,301  
                     
Non-current liabilities                    
Interest bearing borrowings   17     322,331       -  
Lease liabilities   18     138,124       -  
Total non-current liabilities         460,455       -  
                     
Total liabilities         2,492,001       2,082,301  
                     
Net Assets         462,506       548,796  
                     
Equity                    
Issued capital   19     24,355,213       13,782,565  
Reserves         4,576,829       9,929,789  
Accumulated losses         (28,469,536 )     (23,163,558 )
                     
Total Equity         462,506       548,796  

 

The notes to the financial statements form part of this Statement of Financial Position.

 

F-37

 

 

Statement of Changes in Equity

For the financial year ended 30 June 2020

(audited)

 

 

 

    Issued
capital
A$
    Accumulated
losses
A$
    Equity
compensation
reserve
A$
    Convertible note
reserve
A$
    Total
A$
 
                               
At 1 July 2018     7,212,356       (18,806,396 )     12,262,363       27,633       695,956  
                                         
Net loss for the year     -       (4,357,162 )     -       -       (4,357,162 )
Other comprehensive income     -       -       -       -       -  
Total comprehensive loss for the year     -       (4,357,162 )     -       -       (4,357,162 )
                                         
Capital raising     3,200,000       -       -       -       3,200,000  
Costs of capital raising     (231,541 )     -       -       -       (231,541 )
Exercise of Performance Rights     3,261,750       -       (3,261,750 )     -       -  
Share-based payments                                        
Suppliers     -       -       34,741       -       34,741  
Directors     340,000       -       -       -       340,000  
Employees     -       -       866,802       -       866,802  
At 30 June 2019     13,782,565       (23,163,558 )     9,902,156       27,633       548,796  

 

   

Issued

capital
A$

    Accumulated
losses
A$
    Equity
compensation
reserve
A$
   

Convertible note

reserve
A$

    Total
A$
 
                               
At 1 July 2019     13,782,565       (23,163,558 )     9,902,156       27,633       548,796  
                                         
Net loss for the year     -       (5,396,512 )     -       -       (5,396,512 )
Other comprehensive income                                        
Total comprehensive loss for the year     -       (5,396,512 )     -       -       (5,396,512 )
                                         
Capital raising     2,000,000       -       -       -       2,000,000  
Costs of capital raising     (123,000 )     -       -       -       (123,000 )
Performance Rights and Options exercised     6,262,369       -       (6,166,243 )     -       96,126  
Options expired             90,534       (90,534 )     -       -  
Performance shares expired     (300 )     -       -       -       (300 )
Conversion of convertible notes     1,337,079       -       -       (27,633 )     1,309,446  
Share-based payments                                        
Suppliers     556,500       -       396,919       -       953,419  
Directors     540,000       -       -       -       540,000  
Employees     -       -       534,531       -       534,531  

At 30 June 2020

    24,355,213       (28,469,536 )     4,576,829       -       462,506  

 

The notes to the financial statements form part of this Statement of Changes in Equity.

 

F-38

 

 

Statement to Cash Flows

For the financial year ended 30 June 2020

 

 

 

    Note  

Year Ended
30 June
2020
(audited)
A$

    Year Ended
30 June
2019
(audited)
A$
 
                 
Cash flows from operating activities                
Receipts from customers         153,291       579,876  
Other income         663,624       51,553  
Research & Development tax incentive and EDMG grant         666,218       598,699  
Interest received         14       -  
Interest and other costs of finance paid         (53,472 )     (20,559 )
Payments to suppliers and employees         (4,126,939 )     (4,468,370 )
Net cash flows used in operating activities   7     (2,697,264 )     (3,258,801 )
                     
Cash flows from investing activities                    
Payments for property, plant and equipment         (62,372 )     (43,565 )
Payments for application development costs         (103,810 )     (48,633 )
Loans to related party         81,500       (150,000 )
Payments for investments         -       -  
Net cash flows used in investing activities         (84,682 )     (242,198 )
                     
Cash flows from financing activities                    
Proceeds from borrowings         1,612,331       1,350,000  
Repayment of borrowings         (698,000 )     (450,000 )
Repayment of lease liabilities   18     (4,923 )     -  
Proceeds from the issue of shares         2,050,000       3,200,000  
Payments for share issue costs         (123,000 )     (196,800 )
Net cash flows from financing activities         2,836,408       3,903,200  
                     
Net decrease in cash assets         54,462       402,201  
                     
Cash at the beginning of the financial year         573,977       171,776  
                     
Cash at the end of the financial year   7     628,439       573,977  
Unrealised foreign currency losses         (1,135 )     -  
Cash at the bank as per the balance sheet         627,304       573,977  

 

The notes to the financial statements form part of this Statement of Cash Flows.

 

F-39

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies

 

(a) Basis of preparation of financial report

 

These financial statements are general purpose financial statements, which have been prepared in accordance with the requirements of the Corporations Act 2001 and comply with other requirements of the law.

 

The Company is a for profit entity. A wholly owned subsidiary, MyFiziq Inc. was incorporated in January 2018 in the United States of America in preparation for the commercialisation of the technology in the USA. The subsidiary was inactive during the period, and as a result, consolidated financial statements have not been prepared.

 

The accounting policies below have been consistently applied to all of the periods presented unless otherwise stated.

 

The financial statements are presented in Australian dollars and have been prepared on a historical cost basis, except for available for sale investments and derivative financial instruments which have been measured at fair value. Cost is based on the fair values of consideration given in exchange for assets.

 

The financial statements are presented in Australian dollars.

 

The financial report of the Company was authorised for issue in accordance with a resolution of Directors on 18th December 2020.

 

(i) Going Concern

 

These financial statements have been prepared on the going concern basis which contemplates the continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

 

For the year ended 30 June 2020, the Company incurred an operating loss of A$5,396,512. Notwithstanding the fact that the Company incurred an operating loss and a net cash outflow from operating activities amounting to A$2,697,265, the Directors are of the opinion that the Company is a going concern for the following reasons:

 

The Company completed a A$5 million capital raise on 14 October 2020 to significantly improve its balance sheet position and provide additional cash flow cover for a further 12 – 18 months.

 

2.5 million options have been exercised between the balance sheet date and the signing date of this report, generating an additional A$925,000 in cleared funds for the Company, which represents approximately 1/3 of the net cash flows used in operating activities for the 12 months ended 30 June 2020.

 

MyFiziq is transitioning to “growth” phase and commercialising operations, courtesy of the fourteen binding term sheets that it has executed with partners across its five business verticals. Each partner is expected to launch the MyFiziq technology (which becomes embedded in the partner’s app) and this is anticipated to generate significant revenue and bring the Company to breakeven point within the next 6 to 12 months.

 

Following the execution of a formal funding agreement for US$1.5 million with Asia cornerstone Asset Management (ACAM) on 1 June 2020, the Company had accumulated over $1.8 million in cash facilities by the end of June 2020 and had cash at bank of A$627,127. Under the terms of the agreement, the full US$1,500,000 had been received by 16 October 2020.

 

On 23 September 2020, the Company’s joint venture partner, Body Composition Technologies Pte Ltd, completed a A$2,000,000 funding round, resulting in additional licence fee income of A$300,000 payable to the Company.

 

The Company signed an agreement with Nexus Vita Pte Ltd (“Nexus-Vita”) on 6 October 2020. Nexus-Vita agreed to guarantee the Company a minimum annual revenue of US$3,588,000 per annum (on a cash basis), from the date of the commercial launch of its app (anticipated to occur by the end of March 2021).

 

The Company received its largest R&D refund to date, A$784,412, in October 2020.

 

COVID-19 has not had any material adverse financial effects on the Company, as announced on the ASX platform on 30 March 2020 and 29 June 2020. Furthermore, as announced to the ASX platform on 30 June 2020, the Company had made significant progress over the period 1 March 2020 to 30 June 2020 (“COVID period”) and had experienced an increase in demand for its technology, driven by global health concerns. In addition, the Company has managed to strengthen its balance sheet over the COVID period as follows:

 

F-40

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

(a) Basis of preparation of financial report (continued)

 

(i) Going Concern (continued)

 

(ii) By securing the ACAM funding of USD1,500,000 of which USD1,125,000 had already been received by 6 August 2020.

 

(iii)

By reducing convertible note debt in the amount of A$1,387,078 by way of share conversion. By reducing cash burn (operating overheads) by 49% over the COVID-19 period, and with the ability to defer a minimum of A$3.34 million in planned spending if required to do so.

 

(iv) By receiving over A$1,063,624 in collectables from its JV partner, Body Composition Technologies Pty Ltd, from 1 April 2020 to August 6, 2020, for work carried out on partner builds and integrations, as well as license fees owing.

 

(v) The Company’s ability to continue as a going concern and meet future working capital requirements is substantiated by the significant inflow of cash flow after the balance sheet date, as mentioned above.

 

(vi)

The Company successfully executed a A$600,000 research and development (“R & D”) advance with R&D Capital Partners Pty Ltd for an R & D tax incentive payment that is expected to be received in relation to the 2020 financial year (2019: A$666,218).

 

(ii) Statement of Compliance

 

The financial report complies with Australian Accounting Standards, which include Australian Equivalents to International Financial Reporting Standards (AIFRS), in their entirety. Compliance with AIFRS ensures that the financial report also complies with International Financial Reporting Standards (IFRS) in their entirety.

 

Material accounting policies adopted in the presentation of these financial statements are presented below.

 

(iii) New Accounting Standards adopted in the current year

 

Application of New and Revised Accounting Standards

 

The Company has adopted all the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (“AASB”) that are mandatory for the current reporting period.

 

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted by the Company for the reporting year ended 30 June 2020.

 

The following Accounting Standards and interpretations are most relevant to the Company:

 

AASB 16 Leases

 

AASB 16 Leases supersedes AASB 117 Leases. The new standard removes the former distinction between ‘operating and ‘finance’ leases and requires recognition of a right-of-use asset (the leased item) and a financial liability (to pay rentals) on the Statement of Financial Position. The exceptions are short-term leases and leases of low value assets.

 

The Company leases its office premises which, prior to the application of AASB 16, was treated as an operating lease and payments made were charged to profit or loss on a straight-line basis over the period of the lease. For the first half of the reporting period, the office lease was renewed on a monthly basis and as such, the Company has applied the optional exemptions to not capitalise this lease and instead account for the lease expense on a straight-line basis over the lease term. An amount of A$45,390 has been expensed in relation to the short-term lease for the 6 months ending 31 December 2019.

 

F-41

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

On 1 January 2020, the Company entered a 3-year lease for office premises which is accounted for under AASB 16. The Company has recognised a right-of-use asset and a corresponding liability at the commencement date. Each lease payment is allocated between the liability and the finance cost. The finance cost is charged to profit or loss over the lease period to produce a consistent period rate of interest on the remaining balance of the liability for each period. Right-of-use assets are depreciated on a straight-line basis over the term of the lease (or the useful life of the leased asset if this is shorter). Depreciation starts on commencement date of the lease.

 

For classification within the statement of cash flows, the interest portion is disclosed in operating activities and the principal portion of the lease payments is separately disclosed in financing activities.

 

New accounting policies adopted for the first time during this reporting period in relation to operating leases are disclosed in notes 1(l) and 1(o). Further information on the Right of use Asset and the Lease liability can be found in notes 11 and 18 respectively.

 

New Accounting Standards and Interpretations Not Yet Mandatory or Early Adopted

 

The AASB has issued new and amended Accounting Standards and Interpretations that have mandatory application date for future reporting periods.

 

There are no material new or amended Accounting Standards which will materially affect the Company.

 

(b) Income tax

 

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the reporting date.

 

Deferred income tax is provided on all temporary differences at reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

 

Deferred income tax liabilities are recognised for all taxable temporary differences except:

 

when the deferred income tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or

 

when the taxable temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, and the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

 

Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilised, except:

 

when the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or

 

when the deductible temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, in which case a deferred tax asset is only recognised to the extent that it is probable that the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilised.

 

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

 

Unrecognised deferred income tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

 

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance date.

 

Income taxes relating to items recognised directly in equity are recognised in equity and not in the statement of profit or loss and other comprehensive income.

 

F-42

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to the same taxable entity and the same taxation authority.

 

(c) Goods and services tax

 

Revenues, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the Australian Tax Office (ATO). In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense.

 

Receivables and payables are stated with the amount of GST included.

 

The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the statement of financial position.

 

Cash flows are included in the statement of cash flows on a gross basis. The GST components of cash flows arising from investing and financing activities that are recoverable from or payable to the ATO are classified as operating cash flows.

 

(d) Impairment of tangible and intangible assets other than goodwill

 

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Company makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.

 

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to continuing operations are recognised in those expense categories consistent with the function of the impaired asset unless the asset is carried at revalued amount (in which case the impairment loss is treated as a revaluation decrease).

 

An assessment is also made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognised impairment loss is reversed only if there has been a change in the estimate used to determine the assets recoverable amount since the last impairment loss was recognised. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in previous years. Such reversal is recognised in profit or loss unless the asset is carried at revalued amount, in which case the reversal is treated as a revaluation increase. After such reversal the depreciation charge is adjusted in future periods to allocate the assets revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.

 

(e) Impairment of financial assets

 

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Company makes an estimate of the asset’s recoverable amount. An asset’s recoverable amount is the higher of its fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset’s value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.

 

F-43

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Impairment losses relating to continuing operations are recognised in those expense categories consistent with the function of the impaired asset unless the asset is carried at revalued amount (in which case the impairment loss is treated as a revaluation decrease).

 

(f) Intangible assets

 

An intangible asset arising from externally acquired intellectual property and development expenditure on an internal project is recognised only when the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the development and the ability to measure reliably the expenditure attributable to the intangible asset during its development. Following the initial recognition, the cost model is applied requiring the asset to be carried at cost less any accumulated amortisation and accumulated impairment losses.

 

The amortisation method and useful life of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

 

The following useful life is used in the calculation of amortisation:

 

Development asset at cost 10 years

 

(g) Revenue and other income

 

Revenue is measured at the fair value of the consideration received or receivable and is recognised when performance obligations under customer contracts are satisfied.

 

1. Revenue from customers

 

The Company’s primary revenue stream is software development kits provided to customers by way of a license agreement (for the use MyFiziq’s intellectual property) and charged to our customer’s end-users on a per user or per body scan basis.

 

The Company also has secondary revenue streams including:

 

Integration fees

 

Licence fees

 

Other application development and support fees

 

i) Identification of distinct elements and separate performance obligations

 

Primary revenue streams

 

Revenue is generated from the usage by end-users of MyFiziq’s software development kits, which have been integrated into a customer’s platform. Most contracts will be structured on a monthly recurring basis and have a minimum term of 1 year.

 

Per user - Revenue is charged per subscribed user, where per user price reduces based on the volume of users.

 

Per body scan - The customer is charged when an image is captured by an end-user.

 

Secondary revenue streams

 

These services can be provided at any point in time over the life of the contract and are usually a one off, or a series of one-off events.

 

F-44

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

(g) Revenue and other income (continued)

 

ii. Revenue recognition under AASB 15

 

Revenue Stream   Performance Obligation   Timing of Recognition
Software development kits - per user   Integration of the MyFiziq software development kits into the customer’s platform, a performance obligation is triggered when an end-user subscribes (to the customer’s platform)   Over the life of the agreement between our customer and the end-user, as the end-user simultaneously receives and consumes the benefits of accessing the software
         
Software development kits - per body scan   Integration of the MyFiziq software development kits into the customer’s platform, a performance obligation is triggered each time an image is captured by the end-user   Recognised over time, but because time delivered is minimal, point in time recognition has been applied
         
Secondary revenue streams   As defined in the contract, either at the start of the service or as requested by the customer over the life of the contract   Recognised over time, but because time delivered is minimal, point in time recognition has been applied

 

2. Other income

 

Revenue recognised in any period is based on the delivery of performance obligations and an assessment of when control is transferred to the customer. Revenue is recognised either when the performance obligation has been performed, or over time as control of the performance obligation is transferred to the customer.

 

3. Interest received

 

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be reliably measured.

 

All revenue is stated net of the amount of goods and services tax.

 

(h) Cash and cash equivalents

 

Cash and short-term deposits in the statement of financial position comprise cash at bank and in hand. Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

 

For the purposes of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

 

(i) Trade and other receivables

 

Trade receivables, which generally have 30–90-day terms, are recognised and carried at original invoice amount less an allowance for any uncollectible amounts. An allowance for doubtful debts is made when there is objective evidence that the Company will not be able to collect the debts. Bad debts are written off when identified.

 

(j) Inventories

 

Inventories are valued at the lower of cost and net realisable value. Net realisable value represents the estimated selling price less all estimated costs of completion and costs necessary to make the sale.

 

F-45

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

(k) Property, Plant and Equipment

 

Plant and equipment is stated at cost less accumulated depreciation and any accumulated impairment losses. The carrying amount of plant and equipment is reviewed annually to ensure it is not more than the recoverable amount from these assets.

 

Depreciation is calculated on a straight-line basis over the estimated useful life of the assets as follows:

 

Class of Asset   Useful Life
Office Equipment   3 – 5 years
Furniture & Fixtures   5 – 7 years

 

The assets’ residual values, useful lives and amortisation methods are reviewed, and adjusted if appropriate, at each financial year end.

 

(l) Right-of-use Assets

 

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

 

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

 

The Company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

 

(m) Investments in equity-accounted investees

 

The Company’s interest in equity-accounted investees comprise an interest in a joint venture. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to its assets and obligations for its liabilities.

 

Interests in the joint venture are accounted for using the equity method. The interest is initially recognised at cost, which includes transaction costs. After initial recognition, the financial statements include the Company’s share of the profit or loss of equity-accounted investees, until the date on which joint control ceases.

 

(n) Trade and other payables

 

Trade payables and other payables are carried at amortised costs and represent liabilities for goods and services provided to the Company prior to the end of the financial period that are unpaid and arise when the Company becomes obliged to make future payments in respect of the purchase of these goods and services.

 

F-46

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 1 Summary of Significant Accounting Policies (continued)

  

(o) Lease liabilities

 

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

 

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

 

(p) Issued capital

 

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

 

Performance shares are classified as equity and are convertible into fully paid ordinary shares of the Company on successful achievement of certain predetermined key performance indicators. Refer to note 19 for details of key performance indicators applying to performance shares currently on issue.

 

(q) Share-based Payments

 

Equity Settled Transactions:

 

The Company provides benefits to employees (including senior executives) of the Company in the form of share-based payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions).

 

The cost of these equity-settled transactions with employees is measured by reference to the fair value of the equity instruments at the date at which they are granted. The fair value of Options is determined by using an appropriate valuation model. Share rights are valued at the underlying market value of the ordinary shares over which they are granted.

 

In valuing equity-settled transactions, no account is taken of any performance conditions, other than conditions linked to the price of the underlying Shares (market conditions) if applicable.

 

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (the vesting period).

 

The cumulative expense recognised for equity-settled transactions at each reporting date until vesting date reflects:

 

(i) the extent to which the vesting period has expired; and

 

(ii) the Company’s best estimate of the number of equity instruments that will ultimately vest.

 

No adjustment is made for the likelihood of market performance conditions being met as the effect of these conditions is included in the determination of fair value at grant date. The income statement charge or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of that period.

 

No expense is recognised for awards that do not ultimately vest, except for awards where vesting is only conditional upon a market condition.

 

F-47

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 1 Summary of Significant Accounting Policies (continued)

 

(q) Share-based Payments (continued)

 

If the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any modification that increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee, as measured at the date of modification.

 

If an equity-settled award is cancelled, the cumulative expense recognised in respect of that award is transferred from its respective reserve to accumulated losses. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled award and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

 

(r) Critical accounting estimates and judgements

 

The preparation of financial reports requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

 

Coronavirus (COVID-19) pandemic

 

Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the entity based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the entity operates. Other than as addressed in specific notes, there does not currently appear to be either any significant impact upon the financial statements or any significant uncertainties with respect to events or conditions which may impact the entity unfavourably as at the reporting date or subsequently as a result of the Coronavirus (COVID-19) pandemic.

 

Estimation of useful life of assets

 

The Company determines the estimated useful lives and related depreciation and amortisation charges for its finite life intangible assets. The useful lives could change significantly as a result of technical innovation or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

 

Capitalisation of internally developed software

 

Distinguishing the research and development phases of a new customised software project and determining whether the recognition requirements for the capitalisation of development costs are met requires judgement. After capitalisation, management monitors whether the recognition requirements continue to be met and whether there are any indicators that capitalised costs may be impaired. Management is required to make judgements, estimates and assumptions for the Net Present Value model which supports the carrying value of the software, its useful life and its amortisation rate.

 

Share-based Payments

 

The Company measures the cost of cash-settled share-based payments at fair value using the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted, as well as estimates made by management.

 

Determination of incremental borrowing rate

 

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, an estimate of the Company’s incremental borrowing rate is used.

 

To determine the incremental borrowing rate, where possible recent third-party financing received is used as a starting point and adjusted to reflect changes in financing conditions since third party financing was received. If there was no recent third-party financing agreement, a build-up approach is used that starts with a risk-free interest rate adjusted for credit risk for the lessee and any further relevant adjustments specific to the lease.

 

F-48

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 2 Segment Information

 

Currently, the Company’s sole activity is mobile application and technology development wholly within Australia, therefore it has aggregated all operating segments into the one reportable segment being technological development.

 

Note 3 Revenue and Expenses

 

    2020
A$
(audited)
    2019
A$
(audited)
 
Loss for the period includes the following specific income and expenses:            
Income:            
Dr Katherine consultancy income     19,105       31,595  
Grant income     80,000       67,057  
Proof of concept income     -       50,000  
Joint venture income     420,839       743,614  
Other income     7,349       1,554  
      527,293       893,820  
                 
Supplier share-based payment 1,2     953,419       34,741  
Employee expenses:                
Salaries and wages     2,489,955       2,116,740  
Defined contribution superannuation     236,502       200,754  
Share-based payments expense 2     1,120,357       1,206,802  
Employment taxes and insurances     99,294       177,934  
Other employment expenses     97,324       121,655  
Government assistance     (144,000 )     -  
                 
      3,899,432       3,823,885  

 

1 Options issued to suppliers under corporate advisory and investor relations consultancy agreements.

 

2 The fair value of equity settled transactions with employees, directors and suppliers is apportioned over the period from grant date to vesting date. See Note 20 for details of transactions vesting within the financial year.

 

F-49

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 4 Income Tax

 

    2020
A$
(audited)
    2019
A$
(audited)
 
a) Income tax expense            
Current income tax:            
Current income tax charge (benefit)     (527,876 )     (317,074 )
Current income tax not recognised     527,876       317,074  
Research and development tax concession     (666,218 )     (531,642 )
Deferred income tax:                
Relating to origination and reversal of timing differences     1,889,890       1,929,986  
Deferred income tax benefit not recognised     (1,889,890 )     (1,929,986 )
Income tax benefit reported in the Statement of profit or loss and other comprehensive income     (666,218 )     (531,642 )

 

b) Reconciliation of income tax expense to prima facie tax payable            
Loss from continuing operations before income tax expense     (6,062,730 )     (4,888,804 )
                 
Tax at the Australian rate of 25% (2019: 27.5%)
    (1,515,682 )     (1,344,421 )
Capital raising costs claimed     (43,509 )     (52,166 )
Non-deductible expenses     118,321       109,372  
Impact of reduction of future corporate tax rate     (151,569 )     -  
Research and development tax concession     (666,218 )     (531,642 )
Unused tax losses and temporary differences not recognised as deferred tax assets     1,592,439       1,287,214  
Tax benefit     (666,218 )     (531,642 )

 

c) Deferred tax – Statement of Financial Position (unrecognised)            
Liabilities            
Accrued income     (21,450 )     -  
Prepaid expenses     (81,006 )     -  
      (102,456 )     -  
Assets                
Revenue losses available to offset against future taxable income     1,805,745       1,812,962  
Accrued expenses and leave provisions     121,337       79,980  
Deductible equity raising costs     65,264       37,044  
      1,992,346       1,929,986  
Net deferred tax asset     1,889,890       1,929,986  

 

F-50

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 4 Income Tax (continued)

 

Deferred tax assets have been recognised to the extent that they extinguish deferred tax liabilities of the Company as at the reporting date.

 

Net deferred tax assets have not been recognised, in either reporting period, in respect of amounts in excess of deferred tax liabilities.

 

The deferred tax benefit of tax losses not brought to account will only be obtained if:

 

(i) The Company derives future assessable income of a nature and an amount sufficient to enable the benefit from the tax losses to be realised;

 

(ii) The Company continues to comply with the conditions for deductibility imposed by tax legislation; and

 

(iii) No changes in tax legislation adversely affect the Company realising the benefit from the deduction of the losses.

 

All unused tax losses were incurred by Australian entities.

 

Note 5 Loss per Share

 

    2020
A$
(audited)
    2019
A$
(audited)
 
a) Basic loss per share            
Loss attributable to ordinary equity holders of the Company (cents)     (5.16 )     (5.16 )

 

b) Diluted loss per share            
Loss attributable to ordinary equity holders of the Company (cents)     (5.16 )     (5.16 )

 

c) Loss used in calculation of basic and diluted loss per share            
Loss after tax from continuing operations     (5,396,512 )     (4,357,162 )

 

d) Weighted average number of shares used as the denominator  

No.

    No.  
Weighted average number of shares used as the denominator in calculating basic and dilutive loss per share     104,619,383       84,454,765  

 

Note 6 Dividends

 

No dividends were paid or proposed during the financial years ended 30 June 2020 and 30 June 2019.

 

The Company has no franking credits available as at 30 June 2020 and 2019.

 

Note 7 Cash and Cash Equivalents

 

Cash at bank1     627,304       573,977  

  

1 Cash at bank earns interest at floating rates based on daily deposit rates.

 

F-51

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 7 Cash and Cash Equivalents (continued)

 

Reconciliation to the Statement of Cash Flows:

 

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise cash on hand and at bank and investments in money market instruments, net of any outstanding bank overdrafts.

 

Cash and cash equivalents as shown in the Statement of Cash Flows is reconciled to the related items in the Statement of Financial Position as follows:

 

   

2020
A$

(audited)

    2019
A$
(audited)
 
Cash and cash equivalents     627,304       573,977  

  

Non-cash financing and investing activities:

 

There were no non-cash financing or investing activities during the years ended 30 June 2020 and 30 June 2019.

 

Cash balances not available for use:

 

There are no amounts included in cash and cash equivalents not available for use as at 30 June 2020 (30 June 2019: Nil).

 

Reconciliation of loss after tax to net cash outflow from operating activities:

 

Loss from ordinary activities after income tax     (5,396,512 )     (4,357,162 )
Adjustments for non-cash items:                
Depreciation and amortisation     245,645       199,570  
Share-based payments expense     2,073,776       1,206,802  
Finance costs     90,110       116,043  
Unrealised foreign currency losses     1,135       -  
                 
Movement in assets and liabilities:                
Decrease/(increase) in prepaid expenses     (294,568 )     61,966  
Decrease in inventories     27       27  
Decrease/(increase) in trade and other receivables     (268,695 )     108,524  
(Decrease)/increase in loans to other entities     332,201       (332,201 )
(Decrease)/increase in employee liabilities/provisions     73,117       (222,706 )
(Decrease)/increase in trade and other payables     446,500       (39,664 )
Net cash flow used in operating activities     (2,697,264 )     (3,258,801 )

F-52

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 8 Trade and Other Receivables

 

   

2020
A$

(audited)

    2019
A$
(audited)
 
Current assets            
Trade receivables     209,979       5,109  
Accrued income     78,000       -  
GST receivable     6,143       20,318  
      294,122       25,427  

 

Note 9 Prepayments

 

Current assets                
Prepaid IPO costs     190,397       -  
Prepaid insurance     91,438       -  
Other prepayments     12,733       -  
      294,568       -  

 

Note 10 Inventories

 

Current assets

 

Finished goods - at cost     4,734       4,761  

 

Note 11 Other Financial Assets

 

Non-current assets

 

Security Bonds and Deposits:

 

Balance at the start of the financial year     37,500       37,500  
Security deposits (refunded)/paid during the financial year     -       -  
Balance at the end of the financial year     37,500       37,500  

 

A security deposit of A$37,500 is in place in respect of the lease on the Company’s offices. Refer Note 22.

 

Note 12 Right of Use Assets

 

Non-current assets

 

Balance at the start of the financial year   -     -  
Additions - new operating leases     211,191          
Amortisation expense     (35,199 )     -  
Balance at the end of the financial year     175,992       -  

 

The Company leases land and buildings for its offices in Perth, Australia under an agreement with a 3-year term. Refer Note 18.

 

F-53

 

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

 

Note 13 Property, Plant and Equipment

 

   

2020

A$
(audited)

   

2019

A$
(audited)

 

 

Carrying values

           
Office Equipment:            
Cost     123,963       114,096  
Depreciation     (89,144 )     (61,648 )
      34,819       52,448  
Fixtures and fittings:                
Cost     13,524       13,524  
Depreciation     (12,594 )     (9,889 )
      930       3,635  
Leasehold improvements                
Cost     51,055       -  
Depreciation     (8,509 )     -  
      42,546       -  
      78,295       56,083  
Reconciliation of movements                
                 
Office Equipment:                
Opening net book value     52,448       33,594  
Additions     9,867       43,983  
Depreciation     (27,496 )     (25,129 )
Closing net book value     34,819       52,448  
                 
Fixtures and fittings:                
Opening net book value     3,635       6,340  
Additions     -       -  
Depreciation     (2,705 )     (2,705 )
Closing net book value     930       3,635  
                 
Leasehold improvements                
Opening net book value     -       -  
Additions     51,055       -  
Depreciation     (8,509 )     -  
Closing net book value     42,546       -  
      78,295       56,083  

 

No assets included in property, plant and equipment have been pledged as security in respect of liabilities.

 

F-54

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

   

Note 14 Development Asset

 

   

2020

A$
(audited)

   

2019

A$
(audited)

 
Balance at the start of the financial year     1,451,248       1,560,388  
Application development costs incurred during the year     93,980       62,496  
Amortisation     (171,736 )     (171,736 )
Balance at the end of the financial year     1,373,492       1,451,148  

 

The recoupment of costs carried forward in relation to intangible assets is dependent upon the successful development or commercial exploitation or sale of the application technology.

 

Note 15 Trade and other payables

 

Current liabilities            
             
Trade payables and other payables     343,603       101,057  
Accrued expenses     128,763       51,491  
Employment related payables     313,573       193,448  
      785,939       345,996  

 

Trade payables are non-interest bearing and normally settled on 30-day terms. See note 21 for financial instrument disclosures relating to trade and other payables.

 

Note 16 Employee leave liabilities

 

Current liabilities            
             
Annual leave liability     312,463       239,346  

 

F-55

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 17 Interest bearing borrowings

 

   

2020

A$
(audited)

   

2019

A$
(audited)

 

Current

           
Convertible notes-Prosser Facility 1     -       539,042  
Convertible notes-2018 Facility 2     75,000       957,917  
Total convertible notes 3     75,000       1,496,959  
R&D tax prepayment loan 4     600,000       -  
Other loans 5     190,000       -  
      865,000       1,496,959  
                 
Non-current                
Convertible notes-ACAM 6     322,331       -  

 

1 Convertible Note agreement with Prosser Enterprises Pty Ltd as Trustee for the Prosser Family Trust. Company director Mr Nicholas Prosser is a director and shareholder of Prosser Enterprises Pty Ltd. The maximum facility limit is A$2 million and attracts interest at 8% per annum. Drawdowns against this facility of A$500,000 and accrued and unpaid interest at 30 June 2020 of A$28,436 (2019: A$58,125) were converted to shares on 30 June 2020 at a price of 30 cents per share.

 

2 Convertible Note facility entered into with a number of professional investors who are not related parties of the Company. The notes attract interest at 8% per annum. The investors may elect to redeem the outstanding principal amount of the notes in cash on the Maturity Date, rather than convert to shares. If the investors don’t elect to redeem the outstanding principal amount in cash, the outstanding principal amount of the notes will be converted into shares at an issue price equal to the greater of A$0.30 per share or a 30% discount to the volume weighted average price of the Company’s shares as traded on ASX for the period of 14 trading days up to and including the trading day prior to the conversion. At 30 June 2020, a total of A$825,000 principal and accrued interest were converted to shares at a price of 30 cents per share.

 

3 The carrying value of the convertible note as at 30 June 2020, based on a discount rate of 12%, is calculated as follows:

 

     

2020

A$
(audited)

   

2019

A$
(audited)

 
  Balance at the start of the financial year     1,496,959       480,915  
  Proceeds from drawdown     -       900,000  
  Amount classified as equity     27,633       -  
  Interest accrued     85,487       116,044  
  Principal and Interest repayments     (198,000 )     -  
  Converted to equity at A$0.30 per share     (1,337,079 )     -  
  Balance at the end of the financial year     75,000       1,496,959  

 

F-56

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 17 Interest bearing borrowings (continued)

 

4 On 29 May 2020, the Company received a A$600,000 R&D tax prepayment loan from R&D Capital Partners Pty Ltd: The loan attracts interest at a rate of 1.15% per month and is due to be repaid on the earlier of the date the Company receives it 2020 tax refund from the Australian Taxation Office or 31 October 2020. The loan is secured by a lien on the Company’s 2020 R&D tax refund.

 

5 Other loans are unsecured and interest bearing. These loans were repaid in full subsequent to the end of the financial year.

 

6 The Company entered into a funding agreement for US$1,500,000 with Asia Cornerstone Asset Management (ACAM) by way of an unsecured convertible note which attracts interest at 10% per annum. The funds received will enable the Company to seek a dual listing of the Company’s securities on the NASDAQ Capital Market and for general working capital purposes. The funding will be received in 4 tranches, with the first tranche of US$225,000 being received in the financial year. The convertible note has a mandatory conversion upon successful NASDAQ listing. On conversion, ACAM will be issued shares in the NASDAQ listed company at the greater of US$1.00 and a 25% discount to the price at which the Company issues shares in conjunction with the listing. In the event that the Company is not successful in attaining a listing on the NASDAQ on or prior to 30 June 2021, the Company will have an additional 6 months to repay the convertible note.

 

Note 18 Lease liabilities

 

   

2020

A$
(audited)

   

2019

A$
(audited)

 
Current liability     68,144       -  
Non-current liability     138,124       -  
Balance at the end of the financial year     206,268       -  
                 
Reconciliation of lease liabilities                
Balance at the beginning of the financial year     -       -  
Lease liability recognised - new operating lease 1     211,191          
Repayment of lease liability     (4,923 )     -  
Balance at the end of the financial year     206,268       -  

 

1 The Company entered into a 3-year lease agreement for office premises in Perth, Australia. During the year, total payments under the lease amounting to A$299,129 were discounted at the Company’s incremental borrowing rate of 10% in order to determine the initial lease liability of A$211,191. To determine the incremental borrowing rate, recent third-party financing received was used as a starting point and adjusted to reflect changes in financing conditions since the third-party financing was received.

 

During the financial year, A$21,119 interest on the lease was expensed as financing costs.

 

F-57

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 19 Issued Capital and Reserves

 

a) Ordinary shares

 

The Company is a public company limited by shares, incorporated in Perth, Western Australia. The Company’s shares are limited whereby the liability of its members is limited to the amount (if any) unpaid on the shares respectively held by them.

 

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.

 

Ordinary shares have no par value. There is no limit to the authorised share capital of the Company. There are no externally exposed capital requirements.

 

    2020     2019     2020     2019  
    No.
(audited)
    No.
(audited)
    A$
(audited)
    A$
(audited)
 
                         
b) Share capital                                
Issued capital-ordinary shares     114,392,923       91,621,888       24,355,213       13,782,265  
Issued capital-performance shares     -       30,000,000       -       300  
Issued share capital     114,392,923       121,621,888       24,355,213       13,782,565  
                                 
c) Share movements during the year – ordinary shares                                
At the start of the financial year     91,621,888       79,038,555       13,782,265       7,212,056  
Shares issued on exercise of Performance Rights     9,550,000       6,250,000       6,055,875       3,261,750  
Shares issued on exercise of Options     730,769       -       206,494       -  
Shares issued to related party     2,000,000       1,000,000       540,000       340,000  
Share based payments     2,700,000       -       556,500       -  
Share issues - capital raising     3,333,334       5,333,333       2,000,000       3,200,000  
Shares issues – conversion of convertible notes     4,456,932       -       1,337,079       -  
Less share issue costs     -       -       (123,000 )     (231,541 )
      114,392,923       91,621,888       24,355,213       13,782,265  
                                 
d) Share movements during the year – performance shares                                
At the start of the financial year     30,000,000       30,000,000       300       300  
Less expired shares 1     (30,000,000 )     -       (300 )     -  
      -       30,000,000       -       300  

 

1 Performance Shares (15,000,000 Class A Performance Shares and 15,000,000 Class B Performance Shares) were cancelled due to performance milestones not being met within the stipulated timeframe.

 

F-58

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 20 Share-based Payments

 

(i) Options

 

The Company has an Incentive Option Plan which was re-adopted following Shareholder approval in November 2019. Options over unissued shares are issued at the discretion of the Board.

 

a) Options granted, issued, exercised and lapsed during the year

 

During the reporting period the following options were issued:

 

Date granted   Number of
options granted
 

Exercise price

(cents)

  Vesting Date   Expiry date  

Fair value
A$

 
27 Nov 2019   1,000,000   25   4 Dec 2019   4 Dec 2022   118,889  
27 Nov 2019   1,500,000   45   4 Jun 2020   4 Dec 2022   148,503  
27 Nov 2019   2,500,000   60   4 Dec 2020   4 Dec 2022   222,047  
24 Feb 2020   400,000   50   31 Jan 2021   31 Jan 2022   19,786  
Total   5,400,000                  

 

During the reporting period the following options were cancelled:

 

Date granted   Number of options  

Exercise price

(cents)

  Vesting date   Expiry date
14 Dec 2018     150,000     50   31 Dec 2019   31 Dec 2022
14 Dec 2018     150,000     50   31 Dec 2020   31 Dec 2023
Total     300,000              

 

During the reporting period the following options vested, but were not exercised:

 

Date granted   Number of
options Vested
 

Exercise price

(cents)

  Vesting date   Expiry date
21 Dec 2016     500,000     10   26 Oct 2019   31 Dec 2021
3 Sep 2018     400,000     50   31 Dec 2019   31 Dec 2022
14 Dec 2018     250,000     50   31 Dec 2019   31 Dec 2022
1 Feb 2019     400,000     65   31 Dec 2019   31 Dec 2022
27 Nov 2019     1,000,000     25   4 Dec 2019   4 Dec 2022
27 Nov 2019     1,500,000     45   4 Jun 2020   4 Dec 2022
Total     4,050,000              

 

During the reporting period the following options were exercised:

 

Date granted   Number of
options exercised
 

Exercise price

(cents)

  Vesting date   Expiry date
21 Dec 2016 1     1,000,000     20   30 Sept 2017   30 Sept 2020
6 Apr 2018     500,000     10   6 Apr 2018   31 Dec 2020
Total     1,500,000              

 

1 During the reporting period 1,000,000 options exercisable at 20 cents each and expiring 30 September 2020, were exercised utilising the cashless exercise provisions of the Option Incentive Scheme. This resulted in the issue of 230,769 ordinary shares.

 

F-59

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 20 Share-based Payments (continued)

 

b) Options on issue at balance date

 

The number of options outstanding over unissued ordinary shares at 30 June 2020 is 11,450,000 as follows:

 

Date granted

  Number of options granted  

Exercise price

(cents)

  Vesting date   Expiry date
21 Dec 2016     1,750,000     10   31 Dec 2017   31 Dec 2020
21 Dec 2016     500,000     10   26 Oct 2018   31 Dec 2020
21 Dec 2016     1,250,000     10   31 Dec 2018   31 Dec 2021
21 Dec 2016     500,000     10   26 Oct 2019   30 Dec 2021
31 Jul 2018     400,000     50   31 Dec 2019   31 Dec 2022
31 Jul 2018     400,000     50   31 Dec 2020   31 Dec 2023
7 Dec 2018     100,000     50   31 Dec 2019   31 Dec 2022
7 Dec 2018     100,000     50   31 Dec 2020   31 Dec 2023
1 Feb 2019     400,000     65   31 Dec 2019   31 Dec 2022
1 Feb 2019     400,000     65   31 Dec 2020   31 Dec 2023
12 Feb 2019     250,000     60   5 Mar 2019   20 Feb 2022
27 Nov 2019     1,000,000     25   4 Dec 2019   4 Dec 2022
27 Nov 2019     1,500,000     45   4 Jun 2020   4 Dec 2022
27 Nov 2019     2,500,000     60   4 Dec 2020   4 Dec 2022
24 Feb 2020     400,000     50   31 Jan 2021   31 Jan 2022
Total     11,450,000              

 

During the current period the following movements in options over unissued shares occurred:

 

    2020     2020     2019     2019  
    No.
(audited)
    WAEP
(audited)
    No
(audited)
    WAEP
(audited)
 
                         
Outstanding at 1 July     7,850,000     A$ 0.251       10,000,000     A$ 0.258  
Granted during the year     5,400,000     A$ 0.486       6,350,000     A$ 0.523  
Exercised during the year     (1,500,000 )   A$ 0.167       -       -  
Forfeited/cancelled during the year     (300,000 )   A$ 0.500       (8,500,000 )   A$ 0.462  
Outstanding at 30 June     11,450,000     A$ 0.366       7,850,000     A$ 0.251  
Exercisable at 30 June     7,650,000     A$ 0.173       5,250,000     A$ 0.143  

 

The range of exercise prices for options outstanding at the end of the year was A$0.10 to A$0.65 (2019: A$0.10 to A$0.65).

 

The weighted average contractual life for unexercised options is 23.4 months (2019: 13.1 months).

 

c) Subsequent to balance date

 

On August 11, 2020, 100,000 options with an exercise price of A$0.50, vesting date of 31 January 2021 and an expiry date of 31 January 2022 were cancelled.

 

F-60

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 20 Share-based Payments (continued)

 

d) Basis and assumptions used in the valuation of options

 

5,400,000 options were issued during the financial year and have been valued and expensed in the financial statements over the periods that they vest. The share-based payments expense for the period of A$544,113 (2019: A$194,372) relates to the fair value of options apportioned over their respective vesting periods.

 

The options issued during the current reporting period were valued using the Black-Scholes option valuation methodology, as follows:

 

 

Date granted

  Number of options granted  

Exercise price

(cents)

  Expiry date   Risk free interest rate used     Volatility applied     Value per Option (cents)  
27 Nov 2019     1,000,000     25   31 Dec 2022     0.77 %     106 %     11.89  
27 Nov 2019     1,500,000     45   31 Dec 2022     0.77 %     106 %     9.90  
27 Nov 2019     2,500,000     60   31 Dec 2022     0.77 %     106 %     8.88  
24 Feb 2020     400,000     50   31 Jan 2022     0.65 %     100 %     4.95  

 

Historical volatility at the time of issue has been used as the basis for determining expected share price volatility, as it is assumed that this is an indicator of future share price performance, which may not eventuate. A discount of 30% in respect of a lack of marketability has been applied to the Black-Scholes option valuation to reflect the non-negotiability and non-transferability of the unlisted options granted.

 

e) Purpose of Equity Compensation Reserve

 

This reserve is used to record the value of equity benefits provided to employees (including directors) and suppliers for services rendered.

 

F-61

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 20 Share-based Payments (continued)

 

(ii) Performance Rights

 

The Company adopted an Incentive Performance Rights Plan Following Shareholder approval in February 2017.

 

a) Performance rights granted, vested and lapsed during the year

 

During the reporting period the following performance rights were granted:

 

Grant Date   No of Rights   Expiry Date   Fair Value per Right at Grant Date   Vesting
6 Sep 2019     50,000   31 Dec 2020   A$ 0.157   Subject to performance criteria
6 Sep 2019     5,000,000   4 Dec 2023   A$ 0.265   Subject to performance criteria
6 Sep 2019     1,250,000   28 Feb 2021   A$ 0.182   Subject to performance criteria
Total     6,300,000              

 

During the reporting period the following performance rights vested:

 

Grant Date   No of Rights   Expiry Date   Fair Value per Right at Grant Date   Vesting
3 Sep 2018     1,000,000   30 Nov 2020   A$ 0.185   30 Nov 2019
6 Sep 2019 1     50,000   31 Dec 2020   A$ 0.157   6 Sep 2019
Total     1,050,000              

 

During the reporting period the following performance rights were exercised and converted to shares:

 

Grant Date   No of Rights   Expiry Date   Fair Value per Right at Grant Date   Vesting
29 Nov 2017     6,000,000   30 Nov 2019   A$ 0.720   Subject to various performance criteria
3 Sep 2018     1,000,000   31 Dec 2019   A$ 0.185   Subject to various performance criteria
15 Nov 2017     500,000   31 Dec 2020   A$ 0.205   Subject to various performance criteria
6 Sep 2019 1     50,000   31 Dec 2020   A$ 0.157   6 Sep 2019
3 Mar 2017     2,000,000   3 Mar 2020   A$ 0.720   Subject to various performance criteria
Total     9,550,000              

 

During the reporting period no performance rights lapsed or were cancelled.

 

F-62

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 20 Share-based Payments (continued)

 

b) Performance rights on issue at balance date

 

The number of performance rights outstanding over unissued ordinary shares at 30 June 2020 is as follows:

 

 

Grant Date

  No of Rights   Expiry Date   Fair Value per Right at Grant Date   Vesting
03 Mar 2017     2,000,000   03 Mar 2021   A$ 0.720 1 Vested
03 Mar 2017     2,000,000   03 Mar 2022   A$ 0.720 1 Vested
15 Nov 2017     500,000   31 Dec 2020   A$ 0.205   Vested
3 Sep 2018     3,000,000   3 Sep 2021   A$ 0.185   Vested
3 Sep 2018     1,000,000   30 Nov 2020   A$ 0.185   Vested
3 Sep 2018     1,000,000   30 Nov 2020   A$ 0.185   Vested
6 Sep 2019     5,000,000   04 Dec 2023   A$ 0.00   Subject to performance criteria
6 Sep 2019     1,250,000   28 Feb 2021   A$ 0.182   Subject to performance criteria
Total     15,750,000              

 

c) Subsequent to balance date

 

Subsequent to balance date, 3,750,000 Performance Rights were exercised for nil consideration on 14 December 2020 and 10,150,000 Performance Rights were issued on 18 December 2020 pursuant to the Company Incentive Performance Rights Plan.

 

d) Basis and assumptions used in the valuation of performance rights

 

Performance rights were valued at the Company’s share price on the date of grant.

 

F-63

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 21 Financial Instruments

 

The Company has exposure to a variety of risks arising from its use of financial instruments. This note presents information about the Company’s exposure to the specific risks, and the policies and processes for measuring and managing those risks. The Board of Directors has the overall responsibility for the risk management framework and has adopted a Risk Management Policy.

 

(a) Credit risk

 

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from transactions with customers and investments.

 

Trade and other receivables

 

The carrying amount recorded in the financial statements, net of any allowance for losses, represents the Company’s maximum exposure to credit risk.

 

Cash deposits

 

The Directors believe any risk associated with the use of predominantly only one bank is addressed through the use of at least an A-rated bank as a primary banker and by the holding of a portion of funds on deposit with alternative A-rated institutions. Except for this matter the Company currently has no significant concentrations of credit risk.

 

The Directors do not consider that the Company’s financial assets are subject to anything more than a negligible level of credit risk, and as such no disclosures are made.

 

(b) Liquidity risk

 

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company’s reputation.

 

The Company manages its liquidity risk by monitoring its cash reserves and forecast spending. Management is cognisant of the future demands for liquid finance resources to finance the Company’s current and future operations, and consideration is given to the liquid assets available to the Company before commitment is made to future expenditure or investment.

 

F-64

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 21 Financial Instruments (continued)

 

Liquidity risk

 

The following are the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements:

 

    Weighted average
interest rate
  Carrying amount     Contractual cash flows     6 months or less     6-12 months     1-2 years     2-5 years     More than
5 years
 
    %     A$     A$     A$     A$     A$     A$     A$  
2020                                                
                                                 
Trade and other payables             785,939       785,939       785,939       -       -       -       -  
Convertible notes     9.6 %     397,331       397,331       75,000       -       322,331       -       -  
Interest bearing borrowings     10.3 %     790,000       790,000       790,000       -       -       -       -  
Lease liabilities     10.0 %     206,268       206,268       31,457       36,686       86,913       51,213       -  
              2,179,538       2,179,538       1,682,396       36,686       409,244       51,213       -  
2019                                                                
                                                                 
Trade and other payables     -       345,996       345,996       345,996       -       -       -       -  
Convertible notes     8 %     1,496,959       -       1,496,959       -       -                  
              1,842,995       -       1,842,995       -       -       -       -  

 

(c) Market risk

 

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising any return.

 

Interest rate risk

 

The Company has cash assets which may be susceptible to fluctuations in changes in interest rates. Whilst the Company requires the cash assets to be sufficiently liquid to cover any planned or unforeseen future expenditure, which prevents the cash assets being committed to long term fixed interest arrangements; the Company does mitigate potential interest rate risk by entering into short to medium term fixed interest investments.

 

Foreign exchange risk

 

The Company is currently in the process of listing on the NASDAQ capital market and holds a portion of its cash assets in US dollar denominated bank accounts. The Company is exposed to foreign exchange risk through transactions in relation to the NASDAQ listing.

 

The Company does not have any direct exposure to equity risk.

 

F-65

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 21 Financial Instruments (continued)

 

At the reporting date the interest profile of the Company’s interest-bearing financial instruments was:

 

    Carrying value ($)  
   

30 June
2020

A$
(audited)

    30 June
2019
A$
(audited)
 

Fixed rate instruments

           
Financial assets     68,500       482,201  
                 
Variable rate instruments                
Financial assets     627,304       573,977  

 

Cash flow sensitivity analysis for variable rate instruments

 

A change of 100 basis points in interest rates at the reporting date would have increased/(decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables remain constant.

 

    Profit or loss     Equity  
    1%     1%     1%     1%  
    increase     decrease     increase     decrease  
                         
2020                        
Variable rate instruments     6,273       (6,273 )     6,273       (6,273 )
                                 
2019                                
Variable rate instruments     5,740       (5,740 )     5,740       (5,740 )

  

d) Fair values

 

Fair values versus carrying amounts

 

The fair values of financial assets and liabilities, together with the carrying amounts shown in the statement of financial position are as follows:

 

    2020
(audited)
    2019
(audited)
 
    Carrying amount     Fair value     Carrying amount     Fair value  
    A$     A$     A$     A$  
                         
Cash and cash equivalents     627,804       627,804       573,977       573,977  
Trade and other receivables     294,122       294,122       25,427       25,427  
Loan to related party     68,500       68,500       482,201       482,201  
Trade and other payables     (785,939 )     (785,939 )     (345,996 )     (345,996 )
Interest bearing borrowings     (1,187,331 )     (1,187,331 )     (1,496,759 )     (1,496,759 )
Lease liabilities     (206,268 )     (206,268 )     -       -  
Net financial (liabilities) / assets     (1,189,112 )     (1,189,112 )     (761,150 )     (761,150 )

 

e) Impairment losses

 

The Directors do not consider that any of the Company’s financial assets are subject to impairment at the reporting date.

 

No impairment expense or reversal of impairment charge has occurred during the reporting period.

 

F-66

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 22 Commitments

 

a) Operating lease commitments:

 

The Company’s lease for its principal place of business at Unit 5, 71-73 South Perth Esplanade in Western Australia (Lease) expired on 30.6.2019. The office premises were leased on a month by month basis until a new lease was entered into on 1 January 2020. The new lease is accounted for under new accounting standard AASB 16 Leases. Refer to notes 11 and 18.

 

The Lease was secured by a cash bond in favour of the Landlord for the amount of A$37,500 and this amount is being held and will be applied as bond for the new lease.

 

b) Finance lease commitments:

 

The Company has no finance lease commitments contracted for as at 30 June 2020 (30 June 2019: Nil).

 

c) Capital commitments

 

The Company has no capital commitments contracted for as at 30 June 2020 (30 June 2019: Nil):

 

d) Other commitments

 

The Company has entered into an agreement with Lucosky Brookman for the provision of US$200,000 legal services in relation to the listing of the Company on the NASDAQ Capital Market.

 

Note 23 Contingencies

 

a) Contingent liabilities

 

There are no material contingent liabilities at the reporting date.

 

b) Contingent assets

 

There are no material contingent assets at the reporting date.

 

Note 24 Key Management Personnel

 

(a) Directors and key management personnel

 

The following persons were directors of MyFiziq Limited during the current financial year:

 

Mr Peter Wall Non-Executive Chairman
Mr Vlado Bosanac Executive Director and CEO
Mr Mike Melby Non-Executive Director (appointed 27 October 2017)
Mr Nick Prosser Non-Executive Director (appointed 18 April 2018)
Mr Steven Richards Chief Financial Officer and Company Secretary (appointed 2 September 2019)

 

There were no other persons employed by or contracted to the Company during the financial year, having responsibility for planning, directing and controlling the activities of the Company, either directly or indirectly.

 

F-67

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 24 Key Management Personnel (continued)

 

(b) Key management personnel compensation

 

Details of key management personnel remuneration are contained in the Audited Remuneration Report in the Directors’ Report. A summary of total compensation paid to key management personnel during the year is as follows:

 

   

 

Year ended
30 June
2020

    Year ended
30 June
2019
 
    A$
(audited)
    A$
(audited)
 
             
Total short-term employment benefits     538,364       402,000  
Total share-based payments     540,000       340,000  
Total post-employment benefits     42,025       29,070  
      1,120,389       771,070  

 

Note 25 Related Party Disclosures

 

a) Subsidiaries

 

In January 2018, wholly owned subsidiary MyFiziq Inc. was incorporated in the United States of America in preparation for the commercialisation of the technology in the USA. During the financial year there was no activity in this subsidiary.

 

b) Holding company

 

The ultimate holding company is MyFiziq Limited.

 

c) Joint agreement in which the Company is a joint venture

 

The Company has a 50% interest in Body Composition Technologies Pte. Limited (BCT), a company incorporated in Singapore for the purpose of developing the MyFiziq platform for commercialisation within the medical or insurance sector. See Note 26.

 

During 2020, the Company provided services to Body Composition Technologies Pty Ltd (“BCT Australia” an Australian incorporated wholly owned subsidiary of BCT) for which the Company earned revenue of A$420,839 (2019: A$743,614).

 

During the previous financial year, the Company entered into a loan agreement with BCT Australia. The loan is interest free and payable by 30 June 2021; or within 30 days of BCT receiving cash from capital raise activities currently under way, whichever occurs sooner. At 30 June 2020, the balance of the loan was A$68,500.

 

F-68

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 25 Related Party Disclosures (continued)

 

d) Transactions with Directors

 

Transactions with Directors, as Directors of the Company, during the year are disclosed at Note 24.

 

Other transactions with key management personnel

 

During the financial year ended 30 June 2020, the Company paid A$26,156 (2019: A$10,676) to Steinepreis Paganin, an entity associated with Mr Peter Wall, for legal services. At 30 June 2020, a further A$10,622 was owing to Steinepreis Paganin (2019: nil).

 

The Company entered into a A$2,000,000 Convertible Loan facility with a company related to director Mr Nicholas Prosser. A drawdown of, A$500,000 had been made against this facility, with total unpaid interest owing of A$28,436. The balance of principal and interest owing was converted to shares in June 2020 at an issue price of A$0.30 per share. Refer to Note 17.

 

In January 2020, the Company received an unsecured short-term loan of A$250,000 from Pheakes Pty Ltd, a company associated with director Mr Peter Wall. The loan attracted interest at a rate of 10% per annum. A further loan of A$250,000 with similar terms was received in February 2020. The loan and accrued interest was repaid in full in June 2020.

 

Other than the key management personnel related party disclosure in the Remuneration Report and in Note 24, there were no related party transactions with directors to report for the financial year ended 30 June 2020.

 

Note 26 Interest in a Joint Venture

 

The Company has a 50% interest in Body Composition Technologies Pte Limited (BCT). The Company’s interest in BCT is accounted for using the equity method. Under the equity method, the Company’s investment in a joint venture is initially recorded at cost, and subsequently the carrying value of the investment is increased or decreased to recognise the Company’s share of the joint venture profit or loss.

 

The Company was issued 680 shares in BCT at a value of A$1.00 per share.

 

F-69

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 26 Interest in a Joint Venture (continued)

 

The following tables illustrate the summarised financial information of the Company’s investment in BCT.

 

   

30 June

2020

    30 June
2019
 
    A$
(audited)
    A$
(audited)
 
Current assets     25,330       40,726  
Non-current assets     40,276       99,797  
Current liabilities     (892,168 )     (117,446 )
Non-current liabilities     (350,000 )     (482,201 )
Equity     (1,176,562 )     (459,124 )
Company’s carrying amount of the investment     -       -  
                 
Revenue     290,815       -  
Expenses     (1,442,712 )     (1,680,898 )
Loss for the year     (1,151,897 )     (1,680,898 )
Company’s share of the loss (i)     (575,949 )     (840,449 )
                 
Carrying value of the BCT investment                
Investment brought to account at cost     680       680  
Share of the joint venture’s loss (i)     (680 )     (680 )
Closing carrying value of the investment     -       -  

 

(i) As the investment in the joint venture has been written down to nil, no share of the joint venture’s loss has been brought to account in the Company’s loss from ordinary activities for the current financial period.

 

Note 27 Events Subsequent to the Reporting Date

 

On 9 July 2020, the Company received its third payment under the convertible note subscription deed concluded with Asia Cornerstone Asset Management on 1 June 2020, in the amount of US$450,000, as well as A$382,139 from its joint venture partner, Body Composition Technologies Pty Ltd.

 

On 13 July 2020, Dato Low Koon Poh (“Ken Low”) was appointed as a non-executive director of the Company. More information on Ken Low can be found in the “Directors’ section of this report.

 

On 20 July 2020, the Company announced that it would participate in the Body Composition Technologies Pte Ltd (BCT) capital raising in the amount of approximately A$671,000. The participation will increase MyFiziq’s shareholding in BCT, upon conversion, to a majority stake of 54.5% in BCT (on a fully diluted basis).

 

On 22 July 2020, the Company received A$250,000 in payments from Body Composition Technologies Pte Ltd for work carried out on partner builds and integrations as well as a license fee instalment of A$200,000. Furthermore, MyFiziq concluded its uptake of the A$670,833 of convertible notes (refer above).

 

On 23 September 2020, the Company’s joint venture partner, Body Composition Technologies Pte Ltd, completed a A$2,000,000 funding round, resulting in additional licence fee income of A$300,000 payable to the Company.

 

F-70

 

 

Notes to the Financial Statements

For the financial year ended 30 June 2020

 

 

Note 27 Events Subsequent to the Reporting Date (continued)

 

The Company signed an agreement with Nexus Vita Pte Ltd (“Nexus-Vita”) on 6 October 2020. Nexus-Vita agreed to guarantee the Company a minimum annual revenue of US$3,588,000 per annum (on a cash basis), from the date of the commercial launch of its app (anticipated to occur by the end of March 2021).

 

The Company completed a A$5 million capital raise on 14 October 2020 to significantly improve its balance sheet position and provide additional cash flow cover for a further 12 – 18 months.

 

On 3 December 2020, the Company reached an agreement to invest US$6 million in Triage Technologies Inc over a 14 month period (subject to shareholder approval), being US$3 million in cash and US$3 million in equity (MyFiziq ordinary shares), as part of a strategic investment to expand its service offering.

 

Following the execution of a formal funding agreement for US$1.5 million with Asia cornerstone Asset Management (ACAM), all four tranches had been received by the Company by 16 October 2020.

 

The impact of the Coronavirus (‘COVID-19’) pandemic is ongoing for the entity up to 30 June 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian Government and other countries, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.

 

Note 28 Auditor’s Remuneration

 

Total remuneration paid or payable to auditors during the financial year:      
    2020     2019  
    A$
(audited)
    A$
(audited)
 
Audit and review of the Company’s financial statements     50,200       39,263  
Taxation services     2,900       6,387  
Total     53,100       45,650  

 

F-71

 

 

Certification

 

 

Certification pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

 

I, Vlado Bosanac, certify that:

 

1. I have reviewed this annual report on Form 20-F of MyFiziq Limited;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

 

4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) [paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];

 

(c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5. The company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

 

 

 

CEO

 

Date 18 December 2020

 

F-72

 

 

Certification

 

 

Certification pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

 

I, Steven Richards, certify that:

 

1. I have reviewed this annual report on Form 20-F of MyFiziq Limited;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

 

4. The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) [paragraph omitted in accordance with Exchange Act Rule 13a-14(a)];

 

(c) Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

 

5. The company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting

 

 

 

CFO

 

Date 18 December 2020

 

F-73

 

 


Certification Pursuant to 18 U.S.C. Section

 

 

In connection with the Annual Report of MyFiziq Limited (the “Company”) on Form 20-F for the period ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Vlado Bosanac, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, that, to my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

CEO

 

Date 18 December 2020

 

F-74

 

 

 

Certification Pursuant to 18 U.S.C. Section 1350

 

 

In connection with the Annual Report of MyFiziq Limited (the “Company”) on Form 20-F for the period ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Richards, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, that, to my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

CFO

 

Date 18 December 2020

 

F-75

 

 

PKF Perth

 

 

INDEPENDENT AUDITOR’S REPORT

 

TO THE MEMBERS OF MYFIZIQ LIMITED

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Opinion on the Financial Statements

 

We have audited the accompanying statement of financial position of MyFiziq Limited (the “Company”) as of June 30, 2020 and 2019, and the related statement of comprehensive income, statement of cash flow and statement of changes in equity for each of the two years in the period ended June 30, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June 30, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended June 30, 2020, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

We have served as the Company’s auditors since 2018.

 

/s/ PKF Perth  
PKF Perth  

 

/s/ Simon Fermanis  
Simon Fermanis  
   
18 December 2020  

 

Level 4, 35 Havelock Street, West Perth, WA 6005

PO Box 609, West Perth, WA 6872

T: +61 8 9426 8999 F: +61 8 9426 8900 www.pkfperth.com.au

 

PKF Perth is a member firm of the PKF International Limited family of legally independent firms and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm or firms.

 

Liability limited by a scheme approved under Professional Standards Legislation.

 

F-76

 

 

 

 

Up to _______ ADS

 

PROSPECTUS

 

, 2021

 

Sole Book-Running Manager

 

Maxim Group LLC

 

 

 

 

PART II

OR  

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 6. Indemnification of Directors and Officers.

 

Except as hereinafter set forth, there is no provision of our Constitution or any contract, arrangement or statute under which any of our director or officer are insured or indemnified in any manner against liability which he or she may incur in his or her capacity as such.

 

Clause 28 of Constitution provides:

 

To the extent permitted by law, we shall indemnify each person who is or has been an officer of ours or an officer of a company related to us, on a full indemnity basis against any liability incurred by such person:

 

  in his or her capacity as an officer of ours or am officer of or a company related to us; and
     
  to a person other than us or a company related to us, unless the liability arises out of conduct of the officer which involves a lack of good faith.

 

To the extent permitted by law, we shall indemnify each person who is or has been an officer of our or an officer of a company related to us, on a full indemnity basis against any liability for costs and expenses incurred by such person in connection with proceedings involving such person in his or her capacity as an officer of ours or a company related to.

 

We may:

 

  enter into, or agree to enter into; and
     
  pay, or agree to pay, a premium in respect of,

 

a contract insuring a person who is or has been an officer of ours or an officer of a company related to us, against a liability incurred by the person as such an officer, except in circumstances prohibited by the Law.

 

Without limiting a person’s right under this Clause 28, we may enter into a deed agreeing with the person to give effect to the rights of the person conferred by this rule or the exercise of a discretion under this rule, on such terms and conditions as the directors think fit and which are not inconsistent with this Clause 28.

 

This Clause 28 does not limit any right the person otherwise has.

 

In this Clause 28, an officer means a director or secretary of us and such other persons as the directors decide from time to time.

 

We maintain liability insurance policies insuring our directors and officers against certain liabilities that they may incur in such capacities.

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the charter provision, by-law, contract, arrangements, statute or otherwise, we have been informed that, in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

II-1

 

 

Item 7. Recent sales of unregistered securities.

 

During the prior three years, we issued and sold to third parties the securities listed below without registering the securities under the Securities Act of 1933, as amended (the “Securities Act”) pursuant to Section 4(a)(2) thereof and Regulations D and S thereunder. None of these transactions involved any public offering. All our securities were sold through private placement either (i) outside the United States or (ii) in the United States to a limited number of investors in transactions not involving any public offering. As discussed below, we believe that each issuance of these securities was exempt from, or not subject to, registration under the Securities Act.

  

In December 2018, we issued 1,000,000 shares to a director as payment for services rendered.

 

From March 2019 through June 2019, we issued 5,333,333 shares at a price per share of A$0.60 for total gross proceeds of A$3,200,000.

 

In July 2019, we issued 6,000,000 shares to a director as payment for services rendered.

 

In July 2019, we issued 230,769 shares at a price per share of A$0.20 for total gross proceeds of A$46,154.

 

From August 2019 through December 2019, we issued 33,333,334 shares at a price per share of A$0.60 for total gross proceeds of A$2,000,000.

 

In September 2019, we issued 3,500,000 shares to directors as payment for services rendered.

 

In September 2019, we issued 1,000,000 shares to an employee as payment for services rendered.

 

In September 2019, we issued 500,000 shares at a price per share of A$0.10 for total gross proceeds of A$50,000.

 

In October 2019, we issued 50,000 shares to an employee as payment for services rendered.

 

In November 2019, we issued 1,200,000 shares as part of a litigation settlement.

 

In December 2019, we issued 2,000,000 shares to directors as payment for services rendered.

 

In December 2019, we issued 500,000 shares to an employee as payment for services rendered.

 

In February and March 2020, we 2,750,000 shares to directors as payment for services rendered.

 

In February 2020, we issued 2,000,000 shares to a director as payment for services rendered.

 

In April and July 2020, we issued 1,750,000 shares to a supplier as payment.

 

In June 2020, we issued 4,456,932 shares at a price per share of A$0.30 for total gross proceeds of A$1,337,080.

 

In July 2020, we issued 250,000 shares to a supplier as payment.

 

In September 2020, we issued 247,500 shares to a supplier as payment.

 

In September 2020, we issued 76,470 shares to an employee as payment for services rendered.

 

In October we issued 4,166,667 shares at a price per share of A$1.20 as part of A$5 million capital raise.

 

II-2

 

 

In November 2020, we issued 1,000,000 shares at a price per share of A$0.25 for total gross proceeds of A$250,000.

 

In November 2020, we issued 101,667 shares at a price per share of A$0.60 for total gross proceeds of A$61,000.20.

 

In November 2020, we issued 102,255 shares to an employee as payment for services rendered.

 

In November 2020, we issued 1,500,000 shares at a price per share of A$0.45 for total gross proceeds of A$675,000.

 

In November 2020, we issued 4,198,979 shares to employees as payment for services rendered.

 

In December 2020, we issued 2,000,000 shares to directors as payment for services rendered.

 

In December 2020, we issued 347,500 shares to suppliers as payment.

 

In February 2021, we issued 2,357,142 shares to employees as payment for services rendered.

 

In February 20201, we issued 312,500 shares at a price per share of A$1.60 for total gross proceeds of A$500,000.

 

In February 2021, we issued 25,000 shares at a price per share of A$0.60 for total gross proceeds of A$15,000.

 

In February 2021, we issued 250,000 shares to a supplier as payment for services rendered.

 

In March 2021, we issued 2,426,726 shares to employees as payment for services rendered.

 

In March 2021, we issued 432,209 shares at a price per share of A$1.60 for total gross proceeds of A$691,534.

 

In March 2021, we issued 500,000 shares at a price per share of A$0.60 for total gross proceeds of A$300,000.

 

In April 2021, we issued 1,000,000 shares to employees as payment for services rendered.

 

In April 2021, we issued 175,000 shares at a price per share of A$1.60 for total gross proceeds of A$280,000.

 

In April 2021, we issued 500,000 shares at a price per share of A$0.60 for total gross proceeds of A$300,000.

 

In July 2021, we issued 558,333 shares at a price per share of A$0.60 for total gross proceeds of A$335,000.

 

II-3

 

 

Item 8. Exhibits and Financial Statement Schedules 

 

(a) The following documents are filed as part of this registration statement:

 

EXHIBIT INDEX

 

The following documents are filed as part of this registration statement:

 

Exhibit
Number
  Description
     
1.1+   Form of Underwriting Agreement
     
3.1*   Constitution of MyFiziq Limited
     
4.1*   Form of Deposit Agreement among the Company, The Bank of New York Mellon, as depositary, and the holders and beneficial owners of ADSs issued thereunder, as depositary
     
5.1+   Opinion of Steinepreis Paganin regarding the validity of the Ordinary Shares being issued
     
5.2+   Opinion of Lucosky Brookman, LLP regarding the validity of the Ordinary Shares being issued
     
10.1*   Subscription Agreement, dated February 11, 2019, by and between MyFiziq Limited and Asia Cornerstone Asset Management
     
10.2*  

Variation Letter (amended to Subscription Agreement), dated June 4, 2019, by and between MyFiziq Limited and Asia Cornerstone Asset Management 

     
10.3*   Executive Service Agreement by and between MyFiziq Limited and Vlado Bosanac dated December 5, 2016
     
10.4*   Executive Service Agreement by and between MyFiziq Limited and Steven Richards dated July 21, 2019
     
10.5*   Employment Agreement, dated April 1, 2016, by and between MyFiziq Limited and David Tabb
     
10.6*   Employment Agreement, dated November 30, 2018, by and between MyFiziq Limited and Terrence Stupple
     
10.7*   Employment Agreement, dated January 1, 2021, by and between MyFiziq Limited and William Bradford
     
10.8*   Marketing and Funding Agreement by and between Tinjoy Biotech Limited and Advanced Human Imaging Limited, dated April 24, 2021
     
10.9*   Binding Heads of Agreement by and between Advanced Human Imaging Limited. and Physimax Technologies Limited, dated April 27, 2021
     
10.10*   MyFiziq Limited Incentive Performance Rights Plan
     
10.11*   MyFiziq Limited Incentive Options Plan
     
10.12*   Technology License Agreement by and between Triage Technologies, Inc. and Advance Human Imaging Limited dated, April 1, 2021
     
10.13*   Letter of Variation –Term Sheet by and between Triage Technologies, Inc. and Advance Human Imaging Limited dated, January 29, 2021
     
10.14*   Binding Terms Sheet by and between Triage Technologies, Inc. and Advance Human Imaging Limited dated, November 27, 2020

 

II-4

 

 

10.15*   Amended and Restated Shareholder Agreement by and between Triage Technologies, Inc. and Advance Human Imaging Limited dated, March 31, 2021
     
10.16*   Subscription Agreement by and between Triage Technologies, Inc. and Advance Human Imaging Limited dated, March 31, 2021
     
10.17*   Convertible Note Subscription Deed by and between MyFiziq Limited and Asia Cornerstone Asset Management Co. dated, May 28, 2020
     
10.18*   Convertible Note Subscription Deed by and between MyFiziq Limited and I Concept Global Growth Fund dated, October 15, 2020
     
10.19*   Software Reseller Agreement by and between Nuralogix Corporation and MyFiziq Limited dated, August 21, 2020
     
10.20*   Data Processing Agreement by and between Nuralogix Corporation and MyFiziq Limited dated, September 22, 2020
     
10.21*   Letter of Variation, dated December 10, 2019, between MyFiziq Limited and Prosser Enterprises Ltd.
     
10.22*   Commercial Contract, dated January 1, 2019, between MyFiziq Limited and Body Composition Technologies Pty Limited
     
10.23*   IP License Agreement, dated September 22, 2017, between MyFiziq Ltd. and Body Composition Technologies Pty Limited
     
10.24*   Binding Term Sheet by and between Advanced Human Imaging Limited and Nexus Vita, dated June 21, 2021.
     
10.25*   Binding Term Sheet by and between the Advanced Human Imaging Limited and Jana Care Inc, dated May 20, 2021.
     
10.26*   Binding Term Sheet by and between the Advanced Human Imaging Limited and Inter -Psy, dated May 31, 2021
     
10.27*   Binding Term Sheet by and between the Advanced Human Imaging Limited and Cubert Inc, dated June 10, 2021.
     
10.28*   Promissory Note of Bearn LLC issued in favor of the Company, dated January 2021
     
10.29*   Pledge Agreement by and between AARON DREW, an individual, (the “Pledgor”), and the Company dated January 2021
     
10.30*   Security Agreement by and between by Bearn LLC and the Company dated January 2021
     
14.1*   Code of Conduct
     
21.1+   Subsidiaries of the Registrant
     
23.1*   Consent of PKF Perth
     
23.2*   Consent of Steinepreis Paganin (see Exhibit 5.1)
     
23.3*   Consent of Lucosky Brookman, LLP (see Exhibit 5.2)
     
99.1*   Consent of Director Nominee Mr Edward Greissing Jr
     
99.2*   Audit and Risk Committee Charter
     
99.3*   Nominating and Governance Committee Charter
     
99.4*   Compensation Committee Charter

 

+ To be filed by amendment.
* Filed herewith.

II-5

 

 

Item 9. Undertakings.

 

The undersigned registrant hereby undertakes to provide to the Underwriter at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the Underwriter to permit prompt delivery to each purchaser.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described in Item 6, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

The undersigned registrant hereby undertakes that:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

i. To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

ii. To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

 

iii. To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

  

(4) To file a post-effective amendment to the registration statement to include any financial statements required by “Item 8.A. of Form 20-F (17 CFR 249.220f)” at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements.

 

II-6

 

 

(5) That, for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

(6) That, for the purpose of determining liability under the Securities Act to any purchaser:

 

Each prospectus filed by the Registrant pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

  

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the small business issuer pursuant to the foregoing provisions, or otherwise, the small business issuer has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the small business issuer of expenses incurred or paid by a director, officer or controlling person of the small business issuer in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the small business issuer will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

  

(7) For the purposes of determining liability under the Securities Act of 1933 to any purchaser in the initial distributions of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant.

 

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

 

II-7

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Vlado Bosanac   Chief Executive Officer   August 26, 2021
Name: Vlado Bosanac        

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Vlado Bosanac   Chief Executive Officer and Executive Director   August 26, 2021
Name: Vlado Bosanac   (Principal Executive Officer)    
         
/s/ Steven Richards   Chief Financial Officer   August 26, 2021
Name: Steven Richards   (Principal Accounting and Financial Officer)    

 

II-8

 

 

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

 

Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement on August 26, 2021.

 

By:

/s/ Lucosky Brookman LLP

 
Name: Lucosky Brookman LLP  

 

 

II-9

 

 

 

Exhibit 3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 4.1

 

 

 

 

ADVANCED HUMAN IMAGING LIMITED

 

AND

 

THE BANK OF NEW YORK MELLON

 

As Depositary

 

AND

 

OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES

 

Deposit Agreement

 

__________, 2021

 

 

 

 

 

 

 

TABLE OF CONTENTS

 

ARTICLE 1. DEFINITIONS 1
     
SECTION 1.1. American Depositary Shares. 1
SECTION 1.2. Commission. 2
SECTION 1.3. Company. 2
SECTION 1.4. Custodian. 2
SECTION 1.5. Deliver; Surrender. 2
SECTION 1.6. Deposit Agreement. 3
SECTION 1.7. Depositary; Depositary’s Office. 3
SECTION 1.8. Deposited Securities. 3
SECTION 1.9. Disseminate. 3
SECTION 1.10. Dollars. 3
SECTION 1.11. DTC. 3
SECTION 1.12. Foreign Registrar. 4
SECTION 1.13. Holder. 4
SECTION 1.14. Owner. 4
SECTION 1.15. Receipts. 4
SECTION 1.16. Registrar. 4
SECTION 1.17. Replacement. 4
SECTION 1.18. Restricted Securities. 4
SECTION 1.19. Securities Act of 1933. 5
SECTION 1.20. Shares. 5
SECTION 1.21. SWIFT. 5
SECTION 1.22. Termination Option Event. 5
     
ARTICLE 2. FORM OF RECEIPTS, DEPOSIT OF SHARES, DELIVERY, TRANSFER AND SURRENDER OF AMERICAN DEPOSITARY SHARES 6
     
SECTION 2.1. Form of Receipts; Registration and Transferability of American Depositary Shares. 6
SECTION 2.2. Deposit of Shares. 7
SECTION 2.3. Delivery of American Depositary Shares. 8
SECTION 2.4. Registration of Transfer of American Depositary Shares; Combination and Split-up of Receipts; Interchange of Certificated and Uncertificated American Depositary Shares. 8
SECTION 2.5. Surrender of American Depositary Shares and Withdrawal of Deposited Securities. 9
SECTION 2.6. Limitations on Delivery, Registration of Transfer and Surrender of American Depositary Shares. 10
SECTION 2.7. Lost Receipts, etc. 11
SECTION 2.8. Cancellation and Destruction of Surrendered Receipts. 11
SECTION 2.9. DTC Direct Registration System and Profile Modification System. 11

 

-i

 

 

ARTICLE 3. CERTAIN OBLIGATIONS OF OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES 12
     
SECTION 3.1. Filing Proofs, Certificates and Other Information. 12
SECTION 3.2. Liability of Owner for Taxes. 12
SECTION 3.3. Warranties on Deposit of Shares. 13
SECTION 3.4. Disclosure of Interests. 13
     
ARTICLE 4. THE DEPOSITED SECURITIES 13
     
SECTION 4.1. Cash Distributions. 13
SECTION 4.2. Distributions Other Than Cash, Shares or Rights. 14
SECTION 4.3. Distributions in Shares. 15
SECTION 4.4. Rights. 16
SECTION 4.5. Conversion of Foreign Currency. 17
SECTION 4.6. Fixing of Record Date. 19
SECTION 4.7. Voting of Deposited Shares. 19
SECTION 4.8. Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities. 20
SECTION 4.9. Reports. 22
SECTION 4.10. Lists of Owners. 22
SECTION 4.11. Withholding. 22
     
ARTICLE 5. THE DEPOSITARY, THE CUSTODIANS AND THE COMPANY 23
     
SECTION 5.1. Maintenance of Office and Register by the Depositary. 23
SECTION 5.2. Prevention or Delay of Performance by the Company or the Depositary. 23
SECTION 5.3. Obligations of the Depositary and the Company. 24
SECTION 5.4. Resignation and Removal of the Depositary. 25
SECTION 5.5. The Custodians. 26
SECTION 5.6. Notices and Reports. 26
SECTION 5.7. Distribution of Additional Shares, Rights, etc. 27
SECTION 5.8. Indemnification. 27
SECTION 5.9. Charges of Depositary. 28
SECTION 5.10. Retention of Depositary Documents. 29
SECTION 5.11. Exclusivity. 29
SECTION 5.12. Information for Regulatory Compliance. 29
     
ARTICLE 6. AMENDMENT AND TERMINATION 29
     
SECTION 6.1. Amendment. 29
SECTION 6.2. Termination. 30

 

-ii

 

 

ARTICLE 7. MISCELLANEOUS 31
     
SECTION 7.1. Counterparts; Signatures; Delivery. 31
SECTION 7.2. No Third Party Beneficiaries. 32
SECTION 7.3. Severability. 32
SECTION 7.4. Owners and Holders as Parties; Binding Effect. 32
SECTION 7.5. Notices. 32
SECTION 7.6. Appointment of Agent for Service of Process; Submission to Jurisdiction; Jury Trial Waiver. 33
SECTION 7.7. Waiver of Immunities. 34
SECTION 7.8. Governing Law. 34

 

-iii

 

 

DEPOSIT AGREEMENT

 

DEPOSIT AGREEMENT dated as of __________, 2021 among ADVANCED HUMAN IMAGING LIMITED, a company incorporated under the laws of Australia (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.

 

W I T N E S S E T H:

 

WHEREAS, the Company desires to provide, as set forth in this Deposit Agreement, for the deposit of Shares (as hereinafter defined) of the Company from time to time with the Depositary or with the Custodian (as hereinafter defined) under this Deposit Agreement, for the creation of American Depositary Shares representing the Shares so deposited and for the execution and delivery of American Depositary Receipts evidencing the American Depositary Shares; and

 

WHEREAS, the American Depositary Receipts are to be substantially in the form of Exhibit A annexed to this Deposit Agreement, with appropriate insertions, modifications and omissions, as set forth in this Deposit Agreement;

 

NOW, THEREFORE, in consideration of the premises, it is agreed by and between the parties hereto as follows:

 

ARTICLE 1. DEFINITIONS

 

The following definitions shall for all purposes, unless otherwise clearly indicated, apply to the respective terms used in this Deposit Agreement:

 

SECTION 1.1. American Depositary Shares.

 

The term “American Depositary Shares” shall mean the securities created under this Deposit Agreement representing rights with respect to the Deposited Securities. American Depositary Shares may be certificated securities evidenced by Receipts or uncertificated securities. The form of Receipt annexed as Exhibit A to this Deposit Agreement shall be the prospectus required under the Securities Act of 1933 for sales of both certificated and uncertificated American Depositary Shares. Except for those provisions of this Deposit Agreement that refer specifically to Receipts, all the provisions of this Deposit Agreement shall apply to both certificated and uncertificated American Depositary Shares.

 

Each American Depositary Share shall represent the number of Shares specified in Exhibit A to this Deposit Agreement, except that, if there is a distribution upon Deposited Securities covered by Section 4.3, a change in Deposited Securities covered by Section 4.8 with respect to which additional American Depositary Shares are not delivered or a sale of Deposited Securities under Section 3.2 or 4.8, each American Depositary Share shall thereafter represent the amount of Shares or other Deposited Securities that are then on deposit per American Depositary Share after giving effect to that distribution, change or sale.

 

-1-

 

 

SECTION 1.2. Commission.

 

The term “Commission” shall mean the Securities and Exchange Commission of the United States or any successor governmental agency in the United States.

 

SECTION 1.3. Company.

 

The term “Company” shall mean Advanced Human Imaging Limited, a company incorporated under the laws of Australia, and its successors.

 

SECTION 1.4. Custodian.

 

The term “Custodian” shall mean HSBC Australia, as custodian for the Depositary in Australia for the purposes of this Deposit Agreement, and any other firm or corporation the Depositary appoints under Section 5.5 as a substitute or additional custodian under this Deposit Agreement, and shall also mean all of them collectively.

 

SECTION 1.5. Deliver; Surrender.

 

(a) The term “deliver”, or its noun form, when used with respect to Shares or other Deposited Securities, shall mean (i) book-entry transfer of those Shares or other Deposited Securities to an account maintained by an institution authorized under applicable law to effect transfers of such securities designated by the person entitled to that delivery or (ii) physical transfer of certificates evidencing those Shares or other Deposited Securities registered in the name of, or duly endorsed or accompanied by proper instruments of transfer to, the person entitled to that delivery.

 

(b) The term “deliver”, or its noun form, when used with respect to American Depositary Shares, shall mean (i) registration of those American Depositary Shares in the name of DTC or its nominee and book-entry transfer of those American Depositary Shares to an account at DTC designated by the person entitled to that delivery, (ii) registration of those American Depositary Shares not evidenced by a Receipt on the books of the Depositary in the name requested by the person entitled to that delivery and mailing to that person of a statement confirming that registration or (iii) if requested by the person entitled to that delivery, execution and delivery at the Depositary’s Office to the person entitled to that delivery of one or more Receipts evidencing those American Depositary Shares registered in the name requested by that person.

 

(c) The term “surrender”, when used with respect to American Depositary Shares, shall mean (i) one or more book-entry transfers of American Depositary Shares to the DTC account of the Depositary, (ii) delivery to the Depositary at its Office of an instruction to surrender American Depositary Shares not evidenced by a Receipt or (iii) surrender to the Depositary at its Office of one or more Receipts evidencing American Depositary Shares.

 

-2-

 

 

SECTION 1.6. Deposit Agreement.

 

The term “Deposit Agreement” shall mean this Deposit Agreement, as it may be amended from time to time in accordance with the provisions of this Deposit Agreement.

 

SECTION 1.7. Depositary; Depositary’s Office.

 

The term “Depositary” shall mean The Bank of New York Mellon, a New York banking corporation, and any successor as depositary under this Deposit Agreement. The term “Office”, when used with respect to the Depositary, shall mean the office at which its depositary receipts business is administered, which, at the date of this Deposit Agreement, is located at 240 Greenwich Street, New York, New York 10286.

 

SECTION 1.8. Deposited Securities.

 

The term “Deposited Securities” as of any time shall mean Shares at such time deposited or deemed to be deposited under this Deposit Agreement, including without limitation, Shares that have not been successfully delivered upon surrender of American Depositary Shares, and any and all other securities, property and cash received by the Depositary or the Custodian in respect of Deposited Securities and at that time held under this Deposit Agreement.

 

SECTION 1.9. Disseminate.

 

The term “Disseminate,” when referring to a notice or other information to be sent by the Depositary to Owners, shall mean (i) sending that information to Owners in paper form by mail or another means or (ii) with the consent of Owners, another procedure that has the effect of making the information available to Owners, which may include (A) sending the information by electronic mail or electronic messaging or (B) sending in paper form or by electronic mail or messaging a statement that the information is available and may be accessed by the Owner on an Internet website and that it will be sent in paper form upon request by the Owner, when that information is so available and is sent in paper form as promptly as practicable upon request.

 

SECTION 1.10. Dollars.

 

The term “Dollars” shall mean United States dollars.

 

-3-

 

 

SECTION 1.11. DTC.

 

The term “DTC” shall mean The Depository Trust Company or its successor.

 

SECTION 1.12. Foreign Registrar.

 

The term “Foreign Registrar” shall mean the entity that carries out the duties of registrar for the Shares and any other agent of the Company for the transfer and registration of Shares, including, without limitation, any securities depository for the Shares.

 

SECTION 1.13. Holder.

 

The term “Holder” shall mean any person holding a Receipt or a security entitlement or other interest in American Depositary Shares, whether for its own account or for the account of another person, but that is not the Owner of that Receipt or those American Depositary Shares.

 

SECTION 1.14. Owner.

 

The term “Owner” shall mean the person in whose name American Depositary Shares are registered on the books of the Depositary maintained for that purpose.

 

SECTION 1.15. Receipts.

 

The term “Receipts” shall mean the American Depositary Receipts issued under this Deposit Agreement evidencing certificated American Depositary Shares, as the same may be amended from time to time in accordance with the provisions of this Deposit Agreement.

 

SECTION 1.16. Registrar.

 

The term “Registrar” shall mean any corporation or other entity that is appointed by the Depositary to register American Depositary Shares and transfers of American Depositary Shares as provided in this Deposit Agreement.

 

SECTION 1.17. Replacement.

 

The term “Replacement” shall have the meaning assigned to it in Section 4.8.

 

SECTION 1.18. Restricted Securities.

 

The term “Restricted Securities” shall mean Shares that (i) are “restricted securities,” as defined in Rule 144 under the Securities Act of 1933, except for Shares that could be resold in reliance on Rule 144 without any conditions, (ii) are beneficially owned by an officer, director (or person performing similar functions) or other affiliate of the Company, (iii) otherwise would require registration under the Securities Act of 1933 in connection with the public offer and sale thereof in the United States or (iv) are subject to other restrictions on sale or deposit under the laws of Australia, a shareholder agreement or the articles of association or similar document of the Company.

 

-4-

 

 

SECTION 1.19. Securities Act of 1933.

 

The term “Securities Act of 1933” shall mean the United States Securities Act of 1933, as from time to time amended.

 

SECTION 1.20. Shares.

 

The term “Shares” shall mean [shareclass] shares of the Company that are validly issued and outstanding, fully paid and nonassessable and that were not issued in violation of any pre-emptive or similar rights of the holders of outstanding securities of the Company; provided, however, that, if there shall occur any change in nominal or par value, a split-up or consolidation or any other reclassification or, upon the occurrence of an event described in Section 4.8, an exchange or conversion in respect of the Shares of the Company, the term “Shares” shall thereafter also mean the successor securities resulting from such change in nominal value, split-up or consolidation or such other reclassification or such exchange or conversion.

 

SECTION 1.21. SWIFT.

 

The term “SWIFT” shall mean the financial messaging network operated by the Society for Worldwide Interbank Financial Telecommunication, or its successor.

 

SECTION 1.22. Termination Option Event.

 

The term “Termination Option Event” shall mean any of the following events or conditions:

 

(i) the Company institutes proceedings to be adjudicated as bankrupt or insolvent, consents to the institution of bankruptcy or insolvency proceedings against it, files a petition or answer or consent seeking reorganization or relief under any applicable law in respect of bankruptcy or insolvency, consents to the filing of any petition of that kind or to the appointment of a receiver, liquidator, assignee, trustee, custodian or sequestrator (or other similar official) of it or any substantial part of its property or makes an assignment for the benefit of creditors, or if information becomes publicly available indicating that unsecured claims against the Company are not expected to be paid;

 

(ii) the Shares are delisted, or the Company announces its intention to delist the Shares, from a stock exchange outside the United States, and the Company has not applied to list the Shares on any other stock exchange outside the United States;

 

-5-

 

 

(iii) the American Depositary Shares are delisted from a stock exchange in the United States on which the American Depositary Shares were listed and, 30 days after that delisting, the American Depositary Shares have not been listed on another stock exchange in the United States, nor is there a symbol available for over-the-counter trading of the American Depositary Shares in the United States;

 

(iv) the Depositary has received notice of facts that indicate, or otherwise has reason to believe, that the American Depositary Shares have become, or with the passage of time will become, ineligible for registration on Form F-6 under the Securities Act of 1933; or

 

(v) an event or condition that is defined as a Termination Option Event in Section 4.1, 4.2 or 4.8.

 

ARTICLE 2. FORM OF RECEIPTS, DEPOSIT OF SHARES, DELIVERY, TRANSFER AND SURRENDER OF AMERICAN DEPOSITARY SHARES

 

SECTION 2.1. Form of Receipts; Registration and Transferability of American Depositary Shares.

 

Definitive Receipts shall be substantially in the form set forth in Exhibit A to this Deposit Agreement, with appropriate insertions, modifications and omissions, as permitted under this Deposit Agreement. No Receipt shall be entitled to any benefits under this Deposit Agreement or be valid or obligatory for any purpose, unless that Receipt has been (i) executed by the Depositary by the manual signature of a duly authorized officer of the Depositary or (ii) executed by the facsimile signature of a duly authorized officer of the Depositary and countersigned by the manual signature of a duly authorized signatory of the Depositary or the Registrar or a co-registrar. The Depositary shall maintain books on which (x) each Receipt so executed and delivered as provided in this Deposit Agreement and each transfer of that Receipt and (y) all American Depositary Shares delivered as provided in this Deposit Agreement and all registrations of transfer of American Depositary Shares, shall be registered. A Receipt bearing the facsimile signature of a person that was at any time a proper officer of the Depositary shall, subject to the other provisions of this paragraph, bind the Depositary, even if that person was not a proper officer of the Depositary on the date of issuance of that Receipt.

 

The Receipts and statements confirming registration of American Depositary Shares may have incorporated in or attached to them such legends or recitals or modifications not inconsistent with the provisions of this Deposit Agreement as may be required by the Depositary or required to comply with any applicable law or regulations thereunder or with the rules and regulations of any securities exchange upon which American Depositary Shares may be listed or to conform with any usage with respect thereto, or to indicate any special limitations or restrictions to which any particular Receipts and American Depositary Shares are subject by reason of the date of issuance of the underlying Deposited Securities or otherwise.

 

-6-

 

 

American Depositary Shares evidenced by a Receipt, when the Receipt is properly endorsed or accompanied by proper instruments of transfer, shall be transferable as certificated registered securities under the laws of the State of New York. American Depositary Shares not evidenced by Receipts shall be transferable as uncertificated registered securities under the laws of the State of New York. The Depositary, notwithstanding any notice to the contrary, may treat the Owner of American Depositary Shares as the absolute owner thereof for the purpose of determining the person entitled to distribution of dividends or other distributions or to any notice provided for in this Deposit Agreement and for all other purposes, and neither the Depositary nor the Company shall have any obligation or be subject to any liability under this Deposit Agreement to any Holder of American Depositary Shares (but only to the Owner of those American Depositary Shares).

 

SECTION 2.2. Deposit of Shares.

 

Subject to the terms and conditions of this Deposit Agreement, Shares or evidence of rights to receive Shares may be deposited under this Deposit Agreement by delivery thereof to any Custodian, accompanied by any appropriate instruments or instructions for transfer, or endorsement, in form satisfactory to the Custodian.

 

As conditions of accepting Shares for deposit, the Depositary may require (i) any certification required by the Depositary or the Custodian in accordance with the provisions of this Deposit Agreement, (ii) a written order directing the Depositary to deliver to, or upon the written order of, the person or persons stated in that order American Depositary Shares representing those deposited Shares, (iii) evidence satisfactory to the Depositary that those Shares have been re-registered in the books of the Company or the Foreign Registrar in the name of the Depositary, a Custodian or a nominee of the Depositary or a Custodian, (iv) evidence satisfactory to the Depositary that any necessary approval for the transfer or deposit has been granted by any governmental body in each applicable jurisdiction and (v) an agreement or assignment, or other instrument satisfactory to the Depositary, that provides for the prompt transfer to the Custodian of any dividend, or right to subscribe for additional Shares or to receive other property, that any person in whose name those Shares are or have been recorded may thereafter receive upon or in respect of those Shares, or, in lieu thereof, such agreement of indemnity or other agreement as shall be satisfactory to the Depositary.

 

At the request and risk and expense of a person proposing to deposit Shares, and for the account of that person, the Depositary may receive certificates for Shares to be deposited, together with the other instruments specified in this Section, for the purpose of forwarding those Share certificates to the Custodian for deposit under this Deposit Agreement.

 

The Depositary shall instruct each Custodian that, upon each delivery to a Custodian of a certificate or certificates for Shares to be deposited under this Deposit Agreement, together with the other documents specified in this Section, that Custodian shall, as soon as transfer and recordation can be accomplished, present that certificate or those certificates to the Company or the Foreign Registrar, if applicable, for transfer and recordation of the Shares being deposited in the name of the Depositary or its nominee or that Custodian or its nominee.

 

-7-

 

 

Deposited Securities shall be held by the Depositary or by a Custodian for the account and to the order of the Depositary or at such other place or places as the Depositary shall determine.

 

SECTION 2.3. Delivery of American Depositary Shares.

 

The Depositary shall instruct each Custodian that, upon receipt by that Custodian of any deposit pursuant to Section 2.2, together with the other documents or evidence required under that Section, that Custodian shall notify the Depositary of that deposit and the person or persons to whom or upon whose written order American Depositary Shares are deliverable in respect thereof. Upon receiving a notice of a deposit from a Custodian, or upon the receipt of Shares or evidence of the right to receive Shares by the Depositary, the Depositary, subject to the terms and conditions of this Deposit Agreement, shall deliver, to or upon the order of the person or persons entitled thereto, the number of American Depositary Shares issuable in respect of that deposit, but only upon payment to the Depositary of the fees and expenses of the Depositary for the delivery of those American Depositary Shares as provided in Section 5.9, and of all taxes and governmental charges and fees payable in connection with that deposit and the transfer of the deposited Shares. However, the Depositary shall deliver only whole numbers of American Depositary Shares.

 

SECTION 2.4. Registration of Transfer of American Depositary Shares; Combination and Split-up of Receipts; Interchange of Certificated and Uncertificated American Depositary Shares.

 

The Depositary, subject to the terms and conditions of this Deposit Agreement, shall register a transfer of American Depositary Shares on its transfer books upon (i) in the case of certificated American Depositary Shares, surrender of the Receipt evidencing those American Depositary Shares, by the Owner or by a duly authorized attorney, properly endorsed or accompanied by proper instruments of transfer or (ii) in the case of uncertificated American Depositary Shares, receipt from the Owner of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in Section 2.9), and, in either case, duly stamped as may be required by the laws of the State of New York and of the United States of America. Upon registration of a transfer, the Depositary shall deliver the transferred American Depositary Shares to or upon the order of the person entitled thereto.

 

The Depositary, subject to the terms and conditions of this Deposit Agreement, shall upon surrender of a Receipt or Receipts for the purpose of effecting a split-up or combination of such Receipt or Receipts, execute and deliver a new Receipt or Receipts for any authorized number of American Depositary Shares requested, evidencing the same aggregate number of American Depositary Shares as the Receipt or Receipts surrendered.

 

-8-

 

 

The Depositary, upon surrender of certificated American Depositary Shares for the purpose of exchanging for uncertificated American Depositary Shares, shall cancel the Receipt evidencing those certificated American Depositary Shares and send the Owner a statement confirming that the Owner is the owner of the same number of uncertificated American Depositary Shares. The Depositary, upon receipt of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in Section 2.9) from the Owner of uncertificated American Depositary Shares for the purpose of exchanging for certificated American Depositary Shares, shall cancel those uncertificated American Depositary Shares and register and deliver to the Owner a Receipt evidencing the same number of certificated American Depositary Shares.

 

The Depositary may appoint one or more co-transfer agents for the purpose of effecting registration of transfers of American Depositary Shares and combinations and split-ups of Receipts at designated transfer offices on behalf of the Depositary. In carrying out its functions, a co-transfer agent may require evidence of authority and compliance with applicable laws and other requirements by Owners or persons entitled to American Depositary Shares and will be entitled to protection and indemnity to the same extent as the Depositary.

 

SECTION 2.5. Surrender of American Depositary Shares and Withdrawal of Deposited Securities.

 

Upon surrender of American Depositary Shares for the purpose of withdrawal of the Deposited Securities represented thereby and payment of the fee of the Depositary for the surrender of American Depositary Shares as provided in Section 5.9 and payment of all taxes and governmental charges payable in connection with that surrender and withdrawal of the Deposited Securities, and subject to the terms and conditions of this Deposit Agreement, the Owner of those American Depositary Shares shall be entitled to delivery (to the extent delivery can then be lawfully and practicably made), to or as instructed by that Owner, of the amount of Deposited Securities at the time represented by those American Depositary Shares, but not any money or other property as to which a record date for distribution to Owners has passed (since money or other property of that kind will be delivered or paid on the scheduled payment date to the Owner as of that record date), and except that the Depositary shall not be required to accept surrender of American Depositary Shares for the purpose of withdrawal to the extent it would require delivery of a fraction of a Deposited Security. That delivery shall be made, as provided in this Section, without unreasonable delay.

 

As a condition of accepting a surrender of American Depositary Shares for the purpose of withdrawal of Deposited Securities, the Depositary may require (i) that each surrendered Receipt be properly endorsed in blank or accompanied by proper instruments of transfer in blank and (ii) that the surrendering Owner execute and deliver to the Depositary a written order directing the Depositary to cause the Deposited Securities being withdrawn to be delivered to or upon the written order of a person or persons designated in that order.

 

-9-

 

 

Thereupon, the Depositary shall direct the Custodian to deliver, subject to Sections 2.6, 3.1 and 3.2, the other terms and conditions of this Deposit Agreement and local market rules and practices, to the surrendering Owner or to or upon the written order of the person or persons designated in the order delivered to the Depositary as above provided, the amount of Deposited Securities represented by the surrendered American Depositary Shares, and the Depositary may charge the surrendering Owner a fee and its expenses for giving that direction by cable (including SWIFT) or facsimile transmission.

 

If Deposited Securities are delivered physically upon surrender of American Depositary Shares for the purpose of withdrawal, that delivery will be made at the Custodian’s office, except that, at the request, risk and expense of an Owner surrendering American Depositary Shares for withdrawal of Deposited Securities, and for the account of that Owner, the Depositary shall direct the Custodian to forward any cash or other property comprising, and forward a certificate or certificates, if applicable, and other proper documents of title, if any, for, the Deposited Securities represented by the surrendered American Depositary Shares to the Depositary for delivery at the Depositary’s Office or to another address specified in the order received from the surrendering Owner.

 

SECTION 2.6. Limitations on Delivery, Registration of Transfer and Surrender of American Depositary Shares.

 

As a condition precedent to the delivery, registration of transfer or surrender of any American Depositary Shares or split-up or combination of any Receipt or withdrawal of any Deposited Securities, the Depositary, Custodian or Registrar may require payment from the depositor of Shares or the presenter of the Receipt or instruction for registration of transfer or surrender of American Depositary Shares not evidenced by a Receipt of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees as provided in this Deposit Agreement, may require the production of proof satisfactory to it as to the identity and genuineness of any signature and may also require compliance with any regulations the Depositary may establish consistent with the provisions of this Deposit Agreement, including, without limitation, this Section 2.6.

 

The Depositary may refuse to accept deposits of Shares for delivery of American Depositary Shares or to register transfers of American Depositary Shares in particular instances, or may suspend deposits of Shares or registration of transfer generally, whenever it or the Company considers it necessary or advisable to do so. The Depositary may refuse surrenders of American Depositary Shares for the purpose of withdrawal of Deposited Securities in particular instances, or may suspend surrenders for the purpose of withdrawal generally, but, notwithstanding anything to the contrary in this Deposit Agreement, only for (i) temporary delays caused by closing of the Depositary’s register or the register of holders of Shares maintained by the Company or the Foreign Registrar, or the deposit of Shares, in connection with voting at a shareholders’ meeting or the payment of dividends, (ii) the payment of fees, taxes and similar charges, (iii) compliance with any U.S. or foreign laws or governmental regulations relating to the American Depositary Shares or to the withdrawal of the Deposited Securities or (iv) any other reason that, at the time, is permitted under paragraph I(A)(1) of the General Instructions to Form F-6 under the Securities Act of 1933 or any successor to that provision.

 

-10-

 

 

The Depositary shall not knowingly accept for deposit under this Deposit Agreement any Shares that, at the time of deposit, are Restricted Securities.

 

SECTION 2.7. Lost Receipts, etc.

 

If a Receipt is mutilated, destroyed, lost or stolen, the Depositary shall deliver to the Owner the American Depositary Shares evidenced by that Receipt in uncertificated form or, if requested by the Owner, execute and deliver a new Receipt of like tenor in exchange and substitution for such mutilated Receipt, upon surrender and cancellation of that mutilated Receipt, or in lieu of and in substitution for that destroyed, lost or stolen Receipt. However, before the Depositary will deliver American Depositary Shares in uncertificated form or execute and deliver a new Receipt, in substitution for a destroyed, lost or stolen Receipt, the Owner must (a) file with the Depositary (i) a request for that replacement before the Depositary has notice that the Receipt has been acquired by a bona fide purchaser and (ii) a sufficient indemnity bond and (b) satisfy any other reasonable requirements imposed by the Depositary.

 

SECTION 2.8. Cancellation and Destruction of Surrendered Receipts.

 

The Depositary shall cancel all Receipts surrendered to it and is authorized to destroy Receipts so cancelled.

 

SECTION 2.9. DTC Direct Registration System and Profile Modification System.

 

(a) Notwithstanding the provisions of Section 2.4, the parties acknowledge that DTC’s Direct Registration System (“DRS”) and Profile Modification System (“Profile”) apply to the American Depositary Shares upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC that facilitates interchange between registered holding of uncertificated securities and holding of security entitlements in those securities through DTC and a DTC participant. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of an Owner of American Depositary Shares, to direct the Depositary to register a transfer of those American Depositary Shares to DTC or its nominee and to deliver those American Depositary Shares to the DTC account of that DTC participant without receipt by the Depositary of prior authorization from the Owner to register that transfer.

 

-11-

 

 

(b) In connection with DRS/Profile, the parties acknowledge that the Depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an Owner in requesting a registration of transfer and delivery as described in paragraph (a) above has the actual authority to act on behalf of that Owner (notwithstanding any requirements under the Uniform Commercial Code). For the avoidance of doubt, the provisions of Sections 5.3 and 5.8 apply to the matters arising from the use of the DRS/Profile. The parties agree that the Depositary’s reliance on and compliance with instructions received by the Depositary through the DRS/Profile system and otherwise in accordance with this Deposit Agreement shall not constitute negligence or bad faith on the part of the Depositary.

 

ARTICLE 3. CERTAIN OBLIGATIONS OF OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES

 

SECTION 3.1. Filing Proofs, Certificates and Other Information.

 

Any person presenting Shares for deposit or any Owner or Holder may be required from time to time to file with the Depositary or the Custodian such proof of citizenship or residence, exchange control approval, or such information relating to the registration on the books of the Company or the Foreign Registrar, if applicable, to execute such certificates and to make such representations and warranties, as the Depositary may deem necessary or proper. The Depositary may withhold the delivery or registration of transfer of American Depositary Shares, the distribution of any dividend or other distribution or of the proceeds thereof or the delivery of any Deposited Securities until that proof or other information is filed or those certificates are executed or those representations and warranties are made.

 

SECTION 3.2. Liability of Owner for Taxes.

 

If any tax or other governmental charge shall become payable by the Custodian or the Depositary with respect to or in connection with any American Depositary Shares or any Deposited Securities represented by any American Depositary Shares or in connection with a transaction to which Section 4.8 applies, that tax or other governmental charge shall be payable by the Owner of those American Depositary Shares to the Depositary. The Depositary may refuse to register any transfer of those American Depositary Shares or any withdrawal of Deposited Securities represented by those American Depositary Shares until that payment is made, and may withhold any dividends or other distributions or the proceeds thereof, or may sell for the account of the Owner any part or all of the Deposited Securities represented by those American Depositary Shares and apply those dividends or other distributions or the net proceeds of any sale of that kind in payment of that tax or other governmental charge but, even after a sale of that kind, the Owner of those American Depositary Shares shall remain liable for any deficiency. The Depositary shall distribute any net proceeds of a sale made under this Section that are not used to pay taxes or governmental charges to the Owners entitled to them in accordance with Section 4.1. If the number of Shares represented by each American Depositary Share decreases as a result of a sale of Deposited Securities under this Section, the Depositary may call for surrender of the American Depositary Shares to be exchanged on a mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that sale to the Owners entitled to them.

 

-12-

 

 

SECTION 3.3. Warranties on Deposit of Shares.

 

Every person depositing Shares under this Deposit Agreement shall be deemed thereby to represent and warrant that those Shares and each certificate therefor, if applicable, are validly issued, fully paid and nonassessable and were not issued in violation of any preemptive or similar rights of the holders of outstanding securities of the Company and that the person making that deposit is duly authorized so to do. Every depositing person shall also be deemed to represent that the Shares, at the time of deposit, are not Restricted Securities. All representations and warranties deemed made under this Section shall survive the deposit of Shares and delivery of American Depositary Shares.

 

SECTION 3.4. Disclosure of Interests.

 

When required in order to comply with applicable laws and regulations or the articles of association or similar document of the Company, the Company may from time to time request each Owner and Holder to provide to the Depositary information relating to: (a) the capacity in which it holds American Depositary Shares, (b) the identity of any Holders or other persons or entities then or previously interested in those American Depositary Shares and the nature of those interests and (c) any other matter where disclosure of such matter is required for that compliance.   Each Owner and Holder agrees to provide all information known to it in response to a request made pursuant to this Section.  Each Holder consents to the disclosure by the Depositary and the Owner or any other Holder through which it holds American Depositary Shares, directly or indirectly, of all information responsive to a request made pursuant to this Section relating to that Holder that is known to that Owner or other Holder.  The Depositary agrees to use reasonable efforts to comply with written instructions requesting that the Depositary forward any request authorized under this Section to the Owners and to forward to the Company any responses it receives in response to that request. The Depositary may charge the Company a fee and its expenses for complying with requests under this Section 3.4.

 

ARTICLE 4. THE DEPOSITED SECURITIES

 

SECTION 4.1. Cash Distributions.

 

Whenever the Depositary receives any cash dividend or other cash distribution on Deposited Securities, the Depositary shall, subject to the provisions of Section 4.5, convert that dividend or other distribution into Dollars and distribute the amount thus received (net of the fees and expenses of the Depositary as provided in Section 5.9) to the Owners entitled thereto, in proportion to the number of American Depositary Shares representing those Deposited Securities held by them respectively; provided, however, that if the Custodian or the Depositary shall be required to withhold and does withhold from that cash dividend or other cash distribution an amount on account of taxes or other governmental charges, the amount distributed to the Owners of the American Depositary Shares representing those Deposited Securities shall be reduced accordingly. However, the Depositary will not pay any Owner a fraction of one cent, but will round each Owner’s entitlement to the nearest whole cent.

 

-13-

 

 

The Company or its agent will remit to the appropriate governmental agency in each applicable jurisdiction all amounts withheld and owing to such agency.

 

If a cash distribution would represent a return of all or substantially all the value of the Deposited Securities underlying American Depositary Shares, the Depositary may:

 

(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of American Depositary Shares) as a condition of making that cash distribution; or

 

(ii) sell all Deposited Securities other than the subject cash distribution and add any net cash proceeds of that sale to the cash distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that cash distribution.

 

If the Depositary acts under this paragraph, that action shall also be a Termination Option Event.

 

SECTION 4.2. Distributions Other Than Cash, Shares or Rights.

 

Subject to the provisions of Sections 4.11 and 5.9, whenever the Depositary receives any distribution other than a distribution described in Section 4.1, 4.3 or 4.4 on Deposited Securities (but not in exchange for or in conversion or in lieu of Deposited Securities), the Depositary shall cause the securities or property received by it to be distributed to the Owners entitled thereto, after deduction or upon payment of any fees and expenses of the Depositary and any taxes or other governmental charges, in proportion to the number of American Depositary Shares representing such Deposited Securities held by them respectively, in any manner that the Depositary deems equitable and practicable for accomplishing that distribution (which may be a distribution of depositary shares representing the securities received); provided, however, that if in the opinion of the Depositary such distribution cannot be made proportionately among the Owners entitled thereto, or if for any other reason (including, but not limited to, any requirement that the Company or the Depositary withhold an amount on account of taxes or other governmental charges or that securities received must be registered under the Securities Act of 1933 in order to be distributed to Owners or Holders) the Depositary deems such distribution not to be lawful and feasible, the Depositary may adopt such other method as it may deem equitable and practicable for the purpose of effecting such distribution, including, but not limited to, the public or private sale of the securities or property thus received, or any part thereof, and distribution of the net proceeds of any such sale (net of the fees and expenses of the Depositary as provided in Section 5.9) to the Owners entitled thereto, all in the manner and subject to the conditions set forth in Section 4.1. The Depositary may withhold any distribution of securities under this Section 4.2 if it has not received satisfactory assurances from the Company that the distribution does not require registration under the Securities Act of 1933. The Depositary may sell, by public or private sale, an amount of securities or other property it would otherwise distribute under this Section 4.2 that is sufficient to pay its fees and expenses in respect of that distribution.

 

-14-

 

 

If a distribution to be made under this Section 4.2 would represent a return of all or substantially all the value of the Deposited Securities underlying American Depositary Shares, the Depositary may:

 

(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of American Depositary Shares) as a condition of making that distribution; or

 

(ii) sell all Deposited Securities other than the subject distribution and add any net cash proceeds of that sale to the distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that distribution.

 

If the Depositary acts under this paragraph, that action shall also be a Termination Option Event.

 

SECTION 4.3. Distributions in Shares.

 

Whenever the Depositary receives any distribution on Deposited Securities consisting of a dividend in, or free distribution of, Shares, the Depositary may deliver to the Owners entitled thereto, in proportion to the number of American Depositary Shares representing those Deposited Securities held by them respectively, an aggregate number of American Depositary Shares representing the amount of Shares received as that dividend or free distribution, subject to the terms and conditions of this Deposit Agreement with respect to the deposit of Shares and issuance of American Depositary Shares, including withholding of any tax or governmental charge as provided in Section 4.11 and payment of the fees and expenses of the Depositary as provided in Section 5.9 (and the Depositary may sell, by public or private sale, an amount of the Shares received (or American Depositary Shares representing those Shares) sufficient to pay its fees and expenses in respect of that distribution). In lieu of delivering fractional American Depositary Shares, the Depositary may sell the amount of Shares represented by the aggregate of those fractions (or American Depositary Shares representing those Shares) and distribute the net proceeds, all in the manner and subject to the conditions described in Section 4.1. If and to the extent that additional American Depositary Shares are not delivered and Shares or American Depositary Shares are not sold, each American Depositary Share shall thenceforth also represent the additional Shares distributed on the Deposited Securities represented thereby.

 

-15-

 

 

If the Company declares a distribution in which holders of Deposited Securities have a right to elect whether to receive cash, Shares or other securities or a combination of those things, or a right to elect to have a distribution sold on their behalf, the Depositary may, after consultation with the Company, make that right of election available for exercise by Owners in any manner the Depositary considers to be lawful and practical. As a condition of making a distribution election right available to Owners, the Depositary may require satisfactory assurances from the Company that doing so does not require registration of any securities under the Securities Act of 1933 that has not been effected.

 

SECTION 4.4. Rights.

 

(a) If rights are granted to the Depositary in respect of deposited Shares to purchase additional Shares or other securities, the Company and the Depositary shall endeavor to consult as to the actions, if any, the Depositary should take in connection with that grant of rights. The Depositary may, to the extent deemed by it to be lawful and practical (i) if requested in writing by the Company, grant to all or certain Owners rights to instruct the Depositary to purchase the securities to which the rights relate and deliver those securities or American Depositary Shares representing those securities to Owners, (ii) if requested in writing by the Company, deliver the rights to or to the order of certain Owners, or (iii) sell the rights to the extent practicable and distribute the net proceeds of that sale to Owners entitled to those proceeds. To the extent rights are not exercised, delivered or disposed of under (i), (ii) or (iii) above, the Depositary shall permit the rights to lapse unexercised.

 

(b) If the Depositary will act under (a)(i) above, the Company and the Depositary will enter into a separate agreement setting forth the conditions and procedures applicable to the particular offering. Upon instruction from an applicable Owner in the form the Depositary specified and upon payment by that Owner to the Depositary of an amount equal to the purchase price of the securities to be received upon the exercise of the rights, the Depositary shall, on behalf of that Owner, exercise the rights and purchase the securities. The purchased securities shall be delivered to, or as instructed by, the Depositary. The Depositary shall (i) deposit the purchased Shares under this Deposit Agreement and deliver American Depositary Shares representing those Shares to that Owner or (ii) deliver or cause the purchased Shares or other securities to be delivered to or to the order of that Owner. The Depositary will not act under (a)(i) above unless the offer and sale of the securities to which the rights relate are registered under the Securities Act of 1933 or the Depositary has received an opinion of United States counsel that is satisfactory to it to the effect that those securities may be sold and delivered to the applicable Owners without registration under the Securities Act of 1933.

 

-16-

 

 

(c) If the Depositary will act under (a)(ii) above, the Company and the Depositary will enter into a separate agreement setting forth the conditions and procedures applicable to the particular offering. Upon (i) the request of an applicable Owner to deliver the rights allocable to the American Depositary Shares of that Owner to an account specified by that Owner to which the rights can be delivered and (ii) receipt of such documents as the Company and the Depositary agreed to require to comply with applicable law, the Depositary will deliver those rights as requested by that Owner.

 

(d) If the Depositary will act under (a)(iii) above, the Depositary will use reasonable efforts to sell the rights in proportion to the number of American Depositary Shares held by the applicable Owners and pay the net proceeds to the Owners otherwise entitled to the rights that were sold, upon an averaged or other practical basis without regard to any distinctions among such Owners because of exchange restrictions or the date of delivery of any American Depositary Shares or otherwise.

 

(e) Payment or deduction of the fees of the Depositary as provided in Section 5.9 and payment or deduction of the expenses of the Depositary and any applicable taxes or other governmental charges shall be conditions of any delivery of securities or payment of cash proceeds under this Section 4.4.

 

(f) The Depositary shall not be responsible for any failure to determine that it may be lawful or feasible to make rights available to or exercise rights on behalf of Owners in general or any Owner in particular, or to sell rights.

 

SECTION 4.5. Conversion of Foreign Currency.

 

Whenever the Depositary or the Custodian receives foreign currency, by way of dividends or other distributions or the net proceeds from the sale of securities, property or rights, and if at the time of the receipt thereof the foreign currency so received can in the judgment of the Depositary be converted on a reasonable basis into Dollars and the resulting Dollars transferred to the United States, the Depositary or one of its agents or affiliates or the Custodian shall convert or cause to be converted by sale or in any other manner that it may determine that foreign currency into Dollars, and those Dollars shall be distributed to the Owners entitled thereto.  A cash distribution may be made upon an averaged or other practicable basis without regard to any distinctions among Owners based on exchange restrictions, the date of delivery of any American Depositary Shares or otherwise and shall be net of any expenses of conversion into Dollars incurred by the Depositary as provided in Section 5.9.

 

-17-

 

 

If a conversion of foreign currency or the repatriation or distribution of Dollars can be effected only with the approval or license of any government or agency thereof, the Depositary may, but will not be required to, file an application for that approval or license.

 

If the Depositary determines that in its judgment any foreign currency received by the Depositary or the Custodian is not convertible on a reasonable basis into Dollars transferable to the United States, or if any approval or license of any government or agency thereof that is required for such conversion is not filed or sought by the Depositary or is not obtained within a reasonable period as determined by the Depositary, the Depositary may distribute the foreign currency received by the Depositary to, or in its discretion may hold such foreign currency uninvested and without liability for interest thereon for the respective accounts of, the Owners entitled to receive the same.

 

If any conversion of foreign currency, in whole or in part, cannot be effected for distribution to some of the Owners entitled thereto, the Depositary may in its discretion make that conversion and distribution in Dollars to the extent practicable and permissible to the Owners entitled thereto and may distribute the balance of the foreign currency received by the Depositary to, or hold that balance uninvested and without liability for interest thereon for the account of, the Owners entitled thereto.

 

The Depositary may convert currency itself or through any of its affiliates, or the Custodian or the Company may convert currency and pay Dollars to the Depositary. Where the Depositary converts currency itself or through any of its affiliates, the Depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account.  The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under this Deposit Agreement and the rate that the Depositary or its affiliate receives when buying or selling foreign currency for its own account.  The Depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under this Deposit Agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to Owners, subject to the Depositary’s obligations under Section 5.3.  The methodology used to determine exchange rates used in currency conversions made by the Depositary is available upon request. Where the Custodian converts currency, the Custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to Owners, and the Depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, the Depositary may receive dividends or other distributions from the Company in Dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by or on behalf of the Company and, in such cases, the Depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor the Company makes any representation that the rate obtained or determined by the Company is the most favorable rate and neither it nor the Company will be liable for any direct or indirect losses associated with the rate.

 

-18-

 

 

SECTION 4.6. Fixing of Record Date.

 

Whenever a cash dividend, cash distribution or any other distribution is made on Deposited Securities or rights to purchase Shares or other securities are issued with respect to Deposited Securities (which rights will be delivered to or exercised or sold on behalf of Owners in accordance with Section 4.4) or the Depositary receives notice that a distribution or issuance of that kind will be made, or whenever the Depositary receives notice that a meeting of holders of Shares will be held in respect of which the Company has requested the Depositary to send a notice under Section 4.7, or whenever the Depositary will assess a fee or charge against the Owners, or whenever the Depositary causes a change in the number of Shares that are represented by each American Depositary Share, or whenever the Depositary otherwise finds it necessary or convenient, the Depositary shall fix a record date, which shall be the same as, or as near as practicable to, any corresponding record date set by the Company with respect to Shares, (a) for the determination of the Owners (i) who shall be entitled to receive the benefit of that dividend or other distribution or those rights, (ii) who shall be entitled to give instructions for the exercise of voting rights at that meeting, (iii) who shall be responsible for that fee or charge or (iv) for any other purpose for which the record date was set, or (b) on or after which each American Depositary Share will represent the changed number of Shares. Subject to the provisions of Sections 4.1 through 4.5 and to the other terms and conditions of this Deposit Agreement, the Owners on a record date fixed by the Depositary shall be entitled to receive the amount distributable by the Depositary with respect to that dividend or other distribution or those rights or the net proceeds of sale thereof in proportion to the number of American Depositary Shares held by them respectively, to give voting instructions or to act in respect of the other matter for which that record date was fixed, or be responsible for that fee or charge, as the case may be.

 

SECTION 4.7. Voting of Deposited Shares.

 

(a) Upon receipt of notice of any meeting of holders of Shares at which holders of Shares will be entitled to vote, if requested in writing by the Company, the Depositary shall, as soon as practicable thereafter, Disseminate to the Owners a notice, the form of which shall be in the sole discretion of the Depositary, that shall contain (i) the information contained in the notice of meeting received by the Depositary, (ii) a statement that the Owners as of the close of business on a specified record date will be entitled, subject to any applicable provision of Australian law and of the articles of association or similar documents of the Company, to instruct the Depositary as to the exercise of the voting rights pertaining to the amount of Shares represented by their respective American Depositary Shares, (iii) a statement as to the manner in which those instructions may be given and (iv) the last date on which the Depositary will accept instructions (the “Instruction Cutoff Date”).

 

-19-

 

 

(b) Upon the written request of an Owner of American Depositary Shares, as of the date of the request or, if a record date was specified by the Depositary, as of that record date, received on or before any Instruction Cutoff Date established by the Depositary, the Depositary may, and if the Depositary sent a notice under the preceding paragraph shall, endeavor, in so far as practicable, to vote or cause to be voted the amount of deposited Shares represented by those American Depositary Shares in accordance with the instructions set forth in that request. The Depositary shall not vote or attempt to exercise the right to vote that attaches to the deposited Shares other than in accordance with instructions given by Owners and received by the Depositary.

 

(c) There can be no assurance that Owners generally or any Owner in particular will receive the notice described in paragraph (a) above in time to enable Owners to give instructions to the Depositary prior to the Instruction Cutoff Date.

 

(d) In order to give Owners a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Shares, if the Company will request the Depositary to Disseminate a notice under paragraph (a) above, the Company shall give the Depositary notice of the meeting, details concerning the matters to be voted upon and copies of materials to be made available to holders of Shares in connection with the meeting not less than 45 days prior to the meeting date.

 

SECTION 4.8. Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities.

 

(a) The Depositary shall not tender any Deposited Securities in response to any voluntary cash tender offer, exchange offer or similar offer made to holders of Deposited Securities (a “Voluntary Offer”), except when instructed in writing to do so by an Owner surrendering American Depositary Shares and subject to any conditions or procedures the Depositary may require.

 

(b) If the Depositary receives a written notice that Deposited Securities have been redeemed for cash or otherwise purchased for cash in a transaction that is mandatory and binding on the Depositary as a holder of those Deposited Securities (a “Redemption”), the Depositary, at the expense of the Company, shall (i) if required, surrender Deposited Securities that have been redeemed to the issuer of those securities or its agent on the redemption date, (ii) Disseminate a notice to Owners (A) notifying them of that Redemption, (B) calling for surrender of a corresponding number of American Depositary Shares and (C) notifying them that the called American Depositary Shares have been converted into a right only to receive the money received by the Depositary upon that Redemption and those net proceeds shall be the Deposited Securities to which Owners of those converted American Depositary Shares shall be entitled upon surrenders of those American Depositary Shares in accordance with Section 2.5 or 6.2 and (iii) distribute the money received upon that Redemption to the Owners entitled to it upon surrender by them of called American Depositary Shares in accordance with Section 2.5 (and, for the avoidance of doubt, Owners shall not be entitled to receive that money under Section 4.1). If the Redemption affects less than all the Deposited Securities, the Depositary shall call for surrender a corresponding portion of the outstanding American Depositary Shares and only those American Depositary Shares will automatically be converted into a right to receive the net proceeds of the Redemption. The Depositary shall allocate the American Depositary Shares converted under the preceding sentence among the Owners pro-rata to their respective holdings of American Depositary Shares immediately prior to the Redemption, except that the allocations may be adjusted so that no fraction of a converted American Depositary Share is allocated to any Owner. A Redemption of all or substantially all of the Deposited Securities shall be a Termination Option Event.

 

-20-

 

 

(c) If the Depositary is notified of or there occurs any change in nominal value or any subdivision, combination or any other reclassification of the Deposited Securities or any recapitalization, reorganization, sale of assets substantially as an entirety, merger or consolidation affecting the issuer of the Deposited Securities or to which it is a party that is mandatory and binding on the Depositary as a holder of Deposited Securities and, as a result, securities or other property have been or will be delivered in exchange, conversion, replacement or in lieu of, Deposited Securities (a “Replacement”), the Depositary shall, if required, surrender the old Deposited Securities affected by that Replacement of Shares and hold, as new Deposited Securities under this Deposit Agreement, the new securities or other property delivered to it in that Replacement. However, the Depositary may elect to sell those new Deposited Securities if in the opinion of the Depositary it is not lawful or not practical for it to hold those new Deposited Securities under this Deposit Agreement because those new Deposited Securities may not be distributed to Owners without registration under the Securities Act of 1933 or for any other reason, at public or private sale, at such places and on such terms as it deems proper and proceed as if those new Deposited Securities had been Redeemed under paragraph (b) above. A Replacement shall be a Termination Option Event.

 

(d) In the case of a Replacement where the new Deposited Securities will continue to be held under this Deposit Agreement, the Depositary may call for the surrender of outstanding Receipts to be exchanged for new Receipts specifically describing the new Deposited Securities and the number of those new Deposited Securities represented by each American Depositary Share. If the number of Shares represented by each American Depositary Share decreases as a result of a Replacement, the Depositary may call for surrender of the American Depositary Shares to be exchanged on a mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that sale to the Owners entitled to them.

 

-21-

 

 

(e) If there are no Deposited Securities with respect to American Depositary Shares, including if the Deposited Securities are cancelled, or the Deposited Securities with respect to American Depositary Shares have become apparently worthless, the Depositary may call for surrender of those American Depositary Shares or may cancel those American Depositary Shares, upon notice to Owners, and that condition shall be a Termination Option Event.

 

SECTION 4.9. Reports.

 

The Depositary shall make available for inspection by Owners at its Office any reports and communications, including any proxy solicitation material, received from the Company which are both (a) received by the Depositary as the holder of the Deposited Securities and (b) made generally available to the holders of those Deposited Securities by the Company. The Company shall furnish reports and communications, including any proxy soliciting material to which this Section applies, to the Depositary in English, to the extent those materials are required to be translated into English pursuant to any regulations of the Commission.

 

SECTION 4.10. Lists of Owners.

 

Upon written request by the Company, the Depositary shall, at the expense of the Company, furnish to it a list, as of a recent date, of the names, addresses and American Depositary Share holdings of all Owners.

 

SECTION 4.11. Withholding.

 

If the Depositary determines that any distribution received or to be made by the Depositary (including Shares and rights to subscribe therefor) is subject to any tax or other governmental charge that the Depositary is obligated to withhold, the Depositary may sell, by public or private sale, all or a portion of the distributed property (including Shares and rights to subscribe therefor) in the amounts and manner the Depositary deems necessary and practicable to pay those taxes or charges, and the Depositary shall distribute the net proceeds of that sale, after deduction of those taxes or charges, to the Owners entitled thereto in proportion to the number of American Depositary Shares held by them respectively.

 

Services for Owners and Holders that may permit them to obtain reduced rates of tax withholding at source or reclaim excess tax withheld, and the fees and costs associated with using services of that kind, are not provided under, and are outside the scope of, this Deposit Agreement.

 

Each Owner and Holder agrees to indemnify the Company, the Depositary, the Custodian and their respective directors, employees, agents and affiliates for, and hold each of them harmless against, any claim by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced withholding at source or other tax benefit received by it.

 

-22-

 

 

ARTICLE 5. THE DEPOSITARY, THE CUSTODIANS AND THE COMPANY

 

SECTION 5.1. Maintenance of Office and Register by the Depositary.

 

Until termination of this Deposit Agreement in accordance with its terms, the Depositary shall maintain facilities for the delivery, registration of transfers and surrender of American Depositary Shares in accordance with the provisions of this Deposit Agreement.

 

The Depositary shall keep a register of all Owners and all outstanding American Depositary Shares, which shall be open for inspection by the Owners at the Depositary’s Office during regular business hours, but only for the purpose of communicating with Owners regarding the business of the Company or a matter related to this Deposit Agreement or the American Depositary Shares.

 

The Depositary may close the register for delivery, registration of transfer or surrender for the purpose of withdrawal from time to time as provided in Section 2.6.

 

If any American Depositary Shares are listed on one or more stock exchanges, the Depositary shall act as Registrar or appoint a Registrar or one or more co-registrars for registration of those American Depositary Shares in accordance with any requirements of that exchange or those exchanges.

 

SECTION 5.2. Prevention or Delay of Performance by the Company or the Depositary.

 

Neither the Depositary nor the Company nor any of their respective directors, employees, agents or affiliates shall incur any liability to any Owner or Holder:

 

(i) if by reason of (A) any provision of any present or future law or regulation or other act of the government of the United States, any State of the United States or any other state or jurisdiction, or of any governmental or regulatory authority or stock exchange; (B) (in the case of the Depositary only) any provision, present or future, of the articles of association or similar document of the Company, or any provision of any securities issued or distributed by the Company, or any offering or distribution thereof; or (C) any event or circumstance, whether natural or caused by a person or persons, that is beyond the ability of the Depositary or the Company, as the case may be, to prevent or counteract by reasonable care or effort (including, but not limited to, earthquakes, floods, severe storms, fires, explosions, war, terrorism, civil unrest, labor disputes, criminal acts or outbreaks of infectious disease; interruptions or malfunctions of utility services, Internet or other communications lines or systems; unauthorized access to or attacks on computer systems or websites; or other failures or malfunctions of computer hardware or software or other systems or equipment), the Depositary or the Company is, directly or indirectly, prevented from, forbidden to or delayed in, or could be subject to any civil or criminal penalty on account of doing or performing and therefore does not do or perform, any act or thing that, by the terms of this Deposit Agreement or the Deposited Securities, it is provided shall be done or performed;

 

-23-

 

 

(ii) for any exercise of, or failure to exercise, any discretion provided for in this Deposit Agreement (including any determination by the Depositary to take, or not take, any action that this Deposit Agreement provides the Depositary may take);

 

(iii) for the inability of any Owner or Holder to benefit from any distribution, offering, right or other benefit that is made available to holders of Deposited Securities but is not, under the terms of this Deposit Agreement, made available to Owners or Holders; or

 

(iv) for any special, consequential or punitive damages for any breach of the terms of this Deposit Agreement.

 

Where, by the terms of a distribution to which Section 4.1, 4.2 or 4.3 applies, or an offering to which Section 4.4 applies, or for any other reason, that distribution or offering may not be made available to Owners, and the Depositary may not dispose of that distribution or offering on behalf of Owners and make the net proceeds available to Owners, then the Depositary shall not make that distribution or offering available to Owners, and shall allow any rights, if applicable, to lapse.

 

SECTION 5.3. Obligations of the Depositary and the Company.

 

The Company assumes no obligation nor shall it be subject to any liability under this Deposit Agreement to any Owner or Holder, except that the Company agrees to perform its obligations specifically set forth in this Deposit Agreement without negligence or bad faith.

 

The Depositary assumes no obligation nor shall it be subject to any liability under this Deposit Agreement to any Owner or Holder (including, without limitation, liability with respect to the validity or worth of the Deposited Securities), except that the Depositary agrees to perform its obligations specifically set forth in this Deposit Agreement without negligence or bad faith, and the Depositary shall not be a fiduciary or have any fiduciary duty to Owners or Holders.

 

Neither the Depositary nor the Company shall be under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any Deposited Securities or in respect of the American Depositary Shares on behalf of any Owner or Holder or any other person.

 

-24-

 

 

Each of the Depositary and the Company may rely, and shall be protected in relying upon, any written notice, request, direction or other document believed by it to be genuine and to have been signed or presented by the proper party or parties.

 

Neither the Depositary nor the Company shall be liable for any action or non-action by it in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Owner or any other person believed by it in good faith to be competent to give such advice or information.

 

The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with any matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises the Depositary performed its obligations without negligence or bad faith while it acted as Depositary.

 

The Depositary shall not be liable for the acts or omissions of any securities depository, clearing agency or settlement system in connection with or arising out of book-entry settlement of American Depositary Shares or Deposited Securities or otherwise.

 

In the absence of bad faith on its part, the Depositary shall not be responsible for any failure to carry out any instructions to vote any of the Deposited Securities, or for the manner in which any such vote is cast or the effect of any such vote.

 

The Depositary shall have no duty to make any determination or provide any information as to the tax status of the Company or any liability for any tax consequences that may be incurred by Owners or Holders as a result of owning or holding American Depositary Shares. The Depositary shall not be liable for the inability or failure of an Owner or Holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.

 

SECTION 5.4. Resignation and Removal of the Depositary.

 

The Depositary may at any time resign as Depositary hereunder by written notice of its election so to do delivered to the Company, to become effective upon the appointment of a successor depositary and its acceptance of that appointment as provided in this Section. The effect of resignation if a successor depositary is not appointed is provided for in Section 6.2.

 

The Depositary may at any time be removed by the Company by 120 days’ prior written notice of that removal, to become effective upon the later of (i) the 120th day after delivery of the notice to the Depositary and (ii) the appointment of a successor depositary and its acceptance of its appointment as provided in this Section.

 

-25-

 

 

If the Depositary resigns or is removed, the Company shall use its best efforts to appoint a successor depositary, which shall be a bank or trust company having an office in the Borough of Manhattan, The City of New York. Every successor depositary shall execute and deliver to the Company an instrument in writing accepting its appointment under this Deposit Agreement. If the Depositary receives notice from the Company that a successor depositary has been appointed following its resignation or removal, the Depositary, upon payment of all sums due it from the Company, shall deliver to its successor a register listing all the Owners and their respective holdings of outstanding American Depositary Shares and shall deliver the Deposited Securities to or to the order of its successor. When the Depositary has taken the actions specified in the preceding sentence (i) the successor shall become the Depositary and shall have all the rights and shall assume all the duties of the Depositary under this Deposit Agreement and (ii) the predecessor depositary shall cease to be the Depositary and shall be discharged and released from all obligations under this Deposit Agreement, except for its duties under Section 5.8 with respect to the time before that discharge. A successor Depositary shall notify the Owners of its appointment as soon as practical after assuming the duties of Depositary.

 

Any corporation or other entity into or with which the Depositary may be merged or consolidated shall be the successor of the Depositary without the execution or filing of any document or any further act.

 

SECTION 5.5. The Custodians.

 

The Custodian shall be subject at all times and in all respects to the directions of the Depositary and shall be responsible solely to it. The Depositary in its discretion may at any time appoint a substitute or additional custodian or custodians, each of which shall thereafter be one of the Custodians under this Deposit Agreement. If the Depositary receives notice that a Custodian is resigning and, upon the effectiveness of that resignation there would be no Custodian acting under this Deposit Agreement, the Depositary shall, as promptly as practicable after receiving that notice, appoint a substitute custodian or custodians, each of which shall thereafter be a Custodian under this Deposit Agreement. The Depositary shall require any Custodian that resigns or is removed to deliver all Deposited Securities held by it to another Custodian.

 

SECTION 5.6. Notices and Reports.

 

If the Company takes or decides to take any corporate action of a kind that is addressed in Sections 4.1 to 4.4, or 4.6 to 4.8, or that effects or will effect a change of the name or legal structure of the Company, or that effects or will effect a change to the Shares, the Company shall notify the Depositary and the Custodian of that action or decision as soon as it is lawful and practical to give that notice.  The notice shall be in English and shall include all details that the Company is required to include in any notice to any governmental or regulatory authority or securities exchange or is required to make available generally to holders of Shares by publication or otherwise.

 

-26-

 

 

The Company will arrange for the translation into English, if not already in English, to the extent required pursuant to any regulations of the Commission, and the prompt transmittal by the Company to the Depositary and the Custodian of all notices and any other reports and communications which are made generally available by the Company to holders of its Shares. If requested in writing by the Company, the Depositary will Disseminate, at the Company’s expense, those notices, reports and communications to all Owners or otherwise make them available to Owners in a manner that the Company specifies as substantially equivalent to the manner in which those communications are made available to holders of Shares and compliant with the requirements of any securities exchange on which the American Depositary Shares are listed. The Company will timely provide the Depositary with the quantity of such notices, reports, and communications, as requested by the Depositary from time to time, in order for the Depositary to effect that Dissemination.

 

The Company represents, continuously, that the statements in Article 11 of the form of Receipt appearing as Exhibit A to this Deposit Agreement or, if applicable, most recently filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933 with respect to the Company’s obligation to file periodic reports under the United States Securities Exchange Act of 1934, as amended, or its qualification for exemption from registration under that Act pursuant to Rule 12g3-2(b) under that Act, as the case may be, are true and correct. The Company agrees to promptly notify the Depositary upon becoming aware of any change in the truth of any of those statements or if there is any change in the Company’s status regarding those reporting obligations or that qualification.

 

SECTION 5.7. Distribution of Additional Shares, Rights, etc.

 

If the Company or any affiliate of the Company determines to make any issuance or distribution of (1) additional Shares, (2) rights to subscribe for Shares, (3) securities convertible into Shares, or (4) rights to subscribe for such securities (each a “Distribution”), the Company shall notify the Depositary in writing in English as promptly as practicable and in any event before the Distribution starts and, if requested in writing by the Depositary, the Company shall promptly furnish to the Depositary either (i) evidence satisfactory to the Depositary that the Distribution is registered under the Securities Act of 1933 or (ii) a written opinion from U.S. counsel for the Company that is reasonably satisfactory to the Depositary, stating that the Distribution does not require, or, if made in the United States, would not require, registration under the Securities Act of 1933.

 

The Company agrees with the Depositary that neither the Company nor any company controlled by, controlling or under common control with the Company will at any time deposit any Shares that, at the time of deposit, are Restricted Securities.

 

-27-

 

 

SECTION 5.8. Indemnification.

 

The Company agrees to indemnify the Depositary, its directors, employees, agents and affiliates and each Custodian against, and hold each of them harmless from, any liability or expense (including, but not limited to any fees and expenses incurred in seeking, enforcing or collecting such indemnity and the fees and expenses of counsel) that may arise out of or in connection with (a) any registration with the Commission of American Depositary Shares or Deposited Securities or the offer or sale thereof or (b) acts performed or omitted, pursuant to the provisions of or in connection with this Deposit Agreement and the American Depositary Shares, as the same may be amended, modified or supplemented from time to time, (i) by either the Depositary or a Custodian or their respective directors, employees, agents and affiliates, except for any liability or expense arising out of the negligence or bad faith of either of them, or (ii) by the Company or any of its directors, employees, agents and affiliates.

 

The Depositary agrees to indemnify the Company, its directors, employees, agents and affiliates and hold them harmless from any liability or expense that may arise out of acts performed or omitted by the Depositary or any Custodian or their respective directors, employees, agents and affiliates due to their negligence or bad faith.

 

SECTION 5.9. Charges of Depositary.

 

The following charges shall be incurred by any party depositing or withdrawing Shares or by any party surrendering American Depositary Shares or to whom American Depositary Shares are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by the Company or an exchange of stock regarding the American Depositary Shares or Deposited Securities or a delivery of American Depositary Shares pursuant to Section 4.3), or by Owners, as applicable: (1) taxes and other governmental charges, (2) such registration fees as may from time to time be in effect for the registration of transfers of Shares generally on the Share register of the Company or Foreign Registrar and applicable to transfers of Shares to or from the name of the Depositary or its nominee or the Custodian or its nominee on the making of deposits or withdrawals hereunder, (3) such cable (including SWIFT) and facsimile transmission fees and expenses as are expressly provided in this Deposit Agreement, (4) such expenses as are incurred by the Depositary in the conversion of foreign currency pursuant to Section 4.5, (5) a fee of $5.00 or less per 100 American Depositary Shares (or portion thereof) for the delivery of American Depositary Shares pursuant to Section 2.3, 4.3 or 4.4 and the surrender of American Depositary Shares pursuant to Section 2.5 or 6.2, (6) a fee of $.05 or less per American Depositary Share (or portion thereof) for any cash distribution made pursuant to this Deposit Agreement, including, but not limited to Sections 4.1 through 4.4 and Section 4.8, (7) a fee for the distribution of securities pursuant to Section 4.2 or of rights pursuant to Section 4.4 (where the Depositary will not exercise or sell those rights on behalf of Owners), such fee being in an amount equal to the fee for the execution and delivery of American Depositary Shares referred to above which would have been charged as a result of the deposit of such securities under this Deposit Agreement (for purposes of this item 7 treating all such securities as if they were Shares) but which securities are instead distributed by the Depositary to Owners, (8) in addition to any fee charged under item 6 above, a fee of $.05 or less per American Depositary Share (or portion thereof) per annum for depositary services, which will be payable as provided in item 9 below, and (9) any other charges payable by the Depositary or the Custodian, any of the Depositary's or Custodian’s agents or the agents of the Depositary's or Custodian’s agents, in connection with the servicing of Shares or other Deposited Securities (which charges shall be assessed against Owners as of the date or dates set by the Depositary in accordance with Section 4.6 and shall be payable at the sole discretion of the Depositary by billing those Owners for those charges or by deducting those charges from one or more cash dividends or other cash distributions).

 

-28-

 

 

The Depositary may collect any of its fees by deduction from any cash distribution payable, or by selling a portion of any securities to be distributed, to Owners that are obligated to pay those fees.

 

In performing its duties under this Deposit Agreement, the Depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the Depositary and that may earn or share fees, spreads or commissions.

 

The Depositary may own and deal in any class of securities of the Company and its affiliates and in American Depositary Shares.

 

SECTION 5.10. Retention of Depositary Documents.

 

The Depositary is authorized to destroy those documents, records, bills and other data compiled during the term of this Deposit Agreement at the times permitted by the laws or regulations governing the Depositary.

 

SECTION 5.11. Exclusivity.

 

Without prejudice to the Company’s rights under Section 5.4, the Company agrees not to appoint any other depositary for issuance of depositary shares, depositary receipts or any similar securities or instruments so long as The Bank of New York Mellon is acting as Depositary under this Deposit Agreement.

 

SECTION 5.12. Information for Regulatory Compliance.

 

Each of the Company and the Depositary shall provide to the other, as promptly as practicable, information from its records or otherwise available to it that is reasonably requested by the other to permit the other to comply with applicable law or requirements of governmental or regulatory authorities.

 

-29-

 

 

ARTICLE 6. AMENDMENT AND TERMINATION

 

SECTION 6.1. Amendment.

 

The form of the Receipts and any provisions of this Deposit Agreement may at any time and from time to time be amended by agreement between the Company and the Depositary without the consent of Owners or Holders in any respect that they may deem necessary or desirable. Any amendment that would impose or increase any fees or charges (other than taxes and other governmental charges, registration fees, cable (including SWIFT) or facsimile transmission costs, delivery costs or other such expenses), or that would otherwise prejudice any substantial existing right of Owners, shall, however, not become effective as to outstanding American Depositary Shares until the expiration of 30 days after notice of that amendment has been Disseminated to the Owners of outstanding American Depositary Shares. Every Owner and Holder, at the time any amendment so becomes effective, shall be deemed, by continuing to hold American Depositary Shares or any interest therein, to consent and agree to that amendment and to be bound by this Deposit Agreement as amended thereby. Upon the effectiveness of an amendment to the form of Receipt, including a change in the number of Shares represented by each American Depositary Share, the Depositary may call for surrender of Receipts to be replaced with new Receipts in the amended form or call for surrender of American Depositary Shares to effect that change of ratio. In no event shall any amendment impair the right of the Owner to surrender American Depositary Shares and receive delivery of the Deposited Securities represented thereby, except in order to comply with mandatory provisions of applicable law.

 

SECTION 6.2. Termination.

 

(a) The Company may initiate termination of this Deposit Agreement by notice to the Depositary. The Depositary may initiate termination of this Deposit Agreement if (i) at any time 60 days shall have expired after the Depositary delivered to the Company a written resignation notice and a successor depositary has not been appointed and accepted its appointment as provided in Section 5.4 or (ii) a Termination Option Event has occurred or will occur. If termination of this Deposit Agreement is initiated, the Depositary shall Disseminate a notice of termination to the Owners of all American Depositary Shares then outstanding setting a date for termination (the “Termination Date”), which shall be at least 90 days after the date of that notice, and this Deposit Agreement shall terminate on that Termination Date.

 

-30-

 

 

(b) After the Termination Date, the Company shall be discharged from all obligations under this Deposit Agreement except for its obligations to the Depositary under Sections 5.8 and 5.9.

 

(c) At any time after the Termination Date, the Depositary may sell the Deposited Securities then held under this Deposit Agreement and may thereafter hold uninvested the net proceeds of any such sale, together with any other cash then held by it hereunder, unsegregated and without liability for interest, for the pro rata benefit of the Owners of American Depositary Shares that remain outstanding, and those Owners will be general creditors of the Depositary with respect to those net proceeds and that other cash. After making that sale, the Depositary shall be discharged from all obligations under this Deposit Agreement, except (i) to account for the net proceeds and other cash (after deducting, in each case, the fee of the Depositary for the surrender of American Depositary Shares, any expenses for the account of the Owner of such American Depositary Shares in accordance with the terms and conditions of this Deposit Agreement and any applicable taxes or governmental charges) and (ii) for its obligations under Section 5.8 and (iii) to act as provided in paragraph (d) below.

 

(d) After the Termination Date, the Depositary shall continue to receive dividends and other distributions pertaining to Deposited Securities (that have not been sold), may sell rights and other property as provided in this Deposit Agreement and shall deliver Deposited Securities (or sale proceeds) upon surrender of American Depositary Shares (after payment or upon deduction, in each case, of the fee of the Depositary for the surrender of American Depositary Shares, any expenses for the account of the Owner of those American Depositary Shares in accordance with the terms and conditions of this Deposit Agreement and any applicable taxes or governmental charges). After the Termination Date, the Depositary shall not accept deposits of Shares or deliver American Depositary Shares. After the Termination Date, (i) the Depositary may refuse to accept surrenders of American Depositary Shares for the purpose of withdrawal of Deposited Securities (that have not been sold) or reverse previously accepted surrenders of that kind that have not settled if in its judgment the requested withdrawal would interfere with its efforts to sell the Deposited Securities, (ii) the Depositary will not be required to deliver cash proceeds of the sale of Deposited Securities until all Deposited Securities have been sold and (iii) the Depositary may discontinue the registration of transfers of American Depositary Shares and suspend the distribution of dividends and other distributions on Deposited Securities to the Owners and need not give any further notices or perform any further acts under this Deposit Agreement except as provided in this Section.

 

ARTICLE 7. MISCELLANEOUS

 

SECTION 7.1. Counterparts; Signatures; Delivery.

 

This Deposit Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of those counterparts shall constitute one and the same instrument. Copies of this Deposit Agreement shall be filed with the Depositary and the Custodians and shall be open to inspection by any Owner or Holder during regular business hours.

 

-31-

 

 

The exchange of copies of this Deposit Agreement and manually-signed signature pages by facsimile, or email attaching a pdf or similar bit-mapped image, shall constitute effective execution and delivery of this Deposit Agreement as to the parties to it; copies and signature pages so exchanged may be used in lieu of the original Deposit Agreement and signature pages for all purposes and shall have the same validity, legal effect and admissibility in evidence as an original manual signature; the parties to this Deposit Agreement hereby agree not to argue to the contrary.

 

SECTION 7.2. No Third Party Beneficiaries.

 

This Deposit Agreement is for the exclusive benefit of the Company, the Depositary, the Owners and the Holders and their respective successors and shall not be deemed to give any legal or equitable right, remedy or claim whatsoever to any other person.

 

SECTION 7.3. Severability.

 

In case any one or more of the provisions contained in this Deposit Agreement or in a Receipt should be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained in this Deposit Agreement or that Receipt shall in no way be affected, prejudiced or disturbed thereby.

 

SECTION 7.4. Owners and Holders as Parties; Binding Effect.

 

The Owners and Holders from time to time shall be parties to this Deposit Agreement and shall be bound by all of the terms and conditions of this Deposit Agreement and of the Receipts by acceptance of American Depositary Shares or any interest therein.

 

SECTION 7.5. Notices.

 

Any and all notices to be given to the Company shall be in writing and shall be deemed to have been duly given if personally delivered or sent by domestic first class or international air mail or air courier or sent by facsimile transmission or email attaching a pdf or similar bit-mapped image of a signed writing, addressed to Advanced Human Imaging Limited, _________________________________________, Attention: _____________, or any other place to which the Company may have transferred its principal office with notice to the Depositary.

 

Any and all notices to be given to the Depositary shall be in writing and shall be deemed to have been duly given if in English and personally delivered or sent by first class domestic or international air mail or air courier or sent by facsimile transmission or email attaching a pdf or similar bit-mapped image of a signed writing, addressed to The Bank of New York Mellon, 240 Greenwich Street, New York, New York 10286, Attention: Depositary Receipt Administration, or any other place to which the Depositary may have transferred its Office with notice to the Company.

 

-32-

 

 

Delivery of a notice to the Company or Depositary by mail or air courier shall be deemed effected when deposited, postage prepaid, in a post-office letter box or received by an air courier service. Delivery of a notice to the Company or Depositary sent by facsimile transmission or email shall be deemed effected when the recipient acknowledges receipt of that notice.

 

A notice to be given to an Owner shall be deemed to have been duly given when Disseminated to that Owner. Dissemination in paper form will be effective when personally delivered or sent by first class domestic or international air mail or air courier, addressed to that Owner at the address of that Owner as it appears on the transfer books for American Depositary Shares of the Depositary, or, if that Owner has filed with the Depositary a written request that notices intended for that Owner be mailed to some other address, at the address designated in that request. Dissemination in electronic form will be effective when sent in the manner consented to by the Owner to the electronic address most recently provided by the Owner for that purpose.

 

SECTION 7.6. Appointment of Agent for Service of Process; Submission to Jurisdiction; Jury Trial Waiver.

 

The Company hereby (i) designates and appoints the person named in Exhibit A to this Deposit Agreement as the Company's authorized agent in the United States upon which process may be served in any suit or proceeding arising out of or relating to the Shares or Deposited Securities, the American Depositary Shares, the Receipts or this Deposit Agreement (a “Proceeding”), (ii) consents and submits to the jurisdiction of any state or federal court in the State of New York in which any Proceeding may be instituted and (iii) agrees that service of process upon said authorized agent shall be deemed in every respect effective service of process upon the Company in any Proceeding. The Company agrees to deliver to the Depositary, upon the execution and delivery of this Deposit Agreement, a written acceptance by the agent named in Exhibit A to this Deposit Agreement of its appointment as process agent. The Company further agrees to take any and all action, including the filing of any and all such documents and instruments, as may be necessary to continue that designation and appointment in full force and effect, or to appoint and maintain the appointment of another process agent located in the United States as required above, and to deliver to the Depositary a written acceptance by that agent of that appointment, for so long as any American Depositary Shares or Receipts remain outstanding or this Deposit Agreement remains in force. In the event the Company fails to maintain the designation and appointment of a process agent in the United States in full force and effect, the Company hereby waives personal service of process upon it and consents that a service of process in connection with a Proceeding may be made by certified or registered mail, return receipt requested, directed to the Company at its address last specified for notices under this Deposit Agreement, and service so made shall be deemed completed five (5) days after the same shall have been so mailed.

 

-33-

 

 

EACH PARTY TO THIS DEPOSIT AGREEMENT (INCLUDING, FOR AVOIDANCE OF DOUBT, EACH OWNER AND HOLDER) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING AGAINST THE COMPANY AND/OR THE DEPOSITARY DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THE SHARES OR OTHER DEPOSITED SECURITIES, THE AMERICAN DEPOSITARY SHARES OR THE RECEIPTS, THIS DEPOSIT AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREIN OR THEREIN, OR THE BREACH HEREOF OR THEREOF, INCLUDING, WITHOUT LIMITATION, ANY QUESTION REGARDING EXISTENCE, VALIDITY OR TERMINATION (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY) OR ANY CLAIM BASED ON U.S. FEDERAL SECURITIES LAWS.

 

No disclaimer of liability under the United States federal securities laws or the rules and regulations thereunder is intended by any provision of this Deposit Agreement, inasmuch as no person is able to effectively waive the duty of any other person to comply with its obligations under those laws, rules and regulations.

 

SECTION 7.7. Waiver of Immunities.

 

To the extent that the Company or any of its properties, assets or revenues may have or may hereafter become entitled to, or have attributed to it, any right of immunity, on the grounds of sovereignty or otherwise, from any legal action, suit or proceeding, from the giving of any relief in any respect thereof, from setoff or counterclaim, from the jurisdiction of any court, from service of process, from attachment upon or prior to judgment, from attachment in aid of execution or judgment, or from execution of judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of any judgment, in any jurisdiction in which proceedings may at any time be commenced, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with the Shares or Deposited Securities, the American Depositary Shares, the Receipts or this Deposit Agreement, the Company, to the fullest extent permitted by law, hereby irrevocably and unconditionally waives, and agrees not to plead or claim, any immunity of that kind and consents to relief and enforcement as provided above.

 

SECTION 7.8. Governing Law.

 

This Deposit Agreement and the Receipts shall be interpreted in accordance with and all rights hereunder and thereunder and provisions hereof and thereof shall be governed by the laws of the State of New York.

 

-34-

 

 

IN WITNESS WHEREOF, ADVANCED HUMAN IMAGING LIMITED and THE BANK OF NEW YORK MELLON have duly executed this Deposit Agreement as of the day and year first set forth above and all Owners and Holders shall become parties hereto upon acceptance by them of American Depositary Shares or any interest therein.

 

  ADVACED HUMAN IMAGING  LIMITED
 
  By:                   
  Name: 
  Title:
  THE BANK OF NEW YORK MELLON, as Depositary
   
  By:
  Name: 
  Title:

 

-35-

 

 

EXHIBIT A

 

AMERICAN DEPOSITARY SHARES

(Each American Depositary Share represents

_____ deposited Shares)

 

THE BANK OF NEW YORK MELLON

AMERICAN DEPOSITARY RECEIPT

FOR ORDINARY SHARES OF

ADVANCED HUMAN IMAGING LIMITED

(INCORPORATED UNDER THE LAWS OF AUSTRALIA)

 

The Bank of New York Mellon, as depositary (hereinafter called the “Depositary”), hereby certifies that_________________________________________, or registered assigns IS THE OWNER OF _____________________________

 

AMERICAN DEPOSITARY SHARES

 

representing deposited [shareclass] shares (herein called “Shares”) of Advanced Human Imaging Limited, incorporated under the laws of Australia (herein called the “Company”). At the date hereof, each American Depositary Share represents _____ Shares deposited or subject to deposit under the Deposit Agreement (as such term is hereinafter defined) with a custodian for the Depositary (herein called the “Custodian”) that, as of the date of the Deposit Agreement, was HSBC Australia located in Australia. The Depositary's Office and its principal executive office are located at 240 Greenwich Street, New York, N.Y. 10286.

 

THE DEPOSITARY'S OFFICE ADDRESS IS

240 GREENWICH STREET, NEW YORK, N.Y. 10286

 

A-1

 

 

1. THE DEPOSIT AGREEMENT.

 

This American Depositary Receipt is one of an issue (herein called “Receipts”), all issued and to be issued upon the terms and conditions set forth in the Deposit Agreement dated as of __________, 2020 (herein called the “Deposit Agreement”) among the Company, the Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder, each of whom by accepting American Depositary Shares agrees to become a party thereto and become bound by all the terms and conditions thereof. The Deposit Agreement sets forth the rights of Owners and Holders and the rights and duties of the Depositary in respect of the Shares deposited thereunder and any and all other securities, property and cash from time to time received in respect of those Shares and held thereunder (those Shares, securities, property, and cash are herein called “Deposited Securities”). Copies of the Deposit Agreement are on file at the Depositary's Office in New York City and at the office of the Custodian.

 

The statements made on the face and reverse of this Receipt are summaries of certain provisions of the Deposit Agreement and are qualified by and subject to the detailed provisions of the Deposit Agreement, to which reference is hereby made. Capitalized terms defined in the Deposit Agreement and not defined herein shall have the meanings set forth in the Deposit Agreement.

 

2. SURRENDER OF AMERICAN DEPOSITARY SHARES AND WITHDRAWAL OF SHARES.

 

Upon surrender of American Depositary Shares for the purpose of withdrawal of the Deposited Securities represented thereby and payment of the fee of the Depositary for the surrender of American Depositary Shares as provided in Section 5.9 of the Deposit Agreement and payment of all taxes and governmental charges payable in connection with that surrender and withdrawal of the Deposited Securities, and subject to the terms and conditions of the Deposit Agreement, the Owner of those American Depositary Shares shall be entitled to delivery (to the extent delivery can then be lawfully and practicably made), to or as instructed by that Owner, of the amount of Deposited Securities at the time represented by those American Depositary Shares, but not any money or other property as to which a record date for distribution to Owners has passed (since money or other property of that kind will be delivered or paid on the scheduled payment date to the Owner as of that record date), and except that the Depositary shall not be required to accept surrender of American Depositary Shares for the purpose of withdrawal to the extent it would require delivery of a fraction of a Deposited Security. The Depositary shall direct the Custodian with respect to delivery of Deposited Securities and may charge the surrendering Owner a fee and its expenses for giving that direction by cable (including SWIFT) or facsimile transmission. If Deposited Securities are delivered physically upon surrender of American Depositary Shares for the purpose of withdrawal, that delivery will be made at the Custodian’s office, except that, at the request, risk and expense of the surrendering Owner, and for the account of that Owner, the Depositary shall direct the Custodian to forward any cash or other property comprising, and forward a certificate or certificates, if applicable, and other proper documents of title, if any, for, the Deposited Securities represented by the surrendered American Depositary Shares to the Depositary for delivery at the Depositary’s Office or to another address specified in the order received from the surrendering Owner.

 

A-2

 

 

3. REGISTRATION OF TRANSFER OF AMERICAN DEPOSITARY SHARES; COMBINATION AND SPLIT-UP OF RECEIPTS; INTERCHANGE OF CERTIFICATED AND UNCERTIFICATED AMERICAN DEPOSITARY SHARES.

 

The Depositary, subject to the terms and conditions of the Deposit Agreement, shall register a transfer of American Depositary Shares on its transfer books upon (i) in the case of certificated American Depositary Shares, surrender of the Receipt evidencing those American Depositary Shares, by the Owner or by a duly authorized attorney, properly endorsed or accompanied by proper instruments of transfer or (ii) in the case of uncertificated American Depositary Shares, receipt from the Owner of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in Section 2.9 of that Agreement), and, in either case, duly stamped as may be required by the laws of the State of New York and of the United States of America. Upon registration of a transfer, the Depositary shall deliver the transferred American Depositary Shares to or upon the order of the person entitled thereto.

 

The Depositary, subject to the terms and conditions of the Deposit Agreement, shall upon surrender of a Receipt or Receipts for the purpose of effecting a split-up or combination of such Receipt or Receipts, execute and deliver a new Receipt or Receipts for any authorized number of American Depositary Shares requested, evidencing the same aggregate number of American Depositary Shares as the Receipt or Receipts surrendered.

 

The Depositary, upon surrender of certificated American Depositary Shares for the purpose of exchanging for uncertificated American Depositary Shares, shall cancel the Receipt evidencing those certificated American Depositary Shares and send the Owner a statement confirming that the Owner is the owner of the same number of uncertificated American Depositary Shares. The Depositary, upon receipt of a proper instruction (including, for the avoidance of doubt, instructions through DRS and Profile as provided in Section 2.9 of the Deposit Agreement) from the Owner of uncertificated American Depositary Shares for the purpose of exchanging for certificated American Depositary Shares, shall cancel those uncertificated American Depositary Shares and register and deliver to the Owner a Receipt evidencing the same number of certificated American Depositary Shares.

 

As a condition precedent to the delivery, registration of transfer, or surrender of any American Depositary Shares or split-up or combination of any Receipt or withdrawal of any Deposited Securities, the Depositary, the Custodian, or Registrar may require payment from the depositor of the Shares or the presenter of the Receipt or instruction for registration of transfer or surrender of American Depositary Shares not evidenced by a Receipt of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or registration fee with respect thereto (including any such tax or charge and fee with respect to Shares being deposited or withdrawn) and payment of any applicable fees as provided in the Deposit Agreement, may require the production of proof satisfactory to it as to the identity and genuineness of any signature and may also require compliance with any regulations the Depositary may establish consistent with the provisions of the Deposit Agreement.

 

A-3

 

 

The Depositary may refuse to accept deposits of Shares for delivery of American Depositary Shares or to register transfers of American Depositary Shares in particular instances, or may suspend deposits of Shares or registration of transfer generally, whenever it or the Company considers it necessary or advisable to do so. The Depositary may refuse surrenders of American Depositary Shares for the purpose of withdrawal of Deposited Securities in particular instances, or may suspend surrenders for the purpose of withdrawal generally, but, notwithstanding anything to the contrary in the Deposit Agreement, only for (i) temporary delays caused by closing of the Depositary’s register or the register of holders of Shares maintained by the Company or the Foreign Registrar, or the deposit of Shares, in connection with voting at a shareholders’ meeting or the payment of dividends, (ii) the payment of fees, taxes and similar charges, (iii) compliance with any U.S. or foreign laws or governmental regulations relating to the American Depositary Shares or to the withdrawal of the Deposited Securities or (iv) any other reason that, at the time, is permitted under paragraph I(A)(1) of the General Instructions to Form F-6 under the Securities Act of 1933 or any successor to that provision.

 

The Depositary shall not knowingly accept for deposit under the Deposit Agreement any Shares that, at the time of deposit, are Restricted Securities.

 

4. LIABILITY OF OWNER FOR TAXES.

 

If any tax or other governmental charge shall become payable by the Custodian or the Depositary with respect to or in connection with any American Depositary Shares or any Deposited Securities represented by any American Depositary Shares or in connection with a transaction to which Section 4.8 of the Deposit Agreement applies, that tax or other governmental charge shall be payable by the Owner of those American Depositary Shares to the Depositary. The Depositary may refuse to register any transfer of those American Depositary Shares or any withdrawal of Deposited Securities represented by those American Depositary Shares until that payment is made, and may withhold any dividends or other distributions or the proceeds thereof, or may sell for the account of the Owner any part or all of the Deposited Securities represented by those American Depositary Shares, and may apply those dividends or other distributions or the net proceeds of any sale of that kind in payment of that tax or other governmental charge but, even after a sale of that kind, the Owner shall remain liable for any deficiency. The Depositary shall distribute any net proceeds of a sale made under Section 3.2 of the Deposit Agreement that are not used to pay taxes or governmental charges to the Owners entitled to them in accordance with Section 4.1 of the Deposit Agreement. If the number of Shares represented by each American Depositary Share decreases as a result of a sale of Deposited Securities under Section 3.2 of the Deposit Agreement, the Depositary may call for surrender of the American Depositary Shares to be exchanged on a mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that sale to the Owners entitled to them.

 

A-4

 

 

5. WARRANTIES ON DEPOSIT OF SHARES.

 

Every person depositing Shares under the Deposit Agreement shall be deemed thereby to represent and warrant that those Shares and each certificate therefor, if applicable, are validly issued, fully paid and nonassessable and were not issued in violation of any preemptive or similar rights of the holders of outstanding securities of the Company and that the person making that deposit is duly authorized so to do. Every depositing person shall also be deemed to represent that the Shares, at the time of deposit, are not Restricted Securities. All representations and warranties deemed made under Section 3.3 of the Deposit Agreement shall survive the deposit of Shares and delivery of American Depositary Shares.

 

6. FILING PROOFS, CERTIFICATES, AND OTHER INFORMATION.

 

Any person presenting Shares for deposit or any Owner or Holder may be required from time to time to file with the Depositary or the Custodian such proof of citizenship or residence, exchange control approval, or such information relating to the registration on the books of the Company or the Foreign Registrar, if applicable, to execute such certificates and to make such representations and warranties, as the Depositary may deem necessary or proper. The Depositary may withhold the delivery or registration of transfer of any American Depositary Shares, the distribution of any dividend or other distribution or of the proceeds thereof or the delivery of any Deposited Securities until that proof or other information is filed or those certificates are executed or those representations and warranties are made. As conditions of accepting Shares for deposit, the Depositary may require (i) any certification required by the Depositary or the Custodian in accordance with the provisions of the Deposit Agreement, (ii) a written order directing the Depositary to deliver to, or upon the written order of, the person or persons stated in that order, the number of American Depositary Shares representing those Deposited Shares, (iii) evidence satisfactory to the Depositary that those Shares have been re-registered in the books of the Company or the Foreign Registrar in the name of the Depositary, a Custodian or a nominee of the Depositary or a Custodian, (iv) evidence satisfactory to the Depositary that any necessary approval has been granted by any governmental body in each applicable jurisdiction and (v) an agreement or assignment, or other instrument satisfactory to the Depositary, that provides for the prompt transfer to the Custodian of any dividend, or right to subscribe for additional Shares or to receive other property, that any person in whose name those Shares are or have been recorded may thereafter receive upon or in respect of those Shares, or, in lieu thereof, such agreement of indemnity or other agreement as shall be satisfactory to the Depositary.

 

A-5

 

 

7. CHARGES OF DEPOSITARY.

 

The following charges shall be incurred by any party depositing or withdrawing Shares or by any party surrendering American Depositary Shares or to whom American Depositary Shares are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by the Company or an exchange of stock regarding the American Depositary Shares or Deposited Securities or a delivery of American Depositary Shares pursuant to Section 4.3 of the Deposit Agreement), or by Owners, as applicable: (1) taxes and other governmental charges, (2) such registration fees as may from time to time be in effect for the registration of transfers of Shares generally on the Share register of the Company or Foreign Registrar and applicable to transfers of Shares to or from the name of the Depositary or its nominee or the Custodian or its nominee on the making of deposits or withdrawals hereunder, (3) such cable (including SWIFT) and facsimile transmission fees and expenses as are expressly provided in the Deposit Agreement, (4) such expenses as are incurred by the Depositary in the conversion of foreign currency pursuant to Section 4.5 of the Deposit Agreement, (5) a fee of $5.00 or less per 100 American Depositary Shares (or portion thereof) for the delivery of American Depositary Shares pursuant to Section 2.3, 4.3 or 4.4 of the Deposit Agreement and the surrender of American Depositary Shares pursuant to Section 2.5 or 6.2 of the Deposit Agreement, (6) a fee of $.05 or less per American Depositary Share (or portion thereof) for any cash distribution made pursuant to the Deposit Agreement, including, but not limited to Sections 4.1 through 4.4 and 4.8 of the Deposit Agreement, (7) a fee for the distribution of securities pursuant to Section 4.2 of the Deposit Agreement or of rights pursuant to Section 4.4 of that Agreement (where the Depositary will not exercise or sell those rights on behalf of Owners), such fee being in an amount equal to the fee for the execution and delivery of American Depositary Shares referred to above which would have been charged as a result of the deposit of such securities under the Deposit Agreement (for purposes of this item 7 treating all such securities as if they were Shares) but which securities are instead distributed by the Depositary to Owners, (8) in addition to any fee charged under item 6, a fee of $.05 or less per American Depositary Share (or portion thereof) per annum for depositary services, which will be payable as provided in item 9 below, and (9) any other charges payable by the Depositary or the Custodian, any of the Depositary's or Custodian’s agents or the agents of the Depositary's or Custodian’s agents, in connection with the servicing of Shares or other Deposited Securities (which charges shall be assessed against Owners as of the date or dates set by the Depositary in accordance with Section 4.6 of the Deposit Agreement and shall be payable at the sole discretion of the Depositary by billing those Owners for those charges or by deducting those charges from one or more cash dividends or other cash distributions).

 

A-6

 

 

The Depositary may collect any of its fees by deduction from any cash distribution payable, or by selling a portion of any securities to be distributed, to Owners that are obligated to pay those fees.

 

The Depositary may own and deal in any class of securities of the Company and its affiliates and in American Depositary Shares.

 

From time to time, the Depositary may make payments to the Company to reimburse the Company for costs and expenses generally arising out of establishment and maintenance of the American Depositary Shares program, waive fees and expenses for services provided by the Depositary or share revenue from the fees collected from Owners or Holders. In performing its duties under the Deposit Agreement, the Depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the Depositary and that may earn or share fees, spreads or commissions.

 

8. DISCLOSURE OF INTERESTS.

 

When required in order to comply with applicable laws and regulations or the articles of association or similar document of the Company, the Company may from time to time request each Owner and Holder to provide to the Depositary information relating to: (a) the capacity in which it holds American Depositary Shares, (b) the identity of any Holders or other persons or entities then or previously interested in those American Depositary Shares and the nature of those interests and (c) any other matter where disclosure of such matter is required for that compliance.   Each Owner and Holder agrees to provide all information known to it in response to a request made pursuant to Section 3.4 of the Deposit Agreement.  Each Holder consents to the disclosure by the Depositary and the Owner or other Holder through which it holds American Depositary Shares, directly or indirectly, of all information responsive to a request made pursuant to that Section relating to that Holder that is known to that Owner or other Holder. 

 

9. TITLE TO AMERICAN DEPOSITARY SHARES.

 

It is a condition of the American Depositary Shares, and every successive Owner and Holder of American Depositary Shares, by accepting or holding the same, consents and agrees that American Depositary Shares evidenced by a Receipt, when the Receipt is properly endorsed or accompanied by proper instruments of transfer, shall be transferable as certificated registered securities under the laws of the State of New York, and that American Depositary Shares not evidenced by Receipts shall be transferable as uncertificated registered securities under the laws of the State of New York. The Depositary, notwithstanding any notice to the contrary, may treat the Owner of American Depositary Shares as the absolute owner thereof for the purpose of determining the person entitled to distribution of dividends or other distributions or to any notice provided for in the Deposit Agreement and for all other purposes, and neither the Depositary nor the Company shall have any obligation or be subject to any liability under the Deposit Agreement to any Holder of American Depositary Shares, but only to the Owner.

 

A-7

 

 

10. VALIDITY OF RECEIPT.

 

This Receipt shall not be entitled to any benefits under the Deposit Agreement or be valid or obligatory for any purpose, unless this Receipt shall have been (i) executed by the Depositary by the manual signature of a duly authorized officer of the Depositary or (ii) executed by the facsimile signature of a duly authorized officer of the Depositary and countersigned by the manual signature of a duly authorized signatory of the Depositary or the Registrar or a co-registrar.

 

11. REPORTS; INSPECTION OF TRANSFER BOOKS.

 

The Company is subject to the periodic reporting requirements of the Securities Exchange Act of 1934 and, accordingly, files certain reports with the Securities and Exchange Commission. Those reports will be available for inspection and copying through the Commission's EDGAR system or at public reference facilities maintained by the Commission in Washington, D.C.

 

The Depositary will make available for inspection by Owners at its Office any reports, notices and other communications, including any proxy soliciting material, received from the Company which are both (a) received by the Depositary as the holder of the Deposited Securities and (b) made generally available to the holders of those Deposited Securities by the Company. The Company shall furnish reports and communications, including any proxy soliciting material to which Section 4.9 of the Deposit Agreement applies, to the Depositary in English, to the extent such materials are required to be translated into English pursuant to any regulations of the Commission.

 

The Depositary will maintain a register of American Depositary Shares and transfers of American Depositary Shares, which shall be open for inspection by the Owners at the Depositary’s Office during regular business hours, but only for the purpose of communicating with Owners regarding the business of the Company or a matter related to this Deposit Agreement or the American Depositary Shares.

 

12. DIVIDENDS AND DISTRIBUTIONS.

 

Whenever the Depositary receives any cash dividend or other cash distribution on Deposited Securities, the Depositary will, if at the time of receipt thereof any amounts received in a foreign currency can in the judgment of the Depositary be converted on a reasonable basis into Dollars transferable to the United States, and subject to the Deposit Agreement, convert that dividend or other cash distribution into Dollars and distribute the amount thus received (net of the fees and expenses of the Depositary as provided in Article 7 hereof and Section 5.9 of the Deposit Agreement) to the Owners entitled thereto; provided, however, that if the Custodian or the Depositary is required to withhold and does withhold from that cash dividend or other cash distribution an amount on account of taxes or other governmental charges, the amount distributed to the Owners of the American Depositary Shares representing those Deposited Securities shall be reduced accordingly.

 

A-8

 

 

If a cash distribution would represent a return of all or substantially all the value of the Deposited Securities underlying American Depositary Shares, the Depositary may:

 

(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of American Depositary Shares) as a condition of making that cash distribution; or

 

(ii) sell all Deposited Securities other than the subject cash distribution and add any net cash proceeds of that sale to the cash distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that cash distribution.

 

If the Depositary acts under this paragraph, that action shall also be a Termination Option Event.

 

Subject to the provisions of Section 4.11 and 5.9 of the Deposit Agreement, whenever the Depositary receives any distribution other than a distribution described in Section 4.1, 4.3 or 4.4 of the Deposit Agreement on Deposited Securities (but not in exchange for or in conversion or in lieu of Deposited Securities), the Depositary will cause the securities or property received by it to be distributed to the Owners entitled thereto, after deduction or upon payment of any fees and expenses of the Depositary and any taxes or other governmental charges, in any manner that the Depositary deems equitable and practicable for accomplishing that distribution (which may be a distribution of depositary shares representing the securities received); provided, however, that if in the opinion of the Depositary such distribution cannot be made proportionately among the Owners entitled thereto, or if for any other reason the Depositary deems such distribution not to be lawful and feasible, the Depositary may adopt such other method as it may deem equitable and practicable for the purpose of effecting such distribution, including, but not limited to, the public or private sale of the securities or property thus received, or any part thereof, and distribution of the net proceeds of any such sale (net of the fees and expenses of the Depositary as provided in Article 7 hereof and Section 5.9 of the Deposit Agreement) to the Owners entitled thereto all in the manner and subject to the conditions set forth in Section 4.1 of the Deposit Agreement. The Depositary may withhold any distribution of securities under Section 4.2 of the Deposit Agreement if it has not received satisfactory assurances from the Company that the distribution does not require registration under the Securities Act of 1933. The Depositary may sell, by public or private sale, an amount of securities or other property it would otherwise distribute under this Article that is sufficient to pay its fees and expenses in respect of that distribution.

 

A-9

 

 

If a distribution to be made under Section 4.2 of the Deposit Agreement would represent a return of all or substantially all the value of the Deposited Securities underlying American Depositary Shares, the Depositary may:

 

(i) require payment of or deduct the fee for surrender of American Depositary Shares (whether or not it is also requiring surrender of American Depositary Shares) as a condition of making that distribution; or

 

(ii) sell all Deposited Securities other than the subject distribution and add any net cash proceeds of that sale to the distribution, call for surrender of all those American Depositary Shares and require that surrender as a condition of making that distribution.

 

If the Depositary acts under this paragraph, that action shall also be a Termination Option Event.

 

Whenever the Depositary receives any distribution consisting of a dividend in, or free distribution of, Shares, the Depositary may deliver to the Owners entitled thereto, an aggregate number of American Depositary Shares representing the amount of Shares received as that dividend or free distribution, subject to the terms and conditions of the Deposit Agreement with respect to the deposit of Shares and issuance of American Depositary Shares, including the withholding of any tax or other governmental charge as provided in Section 4.11 of the Deposit Agreement and the payment of the fees and expenses of the Depositary as provided in Article 7 hereof and Section 5.9 of the Deposit Agreement (and the Depositary may sell, by public or private sale, an amount of Shares received (or American Depositary Shares representing those Shares) sufficient to pay its fees and expenses in respect of that distribution). In lieu of delivering fractional American Depositary Shares, the Depositary may sell the amount of Shares represented by the aggregate of those fractions (or American Depositary Shares representing those Shares) and distribute the net proceeds, all in the manner and subject to the conditions described in Section 4.1of the Deposit Agreement. If and to the extent that additional American Depositary Shares are not delivered and Shares or American Depositary Shares are not sold, each American Depositary Share shall thenceforth also represent the additional Shares distributed on the Deposited Securities represented thereby.

 

If the Company declares a distribution in which holders of Deposited Securities have a right to elect whether to receive cash, Shares or other securities or a combination of those things, or a right to elect to have a distribution sold on their behalf, the Depositary may, after consultation with the Company, make that right of election available for exercise by Owners in any manner the Depositary considers to be lawful and practical. As a condition of making a distribution election right available to Owners, the Depositary may require satisfactory assurances from the Company that doing so does not require registration of any securities under the Securities Act of 1933 that has not been effected.

 

If the Depositary determines that any distribution received or to be made by the Depositary (including Shares and rights to subscribe therefor) is subject to any tax or other governmental charge that the Depositary is obligated to withhold, the Depositary may sell, by public or private sale, all or a portion of the distributed property (including Shares and rights to subscribe therefor) in the amounts and manner the Depositary deems necessary and practicable to pay those taxes or charges, and the Depositary shall distribute the net proceeds of that sale, after deduction of those taxes or charges, to the Owners entitled thereto in proportion to the number of American Depositary Shares held by them respectively.

 

A-10

 

 

Each Owner and Holder agrees to indemnify the Company, the Depositary, the Custodian and their respective directors, employees, agents and affiliates for, and hold each of them harmless against, any claim by any governmental authority with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced withholding at source or other tax benefit received by it. Services for Owners and Holders that may permit them to obtain reduced rates of tax withholding at source or reclaim excess tax withheld, and the fees and costs associated with using services of that kind, are not provided under, and are outside the scope of, the Deposit Agreement.

 

13. RIGHTS.

 

(a) If rights are granted to the Depositary in respect of deposited Shares to purchase additional Shares or other securities, the Company and the Depositary shall endeavor to consult as to the actions, if any, the Depositary should take in connection with that grant of rights. The Depositary may, to the extent deemed by it to be lawful and practical (i) if requested in writing by the Company, grant to all or certain Owners rights to instruct the Depositary to purchase the securities to which the rights relate and deliver those securities or American Depositary Shares representing those securities to Owners, (ii) if requested in writing by the Company, deliver the rights to or to the order of certain Owners, or (iii) sell the rights to the extent practicable and distribute the net proceeds of that sale to Owners entitled to those proceeds. To the extent rights are not exercised, delivered or disposed of under (i), (ii) or (iii) above, the Depositary shall permit the rights to lapse unexercised.

 

(b) If the Depositary will act under (a)(i) above, the Company and the Depositary will enter into a separate agreement setting forth the conditions and procedures applicable to the particular offering. Upon instruction from an applicable Owner in the form the Depositary specified and upon payment by that Owner to the Depositary of an amount equal to the purchase price of the securities to be received upon the exercise of the rights, the Depositary shall, on behalf of that Owner, exercise the rights and purchase the securities. The purchased securities shall be delivered to, or as instructed by, the Depositary. The Depositary shall (i) deposit the purchased Shares under the Deposit Agreement and deliver American Depositary Shares representing those Shares to that Owner or (ii) deliver or cause the purchased Shares or other securities to be delivered to or to the order of that Owner. The Depositary will not act under (a)(i) above unless the offer and sale of the securities to which the rights relate are registered under the Securities Act of 1933 or the Depositary has received an opinion of United States counsel that is satisfactory to it to the effect that those securities may be sold and delivered to the applicable Owners without registration under the Securities Act of 1933.

 

A-11

 

 

(c) If the Depositary will act under (a)(ii) above, the Company and the Depositary will enter into a separate agreement setting forth the conditions and procedures applicable to the particular offering. Upon (i) the request of an applicable Owner to deliver the rights allocable to the American Depositary Shares of that Owner to an account specified by that Owner to which the rights can be delivered and (ii) receipt of such documents as the Company and the Depositary agreed to require to comply with applicable law, the Depositary will deliver those rights as requested by that Owner.

 

(d) If the Depositary will act under (a)(iii) above, the Depositary will use reasonable efforts to sell the rights in proportion to the number of American Depositary Shares held by the applicable Owners and pay the net proceeds to the Owners otherwise entitled to the rights that were sold, upon an averaged or other practical basis without regard to any distinctions among such Owners because of exchange restrictions or the date of delivery of any American Depositary Shares or otherwise.

 

(e) Payment or deduction of the fees of the Depositary as provided in Section 5.9 of the Deposit Agreement and payment or deduction of the expenses of the Depositary and any applicable taxes or other governmental charges shall be conditions of any delivery of securities or payment of cash proceeds under Section 4.4 of that Agreement.

 

(f) The Depositary shall not be responsible for any failure to determine that it may be lawful or feasible to make rights available to or exercise rights on behalf of Owners in general or any Owner in particular , or to sell rights.

 

14. CONVERSION OF FOREIGN CURRENCY.

 

Whenever the Depositary or the Custodian receives foreign currency, by way of dividends or other distributions or the net proceeds from the sale of securities, property or rights, and if at the time of the receipt thereof the foreign currency so received can in the judgment of the Depositary be converted on a reasonable basis into Dollars and the resulting Dollars transferred to the United States, the Depositary or one of its agents or affiliates or the Custodian shall convert or cause to be converted by sale or in any other manner that it may determine that foreign currency into Dollars, and those Dollars shall be distributed to the Owners entitled thereto.  A cash distribution may be made upon an averaged or other practicable basis without regard to any distinctions among Owners based on exchange restrictions, the date of delivery of any American Depositary Shares or otherwise and shall be net of any expenses of conversion into Dollars incurred by the Depositary as provided in Section 5.9 of the Deposit Agreement.

 

If a conversion of foreign currency or the repatriation or distribution of Dollars can be effected only with the approval or license of any government or agency thereof, the Depositary may, but will not be required to, file an application for that approval or license.

 

A-12

 

 

If the Depositary determines that in its judgment any foreign currency received by the Depositary or the Custodian is not convertible on a reasonable basis into Dollars transferable to the United States, or if any approval or license of any government or agency thereof that is required for such conversion is not filed or sought by the Depositary or is not obtained within a reasonable period as determined by the Depositary, the Depositary may distribute the foreign currency received by the Depositary to, or in its discretion may hold such foreign currency uninvested and without liability for interest thereon for the respective accounts of, the Owners entitled to receive the same.

 

If any conversion of foreign currency, in whole or in part, cannot be effected for distribution to some of the Owners entitled thereto, the Depositary may in its discretion make that conversion and distribution in Dollars to the extent practicable and permissible to the Owners entitled thereto and may distribute the balance of the foreign currency received by the Depositary to, or hold that balance uninvested and without liability for interest thereon for the account of, the Owners entitled thereto.

 

The Depositary may convert currency itself or through any of its affiliates, or the Custodian or the Company may convert currency and pay Dollars to the Depositary. Where the Depositary converts currency itself or through any of its affiliates, the Depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account.  The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the Deposit Agreement and the rate that the Depositary or its affiliate receives when buying or selling foreign currency for its own account.  The Depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the Deposit Agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to Owners, subject to the Depositary’s obligations under Section 5.3 of that Agreement.  The methodology used to determine exchange rates used in currency conversions made by the Depositary is available upon request. Where the Custodian converts currency, the Custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to Owners, and the Depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, the Depositary may receive dividends or other distributions from the Company in Dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by or on behalf of the Company and, in such cases, the Depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor the Company makes any representation that the rate obtained or determined by the Company is the most favorable rate and neither it nor the Company will be liable for any direct or indirect losses associated with the rate.

 

A-13

 

 

15. RECORD DATES.

 

Whenever a cash dividend, cash distribution or any other distribution is made on Deposited Securities or rights to purchase Shares or other securities are issued with respect to Deposited Securities (which rights will be delivered to or exercised or sold on behalf of Owners in accordance with Section 4.4 of the Deposit Agreement) or the Depositary receives notice that a distribution or issuance of that kind will be made, or whenever the Depositary receives notice that a meeting of holders of Shares will be held in respect of which the Company has requested the Depositary to send a notice under Section 4.7 of the Deposit Agreement, or whenever the Depositary will assess a fee or charge against the Owners, or whenever the Depositary causes a change in the number of Shares that are represented by each American Depositary Share, or whenever the Depositary otherwise finds it necessary or convenient, the Depositary shall fix a record date, which shall be the same as, or as near as practicable to, any corresponding record date set by the Company with respect to Shares, (a) for the determination of the Owners (i) who shall be entitled to receive the benefit of that dividend or other distribution or those rights, (ii) who shall be entitled to give instructions for the exercise of voting rights at that meeting, (iii) who shall be responsible for that fee or charge or (iv) for any other purpose for which the record date was set, or (b) on or after which each American Depositary Share will represent the changed number of Shares. Subject to the provisions of Sections 4.1 through 4.5 of the Deposit Agreement and to the other terms and conditions of the Deposit Agreement, the Owners on a record date fixed by the Depositary shall be entitled to receive the amount distributable by the Depositary with respect to that dividend or other distribution or those rights or the net proceeds of sale thereof in proportion to the number of American Depositary Shares held by them respectively, to give voting instructions or to act in respect of the other matter for which that record date was fixed, or be responsible for that fee or charge, as the case may be.

 

16. VOTING OF DEPOSITED SHARES.

 

(a) Upon receipt of notice of any meeting of holders of Shares at which holders of Shares will be entitled to vote, if requested in writing by the Company, the Depositary shall, as soon as practicable thereafter, Disseminate to the Owners a notice, the form of which shall be in the sole discretion of the Depositary, that shall contain (i) the information contained in the notice of meeting received by the Depositary, (ii) a statement that the Owners as of the close of business on a specified record date will be entitled, subject to any applicable provision of Australian law and of the articles of association or similar documents of the Company, to instruct the Depositary as to the exercise of the voting rights pertaining to the amount of Shares represented by their respective American Depositary Shares, (iii) a statement as to the manner in which those instructions may be given and (iv) the last date on which the Depositary will accept instructions (the “Instruction Cutoff Date”).

 

(b) Upon the written request of an Owner of American Depositary Shares, as of the date of the request or, if a record date was specified by the Depositary, as of that record date, received on or before any Instruction Cutoff Date established by the Depositary, the Depositary may, and if the Depositary sent a notice under the preceding paragraph shall, endeavor, in so far as practicable, to vote or cause to be voted the amount of deposited Shares represented by those American Depositary Shares in accordance with the instructions set forth in that request. The Depositary shall not vote or attempt to exercise the right to vote that attaches to the deposited Shares other than in accordance with instructions given by Owners and received by the Depositary.

 

A-14

 

 

(c) There can be no assurance that Owners generally or any Owner in particular will receive the notice described in paragraph (a) above in time to enable Owners to give instructions to the Depositary prior to the Instruction Cutoff Date.

 

(d) In order to give Owners a reasonable opportunity to instruct the Depositary as to the exercise of voting rights relating to Shares, if the Company will request the Depositary to Disseminate a notice under paragraph (a) above, the Company shall give the Depositary notice of the meeting, details concerning the matters to be voted upon and copies of materials to be made available to holders of Shares in connection with the meeting not less than 45 days prior to the meeting date.

 

17. TENDER AND EXCHANGE OFFERS; REDEMPTION, REPLACEMENT OR CANCELLATION OF DEPOSITED SECURITIES.

 

(a) The Depositary shall not tender any Deposited Securities in response to any voluntary cash tender offer, exchange offer or similar offer made to holders of Deposited Securities (a “Voluntary Offer”), except when instructed in writing to do so by an Owner surrendering American Depositary Shares and subject to any conditions or procedures the Depositary may require.

 

(b) If the Depositary receives a written notice that Deposited Securities have been redeemed for cash or otherwise purchased for cash in a transaction that is mandatory and binding on the Depositary as a holder of those Deposited Securities (a “Redemption”), the Depositary, at the expense of the Company, shall (i) if required, surrender Deposited Securities that have been redeemed to the issuer of those securities or its agent on the redemption date, (ii) Disseminate a notice to Owners (A) notifying them of that Redemption, (B) calling for surrender of a corresponding number of American Depositary Shares and (C) notifying them that the called American Depositary Shares have been converted into a right only to receive the money received by the Depositary upon that Redemption and those net proceeds shall be the Deposited Securities to which Owners of those converted American Depositary Shares shall be entitled upon surrenders of those American Depositary Shares in accordance with Section 2.5 or 6.2 of the Deposit Agreement and (iii) distribute the money received upon that Redemption to the Owners entitled to it upon surrender by them of called American Depositary Shares in accordance with Section 2.5 of that Agreement (and, for the avoidance of doubt, Owners shall not be entitled to receive that money under Section 4.1 of that Agreement). If the Redemption affects less than all the Deposited Securities, the Depositary shall call for surrender a corresponding portion of the outstanding American Depositary Shares and only those American Depositary Shares will automatically be converted into a right to receive the net proceeds of the Redemption. The Depositary shall allocate the American Depositary Shares converted under the preceding sentence among the Owners pro-rata to their respective holdings of American Depositary Shares immediately prior to the Redemption, except that the allocations may be adjusted so that no fraction of a converted American Depositary Share is allocated to any Owner. A Redemption of all or substantially all of the Deposited Securities shall be a Termination Option Event.

 

A-15

 

 

(c) If the Depositary is notified of or there occurs any change in nominal value or any subdivision, combination or any other reclassification of the Deposited Securities or any recapitalization, reorganization, sale of assets substantially as an entirety, merger or consolidation affecting the issuer of the Deposited Securities or to which it is a party that is mandatory and binding on the Depositary as a holder of Deposited Securities and, as a result, securities or other property have been or will be delivered in exchange, conversion, replacement or in lieu of, Deposited Securities (a “Replacement”), the Depositary shall, if required, surrender the old Deposited Securities affected by that Replacement of Shares and hold, as new Deposited Securities under the Deposit Agreement, the new securities or other property delivered to it in that Replacement. However, the Depositary may elect to sell those new Deposited Securities if in the opinion of the Depositary it is not lawful or not practical for it to hold those new Deposited Securities under the Deposit Agreement because those new Deposited Securities may not be distributed to Owners without registration under the Securities Act of 1933 or for any other reason, at public or private sale, at such places and on such terms as it deems proper and proceed as if those new Deposited Securities had been Redeemed under paragraph (b) above. A Replacement shall be a Termination Option Event.

 

(d) In the case of a Replacement where the new Deposited Securities will continue to be held under the Deposit Agreement, the Depositary may call for the surrender of outstanding Receipts to be exchanged for new Receipts specifically describing the new Deposited Securities and the number of those new Deposited Securities represented by each American Depositary Share. If the number of Shares represented by each American Depositary Share decreases as a result of a Replacement, the Depositary may call for surrender of the American Depositary Shares to be exchanged on a mandatory basis for a lesser number of American Depositary Shares and may sell American Depositary Shares to the extent necessary to avoid distributing fractions of American Depositary Shares in that exchange and distribute the net proceeds of that sale to the Owners entitled to them.

 

(e) If there are no Deposited Securities with respect to American Depositary Shares, including if the Deposited Securities are cancelled, or the Deposited Securities with respect to American Depositary Shares become apparently worthless, the Depositary may call for surrender of those American Depositary Shares or may cancel those American Depositary Shares, upon notice to Owners, and that condition shall be a Termination Option Event.

 

A-16

 

 

18. LIABILITY OF THE COMPANY AND DEPOSITARY.

 

Neither the Depositary nor the Company nor any of their respective directors, employees, agents or affiliates shall incur any liability to any Owner or Holder:

 

(i) if by reason of (A) any provision of any present or future law or regulation or other act of the government of the United States, any State of the United States or any other state or jurisdiction, or of any governmental or regulatory authority or stock exchange; (B) (in the case of the Depositary only) any provision, present or future, of the articles of association or similar document of the Company, or by reason of any provision of any securities issued or distributed by the Company, or any offering or distribution thereof; or (C) any event or circumstance, whether natural or caused by a person or persons, that is beyond the ability of the Depositary or the Company, as the case may be, to prevent or counteract by reasonable care or effort (including, but not limited to earthquakes, floods, severe storms, fires, explosions, war, terrorism, civil unrest, labor disputes, criminal acts or outbreaks of infectious disease; interruptions or malfunctions of utility services, Internet or other communications lines or systems; unauthorized access to or attacks on computer systems or websites; or other failures or malfunctions of computer hardware or software or other systems or equipment), the Depositary or the Company is, directly or indirectly, prevented from, forbidden to or delayed in, or could be subject to any civil or criminal penalty on account of doing or performing and therefore does not do or perform, any act or thing that, by the terms of the Deposit Agreement or the Deposited Securities, it is provided shall be done or performed;

 

(ii) for any exercise of, or failure to exercise, any discretion provided for in the Deposit Agreement (including any determination by the Depositary to take, or not take, any action that the Deposit Agreement provides the Depositary may take);

 

(iii) for the inability of any Owner or Holder to benefit from any distribution, offering, right or other benefit that is made available to holders of Deposited Securities but is not, under the terms of the Deposit Agreement, made available to Owners or Holders; or

 

(iv) for any special, consequential or punitive damages for any breach of the terms of the Deposit Agreement.

 

Where, by the terms of a distribution to which Section 4.1, 4.2 or 4.3 of the Deposit Agreement applies, or an offering to which Section 4.4 of that Agreement applies, or for any other reason, that distribution or offering may not be made available to Owners, and the Depositary may not dispose of that distribution or offering on behalf of Owners and make the net proceeds available to Owners, then the Depositary shall not make that distribution or offering available to Owners, and shall allow any rights, if applicable, to lapse.

 

A-17

 

 

Neither the Company nor the Depositary assumes any obligation or shall be subject to any liability under the Deposit Agreement to Owners or Holders, except that they agree to perform their obligations specifically set forth in the Deposit Agreement without negligence or bad faith. The Depositary shall not be a fiduciary or have any fiduciary duty to Owners or Holders. The Depositary shall not be subject to any liability with respect to the validity or worth of the Deposited Securities. Neither the Depositary nor the Company shall be under any obligation to appear in, prosecute or defend any action, suit, or other proceeding in respect of any Deposited Securities or in respect of the American Depositary Shares, on behalf of any Owner or Holder or other person. Neither the Depositary nor the Company shall be liable for any action or non-action by it in reliance upon the advice of or information from legal counsel, accountants, any person presenting Shares for deposit, any Owner or Holder, or any other person believed by it in good faith to be competent to give such advice or information. Each of the Depositary and the Company may rely, and shall be protected in relying upon, any written notice, request, direction or other document believed by it to be genuine and to have been signed or presented by the proper party or parties. The Depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the Depositary or in connection with a matter arising wholly after the removal or resignation of the Depositary, provided that in connection with the issue out of which such potential liability arises, the Depositary performed its obligations without negligence or bad faith while it acted as Depositary. The Depositary shall not be liable for the acts or omissions of any securities depository, clearing agency or settlement system in connection with or arising out of book-entry settlement of American Depositary Shares or Deposited Securities or otherwise. In the absence of bad faith on its part, the Depositary shall not be responsible for any failure to carry out any instructions to vote any of the Deposited Securities or for the manner in which any such vote is cast or the effect of any such vote. The Depositary shall have no duty to make any determination or provide any information as to the tax status of the Company or any liability for any tax consequences that may be incurred by Owners or Holders as a result of owning or holding American Depositary Shares. The Depositary shall not be liable for the inability or failure of an Owner or Holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit. No disclaimer of liability under the United States federal securities laws is intended by any provision of the Deposit Agreement.

 

19. RESIGNATION AND REMOVAL OF THE DEPOSITARY; APPOINTMENT OF SUCCESSOR CUSTODIAN.

 

The Depositary may at any time resign as Depositary under the Deposit Agreement by written notice of its election so to do delivered to the Company, to become effective upon the appointment of a successor depositary and its acceptance of such appointment as provided in the Deposit Agreement. The Depositary may at any time be removed by the Company by 120 days’ prior written notice of that removal, to become effective upon the later of (i) the 120th day after delivery of the notice to the Depositary and (ii) the appointment of a successor depositary and its acceptance of its appointment as provided in the Deposit Agreement. The Depositary in its discretion may at any time appoint a substitute or additional custodian or custodians.

 

A-18

 

 

20. AMENDMENT.

 

The form of the Receipts and any provisions of the Deposit Agreement may at any time and from time to time be amended by agreement between the Company and the Depositary without the consent of Owners or Holders in any respect which they may deem necessary or desirable. Any amendment that would impose or increase any fees or charges (other than taxes and other governmental charges, registration fees, cable (including SWIFT) or facsimile transmission costs, delivery costs or other such expenses), or that would otherwise prejudice any substantial existing right of Owners, shall, however, not become effective as to outstanding American Depositary Shares until the expiration of 30 days after notice of that amendment has been Disseminated to the Owners of outstanding American Depositary Shares. Every Owner and Holder, at the time any amendment so becomes effective, shall be deemed, by continuing to hold American Depositary Shares or any interest therein, to consent and agree to that amendment and to be bound by the Deposit Agreement as amended thereby. Upon the effectiveness of an amendment to the form of Receipt, including a change in the number of Shares represented by each American Depositary Share, the Depositary may call for surrender of Receipts to be replaced with new Receipts in the amended form or call for surrender of American Depositary Shares to effect that change of ratio. In no event shall any amendment impair the right of the Owner to surrender American Depositary Shares and receive delivery of the Deposited Securities represented thereby, except in order to comply with mandatory provisions of applicable law.

 

21. TERMINATION OF DEPOSIT AGREEMENT.

 

(a) The Company may initiate termination of the Deposit Agreement by notice to the Depositary. The Depositary may initiate termination of the Deposit Agreement if (i) at any time 60 days shall have expired after the Depositary delivered to the Company a written resignation notice and a successor depositary has not been appointed and accepted its appointment as provided in Section 5.4 of that Agreement or (ii) a Termination Option Event has occurred. If termination of the Deposit Agreement is initiated, the Depositary shall Disseminate a notice of termination to the Owners of all American Depositary Shares then outstanding setting a date for termination (the “Termination Date”), which shall be at least 90 days after the date of that notice, and the Deposit Agreement shall terminate on that Termination Date.

 

(b) After the Termination Date, the Company shall be discharged from all obligations under the Deposit Agreement except for its obligations to the Depositary under Sections 5.8 and 5.9 of that Agreement.

 

(c) At any time after the Termination Date, the Depositary may sell the Deposited Securities then held under the Deposit Agreement and may thereafter hold uninvested the net proceeds of any such sale, together with any other cash then held by it hereunder, unsegregated and without liability for interest, for the pro rata benefit of the Owners of American Depositary Shares that remain outstanding, and those Owners will be general creditors of the Depositary with respect to those net proceeds and that other cash. After making that sale, the Depositary shall be discharged from all obligations under the Deposit Agreement, except (i) to account for the net proceeds and other cash (after deducting, in each case, the fee of the Depositary for the surrender of American Depositary Shares, any expenses for the account of the Owner of such American Depositary Shares in accordance with the terms and conditions of the Deposit Agreement and any applicable taxes or governmental charges) and (ii) for its obligations under Section 5.8 of that Agreement and (iii) to act as provided in paragraph (d) below.

 

A-19

 

 

(d) After the Termination Date, the Depositary shall continue to receive dividends and other distributions pertaining to Deposited Securities (that have not been sold), may sell rights and other property as provided in the Deposit Agreement and shall deliver Deposited Securities (or sale proceeds) upon surrender of American Depositary Shares (after payment or upon deduction, in each case, of the fee of the Depositary for the surrender of American Depositary Shares, any expenses for the account of the Owner of those American Depositary Shares in accordance with the terms and conditions of the Deposit Agreement and any applicable taxes or governmental charges). After the Termination Date, the Depositary shall not accept deposits of Shares or deliver American Depositary Shares. After the Termination Date, (i) the Depositary may refuse to accept surrenders of American Depositary Shares for the purpose of withdrawal of Deposited Securities (that have not been sold) or reverse previously accepted surrenders of that kind that have not settled if in its judgment the requested withdrawal would interfere with its efforts to sell the Deposited Securities, (ii) the Depositary will not be required to deliver cash proceeds of the sale of Deposited Securities until all Deposited Securities have been sold and (iii) the Depositary may discontinue the registration of transfers of American Depositary Shares and suspend the distribution of dividends and other distributions on Deposited Securities to the Owners and need not give any further notices or perform any further acts under the Deposit Agreement except as provided in Section 6.2 of that Agreement.

 

22. DTC DIRECT REGISTRATION SYSTEM AND PROFILE MODIFICATION SYSTEM.

 

(a) Notwithstanding the provisions of Section 2.4 of the Deposit Agreement, the parties acknowledge that DTC’s Direct Registration System (“DRS”) and Profile Modification System (“Profile”) apply to the American Depositary Shares upon acceptance thereof to DRS by DTC. DRS is the system administered by DTC that facilitates interchange between registered holding of uncertificated securities and holding of security entitlements in those securities through DTC and a DTC participant. Profile is a required feature of DRS that allows a DTC participant, claiming to act on behalf of an Owner of American Depositary Shares, to direct the Depositary to register a transfer of those American Depositary Shares to DTC or its nominee and to deliver those American Depositary Shares to the DTC account of that DTC participant without receipt by the Depositary of prior authorization from the Owner to register that transfer.

 

A-20

 

 

(b) In connection with DRS/Profile, the parties acknowledge that the Depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an Owner in requesting registration of transfer and delivery as described in paragraph (a) above has the actual authority to act on behalf of that Owner (notwithstanding any requirements under the Uniform Commercial Code). For the avoidance of doubt, the provisions of Sections 5.3 and 5.8 of the Deposit Agreement apply to the matters arising from the use of the DRS/Profile. The parties agree that the Depositary’s reliance on and compliance with instructions received by the Depositary through the DRS/Profile system and otherwise in accordance with the Deposit Agreement, shall not constitute negligence or bad faith on the part of the Depositary.

 

23. APPOINTMENT OF AGENT FOR SERVICE OF PROCESS; SUBMISSION TO JURISDICTION; JURY TRIAL WAIVER; WAIVER OF IMMUNITIES.

 

The Company has (i) appointed ______________________________________ as the Company's authorized agent in the United States upon which process may be served in any suit or proceeding arising out of or relating to the Shares or Deposited Securities, the American Depositary Shares, the Receipts or this Agreement, (ii) consented and submitted to the jurisdiction of any state or federal court in the State of New York in which any such suit or proceeding may be instituted, and (iii) agreed that service of process upon said authorized agent shall be deemed in every respect effective service of process upon the Company in any such suit or proceeding.

 

EACH PARTY TO THE DEPOSIT AGREEMENT (INCLUDING, FOR AVOIDANCE OF DOUBT, EACH OWNER AND HOLDER) THEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING AGAINST THE COMPANY AND/OR THE DEPOSITARY DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THE SHARES OR OTHER DEPOSITED SECURITIES, THE AMERICAN DEPOSITARY SHARES OR THE RECEIPTS, THE DEPOSIT AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREIN OR THEREIN, OR THE BREACH HEREOF OR THEREOF, INCLUDING, WITHOUT LIMITATION, ANY QUESTION REGARDING EXISTENCE, VALIDITY OR TERMINATION (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY) OR ANY CLAIM BASED ON U.S. FEDERAL SECURITIES LAWS.

 

No disclaimer of liability under the United States federal securities laws or the rules and regulations thereunder is intended by any provision of the Deposit Agreement, inasmuch as no person is able to effectively waive the duty of any other person to comply with its obligations under those laws, rules and regulations.

 

A-21

 

 

To the extent that the Company or any of its properties, assets or revenues may have or hereafter become entitled to, or have attributed to it, any right of immunity, on the grounds of sovereignty or otherwise, from any legal action, suit or proceeding, from the giving of any relief in any respect thereof, from setoff or counterclaim, from the jurisdiction of any court, from service of process, from attachment upon or prior to judgment, from attachment in aid of execution or judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of any judgment, in any jurisdiction in which proceedings may at any time be commenced, with respect to its obligations, liabilities or any other matter under or arising out of or in connection with the Shares or Deposited Securities, the American Depositary Shares, the Receipts or the Deposit Agreement, the Company, to the fullest extent permitted by law, hereby irrevocably and unconditionally waives, and agrees not to plead or claim, any such immunity and consents to such relief and enforcement.

 

 

A-22

 

Exhibit 10.1

 

 

 

 

 

 

 

 

 

 

MYFIZIQ LIMITED
ACN 602 111 115
(Company)

 

and

 

ASIA CORNERSTONE ASSET MANAGEMENT LIMITED

(Investor)

 

 

 

 

 

 

SUBSCRIPTION AGREEMENT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THIS SUBSCRIPTION AGREEMENT is made the 11th day of February 2019

 

 

B E T W E E N

 

 

MYFIZIQ LIMITED (ACN 602 111 115) of Suite 5, 71-73 South Perth Esplanade, South Perth, WA, 6151 (Company);

 

AND

 

ASIA CORNERSTONE ASSET MANAGEMENT LIMITED, a company incorporated in Hong Kong of Unit 1914, 19th Floor, Miramar Tower, 132 Nathan Road, Tsim Sha Tsui, Kowloon, Hong Kong (Investor).

 

 

R E C I T A L S

 

 

A. The Company is a public company limited by shares and listed on the ASX.

 

B. Pursuant to the Binding Terms Sheet between the Parties dated 29 January 2019, the Investor has agreed to subscribe for the Subscription Shares at the Subscription Price and the Company has agreed to issue the Subscription Shares to the Investor (or its nominees).

 

C. The Parties have agreed to enter into this agreement to record the terms of the Subscription.

 

IT IS AGREED as follows:

 

 
1. INTERPRETATION

 

1.1 Definitions

 

In this agreement:

 

Application Form means the application form set out in Schedule 1.

 

Applicable Law means the constitution of the Company, the Corporations Act, the Listing Rules, the ASX Settlement Operating Rules, any regulatory guides published by ASIC and all other applicable laws and regulations in any jurisdiction.

 

ASIC means the Australian Securities and Investments Commission.

 

ASX means ASX Limited (ABN 98 008 624 691) or the market which it operates.

 

ASX Settlement Operating Rules means the operating rules of ASX Settlement Pty Ltd (ACN 008 504 532) in its capacity as a CS facility licensee.

 

Business Day means a day on which banks are open for business in Perth, Western Australia, excluding a Saturday or a Sunday or a public holiday.

 

Company Warranties means the representations and warranties given by the Company to the Investor pursuant to clause 4.1.

 

 1

 

 

 

Confidential Information means all confidential, non-public or proprietary information regardless of how the information is stored or delivered, exchanged between the Parties before, on or after the date of this agreement relating to the business, technology or other affairs of the Party who provides the information, but excludes information which:

 

(a) is in or becomes part of the public domain other than through a breach of this agreement or an obligation of confidence owed to the Party to whom the information belongs;

 

(b) the recipient of the information can prove was already known to it at the time of disclosure by the Party to whom the information belongs (unless such knowledge arose from disclosure of information in breach of an obligation of confidentiality); or

 

(c) the recipient acquires from a source other than the Party to whom the information belongs, where such source is entitled to disclose it.

 

Corporations Act means the Corporations Act 2001 (Cth).

 

Duty means any transfer, transaction or registration duty or similar charge imposed by any Government Authority and includes any interest, fine, penalty, charge or other amount imposed in respect of any of them.

 

Encumbrance means an interest or power:

 

(a) reserved in or over an interest in any share or asset including, but not limited to, any retention of title; or

 

(b) created or otherwise arising in or over any interest in any share or asset under a bill of sale, mortgage, charge, lien, pledge, trust or power,

 

by way of security for the payment of a debt, any other monetary obligation or the performance of any other obligation, and includes, but is not limited to, any or third party rights or interests and any agreement to grant or create any of the above.

 

Event of Insolvency means, in relation to a corporation:

 

(a) a receiver, manager, receiver and manager, trustee, administrator or similar officer is appointed in respect of a person or any material asset of a corporation;

 

(b) a liquidator or provisional or interim liquidator is appointed in respect of a corporation;

 

(c) any application (not being an application withdrawn or dismissed within 7 days) is made to a court for an order, or an order is made, or a meeting is convened, or a resolution is passed, for the purpose of:

 

(i) appointing a person referred to in paragraphs (a) or (b);

 

(ii) winding up the relevant corporation; or

 

(iii) proposing or implementing a compromise with creditors (including a scheme of arrangement, other than to carry out a reconstruction or amalgamation while solvent);

 

(d) a final order, judgment or award is made against the corporation which it fails to satisfy within 7 days of being required to do so;

 

 2

 

 

 

(e) the corporation becomes, or admits in writing that it is, is declared to be, or is deemed under any Applicable Law to be, insolvent or unable to pay its debts; or

 

(f) anything analogous or having a substantially similar effect occurring in relation to a Group member.

 

Excluded Information means information which would be required to be disclosed as “excluded information” under subsection 708A(6) (e).

 

Government Authority means a government or government department, a governmental or semi-governmental or judicial person (whether autonomous or not) charged with the administration of any applicable law.

 

Group means in relation to either Party, entities directly or indirectly controlling, controlled by, or in common control with, that party and any Related Body Corporate of that Party.

 

Indemnified Losses means, in relation to any fact, matter or circumstance, all losses, costs, damages, expenses and other liabilities arising out of or in connection with that fact, matter or circumstance, including all reasonable legal and other professional expenses on a solicitor-client basis incurred in connection with investigating, disputing, defending or settling any claim, action, demand or proceeding relating to that fact, matter or circumstance (including any claim, action, demand or proceeding based on the terms of this agreement).

 

Investor Shareholding means, at any time, the total of all Shares held in the Company by the Investor (including its Group) at that time.

 

Investor Warranties means the representations and warranties given by the Investor to the Company pursuant to clause 4.2.

 

Listing Rules means the listing rules of ASX.

 

Official Quotation means official quotation on ASX.

 

Party means a party to this agreement and Parties means all of them.

 

Related Body Corporate has the meaning given that expression in the Corporations Act.

 

Share means an ordinary fully paid share in the capital of the Company.

 

Shareholder means, at any time, is the registered holder of a Share.

 

Subscription means the subscription by the Investor (or its nominees) for the Subscription Shares under this agreement.

 

Subscription Date means the relevant date for the issue of each Tranche as set out in clause 2.1, or such other date as may be mutually agreed between the Parties.

 

Subscription Price means $0.60 per Subscription Share.

 

Subscription Shares means a total of 10,000,000 Shares, to be paid for and issued to the Investor in accordance with the terms and conditions of this agreement.

 

 3

 

 

 

Tranches has the meaning given to that term in clause 2.1 and Tranche means any one of those Tranches as the context requires.

 

1.2 Interpretation

 

In this agreement unless the context otherwise requires:

 

(a) headings are for convenience only and do not affect its interpretation;

 

(b) an obligation or liability assumed by, or a right conferred on, two or more Parties binds or benefits all of them jointly and each of them severally;

 

(c) the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;

 

(d) a reference to any party includes that party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;

 

(e) a reference to any document (including this agreement) is to that document as varied, novated, ratified or replaced from time to time;

 

(f) a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;

 

(g) words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;

 

(h) reference to clauses, schedules, exhibits or annexures are references to clauses, schedules, exhibits and annexures to or of this agreement and a reference to this agreement includes any schedule, exhibit or annexure to this agreement;

 

(i) where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning;

 

(j) a reference to time is to Western Standard Time as observed in Perth, Western Australia;

 

(k) where an action is required to be undertaken on a day that is not a Business Day it shall be undertaken on the next Business Day;

 

(I) a reference to a payment is to a payment by bank cheque or such other form of cleared funds the recipient otherwise allows in the relevant lawful currency specified;

 

(m) “includes” in any form is not a word of limitation; and

 

(n) a reference to $ or dollar is to Australian currency.

 

 4

 

 

 

1.3 Knowledge and awareness of the Company

 

A reference in this agreement to the Company’s awareness or knowledge (in any grammatical form) will be taken to include all matters, facts and circumstances of which the Company or any officer or senior executive of the Company is actually aware or should reasonably have been aware had such persons made due and proper inquiries.

 

 
2. SUBSCRIPTION

 

2.1 Subscription and issue

 

Subject to the terms and conditions of this agreement, the Investor agrees to subscribe for, and the Company agrees to allot and issue to the Investor (or its nominees), the Subscription Shares in the following tranches:

 

(a) (Tranche 1): on 25 February 2019, 2,000,000 Subscription Shares to be issued at the Subscription Price;

 

(b) (Tranche 2): on 8 April 2019, 1,666,667 Subscription Shares to be issued at the Subscription Price;

 

(c) (Tranche 3): on 20 May 2019, 1,666,667 Subscription Shares to be issued at the Subscription Price;

 

(d) (Tranche 4): on 1 July 2019, 1,666,667 Subscription Shares to be issued at the Subscription Price;

 

(e) (Tranche 5): on 12 August 2019, 1,666,667 Subscription Shares to be issued at the Subscription Price; and

 

(f) (Tranche 6): on 23 September 2019, 1,333,333 Subscription Shares to be issued at the Subscription Price,

 

(together, the Tranches).

 

2.2 Payment of Subscription Price

 

On the relevant Subscription Date of each Tranche, the Investor (or its nominees) must:

 

(a) deliver to the Company the Application Form duly completed and executed by the Investor (or its nominees);

 

(b) pay to the Company the Subscription Price in accordance with clause 2.6; and

 

(c) deliver to the Company written evidence of payment in the form of a confirmation of receipt of payment from the bank referred to in clause 2.6 of the Subscription Price made under clause 2.2(b),

 

in respect of the relevant Tranche.

 

 5

 

 

 

2.3 Issue of Subscription Shares

 

Subject to the Investor (or its nominee(s)) complying with its obligations under clause 2.2, following the receipt by the Company of the Subscription Price in cleared funds for each relevant Tranche, the Company must immediately:

 

(a) allot and issue the Subscription Shares to the Investor (or its nominee(s));

 

(b) enter the Investor (or its nominee(s)) in the Company’s register of members as the holder of the Subscription Shares;

 

(c) within two (2) Business Days of the receipt by the Company of the Subscription Price in cleared funds:

 

(i) send holding statements in respect of the Subscription Shares to the Investor (or its nominee(s)) in accordance with Applicable Law;

 

(i) apply to ASX for official quotation of the Subscription Shares in the same class and on the same terms as all other Shares quoted on ASX on the relevant Subscription Date; and

 

(ii) take all other steps necessary to give effect to the allotment of the Subscription Shares to the Investor (or its nominee(s)) in accordance with Applicable Law;

 

(d) following the receipt by the Company of the Subscription Price in cleared funds and issue of the Subscription Shares, the Company shall lodge with ASX a notice in accordance with section 708A(5) (e) of the Corporations Act; and

 

(e) if the Company is unable to comply with the requirements of section 708A(5) of the Corporations Act for any reason, the Company shall, at its own expense, do everything necessary to ensure the Subscription Shares so allotted are able to be freely traded on ASX in compliance with the requirements of the ASX Listing Rules and the Corporations Act, including, if considered necessary by the Investor, lodging a disclosure document with ASIC in accordance with Chapter 6D of the Corporations Act.

 

2.4 Completion

 

The Parties acknowledge and agree that:

 

(a) completion of each Subscription does not occur, and shall be taken not to have occurred, unless and until all of the obligations of the Parties under clauses 2.2, 2.3 and 2.3 have been satisfied in respect of that Tranche; and

 

(b) if any obligation specified in clauses 2.2, 2.3 and 2.3 is not performed on the due date then, without prejudice to any other rights of the Parties, any document delivered or payment made under those clauses must be returned to the Party that delivered such document or paid such amount.

 

2.5 Reasonable endeavours

 

The Company and the Investor must:

 

(a) use their reasonable endeavours to obtain fulfilment of the requirements under this clause 2 applicable to it; and

 

 6

 

 

 

(b) keep each other informed of any circumstances which may result in any requirement under this clause 2 not being completed or satisfied in accordance with its terms.

 

2.6 Suspension

 

Should the Company’s Shares be suspended from Official Quotation for more than 5 consecutive trading days after the date of this agreement, the Investor may terminate its obligations to subscribe for any future Tranches by notice in writing to the Company.

 

 

3. MANNER OF PAYMENT

 

On or prior to 4:00 pm on the relevant Subscription Date, the Investor ((or its nominee(s)) must pay the Subscription Price per Subscription Share for the relevant Tranche in immediately available funds to the account with the following details (or as otherwise directed by the Company):

 

Account Name:
Bank:
BSB:
Account:
Swift Code:
MyFiziq Limited
National Australia Bank
086 006
744 464 625
NATAAU3302S

 

 

4. REPRESENTATIONS AND WARRANTIES

 

4.1 Representations and warranties by Company

 

The Company represents and warrants to the Investor that, as at the date of this agreement and separately as at the date on which each Tranche of Subscription Shares are issued to the Investor, except as otherwise fairly disclosed by the Company to the Investor in writing and countersigned by the Investor prior to the date of this agreement:

 

(a) (Registration): it is a corporation as that expression is defined in the Corporations Act having limited liability, registered (or taken to be registered) and validly existing under the Corporations Act;

 

(b) (Authority): it has full power and authority to enter into this agreement and to perform its obligations under it;

 

(c) (Corporate authorisations): it has taken all necessary action to authorise the execution, delivery and performance by it of this agreement in accordance with its terms;

 

(d) (Binding obligations): this agreement constitutes its legal, valid and binding obligations and is enforceable in accordance with its terms;

 

(e) (Issue of Subscription Shares): it has full power and authority and has obtained all third party consents necessary to allot and issue the Subscription Shares to the Investor in accordance with Applicable Law;

 

(f) (Encumbrances): the Group has not granted or registered and there is not in existence any Encumbrance over any assets of the Group;

 

(g) (Ranking): the Subscription Shares will be credited as fully paid and rank pari passu in all respects with all other Shares on issue;

 

 7

 

 

 

(h) (Title to Subscription Shares): upon issue of the Subscription Shares, the Investor will acquire full legal and beneficial title to the Subscription Shares, free and clear of any Encumbrance;

 

(i) (No Event of Insolvency): no Event of Insolvency has occurred in relation to the Company or a member of the Group, nor is there any act which has occurred or to the best of its knowledge, is anticipated to occur which is likely to result in an Event of Insolvency in relation to the Company or a member of the Group;

 

(j) (No litigation): the Company and any member of the Group is not a party to any investigation, prosecution, litigation, legal proceeding, arbitration, mediation or any other form of dispute resolution, and to the best of its knowledge no such proceedings are pending or threatened and there is no circumstance or fact that is likely to give rise to any such proceedings;

 

(k) (Compliance with Applicable Law): the Company and each member of the Group is in compliance in all material respects with the Applicable Laws; and

 

(I) (Subscription will comply with section 708A of the Corporations Act): subject to the requirements of section 708A(6)(a), the Company is able to provide, and there is nothing preventing it from providing, a notice in accordance with section 708A(5) (e) and the offer of the Subscription Shares will be an offer to which section 708A of the Corporations Act applies.

 

4.2 Representations and warranties by Investor

 

The Investor represents and warrants to the Company that, as at the date of this agreement and separately as at each date on which the Subscription Shares are issued to the Investor (or its nominees), except as otherwise fairly disclosed by the Investor to the Company in writing prior to the date of this agreement:

 

(a) (Authority): it has full power and authority to enter into this agreement and to perform its obligations under it;

 

(b) (Binding obligations): this agreement constitutes its legal, valid and binding obligations and is enforceable in accordance with its terms; and

 

(c) (No breach): this agreement and the Subscription does not conflict with or result in a breach of any of the Investor’s legal obligations (including any statutory, contractual or fiduciary obligation) or constitute or result in any default under any provision of its constitution or any material provision of any agreement, deed, writ, order, injunction, judgment, law, rule or regulation to which it is a party or is subject or by which it is bound.

 

4.3 Indemnity by Company

 

(a) The Company indemnifies the Investor against all Indemnified Losses incurred by the Investor as a consequence of any matter or thing being found to be in breach of or inconsistent with the Company Warranties.

 

 8

 

 

 

(b) The maximum amount which the Investor may claim against the Company for a breach of the Company Warranties is 100% of the Subscription Price paid by the Investor at the time of the claim. A claim for breach of the Company Warranties shall not be made unless the amount of the Indemnified Losses reasonably claimed exceeds $1,000,000 (in which event, for the avoidance of doubt, the Company shall be liable for the whole of that amount and not merely the excess).

 

(c) The Company shall not be liable in respect of a claim in connection with a breach of Company Warranties unless the Investor has given written notice to the Company setting out reasonable details of the specific matter in respect of which the claim is made within 12 months after the relevant Subscription Date.

 

4.4 Indemnity by Investor

 

(a) The Investor indemnifies the Company against all Indemnified Losses incurred by the Company as a consequence of any matter or thing being found to be in breach of or inconsistent with the Investor Warranties.

 

(b) The maximum amount which the Company may claim against the Investor for a breach of the Investor Warranties is 100% of the Subscription Price that has been paid by the Investor at the time of the claim. A claim for breach of the Investor Warranties shall not be made unless the amount of the Indemnified Losses reasonably claimed exceeds $1,000,000 (in which event, for the avoidance of doubt, the Investor shall be liable for the whole of that amount and not merely the excess).

 

(c) The Investor shall not be liable in respect of a claim in connection with a breach of Investor Warranties unless the Company has given written notice to the Investor setting out reasonable details of the specific matter in respect of which the claim is made within 12 months after the relevant Subscription Date.

 

 

5. CONFIDENTIALITY

 

5.1 Disclosure of Confidential Information

 

All Confidential Information exchanged between the Parties under this agreement or during negotiations preceding this agreement is confidential to them and may not be disclosed to any person except:

 

(a) employees, directors, officers, legal advisers auditors and other consultants of the Party or any of its Related Bodies Corporate requiring the information for the purposes of this agreement;

 

(b) with the consent of the Party who supplied the information which consent may be given or withheld in its absolute discretion;

 

(c) if a Party is required to do so by law or a stock exchange; or

 

(d) if a Party is required to do so in connection with legal proceedings relating to this agreement.

 

 9

 

 

 

 

6. ANNOUNCEMENTS

 

6.1 Public announcements

 

Subject to clause 6.2, no Party may, before or after the relevant Subscription Date, make or send a public announcement, communication or circular concerning the transactions referred to in this agreement unless it has first obtained the other Party’s written consent. That consent is not to be unreasonably withheld or delayed and should be completed within 48 hours of signing this agreement.

 

6.2 Public announcements required by law

 

Clause 6.1 does not apply to a public announcement, communication or circular required by law or a regulation of a stock exchange, if the Party (including its Group) required to make or send it has, if practicable, first consulted and taken into account the reasonable requirements of the other Party.

 

 

7. COSTS AND DUTY

 

7.1 Costs and expenses

 

The Company and the Investor agree to pay their own legal fees and other costs and expenses incurred in connection with the preparation, negotiation and completion of this agreement and of other related documentation.

 

7.2 Duty

 

The Company must pay all Duty chargeable, payable or assessed in relation to this agreement and the issue of the Subscription Shares to the Investor.

 

 

8. NOTICES

 

8.1 Notices in writing

 

Each notice authorised or required to be given to a Party shall be in legible writing and in English addressed to the Party’s address set out in clause 8.2 (or such other address nominated in accordance with clause 8.3).

 

8.2 Initial address of Parties

 

The initial address of the Parties shall be as follows:

 

  Party   Address   Attention   E-mail

MYFIZIQ LIMITED

 

Unit 5, 71-73 South Perth Esplanade,
South Perth,
WA 6151

 

The Board of Directors

 

 

VIado Bosanac
<vlado@myfiziq.com>

Asia Cornerstone Asset Management Limited

 

Unit 1914, 19th Floor,

Miramar Tower,
132 Nathan Road,
Tsim Sha Tsui, Kowloon, Hong Kong

 

Marcus Liew

 

mi@marcusliew.com

 

 10

 

 

 

8.3 Change of address

 

Each Party may from time to time change its address by giving notice pursuant to clause 8.1 to the other Parties.

 

8.4 Receipt of notice

 

Any notice given pursuant to clause 8.1 will be conclusively deemed to have been received:

 

(a) in the case of personal delivery, on the actual day of delivery;

 

(b) if sent by mail, two (2) Business Days from and including the day of posting; or

 

(c) if sent by facsimile, when a facsimile confirmation receipt is received indicating successful delivery; or

 

(d) if sent by e-mail, when a delivery confirmation report is received by the sender which records the time that the e-mail was delivered to the addressee’s e-mail address (unless the sender receives a delivery failure notification indicating that the e-mail has not been delivered to the addressee),

 

but if the delivery or receipt is on a day that is not a Business Day or is after 5:00 pm (addressee’s time) it is regarded as received at 9:00 am on the following Business Day.

 

 

9. VARIATION

 

No modification or alteration of the terms of this agreement shall be binding unless made in writing dated subsequent to the date of this agreement and duly executed by the Parties.

 

 

10. WAIVER

 

(a) Waiver of any right, power, authority discretion or remedy arising upon default under this agreement must be in writing and signed by the Party granting the waiver.

 

(b) A failure or delay in exercise, or partial exercise, of a right, power, authority, discretion or remedy created or arising upon default under this agreement, does not result in a waiver of that right.

 

(c) A Party is not entitled to rely on a delay in the exercise or non-exercise of a right, power, authority, discretion or remedy arising from a breach of this agreement or on a default under this agreement as constituting a waiver of that right, power, authority, discretion or remedy.

 

(d) A Party may not rely on any conduct of another Party as a defence to exercise of a right, power, authority, discretion or remedy by that other Party.

 

 

11. FURTHER ASSURANCE

 

Each Party shall sign, execute and do all deeds, acts, documents and things as may reasonably be required by the other Party to effectively carry out and give effect to the terms and intentions of this agreement.

 

 11

 

 

 

EXECUTED BY )  
ASIA CORNERSTONE ASSET MANAGEMENT )  
LIMITED )  
in accordance with its constituent )  
documents and place of incorporation:    
       
/s/ Marcus Liew      
Director      
       
       
Director/Secretary      

 

 12

 

 

 

 

12. GOVERNING LAW AND JURISDICTION

 

This agreement shall be governed by and construed in accordance with the law from time to time in the State of Western Australia and the Parties agree to submit to the non-exclusive jurisdiction of the courts of Western Australia and the courts which hear appeals therefrom.

 

 

13. TIME OF ESSENCE

 

Time is of the essence of this agreement in respect of any date or period determined under this agreement.

 

 

14. ENTIRE AGREEMENT

 

This agreement shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other agreements with respect thereto.

 

 

15. COUNTERPARTS

 

This agreement may be executed in any number of counterparts (including by way of facsimile) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

 

EXECUTED by the Parties as an agreement.      
       
       
EXECUTED BY MYFIZIQ LIMITED )    
ACN 602 111 115 )    
in accordance with section 127 of the )    
Corporations Act 2001 (Cth): )    
       
     
Signature of director     Signature of director/company secretary
(please delete as applicable)
       
Vlado Bosanac      
Chief Executive Office    

Name of director/company secretary
(please delete as applicable)

 

 13

 

 

 

 

S C H E D U L E 1 - A P P L I C A T I O N F O R M

 

 

APPLICATION FORM

 

MYFIZIQ LIMITED
ACN 602 111 115
(Company)

 

Asia Cornerstone Asset Management Limited (Investor) hereby applies to the Company for 10,000,000 fully paid ordinary shares in the capital of the Company (Shares).

 

The Investor will transfer to the Company an amount of AUD$6,000,000 in Australian dollars and in immediately available funds to the account nominated by the Company.

 

Details of the Investor:

 

Name: Asia Cornerstone Asset Management Limited

 

Address: Unit 1730, 17F, Silvercord Tower 2, 30 Canton Road,
Tsim Sha Sui, Kowloon, Hong Kong

 

Contact Person: Michael Marcus Liew

 

Contact Investor: +65 9657 3468

 

By signing and lodging this Application Form with the Company, the Investor:

 

1. declares that the agreements, statements, declarations and acknowledgments contained in the following paragraphs are given for the benefit of the Company;

 

2. declares that all details and statements made by the Investor in this Application Form are complete and accurate;

 

3. agrees to be bound by the Constitution of the Company;

 

4. represents, warrants and undertakes to the Company that the Investor has/have full right and authority to sign and lodge this Application Form, to subscribe for the Shares and to perform the other obligations set out in this Application Form, and has taken all action and obtained all regulatory and other consents, approvals and authorisations necessary in that respect;

 

5. acknowledges that the Investor have/has made its/their own enquiries concerning the Company and its business and affairs and that the Company makes no representation or warranties to the Investor other than set out in the Subscription Agreement dated the same date as this Application Form;

 

6. requests the Company to, upon receipt of this Application Form signed by the Investor, issue the Subscription Shares to the Investor pursuant to the agreement;

 

 14

 

 

 

7. declares that the Investor comes within the definition of a sophisticated investor or a professional investor for the purposes of Section 708(8) or 708(11) of the Corporations Act 2001 respectively;

 

8. acknowledges that this Application form is irrevocable, subject to the agreement; and

 

9. acknowledges that returning this Application Form with the application monies will constitute the Investor’s offer to subscribe for Subscription Shares subject to the agreement, and that no notice of acceptance of this Application Form will be provided.

 

 

NOTE: Return of the Application Form with your payment of the application monies will constitute your offer to subscribe for the Shares. This Application Form is for the Subscriber and must not be passed onto any person without written permission from the Company.

 

 

EXECUTED BY )  
Asia Cornerstone Asset Management )  
Limited )  
in accordance with its constituent )  
documents and place of incorporation:    
       
/s/ Marcus Liew      
Director      
       
       
Director/Secretary      

 

 15

 

Exhibit 10.2

 

 

4 June 2019

 

Asia Cornerstone Asset Management Limited

Unit 1914, 19th Floor, Miramar Tower

132 Nathan Road

Tsim Sha Tsui, Kowloon

HONG KONG

 

Attention: Marcus Liew

 

By email: mi@marcusliew.com

 

Dear Sirs

 

SUBSCRIPTION AGREEMENT - VARIATION

 

We refer to the Subscription Agreement dated 11 February 2019 between MyFiziq Limited (ACN 602 111 115) and Asia Cornerstone Asset Management Limited (a company incorporated in Hong Kong) (Subscription Agreement).

 

Defined terms in this variation agreement (Variation Agreement) have the same meaning as given in the Subscription Agreement.

 

By execution of this Variation Agreement, the Parties agree to vary the Subscription Agreement by:

 

1. in the definition of Subscription Shares in clause 1.1, deleting the number “10,000,000” and replacing it with the number “8,666,667”; and

 

2. deleting clause 2.1 in its entirety and replacing it with the following:

 

2.1 Subscription and issue

 

(a) Subject to the terms and conditions of this agreement, the Investor agrees to subscribe for, and the Company agrees to allot and issue to the Investor (or its nominees), the Subscription Shares in the following tranches:

 

(i) (Tranche 1): on 25 February 2019, 2,000,000 Subscription Shares to be subscribed at the Subscription Price;

 

(ii) (Tranche 2): on 8 April 2019, 1,666,667 Subscription Shares to be issued at the Subscription Price;

 

(iii) (Tranche 3): on 20 May 2019, 833,333 Subscription Shares to be issued at the Subscription Price;

 

(iv) (Tranche 3A): on 14 June, 833,333 Subscription Shares to be issued at the Subscription Price;

 

 

 

MyFiziq Limited

ACN 602 111 115

Postal Address: PO Box 190, South Perth WA 6951

Email: admin@myfiziq.com

 

 1

 

 

 

(v) (Tranche 4): on 1 August 2019, 833,333 Subscription Shares to be issued at the Subscription Price;

 

(vi) (Tranche 4A): on 15 September 2019, 833,333 Subscription Shares to be issued at the Subscription Price;

 

(vii) (Tranche 5): on 12 November 2019, 833,334 Subscription Shares to be issued at the Subscription Price; and

 

(viii) (Tranche 5A6): on 15 December 2019, 833,334 Subscription Shares to be issued at the Subscription Price,

 

(together, Tranches).

 

Other than as varied by this Variation Agreement, the terms and conditions of the Subscription Agreement remain in full force and effect.

 

This Variation Agreement shall be governed by and construed in accordance with the law from time to time in the State of Western Australia and the Parties agree to submit to the non-exclusive jurisdiction of the courts of Western Australia and the courts which hear appeals therefrom.

 

This Variation Agreement may be executed in any number of counterparts (including by way of facsimile) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

Please record your agreement to the above variation by executing this Variation Agreement where indicated below.

 

Yours faithfully  
 
Vlado Bosanac
CEO / Co-Founder, for and on behalf of
MyFiziq Limited
 

 

 2

 

 

 

Executed as a deed.      
       
EXECUTED AS A DEED BY MYFIZIQ LIMITED )    
ACN 602 111 115 )    
in accordance with section 127 of the )    
Corporations Act 2001 (Cth): )    
       
     
Signature of director      
       
       
Vlado Bosanac      
Chief Executive Officer      
       
       
SIGNED, SEALED AND DELIVERED BY      
ASIA CORNERSTONE ASSET MANAGEMENT )    
LIMITED )    
in accordance with its constituent )    
documents and place of incorporation: )    
       
/s/ Marcus Liew      
Director      

 

 3

 

Exhibit 10.3

 

Fiziq

71-73 South Perth Esplanade

South Perth I 6151 IWA

ABN 85 602 111115

www.MyFiziq.com

 

5 December 2016

 

Mr. Vlado Bosanac Unit 2

71 - 73 South Perth Esplanade

South Perth WA 6151

 

Dear Vlado

 

I. Reporting & Res ponsibilities: You will oversee all aspects of the Company’s management and operations, including but not limited to:
      1. Developing long term. medium term and short term strategic objectives for the Company;
         
      ii.  Responsibility for the overall financial performance of the Company within the financial budgets and forecasts approved by the Board of Directorsof the Company from time to time;
      111. Being the chief spokesperson for the Company in all marketing and media for the promotion of the Company;
      iv. promote the interests and welfare of the Company;
      v. Leading all key business development discussions with potential operating partners to expand the user base for the MyFiziq App;
      v1. Development of the adjunct brand “D r. Katherine” in the wellness sector;
      vii. Management and responsibility for all key executive recruitment;
      viii. Reporting to the Board of Directors on a monthly basis (or as otherwise directed by the Board) on all key aspects of the Company’s business; and
      1x. Responsibility for all corporate actions of the Company in line with normal expectations for the role of Chief Executive Officer.

2. Commencement Date: I 7 October 2016.
     
3. Title: Executive Director and Chief Executive Officer (CEO)

 

Corporate Address: Suite S, 71 - 73 South Perth Esplana de, South Perth W.A 6151
Correspondence to: POBox190, South Perth, WA 6951

 

4. Compensatio n: The commencing salary will be $270,000 per annum, paid monthly and exclusive of a 9.50% superannuation contribution by MYQ to a superannuation fund nominated by you. The compensation package will be subject to annual review by the Board of Directors. There are no fixed hours of employment however as a  senior executive you are expected to work the number of hours required to perform the role of CEO. ln context, the minimum working week shall be 37.5 hours, with no provision for over-time however, the Company may grant you time in lieu in the event the Board considers (at its discretion) you are working consistently above the normal working week.
       
    Upon the first annual review of your performance and remuneration, the Board of Directors shall in good faith establish Key Performance Indicators (KPI’s) for the next twelve months upon which bonus compensation can be earned by you, up to a maximum of 100% of your base compensation. The nature of the KPI’s and bonus structu re shall be negotiated with you in good faith.
       
    ln addition , subject to the Company obtaining shareholder approval in general meeting, you shall be issued the following share based compensation (by way of performance rights to be issued under a new Performance Rights Plan to be adopted by the Company):
       
    1st Milestone: 2,000,000
        o Upon signing first commercial transaction where the party or organization has 5m or more active subscribers/followers
        o This milestone must be achieved within 12 months of issuing this class of Performa nce Rights
       
    2nd Milestone: 2,000,000
        o 50,000 users or $500k annualized revenue
        o This is a significant step in user growth. Achieving this alone should be considered a great milestone
        o This milestone must be achieved within 24 months of iss uing this class of Performance Rights
       
    3rd Milestone: 2,000,000
        o I00,000 users or $Im annualized revenue
        o This gets us to a breakeven scenario and therefore should be considered as a milestone
        o This milestone must be achieved within 36 months of issuing this class of Performance Rights
       
    ●  4th Milestone: 2,000,000
      o 200,000 users of $2.5m annualized revenue
      o This is set to at major tipping points in user growth and company growth
      o This milestone must be achieved within 48 months of issuing this class of Performance Rights
       
    ●  5th Milestone: 2,000,000
      o 250,000 users or $5m annualized revenue
          o This is a significant step in user growth. Achieving this alone should be considered a great milestone
          o This milestone must be achieved within 60 months of issuing this class of Performance Rights

MyFiziq Limited. Page 1 of 7

    In the event of a takeover or buyout of the company I technology, all Performance Rights will vest in accordance with the terms of the Performance Rights Plan.
5. Expenses: You will be reimbursed all reasonable expenses supported by official receipts for payments  made on behalf of the Company  whilst carrying out your duties provided however that any individual expense exceeding $2,000 must not be incurred without the prior written consent of the Company.
    You must provide all proper documentation to the Company to verify s uch expenses prior to reimbursement. You must comply  with all lawful directions of the Company  in relation  to incurring expenses on behalf of the Company  and shall not in any way pledge the credit of the Company except inso far as you may have been expressly authorised by the Company either generally or in any particular incidence.
6. Appointme nt Bas is: Full time position.
       
    As a professional qualified employee, you are required to exercise your specialized expertise, independent judgment  and discretion to  provide high quality services and are expected to work the number of hours required to get the job done.
     
7.  Tenure and Review: The appointment basis is full time / permanent with an initial employment and salary review one year from the dateof appointment.
    The Company has appointed you  as  CEO  and  you agree to accept the appointment and the tenure on the terms and conditions set out in this agreement.
    Your engagement under this agreement will be reviewed on the twelve month anniversary of your employment and thereafter on an annual basis. The Review will include such matters determined by the Board, and will include, but is not limited to:
         
      i. your performance during the period prior to the review (including against performance indicators set by the Board);
         
      ii. the performance of the Company during the period prior to the review;
        and
         
      iii. your remuneration relative to economic conditions prevailing in the state of Western Australia and similar positions offered in the market.

MyFiziq Limited. Page 2 of 7

7.1 Termination Without Cause:   I. The Company may terminate this agreement without reason by providing you with not less than three months’ written notice or paying you a cash payment equal to three month’s salary in lieu of notice.
      11. You may terminate your engagement with the Company without reason by providing the Company with not less than three (3) months’ written notice, unless the Board otherwise agrees (at its discretion).
         
8. Annual Leave: Annual leave is accrued at a rate of20 working days per annum, a working day being exclusive of recognized public holidays. Your annual leave may be taken once it is accrued, at any time mutually acceptable to yourself and the Company. Accrued leave shall not accumulate in excess of30 workingdays without written approval of the Board. A waiver may be granted under special circumstances at the Board’s discretion.
       
9. Sick Leave, Compassionate Leave
Carer ’s Leave
S ick Leave
  You are entitled to paid sick leave equivalent to the number of hours you would ordinarily work in a two week period, up to a maximum of75 hours per year. No payment will be made for unused sick leave following resignation or termination. Claims for sick leave taken in excess of two days must be supported by a medical certificate.
       
  Compassionate Leave
    You are entitled to two days paid compassionate leave:
     
      i. ifa member of your immediate family or household requires care or support due to an illness or injury; or
       
    11. in the event of an unexpected emergency involvinga member of your immediate family or household.
       
    Carer ’s Leave
    You are entitled to two days unpaid carer’s leave:
       
      i. ifa member of your immediate family or household has an illness or injury that poses a serious threat to their life; or
       
      11. in the event of the death of a member of your immediate family or household.
       
10. Long Service Leave: You are entitled to long service leave in accordance with the provisions of the
       
    Long Service Leave Act 1958 (WA).
       
11. Proprieta ry Information 11.l Definitio ns of IP and Inventions:
       
    IP means all industria l and intellectual property rights whether protectable by statute, at common law or in equity, including all copyright and similar rights which may s ubsist or may hereafter subsist in works or any subject matter, rights in relation to inventions (including all patentsand patent applications), trade secrets and know-how, rights in relation to designs (whether or not registrable), rights in relation to registered or unregistered trade marks, circ uit layout designs and rights in relation to circuit layouts, whether registered, registrable or unregistered, including:
     
      i. marks, logos, service marks, trade names, business names, internet domain names, slogans, symbols, brand names, copyright or other trade indicia;

 

MyFiziq Limited. Page 3 of 7

      ii. all rights in information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, designs, drawings, trade secrets or data whether or not protectable by patent application design registration, copyright, whether unregistered, registered or registrable; and
       
      iii. any modifications, developments, adaptations, advancements, creations and derivations of any intellectual property,
       
    but excludes non-assignable moral rights and similar non-assignable personal rights of authors and producers.
       
    11.2 Current & New
       
      1. As a condition of employment, you represent and warrant that you will immediately communicate to the Company any new and all new literary and other new works and new subject matter including all new works, new processes, new inventions, new improvements, new innovations, new modifications, new designs, new discoveries, new trademarks and new trade secrets, however embodied, which you may make either alone or in conjunction with others during the course of, in connection with or arising out of your employment and in any way connected with matters specifically pertaining to the business and assets of MyFiziq for which the Company has been or is now or hereafter interested during your employment (“Inventions”).
       
      11. Any new inventions or extension of the IP surrounding Myfiziq, whether or not the Inventions are capable of being protected by copyright, letters patent, registered design or other protection (“Protection”), will be solely owned by the Company for development.
       
      iii. Any new inventions, whether or not the [nventions are capable of being commercialised or able of Protection outside of those ofMyFiziq will be first offered to the Company for first right of refusal. Further proceedings will only go forward if agreed by both you and the Company.
       
    11.3 Co-operation in obtaining Protection for Inve ntions
       
      1. If and whenever required to do so whether during or after termination of your employment, and at the expense of the Company or its nominee, you will apply or join in applying for letters patent or other similar protection in Australia or in any other part of the world for content specifically pertaining to MyFiziq. you will immediately deliver to the Company full particulars concerning these matters and execute all instruments and do all things necessary for vesting the letters patent or other Protection when obtained, and all right and title to and interest in the same, in the Company or its nominee absolutely and as sole beneficial owner or in such other person as the Board requires.

 

MyFiziq Limited. Page 4 of 7

 

      ii. You appoint the Company to be your attorney in your name and on your behalf to execute any such instrument or thing and generally to use your name for the purpose of giving to the Company or its nominee the full benefit of the provisions of this clause.
       
    11.4 Information
       
    Without limiting the generality of the above, and subject to not breaching any laws or breaching any other contractual obligations in existence or arising from time to time, you represent and warrant that:
       
      i. you will immediately inform the Company of any matter which may come to your notice during the Employment which may reasonably be of interest or of any importance or use to the Company or its Subsidiaries and Related Corporations for content specifically pertaining to MyFiziq;
       
      11. you will immediately communicate to the Company any proposals or suggestions occurring to you during your employment which may reasonably be of service for the furtherance of the business of the Company for content specifically pertaining to MyFiziq.
       
    You agree the provisions of this clause survive termination of this agreement.
       
12. Confidentiality: Unless you are authorized to do so by law, you are not to divulge any information you obtain as a result of your appointment either to the med,ia the public generally or to any other third party, except and unless it is of a general nature and of general knowledge and you do so as a consequence of the performance of your responsibilities. All knowledge and/or information, written or otherwise, related to the activities of the Company obtained by you as a consequence and in the course of your employment becomes the property of the Company, and unless otherwise authorized during the term of your employment or thereafter, must not be divulged to any other source. Upon termination of your services with the Company you must return all papers, records, documents (including hard copy and digital copies) and any equipment that are in your possession or control and relate to any of the foregoing.
       
    Confidential information also extends to the contents of this letter and in particular to employee’s remuneration details. You represent and warrant to us that there are no other agreements, written or oral, that would restrict your ability to perform the basic functions of your job, including but not limited to non­ compete, non-disclosure or similar agreements with prior employers. If there are such agreements, you agree to immediately provide the Company with a copy of any such agreements(s) for its review. You further agree not to bring to the Company, use or disclose any trade secrets or other confidential/proprietary information of prior emplo yers.
       

 

  You agree the provisions of this clause survive termination of this agreement.

 

MyFiziq Limited. Page 5 of 7

 

13. Governing Law: This agreement is intended to give rise to legal rights and obligations and constitutes a binding agreement between the parties. This agreement shall be governed by and construed in accordance with the law from time to time in the State of Western Australia and the parties agree to submit to the nonexc lusive jurisdiction of the courts of Western Australia and the courts which hear appeals there from.
     
14. Variation: No modification or alteration of the terms of this agreement shall be binding unless made in writing dated subsequent to the date of this agreement and duly executed by the parties.
     
15. Acceptance: Please indicate your acceptance of the above offer under the above terms and conditions by signing the duplicate copy of the offer and returning to the Company.

 

Yours sincerely  
   
/s/ Peter Wall  
   
Peter Wall  
Non-executive Cha irman
MyFiziq Limited
 

 

I ac ce pt the offe r oa{“ mploJ ment under the above terms and co nditions and agree to abide by the policies and procedures of the toc pany.

 

Signature /s/ Vlado BosanacVlado Bosanac   Date :
  Vlado Bosanac    

 

 

MyFiziq Limited. Page 7 of 7

 

Exhibit 10.4

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

Date of Agreement 22/07/2019

 

PARTIES

 

MyFiziq Limited, ABN 85 602 111 115 of Suite 5, 71-73 South Perth Esplanade, South Perth, Western Australia, 6151 (“MyFiziq”, “MYQ” or the “Company”),

 

Steven Richards of 6 Furlong Road, The Vines, Western Australia, 6069 (the “Employee”).

 

RECITALS

 

The Company wishes to employ the Employee on a permanent full-time basis in the Position, and the Employee wishes to be employed by the Company in the Position on that basis, on the following terms and conditions (“Agreement”).

 

THE PARTIES AGREE AS FOLLOWS:

 

1. Position Chief Financial Officer (CFO)

 

2. Commencement  
Date  

 

3. Manager CEO, Vlado Bosanac

 

4..Reporting & Responsibilities i. Develop and lead the Company’s strategic financial direction, stay on top of emerging financial trends, as well as ASX compliance, legislation and financial practises.

 

    ii. Accounting: establish core financial processes and reporting requirements including financial regulation, ASX requirements, audits and capital structure.
  iii. Budget control: produce budgets at regular intervals for efficient decision making.

 

  iv. Ensure compliance with the law, ASX regulations and company’s policies.

 

  v. Establish and maintain relationships with banks; managing and using financial resources to achieve the company’s general objectives, optimising performance by negotiating terms with banks and financial institutions.

 

  vi. Establish and maintain relationships with key brokers, fund managers, analysts, investors, and the ASX on behalf of the company.

 

  vii. Any other activities as directed by the Employees Manager.

 

5. Compensation The commencing salary will be $150,000 per annum, paid fortnightly and exclusive of a 9,§0% superannuation contribution by MYQ to a superannuation fundnominated by the Employee. The maximum ordinary working week is 38 hours, with no provision for over-time. Any overtime must be prior approved in writing by your Manager.

 

Page 1 of 13

  

MYFIZIQ EMPLOYMENT AGREEMENT  

 

6. Expenses The Employee will be reimbursed all reasonable expenses supported by official receipts for payments made on behalf of the Company whilst carrying out the Employee’s duties provided, however, that any individual expense exceeding $200 must not be incurred without the prior written consent of the Company.
   
  The Employee must provide all proper documentation to the Company to verify such expenses prior to reimbursement. The Employee must comply with all lawful directions of the Company in relation to incurring expenses on behalf of the Company, and shall not in any way pledge the credit of the Company except insofar as the Employee may have been expressly authorised by the Company either generally or in any particular incidence.
   
7. Appointment Basis Full-time position.
   
  As a professional qualified Employee, the Employee is required to exercise their specialised expertise, independent judgment and discretion to provide high-quality services and fulfill all reasonable work-related demands and requirements.
   
  The Employee must comply with all lawful instructions given to them by their Manager, and any delegate of their Manager, and any policies instituted by the Company from time to time. The Company’s policies do not form part of this Agreement and do not give rise to any contractual rights for the Employee.
   
  The Company may modify any of its policies at any time.
   
  In the course of performing the Employee’s duties in the Position, the Employee shall use their best endeavors to promote, develop and protect the business interests and welfare of the Company.
   
8. Qualifications The Employee must not do anything which is harmful to the reputation or interests of the Company.
   
  The Employee must work in a lawful, professional and competent manner and provide faithful service, and act in good faith in all its dealings with and on behalf of the Company.
   
  The Employee warrants to the Company that they hold the qualifications and have the experience set out in their curriculum vitae provided to the Company prior to the Commencement Date, and that all information provided to the Company by the Employee in that curriculum vitae and in any employment application and/or in any job interview, is truthful, accurate, correct and complete.
   
  The Employee warrants that in entering into this Agreement they will not be in breach of any obligations owed to any third parties.
   
  The Employee warrants that they have not entered into, and will not enter into any agreement, that conflicts with their obligations owed to the Company under this Agreement.
   
9. Tenure and Review The Company has appointed the Employee into the Position, and the Employee agrees to accept the appointment and the tenure, on the terms and conditions set out in this Agreement.

 

Page 2 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

9.1 Probation Period The Employee’s employment with the Company is subject to a six (6) month Probation Period from the Commencement Date of this agreement.
     
  On and from the Commencement Date and during the Probation Period, either party may terminate this Agreement by providing the other with not less than two (2) weeks’ notice in writing. This clause does not affect the Company’s right to terminate the Agreement without notice in the event of serious misconduct by the Employee.
     
9.2 Employment Review The Company will use its best endeavours to have the Employee’s engagement under this Agreement reviewed at the end of the Probation Period, and thereafter on or before 31 August each year. The Review will include such matters as determined by the Board, and may include,
     
  i. the Employee’s performance during the period prior to the review (including against performance indicators set by the CEO or the Board);
     
  ii. the performance of the Company during the period prior to the review; and
     
  iii. the Employee’s remuneration relative to economic conditions prevailing in the state of Western Australia and similar positions offered in the market.
     
9.3 Termination i. After the Probation Period, either party may at any time terminate this Agreement by providing the other with four (4) weeks’ prior written notice (“Notice Period”). The Company may choose, in lieu of requiring the Employee to work out the Notice Period, to make a payment  to the Employee of an amount equivalent to the Employee’s Remuneration, pro rated for the Notice Period, or such higher amount prescribed by applicable legislation.
     
  ii. If at the time of termination by the Company the Employee has completed two years’ service and is aged over 45, the Employee will receive one (1) additional week of notice.
     
  iii. The Company shall not be required to provide any notice to the Employee in the case of dismissal for serious misconduct.
     
  iv. On cessation or termination of  employment,  the  Employee  is  entitled  to payment in lieu of the annual leave to which the Employee has become entitled during his or her employment with the Company, but which he or she has not taken.
     
  v. Upon cessation of the Employee’s employment with the Company, the Employee must deliver-up and/or destroy (as required by the Company), all and any Confidential Information and other property of the Company in the possession or control of the Employee, whether in hard copy or held in electronic form or otherwise.
     
  vi. Before and after cessation of the Employee’s employment with the Company, the Employee must not make any derogatory remark or statement about the Company or its personnel or any other remark or statement which may damage the reputation or goodwill of the Company.
     
  vii. Termination does not affect any accrued rights of either party.

 

Page 3 of 13

  

MYFIZIQ EMPLOYMENT AGREEMENT  

 

10. Restrictions and Restraints of trade In the interest of being fair and reasonable, MyFiziq is not looking to restrain the Employee from working in their respective field(s) post-employment with MyFiziq. MyFiziq is only seeking to restrict the Employee from being poached or moving to a competitor and assisting in creating any product that directly competes with MyFiziq for a period after employment with MyFiziq.
     
10.1 Restriction on Activities On and from the Effective Date until the Employee’s employment ends in accordance with the Employee’s Employment Contract, or pursuant to applicable law, the Employee must work full-time for the Company, and without the prior written consent of the Company must not:
     
  i. work in, on or for any other business; or
     
  ii. commence, operate, invest directly or indirectly in, or obtain an interest in, any business that is in competition with the Company (provided that this clause shall not prevent the Employee from holding up to 10% of the shareholding in a publicly-listed company).
     
10.2 Restraint Period and Area The Restraint Period is as follows:
     
  i. twelve (12) months; or
     
  ii. if a court finds twelve (12) months unreasonable, nine (9) months; or
     
  iii. if a court finds nine (9) months unreasonable, six (6) months; or
     
  iv. if a court finds six (6) months umeasonable, three (3) months.
     
  The Restraint Area is as follows:
     
  i. All MyFiziq patented countries; currently China, South Korea, Japan, Singapore, USA and Australia, this will expand to further countries as new patents are received; or
     
  ii. if a court finds all MyFiziq patented countries unreasonable, Asia Pacific countries I. Or
     
  iii. if a court finds Asia Pacific countries unreasonable, Australia.
     
11. IT Devices    
  If the Employee is provided by the Company with access to, or possession of, any computer, smartphone device or other equipment for the use by the Employee, the Employee must take reasonable care to keep such devices and equipment secure and protected. The loss of any such device must be immediately reported by the Employee to the Company.

 

 

 

1 For clarity Asia Pacific countries include countries in geographic regions Asia and Oceania as defined by the United Nations: https://unstats.un.org/unsd/methodology/m49/

 

Page 4 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

12. Surveillance The Employee’s use of the Company’s information technology systems and email accounts will be subject to ongoing and continuous surveillance. Such surveillance will be conducted from the Commencement Date and at all times thereafter during the term of the Employee’s employment with the Company.
  The Employee agrees and acknowledges that the Company may monitor and record all usage of any computer, smartphone device and/or e-mail address allocated to the Employee by the Company, and the Employee consents to the monitoring of all such devices and addresses.
     
  The Employee further agrees and acknowledges that all e-mails and any files and other data transmitted by the Employee using any computer, smartphone device or email address allocated to the Employee, are the sole property of the Company.
     
13. Price Sensitive Information The Employee acknowledges that in the course of carrying out the services pursuant to this Agreement the Employee may receive Confidential Information, including “Price Sensitive Information” (as per the Corporations Act 2001 (Cwth)) affecting the Company. Any disclosure, communication, or misuse of Price Sensitive Information may have very serious implications for the Company and/or the Employee, including possible criminal prosecution and possible civil actions against the Employee.
     
  The Employee acknowledges that the Company has the right to terminate this Agreement without notice if the Employee discloses, communicates, or misuses Price Sensitive Information in the absence of the prior written consent of the Board, except to the extent that the Employee is required by law to disclose, communicate or use it.
     
14. Annual Leave Annual leave accrues progressively at a rate of 20 days per annum. The Employee’s annual leave may be taken once it is accrued at any time mutually acceptable to the Employee and the Company. Accrued annual leave should not accumulate in excess of 30 working days. If you reach this number of accrued annual leave days, the Company may direct you to take annual leave in accordance with the Fair Work Act 2009.
     
15. Personal/Carer’s Leave and Compassionate Leave Personal/Carer’s Leave
     
  Paid personal/carer’s leave accrues progressively at a rate of 10 working days per annum. The Employee’s personal/carer’s leave may be taken once it is accrued. No payment will be made for unused personal/carer’s leave following cessation of employment.
     
  An Employee may take personal leave when he or she is ill or injured and unfit for work.
     
  An Employee may take carer’s leave when he or she is required to provide care or support to a member ofhis or her immediate family or household who is ill, or injured, or experiencing an unexpected emergency.
     
  The Company requires production of suitable evidence in support of any personal/carer’s leave absence.
     
  Unpaid Carer’s Leave
     
  The Employee is entitled to two days’ unpaid carer’s leave on each occasion such leave is required, provided the Employee’s paid personal/carer’s leave balance has been exhausted.

 

Page 5 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

  Compassionate Leave
     
  The Employee is entitled to two days paid compassionate leave if a member of the Employee’s immediate family or household:
     
  i. experiences a life-threatening illness or injury; or
     
  ii. passes away.
     
16. Long Service Leave and Other Leave The Employee is entitled to long service leave in accordance with the provisions of the Long Service Leave Act 1958 CW A). The Employee will be entitled to all other forms of leave provided by the Fair Work Act 2009.
     
17. Proprietary Information and Inventions
     
17 .1 Meaning of “Intellectual Property” “Intellectual Property” (“IP”) means all industrial and intellectual property rights whether protectable by statute, at common law or in equity, including all copyright and similar rights which may subsist or may hereafter subsist in works or any subject matter, rights in relation to inventions (including all patents and patent applications), trade secrets and know-how, rights in relation to designs (whether or not registrable), rights in relation to registered or unregistered trade marks, circuit layout designs and rights in relation to circuit layouts, whether registered, registrable or umegistered, including:
     
  i. marks, logos, service marks, trade names, business names, internet domain names, slogans, symbols, brand names, copyright or other trade indicia;
     
  ii. all rights in information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, designs, drawings, trade secrets or data whether or not protectable by patent application design registration, copyright, whether unregistered, registered or registrable; and
     
  iii. any modifications, developments, adaptations, advancements, creations and derivations of any intellectual property,
     
  but excludes non-assignable moral rights and similar non-assignable personal rights of authors and producers.
     
17.2 Current & New i. As a condition of employment, the Employee represents and warrants that they will immediately communicate to the Company any and all new literary and other new works and new subject matter including all new works, new processes, new inventions, new improvements, new innovations, new modifications, new designs, new discoveries, new trademarks and new trade secrets, however embodied, which the Employee may make either alone or in conjunction with others during the course of, in connection with or arising out of the Employee’s employment and in any way connected with matters specifically pertaining to the business and assets of MyFiziq, including MyFiziq joint ventures, partners and customers, for which the Company has been or is now or hereafter interested during the Employee’s employment (“Inventions”).

 

Page 6 of 13

  

MYFIZIQ EMPLOYMENT AGREEMENT  

  

  ii. Any new Inventions or extension of the IP surrounding MyFiziq, including MyFiziqjoint ventures, partners and customers, whether or not the Inventions are capable of being protected by copyright, letters patent, registered design or other protection (“Protection”), will be solely owned by the Company for development.
     
  iii. Any new Inventions, whether or not the Inventions are capable of being commercialised or able of Protection outside of those of MyFiziq, including MyFiziq joint ventures, partners and customers, will be first offered to the Company for first right of refusal. Further proceedings will only go forward if agreed by both the Employee and the Company.

 

17.3 Co-operation in Obtaining Protection for Inventions i. If and whenever required to do so whether during or after cessation of the Employee’s employment, and at the expense of the Company or its nominee, the Employee will apply or join in applying for letters patent or other similar protection in Australia or in any other part of the world for content specifically pertaining to MyFiziq, including MyFiziq joint ventures, partners and customers where required. The Employee will immediately deliver-up to the Company full particulars concerning these matters and execute all instruments and do all things necessary for vesting the letters patent or other Protection when obtained, and all right and title to and interest in the same, in the Company or its nominee absolutely and as sole beneficial owner or in such other person as the Board requires.
     
  ii. The Employee appoints the Company to be their attorney in the Employee’s name and on the Employee’s behalf to execute any such instrument or thing and generally to use the Employee’s name for the purpose of giving to the Company or its nominee the full benefit of the provisions of this clause.
     
17.4 Information Without limiting the generality of the above, and subject to not breaching any laws or breaching any other contractual obligations in existence or arising from time to time, the Employee represents and warrants that:
     
  i. the Employee will immediately inform the Company of any matter which may come to the Employee’s notice during the Employment which may reasonably be of interest or of any importance or use to the Company or its Subsidiaries and Related Corporations for content specifically pertaining to MyFiziq, including MyFiziqjoint ventures, partners and customers;
     
  ii. the Employee will immediately communicate to the Company any proposals or suggestions occurring to the Employee during the Employee’s employment which may reasonably serve to further the business of the Company for content specifically pertaining to MyFiziq including MyFiziq joint ventures, partners and customers.
     
  The Employee agrees the provisions of this clause survive the cessation of the Employee’s employment with the Company.

 

Page 7 of 13

  

MYFIZIQ EMPLOYMENT AGREEMENT  

 

18. Confidentiality and Confidential Information “Confidential Information” means any information (whether in written, electronic or any other form) in respect of the business and affairs of the Company and its clients, products, research and development projects, customers and suppliers that is not in the public domain including, without limitation, any document, record, computer file, customer or client information, product or service information, sales or financial information, project, contract, deal, discovery, invention, drawing, design, strategy, plan, data, report, process, proposal, budget, idea, formula, concept or know how.
     
  Confidential Information includes, but is not limited to:
     
  i. trade secrets, financial information, designs, formulae, patterns, know-how, devices, inventions, secret or unpatented inventions, research, development, processes, techniques, machines, the identity and requirements of customers, the identity of suppliers and vendors, information received by the Company from third parties under obligation of confidentiality, strategic or financial plans, product pipeline information, financial data, sales and marketing plans and information, and compilations of information, records, and specifications used by the Company;
     
  ii. information about the identity, contact details or requirements of the Company’s clients, prospective clients, suppliers or prospective suppliers;
     
  iii. information belonging to, or concerning clients of the Company;
     
  iv. any agreements, arrangements or terms of trade with a client, prospective client, supplier or prospective supplier;
     
  v. the Company’s contractual, technical and production information; and
     
  vi. the Company’s marketing plans, and marketing and sales techniques.
     
  Confidential Information does not lose its confidential status merely because it was known by a limited number of persons or entities or because it did not originate entirely with the Company.
     
  Confidential information also extends to the contents of this Agreement, including the Employee’s remuneration details.
   
  Unless the Employee is authorised to do so by law, the Employee is not to divulge any information the Employee obtains as a consequence of and in the course of the Employee’s employment to any other third party, including to the media or the public generally, except and unless it is of a general nature and of general knowledge and the Employee does so as a consequence of the performance of the Employee’s responsibilities.
     
  All knowledge and/or information, written or otherwise, related to the activities of the Company, including MyFiziq joint ventures, partners and customers, obtained by the Employee as a consequence and in the course of the Employee’s employment becomes the property of the Company, and unless otherwise authorized during the term of the Employee’s employment or thereafter, must not be divulged to any other source.

 

Page 8 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

  Upon cessation of the Employee’s employment with the Company, the Employee must return all papers, records, documents (including hard copy and digital copies) and any equipment that are in the Employee’s possession or control and relate to any of the foregoing.
     
  The Employee represents and warrants to MyFiziq that there are no other agreements, written or oral, that would restrict the employee’s ability to perform the basic functions of the Employee’s job, including but not limited to non-compete, non-disclosure or similar agreements with prior employers. If there are such agreements, the Employee agree to immediately provide the Company with a copy of any such agreements(s) for the Company’s review. The Employee further agrees not to bring to the Company, use or disclose any trade secrets or other confidential / proprietary information of prior employers.
     
  The Employee agrees that they will not use, copy, transfer, destroy or remove from the Company’s premises, any Confidential Information without the prior written consent of the Company. This includes the use, copy, transfer, destruction or removal of Confidential Information at non-Company premises including the Employee’s home.
     
  Without limiting the above provisions, the Employee must not license or otherwise exploit, directly or indirectly, any products or services which embody or are derived from Confidential Information without the prior written consent of the Company.
     
  The Employee agrees the provisions of this clause survive cessation of the Employee’s employment with the Company.

  

  The Employee must comply with the Privacy Act 1988 (Cth) in respect of all personal information that comes into the possession or control of the Employee, or which the Employee accesses, during the course of the Employee’s employment in the Position.
     
19. Privacy A notice under this Agreement may be given by hand delivery, post or email, using the address specified at the top of the first page of this Agreement, or the email address for the recipient’s representative specified in the Schedule, or such other latest address as a party may have provided to the Company during the course of employment.
     
20. Notices ii. Any notice issued by hand shall be deemed delivered upon delivery.
     
  iii. Any notice issued by post shall be deemed delivered 3 Business Days after posting if posted domestically, or 10 business days after posting if posted internationally.
     
  iv. Any notice issued via email shall be deemed to be delivered upon the email being sent, provided that if an email is sent out of business hours, it shall be deemed to be delivered at 9am on the next business day.
   
21. General Amendment: This Agreement may only be amended by a written document signed by the parties.

 

Page 9 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

  Assignment: The Employee agrees and acknowledges that the Company may assign this Agreement to a related body corporate of the Company, or to an acquirer of the business of the Company upon notice to the Employee.
     
  Severability: If any provision of this Agreement is deemed invalid by a court of competent jurisdiction, the remainder of this Agreement shall remain enforceable.
  Counterparts: This Agreement may be executed in counterparts provided that no binding agreement shall be reached until the executed counterparts are exchanged.
     
  Entire Agreement: This Agreement constitutes the entire agreement between the parties and to the extent possible by law, supersedes all prior understandings, representations, arrangements and agreements between the parties regarding its subject matter.
     
  Jurisdiction: This Agreement will be interpreted in accordance with the laws in force in Westem Australia. The parties irrevocably submit to the non-exclusive jurisdiction of the courts situated in Westem Australia.
     
  Legal advice: The Employee acknowledges that they have had a reasonable opportunity to obtain independent legal advice regarding the contents of this Agreement prior to entering into this Agreement and has either obtained that advice or elected not to obtain it.
     
  Flexible Working Arrangements: if eligible, the Employee may request flexible working arrangements. The Company may refuse a request on reasonable business grounds.
     
  Fair Work Information Statement: The Employee acknowledges receipt of the Fair Work Information Statement annexed to this Agreement marked “Annexure A”.
     
22. Interpretation In this Agreement:
     
  i. Headings and underlining are for convenience only and do not affect the construction of this Agreement.
     
  ii. A provision of this Agreement will not be interpreted against a party because the party prepared or was responsible for the preparation of the provision, or because the party’s legal representative prepared the provision.
     
  iii. Currency refers to Australian Dollars.
     
  iv. A reference to a statute or regulation includes amendments thereto.
     
  v. A reference to a clause, subclause or paragraph is a reference to a clause, subclause or paragraph of this Agreement.
     
  vi. A reference to a subclause or paragraph is a reference to the subclause or paragraph in the clause in which the reference is made.
     
  vii. The recitals are correct and form part of this Agreement.
     
  viii. A reference to time is to time in Westem Australia.
     
  ix. A reference to a person includes a reference to an individual, a partnership, a company, a joint venture, government body, government department, and any other legal entity.\
     
  x. The words “includes”, “including” and similar expressions are not words of limitation.

  

Page 10 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

  

Steven, we look forward to your engagement with our Company at this very exciting stage.

 

Signed as an agreement.

 

Signed for and on behalf of the Company by its authorised representatives:

 

/s/ Vlado Bosanac   /s/ Vlado Bosanac 
CEO and CO-Founder   Signature
     
Signed by:    
     
/s/ Stcuco R.,charos   /s/ Stcuco R.,charos
Name of Employee   Signature
     
   
Name of Witness   Signature Witness

  

Page 11 of 13

  

MYFIZIQ EMPLOYMENT AGREEMENT  

 

Annexure A - See enclosed Fair Work Information Statement

 

 

Page 12 of 13

 

MYFIZIQ EMPLOYMENT AGREEMENT  

 

 

 

Page 13 of 13

 

Exhibit 10.5

 

my Suite 5
Fiziq 71-73 South Perth Esplanade
  South Petth j 6151 f WA
  ABN 85 602111 115
   
  MyFlzlq.com

 

1 April 2016

 

Mr David Tabb

15 Scouler Way

Bateman, WA 6150

 

Dear David,

 

Offer of New Appointment - Operations Manager

 

On behalf of MyFiziq Limited (“MYQ” or the “Company”), I am pleased to continue your permanent employment position in the new role of Operations Manager.

 

this offer is conditional upon your acceptance and agreement to abide by the terms and conditions outlined in this letter.

  

1. Reporting & Responsibllitles: You will oversee all aspects of the Company’s business operations as well as manage projects, customer accounts and strategic partnerships, while also providing direct assistance to the CEO, including but not limited to:
       
    i. Oversee day-to-day operations and keep the CEO apprised of significant events
    ii. Manage the day-to-day planning, development and delivery of projects and proposals
    iii. Improve the operational systems, processes and policies in support of corporate goals
    iv. Communicating strategy, policy and procedures to employees
    v. Maintain customer confidence and protect operations by keeping information confidential
    vi. Manage relationships with key customers and ambassadors
    vii. Develop good relations and maintainexcellent communication channels both internally and externally
    viii. Work together with the CEO, BO and internal team members and partners to co-ordinate the preparation, writing and communicaitons support of viable bids and proposals
    ix. Work with the team’s Marketing Manager to co-ordinating marketing and communication strategies for new and prospective white-label applications and ambassadors
    x. Playing a significant role in long-term planning
       
2. Commencement Date: 4 April 2016.  
       
3. Title Operations Manager (“OM”)

 

Corporate Address: Suite S, 71 - 73 South Perth Esplanade, South Perth WA 6151

admln@)myfizlq.com

 

 

 

 

4.

Compensaiton: The revised salary will be $105.000 per annum, paid fortnightly and exclusive of a 9.50% superannuation contribution by MYQ to a superannuation fund nominated by you. The compensation package will be subject to annual review by the Company, however we will provide an interim review after the first six months of employment. The minimum working week is 37.5 hours, with no provision for over-time however, the Company will grant you time in lieu in the event the Company considers (at its discretion) you are working consistently above the normal working week.
       
5. Expenses: You will be reimbursed all reasonable expenses supported by official receipts for payments made on behalf of the Company whilst carrying out your duties provided however that any individual expense exceeding $200 must not be incurred without the prior written consent of the Company.
       
    You must provide all proper documentation to the Company to verify such expenses prior to reimbursement. You must comply with all lawful directions of the Company in relation to incurring expenses on behalf of the Company and shall not in any way pledge the credit of the Company except insofar as you may have been expressly authorised by the Company either generally or in any particular incidence.
       
6. Appointment Basis: Full time position.
       
    As a professional qualified employee, you are required to exercise your specialized expertise, independent judgment and discretion to provide highquality services and are expected to work the number of hours required to get the job done.
       
7. Tenure and Review: The appointment basis is full time / permanent and a continuation of your initial employment term.
       
    The Company has appointed you as Operations Manager and you agree to accept the appointment and the tenure on the terms and conditions set out in this agreement.
       
    Your engagement under this agreement will be reviewed on the six month anniversary of this letter and thereafter on or before 1 April of each year. The Review will include such matters determined by the Board, and will include, but is not limited to:

 

    i.

your performance during the period prior to the review (including against

performance indicators set by the CEO or the Board);

    ii. the performance of the Company during the period prior to the review; and
    iii. your remuneration relative to economic conditions prevailing in the state of Western Australia and similar positions offered in the market.
     

7.1 TerminationWithout Cause:  
  i. The Company may terminate this agreement without reason by providing you with the greater of; one months’ written notice or one month for each year or part year of employment served or, by paying you  a  cash payment equal to the greater of; one month’s salary or  one  month’s salary for each full or partial year of employment completed.
         
    ii. You may terminate your engagement  with the Company without reason by providing the Company with not less than one (1) month written notice, unless the Board otherwise agrees (at its discretion).

  

MyFiziq Limited

Page 2 of 6

 

  

8. Price Sensitive Information: You acknowledge that in the course of carrying out the services pursuant to this agreement you may receive confidential information, including “price sensitive information” (as per the Corporations Act) affecting the Company. Any disclosure, communication, use or misuse of price sensitive information may have very serious implications for the Company and/or you, including possible criminal prosecution and possible civil actions against you. You acknowledge that the Company has the right to terminate this agreement without notice if you disclose, communicate, use or misuse price sensitive information without the prior written consent of the Board except to the extent that you are required by law to disclose, communicate or use it.
         
9. Annual Leave: Annual leave is accrued at a rate of 20 working days per annum, a working day being exclusive of recognized public holidays. Your annual leave may be taken once it is accrued, at any time mutually acceptable to yourself and the Company. Accrued leave shall not accumulate in excess of 30 working days without written approval of the Board. A waiver may be granted under special circumstances at the Board’s discretion.
         
10. Sick Leave, Sick Leave
  Compassionate Leave and Carer’s Leave: You are entitled to paid sick leave equivalent to the number of hours you would ordinarily work in a two week period, up to a maximum of 76 hours per year. No payment will be made for unused sick leave following resignation or termination. Claims for sick leave taken in excess of two days must be supported by a medical certificate.
         
    Compassionate Leave
    You are entitled to two days paid compassionate leave:
    i. if a member of your immediate family or household requires care or support due to an illness or injury; or
    ii. in the event of an unexpected emergency involving a member of your immediate family or household.
         
    Carer’s Leave
    You are entitled to two days unpaid carer’s leave:
    i. if a member of your immediate family or household has an illness or injury that poses a serious threat to their life; or
    ii. in the event of the death of a member of your immediate family or household.
         
 11. Long Service Leave: You are entitled to long service leave in accordance with the provisions of the Long Service Leave Act 1958 (WA).
         
12. Proprietary Information and Inventions: 12.1 Definitionsof IP
         
    IP means all industrial and intellectual property rights whether protectable by statute, at common law or in equity, including all copyright and similar rights which may subsist or may hereafter subsist in works or any subject matter, rights in relation to inventions (including all patents and patent applications), trade secrets and know-how, rights in relation to designs (whether or not registrable), rights in relation to registered or unregistered trade marks, circuit layout designs and rights in relation to circuit layouts, whether registered, registrable or unregistered, including:
         
    i. marks, logos, service marks, trade names, business names, internet domain names, slogans, symbols, brand names, copyright or other trade indicia;
    ii. all rights in information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, designs, drawings, trade secrets or data whether or not protectable by patent application design registration, copyright, whether unregistered, registered or registrable; and
    iii. any modifications , developments , adaptations , advancements , creations and derivations of any intellectual property,
         
    but excludes non-assignable moral rights and similar non-assignable personal rights of authors and producers.

 

MyFiziq Limited

Page 3 of 6

 

 

  12.2  Current & New
       
    i. As a condition of employment, you represent and warrant that you will immediately communicate to the Company any new and all new literary and other new works and new subject matter including all new works, new processes, new inventions, new improvements, new innovations, new modifications, new designs, new discoveries, new trademarks and new trade secrets, however embodied, which you may make either alone or in conjunction with others during the course of, in connection with or arising out of your employment and in any way connected with matters specifically pertaining to the business and assets of MyFiziq for which the Company has been or is now or hereafter Interested during your employment (“Inventions”).
    ii. Any new inventions or extension of the IP surrounding MyFiziq, whether or not the Inventions are capable of being protected by copyright, letters patent, registered design or other protection (M P rotection ” ), will be solely owned by the Company for development.
    iii. Any new inventions, whether or not the Inventions are capable of being commercialised or able of Protection outside of those of MyFiziq will be first offered to the Company for first right of refusal. Further proceedings will only go forward if agreed by both you and the Company.
         
    12.3 Co-operation In obtaining Protection for Inventions
         
    i. If and whenever required to do so whether during or after termination of your employment, and at the expense of the Company or its nominee, you will apply or join in applying for letters patent or other similar protection in Australia or in any other part of the world for content specifically pertaining to MyFiziq. You will Immediately deliver to the Company full particulars concerning these matters and execute all instruments and do all things necessary for vesting the letters patent or other Protection when obtained, and all right and title to and interest in the same, in the Company or its nominee absolutely and as sole beneficial owner or in such other person as the Board requires.
    ii. You appoint the Company to be your attorney in your name and on your behalf to execute any such instrument or thing and generally to use your name for the purpose of giving to the Company or its nominee the full benefit of the provisions of this clause.

 

MyFiziq Limited

Page 4 of 6

 

 

 

12.4 Information
       
  Without limiting the generality of the above, and subject to not breaching any laws or breaching any other contractual obligations in existence or arising from time to time, you represent and warrant that:
  i. you will immediately inform the Company of any matter which may come to your notice during the Employment which may reasonably be of interest or of any importance or use to the Company or its Subsidiaries and Related Corporations for content specifically pertaining to MyFiziq;
  ii. you will immediately communicate to the Company any proposals or suggestions occurring to you during your employment which may reasonably be of service for the furtherance of the business of the Company for content specifically pertaining to MyFiziq.
       
  You agree the provisions of this clause survive termination of this agreement.
       
13. Confidentiality: Unless you are authorized to do so by law. you are not to divulge any information you obtain as a result of your appointment either to the media,  the public generally or to any other third party, except and unless it is of a general nature and of general knowledge and you do so as a consequence of the performance of your responsibilities. All knowledge and/or information, written or otherwise, related to the activities of the Company obtained by you as a consequence and in the course of your employment becomes the property of the Company, and unless otherwise authorized during the term of your employment or thereafter, must not be divulged to any other source. Upon termination of your services with the Company you must return all papers, records, documents (including hard copy and digital copies) and any equipment that are in your possession or control and relate to any of the foregoing.
       
  Confidential information also extends to the contents of this letter and in particular to employee’s remuneration details.  You represent and warrant to us that there are no other agreements, written or oral, that would restrict your ability to perform the basic functions of your job, including but not limited to non-compete, non disclosure or similar agreements with prior employers. If there are such agreements, you agree to immediately provide the Company with a copy of any such agreements(s) for  its review.  You further agree not to bring to  the Company, use or disclose any trade secrets or other confidential/proprietary information of prior employers.
       
  You agree the provisions of this clause survive termination of this agreement.
       
14. Governing Law: This agreement is intended to give rise to legal rights and obligations and constitutes a binding agreement between the parties. This agreement shall be governed by and construed in accordance with the law from time to time in the State of Western Australia and the parties agree to submit to the nonexclusive jurisdiction of the courts of Western Australia and the courts which hear appeals there from.
       
15. Variation: No modification or alteration of the terms of this agreement shall be binding unless made in writing dated subsequent to the date of this agreement and duly executed by the parties.

 

MyFiziq Limited

Page 5 of 6

 

 

 

16. Acceptance : Please indicate your acceptance of the above offer under the above terms and conditions by signing the duplicate copy of the offer and returning to the Company.
     

David, we look forward to your continued engagement with our Company in this new position.

 

Yours sincerely  
   
/s/ Katherine lscoe  
Katherine lscoe  
Executive Director and Chief Executive Officer MyFlzlq Limited  

 

I accept the offer of employment under the above terms and conditions and agree to abide by the policies and procedures of the Company.

 

signature /s/ David Tabb   Date: /4/2016.
  David Tabb      

 

 

MyFiziq Limited Page 6 of 6

 

 

 

Exhibit 10.6

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

Date of Agreement 30/11/2018

 

PARTIES

 

Myf iziq Limited, ABN 85 602 111 115 of Suite 5, 71-73 South Perth Esplanade, South Perth, Western Australia, 6151 (“MyFiziq”, “MYQ” or the “Company”), Terence Stupple of 23 Doon Way, Hamersley, WA, 6022 (the “Employee”).

 

RECITALS

 

The Company wishes to employ the Employee on a permanent full-time basis in the Position, and the Employee wishes to be employed by the Company in the Position on that basis, on the following terms and conditions (“Agreement”).

 

THE PARTIES AGREE AS FOLLOWS:

 

1. Position Chief Technology Officer
       
2. Commencement Date New Contract commencement date 2nd January 2019.
       
3. Manager CEO Vlado Bosanac
       
4. Reporting & Responsibilities i. Develop and lead the Company’s strategic technical direction, stay on top of emerging technologies, as well as understand the best uses for existing languages and frameworks.
    ii. Play a significant part in attracting, identifying and recruiting talented and motivated technical staff into the organization in support of the Company’s strategic technical direction.
    iii. Assist in developing and fostering a rewarding and encompassing culture that will help retain staff and fend off outside poaching from competitors.
    iv. Manage the technical team and collaborate with vendors that supply product resources.
    v. Implement technologies and develop strategies to enhance Company products, with focus on customers, end products and increasing revenue.
    vi. Any other activities as directed by the Employees Manager.

 

5. Compensation The commencing salary will be $240,000 per annum, paid fortnightly and exclusive of a 9.50% superannuation contribution by MYQ to a superannuation fund nominated by the Employee. The maximum ordinary working week is 37.5 hours, with no provision for over-time. Any overtime must be prior approved in writing by your Manager.
     
6. Expenses The Employee will be reimbursedall reasonable expenses supported by official receipts for payments made on behalf of the Company whilst carrying out the Employee’s duties provided, however, that any individualexpense exceeding $200 must not be incurred without the prior written consent of the Company.
     
    The Employee must provide all proper documentation to the Company to verify such expenses prior to reimbursement. The Employee must comply with all lawful directions of the Company in relation to incurring expenses on behalf of the Company, and shall not in any way pledge the credit of the Company except insofar as the Employee may have been expressly authorised by the Company either generally or in any particular incidence.

 

Page 1 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

7. Appointment Basis Full-time position.
     
   

As a professional qualified Employee, the Employee is required to exercise their specialised expertise, independent judgment and discretion to provide high-quality services and fulfill all reasonable work-related demands and requirements.

 

The Employee must comply with all lawful instructions given to them by their Manager, and any delegate of their Manager, and any policies instituted by the Company from time to time. The Company’s policies do not form part of this Agreement and do not give rise to any contractual rights for the Employee.

 

The Company may modify any of its policies at any time.

 

In the course of performing the Employee’s duties in the Position, the Employee shall use their best endeavors to promote, develop and protect the business interests and welfare of the Company.

 

The Employee must not do anything which is harmful to the reputation or interests of the Company.

 

The Employee must work in a lawful, professional and competent manner and provide faithful service, and act in good faith in all its dealings with and on behalf of the Company.

 

8. Qualifications

The Employee warrants to the Company that they hold the qualifications and have the experience set out in their curriculum vitae provided to the Company prior to the Commencement Date, and that all information provided to the Company by the Employee in that curriculum vitae and in any employment application and/or in any job interview, is truthful, accurate, correct and complete.

 

The Employee warrants that in entering into this Agreement they will not be in breach of any obligations owed to any third parties.

  

9. Tenure and Review The Employee warrants that they have not entered into, and will not enter into any agreement, that conflicts with their obligations owed to the Company under this Agreement.
     
9.1 Probation Period

The Company has appointed the Employee into the Position, and the Employee agrees to accept the appointment and the tenure, on the terms and conditions set out in this Agreement.

 

The Employee’s employment with the Company is subject to a six (6) month Probation Period from the Commencement Date of this agreement.

 

On and from the Commencement Date and during the Probation Period, either party may terminate this Agreement by providing the other with not less than two (2) weeks’ notice in writing. This clause does not affect the Company’s right to terminate the Agreement without notice in the event of serious misconduct by the Employee.

 

Page 2 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

9.2 Employment Review

The Company will use its best endeavours to have the Employee’s engagement under this Agreement reviewed at the end of the Probation Period, and thereafter on or before 31 August each year. The Review will include such matters as determined by the Board, and may include,

 

    i. the Employee’s performance during the period prior to the review (including against performance indicators set by the CEO or the Board);
    ii. the performance of the Company during the period prior to the review; and
    iii. the Employee’s remuneration relative to economic conditions prevailing in the state of Western Australia and similar positions offered in the market.

 

9.3 Termination i. After the Probation Period, either party may at any time terminate this Agreement by providing the other with four (4) weeks’ prior written notice (“Notice Period”). The Company may choose, in lieu of requiring the Employee to work out the Notice Period, to make a payment to the Employee of an amount equivalent to the Employee’s Remuneration, pro rated for the Notice Period, or such higher amount prescribed by applicable legislation.
    ii. If at the time of termination by the Company the Employee has completed two years’ service and is aged over 45, the Employee will receive one (1) additional week of notice.
    iii. The Company shall not be required to provide any notice to the Employee in the case of dismissal for serious misconduct.
    iv. On cessation or termination of employment, the Employee is entitled to payment in lieu of the annual leave to which the Employee has become entitled during his or her employment with the Company, but which he or she has not taken.
    v. Upon cessation of the Employee’s employment with the Company, the Employee must deliver-up and/or destroy (as required by the Company), all and any Confidential Information and other property of the Company in the possession or control of the Employee, whether in hard copy or held in electronic form or otherwise.
    vi. Before and after cessation of the Employee’s employment with the Company, the Employee must not make any derogatory remark or statement about the Company or its personnel or any other remark or statement which may damage the reputation or goodwill of the Company.
    vii. Termination does not affect any accrued rights of either party.

 

10. Restrictions and Restraints of trade

In the interest of being fair and reasonable, MyFiziq is not looking to restrain the Employee from working in their respective field(s) post-employment with MyFiziq. MyFiziq is only seeking to restrict the Employee from being poached or moving to a competitor and assisting in creating any product that directly competes with MyFiziq for a period after employment with MyFiziq.

     
10.1 Restriction on Activities On and from the Effective Date until the Employee’s employment ends in accordance with the Employee’s Employment Contract, or pursuant to applicable law, the Employee must work full-time for the Company, and without the prior written consent of the Company must not:

 

    i. work in, on or for any other business; or

 

    commence, operate, invest directly or indirectly in, or obtain an interest in, any business that is in competition with the Company (provided that this clause shall not prevent the Employee from holding up to 10% of the sharehold ing in a publicly-listed company).

 

Page 3 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

10.2 Restraint Period and Area The Restra int Period is as follows :

 

    i. twelve (12) months; or
    ii. if a court finds twelve (12) months unreasonable, nine (9) months; or
    iii. if a court finds nine (9) months unreasonable, six (6) months; or
    iv. if a court finds six (6) months unreasonable, three (3) months.
       
    The Restraint Area is as follows:
       
    i. All MyFiziq patented countries; currently USA and Australia, this will expand to further countries as new patents are received; or
    ii. if a court finds all MyFiziq patented countries unreasonable, Asia Pacific countries1. or
    iii. if a court finds Asia Pacific countries unreasonable, Australia.

 

11. IT Devices If the Employee is provided by the Company with access to, or possession of, any computer, smartphone device or other equipment for the use by the Employee, the Employee must take reasonable care to keep such devices and equipment secure and protected. The loss of any such device must be immediately reported by the Employee to the Company.
     
12. Surveillance The Employee’s use of the Company’s information technology systems and email accounts will be subject to ongoing and continuous surveillance. Such surveillance will be conducted from the Commencement Date and at all times thereafter during the term of the Employee’s employment with the Company.
     
    The Employee agrees and acknowledges that the Company may monitor and record all usage of any computer, smartphone device and/or e-mail address allocated to the Employee by the Company, and the Employee consents to the monitoring of all such devices and addresses.
     
    The Employee further agrees and acknowledges that all e-mails and any files and other data transmitted by the Employee using any computer, smartphone device or email address allocated to the Employee, are the sole property of the Company.
     
13. Price Sensitive Information The Employee acknowledges that in the course of carrying out the services pursuant to this Agreement the Employee may receive Confidential Information, including “Price Sensitive Information” (as per the Corporations Act 2001 (Cwth)) affecting the Company. Any disclosure, communication, or misuse of Price Sensitive Information may have very serious implications for the Company and/or the Employee, including possible criminal prosecution and possible civil actions against the Employee.
     
    The Employee acknowledges that the Company has the right to terminate this Agreement without notice if the Employee discloses, communicates, or misuses Price Sensitive Information in the absence of the prior written consent of the Board, except to the extent that the Employee is required by law to disclose, communicate or use it.
 
14. Annual Leave Annual leave accrues progressively at a rate of 20 days per annum. The Employee’s annual leave may be taken once it is accrued at any time mutually acceptable to the Employee and the Company. Accrued annual leave should not accumulate in excess of 30 working days. If you reach this number of accrued annual leave days, the Company may direct you to take annual leave in accordance with the Fair Work Act 2009.

 

 

1 For clari ty Asia Pacific countries include countries in geographic regions Asia and Oceania as defined by the United Nations: https:l /unstats.un.org/unsd/methodology/m49/

 

Page 4 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

15. Personal/Carer’s Leave and Compassionate Leave Paid personal/carer’s leave accrues progressively at a rate of 10 working days per annum. The Employee’s personal/carer’s leave may be taken once it is accrued. No payment will be made for unused personal/carer’s leave following cessation of employment.
     
   

An Employee may take personal leave when he or she is ill or injured and unfit for work.

 

An Employee may take carer’s leave when he or she is required to provide care or support to a member of his or her immediate family or household who is ill, or injured, or experiencing an unexpected emergency.

 

The Company requires production of suitable evidence in support of any personal/carer’s leave absence.

 

Unpaid Carer’s Leave

The Employee is entitled to two days’ unpaid carer’s leave on each occasion such leave is required, provided the Employee’s paid personal/carer’s leave balance has been exhausted.

 

Compassionate Leave

The Employee is entitled to two days’ paid compassionate leave if a member of the Employee’s immediate family or household:

 

    i. experiences a life-threatening illness or injury; or
    ii. passes away.

  

16. Long Service Leave and Other Leave The Employee is entitled to long service leave in accordance with the provisions of the Long SeNice Leave Act 1958 (WA). The Employee will be entitled to all other forms of leave provided by the Fair Work Act 2009.

 

17. Proprietary Information and Inventions

 

17. 1 Meaning of “Intellectual Property” “Intellectual Property “ (“IP”) means all industrial and intellectual property rights whether protectable by statute, at common law or in equity, including all copyright and similar rights which may subsist or may hereafter subsist in works or any subject matter, rights in relation to inventions (including all patents and patent applications), trade secrets and know-how, rights in relation to designs (whether or not registrable), rights in relation to registered or unregistered trademarks, circuit layout designs and rights in relation to circuit layouts, whether registered, registrable or unregistered, including:

 

    i. marks, logos, service marks, trade names, business names, internet domain names, slogans, symbols, brand names, copyright or other trade indicia;
    ii. all rights in information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, designs, drawings, trade secrets or data whether or not protectable by patent application design registration, copyright, whether unregistered, registered or registrable; and
    iii. anymodification,sdevelopments, adaptations, advancements, creations and derivations of any intellectual property,

 

    but excludes non-assignable moral rights and similar non-assignable personal rights of authors and producers.
       

Page 5 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

17.2. Current & New i. As a condition of employment, the Employee represents and warrants that they will immediately communicate to the Company any and all new literary and other new works and new subject matter including all new works, new processes, new inventions, new improvements, new innovations, new modifications, new designs, new discoveries, new trademarks and new trade secrets, however embodied, which the Employee may make either alone or in conjunction with others during the course of, in connection with or acising out of the Employee’s employment and in any way connected with matters specifically pertaining to the business and assets of MyFiziq, including MyFiziq joint ventures, partners and customers, for which the Company has been or is now or hereafter interested during the Employee’s employment (“Inventions”).
    ii. Any new Inventions or extension of the IP surrounding MyFiziq, including MyFiziq joint ventures, partners and customers, whether or not the Inventions are capable of being protected by copyright, letters patent, registered design or other protection (“Protection”), will be solely owned by the Company for development.
    iii. Any new Inventions, whether or not the Inventions are capable of being commercialised or able of Protection outside of those of MyFiziq, including MyFiziq joint ventures, partners and customers, will be first offered to the Company for first right of refusal. Further proceedings will only go forward if agreed by both the Employee and the Company.

 

17.3 Co-operation in Obtaining Protection for Inventions i. If and whenever required to do so whether during or after cessation of the Employee’s employment, and at the expense of the Company or its nominee, the Employee will apply or join in applying for letters patent or other similar protection in Australia or in any other part of the world for content specifically pertaining to MyFiziq, including MyFiziq joint ventures, partners and customers where required. The Employee will immediately deliver-up to the Company full particulars concerning these matters and execute all instruments and do all things necessary for vesting the letters patent or other Protection when obtained, and all right and title to and interest in the same, in the Company or its nominee absolutely and as sole beneficial owner or in such other person as the Board requires.
    ii. The Employee appoints the Company to be their attorney in the Employee’s name and on the Employee’s behalf to execute any such instrument or thing and generally to use the Employee’s name for the purpose of giving to the Company or its nominee the full benefit of the provisions of this clause.

 

17.4 Information Without limiting the generality of the above, and subject to not breaching any laws or breaching any other contractual obligations in existence or arising from time to time, the Employee represents and warrants that:

 

    i. the Employee will immediately inform the Company of any matter which may come to the Employee’s notice during the Employmenwt hich may reasonably be of interest or of any importance or use to the Company or its Subsidiaries and Related Corporations for content specifically pertaining to MyFiziq, including MyFiziq joint ventures, partners and customers;
    ii. the Employee will immediately communicate to the Company any proposals or suggestions occurring to the Employee during the Employee’s employment which may reasonably serve to further the business of the Company for content specifically pertaining to MyFiziq including MyFiziq joint ventures, partners and customers.
       
    The Employee agrees the provisions of this clause survive the cessation of the Employee’s employment with the Company.

 

Page 6 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

18 Confident iality and Confidential Information “Confidential Information” means any information (whether in written, electronic or any other form) in respect o-f the business and affairs of the Company and its clients, products, research and development projects, customers and suppliers that is not in the public domain including, without limitation, any document, record, computer file, customer or client information, product or service information, sales or financial information, project, contract, deal, discovery, invention, drawing, design, strategy, plan, data, report, process, proposal, budget, idea, formula, concept or know how.
     
    Confidential Information includes, but is not limited to:

 

  i. trade secrets, financial information, designs, formulae, patterns, know-how, devices, inventions, secret or unpatented inventions, research, development, processes, techniques, machines, the identity and requirements of customers, the identity of suppliers and vendors, information received by the Company from third parties under obligation of confidentiality, strategic or financial plans, product pipeline information, financial data, sales and marketing plans and information, and compilations of information, records, and specifications used by the Company;
  ii. information about the identity, contact details or requirements of the Company’s clients, prospective clients, suppliers or prospective suppliers;
  iii. information belonging to, or concerning clients of the Company;
  iv. any agreements, arrangements or terms of trade with a client, prospective client, supplier or prospective supplier;
  v. the Company’s contractual, technical and production information; and
  vi. the Company’s marketing plans, and marketing and sales techniques.
     
 

Confidential Information does not lose its confidential status merely because it was known by a limited number of persons or entities or because it did not originate entirely with the Company.

 

Confidential information also extends to the contents of this Agreement, including the Employee’s remuneration details.

 

Unless the Employee is authorised to do so by law, the Employee is not to divulge any information the Employee obtains as a consequence of and in the course of the Employee’s employment to any other third party, including to the media or the public generally, except and unless it is of a general nature and of general knowledge and the Employee does so as a consequence of the performance of the Employee’s responsibilities.

 

All knowledge and/or information, written or otherwise, related to the activities of the Company, including MyFiziq joint ventures, partners and customers, obtained by the Employee as a consequence and in the course of the Employee’s employment becomes the property of the Company, and unless otherwise authorized during the term of the Employee’s employment or thereafter, must not be divulged to any other source.

 

Page 7 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

   

Upon cessation of the Employee’s employment with the Company, the Employee must return all papers, records, documents (including hard copy and digital copies) and any equipment that are in the Employee’s possession or control and relate to any of the foregoing.

 

The Employee represents and warrants to MyFiziq that there are no other agreements, written or oral, that would restrict the employee’s ability to perform the basic functions of the Employee’s job, including but not limited to non-compete, non disclosure or similar agreements with prior employers. If there are such agreements, the Employee agree to immediately provide the Company with a copy of any such agreements(s) for the Company’s review. The Employee further agrees not to bring to the Company, use or disclose any trade secrets or other confidential / proprietary information of prior employers.

 

The Employee agrees that they will not use, copy, transfer, destroy or remove from the Company’s premises, any Confidential Information without the prior written consent of the Company. This includes the use, copy, transfer, destruction or removal of Confidential Information at non-Company premises including the Employee’s home.

 

Without limiting the above provisions, the Employee must not license or otherwise exploit, directly or indirectly, any products or services which embody or are derived from Confidential Information without the prior written consent of the Company.

 

The Employee agrees the provisions of this clause survive cessation of the Employee’s employment with the Company.

     
19. Privacy The Employee must comply with the Privacy Act 1988 (Cth) in respect of all personal information that comes into the possession or control of the Employee, or which the Employee accesses, during the course of the Employee’s employment in the Position.

  

20. Notices i. A notice under this Agreement may be given by hand delivery, post or email, using the address specified at the top of the first page of this Agreement, or the email address for the recipient’s representative specified in the Schedule, or such other latest address as a party may have provided to the Company during the course of employment.
    ii. Any notice issued by hand shall be deemed delivered upon delivery.
    iii. Any notice issued by post shall be deemed delivered 3 Business Days after posting if posted domestically, or 10 business days after posting if posted internationally.
    iv. Any notice issued via email shall be deemed to be delivered upon the email being sent, provided that if an email is sent out of business hours, it shall be deemed to be delivered at 9am on the next business day.

 

Page 8 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

21. General

Amendment: This Agreement may only be amended by a written document signed by the parties.

 

Assignment: The Employee agrees and acknowledges that the Company may assign this Agreement to a related body corporate of the Company, or to an acquirer of the business of the Company upon notice to the Employee.

 

Severability: If any provision of this Agreement is deemed invalid by a court of competent jurisdiction, the remainder of this Agreement shall remain enforceable.

 

Counterparts: This Agreement may be executed in counterparts provided that no binding agreement shall be reached until the executed counterparts are exchanged.

 

Entire Agreement: This Agreement constitutes the entire agreement between the parties and to the extent possible by law, supersedes all prior understandings, representations, arrangements and agreements between the parties regarding its subject matter.

 

Jurisdiction: This Agreement will be interpreted in accordance with the laws in force in Western Australia. The parties irrevocably submit to the non-exclusive jurisdiction of the courts situated in Western Australia.

 

Legal advice: The Employee acknowledges that they have had a reasonable opportunity to obtain independent legal advice regarding the contents of this

 

Agreement prior to entering into this Agreement and has either obtained that advice or elected not to obtain it.

 

Flexible Working Arrangements: if eligible, the Employee may request flexible working arrangements. The Company may refuse a request on reasonable business grounds.

 

Fair Work Information Statement: The Employee acknowledges receipt of the Fair Work Information Statement annexed to this Agreement marked “Annexure A”.

 

22. Interpretation In this Agreement:
       
    i. Headings and underlining’s are for convenience only and do not affect the construction of this Agreement.
    ii. A provision of this Agreement will not be interpreted against a party because the party prepared or was responsible for the preparation of the provision, or because the party’s legal representative prepared the provision.
    iii. Currency refers to Australian Dollars.
    iv. A reference to a statute or regulation includes amendments thereto.
    v. A reference to a clause, subclause or paragraph is a reference to a clause, subclause or paragraph of this Agreement.
    vi. A reference to a subclause or paragraph is a reference to the subclause or paragraph in the clause in which the reference is made.

 

Page 9 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

    vii. The recitals are correct and form part of this Agreement.
    viii. A reference to time is to time in Western Australia.
    ix. A reference to a person includes a reference to an individua, la partnership, a company, a joint venture, government body, government department, and any other legal entity.
    X. The words “includes”, “including” and similar expressions are not words of limitation.

 

Te rence , we look forward to your engagement with our Company at this very exciting stage.

 

Signed as an agreement.

 

Signed for and on behalf of the Company by its authorise repr sentatives:

 

Vlado Bosanac   /s/ Vlado Bosanac
CEO and CO-Founder   Signature
     

 

Signed by:

 

     
Name of Employee   Signature
     
     
Name of Witness   Signature of Witness

 

Page 10 of 11

 

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

Annexure A- See enclosed Fair Work Information Statement

 

Page 11 of 11

 

Exhibit 10.7

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

Date of Agreement 01 of January 2021

 

PARTIES

 

MyFiziq Limited, ABN 85 602 111 115 of Suite 5, 71-73 South Perth Esplanade, South Perth, Western Australia, 6151 (“MyFiziq”, “MYQ” or the “Company”),

 

William Bradford of 1837 Tamarack Street, Westlake Village, CA 91361 (the “Employee”).

 

RECITALS

 

The Company wishes to employ the Employee on a permanent full-time basis in the Position, and the Employee wishes to be employed by the Company in the Position on that basis, on the following terms and conditions (“Agreement”).

 

THE PARTIES AGREE AS FOLLOWS:

 

1. Position Chief Business Officer
   
2. Commencement Date 19th of January 2021.
   
3. Manager CEO, Vlado Bosanac
   
4. Reporting & Responsibilities continuation  
 

i.       As set out in consultancy agreement dated 16th October 2019.

 

ii.       make introductions to a minimum of 4 Substantial Organisations (as defined in clause 3) per annum that result in execution by the Company of a binding agreement (whether term sheet or otherwise);

 

iii.      negotiate and procure agreements for the implementation of the MyFiziq technology;

 

iv.      work with the CEO and management to develop an agreed upon target list of Substantial Organisations;

 

v.       identifying new sales leads;

 

vi.       pitching the Company’s products and/or services;

 

vii.     maintaining fruitful relationships with existing US customers of the Company;

 

viii.    researching organisations and individuals online (especially on social media) to identify new leads and potential new markets for the Company;

 

ix.      contacting potential clients of the Company via email or phone to establish rapport and organize meetings;

 

x.       planning and overseeing new marketing initiatives for the Company;

 

Page 1 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

xi.      attending conferences, meetings, and industry events as a representative of the Company;

 

xii.     assisting the Company with the preparation of PowerPoint presentations and sales material;

 

xiii.    contacting clients of the Company to inform them about new developments in the Company’s products;

 

xiv.    developing pricing and proposals appropriate for individual Company client needs;

 

xv.     in the event of client testing, training personnel and helping team members develop their knowledge and technical efficiencies;

 

xvi.    assisting the Company in maintaining healthy relationships with clients; and

 

xvii.   writing reports and provide feedback to the CEO and senior management of the Company.

 

xviii.       Any other activities as directed by the Employees Manager.

   
5. Compensation The commencing salary will be USD$180,000 per annum, paid monthly. The maximum ordinary working week is 38 hours, with no provision for over-time. Any overtime must be prior approved in writing by your Manager.
   
5.1 Remuneration As part of the Employee’s remuneration package, the Company, subject to receipt of shareholder approval in general meeting, will:
   
 

 

i.       The company will maintain the agreement already in place with Tamaracj Media LLC and the shares to be issued under the criteria, previously agreed and set out.

 

ii.       In addition, MyFiziq will issue up to 1,000,000 Performance Rights to the Employee (or its nominee) on the terms set out in the Company Performance Rights Plan, which will include a separate Offer Letter to the Employee, as well as the Performance Rights to be issued at the key milestone’s below, which shall come with a 12 month escrow/ lock up period. The employee must complete a full year of service in the company to achieve the milestone for each consecutive year, and then be convertible into ordinary shares in the Company (on a one for one basis) as follows:

 

-  Milestone 1 – Execution of this Agreement, 250,000 Performance Rights; and

 

-   Milestone 2 – 12 months from the date this Agreement’s execution date, and provided the Employee is still employed by the Company, 250,000 Performance Rights; and

 

Page 2 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

  

  - Milestone 3 – 24 months from the date this Agreement’s execution date, and provided the Employee is still employed by the Company, 250,000 Performance Rights; and
   
  - Milestone 4 – 36 months from the date this Agreement’s execution date, and provided the Employee is still employed by the Company, 250,000 Performance Rights; and
   
 

3.1 Performance Rights

 

In consideration for the services to be provided by the Employee under this engagement, the Company will, issue up to 5,000,000 Performance Rights to the Employee (or its nominee) on the terms set out in Schedule 1 to this agreement which shall vest and be convertible into ordinary shares in the Company (on a one for one basis) as follows:

 

(a) every time the Company enters into a binding agreement (term sheet or otherwise) with a Substantial Organisation, 250,000 of the Performance Rights will vest; and

 

(b) in the event the Company has not entered into a minimum of four (4) binding agreements (term sheet or otherwise) with Substantial Organisations in every 12-month period, then, at the election of the Company, all remaining Performance Rights held by the Employee will lapse;

 

and:

 

(c) subject to paragraph (d) below, if the Mandate is validly terminated in accordance with its terms:

 

(i) any unvested Performance Rights shall remain in existence for a period of 12 months (Run Off Period);

 

(ii) in the event the Company is acquired, during the Run Off Period, by one of the Substantial Organisations that has been introduced by the Employee prior to the date of termination, then all unvested Performance Rights shall automatically vest;

 

(iii) the Employee will no longer be able to achieve vesting of any unvested Performance Rights by achieving the criteria set out in clause 3.1(a) (because the Employee will no longer be performing any services for the Company); and

 

(iv) at the end of the Run Off Period, all unvested Performance Rights shall automatically lapse, unless the period is extended by mutual agreement; and

 

(d) in the event the Company terminates this Mandate in accordance with clause 4.1, all unvested Performance Rights will automatically lapse.

 

Page 3 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

All shares and performance right are issued under the Australian capital structure and we be required to comply with any share split or reduction as undertaken by the company with the anticipated NASDAQ listing. These shares and performance rights will not be treated any differently to those of the current executive team.

 

For the purposes of this clause, a “Substantial Organisation” means any company or organisation that is introduced by the Employee or the Company agrees is a target and which company or organisation must, unless otherwise agreed to by the Company, have a minimum of 1.5m monthly active users or followers that results in an undertaking from the company or organisation to deliver a minimum of 500,000 paid active users / subscribers to the Company within the first 24 month contract period with the Company.

   
 

3.2 Out of Pocket Expenses

 

Under the terms and conditions of this Mandate, the Company will be responsible for all reasonable out-of-pocket expenses incurred by the employee during completing the Services. The Employee will require written consent from the Company prior to incurring expenses greater than USD$500.

 

3.3 Employee to pay all taxes etc

 

The remuneration set out in clause 3.1 is inclusive of all taxes and any taxes, levies, imposts, deductions, charges, withholdings and duties imposed by any authorities on any matter relating to or connected with the employment fee shall be for the account of the Employee and the Employee shall indemnify and hold the Company harmless against any liability for the same.

 

4. TERMINATION OF ENGAGEMENT

 

4.1 Termination without prior notice

 

The engagement with the Company may be terminated without notice if the Employee is guilty of serious misconduct, that is, misconduct of a kind such that it would be unreasonable to require the Company to continue the engagement during any notice period. Examples of such misconduct include if at any time the Employee:

 

(a) is affected by alcohol to a degree where, in the Company’s reasonable opinion, it cannot fully perform its duties;

 

(b) is convicted of any criminal offence other than an offence which in the reasonable opinion of the Company does not affect its position as employee to the Company;

 

(c) is guilty of any grave misconduct or wilful neglect in the discharge of its duties;

 

(d) commits any serious or persistent breach of any of the provisions contained in this agreement; or

 

(e) becomes of unsound mind or under the control of any committee or officer under any law relating to mental health.

 

Page 4 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

4.2 Termination with notice

 

The Company may terminate the engagement by giving 60 days written notice in the following situations:

 

(a) the Company deems in its sole and absolute discretion that the Employee’s services are no longer required, or the Employee’s performance is inadequate; or

 

(b) the Employee’s position becomes redundant.

 

4.3 Termination by the Employee

   
 

The Employee may terminate the engagement by giving at least 4 weeks’ written notice to the Company.

 

4.4 Effect of termination

 

Upon termination of the engagement with the Company:

 

(a) the Company’s and the Employee’s rights and obligations shall, subject to clauses 4.4(b) and 5, be at an end and the Company and the Employee shall be free of and discharged from all liabilities under this agreement except for the performance of those covenants and agreements (if any) which should have been performed prior to the termination of this agreement and all damages for breach of the same;

 

(b) the Employee shall immediately return to the Company all originals and copies of documents, records, notebooks and the like, in its possession, containing confidential information for the purposes of clause 5; and

 

(c) all unvested Performance Rights shall immediately lapse.

 

5. COVENANTS, REPRESENTATIONS AND WARRANTIES

 

5.1 Confidential Information

 

The Employee shall not, except as authorised by the Company or required by its duties, reveal to any person, any of the trade secrets, secret or confidential operations, processes or dealings or any information concerning the organisation, business, finances, transactions or affairs of the Company or any of its subsidiaries or related corporations (Confidential Information) which may come to its knowledge during its engagement and shall keep with complete secrecy all Confidential Information entrusted to it and shall not use or attempt to use any such information in any manner which may injure or cause loss, either directly or indirectly, to the Company or to the business carried on by the Company or which may be likely to do so. This restriction shall continue to apply after the termination of this agreement without limit in point of time but shall cease to apply to any information which may come into the public domain otherwise than as a result of breach of this clause.

 

5.2 Non-Competition

 

The Employee will not, and the Employee will do everything within its power to ensure the Approved Person does not, during the Term and for the period of 3 months from the expiry of the Term (unless otherwise approved in writing by the Company):

 

Page 5 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

(a) solicit the custom of, or accept or carry out any work for any of the clients, customers or suppliers of the Company; or

 

(b) employ or engage any person who was or in the 12 months prior to the expiry of the Term an employee, agent or contractor of the Company. The Company and the Employee acknowledge that the inclusion of this clause is to protect the goodwill of the Company and the income of the Company and any breach of this clause will cause significant loss and damage to the business of the Company and the Company may, if appropriate, seek injunctive relief. The parties further acknowledge that the restraint is reasonable in the circumstances.

 

   
 

5.3 Company Property

 

The Employee shall not, without the prior written consent of the Company, remove any property of the Company from the workplace and, for this purpose, the Employee acknowledges that, upon the Company forming a reasonable suspicion that the Employee may be removing company property from the workplace, the Company may, through its officers, employees or delegates, inspect the Employee’s personal property while it is on Company premises for security reasons.

 

5.4 Personal Belongings

 

The Employee agrees and acknowledges that all of its personal belongings, either in the office premises, in transit or on site, are not covered by the Company’s insurance.

 

5.5 Computer Software

 

The Employee acknowledges that the Company uses various computer software under licence which may not be reproduced or copied in any way, unless specifically approved by the Company.

 

6. PRICE SENSITIVE INFORMATION

 

6.1 Acknowledgment

 

The Employee acknowledges that in the course of carrying out the services as an employee to the Company, it may receive Confidential Information, including information which a reasonable person would expect to have a material effect on the price or value of securities of a body corporate and the expression “material effect on the price or value” will have the meaning given under section 1042D of the Corporations Act (Price Sensitive Information), affecting the Company and clients of the business. Any disclosure, communication, use or misuse of Price Sensitive Information may have very serious implications for the Company and for the Employee including, investigation by the Australian Securities and Investments Commission, possible criminal prosecution and possible civil actions.

 

6.2 Termination if Breach

 

The Employee acknowledges that the Company has the right to terminate the engagement without notice if the Employee discloses, communicates, uses or misuses Price Sensitive Information without the prior written consent of the Board except to the extent that the Employee is required by law to disclose, communicate or use it.

 

Page 6 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

7. COMPLIANCE WITH STATUTES

 

7.1 Compliance

 

The Employee acknowledges the existence of and agrees to comply with the following relevant laws during its engagement with the Company:

 

(a) workplace health and safety laws which, among other things, place a positive obligation on you as an employee to, among other things, comply with all safety instructions, use protective equipment and not wilfully place at risk the health and safety of others or yourself;

   
 

(b) anti-discrimination laws which prohibit, among other things, sexual harassment, racial discrimination, discrimination on the basis of marital status, age, pregnancy, political belief or activity, sex, trade union activity, impairment, lawful sexual activity, religion, breastfeeding and parental status;

 

(c) health laws which prohibit, among other things, causing premises to be a nuisance, injurious or prejudicial to public health or a workplace that is not in a clean state or that is not ventilated or overcrowded; and

 

(d) corporations laws which, among other things, place a positive obligation on officers of a corporation to act honestly and use reasonable care and diligence, not to make improper use of information acquired by virtue of their position, make improper use of their position to gain directly or indirectly an advantage for themselves or for any other person or to cause detriment to the corporation.

   
 

7.2 Notification

 

The Employee must immediately notify the Company of any event which may be or may lead to a breach of any law, including the laws set out at clause 7.1 above, of which it becomes aware or ought to be aware.

 

8. INSURANCE

 

8.1 Employee to maintain insurance

 

The Employee shall procure and maintain throughout the engagement at its own cost and expense the following insurances:

 

(a) workers’ compensation/employers’ indemnity insurance as required under any relevant laws;

 

(b) any additional insurance required by law.

 

Page 7 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

8.2 Insurers to be acceptable

 

All insurances pursuant to this clause 8 shall be effected within insurers approved by the Company on terms and conditions acceptable to the Company and the Employee shall upon request provide the Company with a copy of each policy.

 

9. INDEMNITY

 

9.1 By the Employee

 

The Employee will indemnify the Company and of its related bodies corporate to which they are providing services against all claims, losses, actions, damages, costs and expenses whether arising from personal injury or death or damage to property caused to any person including but not by way of limitation employees and other servants or agents of the Employee to the extent caused directly or indirectly by any negligent act or omission of the Employee or their sub-contractors or servants in breach of this agreement.

   
 

9.2 Survival of clause

 

The provisions of this clause 9 shall survive termination of this agreement as well as completion of any services performed under this agreement.

 

10. RELATIONSHIP

 

The relationship between the Company and the Employee is that of principal and contractor. Nothing in this agreement shall be taken as constituting the Employee an employee or servant of the Company or any of its related bodies corporate.

 

11. DELEGATION AND ASSIGNMENT

 

This agreement is personal to the parties and:

 

(a) the Employee will not delegate the performance of the duties set out in this agreement to any employee or agent of the Employee without the prior written consent of the Board or any nominee of the Board (other than Mr William Bradford); and

 

(b) this agreement will not be assigned by either party without the prior written consent of the other party.

 

12. PRIOR AGREEMENT SUPERSEDED

 

This agreement supersedes and replaces any prior written or verbal agreement between the parties.

 

13. AGREEMENT TO ARBITRATE & GOVERNING LAW

 

Any disputes arising from or related to this contract shall be resolved by arbitration pursuant to the International Arbitration Rules of the International Centre for Dispute Resolution. The Expedited Procedures in Article E of those Rules shall apply, regardless of the amount that is claimed. The legal seat of the arbitration shall be determined by the International Centre for Dispute Resolution of Western Australia, but the parties agree that any hearing may be conducted by phone or videoconference, with no need for any in-person appearances. This agreement, including this arbitration agreement, shall be governed by and construed in accordance with the State of Western Australia. The arbitration shall be held, and the award rendered, in the English language. The award rendered by the arbitrator[s] shall be final, non-reviewable, non-appealable, and binding on the parties and may be entered and enforced in the courts of Western Australia, and/or any court where a party or its assets is located, to whose jurisdiction the parties consent for the purposes of enforcing the award. Judgment on the award shall be final and non-appealable.

 

Page 8 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

14. VARIATION

 

No modification or alteration of the terms of this agreement shall be binding unless made in writing dated subsequent to the date of this agreement and duly executed by the parties.

   
 

15. MISCELLANEOUS

   
 

15.1 Severance

 

If any provision of this agreement is invalid and not enforceable in accordance with its terms, all other provisions which are self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and forceful in accordance with their terms.

 

15.2 Entire agreement

 

This agreement shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other agreements with respect thereto.

 

15.3 Counterparts

 

This agreement may be executed in any number of counterparts (including by way of facsimile) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

15.4 Time

 

Time shall be of the essence in this agreement in all respects. I trust that the Employee and the Company will work together to build a long lasting and mutually rewarding relationship.

Yours sincerely

_______________________

Vlado Bosanac

CHIEF EXECUTIVE OFFICER

 

SCHEDULE

 

TERMS AND CONDITIONS OF MYFIZIQ LIMITED PERFORMANCE RIGHTS

 

The MyFiziq Limited Performance Rights are issued on the following terms and conditions:

 

(a) (Entitlement) Each Performance Right entitles the holder (Holder) to subscribe for one fully paid ordinary share in the capital of the Company (Share) upon satisfaction of the Milestones (defined below) and issue of the Conversion Notice (defined below) by the Holder.

 

Page 9 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

(b) (Notice of satisfaction of Milestones) The Company shall give written notice to the Holder promptly following satisfaction of any of the Milestones (defined below) or lapse of a Performance Right where the Milestones are not satisfied.

 

(c) (No voting rights) A Performance Right does not entitle the Holder to vote on any resolutions proposed by the Company except as otherwise required by law.

 

(d) (No dividend rights) A Performance Right does not entitle the Holder to any dividends.

 

(e) (No rights to return of capital) A Performance Right does not entitle the Holder to a return of capital, whether in a winding up, upon a reduction of capital or otherwise.

   
 

(f) (Rights on winding up) A Performance Right does not entitle the Holder to participate in the surplus profits or assets of the Company upon winding up.

 

(g) (Not transferable) A Performance Right is not transferable. (h) (Reorganisation of capital) If at any time the issued capital of the Company is reconstructed, all rights of a Holder will be changed in a manner consistent with the applicable ASX Listing Rules and Corporations Act at the time of reorganisation.

 

(i) (Application to ASX) The Performance Rights will not be quoted on ASX. However, the Company must apply for the official quotation of a Share issued on conversion of a Performance Right on ASX within the time period required by the ASX Listing

Rules.

 

(j) (Participation in new issues) A Performance Right does not entitle a Holder (in its capacity as a holder of a Performance Right) to participate in new issues of capital offered to holders of Shares such as bonus issues and entitlement issues.

 

(k) (No other rights) A Performance Right gives the Holder no rights other than those expressly provided by these terms and those provided at law where such rights at law cannot be excluded by these terms.

 

Conversion of the Performance Rights

 

(l) (Milestones) The ‘Milestones” shall be defined as achieving the vesting criteria set out in clause 3.1 of the Employeey Letter Agreement entered into between the Company and the Holder on 16th October 2019.

 

(m) (Term) Each Performance Right shall have a term of four (4) years, subject to any conditions relating to earlier lapsing.

 

(n) (Conversion Notice) A Performance Right may be converted by the Holder giving written notice to the Company (Conversion Notice) within twelve months from the date of the achievement of each of the Milestones. No payment is required to be made for conversion of a Performance Right to a Share.

 

Page 10 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

(o) (Obligation not to dispose) For the period of 12 months from the date of the conversion under (n) above, the new Shares will be incapable of being disposed of or sold by the Holder and will be subject to a holding lock imposed by the Company (unless otherwise agreed to by the Company).

 

(p) (Lapse) If the Milestones are not achieved by the required date or the Conversion Notice not given to the Company by the required date, then the relevant Performance Right will automatically lapse.

 

(q) (Issue of Shares) The Company will issue the Share on conversion of a Performance Right within 10 business days following the conversion or such other period required by the ASX Listing Rules.

 

(r) (Holding statement) The Company will issue the Holder with a new holding statement for any Share issued upon conversion of a Performance Right within 10 business days following the issue of the Share.

   
 

(s) (Ranking upon conversion) The Share into which a Performance Right may convert will rank pari passu in all respects with existing Shares.

   

6.       Expenses

The Employee will be reimbursed all reasonable expenses supported by official receipts for payments made on behalf of the Company whilst carrying out the Employee’s duties provided, however, that any individual expense exceeding $500 must not be incurred without the prior written consent of the Company.

   

7.       Appointment Basis

The Employee must provide all proper documentation to the Company to verify such expenses prior to reimbursement. The Employee must comply with all lawful directions of the Company in relation to incurring expenses on behalf of the Company, and shall not in any way pledge the credit of the Company except insofar as the Employee may have been expressly authorised by the Company either generally or in any particular incidence.

 

Full-time position.

 

As a professional qualified Employee, the Employee is required to exercise their specialised expertise, independent judgment and discretion to provide high-quality services and fulfill all reasonable work-related demands and requirements.

 

The Employee must comply with all lawful instructions given to them by their Manager, and any delegate of their Manager, and any policies instituted by the Company from time to time. The Company’s policies do not form part of this Agreement and do not give rise to any contractual rights for the Employee.

 

The Company may modify any of its policies at any time.

 

In the course of performing the Employee’s duties in the Position, the Employee shall use their best endeavors to promote, develop and protect the business interests and welfare of the Company.

 

Page 11 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

The Employee must not do anything which is harmful to the reputation or interests of the Company.

 

The Employee must work in a lawful, professional and competent manner and provide faithful service, and act in good faith in all its dealings with and on behalf of the Company.

 

8. Qualifications

The Employee warrants to the Company that they hold the qualifications and have the experience set out in their curriculum vitae provided to the Company prior to the Commencement Date, and that all information provided to the Company by the Employee in that curriculum vitae and in any employment application and/or in any job interview, is truthful, accurate, correct and complete.

 

The Employee warrants that in entering into this Agreement they will not be in breach of any obligations owed to any third parties.

 

The Employee warrants that they have not entered into, and will not enter into any agreement, that conflicts with their obligations owed to the Company under this Agreement.

   
9. Tenure and Review The Company has appointed the Employee into the Position, and the Employee agrees to accept the appointment and the tenure, on the terms and conditions set out in this Agreement.

 

9.1 Probation Period

The Employee’s employment with the Company is subject to a six (6) month Probation Period from the Commencement Date of this agreement.

 

On and from the Commencement Date and during the Probation Period, either party may terminate this Agreement by providing the other with not less than two (2) weeks’ notice in writing. This clause does not affect the Company’s right to terminate the Agreement without notice in the event of serious misconduct by the Employee.

   
9.2 Employment Review

The Company will use its best endeavours to have the Employee’s engagement under this Agreement reviewed at the end of the Probation Period, and thereafter on or before 31 August each year. The Review will include such matters as determined by the Board, and may include,

 

i.       the Employee’s performance during the period prior to the review (including against performance indicators set by the CEO or the Board);

 

Page 12 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

ii.       the performance of the Company during the period prior to the review; and

 

iii.       the Employee’s remuneration relative to economic conditions prevailing in the state of California, USA and similar positions offered in the market.

 

   
9.3 Termination

i.       After the Probation Period, either party may at any time terminate this Agreement by providing the other with four (4) weeks’ prior written notice (“Notice Period”). The Company may choose, in lieu of requiring the Employee to work out the Notice Period, to make a payment to the Employee of an amount equivalent to the Employee’s Remuneration, pro rated for the Notice Period, or such higher amount prescribed by applicable legislation.

 

ii.       If at the time of termination by the Company the Employee has completed two years’ service and is aged over 45, the Employee will receive one (1) additional week of notice.

 

iii.       The Company shall not be required to provide any notice to the Employee in the case of dismissal for serious misconduct.

 

iv.       On cessation or termination of employment, the Employee is entitled to payment in lieu of the annual leave to which the Employee has become entitled during his or her employment with the Company, but which he or she has not taken.

 

v.       Upon cessation of the Employee’s employment with the Company, the Employee must deliver-up and/or destroy (as required by the Company), all and any Confidential Information and other property of the Company in the possession or control of the Employee, whether in hard copy or held in electronic form or otherwise.

 

 

vi.       Before and after cessation of the Employee’s employment with the Company, the Employee must not make any derogatory remark or statement about the Company or its personnel or any other remark or statement which may damage the reputation or goodwill of the Company.

 

vii.       Termination does not affect any accrued rights of either party.

   
10. Restrictions and Restraints of trade In the interest of being fair and reasonable, MyFiziq is not looking to restrain the Employee from working in their respective field(s) post-employment with MyFiziq. MyFiziq is only seeking to restrict the Employee from being poached or moving to a competitor and assisting in creating any product that directly competes with MyFiziq for a period after employment with MyFiziq.
   
10.1 Restriction on Activities

On and from the Effective Date until the Employee’s employment ends in accordance with the Employee’s Employment Contract, or pursuant to applicable law, the Employee must work full-time for the Company, and without the prior written consent of the Company must not:

 

i.       work in, on or for any other business; or

 

ii.       commence, operate, invest directly or indirectly in, or obtain an interest in, any business that is in competition with the Company (provided that this clause shall not prevent the Employee from holding up to 10% of the shareholding in a publicly-listed company).

 

Page 13 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

10.2 Restraint Period and Area

The Restraint Period is as follows:

 

i.       twelve (12) months; or

 

ii.       if a court finds twelve (12) months unreasonable, nine (9) months; or

 

iii.       if a court finds nine (9) months unreasonable, six (6) months; or

 

iv.       if a court finds six (6) months unreasonable, three (3) months.

 

The Restraint Area is as follows:

 

i.       All MyFiziq patented countries; currently China, South Korea, Japan, Singapore, USA and Australia, this will expand to further countries as new patents are received; or

 

ii.       if a court finds all MyFiziq patented countries unreasonable, USA and Asia Pacific countries1. Or

 

iii.       if a court finds USA and Asia Pacific countries unreasonable, USA.

 

11. IT Devices

If the Employee is provided by the Company with access to, or possession of, any computer, smartphone device or other equipment for the use by the Employee, the Employee must take reasonable care to keep such devices and equipment secure and protected. The loss of any such device must be immediately reported by the Employee to the Company.

  

12. Surveillance

The Employee’s use of the Company’s information technology systems and email accounts will be subject to ongoing and continuous surveillance. Such surveillance will be conducted from the Commencement Date and at all times thereafter during the term of the Employee’s employment with the Company.

The Employee agrees and acknowledges that the Company may monitor and record all usage of any computer, smartphone device and/or e-mail address allocated to the Employee by the Company, and the Employee consents to the monitoring of all such devices and addresses.

 

The Employee further agrees and acknowledges that all e-mails and any files and other data transmitted by the Employee using any computer, smartphone device or email address allocated to the Employee, are the sole property of the Company.

 

13.       Price Sensitive Information

 

The Employee acknowledges that in the course of carrying out the services pursuant to this Agreement the Employee may receive Confidential Information, including “Price Sensitive Information” (as per the Corporations Act 2001 (Cwth)) affecting the Company. Any disclosure, communication, or misuse of Price Sensitive Information may have very serious implications for the Company and/or the Employee, including possible criminal prosecution and possible civil actions against the Employee.

 

The Employee acknowledges that the Company has the right to terminate this Agreement without notice if the Employee discloses, communicates, or misuses Price Sensitive Information in the absence of the prior written consent of the Board, except to the extent that the Employee is required by law to disclose, communicate or use it.

 

1 For clarity Asia Pacific countries include countries in geographic regions Asia and Oceania as defined by the United Nations: https://unstats.un.org/unsd/methodology/m49/

 

Page 14 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

14.       Annual Leave

Annual leave accrues progressively at a rate of 20 days per annum. The Employee’s annual leave may be taken once it is accrued at any time mutually acceptable to the Employee and the Company. Accrued annual leave should not accumulate in excess of 30 working days. If you reach this number of accrued annual leave days, the Company may direct you to take annual leave in accordance with the Fair Work Act 2009.

 

15.       Personal/Carer’s Leave and Compassionate Leave

Personal/Carer’s Leave

 

Paid personal/carer’s leave accrues progressively at a rate of 10 working days per annum. The Employee’s personal/carer’s leave may be taken once it is accrued. No payment will be made for unused personal/carer’s leave following cessation of employment.

 

An Employee may take personal leave when he or she is ill or injured and unfit for work.

 

An Employee may take carer’s leave when he or she is required to provide care or support to a member of his or her immediate family or household who is ill, or injured, or experiencing an unexpected emergency.

 

The Company requires production of suitable evidence in support of any personal/carer’s leave absence.

 

Unpaid Carer’s Leave

 

The Employee is entitled to two days’ unpaid carer’s leave on each occasion such leave is required, provided the Employee’s paid personal/carer’s leave balance has been exhausted.

 

Compassionate Leave

 

The Employee is entitled to two days paid compassionate leave if a member of the Employee’s immediate family or household:

 

i. experiences a life-threatening illness or injury; or

 

ii. passes away.

 

 

16.       Long Service Leave and Other Leave

 

The Employee is entitled to long service leave in accordance with the provisions of the Long Service Leave Act 1958 (WA). The Employee will be entitled to all other forms of leave provided by the Fair Work Act 2009.

 

17.       Proprietary Information and Inventions

 

Page 15 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

17.1 Meaning of “Intellectual Property”

“Intellectual Property” (“IP”) means all industrial and intellectual property rights whether protectable by statute, at common law or in equity, including all copyright and similar rights which may subsist or may hereafter subsist in works or any subject matter, rights in relation to inventions (including all patents and patent applications), trade secrets and know-how, rights in relation to designs (whether or not registrable), rights in relation to registered or unregistered trade marks, circuit layout designs and rights in relation to circuit layouts, whether registered, registrable or unregistered, including:

 

i.       marks, logos, service marks, trade names, business names, internet domain names, slogans, symbols, brand names, copyright or other trade indicia;

 

ii.       all rights in information, know-how, processes, procedures, compositions, devices, methods, formulae, protocols, techniques, designs, drawings, trade secrets or data whether or not protectable by patent application design registration, copyright, whether unregistered, registered or registrable; and

 

iii.       any modifications, developments, adaptations, advancements, creations and derivations of any intellectual property,

 

but excludes non-assignable moral rights and similar non-assignable personal rights of authors and producers.

 

17.2       Current & New

 

i.       As a condition of employment, the Employee represents and warrants that they will immediately communicate to the Company any and all new literary and other new works and new subject matter including all new works, new processes, new inventions, new improvements, new innovations, new modifications, new designs, new discoveries, new trademarks and new trade secrets, however embodied, which the Employee may make either alone or in conjunction with others during the course of, in connection with or arising out of the Employee’s employment and in any way connected with matters specifically pertaining to the business and assets of MyFiziq, including MyFiziq joint ventures, partners and customers, for which the Company has been or is now or hereafter interested during the Employee’s employment (“Inventions”).

 

ii.       Any new Inventions or extension of the IP surrounding MyFiziq, including MyFiziq joint ventures, partners and customers, whether or not the Inventions are capable of being protected by copyright, letters patent, registered design or other protection (“Protection”), will be solely owned by the Company for development.

 

iii.       Any new Inventions, whether or not the Inventions are capable of being commercialised or able of Protection outside of those of MyFiziq, including MyFiziq joint ventures, partners and customers, will be first offered to the Company for first right of refusal. Further proceedings will only go forward if agreed by both the Employee and the Company.

 

Page 16 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

17.3       Co-operation in Obtaining Protection for Inventions

 

i.       If and whenever required to do so whether during or after cessation of the Employee’s employment, and at the expense of the Company or its nominee, the Employee will apply or join in applying for letters patent or other similar protection in Australia or in any other part of the world for content specifically pertaining to MyFiziq, including MyFiziq joint ventures, partners and customers where required. The Employee will immediately deliver-up to the Company full particulars concerning these matters and execute all instruments and do all things necessary for vesting the letters patent or other Protection when obtained, and all right and title to and interest in the same, in the Company or its nominee absolutely and as sole beneficial owner or in such other person as the Board requires.

 

ii.       The Employee appoints the Company to be their attorney in the Employee’s name and on the Employee’s behalf to execute any such instrument or thing and generally to use the Employee’s name for the purpose of giving to the Company or its nominee the full benefit of the provisions of this clause.

 

17.4       Information

 

Without limiting the generality of the above, and subject to not breaching any laws or breaching any other contractual obligations in existence or arising from time to time, the Employee represents and warrants that:

 

i.       the Employee will immediately inform the Company of any matter which may come to the Employee’s notice during the Employment which may reasonably be of interest or of any importance or use to the Company or its Subsidiaries and Related Corporations for content specifically pertaining to MyFiziq, including MyFiziq joint ventures, partners and customers;

 

ii.       the Employee will immediately communicate to the Company any proposals or suggestions occurring to the Employee during the Employee’s employment which may reasonably serve to further the business of the Company for content specifically pertaining to MyFiziq including MyFiziq joint ventures, partners and customers.

 

The Employee agrees the provisions of this clause survive the cessation of the Employee’s employment with the Company.

  

18. Confidentiality and Confidential Information

“Confidential Information” means any information (whether in written, electronic or any other form) in respect of the business and affairs of the Company and its clients, products, research and development projects, customers and suppliers that is not in the public domain including, without limitation, any document, record, computer file, customer or client information, product or service information, sales or financial information, project, contract, deal, discovery, invention, drawing, design, strategy, plan, data, report, process, proposal, budget, idea, formula, concept or know how.

 

 

Page 17 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

Confidential Information includes, but is not limited to:

 

i. trade secrets, financial information, designs, formulae, patterns, know-how, devices, inventions, secret or unpatented inventions, research, development, processes, techniques, machines, the identity and requirements of customers, the identity of suppliers and vendors, information received by the Company from third parties under obligation of confidentiality, strategic or financial plans, product pipeline information, financial data, sales and marketing plans and information, and compilations of information, records, and specifications used by the Company;

 

ii. information about the identity, contact details or requirements of the Company’s clients, prospective clients, suppliers or prospective suppliers;

 

iii. information belonging to, or concerning clients of the Company;

 

iv. any agreements, arrangements or terms of trade with a client, prospective client, supplier or prospective supplier;

 

v. the Company’s contractual, technical and production information; and

 

vi. the Company’s marketing plans, and marketing and sales techniques.

 

Confidential Information does not lose its confidential status merely because it was known by a limited number of persons or entities or because it did not originate entirely with the Company.

 

Confidential information also extends to the contents of this Agreement, including the Employee’s remuneration details.

 

Unless the Employee is authorised to do so by law, the Employee is not to divulge any information the Employee obtains as a consequence of and in the course of the Employee’s employment to any other third party, including to the media or the public generally, except and unless it is of a general nature and of general knowledge and the Employee does so as a consequence of the performance of the Employee’s responsibilities.

All knowledge and/or information, written or otherwise, related to the activities of the Company, including MyFiziq joint ventures, partners and customers, obtained by the Employee as a consequence and in the course of the Employee’s employment becomes the property of the Company, and unless otherwise authorized during the term of the Employee’s employment or thereafter, must not be divulged to any other source.

Upon cessation of the Employee’s employment with the Company, the Employee must return all papers, records, documents (including hard copy and digital copies) and any equipment that are in the Employee’s possession or control and relate to any of the foregoing.

 

The Employee represents and warrants to MyFiziq that there are no other agreements, written or oral, that would restrict the employee’s ability to perform the basic functions of the Employee’s job, including but not limited to non-compete, non-disclosure or similar agreements with prior employers. If there are such agreements, the Employee agree to immediately provide the Company with a copy of any such agreements(s) for the Company’s review. The Employee further agrees not to bring to the Company, use or disclose any trade secrets or other confidential / proprietary information of prior employers.

 

Page 18 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

The Employee agrees that they will not use, copy, transfer, destroy or remove from the Company’s premises, any Confidential Information without the prior written consent of the Company. This includes the use, copy, transfer, destruction or removal of Confidential Information at non-Company premises including the Employee’s home.

 

Without limiting the above provisions, the Employee must not license or otherwise exploit, directly or indirectly, any products or services which embody or are derived from Confidential Information without the prior written consent of the Company.

 

The Employee agrees the provisions of this clause survive cessation of the Employee’s employment with the Company.

   
19. Privacy The Employee must comply with the Privacy Act 1988 (Cth) in respect of all personal information that comes into the possession or control of the Employee, or which the Employee accesses, during the course of the Employee’s employment in the Position.
   
20. Notices

i.       A notice under this Agreement may be given by hand delivery, post or email, using the address specified at the top of the first page of this Agreement, or the email address for the recipient’s representative specified in the Schedule, or such other latest address as a party may have provided to the Company during the course of employment.

 

ii.       Any notice issued by hand shall be deemed delivered upon delivery.

 

iii.       Any notice issued by post shall be deemed delivered 3 Business Days after posting if posted domestically, or 10 business days after posting if posted internationally.

iv.       Any notice issued via email shall be deemed to be delivered upon the email being sent, provided that if an email is sent out of business hours, it shall be deemed to be delivered at 9am on the next business day.

 

21. General

Amendment: This Agreement may only be amended by a written document signed by the parties.

 

Assignment: The Employee agrees and acknowledges that the Company may assign this Agreement to a related body corporate of the Company, or to an acquirer of the business of the Company upon notice to the Employee.

 

Severability: If any provision of this Agreement is deemed invalid by a court of competent jurisdiction, the remainder of this Agreement shall remain enforceable.

Counterparts: This Agreement may be executed in counterparts provided that no binding agreement shall be reached until the executed counterparts are exchanged.

 

Entire Agreement: This Agreement constitutes the entire agreement between the parties and to the extent possible by law, supersedes all prior understandings, representations, arrangements and agreements between the parties regarding its subject matter.

 

Jurisdiction: This Agreement will be interpreted in accordance with the laws in force in Western Australia. The parties irrevocably submit to the non-exclusive jurisdiction of the courts situated in Western Australia.

 

Page 19 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

 

Legal advice: The Employee acknowledges that they have had a reasonable opportunity to obtain independent legal advice regarding the contents of this Agreement prior to entering into this Agreement and has either obtained that advice or elected not to obtain it.

 

Flexible Working Arrangements: if eligible, the Employee may request flexible working arrangements. The Company may refuse a request on reasonable business grounds.

 

Fair Work Information Statement: The Employee acknowledges receipt of the Fair Work Information Statement annexed to this Agreement marked “Annexure A”.

   
22. Interpretation

In this Agreement:

 

i.       Headings and underlining are for convenience only and do not affect the construction of this Agreement.

 

ii.       A provision of this Agreement will not be interpreted against a party because the party prepared or was responsible for the preparation of the provision, or because the party’s legal representative prepared the provision.

 

iii.       Currency, US$ and USD refers to the currency of the United States of America.

 

iv.       A reference to a statute or regulation includes amendments thereto.

 

v.       A reference to a clause, subclause or paragraph is a reference to a clause, subclause or paragraph of this Agreement.

 

vi.       A reference to a subclause or paragraph is a reference to the subclause or paragraph in the clause in which the reference is made.

 

vii.       The recitals are correct and form part of this Agreement.

viii.       A reference to time is to time in California, USA.

 

ix.       A reference to a person includes a reference to an individual, a partnership, a company, a joint venture, government body, government department, and any other legal entity.\

x.       The words “includes”, “including” and similar expressions are not words of limitation.

   

 

Page 20 of 21

 

MYFIZIQ EMPLOYMENT AGREEMENT

 

 

William, we look forward to your engagement with our Company at this very exciting stage.

 

Signed as an agreement.

 

Signed for and on behalf of the Company by its authorised representatives:

 

Vlado Bosanac    
CEO and CO-Founder   Signature
     
Signed by:    
     
     
William Bradford    
Name of Employee   Signature
     
     
Name of Witness   Signature of Witness

 

 

Page 21 of 21

 

 

Exhibit 10.8

 

 

Marketing and Funding Agreement

April 24th 2021

 

Russell Bateman Executive Director Tinjoy Biotech Limited

23floor, China Southern CITIC Tower, Haibin South Road, Xiangzhou District, Zhuhai, 519000, Peoples Republic of China

 

Dear Russell,

 

We refer to marketing funding agreement within clause 4 of the binding term sheet dated 18th February 2021. Advanced Human Imaging (AHI) will contribute a total of USD$200,000 in funding toward the development, training and launch of the WinScan / AHI integrated health application.

 

Unless the context otherwise requires, words and expressions defined in the Binding Term Sheet shall have the same meanings when used in this letter agreement. The staged payments are as follows.

 

Commitments by the parties

 

Initial Funding Commitment 3rd May 2021

 

Employment of dedicated marketing resource within the Tinjoy Group ~ USD$10,000

 

Translation of SDK text and repurposing of English Language marketing materials into Mandarin ~ USD$10,000.

 

Production of WinScan specific local marketing materials ~ USD$15,000

 

Training and development of digital and retails sales teams for first phase of launch ~ USD$15,000

 

Payment 2 June 1st, 2021

 

AHI agree to commit a further USD$10,000.

 

Post launch enhancements to app functionality back ~ USD$30,000

 

Direct marketing campaign to be initiated after product launch, digital marketing, KOL briefings and similar ~ USD$20,000.

 

*(NB Tranche 2 Subject to Confirmation of launch date)

 

Payment 3 July 1st, 2021

 

Major market entry campaign ~ USD$60,000

 

Expansion of dedicated marketing and training team ~ USD$40,000

 

Each payment staged will be confirmed in writing prior to funding drawdown. Samples of all material develop for the launch and marketing will be agreed to by the parties. Tinjoy will supply marketing reports on a monthly basis, being the first week of every month.

 

Yours sincerely

 

Mr Vlado Bosanac CEO & Chairman

Advanced Human Imaging Limited

 

 

 

 

 

 

Marketing and Funding Agreement

April 24th 2021

 

Executed by the parties as a deed.

 

Executed for and on behalf of Advanced )
Human Imaging Limited )
ACN 602 111 115 )
in accordance with section 127 of the )
Corporations Act 2001 (Cth):  

 

 
 

Signature of director

 

Vlado Bosanac (CEO)  
Chief Executive Officer  

 

Executed for and on behalf of Tinjoy Biotech )
Limited Unified Code 91440400MA52AJ7419 )
)
in accordance with the laws of its place of ) incorporation:

  

 

 

Russell Bateman

 
Executive Officer  

 

 

 

 

Exhibit 10.9

 

BINDING HEADS OF AGREEMENT
PRIVATE AND CONFIDENTIAL

 

The parties set out in Schedule 1 (together, the Vendors) are the holders of such majority of shares of Physimax as required to enforce a sale of 100% of the issued share capital of Physimax Technologies Limited (an entity incorporated in Israel) (Physimax). Without derogating from the above, Physimax will endeavor to solicit the signatures of all its shareholders on this Heads of Agreement prior to Completion (the Selling Shareholders).

 

This Heads of Agreement sets out the terms upon which Advanced Human Imaging Limited (ACN 602 111 115) of Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 Australia (the Purchaser) agrees to acquire 100% of the issued Physimax Shares (as defined below), and the Vendors agree to sell the Physimax Shares to the Purchaser.

 

Each of the Purchaser and the Vendors are referred to as a Party and together the Parties

(as the context requires).

 

This Heads of Agreement is binding on the Parties and supersedes any and all previous correspondence, agreements or understandings between the Parties.

 

  Term Details
     
1. Acquisition

Subject to the satisfaction (or waiver) of the Conditions (as defined in clause 5 below) and in consideration for the issue of the Consideration Securities (as that term is defined in clause 2) by the Purchaser to the Selling Shareholders, the Purchaser agrees to purchase, and the Vendors agree to sell, the Physimax Shares, free from any encumbrances and waiving any pre-emptive or call option rights associated with the Physimax Shares, on the terms and conditions pursuant to this Heads of Agreement (Acquisition).

Title to and risk in the Physimax Shares shall pass to the Purchaser on completion of the Acquisition.

     
2. Consideration

(a)             In consideration for the Acquisition, the Purchaser will issue the Selling Shareholders and the current holders of Physimax Options (or their nominees):

(i)       AHI Shares at the Deemed Issue Price (Consideration Shares); and

(ii)       AHI Options at the Deemed Conversion Price (Consideration Options),

worth a total of $6,000,000 in aggregate (together, the Consideration Securities).

(b)             The allocation of the Consideration Securities between the Selling Shareholders and the holders of the Physimax Options will be in accordance with an allocation list to be provided by Physimax as part of the due diligence.

(c)             It is acknowledged and agreed that 50% of the Consideration Securities of each Vendor will be subject to six (6) months of voluntary escrow. The terms of the voluntary escrow will be set out in voluntary restriction deeds (Voluntary Restriction Deeds) in form and substance to be agreed upon before Completion.

 

1

 

 

  Term Details
     
3. Shareholder approval

The issue of AHI ASX Shares and AHI Options that is contemplated in this Heads of Agreement is subject to and conditional on the Purchaser obtaining the required approvals from its shareholders at a General Meeting to issue AHI ASX Shares to the Selling Shareholders and the Consideration Options to the current holders of Physimax Options (Shareholder Approval).

The Purchaser shall initiate the process of the Shareholder Approval (and its filing with the ASX) as soon as possible after execution of this Heads of Agreement.

     
4. Waiver By execution of this Heads of Agreement, the Vendors waive any pre-emptive rights or other rights which they may have over any Physimax Shares or Options to be transferred to the Purchaser under this Heads of Agreement, including (but not limited to) under any shareholders agreement, articles of association or call option or other legal right, effective from and subject to Completion
     
5. Condition Precedent

Completion of the Acquisition is conditional upon the satisfaction (or waiver by the Parties) of the following conditions precedent, in addition to the satisfaction of the conditions for completion set forth in clause 8:

 

(a)             the Purchaser obtaining all required third party, regulatory and governmental approvals and consents to give effect to the Acquisition, including any necessary shareholder approvals required by the Corporations Act or ASX Listing Rules (and any other applicable law or regulations);

 

(b)             the Purchaser completing due diligence on Physimax to its satisfaction (in its sole and absolute discretion);

 

(c)             Physimax and each of the parties that hold Physimax Option executing a deed in relation to the cancellation of the Physimax Options upon issuance of the Consideration Options, with effect from Completion (Option Cancellation Deeds);

 

(d)             the Purchaser adopting an Israeli appendix to its share option plan, allowing issuance of options under the capital gain track (through a trustee) under section 102 of the Israeli Tax Ordinance and ready for filing with the Israeli tax authority immediately following Completion (the "IL Plan");

 

(e)             Physimax obtaining all required third party, regulatory and governmental approvals and consents to give effect to the Acquisition, including any necessary shareholder approvals and the consent of the Israeli Innovation Authority;

 

(f)             the issuance of a ruling by the Israeli Taxing Authority, approving the deferral of taxes arising from the Acquisition; and

 

(g)             Physimax completing due diligence on Purchaser (for the benefit of its shareholders) to its satisfaction (in its sole and absolute discretion, (together, the Conditions).

 

2

 

  Term Details
     
   

Conditions (a), (b) and (c) are for the benefit of the Purchaser and may only be waived by the Purchaser.

 

Conditions (d) through (g) (inclusive)are for the benefit of the Vendors and may only be waived by the Controlling Shareholders (on behalf of the other Vendors).

 

The Parties will use their respective best endeavours and agree to cooperate and provide each other with all reasonable assistance, and to execute such documents and take such actions as required to ensure that the Conditions are satisfied promptly after the date of this Heads of Agreement.

     
6. Termination

If by June 30, 2021, the Conditions are not satisfied or waived (as set forth above), either Party may terminate the agreement constituted by this Heads of Agreement by notice in writing to the other and the Parties will be released from their obligations under this Heads of Agreement. In addition, this Heads of Agreement may be terminated by mutual written consent of the parties at any time before June 30, 2021. In such events, this agreement will be at an end and the Parties will be released from their obligations under this agreement (other than in respect of any breaches that occur prior to termination).

In the event this Heads of Agreement is in effect on May 21, 2021, then the mutual Due Diligence process will be considered as successfully completed and the Purchaser shall pay Physimax an amount of US$60,000 (Due Diligence Payment) within no later than ten (10) days thereafter. The Due Diligence Payment shall be in addition to the Consideration Securities.

 

The Due Diligence Payment is fully refundable in the event that any of the warranties set out in Part 2 of Schedule 3 are misleading or incorrect in circumstances involving fraud or intentional or deliberate misleading or deceptive conduct on the part of a Controlling Shareholder.

     
7. Key Contributors

(a)             Physimax must provide the Purchaser with a list of its key employees and consultants (Key Contributors).

 

(b)             The Purchaser is to use reasonable endeavours to amend the employment and consultancy agreements of the Key Contributors as soon as practicable after Completion, under which the Key Contributors are to agree to serve a minimum term of two additional years from the date of Completion (AHI Agreements). The terms and conditions of the AHI Agreements to be offered to the Key Contributors, including the engagement term and performance criteria, shall be agreed upon between the management of Physimax and the Purchaser prior to and as a condition to Completion.

 

(c)             Subject to (f) below, the Key Contributors (and/or future employees and consultant identified as key contributors at the discretion of the founders of Physimax) will receive an aggregate of $2,000,000 worth of AHI Performance Rights at the same conversion price as the conversion price determined for the conversion of the ordinary shares of Physimax to Consideration Shares (Key Contributor Performance Rights) under the Purchaser’s Incentive Performance Rights Plan in proportions to be decided by Mr Ram Shalev, Physimax’s Chief Executive Officer at the date of this Heads of Agreement. The Purchaser shall work together with the management of Physimax in order to determine the appropriate mechanism for issuance of the Performance Rights (such as options / shares / RSUs) taking into account the tax benefits available to the Key Contributors. The AHI Performance Rights shall be for ADRs or AHI ASX, as shall be chosen by the Vendors for their Consideration Shares.

3

 

  Term Details
   

(d)             The terms of the Key Employee Performance Rights, including any milestones, are to be set out in the AHI Agreements.

 

(e)             If required, the Purchase must obtain ASX approval of the terms of the Key Employee Performance Rights prior to issuing them to the Key Contributors (which approval shall be obtained before Completion).

 

(f)             The Purchaser shall initiate the process of the Shareholder Approval (and its filing with the ASX) as soon as possible after execution of this Heads of Agreement for the issue of the AHI Performance Rights.

 

(g)             Subject to Physimax continuing to meet reasonable commercial objectives that are determined by the board of directors of the Purchaser (AHI Board) and the AHI Board determining that it continues to be the best interests of AHI’s shareholders to do so, the Purchaser shall fund the operation of Physimax as of Completion with a budget of US$60,000 per month. The budget shall be updated from time to time according to plan and needs as required to facilitate adequate resources to obtain the business goals agreed mutually by the Physimax management and the Purchaser.

     
8. Completion

Completion of the Acquisition (Completion) will occur on the Completion Date at a time and place to be agreed by the Controlling Shareholders and the Purchaser. Without derogating from clause 3 above, at Completion:

 

(a)             the Purchaser must issue the Consideration Shares to the Vendors in the proportions set out in the Formal Agreement;

(b)             Physimax and the Vendors shall deliver, or cause to be delivered, to the Purchaser:

 

(i)             share certificates in respect of 100% of the Physimax Shares;

(ii)             the fully executed Option Cancellation Deeds;

 

(iii)             separate instruments of transfer in registrable form for 100% of the Physimax Shares in favour of the Purchaser (as transferee) which have each been duly executed by or on behalf of the Vendors (as transferor);

4

 

  Term Details
     
   

(iv)             the list of the Key Contributors;

 

(v)             the common seal (and any duplicate common seal, share seal or official seal) of Physimax (if any);

 

(vi)             all available copies of the constituent documents of Physimax;

 

(vii)            the minute books and other records of meetings or resolutions of shareholders and directors of Physimax (as available); and

 

(viii)          all registers of Physimax (including the register of shareholders, register of directors, register of charges and all registers required by applicable laws) in proper order and condition and fully entered up to the Completion Date;

 

(ix)             all cheque books, financial and accounting books and records, copies of tax returns and assessments, mortgages, leases, agreements, insurance policies, title documents, licences, indicia of title, contracts, passwords to computers, certificates and all other records, papers, books and documents of Physimax;

 

(x)             every current permit, approval, authorisation, consent, exemption, filing, licence, notarisation, registration, password and waiver however described and any renewal or variation to any of them and all other documents issued to Physimax under any legislation, ordinance or otherwise relating to Physimax’s business activities;

 

(xi)            all documents of right and/or title to the assets and undertakings of Physimax; and

 

(xii)           the corporate records for Physimax, including all information relating to the assets and undertakings of Physimax and instruments of title for such assets and undertaking.

 

(c)             The Vendors must procure that a meeting of the directors of Physimax is held to attend to the following matters (as applicable):

 

(i)             the approval of the registration (subject to payment of duty) of the transfers of 100% of the Physimax Shares and the issue of a new appropriate certificates for the Physimax Shares in the name of the Purchaser;

 

(ii)             recording the Purchaser as the holder of 100% of the Physimax Shares in Physimax’s registers of shareholders;

 

(iii)             taking all other steps required under Physimax’s constituent documents and applicable laws to constitute and evidence the Purchaser as the sole holder of the Physimax Shares;

5

 

  Term Details
     
   

(iv)             the reconstitution of the Physimax board of directors as directed by the Purchaser; and

 

(v)             such other business as may reasonably be required by the Purchaser to give effect to the Acquisition.

 

The Parties’ obligations at Completion are interdependent and must take place simultaneously, as nearly as possible, unless otherwise agreed by the Purchaser and the Vendors, except that the Purchaser may, in its sole discretion, waive any or all of the actions that Physimax and/or the Vendors are required to perform under this clause 8.

 

If a Party (Defaulting Party) fails to satisfy its obligations under clause 3 or this clause 8 on the day and at the place and time for Completion, then any other Party (Notifying Party) may give the Defaulting Party a notice requiring the Defaulting Party to satisfy those obligations within a period of 10 Business Days from the date of the notice and declaring time to be of the essence. The Parties agree, however, that none of Physimax or the Vendors can be a Notifying Party, in the event that one or more of them is a Defaulting Party; and that the Purchaser cannot be a Notifying Party, in the event that it is a Defaulting Party.

 

If the Defaulting Party fails to satisfy those obligations within those 10 Business Days the Notifying Party may, without limitation to any other rights it may have, terminate this Heads of Agreement by giving written notice to the Defaulting Party.

     
9. Warranties

(a)             Vendor Warranties

 

By execution of this Heads of Agreement, each Vendor makes the representations and warranties set out in Part 1 of Schedule 3 at the date of this Heads of Agreement and on the Completion Date, subject to adjustments to be disclosed by the Vendor to the Purchaser in writing after the date hereof and on or before Completion (if any). In the event the Purchaser believes such adjustment to have a material adverse effect, the Purchaser may decide that Condition 5(b) above is not completed.

 

(b)             Physimax Warranties

 

By execution of this Heads of Agreement, each Controlling Shareholder makes the representations and warranties set out in Part 2 of Schedule 3 at the date of this Heads of Agreement and on the Completion Date, subject to any adjustment to be disclosed by the Controlling Shareholders to the Purchaser in writing after the date hereof and on or before Completion. In the event the Purchaser believes such adjustment to have a material adverse effect, the Purchaser may decide that Condition 5(b)

above is not completed.

6

 

  Term Details
     
   

(c)              Purchaser Warranties

 

By execution of this Heads of Agreement, the Purchaser makes the representations and warranties set out in Schedule 4 at the date of this Heads of Agreement and on the Completion Date, subject to any adjustment to be disclosed by the Controlling Shareholders to the Purchaser in writing after the date hereof and on or before Completion. In the event the Controlling Shareholders believe such adjustment to have a material adverse effect, the Controlling Shareholders may decide that Condition 5(g) above

is not completed.

     
10. Indemnities

The following provisions shall become effective as of and subject to Completion:

 

(a)             Each Vendor:

 

(i)             is severally liable for a breach of the representations and warranties set out in Part 1 of Schedule 3 in relation to itself only; and

 

(ii)             indemnifies and must hold the Purchaser harmless against all direct loss, damage and costs suffered by the Purchaser by reason of the warranties or representations set out in Part 1 of Schedule 3 proving to be false, misleading or incorrect in relation to itself only.

 

(b)             The Controlling Shareholders jointly and severally indemnify and must hold the Purchaser harmless against all direct loss, damage and costs suffered by the Purchaser by reason of the warranties or representations set out in Part 2 of Schedule 3 proving to be false, misleading or incorrect. In the event the Purchaser chooses to file a Claim under Part 2 of Schedule 3, it must file it against both the Controlling Shareholders.

 

(c)             The Purchaser indemnifies and keeps indemnified the Vendors against all loss, damage and costs suffered by Physmiax or the Vendors by reason of the warranties or representations set out in Schedule 4 proving to be false, misleading or incorrect.

     
11. Limitations on liability

(a)             The maximum aggregate amount that a Vendor is required to pay in respect of a claim that is made under or in respect of Part 1 of Schedule 3 of this Heads of Agreement is limited to the value of the Consideration Shares that it receives on Completion.

 

(b)             The maximum aggregate amount that a Controlling Shareholder is required to pay in respect of a claim that is made under or in respect of

 

(i)             the warranties set out in paragraphs (a), (b), (c), (d), (m), (n), (p), (q), (r) and (s) of Part 2 of Schedule 3 of this Heads of Agreement is limited to 100% (Fundamental Warranties); and

7

 

  Term Details
     
   

(ii)             all the other warranties set out in Part 2 of Schedule 3 of this Heads of Agreement is limited to 50%, of the value of the Consideration Shares that it receives on Completion. Notwithstanding the above, the Controlling Shareholders shall not be liable for claims, unless the aggregated amount exceeds 60,000USD.

 

(c)             Notwithstanding any other provisions of this Heads of Agreement, no Party will be liable for a claim that is made in respect of the warranties set out in Schedule 3 (Claim) unless written notice of the Claim is given to the applicable Party on or prior to:

 

(i)             for the Fundamental Warranties, 30 September 2022; and

 

(ii)             for the other warranties that are set out in Schedule 3, the date that is 12 months from Completion.

 

(d)             Where a Vendor (including, for the purpose of clauses

 

(d) through (i) hereof, a Controlling Shareholder) is liable under a Claim:

 

(i)             the Vendor may elect to settle the Claim by the cancellation of the Consideration Shares held by it equal in value the liability amount in accordance with clause 11(f); and

(ii)             where any of the Consideration Shares issued to the Vendor have been sold or transferred, the Vendor is liable to settle the Claim in cash in cleared funds to the Purchaser up to the amount of the value of the Consideration Shares sold or transferred (pro rata based on the value of the Consideration Shares that it receives on Completion).

 

(e)             If a Vendor elects to cancel Consideration Shares in accordance with clause 11(d)(i) above, then such cancellation shall be in full and final satisfaction of all liability that the Vendor has in relation to a Claim up to the value of the Consideration Shares cancelled. In the event the Consideration Shares issued to a Vendor are insufficient to cover the damage, no additional compensation shall be payable by the Vendor (subject to (d)(ii) above).

 

(f)             For the purposes of clause 11(d)(i):

 

(i)             the number of Consideration Shares that must be cancelled or relinquished will be determined by the following formula:

 

A = B ÷ C

 

where:

8

 

  Term Details
   

 

 

 

 

 

 

 

 

 

 

 

 

 

(g)

 

 

 

(h)

 

 

 

(i)

A= The number of Consideration Shares that a Vendor must cancel or relinquish;

 

B= The total liability of the Vendor in respect of the relevant Claim (as agreed or adjudicated by a court of competent jurisdiction); and

C= the higher of the market value of the Consideration Shares as quoted on the ASX or NASDAQ (as applicable) (a) at the date of issuance of the Consideration Shares issued to the Vendors, and (b) at the time the relevant Claim is payable;

 

(ii)            the Vendor by this clause grants the Purchaser a power of attorney to do all things necessary including to execute any document to give effect to the cancellation or relinquishment of the Consideration Shares on the Vendor’s behalf (to the extent the Vendor elects to satisfy the claim by cancellation or relinquishment of shares); and

 

where more than one of the Vendors are liable as a result of a Claim, all of the Vendors so liable shall participate in satisfaction of such Claim pro rata to their portion of the Consideration Shares (as determined upon issuance).

 

The limitations in this clause 11 do not apply to any Claim for loss or damage arising from an act of fraud or intentional or deliberate misleading or deceptive conduct on behalf of the Vendor or Controlling Shareholders (as applicable).

The indemnity provisions set forth herein are the exclusive remedy available in connection with a breach of warranties under this Heads of Agreement.

 

12. Maintaining Status Quo Up until the Completion Date or termination of this Heads of Agreement in accordance with its terms, the Controlling Shareholders shall procure that Physimax does not do any of the following without the prior written consent of the Purchaser (other than as contemplated in this Heads of Agreement):
     
    (a)            enter into any material contract or incur any material liability or commitment to any material expenditure, unless specifically approved in writing by the Purchaser’s CEO;
    (b)            sell, assign or dispose of any legal or beneficial interest in Physimax’s business, intellectual property or other material assets;
    (c)            declare any dividends;
    (d)            vary its capital structure;
    (e)            vary, terminate or fail to renew any of its contracts, authorisations or commitments, except in the ordinary course of business;
    (f)             issue, or agree to issue, any equity or debt securities or hybrid securities, or grant or agree to grant any rights

9

 

  Term Details
   

 

 

(g)

 

(h)

 

 

(i)

over existing issued capital, or rights to be issued securities in the capital of Physimax;

alter or agree to alter its constituent documents;

 

create or permit the creation of any encumbrance over any of the assets or undertaking of Physimax; and

 

enter into a buy-back agreement or resolve to approve the terms of a buy-back agreement.

       
13. Formal Agreement Notwithstanding the fact that this Heads of Agreement is legally binding on the Parties, the Parties agree to enter into a formal share sale agreement and any other agreement reasonably necessary to more fully document the terms of the Acquisition (to be prepared by the Purchaser’s solicitors) which shall be on terms acceptable to the Parties (acting reasonably) and which shall be consistent with the terms set out in this Heads of Agreement (Formal Agreement).
     
14. Confidentiality and announcements (a)

This Heads of Agreement and all other information disclosed by the Parties to each other (Confidential Information) is confidential and each Party shall ensure that the Confidential Information remains confidential and shall not be disclosed to any third party, save as required by applicable law or regulations. For the avoidance of doubt, the Vendors is required to comply with the continuous disclosure provisions of the ASX Listing Rules and subject to clause 14(b) will make such ASX announcements as is reasonably necessary in order to comply with the ASX Listing Rules.

       
    (b) Subject to compliance with its continuous disclosure obligations, the Vendors must use reasonable endeavours to consult with Physimax and the Purchaser on the form and content of any announcement to ASX of a matter contemplated by this Heads of Agreement before the announcement is made to ASX.
       
15. Further Assurance Each Party shall sign and execute and do all deeds, acts, documents and things as may reasonably be required by the other Parties to effectively carry out and give effect to the terms and intentions of this Heads of Agreement.
     
16. Governing Law The agreement constituted by this Heads of Agreement shall be governed by and construed in accordance with the law from time to time in Israel. The Parties agree to submit to the non-exclusive jurisdiction of the Courts of Tel Aviv – Jaffa, Israel and the Courts which hear appeals from those Courts.
     
17. Assignment None of the Parties may assign any of the rights or obligations conferred by this Heads of Agreement without the consent of the other Party.
     
18. Costs (a) Each Party shall bear their own legal costs of and incidental to the preparation, negotiation and execution of this Heads of Agreement; it being agreed that the costs and expenses of the Vendors shall be covered by Physimax.

10

 

  Term Details
     
    (b)             The Purchaser will pay any duty assessed on or in respect of this Heads of Agreement.
     
19. Notices Each notice authorised or required to be given to a Party shall be in writing and may be delivered personally or sent by properly addressed prepaid mail or email in each case addressed to the Party at its address or email address notified to the other from time to time.
     
20. Remedies The rights, power and remedies provided in this Heads of Agreement are cumulative with and not exclusive to the rights, power or remedies provided by law independently of this Heads of Agreement.
     
21. Entire Agreement This Heads of Agreement shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other agreements with respect thereto.
     
22. Variation

No modification or alteration of the terms of this Heads of Agreement shall be binding unless made in writing dated subsequent to the date of this Heads of Agreement and duly executed by the Purchaser, the Controlling Shareholders and the Vendors holding a majority of the issued capital of the Company.

 

The Vendors hereby irrevocably nominate the Controlling Shareholders as their representatives and constitute them as their proxy with a power of attorney to execute any document, waiver and consent required to give effect to this Agreement.

 

23. Severance If any provision of this Heads of Agreement is invalid and not enforceable in accordance with its terms, all other provisions, which are self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and forceful in accordance with their terms.
     
24. Counterparts This Heads of Agreement may be executed in any number of counterparts, each of which when executed and delivered to the other Parties shall constitute an original, but all counterparts together shall constitute one and the same agreement.
     
25. Definitions

In this Heads of Agreement:

 

(a)             Acquisition means the acquisition by the Purchaser of 100% of the Physimax Shares.

(b)             ADR mean an American Depositary Receipt representing an interest in fully paid ordinary shares in the in the Purchaser (based on the ratio used under the IPO).

(c)             AHI Share means:

(i)             if the NASDAQ Listing has occurred prior to the relevant issue date, an ADR (or, at the election of the Vendors, an AHI ASX Share); and

(ii)             if the NASDAQ Listing has not occurred prior to the relevant issue date, an AHI ASX Share.

11

 

  Term Details
     
   

(d)             AHI Option means the right to acquire an unissued AHI Share.

 

(e)             AHI Performance Right means a right to be issued or transferred an ASHI Share, subject to the terms of the Purchaser’s Incentive Performance Rights Plan.

 

(f)             Applicable Law means the constitutions of the Vendors and Purchaser and all applicable laws and regulations in any jurisdiction.

 

(g)             ASX means ASX Limited (ACN 008 624 691) or the financial market operated by it as the context requires.

 

(h)             ASX Listing Rules means the official listing rules of ASX.

 

(i)             Controlling Shareholders means Ram Shalev and David Kahani.

 

(j)             Conditions means the conditions precedents set out in clause 5.

 

(k)             Completion Date means the day that is five business days after the last of the Conditions have been satisfied or waived in accordance with this Heads of Agreement.

 

(l)             Corporations Act means the Corporations Act 2001 (Cth).

 

(m)             Deemed Conversion Price means the Deemed Issue Price for the issue of a Consideration Share under clause 2(a)(i).

 

(n)             Deemed Issue Price means:

 

(i)             for AHI ASX Shares, the volume weighted average price of AHI ASX Shares for the five trading days prior to the relevant issue date; and

 

(ii)             for ADRs, the issue price of the Purchaser’s ADRs under the IPO.

 

(o)             Formal Agreement has the meaning given in clause 13.

 

(p)             IPO means the Purchaser’s initial public offering of ADRs on the NASDAQ.

 

(q)             NASDAQ means the NASDAQ Stock Market.

 

(r)             NASDAQ Listing means the Purchaser announcing that NASDAQ has provided confirmation to the Purchaser that it has approved the Purchaser’s application for admission to NASDAQ, subject only to conditions that the Purchaser reasonably believes it can satisfy.

 

(s)             Physimax Share means the Physimax Ordinary Shares and the Physimax Preference Shares.

 

(t)             Physimax Option means an option to acquire a Physimax Share.

 

(u)             Physimax Ordinary Share means a fully paid ordinary share in the capital of Physimax.

12

 

  Term Details
     
    (v)              Physimax Preference  Share  means  a  Series  Pre-A Share in the capital  of the Company, of nominal value of NIS 0.01 each.
     
26. Interpretation

Interpretation:

 

(a)             a reference to the symbol "$" or to dollars in this Heads of Agreement are to US dollars;

 

(b)             capitalised terms used in this Heads of Agreement have the definition ascribed above or otherwise in the terms of this Heads of Agreement;

 

(c)             headings are for convenience only and do not affect its interpretation;

 

(d)             an obligation or liability assumed by, or a right conferred on, 2 or more Parties or persons binds or benefits all of them jointly and each of them severally;

 

(e)             the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;

 

(f)             a reference to any Party includes that Party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;

 

(g)             a reference to any document (including this Heads of Agreement) is to that document as varied, novated, ratified or replaced from time to time;

 

(h)             a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;

 

(i)             words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;

 

(j)             reference to Parties, clauses, Schedules or paragraphs are references to Parties, clauses, Schedules and paragraphs to or of this Heads Agreement and a reference to this Heads Agreement includes any Schedule to this Heads Agreement; and

 

(k)             where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning.

  

If the terms and conditions set out above are acceptable, please execute this Heads of Agreement in the appropriate place below.

13

 

 

SCHEDULE 1 – THE VENDORS

 

[SP Comment: to be reviewed and completed by Physimax, please provide the full names of each of the Vendors]

 

Vendor   Address   Number of
Physimax
Ordinary
Shares held
    Number of
Physimax
Preference
Shares held
  % of
Consideration
Securities
Ram Shalev   [insert]     70,000     1,475 (CLA
conversion)
  [insert]
David Kahani   [insert]     20,000     -   [insert]
LSY
International Inc.
  [insert]     25,023     1,967   [insert]
LionBird I L.P.   [insert]     41,111     2,460 (CLA
conversion)
  [insert]
Amichai & Yael Steimberg   [insert]     11,301     4,919   [insert]
RealVest Profit Sharing Plan, Allan Goldberg, Trustee   [insert]     2,842     492   [insert]
The successors of Uri Yogev   [insert]     2,500     -   [insert]
Dr.Haim Blecher   [insert]     3,071     4,919   [insert]
Edtom   [insert]     42,478     4,820+2,460 (CLA
conversion)
  [insert]
SPORTDOCS INVESTMENT LLC   [insert]     5,381     -   [insert]
Physimax Investment LLC   [insert]     6,152     -   [insert]
BAM Investors LLC   [insert]     4,732     -   [insert]
SportGurus LLC   [insert]     5,915     2,951   [insert]
Chaim Friedman (Trust) Ltd   [insert]     1,183     4,919   [insert]
Rob Rubin   [insert]     3,904     9,838   [insert]
Hunter Hamm (BTG)   [insert]     592     -   [insert]

14

 

Vendor   Address   Number of
Physimax
Ordinary Shares
held
    Number of
Physimax
Preference
Shares held
  % of
Consideration
Securities
Pensco Trust for Ricardo Diaz (BTG)   [insert]     592     -   [insert]
Jodies Zwerner Trust (BTG)   [insert]     592     -   [insert]
Irina Meyer (BTG)   [insert]     710     -   [insert]
Leo Loughead (BTG)   [insert]     592     -   [insert]
[Altshuler Shacham ESOP in trust for exercised options (Gofer,Cohen)]   [insert]     3,176     -   [insert]
Civana Kahani               2,459    
Itschak Friedman 2012 Trust               4,919    
TOTAL         251,847     58,428   [insert]

15

 

 

SCHEDULE 2 – PHYSIMAX’S CAPITAL STRUCTURE

 

(a) Physimax Ordinary Shares: 251,847 fully paid ordinary shares, of nominal value of NIS 0.01 each

 

(b) Physimax Preference Shares: means 58,428 fully paid Series Pre-A Share, of nominal value of NIS 0.01 each.

 

(c) Physimax Options:

 

The Options schedule will be provided in the Formal Agreement.

 

(i) [insert] exercisable at $[insert] on or before [insert date]; and

 

(ii) [insert] exercisable at $[insert] on or before [insert date].

 

16

 

 

SCHEDULE 3 – VENDOR AND PHYSIMAX REPRESENTATIONS AND WARRANTIES

  

Part 1 – Vendor Representations and Warranties

 

(a) Power and capacity

 

It has full power and lawful authority to execute and deliver this document and to observe and perform or cause to be observed and performed all of its obligations in and under this document.

 

(b) Incorporation

 

If the Vendor is a company, it was validly incorporated, organised and subsisting in accordance with the laws of its place of incorporation.

 

(c) Authority

 

The execution and delivery of this document has been duly and validly authorised by all necessary corporate action on behalf of the Vendor.

 

(d) No Trust

 

Unless otherwise specified, it enters into and performs this Heads of Agreement on its own account and not as a trustee for or nominee of any other person.

 

(e) Title

 

(i) It is the legal and beneficial owner of the Physimax Shares that are set out against its name in Schedule 1, which are free of all encumbrances and other third party interests or rights and comprise the total issued share capital of the Physimax.

 

(ii) Subject to the Required Approvals (as defined below), It is able to sell and transfer its shares in Physimax without the consent of any other person and free of any pre-emptive rights or rights of first refusal.

 

(f) No legal impediment

 

The execution, delivery and performance of this document by the Vendor does not constitute a breach of any law or obligation or cause a default under any agreement by which the Vendor is bound.

 

Part 2 – Controlling Shareholders Representations and Warranties

 

(a) Power and capacity

 

Subject to obtaining the required approvals from its Board of Directors and the Vendors, and subject further to the Israeli Tax Authorities and the Israeli Innovation Authority required approvals (the Required Approvals), Physimax has full power and lawful authority to execute and deliver this document and to observe and perform or cause to be observed and performed all of its obligations in and under this document.

 

(b) Incorporation

 

Physimax is incorporated and validly existing in accordance with the laws of its place of incorporation.

 

17

 

 

(c) Issued capital

 

(i) The capital structure of Physimax is set out in Schedule 2 and there are no equity securities, debt securities or hybrid securities on issue. Physimax has not issued securities with conversion rights to shares or securities in it and there are no agreements or arrangements under which options or convertible notes have been issued by it.

 

(ii) 100% of the Physimax Ordinary Shares are fully paid and no money is owing in respect of them.

 

(iii) Subject to the Call Option Agreement (which may be exercised and which shall be terminated prior to Completion), no person has any right or option to subscribe for or otherwise to acquire any further shares in Physimax.

 

(iv) Physimax is not under any obligation to allot any shares to any person or persons, or otherwise to alter the structure of any part of its unissued share capital, and Physimax is not under any obligation to give any option over any part of their respective unissued share capital nor has Physimax offered to do any of the matters stated in this sub-paragraph.

 

(d) Subsidiaries

 

Aside from Physimax Technologies, Inc., Physimax does not have any subsidiaries.

 

(e) Compliance with laws

 

To the best of the Controlling Shareholders' knowledge and belief, neither Physimax nor any of their directors are in material breach of any provision of any relevant laws, that might have adverse effect on the assets of Phyimax or on Completion of the transaction.

 

(f) No legal impediment

 

The execution, delivery and performance of this document by Physimax does not constitute a breach of any law or obligation or cause a default under any agreement by which Physimax is bound.

 

(g) No Event of insolvency

 

No event of insolvency has occurred in relation to Physimax, or to the Controlling Shareholders' knowledge – the Vendors, nor, to their knowledge, is there any act which has occurred, or any omission made which may result in an event of insolvency occurring in relation to the Vendors or Physimax.

 

(h) No litigation or investigations

 

(i) Physimax and, to the Controlling Shareholders' knowledge, its directors are not involved in any litigation, arbitration or administrative proceeding relating to claims or amounts relating to Physimax nor is any such litigation, arbitration or administrative proceeding pending or threatened.

 

(ii) There is no litigation or proceeding pending or threatened against the Vendor which may defeat, impair, detrimentally affect or reduce the right, title and interest of Physimax in the assets described in Schedule 6 or of such Vendor in its Physimax Shares.

18

 

(iii) To the Controlling Shareholders' knowledge, Physimax, its directors, and the Vendors are not the subject of any investigation by any regulatory body of any country nor is any such investigation pending or threatened, related to Physimax and the Physimax Shares.

 

(iv) To the Controlling Shareholders' knowledge, Physimax, its directors, and the Vendors are not the subject of any investigation or audit by the tax office of any country or state nor is any such investigation or audit pending or threatened.

 

(i) Consistency

 

The terms of this Heads of Agreement are not inconsistent with and do not contravene the provisions of any other agreements or contract to which Physimax, or to the Controlling Shareholders' knowledge – the Vendors, is a party.

 

(j) Material Contracts

 

Every material contract, instrument or other commitment to which Physimax is a party is disclosed in Schedule 5, valid and binding according to its terms and no party to any such commitment or contract is in material default under the terms of that commitment or contract.

 

(k) Corporate records

 

Physimax’s statutory books (registers, minutes, resolutions) and returns (forms, lodgements) of that entity are up to date or are in the process of being lodged (including without limitation, tax returns), and have been otherwise properly kept in accordance with all legal requirements or practices.

 

(l) Assets

 

(i) All the material fixed assets, current assets and other assets and property owned by Physimax are:

 

(A) accurately described in full in Schedule 6;

 

(B) legally and beneficially owned by Physimax free of encumbrances (and, in particular, no such assets are the subject of any hire purchase agreement or credit purchase agreement or any agreement for payment of deferred terms); and

 

(C) not used by any person, other than Physimax.

 

(ii) Other than as disclosed in writing to Purchaser prior to the date of this Heads of Agreement, Physimax has no material operations, assets or agreements other than the assets described in Schedule 6.

 

(m) Intellectual Property

 

(i) List in Part A of Schedule 6

 

Part A of Schedule 6 accurately describes:

 

(D) all registered and unregistered business names and trade marks;

 

(E) all registered patents and designs;

19

 

 

(F) all domain names; and

 

(G) all applications for registration of trademarks, domain names, patents and designs.

 

which are owned or used at any time by Physimax in connection with its business (together the Intellectual Property Rights).

 

(ii) Right and title

 

Except as set out Schedule 6, Physimax:

 

(A) owns all right, title and interest in and to the Intellectual Property Rights;

 

(B) has not licensed any of the Intellectual Property Rights, other than as presented in the Due Diligence in the ordinary course of business of Physimax granting use licence to its customers as part of its product; and

 

(C) has not assigned or disposed of any right, title or interest in the Intellectual Property Rights.

 

(iii) Legally and beneficially owned

 

The Intellectual Property Rights are:

 

(A) in good standing in terms of any applicable legislation, regulations and other statutory requirements, and to the knowledge of Physimax, is not subject to any license, royalty obligation, assignment or disposal and as at the date of this Heads of Agreement and at Completion, no applications for patents or other types of intellectual property in respect of Physimax have been refused or are considered likely to be refused;

 

(B) legally and beneficially vested in Physimax;

 

(C) to the Controlling Shareholders' knowledge, not being presently infringed, nor are they the subject of any dispute, litigation or expungement application (whether threatened or otherwise); and

 

(D) not subject to any licence or authority in favour of any third party, and, to the Controlling Shareholders' knowledge, the exercise of them does not infringe the rights of any other parties.

 

(iv) Confidential Information

 

To the Controlling Shareholders' knowledge, there has not been any misuse or unauthorised disclosure of any of Physimax’s confidential information.

 

(v) Intellectual Property Licences

 

Part B of Schedule 6 accurately describes all agreements under which Physimax obtains from any person the exclusive or non-exclusive right to use, but not the ownership of, any of intellectual property rights (the Intellectual Property Licences) and each Intellectual Property Licence is valid, binding and enforceable in accordance with its terms. To the Controlling Shareholders’ knowledge, Physimax has complied at all times in all material terms with the terms of the Intellectual Property Licences, and no act or omission has occurred which would entitle a licensor under an Intellectual Property Licence to terminate that licence.

 

20

 

 

(vi) No use by other persons

 

The Controlling Shareholders are not aware of any use by any other person of any Intellectual Property Rights, except under licenses given by Physimax.

 

(vii) No infringement of other right

 

None of the Intellectual Property Rights or other processes now or at any time employed, or the products now or at any time produced by Physimax, constitutes or may constitute, to the Controlling Shareholders' knowledge, an unauthorised infringement of any intellectual property rights of any other person.

 

(n) Liabilities

 

Physimax does not have liabilities, contingent or otherwise, exceeding $50,000 in aggregate, other than certain convertible loan agreements between Physimax and its current shareholders, which will be converted at Completion into Series Pre-A Shares of Physimax (the CLA’s) and an outstanding liability to the IIA (incurred and payable on the ordinary course of business) and any salaries and recurrent expenses incurred in the ordinary course of business.

 

(o) Licenses and approvals

 

To the Controlling Shareholders’ knowledge, Physimax has all permits, licenses, authorities, registrations and approvals necessary for properly carrying on its business and Physimax is not aware of any circumstance or fact which may result in the revocation, variation or non-renewal in any material respect of any such permits, licenses, authorities, registrations and approvals.

 

(p) Claims

 

(i) At Completion, other than to the extent permitted by written consent from Purchaser, Physimax has no claim or obligations exists or will exist at Completion in relation to any existing, proposed or previous directors, managers, officers, employees, agents, consultants or contractors of Physimax.

 

(ii) Physimax has not failed to give any notice or to present any claim under any existing insurance policy.

 

(q) Accounts

 

The accounts disclosed in Annexure A (Last Accounts)

 

(i) disclose a true and fair view of the state of the consolidated affairs, financial position and assets and liabilities of Physimax as at the balance date disclosed in the Last Accounts (Balance Date); For avoidance of doubt, the 2020FS are internal drafts only, subject to adjustments as be directed by Physimax accountants.

21

 

 

(ii) includes all such reserves and provisions for tax as are adequate to cover all tax liabilities (whether or not assessed and whether actual, contingent, deferred or otherwise) of Physimax up to the Balance Date;

 

(iii) contain adequate provisions in respect of all other liabilities (whether actual, contingent, deferred or otherwise) of Physimax as at the Balance Date and proper disclosure (in note form) of any contingent or other liabilities not included or provided therein; and

 

(iv) were prepared:

 

(A) in accordance with the relevant accounting standards prescribed by the jurisdiction(s) in which it operates and were applied on a consistent basis and without making any revaluation of assets; and

 

(B) in the manner described in the notes to them.

 

Since the Balance Date, Physimax’s business has been conducted in all material respects in the ordinary and usual course of business other than for the Acquisition and:

 

(i) there has not been any material change in the nature, amount, valuation or basis of valuation of the assets or in the nature or amount of any liabilities of any shareholder of Physimax;

 

(ii) there has not arisen since the Balance Date any item, transaction or event of a material or unusual nature likely to have a material adverse effect on the operations or results or state of affairs of any shareholder of Physimax;

 

(iii) no amount has been acquired or disposed of, no liability has been incurred except in the ordinary course of business as disclosed in writing to the Purchaser, and no contingent liability has been incurred by any shareholder of Physimax;

 

(iv) none of the debts shown in the Last Accounts have been released or settled for an amount less than that reflected for such debts in the Last Accounts, and all such debts owing to and accounts receivable of the Purchaser are now and at Completion will be good and collectable in the amount disclosed in the Last Accounts (other than for any allowance in the Last Accounts in respect of doubtful debts). To the knowledge of Physimax, all such accounts receivable and debts are not and will not be subject to any counterclaim or set-off except for moneys payable by persons also shown as creditors of Target in the amounts shown in the Last Accounts (as such amounts may have been affected by transactions in the ordinary course of business since the Balance Date);

 

(v) all dividends declared by all shareholders s of Physimax have been properly and validly declared and no dividends have been declared by any shareholder of Physimax since the Balance Date;

 

(vi) To the knowledge of the Controlling Shareholder, no event of insolvency has occurred in respect of any shareholder of Physimax nor has any act occurred or any omission been made which may result in an event of insolvency occurring in respect of any shareholder of Physimax;

22

 

(vii) no shareholder of Physimax has bought back any of its securities, has not converted its securities into a smaller or larger number nor entered into or resolved to approve a buy-back agreement; nor has any act occurred or any omission been made which may result in any of those events occurring in respect of any shareholder of Physimax; and

 

(viii) there has not been a change in the remuneration or benefits paid to or given or expected by any directors, managers, officers, consultants, contractors, agents or employees of any shareholder of Physimax except as stated in the DD process.

 

(r) Financings

 

There are no:

 

(i) financing arrangements entered into by or on behalf of Physimax for the borrowing of money;

 

(ii) debentures, bonds, notes or similar debt instruments issued by any shareholder of Physimax;

 

(iii) guarantees given by any shareholder of Physimax, or to which any shareholder of Physimax is otherwise subject, in relation to any shareholder of Physimax or any other person;

 

(iv) encumbrances over the assets that are set out in Schedule 6; or

 

(v) except for the CLA’s and IIA grant, financing arrangements that restrict the disposal of Physimax.

 

(s) All material information

 

Any information known to the Vendors or Physimax which might reasonably be regarded as material to a purchaser for value of the Physimax Shares has been disclosed to the Purchaser prior to Completion and is true and accurate in all material respects.

23

 

 

SCHEDULE 4 – PURCHASER REPRESENTATIONS AND WARRANTIES

 

The representations and warranties given by the Purchaser are as follows:

 

(a) Issue of the Consideration Shares

 

The Purchaser has full power and authority and has obtained all third party consents necessary to allot and issue the Consideration Shares to the Vendors in accordance with the Applicable Law.

 

(b) Ranking

 

The Consideration Shares will be credited as fully paid and rank pari passu in all respects with all other Shares in the Purchaser on issue.

 

(c) Title to Consideration Shares

 

Upon issue of the Consideration Shares, the Vendors will acquire full legal and beneficial title to the Consideration Shares, free and clear of any encumbrance

 

(d) Trading

 

Unless stated otherwise in the Heads of Agreement, the Consideration Shares, when issued at Completion, are registered for trading on the ASX or NASDAQ, as applicable.

 

(e) Shareholder approval

 

Approval from the Purchaser’s shareholders is not required to offer or issue the Consideration Shares.

 

(f) No legal impediment

 

The execution, delivery and performance by the Purchaser of this Heads of Agreement complies with:

 

(i) each law, regulation, authorisation, ruling, judgement, order or decree of any government agency;

 

(ii) the constitution or other constituent documents of the Purchaser; and

 

(iii) any security interest or document.

 

(g) No litigation

 

Other than as previously disclosed either publicly or specifically to the Vendors and / or Physimax, the Purchaser, its ultimate holding company and / or its subsidiaries are not involved in any litigation, arbitration or administrative proceeding relating to claims or amounts relating to the Purchaser, its ultimate holding company or its subsidiaries nor is any such litigation, arbitration or administrative proceeding pending or threatened. There are no unsatisfied or outstanding judgments, orders, decrees, stipulations, investigations or notices affecting the Purchaser or its subsidiaries or any person for whom the Purchaser or its subsidiaries may be vicariously liable.

24

 

(h) No Event of insolvency

 

No event of insolvency has occurred in relation to the Purchaser nor is there any act which has occurred or any omission made which may result in an event of insolvency occurring in relation to the Purchaser.

 

(i) Binding obligations

 

This agreement constitutes its legal, valid and binding obligations and is enforceable in accordance with its terms.

 

(j) Authorisations

 

The Purchaser has taken all necessary action to authorise the execution, delivery and performance of this Heads of Agreement in accordance with its terms.

 

(k) Continuous disclosure

 

The Purchaser, its ultimate holding company and / or its subsidiaries has complied with all material disclosure requirements under Australian law, including without limitation ASX Listing Rule 3.1 and is not withholding any information from the market under the carve outs set out in ASX Listing Rule 3.1A.

25

 

 

SCHEDULE 5 – CONTRACTS

 

To be provided in the Formal Agreement.

 

26

 

 

SCHEDULE 6 – PHYSIMAX ASSETS

 

To be provided in the Formal Agreement in the following form.

 

Part A – Intellectual Property Rights

 

(a) Business names and trademarks

 

(i)            [insert]; and (ii)

 

(b) Registered patents and designs

 

(i)            [insert]; and (ii)

 

(c) Domain names

 

(i)            [insert]; and (ii)

 

(d) Applications for registration of trademarks, domain names, patents and designs

 

(i)            [insert]; and (ii)

 

Part B – Intellectual Property Licenses

 

(a) [insert]; and

 

(b) [insert].

 

Part C – Other Assets

 

(a) [insert]; and

 

(b) [insert].

27

 

 

Executed by the Parties as an agreement

 

Dated this 27th day of April 2021

 

EXECUTED by ADVANCED HUMAN IMAGING LIMITED (ACN 602 111 115) in accordance with section 127 of the Corporations Act 2001 (Cth):  

)

)

)

     
 
Signature of Chief Executive Office   Signature of company secretary
     
     
Vlado Bosanac   Steven Richards
Name of Chief Executive Office   Name of company secretary
     
EXECUTED by PHYSIMAX TECHNOLOGIES LIMITED in accordance with its constituent documents and place of incorporation:  

)

)

)

)

     
 
Signature of director   Signature of director/company secretary*
     
/s/ Ram Shalev   /s/ David Kahani
Name of director   Name of director/company secretary*

  

28

 

 [SP Comment: if the Vendor is a company]

 

EXECUTED by [INSERT COMPANY NAME]

in accordance with its constituent documents and place of incorporation:

 

)

)

)

)

 

     
Signature of director   Signature of director/company secretary*
     
     
     
Name of director   Name of director/company secretary*

 

*please delete as applicable

 

[SP Comment: if the Vendor is an individual]

 

SIGNED by [INSERT NAME OF INDIVIDUAL]

in the presence of:

 

)

)

)

     
Signature of witness   Signature
     
     
     
Name of witness    

 

29

 

 

ANNEXURE A – LAST ACCOUNTS

 

To be provided in the Formal Agreement.

 

 

30

 

Exhibit 10.10

 

 

 

 

MYFIZIQ LIMITED

ACN 602 111 115

(Company)

 

 

 

 

 

 

 

 

 

 

 

INCENTIVE PERFORMANCE RIGHTS PLAN

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

T A B L E O F C O N T E N T S

 

 

 

1.

DEFINITIONS AND INTERPRETATION 

1
       
  1.1 Definitions 1
  1.2 Interpretations 6
       
2. PURPOSE 7
     
3. COMMENCEMENT AND TERM 7
       
4. OFFER OF PERFORMANCE RIGHTS 8
       
  4.1 Offer 8
  4.2 Offer Document 8
  4.3 Personal Offer 8
  4.4 Nominee 8
  4.5 Minimum Contents of Offer Document 8
  4.6 Number of Performance Rights 9
  4.7 No Consideration 9
  4.8 Vesting Conditions 9
  4.9 Share Restriction Period 9
  4.10 Deferred Taxation 9
  4.11 Quotation of Performance Rights 9
  4.12

Limit on Offers

9
       
5.

ACCEPTANCE OF OFFER

10
       
  5.1 Acceptance of Offer 10
  5.2 Board’s right to reject 10
  5.3 Participant Agrees to be Bound 10
  5.4

Lapse of Offer

10
       
6.

GRANT OF PERFORMANCE RIGHTS

10
       
  6.1 Grant of Performance Rights 10
  6.2 Approvals 11
  6.3

Restrictions on Transfers, Dealings and Hedging

11
       
7.

VESTING AND EXERCISE OF PERFORMANCE RIGHTS

11
       
  7.1 Vesting Conditions 11
  7.2 Vesting Condition Exceptions 11
  7.3 Exercise on Vesting 12
  7.4

One or Several Parcels

12
       
8.

ISSUE OF SHARES

12
       
  8.1 Issue of Shares 12
  8.2 Blackout Period, Takeover Restrictions and Insider Trading 12
  8.3 Withholding 13
  8.4 Rights attaching to Shares 13
  8.5 Share ranking 13
  8.6 Quotation on ASX 13
  8.7

Sale of Shares

13
       
9.

RESTRICTION ON DEALING IN SHARES

14
       
  9.1 Restriction Period 14
  9.2 Waiver of Restriction Period 14
  9.3 No disposal of Restricted Shares 14
  9.4

Enforcement of Restriction Period

14

 

i

 

 

10.

LAPSE OF PERFORMANCE RIGHTS

14
       
  10.1 Lapsing of Performance Right 14
  10.2

Fraud and Related Matters

15
       
11.

EXCHANGE DUE TO CHANGE OF CONTROL

15
       
12.

PARTICIPATION RIGHTS AND REORGANISATION

16
       
  12.1 Participation Rights 16
  12.2 Adjustment for Reorganisation 16
  12.3 Notice of Adjustments 16
  12.4

Cumulative Adjustments

16
       
13.

OVERRIDING RESTRICTIONS ON ISSUE AND EXERCISE

16
       
14.

AMENDMENTS

17
       
  14.1 Power to amend Plan 17
  14.2 Adjustment to Performance Right Terms 17
  14.3

Notice of amendment

17
       
15.

TRUST

17
       
16.

MISCELLANEOUS

18
     
  16.1 Rights and obligations of Participant 18
  16.2 Power of the Board 19
  16.3 Dispute or disagreement 19
  16.4 ASIC relief 19
  16.5 Non-residents of Australia 19
  16.6 Communication 20
  16.7 Attorney 20
  16.8 Costs and Expenses 20
  16.9 Adverse Tax 20
  16.10 Data protection 21
  16.11 Error in Allocation 21
  16.12 No fiduciary capacity 21
  16.13 ASX Listing Rules 21
  16.14 Enforcement 21
  16.15 Laws governing Plan 21
       
SCHEDULE 1 – PERFORMANCE RIGHTS PLAN – OFFER DOCUMENT 22
SCHEDULE 2 – PERFORMANCE RIGHTS PLAN ACCEPTANCE FORM 25
SCHEDULE 3 – NOTICE OF EXERCISE OF PERFORMANCE RIGHTS 27

 

ii

 

 

MY FIZIQ LIMITED

 

INCENTIVE PERFORMANCERIGHTS PLAN

 

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 Definitions

 

For the purposes of the Plan, the following words have the following meanings.

 

Acceptance Form means the Acceptance Form by which an Eligible Participant or Nominee (as applicable) accepts an Offer for Performance Rights, in substantially the same form as set out in Schedule 2 or as otherwise approved by the Company from time to time.

 

MYQ Incentive Performance Rights Plan (final) 1

 

 

 

ASIC means the Australian Securities and Investments Commission.

 

Associated Body Corporate means:

 

(a) a related body corporate (as defined in the Corporations Act) of the Company;

 

(b) a body corporate which has an entitlement to not less than 20% of the voting Shares of the Company; and

 

(c) a body corporate in which the Company has an entitlement to not less than 20% of the voting shares.

 

ASX means ASX Limited (ACN 008 624 691) or the Australian Securities Exchange, as the context requires.

 

ASX Listing Rules means the official Listing Rules of the ASX as they apply to the Company from time to time.

 

Blackout Period means a period when the Participant is prohibited from trading in the Company's securities by the Company's written policies.

 

Board means the board of Directors of the Company or committee appointed by the Board for the purposes of the Plan.

 

Business Day means a day on which banks are open for general banking business in Western Australia, excluding Saturdays, Sundays and public holidays in Western Australia.

 

Change of Control means:

 

(a) a bona fide Takeover Bid is declared unconditional and the bidder has acquired a Relevant Interest in at least 50.1% of the Company’s issued Shares;

 

(b) a court approves, under Section 411(4)(b) of the Corporations Act, a proposed compromise or arrangement for the purposes of, or in connection with, a scheme for the reconstruction of the Company or its amalgamation with any other company or companies; or

 

(c) in any other case, a person obtains Voting Power in the Company which the Board (which for the avoidance of doubt will comprise those Directors immediately prior to the person acquiring that Voting Power) determines, acting in good faith and in accordance with their fiduciary duties, is sufficient to control the composition of the Board

 

Class Order means ASIC Class Order 14/1000 as amended or replaced.

 

Closing Date means the date on which an Offer is stated to close.

 

Company means MyFiziq Limited (ACN 602 111 115).

 

Corporations Act means the Corporations Act 2001 (Cth).

 

MYQ Incentive Performance Rights Plan (final) 2

 

 

 

Director means any person occupying the position of a director of any Group Company (including an alternate director or managing director appointed in accordance with the relevant constitution).

 

Eligible Participant means:

 

(a) a Director (whether executive or non-executive) of any Group Company;

 

(b) a full or part time employee of any Group Company;

 

(c) a casual employee or contractor of a Group Company to the extent permitted by the Class Order; or

 

(d) a prospective participant, being a person to whom the Offer is made but who can only accept the Offer if an arrangement has been entered into that will result in the person becoming an Eligible Participant under Rules (a), (b) or (c) above,

 

who is declared by the Board to be eligible to receive grants of Performance Rights under the Plan.

 

Expiry Date means, in respect of a Performance Right, the date on which the Performance Right lapses (if it has not already otherwise lapsed in accordance with the Plan).

 

Grant Date means, in relation to a Performance Right, the date on which the Performance Right is granted.

 

Group means the Company and each other Associated Body Corporate. Group Company means the Company or any Associated Body Corporate. Holding Lock has the meaning given to that term in the ASX Listing Rules.

Marketable Parcel has the meaning given to that term in the ASX Listing Rules.

 

Nominee means a nominee of an Eligible Participant that is one of the following:

 

(a) an immediately family member of the Eligible Participant or (subject to Board approval) a trustee of an Eligible Participant’s family trust whose beneficiaries are limited to the Eligible Participant and/or the Eligible Participant’s immediate family members;

 

(b) a company whose members comprise no persons other than the Eligible Participant or immediate family members of the participant; or

 

(c) a corporate trustee of a self-managed superannuation fund (within the meaning of the Superannuation Industry (Supervision) Act 1993) where the Eligible Participant is a director of the trustee.

 

Offer means an offer made to an Eligible Participant to be granted one or more Performance Rights under the Plan as set out in an Offer Document.

 

MYQ Incentive Performance Rights Plan (final) 3

 

 

 

  (e) Offer Document means an offer document in substantially the same form as set out in

 

Schedule 1, or such other form as approved by the Board from time to time consistent with the Corporations Act and the Class Order.

 

Participant means an Eligible Participant to whom Performance Rights have been granted under the Plan or, if Rule 4.4 applies, a Nominee of the Eligible Participant to whom Performance Rights have been granted under the Plan.

 

Performance Right means a right to acquire a Share, subject to satisfaction of any Vesting Conditions, and the corresponding obligation of the Company to provide the Share, under a binding contract made by the Company and an Eligible Participant in the manner set out in this Plan.

 

Plan means the plan as set out in this document, subject to any amendments or additions made under Rule 14.

 

Redundancy means termination of the employment, office or engagement of a Relevant Person due to economic, technological, structural or other organisational change where:

 

(a) no Group Company requires the duties and responsibilities carried out by the Relevant Person to be carried out by anyone; or

 

(b) no Group Company requires the position held by the Relevant Person to be held by anyone.

 

Relevant Interest has the meaning given in the Corporations Act.

 

MYQ Incentive Performance Rights Plan (final) 4

 

 

 

Relevant Person means:

 

(a) in respect of an Eligible Participant, that person; and

 

(b) in respect of a Nominee of an Eligible Participant, that Eligible Participant.

 

Restriction Period means the period during which a Share issued on the exercise of a Performance Right cannot be transferred or otherwise dealt with in accordance with Rule 9.

 

Restricted Shares means Shares issued on the exercise of a Performance Right granted under the Plan that the Board has determined are subject to a Restriction Period.

 

Retirement means where a Relevant Person intends to permanently cease all gainful employment in circumstances where the Relevant Person provides, in good faith, a written statutory declaration to the Board to that effect.

 

Rules means the rules of the Plan set out in this document.

 

Severe Financial Hardship means that the Relevant Person is unable to provide themselves, their family or other dependents with basic necessities such as food, accommodation and clothing, including as a result of family tragedy, financial misfortune, serious illness, impacts of natural disaster and other serious or difficult circumstances.

 

Share means a fully paid ordinary share in the capital of the Company.

 

Shareholder means a holder of Shares.

 

MYQ Incentive Performance Rights Plan (final) 5

 

 

 

Special Circumstances means:

 

(a) a Relevant Person ceasing to be an Eligible Participant due to:

 

(i) death or Total or Permanent Disability of a Relevant Person; or

 

(ii) Retirement or Redundancy of a Relevant Person;

 

(b) a Relevant Person suffering Severe Financial Hardship;

 

(c) any other circumstance stated to constitute “Special Circumstances” in the terms of the relevant Offer made to and accepted by the Participant; or

 

(d) any other circumstances determined by the Board at any time (whether before or after the Offer) and notified to the relevant Participant which circumstances may relate to the Participant, a class of Participant, including the Participant or particular circumstances or class of circumstances applying to the Participant.

 

Takeover Bid means a takeover bid (as defined in the Corporations Act) to acquire Shares.

 

Total and Permanent Disability means that the Relevant Person has, in the opinion of the Board, after considering such medical and other evidence as it sees fit, become incapacitated to such an extent as to render the Relevant Person unlikely ever to engage in any occupation with the Company or its Associated Bodies Corporate for which he or she is reasonably qualified by education, training or experience.

 

Vesting Condition means, in respect of a Performance Right, any condition set out in the Offer which must be satisfied (unless waived in accordance with the Plan) before that Performance Right can be exercised or any other restriction on exercise of that Performance Right specified in the Offer or in this Plan.

 

Voting Power has the meaning given to that term in Section 9 of the Corporations Act.

 

 

1.2 Interpretations

 

In this Plan unless the context otherwise requires:

 

(a) headings are for convenience only and do not affect the interpretation of this Plan;

 

(b) any reference in the Plan to any enactment of the ASX Listing Rules includes a reference to that enactment or those ASX Listing Rules as from time to time amended, consolidated, re-enacted or replaced;

 

(c) the singular includes the plural and vice versa;

 

(d) any words denoting one gender include the other gender;

 

(e) where any word or phrase is given a definite meaning in this Plan, any part of speech or other grammatical form of that word or phrase has a corresponding meaning;

 

MYQ Incentive Performance Rights Plan (final) 6

 

 

 

(f) a reference to:

 

  (i) a person includes a natural person, partnership, joint venture, government agency, association, corporation or other body corporate;
     
  (ii) a document includes all amendments or supplements to that document;
     
  (iii) a Rule is a reference to a Rule of this Plan;
     
  (iv) a law includes a constitutional provision, treaty, decree, convention, statute, regulation, ordinance, by-law, judgment, rule of common law or equity and is a reference to that law as amended, consolidated or replaced;
     
  (v) an agreement other than this Plan includes an undertaking, or legally enforceable arrangement or understanding, whether or not in writing; and
     
  (vi) a monetary amount is in Australian dollars; and

 

(g) when the day on which something must be done is not a Business Day, that thing must be done on the following Business Day.

 

 

2. PURPOSE

 

The purpose of the Plan is to:

 

(a) assist in the reward, retention and motivation of Eligible Participants;

 

(b) link the reward of Eligible Participants to performance and the creation of Shareholder value;

 

(c) align the interests of Eligible Participants more closely with the interests of Shareholders by providing an opportunity for Eligible Participants to receive Shares;

 

(d) provide Eligible Participants with the opportunity to share in any future growth in value of the Company; and

 

(e) provide greater incentive for Eligible Participants to focus on the Company's longer term goals.

 

 

3. COMMENCEMENT AND TERM

 

(a) This Plan will commence on the date determined by resolution of the Board and will continue until terminated by the Board.

 

(b) The Board may terminate the Plan at any time by resolution. Termination shall not affect the rights or obligations of a Participant or the Company which have arisen under the Plan before the date of termination and the provisions of the Plan relating to a Participant’s Performance Rights shall survive termination of the Plan until fully satisfied and discharged.

 

MYQ Incentive Performance Rights Plan (final) 7

 

 

 

 

4. OFFER OF PERFORMANCE RIGHTS

 

4.1 Offer

 

(a) The Board may, from time to time, in its absolute discretion, make a written offer to any Eligible Participant (including an Eligible Participant who has previously received an Offer) to apply for Performance Rights, upon the terms set out in the Plan and upon such additional terms and conditions as the Board determines (Offer).

 

(b) In exercising that discretion, the Board may have regard to the following (without limitation):

 

  (i) the Eligible Participant's length of service with the Group;
     
  (ii) the contribution made by the Eligible Participant to the Group;
     
  (iii) the potential contribution of the Eligible Participant to the Group; or
     
  (iv) any other matter the Board considers relevant.

 

(c) For the avoidance of doubt, nothing in this document obliges the Company at any time to make an Offer, or further Offer, to any Eligible Participant.

 

4.2 Offer Document

 

An Offer must be made using an Offer Document.

 

4.3 Personal Offer

 

Subject to Rule 4.4, an Offer is personal and is not assignable.

 

4.4 Nominee

 

(a) Upon receipt of an Offer, an Eligible Participant may, by notice in writing to the Board, nominate a Nominee in whose favour the Eligible Participant wishes to renounce the Offer.

 

(b) The Board may, in its discretion, resolve not to allow a renunciation of an Offer in favour of a Nominee without giving any reason for that decision.

 

4.5 Minimum Contents of Offer Document

 

An Offer Document must advise the Eligible Participant of the following minimum information regarding the Performance Rights:

 

(a) the maximum number of Performance Rights that the Eligible Participant may apply for, or the formula for determining the number of Performance Rights that may be applied for;

 

(b) the maximum number of Shares that the Participant is entitled to be issued on the exercise of each Performance Right or the formula for determining the maximum number of Shares;

 

(c) any applicable Vesting Conditions;

 

MYQ Incentive Performance Rights Plan (final) 8

 

 

 

(d) any Restriction Period the Board has resolved to apply to Shares issued on exercise of the Performance Rights;

 

(e) when unvested Performance Rights will expire (Expiry Date);

 

(f) the date by which an Offer must be accepted (Closing Date); and

 

(g) any other information required by law or the ASX Listing Rules or considered by the Board to be relevant to the Performance Rights or the Shares to be issued on the exercise of the Performance Rights.

 

4.6 Number of Performance Rights

 

(a) Subject to Rule 4.12, the number of Performance Rights to be offered to an Eligible Participant from time to time will be determined by the Board in its discretion and in accordance with applicable law and the ASX Listing Rules.

 

(b) Each Performance Right will entitle the holder to subscribe for and be allotted one Share unless the Offer otherwise provides.

 

4.7 No Consideration

 

Performance Rights granted under the Plan will be issued for nil cash consideration.

 

4.8 Vesting Conditions

 

A Performance Right may be made subject to Vesting Conditions as determined by the Board in its discretion and as specified in the Offer for the Performance Right.

 

4.9 Share Restriction Period

 

A Share issued on exercise of a Performance Right may be subject to a Restriction Period as determined by the Board in accordance with Rule 9 of this Plan.

 

4.10 Deferred Taxation

 

Subdivision 83A-C of the Income Tax Assessment Act 1997 applies to the Plan except to the extent an Offer provides otherwise.

 

4.11 Quotation of Performance Rights

 

Performance Rights will not be quoted on the ASX, except to the extent provided for by this Plan or unless the Offer provides otherwise.

 

4.12 Limit on Offers

 

The Company must have reasonable grounds to believe, when making an Offer, that the number of Shares to be received on exercise of Performance Rights offered under an Offer, when aggregated with the number of Shares issued or that may be issued as a result of offers made in reliance on the Class Order at any time during the previous 3 year period under an employee incentive scheme covered by the Class Order or an ASIC exempt arrangement of a similar kind to an employee incentive scheme, will not exceed 5% of the total number of Shares on issue at the date of the Offer.

 

MYQ Incentive Performance Rights Plan (final) 9

 

 

 

 

5. ACCEPTANCE OF OFFER

 

5.1 Acceptance of Offer

 

An Eligible Participant (or permitted Nominee) may accept an Offer in whole or in part, by signing and returning an Acceptance Form to the Company no later than the Closing Date.

 

5.2 Board’s right to reject

 

(a) The Board may accept or reject any Acceptance Form in its absolute discretion.

 

(b) Before accepting or rejecting the Acceptance Form, the Board may require the applicant to provide any information that the Board requests concerning the person's entitlement to lodge an Acceptance Form under this Plan.

 

(c) The Board must promptly notify an applicant if an Acceptance Form has been rejected, in whole or in part.

 

5.3 Participant Agrees to be Bound

 

(a) An Eligible Participant, by submitting an Acceptance Form, agrees to be bound by the terms and conditions of the Offer and the Acceptance Form, the Plan and the Constitution of the Company, as amended from time to time.

 

(b) If the Board resolves to allow a renunciation of an Offer in favour of a Nominee, the Eligible Participant will procure that the permitted Nominee accepts the Offer made to that Eligible Participant and that both the Eligible Participant and the Nominee agree be bound by the terms and conditions of the Offer and Acceptance Form, the Plan and the Constitution of the Company, as amended from time to time.
5.4 Lapse of Offer

 

To the extent an Offer is not accepted in accordance with Rule 5.1, the Offer will lapse on the date following the Closing Date, unless the Board determines otherwise.

 

 

6. GRANT OF PERFORMANCE RIGHTS

 

6.1 Grant of Performance Rights

 

(a) Subject to Rule 6.2, once the Board has received and accepted a duly signed and completed Acceptance Form for Performance Rights, the Company must, provided the Eligible Participant to whom the Offer was made remains an Eligible Participant, promptly grant Performance Rights to the applicant, upon the terms set out in the Offer, the Acceptance Form and the Plan and upon such additional terms and conditions as the Board determines.

 

(b) The Company will, within a reasonable period after the Grant Date of the Performance Rights, issue the applicant with a certificate evidencing the grant of the Performance Rights.

 

MYQ Incentive Performance Rights Plan (final) 10

 

 

 

6.2 Approvals

 

The Company’s obligation to grant Performance Rights is conditional on:

 

(a) the grant of the Performance Rights complying with all applicable legislation and the ASX Listing Rules; and

 

(b) all necessary approvals required under any applicable legislation and the ASX Listing Rules being obtained prior to the grant of the Performance Rights.

 

6.3 Restrictions on Transfers, Dealings and Hedging

 

(a) Subject to the ASX Listing Rules, a Performance Right granted under the Plan is only transferable, assignable or able to be otherwise disposed or encumbered:

 

  (i) in Special Circumstances with the consent of the Board (which may be withheld in its absolute discretion); or
     
  (ii) by force of law upon death to the Participant’s legal personal representative or upon bankruptcy to the Participant’s trustee in bankruptcy.

 

(b) A Participant must not enter into any arrangement for the purpose of hedging, or otherwise affecting their economic exposure, to their Performance Rights.

 

(c) Where the Participant purports to transfer, assign, mortgage, charge or otherwise dispose or encumber a Performance Right, other than in accordance with Rule 6.3(a), or hedge a Performance Right contrary to Rule 6.3(b), the Performance Right immediately lapses.

 

 

7. VESTING AND EXERCISE OF PERFORMANCE RIGHTS

 

7.1 Vesting Conditions

 

(a) Subject to Rules 7.2 and 7.3, a Performance Right granted under the Plan will not vest and be exercisable unless the Vesting Conditions (if any) attaching to that Performance Right have been satisfied and the Board has notified the Participant of that fact.

 

(b) The Board must notify a Participant in writing within 10 Business Days of becoming aware that any Vesting Condition attaching to a Performance Right has been satisfied.

 

7.2 Vesting Condition Exceptions

 

Notwithstanding Rule 7.1, the Board may in its absolute discretion except in respect of clause 7.2(b), where Vesting Conditions are deemed to be automatically waived, by written notice to a Participant, resolve to waive any of the Vesting Conditions applying to Performance Rights due to:

 

(a) Special Circumstances arising in relation to a Relevant Person in respect of those Performance Rights;

 

(b) a Change of Control occurring; or

 

(c) the Company passing a resolution for voluntary winding up, or an order is made for the compulsory winding up of the Company, in which case Rule 7.3 applies.

 

MYQ Incentive Performance Rights Plan (final) 11

 

 

 

7.3 Exercise on Vesting

 

A Participant (or their personal legal representative where applicable) may exercise any vested Performance Right at any time after the Board notifies that the Performance Right has vested and before it lapses by providing the Company with:

 

(a) the certificate for the Performance Rights or, if the certificate for the Performance Rights has been lost, mutilated or destroyed, a declaration to that effect, accompanied by an indemnity in favour of the Company against any loss, costs or expenses which might be incurred by the Company as a consequence of its relying on the declaration that the certificate has been lost, mutilated or destroyed; and

 

(b) a notice in the form of Schedule 3 addressed to the Company and signed by the Participant stating that the Participant exercises the Performance Rights and specifying the number of Performance Rights which are exercised.

 

7.4 One or Several Parcels

 

Performance Rights may be exercised in one or more parcels of any size, provided that the number of Shares issued upon exercise of the number of Performance Rights in any parcel is not less than a Marketable Parcel.

 

 

8. ISSUE OF SHARES

 

8.1 Issue of Shares

 

If the items specified in Rule 7.3 are delivered in accordance with that Rule, the Company will, subject to the Corporations Act, the ASX Listing Rules, this Plan and any applicable Offer:

 

(a) within 10 Business Days of delivery of the documents referred to in Rule 7.3 issue to the Participant the Shares credited as being fully paid in respect of which the Performance Rights are exercised, together with any additional Shares an entitlement to which has arisen under Rule 12 in consequence of the exercise of the Performance Rights; and

 

(b) cancel the certificate delivered pursuant to Rule 7.3 and, if any Performance Rights which have not lapsed remain unexercised, deliver to the Participant a replacement certificate reflecting the number of those Performance Rights which remain unexercised.

 

8.2 Blackout Period, Takeover Restrictions and Insider Trading

 

If the issue of Shares on exercise of a Performance Right would otherwise fall within a Blackout Period, or breach the insider trading or takeover provisions of the Corporations Act, the Company may delay the issue of the Shares until 10 Business Days following the expiration, as applicable, of the Blackout Period or the day on which the insider trading or takeover provisions no longer prevent the issue of the Shares.

 

MYQ Incentive Performance Rights Plan (final) 12

 

 

 

8.3 Withholding

 

If a Participant is liable for tax, duties or other amounts on the vesting or exercise of their Performance Rights, and the Company is liable to make a payment to the appropriate authorities on account of that liability, unless the Participant and the Company agree otherwise, the Company must issue and sell such number of Shares which would otherwise be issued and allocated to the Participant so that the net proceeds of sale equal the payment the Company is required to pay to the appropriate authorities.

 

8.4 Rights attaching to Shares

 

A Participant will, from and including the issue date of Shares under this Plan, be the legal owner of the Shares issued in respect of them and will be entitled to dividends and to exercise voting rights attached to the Shares.

 

8.5 Share ranking

 

All Shares issued under the Plan will rank equally in all respects with the Shares of the same class for the time being on issue except as regards any rights attaching to such Shares by reference to a record date prior to the date of their issue.

 

8.6 Quotation on ASX

 

(a) If Shares of the same class as those issued under the Plan are quoted on the ASX, the Company will, subject to the ASX Listing Rules, apply to the ASX for those Shares to be quoted on ASX within the later of 10 Business Days after:

 

  (i) the date the Shares are issued; and
     
  (ii) the date any Restriction Period that applies to the Shares ends.

 

(b) The Company will not apply for quotation of any Performance Rights on the ASX.

 

8.7 Sale of Shares

 

(a) Subject to Rule 9 (Restriction on Dealing in Shares), there will be no transfer restrictions on Shares issued under the Plan unless the sale, transfer or disposal by the Participant of the Shares issued to them on exercise of the Performance Rights (or any interest in them) would require the preparation of a disclosure document (as that term is defined in the Corporations Act).

 

(b) If a disclosure document is required, the Participant agrees to enter into such arrangements with the Company as the Board considers appropriate to prevent the sale, transfer or disposal of the relevant Shares in a manner that would require a disclosure document to be prepared.

 

(c) The Company will issue, where required to enable Shares issued on exercise of Performance Rights to be freely tradeable on the ASX (subject to any Restriction Period), a cleansing statement under Section 708A(5) of the Corporations Act at the time Shares are issued. Where a cleansing statement is required, but cannot be issued, the Company will lodge a prospectus in relation to the Shares with ASIC which complies with the requirements of the Corporations Act and allows the Shares to be freely tradeable on the ASX (subject to any Restriction Period).

 

MYQ Incentive Performance Rights Plan (final) 13

 

 

 

 

9. RESTRICTION ON DEALING IN SHARES

 

9.1 Restriction Period

 

Subject to clause 9.4, the Board may, in its discretion, determine at any time up until exercise of Performance Rights, that a restriction period will apply to some or all of the Shares issued to a Participant on exercise of those Performance Rights (Restricted Shares), up to a maximum of seven (7) years from the Grant Date of the Performance Rights (Restriction Period).

 

9.2 Waiver of Restriction Period

 

Subject to clause 9.4, the Board may, in its sole discretion, having regard to the circumstances at the time, waive a Restriction Period determined pursuant to Rule 9.1.

 

9.3 No disposal of Restricted Shares

 

A Participant must not dispose of or otherwise deal with any Shares issued to them under the Plan while they are Restricted Shares.

 

9.4 ASX Imposed Escrow

 

The Company must impose a Restriction Period on Shares to the extent necessary to comply with any escrow restrictions imposed by the ASX Listing Rules.

 

9.5 Enforcement of Restriction Period

 

(a) The Company may implement any procedure it considers appropriate to restrict a Participant from dealing with any Shares for as long as those Shares are subject to a Restriction Period.

 

(b) The Participant agrees to:

 

  (i) execute an ASX restriction agreement in relation to the Shares reflecting any Restriction Period applying to the Restricted Shares under the Plan;
     
  (ii) the Company lodging the share certificates for Shares (where issuer sponsored) with a bank or recognised trustee to hold until the expiry of any Restriction Period applying to the Shares or until the Shares are otherwise released from restrictions (at which time the Company shall arrange for the share certificates to be provided to the Participant); and
     
  (iii) the application of a Holding Lock over Shares until any Restriction Period applying to the Shares under the Plan has expired (at which time the Company shall arrange for the Holding Lock to be removed).

 

 

10. LAPSE OF PERFORMANCE RIGHTS

 

10.1 Lapsing of Performance Right

 

A Performance Right will lapse upon the earlier to occur of:

 

(a) an unauthorised dealing in, or hedging of, the Performance Right occurring, as governed by Rule 6.3(c);

 

MYQ Incentive Performance Rights Plan (final) 14

 

 

 

(b) a Vesting Condition in relation to the Performance Right is not satisfied by the due date, or becomes incapable of satisfaction, as determined by the Board in its absolute discretion, unless the Board exercises its discretion to waive the Vesting Condition and vest the Performance Right under Rule 7.2 (Vesting Condition Exceptions) or clause 10.1(c)(ii) applies;

 

(c) in respect of unvested Performance Rights only, a Relevant Person ceases to be an Eligible Participant, unless the Board:

 

  (i) exercises its discretion to vest the Performance Right under Rule 7.2 (Vesting Condition Exceptions); or
     
  (ii) in its absolute discretion, resolves to allow the unvested Performance Rights to remain unvested after the Relevant Person ceases to be an Eligible Participant;

 

(d) in respect of vested Performance Rights only, a Relevant Person ceases to be an Eligible Participant and the Performance Right granted in respect of that Relevant Person is not exercised within one (1) month (or such later date as the Board determines) of the date the Relevant Person ceases to be an Eligible Participant;

 

(e) the Board deems that a Performance Right lapses due to fraud, dishonesty or other improper behaviour of the holder/Eligible Participant under Rule 10.2 (Fraud and Related Matters);

 

(f) the Company undergoes a Change of Control or a winding up resolution or order is made, and the Performance Right does not vest in accordance with Rule 7.2 (Vesting Condition Exceptions); and

 

(g) the Expiry Date of the Performance Right.

 

10.2 Fraud and Related Matters

 

Notwithstanding any other provision of this document, where a Relevant Person:

 

(a) in the opinion of the Board, acts fraudulently or dishonestly, is grossly negligent, demonstrates serious and wilful misconduct, or causes a material adverse effect on the reputation of the Company;

 

(b) has his or her employment or office terminated due to serious or wilful misconduct or otherwise for cause without notice; or

 

(c) becomes ineligible to hold his or her office due to Part 2D.6 of the Corporations Act,

 

the Board may, by written notice to the Participant, deem any unvested, or vested but unexercised, Performance Rights of the Participant to have lapsed or require the Participant to do all such things necessary to cancel any Shares issued on exercise of the Participant’s Performance Rights.

 

 

11. EXCHANGE DUE TO CHANGE OF CONTROL

 

If a company (Acquiring Company) obtains control of the Company as a result of a Change of Control and both the Company and the Acquiring Company agree, a Participant may, in respect of any vested Performance Rights that are exercised, be provided with shares of the Acquiring Company, or its parent, in lieu of Shares, on substantially the same terms and subject to substantially the same conditions as the Shares, but with appropriate adjustments to the number and kind of shares subject to the Performance Rights.

 

MYQ Incentive Performance Rights Plan (final) 15

 

 

 

 

12. PARTICIPATION RIGHTS AND REORGANISATION

 

12.1 Participation Rights

 

(a) There are no participating rights or entitlements inherent in the Performance Rights and Participants will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Performance Rights without exercising the Performance Right.

 

(b) A Performance Right does not confer the right to a change in the number of underlying Shares over which the Performance Right can be exercised.

 

(c) A Participant who is not a Shareholder is not entitled to:

 

  (i) notice of, or to vote or attend at, a meeting of the Shareholders of the Company; or
     
  (ii) receive any dividends declared by the Company, unless and until any Performance Right is exercised and the Participant holds Shares that provide the right to notice and dividends.

 

12.2 Adjustment for Reorganisation

 

If, at any time, the issued capital of the Company is reorganised (including consolidation, subdivision, reduction or return), all rights of a Participant are to be changed in a manner consistent with the Corporations Act and the ASX Listing Rules at the time of the reorganisation.

 

12.3 Notice of Adjustments

 

Whenever the number of Shares to be issued on the exercise of a Performance Right is adjusted pursuant to these Rules, the Company will give notice of the adjustment to the Participant and ASX together with calculations on which the adjustment is based.

 

12.4 Cumulative Adjustments

 

Effect will be given to Rule 12.3 in such manner that the effect of the successive applications of them is cumulative, with the intention being that the adjustments they progressively effect will reflect previous adjustments.

 

 

13. OVERRIDING RESTRICTIONS ON ISSUE AND EXERCISE

 

Notwithstanding the Rules or the terms of any Performance Right, no Performance Right may be offered, granted or exercised and no Share may be issued under the Plan if to do so:

 

(a) would contravene the Corporations Act, the ASX Listing Rules or any other applicable law; or

 

(b) would contravene the local laws or customs of an Eligible Participants country of residence or in the opinion of the Board would require actions to comply with those local laws or customs which are impractical.

 

MYQ Incentive Performance Rights Plan (final) 16

 

 

 

 

14. AMENDMENTS

 

14.1 Power to amend Plan

 

Subject to Rule 14.2, the Corporations Act and the ASX Listing Rules:

 

(a) the Board may, at any time, by resolution amend or add to all or any of the provisions of the Plan, an Offer or the terms or conditions of any Performance Right granted under the Plan; and

 

(b) any amendment may be given such retrospective effect as is specified in the written instrument or resolution by which the amendment is made.

 

14.2 Adjustment to Performance Right Terms

 

No adjustment or variation of the terms of a Performance Right will be made without the consent of the Participant who holds the relevant Performance Right if such adjustment or variation would have a materially prejudicial effect upon the Participant (in respect of his or her outstanding Performance Rights), other than an adjustment or variation introduced primarily:

 

(a) for the purpose of complying with or conforming to present or future State, Territory or Commonwealth legislation governing or regulating the maintenance or operation of the Plan or like plans;

 

(b) to correct any manifest error or mistake;

 

(c) to enable a member of the Group to comply with the Corporations Act, the ASX Listing Rules, applicable foreign law, or a requirement, policy or practice of the ASIC or other foreign or Australian regulatory body; or

 

(d) to take into consideration possible adverse taxation implications in respect of the Plan, including changes to applicable taxation legislation or the interpretation of that legislation by a court of competent jurisdiction or any rulings from taxation authorities administering such legislation.

 

14.3 Notice of amendment

 

As soon as reasonably practicable after making any amendment under Rule 14.1, the Board will give notice in writing of that amendment to any Participant affected by the amendment.

 

 

15. TRUST

 

(a) The Board may, at any time, establish a trust for the sole purpose of acquiring and holding Shares in respect of which a Participant may exercise, or has exercised, vested Performance Rights, including for the purpose of enforcing the disposal restrictions and appoint a trustee to act as trustee of the trust.

 

(b) The trustee will hold the Shares as trustee for and on behalf of a Participant as beneficial owner upon the terms of the trust.

 

(c) The Board may at any time amend all or any of the provisions of this Plan to effect the establishment of a trust and the appointment of a trustee as detailed in this Rule.

 

MYQ Incentive Performance Rights Plan (final) 17

 

 

 

 

16. MISCELLANEOUS

 

16.1 Rights and obligations of Participant

 

(a) The rights and obligations of an Eligible Participant under the terms of their office, employment or contract with a Group Company are not affected by their participating in the Plan. This Plan will not form part of, and are not incorporated into, any contract of any Eligible Participant (whether or not they are an employee of a Group Company).

 

(b) No Participant will have any rights to compensation or damages in consequence of:

 

  (i) the termination, for any reason, of the office, employment or other contract with a Group Company of the Participant (or, where the Participant is a Nominee of the Eligible Participant, that Eligible Participant) where those rights arise, or may arise, as a result of the Participant ceasing to have rights under the Plan as a result of such termination; or
     
  (ii) the lapsing of Performance Rights in accordance with this Plan.

 

(c) Nothing in this Plan, participation in the Plan or the terms of any Performance Right:

 

  (i) affects the rights of any Group Company to terminate the employment, engagement or office of an Eligible Participant or a Participant (as the case may be);
     
  (ii) affects the rights and obligations of any Eligible Participant or Participant under the terms of their employment, engagement or office with any Group Company;
     
  (iii) confers any legal or equitable right on an Eligible Participant or a Participant whatsoever to take action against any Group Company in respect of their employment, engagement or office;
     
  (iv) confers on an Eligible Participant or a Participant any rights to compensation or damages in consequence of the termination of their employment, engagement or office by any Group Company for any reason whatsoever including ceasing to have rights under the Plan as a result of such termination; or
     
(v) confers any responsibility or liability or any Group Company or its directors, officers, employees, representatives or agents in respect of any taxation liabilities of the Eligible Participant or Participant.

 

(d) If a Vesting Condition attached to a Performance Right requires a Participant to remain an employee of a Group Company, then the Participant will be treated as having ceased to be an employee of a Group Company at such time the Participant’s employer ceases to be a Group Company.

 

(e) A Participant who is granted an approved leave of absence and who exercises their right to return to work under any applicable award, enterprise agreement, other agreement, statute or regulation before the exercise of a Performance Right under the Plan will be treated for those purposes as not having ceased to be such an employee.

 

MYQ Incentive Performance Rights Plan (final) 18

 

 

 

16.2 Power of the Board

 

(a) The Plan is administered by the Board which has power to:

 

  (i) determine appropriate procedures for administration of the Plan consistent with this Plan; and
     
  (ii) delegate to any one or more persons, for such period and on such conditions as it may determine, the exercise of any of its powers or discretions arising under the Plan.

 

(b) Except as otherwise expressly provided in this Plan, the Board has absolute and unfettered discretion to act, or refrain from acting, under or in connection with the Plan or any Performance Rights under the Plan and in the exercise of any power or discretion under the Plan.

 

16.3 Dispute or disagreement

 

In the event of any dispute or disagreement as to the interpretation of the Plan, or as to any question or right arising from or related to the Plan or to any Performance Rights granted under it, the decision of the Board is final and binding.

 

16.4 ASIC relief

 

(a) Notwithstanding any other provisions of the Plan, every covenant or other provisions set out in an exemption or modification granted from time to time by ASIC in respect of the Plan pursuant to its power to exempt and modify the Corporations Act and required to be included in the Plan in order for that exemption or modification to have full effect, is deemed to be contained in the Plan.

 

(b) To the extent that any covenant or other provision deemed by this Rule to be contained in the Plan is inconsistent with any other provision in the Plan, the deemed covenant or other provision shall prevail.

 

16.5 Non-residents of Australia

 

(a) The Board may adopt additional rules of the Plan applicable in any jurisdiction outside Australia under which rights offered under the Plan may be subject to additional or modified terms, having regard to any securities, exchange control or taxation laws or regulations or similar factors which may apply to the Participant or to any Group Company in relation to the rights. Any additional rule must conform to the basic principles of the Plan.

 

(b) When a Performance Right is granted under the Plan to a person who is not a resident of Australia the provisions of the Plan apply subject to such alterations or additions as the Board determines having regard to any securities, exchange control or taxation laws or regulation or similar factors which may apply to the Participant or to any Group Company in relation to the Performance Right.

 

MYQ Incentive Performance Rights Plan (final) 19

 

 

 

16.6 Communication

 

(a) Any notice or other communication under or in connection with the Plan may be given by personal delivery or by sending the same by post or facsimile:

 

  (i) in the case of a company, to its registered office;
     
  (ii) in the case of an individual, to the individual’s last notified address; or
     
  (iii) where a Participant is a Director or employee of a Group Company, either to the Participant’s last known address or to the address of the place of business at which the Participant performs the whole or substantially the whole of the duties of the Participant’s office of employment.

 

(b) Where a notice or other communication is given by post, it is deemed to have been received 48 hours after it was put into the post properly addressed and stamped. Where a notice or other communication is given by facsimile, it is deemed to have been received on completion of transmission. Where a notice is given by electronic transmission, the notice is taken to have been received at the time the electronic transmission is sent.

 

16.7 Attorney

 

Each Participant:

 

(a) irrevocably appoints the Company and any person nominated from time to time by the Company (each an attorney), severally, as the Participant’s attorney to complete and execute any documents, including applications for Shares and Share transfers, and to do all acts or things on behalf of and in the name of the Participant which may be convenient or necessary for the purpose of giving effect to the provisions of this Plan;

 

(b) covenants that the Participant will ratify and confirm any act or thing done pursuant to this power;

 

(c) releases each Group Company and the attorney from any liability whatsoever arising from the exercise of the powers conferred by this Rule; and

 

(d) indemnifies and holds harmless each Group Company and the attorney in respect thereof.

 

16.8 Costs and Expenses

 

The Company will pay all expenses, costs and charges in relation to the establishment, implementation and administration of the Plan, including all costs incurred in or associated with the issue or purchase of Shares for the purposes of the Plan.

 

16.9 Adverse Tax

 

Where a Participant may suffer an adverse taxation consequence as a direct result of participating in the Plan that was not apparent to the Participant or the Company at the time the Participant was issued Performance Rights under the Plan, the Board may, in its absolute discretion, agree to compensate the Participant in whole or in part.

 

MYQ Incentive Performance Rights Plan (final) 20

 

 

 

16.10 Data protection

 

By lodging an Acceptance Form, each Participant consents to the holding and processing of personal data provided by the Participant to any Group Company for all purposes relating to the operation of the Plan. These include, but are not limited to:

 

(a) administering and maintaining Participants' records;

 

(b) providing information to trustees of any employee benefit trust, registrars, brokers or third party administrators of the Plan;

 

(c) providing information to future purchasers of the Company or the business in which the Participant works; and

 

(d) transferring information about the Participant to a country or territory outside Australia.

 

16.11 Error in Allocation

 

If any Performance Rights are provided under this Plan in error or by mistake to a person (Mistaken Recipient) who is not the intended recipient, the Mistaken Recipient shall have no right or interest, and shall be taken never to have had any right or interest, in those Performance Rights and those Performance Rights will immediately lapse.

 

16.12 No fiduciary capacity

 

The Board may exercise any power or discretion conferred on it by this Plan in the interest or for the benefit of the Company, and in so doing the Board is not required to act in the interests of another person or as requested by another person and will not be under any fiduciary obligation to another person.

 

16.13 ASX Listing Rules

 

While the Company remains admitted to the ASX, the provisions of the ASX Listing Rules of the ASX will apply to the Plan, and to the extent that the Plan and the ASX Listing Rules are inconsistent, the provisions of the ASX Listing Rules will prevail.

 

16.14 Enforcement

 

This Plan, any determination of the Board made pursuant to this Plan, and the terms of any Performance Rights granted under the Plan, will be deemed to form a contract between the Company and the Participant.

 

16.15 Laws governing Plan

 

(a) This Plan, and any Performance Rights issued under it, are governed by the laws of Western Australia and the Commonwealth of Australia.

 

(b) The Company and the Participants submit to the non-exclusive jurisdiction of the courts of Western Australia.

 

MYQ Incentive Performance Rights Plan (final) 21

 

 

 

 

 

 

S C H E D U L E 1 – P E R FO R MANC E R I G H TS P L AN – O F F E R D O C U M E N T

 

 

 

[insert date]

 

 

 

[insert name]

 

 

 

Dear [insert]

 

MyFiziq Limited – PERFORMANCE RIGHTS PLAN

 

The board of directors of MyFiziq Limited (ACN 602 111 115) (Company) is pleased to make an offer to you of Performance Rights under its Performance Rights Plan (Plan) on the terms of this offer letter (Offer). Terms used in this Offer have the same meaning as used in the Plan.

 

The Company is pleased to advise you of the following:

 

(a) this Offer is subject to the terms and conditions of the Plan, a copy of which is attached to this Offer;

 

(b) subject to the following, the Company is willing to offer you the following Performance Rights under the Plan and subject to the following Vesting Conditions:
   
  (i)                       [insert details of Performance Rights];

 

(c) the grant of the Performance Rights is subject to the terms of the Plan, including the Company obtaining any necessary Shareholder approvals and you remaining an Eligible Participant at the time the Performance Rights are to be granted and (subject to a number of exceptions), exercised and converted into Shares;

 

(d) the Performance Rights under the Plan will be granted to you for [nil] cash consideration;

 

(e) the Expiry Date of each Performance Right will be [seven years] after the date of grant;

 

(f) Shares issued on exercise of the Performance Rights will be subject to the following Restriction Periods:
   
 

(i)                       [insert];

 

(ii)                     [insert];

 

(g) this Offer remains open for acceptance by you until 5pm WST on [insert date] (Closing Date) at which time the Offer will close and lapse;

 

(h) you may apply for the Performance Right by filling out Acceptance Form below and returning to the Company Secretary before the Closing Date;

 

MYQ Incentive Performance Rights Plan (final) 22

 

 

 

(i) you may apply for the Performance Right to be registered in your name, or in a Nominee’s name. Examples of acceptable Nominees are set out in the Plan. Please discuss this with the Company Secretary if you have any queries;

 

(j) unless the Plan provides otherwise, the Shares to which you are entitled on exercise of the Performance Right will be issued to you as soon as practicable after the exercise date;

 

(k) Performance Rights are only transferrable in special circumstances as set out in the Plan;

 

(l) the Company will apply for the Shares to be quoted on the ASX in accordance with the ASX Listing Rules within 10 Business Days of the later of the date the Shares are issued and the date any Restriction Period that applies to the Shares ends. The Shares may be subject to restrictions on disposal in accordance with the Plan in which case the Company will impose a Holding Lock with the Company’s share registry and the Shares will not be able to be traded until the Holding Lock is lifted by the Company;

 

(m) the Company will issue, where required to enable Shares issued on exercise of Performance Rights to be freely tradeable on the ASX (subject to any Restriction Period), a cleansing statement under Section 708A(5) of the Corporations Act at the time Shares are issued. Where a cleansing statement is required, but cannot be issued, the Company will have a prospectus available in relation to the Shares which complies with the requirements of the Corporations Act;
(n) the Company undertakes that, during the period commencing on the date of this Offer and expiring on the Closing Date, it will, within a reasonable period of you so requesting, make available to you the current market price of the underlying Shares to which the Performance Rights relate;

 

(o) the current market price of the underlying Shares to which the Performance Rights relate can be found on the Company’s ASX website at [insert]; and

 

(p) Subdivision 83A-C of the Income Tax Assessment Act 1997¸ which enables tax deferral on Performance Rights, [will/will not] apply (subject to the conditions in that Act) to Performance Rights granted to you under this Offer.

 

You should be aware that the business, assets and operations of the Company are subject to certain risk factors that have the potential to influence the operating and financial performance of the Company in the future. These risks can impact on the value of an investment in the securities of the Company, including Performance Rights offered under the Plan, and Shares issued on exercise of the Performance Rights.

 

Any advice given by the Company in relation to the Performance Rights, or underlying Shares offered under the Plan, does not take into account your objectives, financial situation and needs (including financial or taxation issues).

 

This Offer and all other documents provided to you at the time of this Offer contain general advice only and you should consider obtaining your own financial product advice from an independent person who is licensed by the Australian Securities and Investments Commission to give such advice. You are advised to seek independent professional advice regarding the Australian tax consequences of the grant of Performance Rights and the acquiring and disposing of any Shares that are issued on exercise of Performance Rights under the Plan according to your own particular circumstances.

 

MYQ Incentive Performance Rights Plan (final) 23

 

 

 

Please confirm your (or your Nominee’s) acceptance of the Offer set out in this letter by completing the Acceptance Form below and returning it to the Company by no later than [insert].

 

Yours faithfully

 

Peter Wall

Non-executive Chairman

MyFiziq Limited

 

Encl.

 

MYQ Incentive Performance Rights Plan (final) 24

 

 

 

 

 

S CH E D U LE 2 – P E R F O R M A N C E R I G H T S P L A N ACC E P T A N C E F O R M

 

 

 

MyFiziq Limited (ACN 602 111 115) (Company) has invited you (or your Nominee), by an offer dated [insert] (Offer), to apply for the grant under its Performance Rights Plan (Plan) of certain Performance Rights.

 

The person below hereby applies for the Performance Rights under the terms of the Offer, this Acceptance Form and the Plan.

 

Full Name: ______________________    
     
Address: ______________________    
     
Ph: ______________________ Email:  ___________  
     

Tax file number(s) or

exemption: ___________

   
     
CHESS HIN (where applicable): ___________    

 

In applying for the grant of Performance Rights under the Offer, the person below acknowledges and agrees:

 

(a) to be entered on the register of performance rights holders of the Company as the holder of the Performance Rights applied for, and any Shares issued on the exercise of the Performance Rights;

 

(b) to be bound by the terms of the Constitution of the Company;

 

(c) to be bound by the terms and conditions of the Plan;

 

(d) to be bound by the terms and conditions of the Offer;

 

(e) a copy of the full terms of the Plan has been provided to it;

 

(f) that, by completing this Acceptance Form, it agrees to appoint the Company Secretary as its attorney to complete and execute any documents and do all acts on its behalf which may be convenient or necessary for the purpose of giving effect to the provisions of the Plan (if applicable);

 

(g) that any tax liability arising from the Company accepting its application for Performance Rights under the Plan or the issue of Shares on exercise of the Performance Rights is its responsibility and not that of the Company; and

 

(h) to the extent required by the terms of the Plan and the ASX Listing Rules, to enter into any necessary restriction agreement in relation to any Shares provided on the exercise of the Performance Rights and to the placing of a Holding Lock on those Shares.

 

MYQ Incentive Performance Rights Plan (final) 25

 

 

 

Where an individual

 

SIGNED by [insert] in the presence of:

 

 

 

 

)

)

     
     
     
Signature of witness   Signature
     
     
     
Name of witness    

 

Where an Australian company

 

EXECUTED by [INSERT COMPANY NAME] ACN [INSERT ACN]

in accordance with section 127 of the

Corporations Act 2001 (Cth):

 

 

 

 

)

)

)

)

Signature of director

 

 

 

  Signature of director/company secretary*
Name of director   Name of director/company secretary*

 

* please delete as applicable

 

MYQ Incentive Performance Rights Plan (final) 26

 

 

 

 

 

S CH E D U L E 3 – N O T I C E O F E X E R C I S E O F P E R FOR M A N C E R I G H T S

 

 

 

To: The Directors
MyFiziq Limited

 

I/We _____________ of __________________________ being registered holder(s) of performance rights as set out on the certificate annexed to this notice, hereby exercise _____________ of the abovementioned performance rights.

 

I/ We authorise and direct the Company to register me/us as the holder(s) of the Shares to be allotted to me/us and I/we agree to accept such Shares subject to the provisions of the Constitution of the Company.

 

 

Dated: __________________________

 

 

 

 

Signature of Holder(s)

 

Note:

 

1. Each holder must sign.

 

2. An application by a company must be executed in accordance with section 127 of the Corporations Act 2001 (Cth) and if signing for a company as a sole director/secretary – ensure “sole director/secretary” is written beside the signature.

 

 

MYQ Incentive Performance Rights Plan (final) 27

 

 

 

Exhibit 10.11

 

E1 (1) Summarize all efforts (in the last three years) by the Company to raise capital, providing details of whether successful, amount raised, which Investment Banking underwriter/placement agents were involved, investors that participated, and deal terms.

 

- The Company has undergone 4 capital raising initiatives over the last 3 years. All of which have been successful and most at a premium to the market at the time of closing.

 

- August 2018 MyFiziq entered a convertible note on the following terms - MyFiziq shares at the higher of: • $0.30 per share; and • a 30% discount to the volume weighted average price for MyFiziq shares traded on ASX for the period of 14 trading days up to and including the trading day prior to conversion, the facility also offered an 8% coupon. The total amount raised under the offering was $1,500,000. All notes have been converted or repaid and the company has no outstanding obligations to these note holders.

 

- January 2019 The Company completed a placement to Hong Kong based fund Asia Cornerstone Asset Management. The Placement was for $6,000,000 at 60 cents a share. Representing a premium to market of 110% at the time of the placement. The amount was adjusted under a variation agreement later in the year to $5,200,000. All other terms remained the same.

 

- June 2020 MyFiziq raise USD$1,500,000 as part of a bridge funding round to assist in facilitating the US NASDAQ initiative. This again was placed to Asia Cornerstone Asset Management. The terms of the Convertible note were a 25% discount to the US IPO and a coupon of 10% pa.

 

- October 2020, the Company raised $5 million through a private placement with Evolution equities for the issues of 4,166,667 shares at A$1.20 per share. In addition to this the participants in the capital were granted a 1 for 2 option with a strike price of UAD$1.60 to acquire a further fully paid share in the company. Evolution was granted 1,000,000 options at AUD$1.60 in addition to the capital raising fees of 6%.

 

Exhibit 10.12

 

 

 

TECHNOLOGY LICENSE AGREEMENT

 

TECHNOLOGY LICENSE AGREEMENT (the “Agreement”), made and entered into as of March 29, 2021 (the “Effective Date”), by and between Triage Technologies, Inc., a company incorporated under the federal laws of Canada (“Triage”), and Advanced Human Imaging Limited (ACN 602 111 115), a company incorporated in Australia (“Customer”), each of which are referred to in this Agreement as a “Party” and, collectively, as the “Parties.”

 

Background

 

A. Triage™ has developed a proprietary clinical decision support (CDS) system for analysis of dermatological conditions to improve medical treatment and outcomes (the “System”) by healthcare professionals (HCPs). Key components of the System include: The TriageNet Engine (including TriageVisual System and TriageQA System) and Triage’s proprietary web application program interface providing access to the System (the “Triage API”).

 

B. The Triage App is licensed in Canada and regulated as a Class I medical device by Health Canada. The Triage App has not been approved by the U.S. Food and Drug Administration for use by U.S. consumers. CUSTOMER ACKNOWLEDGES AND UNDERSTANDS THAT THE SYSTEM HAS NOT BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND, AS OF THE EFFECTIVE DATE, IS INTENDED FOR INVESTIGATIVE USE ONLY BY HEALTHCARE PROFESSIONALS AND INVESTIGATORS (COLLECTIVELY, “HCPs”) IN CLINICAL TESTING OF THE SYSTEM AS A CLINICAL DECISION SUPPORT “SOFTWARE AS A MEDICAL DEVICE” (SAMD) AND RELATED RESEARCH IN ACCORDANCE WITH 21 C.F.R. PART 812. THE LICENSE GRANTED TO CUSTOMER PURSUANT TO THIS AGREEMENT DOES NOT PERMIT CUSTOMER TO OFFER THE SYSTEM FOR USE BY U.S. CONSUMERS.

 

C. Customer desires to license the System for use by its consumers in the diagnosis and treatment of skin conditions, and Triage desires to provide Customer with such license pursuant to the terms and conditions of this Agreement.

 

D. In addition, Customer has agreed to enter into an agreement with Triage, on terms equal to those set forth in or adopted pursuant to this Agreement, under which Customer will grant Triage, during the Term, a worldwide, non-exclusive license to commercialize (i.e., to use, reproduce, make available, publicize, advertize, market, promote, sub-license, sell, provide or distribute to Triage’s clients) the CompleteScan Platform together with the Triage API, as a separate, non-integrated application to the System, or as a combined, integrated application with the System.

 

Terms

 

1. Definitions. As used in this Agreement, unless the context otherwise requires, the following terms shall have the following meanings and grammatical variations of such terms shall have corresponding meanings:

 

Affiliate(s)” means, in respect of any person, any other person which directly or indirectly controls, is controlled by, or is under common control with, such specified person. For purposes of this definition, “control” is the power, directly or indirectly, to direct the management and policies of a person, whether through ownership of voting securities, by contract or otherwise, and “controlled by” has a similar meaning.

 

Agreement” means this License Agreement and all incorporated exhibits and schedules, as may be amended from time to time in accordance with the provisions of this Agreement.

 

Approved Business” means Customer’s business operations.

 

Business Day” means any day except Saturdays, Sundays, and Canadian public holidays.

 

Confidential Information” means any and all information which is of a confidential, proprietary, or trade secret nature that is furnished or disclosed by one Party to the other Party under this Agreement. Confidential Information includes, without limitation, all information received from third parties that either Party is obligated to treat as confidential and oral information that is identified by either Party or by a third party as confidential. Confidential Information shall not include information that: (a) is or becomes a part of the public domain through no act or omission of the receiving party; (b) was in the receiving Party’s lawful possession prior to the disclosure and had not been obtained by the receiving Party either directly or indirectly from the disclosing Party; (c) is lawfully disclosed to the receiving party by a third party without restriction on disclosure; or (d) is independently developed by the receiving Party without use of or reference to the disclosing Party’s Confidential Information.

 

 

 

 

Documentation” means help files, technical manuals, and other documentation relating to the use of the Triage API made available to Customer by Triage with the Triage API or with Updates to the Triage API.

 

“Equipment” means the central processing unit (CPU), any peripheral equipment and all operating systems, utilities and database software which have been approved by Triage for processing the Triage API including, without limitation, the Modernizing Medicine cloud-based EMR system.

 

Force Majeure Event” means an event not reasonably foreseeable, beyond a Party's reasonable control, and occurring without its fault or negligence including, without limitation (a) an act of nature, such as fire, flood, earthquake, storm, tornado, lightning, landslide, sink hole, or outbreak of disease, (b) a service failure caused by third parties, such as a power or utility outage or a labor dispute affecting suppliers or subcontractors, (c) a civil disruption such as war, invasion, insurrection, trade embargo, or activities by terrorists or public enemies, (d) action by a governmental body that enjoins or prevents performance by a Party, or (e) or other events that are not under a Party’s control, such as internet unavailability or illegal third-party activity (e.g., virus attack or network intrusion attempts). Neither Party shall be liable, nor shall any credit or other remedy be extended, for any failure or delay in performance under this Agreement where such failure or delay is proximately caused by a Force Majeure Event; provided, however, that a Force Majeure Event shall not excuse Customer’s obligation to make a payment of Fees owed except to the extent that the Force Majeure Event physically interferes with and delays delivery of the payment.

 

Governmental Authority(ies)” means a federal, state, provincial, or municipal court, legislative body, agency, commission, board, or regulatory or administrative authority or instrumentality.

 

Insolvency” means the occurrence of any of the following events, whereby a Party: (a) becomes or is declared insolvent or bankrupt; (b) is the subject of any proceedings related to its liquidation, insolvency or for the appointment of a receiver or similar officer for it; (c) makes an assignment for the benefit of all or substantially all of its creditors; or (d) enters into an agreement for the composition, extension, or readjustment of all or substantially all of its obligations.

 

Intellectual Property Rights” means all intellectual property rights of any kind or nature, anywhere in the world, whether protected, created, or arising under any applicable Law, and all worldwide common law, statutory, and other rights in, arising out of, or associated therewith including, without limitation, patents, trademarks, copyrights, publicity rights, moral rights, database rights, domain names, and trade secrets, regardless of whether such rights are registered or perfected.

 

Law(s)” means, as in effect from time to time, any law, rule, regulation, declaration, decree, directive, statute, or other enactment, order, mandate, direction, or resolution that is applicable to a Party, a Party’s industry, or any of the System and that is issued or enacted by any domestic or foreign, supra-national, national, state, county, municipal, local, territorial, or other government or industry self-regulatory authority, court, commission, board, authority, or agency, anywhere in the world.

 

License” means the license granted by Triage to Customer pursuant to Section 3.1. “Losses” has the meaning set out in Section 12.3.

Object Code” means the set of instructions for carrying out the tasks to be performed by software expressed in machine- readable form;

 

Person(s)” means any individual, corporation (including any non-profit corporation), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization, labor union, or other entity or governmental body.

 

Source Code” means the non-executable, human readable version of software, which is fully compatible with the Object Code version thereof, and which is capable of being translated into machine-readable and executable form of the software derived from the source code version of the software following compilation or assembly, recorded in both printed format and on tape or disk in machine-readable format containing no passwords or other devices that would prevent or prohibit its use.

 

Start Date” means the first date on which the System is put into use by Customer for a commercial purpose. “Triage IP” includes, without limitation:

 

(a) the System;

 

(b) all Triage’s trademarks and trade names including, without limitation, Triage and the Triage logo ;

 

(c) all Triage internet domains including, without limitation, www.triage.com; and

 

(d) all Triage proprietary methods, trade secrets, inventions, and/or other confidential information.

 

Update” means an enhancement or modification to the System that Triage makes generally available to its customers and is included within the scope of Triage’s support obligations.

 

Page 2 of 12

 

 

Virus” means: (a) any code, program or sub-program whose known or intended purpose is to damage or interfere with the operation of the computer system containing the Triage API or the Software, or to halt, disable or interfere with the operation of the Triage API or the Software; or (b) any device, method or token that permits any person to circumvent the normal security of the Triage API or the Software.

 

2. Duration of Agreement. This Agreement commences on the Effective Date and will continue in force for an initial term that will end on the third anniversary of the Start Date (“Initial Term”), unless terminated earlier pursuant to Section 14 below; provided, however, that the provisions of Sections 4 (Reservation of Rights), 11 (Protection of the Parties’ Confidential Information), 12 (Limitations of Liability; Indemnification), and 15 (Dispute Resolution) shall survive any expiration or termination of the Agreement. Unless otherwise agreed by the Parties, at the expiration of the Initial Term, the Agreement will be extended automatically on a year-to-year basis, unless either Party has given written notice to the other at least 90 days prior to the scheduled expiration of the Agreement of its election not to extend the Agreement or to adjust any terms and conditions. Any extensions of this Agreement past the Initial Term are referred to as a “Renewal Term. The Initial Term and any Renewal Terms of this Agreement are collectively referred to as the “Term.

 

3. License Grant.

 

3.1 Subject to the terms and conditions of this Agreement, Triage grants Customer during the Term a personal, non- exclusive, non-transferable, non-sublicensable, and terminable right and license to access the System via the internet, to input images and other patient data via the Triage API, and to have customers of its Approved Business use the System under the price, terms, and conditions specified in Exhibit 1 to this Agreement (the “License”). This License includes (a) all Updates and any other modifications or enhancements of any kind to the Triage API supplied by Triage to Customer under this Agreement; and (b) the Documentation and all other written information of a technical and/or proprietary nature related to Updates and modifications of any kind to the Triage API supplied by Triage to Customer under this Agreement. Notwithstanding the foregoing, Customer shall have no right to use or access, other than for purposes of testing and training, the Triage API until it has paid the Annual License Fee specified in Exhibit 1. Source Code as well as any other information pertaining to the logic, design, and structure of the Triage API and the Software is specifically excluded from the License.

 

3.2 Compliance with Applicable Law.

 

(a) The Customer is responsible for ensuring that the manner in which Customer offers use of the System to any Person in any legal jurisdiction complies with the applicable Laws of that jurisdiction including, without limitation, obtaining any approvals required by Governmental Authorities. Triage does not represent or warrant that the System has been approved for use in any jurisdiction other than Canada.

 

(b) The System may be used by the Customer for demonstration purposes in any jurisdiction, however the Customer must not otherwise make the System available in any jurisdiction where Triage or the Customer (as applicable) has not obtained any approval from a Governmental Authority of that jurisdiction which is required for the proposed use of the System by the Customer (or its consumers) in that jurisdiction.

 

3.3 License Restrictions.

 

(a) The License granted to Customer in Section 3.1 above is subject to the condition that if Customer permits all or some component parts of the System to be imbedded in one or more devices owned or controlled by any Person, Customer shall use its best efforts to ensure that Triage’s Intellectual Property Rights with respect to the System are protected in light of the marketing strategies pursued by Customer (e.g., by encrypting all embedded components of the System).

 

(b) Unless subject to a new written agreement with Triage for this specific purpose, Customer may not use the Software or the Triage API for any purpose other than in connection with the Approved Business. Customer may not, except as may expressly be permitted by this Agreement or with Triage’s prior written consent:

 

(i) use, disclose, sublicense, lease, rent, sell, distribute or transfer the Triage API, in whole or in part, to any third party, or provide the benefit of its use to any third party;

 

(ii) modify the Triage API nor merge any part of it with another software program;

 

(iii) attempt to determine the Source Code for the Triage API or the Software, nor modify, reprogram, translate, disassemble, decompile, create derivative works based upon the Triage API or the Software, copy the Triage API or the Software for the purpose of discovering the underlying ideas and/or the development of the Triage API or the Software’s functional specifications, make modifications for interoperability with another computer program, correct errors in the Triage API or the Software or otherwise reverse engineer the Triage API or the Software for any reason whatsoever, including educational reasons; or

 

Page 3 of 12

 

 

(iv) extract, insert, push or otherwise transfer data to and/or from the Triage API into another computer language, any third party software or system for any reason whatsoever;

 

Furthermore, Customer shall secure and protect the Triage IP in accordance with its existing practices and policies, and take all precautions necessary to prevent unauthorized access to the Triage API and/or the introduction of any Viruses into the Triage API or the Software through the Customer’s connection to the Triage API. In the event that Triage reasonably considers that Customer has not taken all necessary precautions or that an abuse or misuse of the Triage API is being performed through Customer’s connection to the Triage API, Triage shall be entitled to automatically suspend the Customer’s access to the Triage API and the Software.

 

If a Virus is found to have been introduced by Customer, then Customer, as its own expense, shall provide reasonable assistance to Triage to mitigate the effects of such Virus and shall reimburse Triage for all costs and expenses incurred in connection with the eradication of the Virus and repair to the damaged applications and systems as a result of the introduction of such Virus. In addition to any other remedies available to Triage against Customer by Law, Customer shall indemnify Triage from and against any compensation claims by other Triage customers directly resulting from a breach of this provision to the extent such Virus impacts the Triage API’s or the Software’s performance in respect such other customers.

 

3.4 Exclusivity During the course of the Term, Triage must not grant an exclusive license to any other customer for the use of the System in any jurisdiction which would prevent Customer from making the System available to its consumers in that jurisdiction.

 

4. Reservation of Rights. Triage expressly reserves all Intellectual Property Rights with respect to the System not expressly granted to Customer by virtue of Section 3 above, and Customer acknowledges and agrees that except as may be specifically granted by Triage in Section 3, Customer shall acquire no rights or interest in or to the Triage IP. Triage may, in its sole discretion, add, delete, or change some or all the features included within the System at any time without affecting any commitments previously agreed to in this Agreement. Without limiting the generality of the foregoing, Customer acknowledges and agrees that any modifications to the System made for Customer’s benefit shall in no way affect or diminish Triage’s right, title, and interest in and to the Triage IP. Customer further acknowledges that Triage may create original works for third parties that may appear similar to a deliverable provided hereunder. Customer agrees that, so long as such original work does not embody and is not created with reference to any of Customer’s Confidential Information, Triage will not be prevented from independently creating original, but similar, works for the benefit of third parties or incorporating a deliverable as part of the general release of the Triage System. In addition, Triage shall have a royalty-free, worldwide, perpetual license to use and to incorporate into the Triage IP any suggestions, ideas, enhancement requests, feedback, recommendations, or other information, excluding Customer’s Confidential Information, provided by Customer or its Affiliates, employees, or agents with respect to the System.

 

5. System Operation. The Parties agree that the System will operate as follows:

 

(a) Customer (or one of Customer’s patients, if they elect to purchase a subscription plan as described in subsection (e) below) will submit a photo of the affected skin area and data regarding the patient’s age, gender and, in some cases, answers to questions regarding the patient’s complaint will be sent to the patient’s virtual chart and processed by the Triage application program interface (API).

 

(b) The System will provide feedback in the form of a list, in ranked order, of the most likely diagnoses of the skin condition(s) depicted in the submitted photo as well as associated SNOMED labels and ICD codes.

 

(c) The photo will be de-identified when submitted and, after submission, may be retained and used by Triage for further development and improvement of the System.

 

(d) Photos may be submitted by Customer, or by other Persons authorized by Customer to do so, directly to Triage and feedback on such submissions will be made directly to Customer by Triage.

 

6. Triage Responsibilities.

 

6.1 Prior to the Start Date, Triage will provide Customer with a description of any applicable requirements including, without limitation, minimum network requirements, specifications, or other information necessary to complete the preparation of the Customer’s Equipment.

 

6.2 During the Term, Triage will operate the System pursuant to the terms and conditions set forth in this Agreement and materially in accordance with (i) the Documentation, (ii) the applicable Laws of Canada, and (iii) if and as directed by Customer, the applicable Laws of any jurisdiction where the Customer offers use of the System by Persons. Triage is not responsible for connectivity problems or other issues caused by factors outside its reasonable control (e.g., problems with Equipment operated by Customer or by any other Person).

 

Page 4 of 12

 

 

6.3 Triage may make any changes in the operation of the System and Triage’s facilities used in operating the System that Triage determines in its sole discretion to be necessary and/or desirable including, without limitation, changes in computer hardware, systems, and/or applications software, programming languages, data communications, and location of systems and service equipment. To the extent possible, Triage will implement such changes during scheduled maintenance windows and will notify Customer in advance of any such changes. In the event that there is a need for emergency maintenance or system changes outside of standard maintenance windows, Triage will provide Customer with as much advance notice as reasonably possible under the circumstances.

 

6.4 During the Term, Triage will provide a Help Desk staffed by Triage personnel to provide support for questions relating to problem troubleshooting for the System. Standard Help Desk hours are from 9 a.m. to 5 p.m. (Eastern Time), Monday through Friday, excluding Canadian public holidays. Technical support may also be closed due to unforeseen emergencies (e.g., weather conditions, power outages, etc.). In the event of such emergencies, diligent efforts will be made to notify Customers and to provide the reason for closure. Triage will be under no obligation to provide support if required due to any improper use, damage, or modification of or to the System caused by Customer or its authorized users.

 

6.5 Triage will update the System as may, in Triage’s sole discretion, be necessary to keep the System efficient for its users or to meet the requirements of existing or future Laws. Triage reserves the right to make the availability of such Updates subject to additional Fees. Triage will deliver Updates and other requested enhancements and modifications to Customer in a ready to install format. Customer will, at its expense, install the Updates and other enhancements and modifications on its Equipment in accordance with the Documentation.

 

6.6 If requested by Customer, Triage may also provide additional enhancements or modifications to the System that Customer considers necessary in order to comply with applicable Laws and/or to properly conduct the Approved Business, such additional enhancements and modifications to be provided at an additional cost to Customer, to be negotiated and agreed upon by the Parties.

 

7. Customer Responsibilities.

 

7.1 Prior to the Start Date, Customer and its personnel will (a) use their reasonable best efforts to cooperate fully with and assist Triage in implementation of the System and ensure that Customer’s systems and personnel are fully prepared for utilization of the System as of the Start Date, and (b) provide assistance, as reasonably requested by Triage in connection with installation, implementation, and configuration of the System including, without limitation, providing Triage with all required information regarding Customer’s records, facilities, and personnel and all necessary access to Customer’s facilities. On and after the Start Date, Customer will make available to Triage all such reasonable information, documents, records, and assistance from officers and employees of Customer as is necessary to enable Triage to perform its obligations, duties, and responsibilities under this Agreement.

 

7.2 Customer will use the System for its internal business operations in accordance with applicable Law and will not permit the System to be used by or for the benefit of anyone other than Customer. Customer will not rent, lease, sublease, sell, assign, loan, copy, distribute or, without Triage’s prior written consent, otherwise enable third party access to or a right to use the System.

 

7.3 Customer will not, nor will it permit any Person to, modify, reverse engineer, disassemble, decompile or otherwise derive or attempt to derive source code from the System or any component of the System, e.g., the TriageNet Engine, TriageLab. Customer will not combine any aspect of the System into another program or create or attempt to create derivative works based on the System. Further, Customer will not copy or distribute any component of the System without Triage’s authorization.

 

7.4 Customer acknowledges that the System, including the Triage API, and other data belonging to Triage embody logic, design, and coding methodology that constitute proprietary, valuable, and confidential information belonging to Triage. Customer agrees to use its best efforts to ensure that no Triage proprietary information (Object Code, etc.) is displayed outside or copied outside of the Customer’s environment or distributed in any way to any third party. Customer will safeguard the right to access and use such System with the same standard of care that Customer uses for its own confidential and/or proprietary materials or technology. Customer shall be responsible for any unauthorized disclosure of Triage Confidential Information by Customer’s personnel or by Customer’s third party users.

 

7.5 Customer agrees that its employees will undertake any training required by Triage in connection with the System. Customer will use its best efforts to ensure that prior to being permitted to access the System, all Customer personnel and third party users shall execute or otherwise accept the terms of Triage’s End User License Agreement (EULA).

 

7.6 Customer agrees to comply with all technical specifications and with all security and operating guidelines, procedures, and protocols with respect to the System as may be directed by Triage.

 

Page 5 of 12

 

 

7.7 Customer will be responsible for providing and maintaining all equipment needed for use of the System, including scanners, computers, and any printing devices needed for on-site printing purposes, and will be responsible for providing and maintaining a high-speed Internet connection or connections that will enable Customer to have proper access to the System.

 

8. No Joint Undertaking. Use of the System by Customer does not constitute a joint undertaking between Customer and Triage to furnish a service or services to any other Person. The Parties are independent parties and shall not be deemed or construed, by virtue of this Agreement, to be the employee, representative, partner, or joint venturer of the other. Neither Party shall have the power to bind the other or to incur obligations on the other’s behalf without the other Party’s prior written consent.

 

9. Fees and Payment.

 

9.1 Fees Generally. Customer will pay Triage the License and Service Fees specified in Exhibit 1 in accordance with the payment schedule set forth Section 9.4 below, as may be amended during the Term by agreement of the Parties. Customer acknowledges that Service Fees will be invoiced on a recurring basis monthly in arrears commencing as of the Start Date and agrees to that invoicing schedule. Such invoices will include any applicable Taxes as provided in Section 9.3 below. Triage may increase Service fees at any time after the Initial Term upon 90 days prior written notice.

 

9.2 Customer acknowledges that prices set forth in Exhibit 1 are based on the requirements and specifications agreed upon by the Parties as of the effective date of such exhibit, and that any subsequent changes in such requirements or specifications requested by Customer will be subject to additional fees and expenses for such changes to be mutually agreed in advance by the Parties.

 

9.3 Taxes. The prices set forth in Exhibit 1 do not include foreign or domestic taxes, withholding taxes, duties, charges, assessments, or fees (collectively, “Taxes”). If Triage is required to pay any Taxes including, without limitation, (i) sales, use, property, value-added, transfer, origin, withholding, repatriation, or other taxes, (ii) any customs or other duties, or (iii) any import, warehouse, or other fees associated with the importation or delivery in respect of Customer’s use of the System or otherwise on the amounts payable to Triage under this Agreement, or on the transfer or exchange of currency, then such Taxes shall be billed to and paid by Customer. If Customer is permitted to declare any such Taxes, Customer shall declare and pay such Taxes, and Triage shall not be required to invoice Customer. This Section 9.3 shall not apply to Triage’s income or payroll taxes.

 

9.4 Triage will invoice Customer for all Service Fees approximately 5 business days after the end of each month. Invoices will be delivered via email to the email address listed for the Customer in Section 16.7 below. Payment of invoices will be due 15 days after invoice delivery (the “Payment Period”), and payment will be made via wire to a designated Triage account; provided, however, that Customer may within the Payment Period provide written notice to Triage that Customer disputes all or part of the invoice. The dispute notice shall set forth all details concerning the disputed charges and the reasons for the dispute. Any charges not disputed within the Payment Period will be considered final and undisputed unless Customer can demonstrate that Customer was not aware during the Payment Period of the basis for the dispute. If Customer disputes part of an invoice, Customer shall pay the undisputed portion of the invoice within the Payment Period.

 

9.5 If Customer does not pay all undisputed portions of an invoice within the Payment Period, the balance due will be subject to an interest charge on delinquent amounts at the lower of 1.5 percent per month, or the highest rate permissible by Law, until paid.

 

9.6 If Customer’s account becomes more than 30 days delinquent (except with respect to invoiced amounts under reasonable and good faith dispute), in addition to any other rights granted in this Agreement, Triage shall have the right to (a) suspend Customer’s use of the System, without liability to Customer, until such amounts have been paid in full (including any applicable late charges), and/or (b) terminate this Agreement and invoice Customer for any unpaid License or Service Fees due for the remainder of the Term as provided in Section 14. If Triage suspends Customer’s usage of the System pursuant to this Section and subsequently agrees at Customer’s request to reconnect the Services, in addition to any other Service Fees due to Triage, Customer may be charged for other costs imposed on or incurred by Triage to reconnect Customer to the System.

 

9.7 Triage and Customer shall attempt in good faith to resolve any charges disputed by Customer within 10 days of delivery of the dispute notice. If the dispute is resolved in favor of Triage, Customer shall pay all amounts agreed or found to be owing to Triage, plus any applicable late charge, within 15 business days. If a dispute cannot be resolved by the Parties, it will be referred for dispute resolution pursuant to Section 15 below.

 

Page 6 of 12

 

 

10. Representations and Warranties.

 

10.1 Each Party warrants and represents that (a) it has the necessary and actual right and authority to enter into and to perform its obligations under this Agreement, (b) it has taken all necessary corporate action to authorize the execution, delivery, and performance of this Agreement, (c) this Agreement constitutes a valid and binding obligation enforceable against the Party in accordance with its terms, and (d) neither the execution of this Agreement nor the performance of its terms will violate any law to which such Party is or may be bound.

 

10.2 Triage Warranties; Disclaimer.

 

(a) With respect to the System, Triage’s exclusive limited warranties are that (i) the System will be provided as described in Exhibit A, (ii) the Services comply with applicable Laws, (iii) the Services do not infringe any third party Intellectual Property Rights, and

(iv) Triage will use reasonable commercial efforts to ensure that each of Triage’s personnel have the proper training to operate the System in a competent and professional manner.

 

(b) CUSTOMER ACKNOWLEDGES AND AGREES THAT EXCEPT AS SET FORTH IN SUBPARAGRAPH (a) ABOVE, TRIAGE HAS MADE NO REPRESENTATIONS, AND HAS EXPRESSLY DISCLAIMED, TO THE MAXIMUM EXTENT PERMITTED BY LAW, ALL WARRANTIES OR REPRESENTATIONS OF EVERY KIND OR NATURE, EITHER IMPLIED OR STATUTORY, AS TO THE SERVICES INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NON-INFRINGEMENT OF THIRD PARTY RIGHTS. Customer further acknowledges and agrees that Triage has made no warranties or representations that the use of the System will be uninterrupted or without delay; bug, virus, or error-free; interoperable with any hardware, software, platform, or system; or suitable for or meet particular business requirements.

 

10.3 Customer Warranties.

 

(a) Customer warrants that submission for analysis to the Triage API will include certain patient information including, without limitation, a digital image of the prospective patient’s skin ailment (which, to the greatest extent possible, will redact any personally identifiable features of the prospective patient), the physical location of the skin ailment on the prospective patient’s body, and the age and gender of the prospective patient. Customer understands and agrees that photos and data submitted to the System will be retained and may be used by Triage for further development and improvement of the System, and Customer grants Triage all Intellectual Property Rights in and to such data and information necessary to permit such retention and usage.

 

(b) Customer acknowledges that photo and associated data delivered to Triage through the Triage API for processing is intended to be anonymous. Accordingly, the Customer warrants and agrees that it shall not submit any photos that include any personally identifiable features of the patient (unless redaction of such features would compromise the data in the photo and the patient’s consent has been obtained). In order to ensure no personally identifiable information is unintentionally submitted by patients, the Customer further agrees, with the assistance of Triage (if necessary), to create an online form for the submission of digital images that contains (i) instructions for the proper submission of digital images free of personally identifiable information, and (ii) image editing tools to allow patients to redact any personally identifiable features in the digital images the patient wishes to submit and anonymize such data. Customer acknowledges and agrees that in the event any photo includes personally identifiable information without a patient consent, Triage may destroy the photo and any associated information and, if such information is discovered prior to processing, Triage may not analyze the photo.

 

(c) Customer warrants that it is and shall at all times operate in compliance with all applicable Laws including, without limitation, laws related to data privacy and personal information. Customer acknowledges and agrees that it shall be solely responsible for ensuring such compliance including, without limitation, by restricting access and maintaining confidentiality and security safeguards in respect of all information obtained from prospective patients in accordance with applicable Laws.

 

(d) Customer warrants that it has a written privacy policy that governs the collection, use and disclosure of personal information by Customer, and that Customer is, and at all times relevant to this Agreement, will be in compliance in all material respects with such policy. Customer further warrants that no misuse or misappropriation of personal information has occurred by the Customer that would reasonably be expected to (i) require disclosure to or result in an investigation by a Governmental Entity or any other Person, or (ii) give rise to any litigation being brought against the Customer.

 

(e) Customer warrants that it has implemented and maintains a comprehensive plan or plans that (i) identifies internal and external risks to the security of data and Confidential Information, (ii) implements, monitors and improves adequate and effective administrative, electronic and physical safeguards to control those risks, (iii) maintains notification procedures in compliance with all applicable Laws and privacy or other policies in the case of any breach of security compromising data, including unencrypted data containing personal information, and (iv) adequately provides for the prevention of data loss.

 

(f) Customer acknowledges its obligation to comply with the privacy, confidentiality, and security requirements relating to “Protected Health Information” (“PHI”), including “Electronic Protected Health Information” (“ePHI”), as defined in 45 C.F.R.

§160.103, and other applicable Laws, and warrants that it will notify Triage promptly regarding any unauthorized disclosures of PHI or ePHI by Customer relating to Submitted Data.

 

Page 7 of 12

 

 

11. Protection of Confidential Information.

 

11.1 By virtue of this Agreement, each Party may have access to Confidential Information of or in the possession of the other Party. The Parties agree not to make each other’s Confidential Information available in any form to any third party or to use such Confidential Information for any purpose other than in the performance of this Agreement. Each Party agrees to take all reasonable steps to ensure that Confidential Information is not disclosed or distributed by its employees, contractors, or agents in violation of the terms of this Agreement.

 

11.2 Each Party acknowledges and agrees that, due to the unique nature of Confidential Information, there can be no adequate remedy at law for breach of this Section and that such breach would cause irreparable harm to the non-breaching Party and, therefore, the non-breaching Party shall be entitled to seek injunctive relief, in addition to whatever remedies it might have at Law or under this Agreement; provided, however, that if Customer or Triage is required by Law or by a governmental authority to disclose the other Party’s Confidential Information, it shall not do so before having given notice to such other Party and having made a reasonable effort to obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued. Solely for purposes of enforcement of Triage’s rights under this Section, Customer consents to personal jurisdiction in the federal and state courts in the State of New York for such injunctive relief.

 

11.3 Customer agrees to notify Triage immediately and in writing of all circumstances surrounding any unauthorized possession or use of any Triage Confidential Information by any Person. Triage agrees to notify Customer immediately and in writing of all circumstances surrounding any unauthorized possession or use of Customer Confidential Information by any Person. The Parties agree to cooperate fully in any litigation relating to or arising from such unauthorized possession or use of Triage Confidential Information or Customer Confidential Information.

 

12. Limitations of Liability; Indemnification.

 

12.1 Limitation of Triage Liability to Customer for Breach of Agreement. Triage’s total liability (including the liability of any of its officers, employees, or agents) relating to claims for damages for breach of contract (other than an indemnification claim pursuant to Section 12.2 below) arising from or relating to the performance of this Agreement shall be limited to direct (reasonably foreseeable) damages and, except for inaccuracies in Triage’s Representations, a breach of Section 11 above, shall in no event exceed the total amount fees paid by Customer to Triage pursuant to this Agreement for the 12-month period immediately preceding the event giving rise to the claim. The limitations under this Section 12.1 will not apply in the event of any fraud, gross negligence or deliberate or wilful misconduct on the part of Triage (or its officers, employees, or agents).

 

12.2 Triage Indemnification of Customer for Infringement Claim. Triage will indemnify and defend Customer from and against any action or proceeding brought by a third party based upon a claim or allegation that the Triage IP and/or the System used by Customer pursuant to this Agreement directly infringe a U.S. or foreign patent, copyright, or other Intellectual Property Right owned by such third party (an “IP Claim”). Triage shall pay any and all damages or costs related to the settlement of such IP Claim or finally awarded against Customer in an action or proceeding based upon such IP Claim including, without limitation, any attorneys’ fees and expenses incurred by Customer; provided, however, that Customer (a) promptly notifies Triage of any such claim, (b) gives Triage full authority, information, and assistance to defend such claim, and (c) gives Triage sole control of the defense of such claim and all negotiations for the compromise or settlement of such claim; and provided further, that Triage shall have no liability for any IP Claim based upon (i) use of a superseded or altered release of Triage IP if the infringement could have been avoided by use of a current unaltered release of the Triage IP, (ii) the modification of the Triage IP by other than Triage, or

(iii) use of the Triage IP other than in accordance with this Agreement. Triage may, at its sole discretion and expense, modify the Triage IP so that it is not infringing or obtain a license that will permit the Customer to continue using the Triage IP.

 

12.3 Customer Indemnification of Triage. Customer will indemnify and hold harmless Triage from and against any expenses, costs, losses, liabilities, fines, awards or settlement amounts (collectively “Losses”) paid or incurred by Triage in respect of any claims, actions, suits or proceedings brought by third parties arising out of or in connection with:

 

(a) negligence of Customer or its employees, agents, or contractors, other than employees of Triage providing services to Customer pursuant to this Agreement;

 

(b) misuse or abuse of the Triage API by Customer or any of Customer’s employees, agents, or contractors;

 

(c) the failure of Customer to perform any of its obligations under this Agreement including, without limitation, a breach of Customer’s warranties in Section 10.3; or

 

(d) unauthorized access to the Triage API from Customer’s premises or systems resulting from the negligence of Customer or its employees, agents, or contractors, other than employees of Triage providing services to Customer pursuant to this Agreement.

 

12.4 No Liability for Consequential or Punitive Damages. Each Party expressly waives any right to seek consequential, indirect, punitive, or special damages for claimed Losses arising from or relating to the performance of this Agreement from the other Party in connection with Sections 12.1, 12.2, or 12.3 above including, without limitation,

claims for loss of business, data, revenue, profits, or goodwill even if the Parties have knowledge of the possibility of such damages and whether or not such damages are foreseeable.

 

Page 8 of 12

 

 

12.5 Time Limitation for Asserting Claims under this Section. No action relating to a claim for damages arising from or relating to the performance of this Agreement (other than an indemnification claim pursuant to Sections 12.2 or 12.3 above) may be commenced by either Party more than one year after the cause of action accrued, even if the basis for such action was not known or discovered during such one-year period.

 

12.6 Limitation of Customer Liability to Triage for Breach of Agreement. Customer’s total liability (including the liability of any of its officers, employees, or agents) relating to claims for damages for breach of contract (including an indemnification claim pursuant to Section 12.3 above) arising from or relating to the performance of this Agreement shall be limited to direct (reasonably foreseeable) damages and shall in no event exceed the total amount fees paid by Customer to Triage pursuant to this Agreement for the 12-month period immediately preceding the event giving rise to the claim. The limitations under this Section 12.6 will not apply in the event of any fraud, gross negligence or deliberate or wilful misconduct on the part of Customer (or its officers, employees, or agents).

 

13. Publicity.

 

13.1 Upon prior consent by Customer, Triage may use, in its promotional and marketing materials and on Triage’s websites, the name, logo, and other marks of Customer as a user of the Services, as well as Customer-authorized quotations about Triage or the System, for so long as Customer uses the System (and for a reasonable period thereafter to remove Customer’s name and marks from Triage’s websites).

 

13.2 The Parties acknowledge and agree that the Customer is listed on ASX and is subject to continuous disclosure obligations applicable to that exchange. Accordingly, details of this Agreement, Triage and the System will need to be disclosed in announcements to ASX.

 

14. Termination. Either Party may terminate this Agreement, (a) for the other Party’s material breach of the Agreement, which breach has not been cured, or cannot reasonably be cured, within 30 days after receipt of written notice by the non-breaching Party; provided, however, that this cure period will not be applicable in the event of a repeat of substantially the same breach, (b) the other Party’s Insolvency, or (c) at the Party’s discretion, for any reason or for no reason upon 90 days written notice to the other Party. Triage may terminate this Agreement pursuant to Section 9.6 above upon 60 days written notice to Customer. As provided in Section 2 above, Sections 4,11,12, and 15 shall survive the termination of this Agreement.

 

15. Dispute Resolution.

 

15.1 All disputes arising out of or in connection with this Agreement that cannot be resolved through good faith negotiation between the Parties shall be resolved through binding arbitration under the Rules of Arbitration of the International Chamber of Commerce; provided, however, that Triage reserves the right to seek equitable relief in any court of competent jurisdiction against threatened violations of Triage’s Intellectual Property Rights. The Parties shall endeavor to select a mutually acceptable arbitrator knowledgeable about issues relating to the subject matter of this Agreement. If the Parties are unable to agree to such a selection, each Party will select an arbitrator and those arbitrators in turn shall select a third arbitrator. The arbitration will take place at a location mutually agreed by the Parties. This agreement to arbitrate shall be specifically enforceable by either Party.

 

15.2 Except as provided in Section 16.8 (Severability), the arbitrator(s) shall not have the authority, power, or right to alter, change, amend, modify, add, or subtract from any provision of this Agreement or to award punitive damages. The award rendered by the arbitrator(s) shall state the reasons for the award and shall be final and binding on the Parties. Judgment may be entered on such award in any court having jurisdiction.

 

16. General Provisions.

 

16.1 Entire Agreement; Amendment. This Agreement and Exhibit 1 constitute the entire agreement among the Parties and supersedes and cancels any prior agreements, representations, warranties, or communications, whether oral or written, among the Parties relating to the subject matter of this Agreement. Neither this Agreement nor any provisions of an Exhibit to the Agreement may be modified, changed, waived, discharged, or terminated orally. Such documents may only be modified, changed, waived, discharged, or terminated by an agreement in writing signed by the party against whom or which the enforcement of such modification, change, waive, discharge, or termination is sought.

 

16.2 Waiver. Any failure on the part of a Party to comply with any of its obligations, agreements, or responsibilities under this Agreement may be waived by the other Party to whom such compliance is owed. No waiver of any provision of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar, nor shall any waiver constitute a waiver of any failure other than that waived.

 

16.3 Assignment. Customer may assign this Agreement to an Affiliate upon written notice to Triage, but may not assign the Agreement to any other Person without Triage’s prior written consent. Triage may assign this Agreement in whole or in part to any successor or affiliate of Triage upon written notice to Customer, but may not otherwise assign this Agreement without Customer’s prior written consent. No such assignments relieve the assigning Party of its obligations prior to the date of the assignment.

 

Page 9 of 12

 

 

16.4 No Third Party Beneficiaries. No person other than the Parties and their respective successors and permitted assigns is intended to be a beneficiary of this Agreement. In executing this Agreement, the Parties do not intend to create third- party beneficiary rights in anyone not a party to this Agreement.

 

16.5 Force Majeure. Neither Party shall have liability to the other as a result of a Force Majeure Event.

 

16.6 Further Assurances. Each Party covenants that at any time, and from time to time during the Term, it will execute such additional instruments and take such actions as may be reasonably requested by the other Party to confirm or perfect or otherwise to carry out the intent and purposes of this Agreement.

 

16.7 Notice(s). All notifications, requests, demands, and other communications required or permitted to be given under this Agreement shall be in writing in the English language and shall be deemed given when mailed (with return receipt requested), emailed (receipt for which is confirmed), faxed (which is confirmed), or sent via a recognized overnight courier service such as DHL or Federal Express, to the Parties at the following addresses, or pursuant to such other instructions as may be designated in writing by the party to receive such notice:

 

If to Triage:

 

Triage Technologies, Inc.

Attn: Tory Jarmain

1 Adelaide Street E., Suite 3001

Toronto, ON M5C 1J4

CANADA

Email: tory@triage.com

 

If to Customer:

 

Advanced Human Imaging Limited

Attn: Vlado Bosanac

Suite 5, 71–73

South Perth Esplanade,

South Perth, WA

AUSTRALIA

Email: vlado@advancedhumanimaging.com

 

16.8 Severability. Any term or provision of this Agreement, that is held to be invalid, void, or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of such agreements or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If any term or provision of this Agreement is declared invalid, void, or unenforceable, the Parties agree that the arbitral tribunal, court, or other authority making such determination shall have the power to reduce the scope, duration, area, or applicability of the term or provision, to delete specific words or phrases, or to replace any invalid, void, or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision. If the economic or legal substance of the transactions contemplated by such agreements is affected in any manner adverse to any Party as a result thereof, the Parties agree to negotiate in good faith such modifications as are appropriate to ensure that the burdens and benefits of each Party under such modified agreement are reasonably comparable to the burdens and benefits originally contemplated.

 

16.9 Governing Law. This Agreement and all matters arising out of or relating to this Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, U.S.A applicable to contracts made and to be performed entirely within such State.

 

16.10 Counterparts. This Agreement may be executed in one or more separate counterparts, each of which shall be considered an original, and all of which together will constitute one and the same instrument.

 

[Signature page follows]

[Signature page to March 29, 2021 Technology License Agreement]

 

Page 10 of 12

 

 

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed and delivered this Agreement as of the Effective Date.

 

  ADVANCED HUMAN IMAGING LIMITED  
   
   
  Vlado Bosanac
  Chief Executive Officer
  Dated: 31 March, 2021.
   
  TRIAGE TECHNOLOGIES, INC.
     
  By
  Its

Chief Executive Officer

  Dated: 1 April, 2021.

 

Page 11 of 12

 

 

EXHIBIT 1

Pricing

 

Triage agrees to invoice Customer, and Customer agrees to pay Triage in accordance with the provisions of Section 8 of the Agreement, for each Submitted Data Set input by Customer to the System as follows:

 

[TBD]

 

During the Initial Term, for photos submitted directly by Customer and analyzed by the System (i.e., rejected submissions not counted), Customer will pay the following Service Fee, which represents Triage’s development and investigational costs for the Triage API:

 

[TBD]

 

 

page 12 of 12

 

Exhibit 10.13

 

 

29 January 2021

 

Tory Jarmain

Triage Technologies, Inc

1 Adelaide Street East, Suite 3001 Toronto, Ontario M5C 2V9, Canada

 

Dear Mr Jarmain,

 

LETTER OF VARIATION – TERMS SHEET

 

1. Introduction

 

We refer to the binding terms sheet dated 27 November 2020 between MyFiziq Limited and Triage Technologies, Inc (Terms Sheet).

 

Unless the context otherwise requires, words and expressions defined in the Terms Sheet shall have the same meanings when used in this letter agreement.

 

2. Extension of due diligence period

 

This letter agreement is intended to vary the Terms Sheet to amend the Terms Sheet completion date and to extend the due diligence period to 12 March 2021, or such other date agreed by the parties in writing.

 

To record your agreement to the above variation of the Terms Sheet, please execute this letter agreement where indicated below and return it to me.

 

3. General

 

This letter agreement may be executed in any number of counterparts. All counterparts will be taken to constitute one instrument.

 

Electronic or facsimile signatures are taken to be valid and binding to the same extent as original signatures.

 

The parties have agreed the terms set out in this letter agreement and intend to be immediately legally bound by them.

 

Yours sincerely

 

/s/ Steven Richards  
Mr Steven Richards  
Company Secretary  
MyFiziq Limited  

 

 

 

 

EXECUTED by the parties as a deed.

 

EXECUTED by MYFIZIQ LIMITED )
ACN 602 111 115 )
in accordance with section 127 of the )
Corporations Act 2001 (Cth): )

 

/s/ Vlado Bosanac   /s/ Steven Richards
Signature of Chief Executive Officer   Signature of Chief Financial Officer
     
Vlado Bosanac   Steven Richards
Chief Executive Officer   Chief Financial Officer

 

EXECUTED by TRIAGE TECHNOLOGIES, )
INC )
  )
  )

 

in accordance with the laws of its place of incorporation:

 

/s/ Tory Jarmain   /s/ Eric Lau
Signature of director   Signature of director/company secretary
     
Tory Jarmain   Eric Lau
Name of director   Name of director/company secretary*

 

 

 

 

 

Exhibit 10.14

 

BINDING TERMS SHEET
PRIVATE AND CONFIDENTIAL

 

MYFIZIQ LIMITED (an entity incorporation in Australia) (MyFiziq) is a technology company that owns a fitness tracking software platform that provides users with a simple means to track body measurements, body circumference change and other biometrics via an application on the user’s smartphone (MyFiziq Platform).

 

TRIAGE TECHNOLOGIES, INC. is a technology company that has developed an application for the identification of dermatologic conditions, using artificial intelligence (AI), to interpret the user’s skin images taken on a smartphone and provide those results to the user (“Triage”),

 

Triage and MyFiziq are each a “Party” and together are the “Parties” in this document

 

This Terms Sheet sets out the terms upon which the Triage and MyFiziq will integrate the Triage technology into the CompleteScan SaaS offering and the basis upon which the companies will generate revenue together. Additionally, MyFiziq will make an equity investment in Triage to create a strategic relationship between the companies

 

This Terms Sheet is binding on the Parties:

 

1. Integration of the Triage Platform The Parties agree to collaborate and work together to design, develop and integrate the Triage Platform into the CompleteScan existing platform according to the timeline and functional specifications set out in Schedule 1 (Product Integration).
     
2. Contributions from the Parties (a) The Parties each agree to make available sufficient personnel and resources to prioritise the Product Integration.
       
    (b) Other than as set out in Schedule 1, each of the Parties will bear their own costs and expenses associated with the Product Integration, where applicable.
       
3. Pricing and Promotion of CompleteScan Platform (a) Once the Product Integration is complete, the Parties agree to use their best efforts to promote the use of the CompleteScan platform to existing and new sales channel partners, across both MyFiziq and Triage.
       
    (b) The Parties agree that the revenue sharing and pricing model for use of the Triage Scan as part of CompleteScan Platform will be agreed upon between the parties as part of the formal agreements.
       
4. Cash and Share Equity Consideration (a) Under the terms of the agreement MyFiziq will provide USD$3M in equity investment to Triage. Use of funds will be outlined in the formal funding agreement.
    (b) MyFiziq will pay to Triage an amount of USD$500,000 upon signing of this Terms Sheet.
    (c) MyFiziq will pay a further USD$500,000 to Triage six months from the signing of the Terms Sheet.
    (d) MyFiziq will make available further equity funding to Triage in allocations of USD$500,000 for a further USD$2M. Triage will give MyFiziq 60 days’ notice of further drawdowns of his amount.

 

1

 

 

    (e) MyFiziq will issue registered common shares to the value of USD$3M to Triage. Share tranches and will be outlined in the formal funding agreement.
       
    (f) The Parties have agreed the cash equity and MyFiziq share payments will be issued at a pre-money valuation of Triage at USD$33.5m
       
    (g) MyFiziq has a first right of refusal on future capital requirements of Triage.
       
       
5. Intellectual Property (a) All intellectual property that is owned by, or is proprietary to, a Party as at the date of this Terms Sheet will at all times remain owned by that Party exclusively.
       
    (b) Other than as expressly set out in this Terms Sheet, nothing in this Terms Sheet confers on a Party any right or interest in, or licence to use (or permit or cause to be used) any of the other Party’s, or any third parties,, intellectual property.
       
    (a) MyFiziq currently owns all intellectual property in the MyFiziq and CompleteScan SaaS platforms, including any modifications or improvements in relation to the platform. Triage covenants that it will not, or attempt to, reverse engineer, copy or otherwise replicate the MyFiziq or CompleteScan Platforms.
       
    (b) Triage owns all intellectual property in the Triage platform, including any modifications or improvements in relation to the platform, excluding any contributed MyFiziq and CompleteScan intellectual property. MyFiziq covenants that it will not, or attempt to, reverse engineer, copy or otherwise replicate Triage’s intellectual property.
       
6. Commercial Contract Notwithstanding the fact that this document is legally binding on the Parties, MyFiziq and the Triage agree to enter into a subsequent, definitive agreement (Formal Agreement) to more fully document the terms/conditions and intent of the Parties as set out in this Terms Sheet no later than 30 days from the execution date of this Terms Sheet. The Formal Agreement shall be shall be consistent with the terms set out in this Terms Sheet, except to the extent otherwise agreed by the Parties, and will include clauses on (but not limited to) licences to be granted, promotion and marketing, support services, implementation services, cloud services, billing, liabilities, IP and confidentiality.
       
7. Warranties, Representations and Covenants The Formal Agreement will also contain warranties, representations and covenants by both MyFiziq and Triage that are customary for transactions of the type contemplated by this Terms Sheet.
       
8. Confidentiality Each Party is to keep confidential the content and existence of this Terms Sheet and any other information obtained from each other during the negotiations preceding the execution of this Terms Sheet or in the course of furthering the transactions contemplated by this Terms Sheet whether in the course of conducting due diligence or otherwise (Confidential Information), and is not to disclose it to any person except:

 

2

 

 

    (a) to employees, shareholders, legal advisers, auditors and other consultants requiring the information for the purposes of this Terms Sheet;
       
    (b) with the consent of a Party which owns or controls the Confidential Information;
       
    (c) if the information is, at the date of this Terms Sheet, lawfully in the possession of the recipient of the information through sources other than any of the other Parties;
       
    (d) if required by a regulatory agency, court or a stock exchange rule/practice;
       
    (e) if strictly and necessarily required in connection with legal proceedings relating to this Terms Sheet;
       
    (f) if the information is generally and publicly available other than as a result of a breach of confidence; or
       
    (g) to a financier or prospective financier (or its advisers) of a Party.
       
    A Party disclosing Confidential Information must use all reasonable endeavours to ensure that persons receiving the Confidential Information from it do not disclose the Confidential Information except in the circumstances permitted in this clause.
       
    The obligations under this clause contain obligations separate and independent from the other obligations of the Parties and remain in existence for a period of two years from the date of this Terms Sheet, regardless of any termination of this Terms Sheet.
       
9. Due Diligence will utilize the following 30-day due diligence period to verify and validate information about each Triage. Triage will supply MyFiziq, in an orderly manner information requested pertaining to the company’s financial standing and technology. Other information may be requested that is contemplated in a transaction of this type.
     
10. Further Assurance Each Party shall sign and execute and do all deeds, acts, documents and things as may reasonably be required by the other Parties to effectively carry out and give effect to the terms and intentions of this Terms Sheet.
     
11. Governing Law The binding terms of this Terms Sheet shall be governed by and construed in accordance with the law from time to time in New York. The Parties agree to submit to the exclusive jurisdiction of the Courts of New York and the Courts which hear appeals from those Courts.
     
12. Assignment None of the Parties may assign any of the rights or obligations conferred by this Terms Sheet without the consent of the other Party which will not be unreasonably delayed or withheld.
     
13. Costs Each Party shall bear its own legal costs of and incidental to the preparation, negotiation and execution of this Terms Sheet.

 

3

 

 

14. Waiver   A provision of, or a right under, this Terms Sheet may only be waived in writing signed by the Party granting the waiver. A failure or delay in exercise, or partial exercise, or a power, right, authority or remedy arising from a default or breach under this Terms Sheet does not result in a waiver of that power, right, authority or remedy.
       
15.   Remedies   The rights, power and remedies provided in this Terms Sheet are cumulative with and not exclusive to the rights, power or remedies provided by law independently of this Terms Sheet.
       
16. Whole Agreement   This Terms Sheet, any formal agreement, and the other agreements envisaged by this Terms Sheet, shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other agreements with respect thereto.
       
17. Variation    No modification or alteration of the terms of this Terms Sheet shall be binding unless made in writing dated subsequent to the date of this Terms Sheet and duly executed by all Parties.
       
18. Notices  

Each notice authorised or required to be given to a Party shall be in writing and may be delivered personally or sent by properly addressed prepaid mail in each case addressed to the Party at its address set out in below:

 

In the case of MyFiziq:

 

Suite 5, 71–73 South Perth Esplanade South Perth, WA, 6151, Australia Email: vlado@myfiziq.com

Attention: Vlado Bosanac

 

In the case of the Triage Technologies, Inc.

 

1 Adelaide Street East, Suite 3001 Toronto,

Ontario M5C 2V9, Canada

Email: legal@triage.com Phone: 1-800-892-4603

Attention: Tory Jarmain

       
19. Severance   If any provision of this Terms Sheet is invalid and not enforceable in accordance with its terms, all other provisions which are self- sustaining and capable of separate enforcement without regard to the invalid provision shall be and continue to be valid and forceful in accordance with their terms.
       
20. Board Approval   Upon execution of this Terms Sheet by the Parties, MyFiziq Limited, as a public company, will immediately seek its Board approval to ratify this binding Terms Sheet by way of signed Board resolution. This approval will be provided no later than Tuesday 1st December 2020.
       
21. Counterparts   This Terms Sheet may be executed in any number of counterparts, including by email, each of which when executed and delivered to the other Parties shall constitute an original, but all counterparts together shall constitute one and the same agreement.
       
22. Interpretation   In this Terms Sheet unless the context otherwise requires:

 

4

 

 

    (a) headings are for convenience only and do not affect its interpretation;
       
    (b) an obligation or liability assumed by, or a right conferred on, two (2) or more Parties binds or benefits all of them jointly and each of them severally;
       
    (c) the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;
       
       
    (d) a reference to any Party includes that Party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;
       
    (e) a reference to any document (including this Terms Sheet) is to that document as varied, novated, ratified or replaced from time to time;
       
    (f) a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;
       
    (g) words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;
       
    (h) reference to Parties, clauses, schedules, exhibits or annexure are references to Parties, clauses, schedules, exhibits and annexure to or of this Terms Sheet and a reference to this Terms Sheet includes any schedule, exhibit or annexure to this Terms Sheet;
       
    (i) where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning; and
       
    (j)

a reference to AUD$ is to Australian currency and USD$ is to the current of the United States of America.

 

INTENTIONALLY LEFT BLANK

 

5

 

 

If the terms and conditions set out above are acceptable, please execute this Terms Sheet in the appropriate place below.

 

Dated this 27th day of November 2020.    
     
EXECUTED by MYFIZIQ LTD )  
ACN 602 111 115 )  
in accordance with section 127 of the )  
Corporations Act 2001 (Cth): )  
   
     
 
Signature of director Signature of Company Secretary
     
Vlado Bosanac (CEO)   Steven Richards
Name/title of Chief Executive Officer   Name of CFO & Company Secretary

 

  )  
  )  
SIGNED by TRIAGE TECHNOLOGIES, INC. )  
     
Company number in the presence of:  
     
 
Signature of Director   Signature
     
Tory Jarmain (CEO)   Eric Lau
Name/title of CEO & Founder   CFO & Director

 

6

 

 

SCHE DUL E 1 – PRO DU CT I NT EG RA T I ON

 

The Triage & MyFiziq will work together to design and implement a full integration within 90 days of the formal agreement being executed. A breakdown of the integration timeline is below.

 

Milestone   Prerequisites   Milestone Completion Date
         
Terms Sheet Execution   Nil.   27th November 2020
MyFiziq SDK EULA Execution   Terms Sheet executed   11th December 2020
Product Integration (including QA)   MyFiziq SDK EULA executed   27th January 2021
Formal Agreement (includes commercials arrangements, data processing and technical support)  

MyFiziq SDK EULA executed

 

27th December 2020

Target market(s) ready “go-live”

  Formal Agreement executed, and Product Integration complete  

TBA

 

Triage will make available to MyFiziq the SDK kits or platform integration requirements to facilitate an integration into the CompleteScan Demonstration Application. This activity is based on the current MyFiziq functionality.

 

The Parties will work together to deliver a demonstratable product not later than 27th January , 2021.

 

MyFiziq will make its continued platform improvements available to Triage from time to time at no cost to Triage.

 

 

7

 

Exhibit 10.15

 

Execution Version

 

AMENDED AND RESTATED
SHAREHOLDERS’ AGREEMENT

 

TRIAGE TECHNOLOGIES INC.

 

 

March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TABLE OF CONTENTS

 

ARTICLE 1
  INTERPRETATION  
     
1.1 Definitions 2
1.2 Additional Definitions 6
1.3 Sections and Headings 6
1.4 Rules of Construction 6
1.5 Governing Law and Submission to Jurisdiction 7
1.6 Severability 7
1.7 No Waiver 7
     
ARTICLE 2
  PURPOSE AND SCOPE  
     
2.1 Compliance with Agreement 8
2.2 Conflict with Articles or By-laws 8
2.3 Change in Shares 8
2.4 Additional Shares 8
2.5 Covenants of Principals 8
2.6 Ceasing to be a Party 9
2.7 Unanimous Shareholders’ Agreement 9
2.8 Schedules 9
     
ARTICLE 3
  CORPORATE GOVERNANCE  
     
3.1 Board of Directors 9
3.2 Shareholder Matters 10
3.3 Information Rights 11
     
ARTICLE 4
  RESTRICTIONS ON TRANSFER  
     
4.1 Restrictions on Transfer 11
4.2 Transfers to Eligible Transferees 11
4.3 Certificates and Legend 12
4.4 Corporation to Enforce 12
4.5 Certain Transfers Ineffective 12
     
ARTICLE 5
  DRAG-ALONG RIGHTS  
     
5.1 Actions to be Taken 13
5.2 Conditions 14
     
ARTICLE 6
TAG-ALONG RIGHTS
 
6.1 Tag-Along Offer 15
6.2 Tag-Along Acceptance 15

 

-i-

 

 

ARTICLE 7
  CLOSING PROCEDURES  
     
7.1 Time and Place of Closing 16
7.2 Governmental Approvals 17
     
ARTICLE 8
CONFIDENTIALITY AND ADDITIONAL COVENANTS
     
8.1 Confidentiality 17
8.2 Equitable Remedies 18
8.3 Non-Solicitation 18
8.4 Non-Disparagement 18
8.5 Non-Merger 19
     
ARTICLE 9
  AMENDMENT AND TERMINATION  
     
9.1 Amendments 19
9.2 Term and Termination Events 19
9.3 Surviving Obligations 19
     
ARTICLE 10
  MISCELLANEOUS  
     
10.1 Notices 20
10.2 Management Shareholder Power of Attorney 20
10.3 Amendment and Restatement 21
10.4 Enurement 21
10.5 Entire Agreement 21
10.6 Independent Legal Advice 21
10.7 Assignment 21
10.8 No Third-party Beneficiaries 21
10.9 Counterparts 21

 

-ii-

 

 

TRIAGE TECHNOLOGIES INC.

 

AMENDED AND RESTATED

SHAREHOLDERS’ AGREEMENT

 

THIS AMENDED AND RESTATED SHAREHOLDERS’ AGREEMENT made this 31st day of March, 2021, B E T W E E N:

 

TRIAGE TECHNOLOGIES INC.,

a corporation existing under the federal laws of Canada,

 

(hereinafter referred to as the “Corporation”),

 

-and-

 

The shareholders of the Corporation as set out on the signature pages hereto, and such additional holders of Shares who subsequently become parties to this Agreement by signing a Counterpart,

 

(hereinafter referred to, collectively, as the “Shareholders” and, individually, as a “Shareholder”),

 

-and-

 

The Principals as set out on the signature pages hereto.

 

WHEREAS the authorized share capital of the Corporation consists of an unlimited number of Series A common shares (the “Series A Commons”), an unlimited number of Series B common shares (the “Series B Commons”) and an unlimited number of Series C common shares (the “Series C Commons”);

 

AND WHEREAS the Corporation and its shareholders are party to a shareholders’ agreement dated April 5, 2016 (the “Original Shareholders’ Agreement”);

 

AND WHEREAS the Corporation and its shareholders wish to amend and restate the Original Shareholders’ Agreement on the terms and conditions set forth in this Agreement;

 

AND WHEREAS the parties wish to establish their respective rights and obligations in respect of the management and control of the Corporation and in respect of certain other matters set forth in this Agreement;

 

NOW THEREFORE THIS AGREEMENT WITNESSES THAT in consideration of the respective covenants, representations and warranties herein contained and for other good and valuable consideration, the receipt and sufficiency of all of which are acknowledged by each of the parties, the parties covenant and agree as follows:

 

 

 

 

ARTICLE 1 INTERPRETATION

 

1.1 Definitions

 

For the purposes of this Agreement, the following terms shall have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings:

 

Act” means the Canada Business Corporations Act;

 

Affiliate” has the meaning set out in the Act;

 

Articles” means the articles of incorporation of the Corporation, as the same may be amended or replaced from time to time in accordance with the Act;

 

ASPE” means Canadian Accounting Standards For Private Enterprises;

 

Asset Sale” means a sale, lease or other disposition of all or substantially all of the assets of the Corporation and its subsidiaries taken as a whole by means of any transaction or series of related transactions, except where such sale, lease or other disposition is to an Affiliate of the Corporation;

 

Board” means the board of directors of the Corporation or, if applicable, any committee of Directors to which the board of directors of the Corporation may delegate any of its powers, duties or authority in accordance with the Act;

 

Business Day” means any day other than a Saturday, Sunday or a statutory holiday in the Province of Ontario on which commercial banks in Toronto, Ontario are open for business;

 

Change of Control Transaction” means either (a) a Share Sale; or (b) an Asset Sale;

 

Common Shares” means, collectively, the Series A Commons, the Series B Commons and the Series C Commons;

 

control” means, in respect of any person, the following:

 

(a) in the case of a corporation,

 

(i) holding voting securities or having the power to vote voting securities carrying more than 50% of the votes for the election of directors; and

 

(ii) the votes carried by such securities are entitled, if exercised, to elect a majority of the directors of the person;

 

(b) in the case of a limited liability company or partnership, other than a limited partnership, holding more than 50% of the equity interests in the limited liability company or partnership; or

 

(c) in the case of a limited partnership, being the general partner;

 

-2-

 

 

provided that “control” includes the possession, directly or indirectly, of the power to control and direct the management and policies of such person, whether through ownership of voting securities, by contract or otherwise;

 

Corporation” means Triage Technologies Inc. and includes any successor to the Corporation resulting from any reorganization, arrangement, amalgamation or merger, statutory or otherwise, or from any continuance under the laws of another jurisdiction;

 

Counterpart” means an agreement substantially in the form attached hereto as Schedule A by which a person agrees to be bound by this Agreement as a Shareholder in accordance with the provisions of this Agreement;

 

CPOA” has the meaning set out in Section 10.2;

 

Director” means a director of the Corporation;

 

Drag-Along Notice” has the meaning set out in Section 5.1;

 

Eligible Transferee” means, in respect of any particular Shareholder:

 

(a) a Personal Entity of such Shareholder;

 

(b) in the case of a Shareholder that is a body corporate, any other body corporate that is an Affiliate of such Shareholder and any person who is the controlling registered and beneficial shareholder or member of such body corporate or any Affiliate of such shareholder or member;

 

(c) a Family Member of such Shareholder; and

 

(d) where the context permits, upon the death of the Shareholder, the beneficiary or beneficiaries of the estate of such Shareholder;

 

Encumbrance” means any hypothec, mortgage, charge, pledge, prior claim, security interest, assignment, lien (statutory or otherwise) or other encumbrance, arrangement or condition of any nature which, in substance, secures payment or performance of an obligation;

 

Family Member” means, in relation to an individual, the parent, aunt, uncle, grandparent, sibling, niece, nephew or cousin (by birth, adoption or marriage) of such individual, the spouse of such individual (and the spouse’s parent, aunt, uncle, grandparent, sibling, niece, nephew or cousin), and lineal descendants (by birth, adoption or marriage) of such individual and/or of the spouse of such individual;

 

Family Trust” means, in relation to an individual, a trust (including a testamentary trust), the beneficiaries and potential beneficiaries of which do not include any person other than the individual or his or her Family Members or a corporation or other entity all of the equity interests or other ownership interests in which are, directly or indirectly, beneficially owned by, or for the benefit of, such individual or his or her Family Members, and all of the voting interests of which are held by such individual or his or her Family Members or persons who are Personal Entities of such individual, and the trustees of which are persons resident in Canada for purposes of the Income Tax Act (Canada);

 

-3-

 

 

Information” has the meaning set out in Section 8.1;

 

IPO” means an initial public offering of Shares by way of a prospectus, offering circular, registration statement or similar disclosure document where, or in connection with which, such Shares are to become listed and posted for trading on a stock exchange in Canada or the United States, including by way of a reverse take-over or similar transaction, in each case resulting in the Shares being freely tradeable in the jurisdiction to and between members of the public without the requirement of filing a prospectus or similar disclosure document;

 

Major Shareholder” means any Shareholder who, together with its Affiliates, holds at least 15% of the issued and outstanding Shares (on a fully-diluted basis);

 

Management Shareholder” means any Shareholder who is, or whose Principal is, an employee or former employee of, or consultant or former consultant to, the Corporation or a subsidiary of the Corporation and includes any Eligible Transferee of such Management Shareholder who becomes a party by executing a Counterpart;

 

Other Shareholders” has the meaning set out in Section 5.1;

 

parties” means, collectively, the Corporation, the Shareholders and the Principals, if any, and “party” means any one of them;

 

person” includes any individual, corporation, partnership, firm, joint venture, syndicate, limited liability company, association, trust, government, governmental agency and any other form of entity or organization;

 

Personal Entity” means a Family Trust, corporation or limited liability company established by or for the benefit of a Shareholder, its Principal or his or her Family Members, all of the equity interests in which are, if applicable, directly or indirectly, beneficially owned by, or for the benefit of, such Shareholder, its Principal or his or her Family Members, the trustees of which are and all of the voting interests of which are, as applicable, held by such Shareholder, its Principal or his or her Family Members or persons who are Personal Entities of the same individual;

 

Principal” means, in relation to a Shareholder and for each person that becomes a party to this Agreement at any time after the date hereof in accordance with the terms of this Agreement, the individual who ultimately controls such person at such time;

 

Proposed Sale” has the meaning set out in Section 5.2.

 

Restriction Period” means, (a) in respect of any Management Shareholder or its Principal, the period commencing on the date such person becomes a Shareholder and ending on the date that is 12 months from the date that such person or its Principal ceased to be an employee of, or consultant to, the Corporation or a subsidiary of the Corporation and (b) in respect of any other Shareholder or its Principal, the period commencing on the date such person becomes a Shareholder and ending on the date that is 12 months from the date that such person ceased to be a Shareholder;

 

-4-

 

 

Securities” means all Shares and all options, warrants, convertible instruments and other similar rights entitling the holder thereof to acquire any Shares, whether or not upon the payment of additional consideration therefor;

 

Selling Shareholders” has the meaning set out in Section 5.1;

 

Series A Commons” has the meaning set out in the recitals to this Agreement;

 

Series B Commons” has the meaning set out in the recitals to this Agreement;

 

Series C Commons” has the meaning set out in the recitals to this Agreement;

 

Share Sale” means the acquisition of the Corporation by another entity by means of any transaction or series of related transactions (including, without limitation, any share acquisition, reorganization, merger, amalgamation, arrangement or consolidation but excluding any issuance of shares for capital raising purposes) which results in a person or group of related persons holding more than 50% of the voting rights attaching to all issued and outstanding Common Shares of the Corporation or such other surviving or continuing entity resulting from such transaction or series of transactions (or if the Corporation or such other surviving or continuing entity is a wholly-owned subsidiary immediately following such acquisition, its parent);

 

Shareholder Majority” means, at any time, one or more Shareholders holding not less than 50% of the voting rights attaching to all issued and outstanding Common Shares at such time;

 

Shareholder Super-Majority” means, at any time, two or more Shareholders holding not less than 80% of the voting rights attaching to all issued and outstanding Common Shares at such time;

 

Shareholder Representative” has the meaning set out in Section 5.1(f).

 

Shareholders” and “Shareholder” have the meanings set out in the parties section hereof;

 

Shares” means the Common Shares and any other shares in the equity capital of the Corporation that may be authorized after the date hereof in accordance with the Act;

 

Tag-Along Acceptance” has the meaning set out in Section 6.1;

 

Tag-Along Offer” has the meaning set out in Section 6.1;

 

Third Party” means, in relation to the Shareholders or any Shareholder (as the context may require), a person with whom all the Shareholders or any one such Shareholder, as the case may be, and the Corporation deals at “arm’s length” (as such term is defined in the Income Tax Act (Canada)), and excludes any Eligible Transferee;

 

Third Party Offer” has the meaning set out in Section 5.1;

 

Third Party Purchaser” has the meaning set out in Section 5.1;

 

Transfer” means any disposition, transfer, sale, exchange, assignment, gift, bequest, disposition, Encumbrance, or any arrangement by which possession, legal title or beneficial ownership passes, directly or indirectly, from one person to another, or to the same person in a different capacity, whether or not voluntary and whether or not for value, and includes any agreement to effect the foregoing; and

 

Transferor” has the meaning set out in Section 4.2(a).

 

-5-

 

 

1.2 Additional Definitions

 

Unless there is something inconsistent in the subject matter or context, or unless otherwise provided in this Agreement, all other words and terms used in this Agreement that are defined in the Act have the meanings set out in the Act.

 

1.3 Sections and Headings

 

The table of contents and the division of this Agreement into Articles and Sections and the insertion of headings are for convenience of reference only and shall not affect the interpretation of this Agreement. The terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement and not to any particular Article, Section, Schedule or other portion hereof and include any agreement or instrument supplementary or ancillary hereto. Unless otherwise specified, any reference to an Article, Section or Schedule refers to the specific Article, Section or Schedule of this Agreement.

 

1.4 Rules of Construction

 

In this Agreement:

 

(a) words importing the singular number only shall include the plural and vice versa and words importing the use of any gender shall include all genders;

 

(b) the word “including” is deemed to mean “including without limitation”;

 

(c) all terms defined in this Agreement have the same defined meanings when used in any certificate or other document made or delivered pursuant hereto, unless otherwise defined therein;

 

(d) references to any agreement or other instrument in writing means such agreement or instrument in writing, as amended, modified, replaced or supplemented from time to time;

 

(e) any reference to a statute, regulation or rule shall be construed to be a reference thereto as the same may from time to time be amended, re-enacted or replaced, and any reference to a statute shall include any regulations or rules made thereunder;

 

(f) unless otherwise specified, all dollar amounts refer to Canadian dollars;

 

(g) references to a particular number of Shares calculated on a “fully-diluted basis” means, at any relevant time, the aggregate of all such issued and outstanding Shares and any such Shares that may be issued upon the exercise, conversion or exchange of all outstanding Securities;

 

-6-

 

 

(h) all accounting terms used herein and not expressly defined herein shall have the meanings given to them under ASPE;

 

(i) any time period within which a payment is to be made or any other action is to be taken hereunder shall be calculated excluding the day on which the period commences and including the day on which the period ends; and

 

(j) whenever any payment is required to be made, action is required to be taken or period of time is to expire on a day other than a Business Day, such payment shall be made, action shall be taken or period shall expire on the next following Business Day.

 

1.5 Governing Law and Submission to Jurisdiction

 

(a) This Agreement shall be interpreted and enforced in accordance with, and the respective rights and obligations of the parties shall be governed by, the laws of the Province of Ontario and the federal laws of Canada applicable in that province.

 

(b) Each of the parties irrevocably and unconditionally (i) submits to the non- exclusive jurisdiction of the courts of the Province of Ontario over any action or proceeding arising out of or relating to this Agreement, (ii) waives any objection that it might otherwise be entitled to assert to the jurisdiction of such courts and (iii) agrees not to assert that such courts are not a convenient forum for the determination of any such action or proceeding.

 

1.6 Severability

 

If any provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, all other provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible.

 

1.7 No Waiver

 

The failure of any party to insist upon strict adherence to any provision of this Agreement on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to such provision or any other provision of this Agreement. No purported waiver shall be effective as against any party unless consented to in writing by such party. The waiver by any party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent or other breach.

 

-7-

 

 

ARTICLE 2
PURPOSE AND SCOPE

 

2.1 Compliance with Agreement

 

Each Shareholder agrees to execute and deliver all such documents, to exercise all voting rights attaching to any Shares held by him, her or it and to do all such other acts and things as the Corporation or any other Shareholder, acting reasonably, may consider necessary or advisable from time to time to give full effect to the provisions and intent of this Agreement and to ensure that the provisions of this Agreement shall govern the affairs of the Corporation to the fullest extent permitted by law (including to amend or waive any provision contained in the Articles or by-laws to the extent inconsistent with the provisions and intent of this Agreement). By its execution of this Agreement, the Corporation acknowledges that it has actual notice of the terms hereof and agrees with each of the Shareholders that, to the fullest extent permitted by law, it will do all things necessary to comply with, and give effect fully to, the provisions and intent of this Agreement.

 

2.2 Conflict with Articles or By-laws

 

To the extent permitted by the Act, in the event of any conflict between the provisions of this Agreement and the provisions of the Articles or by-laws of the Corporation, the provisions of this Agreement shall prevail, and, if necessary or appropriate, upon request by the Corporation, the Shareholders shall vote to amend the Articles and/or by-laws of the Corporation so as to ensure conformity with the terms of this Agreement.

 

2.3 Change in Shares

 

The provisions of this Agreement relating to Shares shall apply, with necessary modifications, to:

 

(a) any securities into which such Shares may be converted, reclassified, redesignated, subdivided, consolidated or otherwise changed from time to time;

 

(b) any securities received as a dividend or distribution on or in respect of any Shares; and

 

(c) any securities of any successor to the Corporation that may be received in respect of any Shares on a reorganization, recapitalization, arrangement, amalgamation or merger, statutory or otherwise.

 

2.4 Additional Shares

 

Each Shareholder agrees that all Shares hereafter acquired by such Shareholder shall be subject in all respects to the provisions of this Agreement.

 

2.5 Covenants of Principals

 

Each Principal hereby agrees to take any such actions as may be necessary to cause the Shareholder which he or she controls to, at all times, fully and faithfully perform and discharge its obligations under this Agreement and comply in all respects with the terms and conditions of this Agreement. The foregoing covenants and obligations of the Principals are absolute, unconditional, present and continuing and are in no way conditional or contingent upon any event or circumstance, action or omission which might in any way discharge a guarantor or surety.

 

-8-

 

 

2.6 Ceasing to be a Party

 

Except as otherwise specifically provided herein, if a person who was a Shareholder no longer holds any Shares, then from that point forward that person shall be deemed to no longer be a party to this Agreement and shall have no further rights or obligations under this Agreement, other than any rights or obligations arising before such Shareholder ceased to be a party.

 

2.7 Unanimous Shareholders’ Agreement

 

This Agreement is intended by the parties to constitute a unanimous shareholders’ agreement for purposes of the Act.

 

2.8 Schedules

 

Schedule A-Form of Counterpart

 

ARTICLE 3 CORPORATE GOVERNANCE

 

3.1 Board of Directors

 

(a) The Board shall consist of such number of Directors as the Shareholders or, subject to the Act, the Directors may from time to time determine. As of the date hereof, the Board shall consist of two Directors, being Tory Jarmain and Eric Lau.

 

(b) Except as may otherwise be provided in this Agreement, all decisions of the Board and any committees of the Board shall be decided by a majority of votes cast at the applicable meeting, or, with respect to any decision made by the Board, by written resolution signed by all of the Directors.

 

(c) The Board shall meet at least once in every calendar quarter and more often as circumstances require in Toronto, Ontario or any other place as the Directors may determine from time to time. Meetings of the Directors may be called by any Director upon not less than 20 days’ notice, which notice shall contain a summary of the business proposed to be transacted at such meeting, a reasonable description of each item of business and copies of the documents or other materials to be considered at the meeting. A Director may, by an instrument in writing delivered before or after the meeting or by participating in the meeting, waive notice of any meeting of the Board, in which event any such meeting, insofar as such Director is concerned, shall be considered to be duly constituted notwithstanding the absence of notice in respect thereof.

 

-9-

 

 

(d) No resolution or other matter shall be voted on, or approved at, any meeting of the Board unless a majority of the Directors then in office is present (in person or by conference call) at the meeting; provided, however, that (i) if no such quorum is present within half an hour following the time at which the meeting is scheduled to take place, the meeting shall stand adjourned to the same day in the immediately following week (or, if that day is not a Business Day, the next following Business Day) at the same time and place and (ii) if no such quorum is present within one hour following the time at which the adjourned meeting is scheduled to take place, the Directors present at the adjourned meeting shall constitute a quorum for the transaction of the business for which the meeting was called if permitted by the Act, failing which the meeting shall again stand adjourned and be rescheduled in accordance with this Section 3.1(d). Directors may attend meetings of the Board from time to time by telephone or any other means of electronic communication that permits all Directors present in person or otherwise participating at the meeting to communicate with each other.

 

(e) The Directors shall serve as such without remuneration. The Corporation shall reimburse the Directors for all reasonable out-of-pocket costs and expenses incurred by them in connection with their attendance at any meetings of the Board, in accordance with such reimbursement policies as may be established or approved from time to time by the Board.

 

(f) The Corporation shall maintain directors’ and officers’ liability insurance in an amount and on terms and conditions satisfactory to the Board and shall use commercially reasonable efforts to cause such insurance to be maintained until such time as the Board may determine.

 

3.2 Shareholder Matters

 

(a) Meetings of Shareholders shall be held in Toronto, Ontario or any other place as the Directors may determine from time to time. Notice of the time and place of any meetings of the Shareholders shall be delivered by email to the Shareholders entitled to vote thereon at their email address for notice, not less than 10 days before the meeting. Such notice can be waived in writing by any of the Shareholders either before or after the meeting. The attendance of a Shareholder at a meeting shall constitute a waiver of notice of such meeting except where such person attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting has not been lawfully called or convened.

 

(b) No resolution shall be considered or voted on, and no other business shall be conducted at, any meeting of the Shareholders unless not fewer than two persons constituting a Shareholder Majority are present at the meeting; provided, however, that (A) if no such quorum is present within half an hour following the time at which the meeting is scheduled to take place, the meeting shall stand adjourned to the same day in the immediately following week (or, if that day is not a Business Day, the next following Business Day) at the same time and place and (B) if no such quorum is present within half an hour following the time at which the adjourned meeting is scheduled to take place, the meeting shall again stand adjourned and be rescheduled in accordance with Section 3.2(a).

 

(c) The chair of a meeting of Shareholders shall be, if present, the Chief Executive Officer of the Corporation, and, if not present, shall be an individual designated by the Shareholder Majority. If the chair is not present within 20 minutes after the time fixed for the holding of any meeting or if the chair is unable or unwilling to act in such capacity, the Shareholders present at the meeting shall appoint an individual to act as chair of such meeting. Notwithstanding any statutory rule or rule of procedure to the contrary, the chair at such meeting shall not be entitled to a second, extra or casting vote in the case of a tie vote at any such meeting.

 

-10-

 

 

3.3 Information Rights

 

(a) Within 90 days following the end of each financial year of the Corporation, the Corporation shall deliver to the Major Shareholders unaudited financial statements of the Corporation in respect of such financial year prepared in accordance with ASPE.

 

(b) The Corporation shall supply on a timely basis all necessary financial and other information to the Shareholders as of the end of their respective fiscal and/or tax accounting years in order to permit each Shareholder to comply on a timely basis with its respective reporting and tax requirements.

 

ARTICLE 4
RESTRICTIONS ON TRANSFER

 

4.1 Restrictions on Transfer

 

Except as specifically provided for in this Agreement, no Shareholder shall Transfer any of his, her or its right, title or interest in or to any Securities now or hereafter owned of record or beneficially by him, her or it without the express prior written consent of the Board and provided further that any such transferee shall agree to be bound by the terms hereof by executing a Counterpart.

 

4.2 Transfers to Eligible Transferees

 

(a) Notwithstanding Section 4.1, a Shareholder (the “Transferor”) may at any time or from time to time Transfer all or a portion of his, her or its Securities to an Eligible Transferee of such Transferor provided that, at or prior to the time of such Transfer:

 

(i) such Eligible Transferee shall execute a Counterpart; and

 

(ii) the Board receives evidence satisfactory to it, acting reasonably, that such Eligible Transferee is an Eligible Transferee of the Transferor and that the Counterpart referred to in Section 4.2(a)(i) is a legal, valid and binding obligation of the Eligible Transferee,

 

provided that, notwithstanding the foregoing, no Shareholder shall, without the prior written consent of the Board, Transfer any Securities to any Eligible Transferee if such Eligible Transferee (in the reasonable determination of the Board) competes with the Corporation and/or any of its subsidiaries.

 

(b) Notwithstanding anything to the contrary in this Agreement,

 

(i) the Transferor shall at all times after the transfer of Securities to the Eligible Transferee be jointly and severally liable with such Eligible Transferee for the observance and performance of the covenants and obligations of the Eligible Transferee under this Agreement, shall cause the Eligible Transferee to remain an Eligible Transferee of the Transferor so long as the Eligible Transferee shall have any registered or beneficial interest in the Securities, and the Transferor and Eligible Transferee shall jointly and severally indemnify the other parties hereto against any loss, damage or expense incurred as a result of the failure by the Eligible Transferee to comply with the provisions of this Agreement; and

 

-11-

 

 

(ii) if a Transferor transfers less than all of his, her or its Securities to an Eligible Transferee, such Transferor and Eligible Transferee shall for the purposes of this Agreement act (through the Transferor only) as a single Shareholder and shall benefit from and exercise all of their rights and obligations under this Agreement as one entity. Without limiting the generality of the foregoing, the exercise of any right, including the right to vote Shares, the giving of any notice, the sending of any document to and the service of any procedure by or upon such Transferor shall be deemed to have been simultaneously exercised, sent to or served by or upon such Eligible Transferee, and vice versa.

 

4.3 Certificates and Legend

 

(a) Each Shareholder acknowledges and agrees that, unless the Board determines otherwise: (i) all Shares held by such Shareholder shall be in uncertificated form; (ii) such Shareholder will only be entitled to a non-transferable written acknowledgement contemplated in Section 49(1) of the Act; and (iii) such Shareholder shall refrain from requesting that any certificates representing such Shares be issued.

 

(b) All certificates (if the Board determines after the date hereof to issue certificates), and all non-transferable written acknowledgements delivered pursuant to Section 49(1) of the Act in respect of uncertificated shares, representing Shares now or hereafter held by a Shareholder shall have the following legend noted conspicuously on such certificate or notice, in addition to any other legends that may imposed pursuant to applicable laws:

 

“THE SECURITIES REPRESENTED BY THIS [CERTIFICATE/NOTICE] ARE SUBJECT TO THE PROVISIONS OF AN AMENDED AND RESTATED UNANIMOUS SHAREHOLDERS’ AGREEMENT MADE AS OF THE 31ST DAY OF MARCH, 2021, WHICH CONTAINS RESTRICTIONS ON THE RIGHT TO TRANSFER, PLEDGE, VOTE AND OTHERWISE DEAL WITH SUCH SECURITIES, A COPY OF WHICH AGREEMENT IS AVAILABLE FOR INSPECTION FROM THE CORPORATION. NOTICE OF SUCH RESTRICTIONS AND THE OTHER PROVISIONS OF SUCH AGREEMENT IS HEREBY GIVEN.”

 

4.4 Corporation to Enforce

 

The Corporation shall not accept for registration in its relevant books of record any Transfer of Securities not made in accordance with the provisions of this Agreement.

 

4.5 Certain Transfers Ineffective

 

Any Transfer of Securities attempted to be made other than in accordance with the provisions of this Agreement shall be void and of no effect.

 

-12-

 

 

ARTICLE 5
DRAG-ALONG RIGHTS

 

5.1 Actions to be Taken

 

If Shareholders constituting a Shareholder Majority (the “Selling Shareholders”) receive and wish to accept a bona fide offer in writing from a Third Party (the “Third Party Purchaser”) to purchase all, but not less than all, of the Shares held by the Selling Shareholders, which, if consummated, would constitute a Change of Control Transaction (a “Third Party Offer”), then the Selling Shareholders may deliver written notice (a “Drag-Along Notice”) to the other Shareholders (the “Other Shareholders”) and the Corporation requiring the Other Shareholders to sell their Shares to the Third Party Purchaser on the same terms and conditions as apply to the sale by the Selling Shareholders of their Shares to the Third Party Purchaser. Upon receipt of a Drag-Along Notice, subject to Section 5.2, each Other Shareholder shall be obligated:

 

(a) if such Change of Control Transaction requires shareholder approval, to vote (in person, by proxy or by action by written consent, as applicable) all Shares owned by or over which such Shareholder otherwise exercises voting power, in favour of such Change of Control Transaction (including any related amendment to the Corporation’s constating documents required to implement such Change of Control Transaction) and to vote in opposition to any and all other proposals that could reasonably be expected to delay or impair the ability of the Corporation to consummate such Change of Control Transaction;

 

(b) if such Change of Control Transaction involves a Share Sale, to sell all the Shares beneficially held by such Other Shareholder to the Person to whom the Selling Shareholders propose to sell their Shares, and, except as permitted in Section 5.2 below, on the same terms and conditions as apply to the Selling Shareholders;

 

(c) to execute and deliver all related documentation and take such other action in support of the Change of Control Transaction as shall reasonably be requested by the Corporation or the Selling Shareholders in order to carry out the terms and conditions of the Change of Control Transaction, including, without limitation, executing and delivering instruments of conveyance and transfer, and any purchase agreement, merger agreement, arrangement agreement, any associated indemnity agreement, or escrow agreement, any associated voting, support, or joinder agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), and any similar or related documents;

 

(d) not to deposit, and to cause their Eligible Transferee not to deposit, except as provided in this Agreement, any Shares of the Corporation owned by such party or Eligible Transferee in a voting trust or subject any Shares to any arrangement or agreement with respect to the voting of such Shares, unless specifically requested to do so by the acquirer in connection with the Change of Control Transaction;

 

(e) to refrain from (i) exercising any dissent rights under applicable law at any time with respect to such Change of Control Transaction, or (ii); asserting any claim or commencing any suit (x) challenging the Change of Control Transaction or this Agreement, or (y) alleging a breach of any fiduciary duty of the Selling Shareholders or any member of the Board in connection with the evaluation, negotiation or entry into the Change of Control Transaction, or the consummation of the transactions contemplated thereby; and

 

-13-

 

 

(f) if the Selling Shareholders, in connection with such Change of Control Transaction, appoint a shareholder representative (the “Shareholder Representative”) with respect to matters affecting the Shareholders under the applicable definitive transaction agreements in connection with such Change of Control Transaction, (x) to consent to (i) the appointment of such Shareholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (i) the payment of such Shareholder’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Shareholder Representative in connection with such Shareholder Representative’s services and duties in connection with such Change of Control Transaction and its related service as the representative of the Shareholders, and (y) not to assert any claim or commence any suit against the Shareholder Representative or any other Shareholder with respect to any action or inaction taken or failed to be taken by the Shareholder Representative, within the scope of the Shareholder Representative’s authority, in connection with its service as the Shareholder Representative, absent fraud, gross negligence or willful misconduct.

 

5.2 Conditions

 

Notwithstanding anything to the contrary set forth herein, a Shareholder will not be required to comply with Section 5.1 in connection with any proposed Change of Control Transaction (the “Proposed Sale”), unless:

 

(a) any representations and warranties to be made by such Shareholder in connection with the Proposed Sale are limited to representations and warranties related to authority, ownership and the ability to convey title to such Shares, including, but not limited to, representations and warranties that (i) the Shareholder holds all right, title and interest in and to the Shares such Shareholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Shareholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be entered into by the Shareholder have been duly executed by the Shareholder and delivered to the acquirer and are enforceable (subject to customary limitations) against the Shareholder in accordance with their respective terms; and (iv) neither the execution and delivery of documents to be entered into by the Shareholder in connection with the transaction, nor the performance of the Shareholder’s obligations thereunder, will cause a breach or violation of the terms of the Shareholder’s constating documents (if applicable), any agreement to which the Shareholder is a party, or any law or judgment, order or decree of any court or governmental agency that applies to the Shareholder;

 

(b) the Shareholder is not liable for the breach of any representation, warranty or covenant made by any other person (except for an Affiliate or Eligible Transferee of such Shareholder) in connection with the Proposed Sale, other than the Corporation (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants of the Corporation as well as breach by any Shareholder of any of identical representations, warranties and covenants provided by all Shareholders);

 

-14-

 

 

(c) liability shall be limited to such Shareholder’s applicable share (determined based on the respective proceeds payable to each Shareholder in connection with such Proposed Sale) of a negotiated aggregate indemnification amount that applies equally to all Shareholders but that in no event exceeds the amount of consideration otherwise payable to such Shareholder in connection with such Proposed Sale, except with respect to claims related to fraud by such Shareholder, the liability for which need not be limited as to such Shareholder; and

 

(d) upon the consummation of the Proposed Sale, each Shareholder will receive the same form of consideration for their Shares and same amount of consideration per Share as is received by other Shareholders in respect of their Shares, and if any Shareholder is given a choice as to the form of consideration to be received as a result of the Proposed Sale, all Shareholders will be given the same option.

 

ARTICLE 6

TAG-ALONG RIGHTS

 

6.1 Tag-Along Offer

 

In the event that the Selling Shareholders receive and wish to accept a Third Party Offer, and such Selling Shareholders do not deliver a Drag-Along Notice in accordance with Section 5.1, then such Selling Shareholders shall, within five Business Days from the receipt of a Third Party Offer, deliver written notice of the proposed sale to the Corporation and the Other Shareholders, which notice shall contain (i) all material information regarding the consideration and terms and conditions of the proposed sale, including the identity of the Third Party Purchaser(s) and the number of Shares it proposes to purchase from the Selling Shareholders, and (ii) an offer in writing to each of the Other Shareholders to purchase all the Shares held by the Other Shareholders (the “Tag-Along Offer”), on terms and conditions identical to those contained in the Third Party Offer, except that the obligations of the Third Party Purchaser under the Tag-Along Offer may be conditional upon completion of the purchase of the Shares held by the Selling Shareholders.

 

6.2 Tag-Along Acceptance

 

Each of the Other Shareholders may exercise its right to accept the Tag-Along Offer and sell all but not less than all of its Shares to the Third Party Purchaser on the same terms and conditions as set out in the Tag-Along Offer, by giving written notice to this effect (a “Tag-Along Acceptance”) to the Selling Shareholders and the Third Party Purchaser, within ten Business Days after receipt of the notice containing the Tag-Along Offer, failing which such Other Shareholder shall be deemed to have declined the Tag-Along Offer. A Tag-Along Acceptance so given by an Other Shareholder shall constitute an irrevocable binding acceptance of the Tag-Along Offer, and a binding contract of purchase and sale between the Other Shareholder and the Third Party Purchaser for the purchase and sale of all the Shares owned by the Other Shareholder, subject only to completion of the sale of the Shares held by the Selling Shareholders to the Third Party Purchaser. The Selling Shareholders may not complete the sale of the Shares to the Third Party Purchaser unless the Third Party Purchaser contemporaneously purchases the Shares from the Other Shareholders that have submitted a Tag-Along Acceptance on the terms and conditions of the Tag-Along Offer.

 

-15-

 

 

ARTICLE 7
CLOSING PROCEDURES

 

7.1 Time and Place of Closing

 

The following provisions shall apply to any Transfer of Securities between Shareholders or between Shareholders and the Corporation pursuant to the terms of this Agreement:

 

(a) The Transfer shall be completed at the Corporation’s registered office on the date specified for closing or electronically if agreed to between the parties. At such time, the transferor(s) shall transfer to the transferee(s) good title to the Securities being transferred free and clear of all Encumbrances and shall cause the transferred Securities to be registered in the name of the transferee if the Securities are uncertificated or deliver or cause to be delivered to the transferee(s) certificates and other documents of title evidencing ownership of the Securities being Transferred, duly endorsed in blank for transfer by the holders of record if such Securities are certificated. In addition, the transferor(s) shall deliver to the Corporation all records, accounts and other documents in its possession belonging to the Corporation. The transferee(s) shall pay the purchase price for the Securities being Transferred by certified cheque or wire transfer.

 

(b) If, at the time of closing, a transferor fails to complete the subject transaction of purchase and sale for any reason, the transferee shall have the right, if not in default under this Agreement, without prejudice to any other rights which it may have, upon payment of that part of the purchase price payable to the transferor at the time of closing to the credit of the transferor in the main branch of the Corporation’s bank, to execute and deliver, on behalf of and in the name of the transferor, such deeds, transfers, share certificates, resignations or other documents as may, in the reasonable opinion of the transferee, be necessary or desirable to complete the subject transaction. In connection with the foregoing, the transferor irrevocably nominates, constitutes and appoints the transferee as its attorney and agent, with full power of substitution, in the name of such transferor to execute and deliver all such documents. Such appointment, being coupled with an interest, is irrevocable by the transferor and shall not be revoked by the insolvency, bankruptcy, death, disability or incapacity of the transferor or its Principal. The transferor hereby ratifies and confirms and agrees to ratify and confirm all that the transferee may lawfully do or cause to be done by virtue of such appointment and power. If payment of the purchase price is deposited in accordance with the foregoing, then from and after the date of deposit, notwithstanding that certificates or instruments evidencing the Securities being Transferred may not have been delivered to the transferee, (i) the Transfer shall be deemed to have been fully completed and the records of the Corporation may be amended accordingly, (ii) all right, title, benefit and interest, both at law and in equity, in and to such Securities shall be conclusively deemed to have been Transferred and become vested in the transferee and (iii) all right, title, benefit and interest of the transferor or of any other person (other than the transferee) having an interest in such Securities, legal or equitable, in any capacity whatsoever shall cease.

 

-16-

 

 

7.2 Governmental Approvals

 

If any governmental approval is required by a transferee of Securities under any provision of this Agreement, then, notwithstanding anything contained in this Agreement, the time period specified in this Agreement for acceptance of the offer by such transferee shall be extended for an additional 90 days to permit such transferee to obtain the necessary governmental approval. Any such application for governmental approval shall be the sole responsibility of such transferee who shall also be responsible for all costs and expenses incurred in connection therewith.

 

ARTICLE 8

CONFIDENTIALITY AND ADDITIONAL COVENANTS

 

8.1 Confidentiality

 

(a) No party shall, at any time or under any circumstances, without the consent of the Corporation, directly or indirectly communicate or disclose to any person (other than the other parties and its or their employees, directors, agents, advisors and representatives) or make use of any confidential knowledge or information howsoever acquired by such party relating to or concerning the customers, products, technology, intellectual property, trade secrets, systems or operations, or other confidential information regarding the property, business and affairs of the Corporation (collectively, “Information”), except for (i) Information that becomes generally known to the public other than through a breach of this Agreement, (ii) Information that is lawfully obtained from a third party without breach of this Agreement by the party, and (iii) Information that is required to be disclosed by law or by the applicable regulations or policies of any regulatory agency of competent jurisdiction or any stock exchange, provided that the party gives the Corporation prompt written notice of the compelled disclosure and cooperates with the Corporation, at the Corporation’s expense, in seeking a protective order or any other protections available to limit the disclosure of the Information.

 

(b) Nothing in this Section 8.1 shall preclude a Shareholder from using or disclosing Information in the course of such Shareholder performing his or her duties as an employee, consultant or Director of the Corporation or a subsidiary of the Corporation.

 

(c) If a Shareholder ceases to be a shareholder of the Corporation, the Shareholder shall use all reasonable efforts to ensure that all Information and all copies thereof are either destroyed or returned to the Corporation if the Corporation so requests, and shall not, directly or indirectly, use for the Shareholder’s own purposes, any Information discovered or acquired by the Shareholder or the Shareholder’s advisors. Each party’s obligations under this Article 8 shall be in addition to and not in derogation of any other obligation of confidentiality owed to the Corporation by such party.

 

(d) Each party hereby agrees that all the restrictions in this Article 8 are reasonable and valid and all defences to the strict enforcement thereof by the Corporation and/or the other parties are hereby waived.

 

-17-

 

 

8.2 Equitable Remedies

 

Each of the parties acknowledges that disclosure of any Information in contravention of Section 8.1 may cause significant harm to the Corporation and that remedies at law may be inadequate to protect against a breach of Section 8.1. Accordingly, each of the parties acknowledges that the Corporation is entitled, in addition to any other relief available to it, to the granting of injunctive relief, specific performance and any other equitable remedies, without proof of actual damages or the requirement to establish the inadequacy of any of the other remedies available to it. Each of the parties covenants not to assert any defense in proceedings regarding the granting of an injunction or specific performance based on the availability to the Corporation of any other remedy.

 

8.3 Non-Solicitation

 

During the applicable Restriction Period, each Shareholder and its Principal shall not, directly or indirectly through any other person or entity, (a) induce or attempt to induce (i) any person who is an employee of the Corporation or any subsidiary of the Corporation to leave such employment, or in any way interfere with the relationship between the Corporation or any subsidiary of the Corporation and any of their respective employees or (ii) any person who is an independent contractor of the Corporation or any subsidiary of the Corporation to terminate its contract with the Corporation or any subsidiary of the Corporation, or in any way interfere with the relationship between the Corporation or any subsidiary of the Corporation and any of their respective independent contractors, provided that general media advertising for employment or related opportunities that is not targeted towards the Corporation’s employees or independent contractors shall not be deemed to be a breach of the foregoing clause (i) or (ii), (b) hire any person who is or was an employee or an independent contractor of the Corporation or a subsidiary of the Corporation during the applicable Restriction Period within 12 months following the termination of the employment or the contract of such person with the Corporation or a subsidiary of the Corporation, (c) contact or solicit any client or customer of the Corporation or a subsidiary of the Corporation for the purpose of selling, offering or supplying to such client or customer any products or services which are the same as the products and services sold, offered or supplied by the Corporation or any subsidiary of the Corporation, or (d) induce or attempt to induce any customer, supplier, licensee, licensor, franchisee or other person or entity having business relations with the Corporation or a subsidiary of the Corporation to cease doing business with the Corporation or a subsidiary of the Corporation, or in any way interfere with the relationship between the Corporation or a subsidiary of the Corporation and any such customer, supplier, licensee, licensor, franchisee or person or entity having business relations with the Corporation or any subsidiary of the Corporation (including making any negative or disparaging statements or communications regarding the Corporation or any subsidiary of the Corporation).

 

8.4 Non-Disparagement

 

No Shareholder shall engage in any pattern of conduct that involves the making or publishing of written or oral statements or remarks (including the repetition or distribution of derogatory rumours, allegations, negative reports or comments) which are disparaging, deleterious or damaging in any material respect to the integrity, reputation or goodwill of the Corporation, any of its subsidiaries or their respective ownership or management.

 

-18-

 

 

8.5 Non-Merger

 

(a) Each Management Shareholder or Principal who entered into an employment agreement or consulting agreement with the Corporation or any subsidiary of the Corporation acknowledges and agrees that he or she is bound by the provisions of his or her employment agreement or consulting agreement, as applicable, and that such agreement and Section 8.3 and 8.4 are separate covenants, which shall not merge into this Agreement.

 

(b) It is acknowledged and agreed that the Corporation shall hold the benefit of each of the covenants made in Section 8.3 and 8.4 and this Section 8.5 in favour of any subsidiary of the Corporation (if any) in trust for the benefit of such subsidiary and that the Corporation shall be entitled to enforce the rights of such subsidiary hereunder on its behalf, if applicable.

 

ARTICLE 9
AMENDMENT AND TERMINATION

 

9.1 Amendments

 

This Agreement may only be amended by an instrument in writing duly executed by the Corporation and the Shareholder Super-Majority, and any such amendment shall be binding on each of the parties to this Agreement as if each such party executed and delivered such amendment. Notwithstanding the foregoing, no amendment that would have the effect of a Shareholder being treated in a materially adverse manner will be permitted without the written consent of such Shareholder, provided that if such Shareholder is not treated differently in any material respect from other holders of the same class or series of Shares, then such amendment will be valid with the prior approval of the Shareholder Super-Majority.

 

9.2 Term and Termination Events

 

This Agreement shall take effect upon its execution by all parties hereto and shall remain in effect until terminated in accordance with the terms hereof. This Agreement shall be automatically terminated (without prior notice) upon an IPO or the date upon which:

 

(a) the Shareholder Super-Majority agree in writing to terminate this Agreement;

 

(b) the Corporation is dissolved, liquidated or formally wound-up; or

 

(c) no Securities remain outstanding or all of the Securities are held by only one person.

 

9.3 Surviving Obligations

 

The termination of this Agreement shall not affect (a) the right of any party to whom money is owed or by whom damages can be claimed hereunder at the time of termination to receive that money or compensation in accordance with the provisions hereof or (b) any other rights or obligations which arose hereunder in respect of matters occurring prior to or concurrent with such termination. Without limiting the generality of the foregoing, the provisions of this Article 9 shall survive the termination of this Agreement.

 

-19-

 

 

ARTICLE 10
MISCELLANEOUS

 

10.1 Notices

 

(a) Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be delivered in person, by email or sent by registered mail, charges prepaid, addressed as follows: (i) if to the Corporation: Triage Technologies Inc., 1 Adelaide Street East, Suite 3001, Toronto, ON M5C 2V9, Attention: Tory Jarmain, email: tory@triage.com, and (ii) if to the Shareholders, as set out on the register of shareholders of the Corporation.

 

(b) Any such notice or other communication, if delivered: (i) by email, shall be deemed to have been given on the day on which it was transmitted if transmitted on a Business Day prior to 5:00 p.m. at the place of receipt or, otherwise, on the next following Business Day;

(ii) by personal delivery, shall be deemed to have been given when delivered in fact; or (iii) by registered mail, shall be deemed to have been given on the fourth Business Day following the date of mailing; provided, however, that if at the time of mailing or within three Business Days thereafter there is or occurs a labour dispute or other event which might reasonably be expected to disrupt the delivery of documents by mail, any notice or other communication hereunder shall be delivered by email.

 

(c) Any party may at any time change its address for service from time to time by giving notice in accordance with this Section 10.1.

 

10.2 Management Shareholder Power of Attorney

 

Each Management Shareholder hereby constitutes and appoints, effective as of the date of termination of such Management Shareholder as an employee of, or consultant to, the Corporation or any of its subsidiaries, any officer or Director of the Corporation as a true and lawful attorney for, in the name and on behalf of such Management Shareholder to execute and deliver any and all resolutions, proxies, voting trust or other agreements, or other instruments required in order to ensure such Management Shareholder’s compliance with its obligations under this Agreement, in each case in respect of any and all Securities held by such Management Shareholder from time to time. This power of attorney is hereby coupled with an interest and shall be irrevocable by each of the terminated Management Shareholders. This power of attorney is not intended to be a continuing power of attorney or similar power of attorney within the meaning of and governed by applicable substitute decision, living will or estate planning legislation in any of the provinces or territories of Canada (a “CPOA”). The execution of this power of attorney does not terminate any CPOA granted previously and this power of attorney is not terminated by the execution by any Management Shareholder in the future of a CPOA and each such Management Shareholder hereby agrees not to take any action that results in the termination of this power of attorney. Any proxy executed and delivered pursuant hereto relating to any meeting of Shareholders or any adjournments thereof shall revoke any proxy otherwise executed and delivered by or on behalf of a terminated Management Shareholder with respect to such meeting or any adjournments thereof, regardless of the respective dates thereof. Each terminated Management Shareholder hereby ratifies and confirms and agrees to ratify and confirm all that such attorney may lawfully do or cause to be done by virtue of the provisions of this Section 10.2.

 

-20-

 

 

10.3 Amendment and Restatement

 

This Agreement amends and restates the Original Shareholders’ Agreement in its entirety. Each of the parties agrees and confirms that all of the rights, liabilities and obligations under the Original Shareholders’ Agreement arising on or prior to the date of this Agreement continue in full force and effect, as further amended and restated in accordance with the terms of this Agreement.

 

10.4 Enurement

 

Except as otherwise provided herein, this Agreement will enure to the benefit of and will be binding upon the parties and their respective successors and assigns.

 

10.5 Entire Agreement

 

This Agreement, together with the agreements and other documents to be delivered pursuant to this Agreement, constitutes the entire agreement between the parties pertaining to the subject matter of this Agreement and supersedes all prior agreements, term sheets, understandings, negotiations and discussions between the parties, whether written or oral. There are no representations, warranties or other agreements between the parties in connection with the subject matter of this Agreement except as specifically set out in this Agreement.

 

10.6 Independent Legal Advice

 

Each Shareholder and Principal acknowledges that he, she or it: (a) has had sufficient time to review and consider this Agreement thoroughly; (b) has read and understands the terms of this Agreement and his, her or its rights and obligations hereunder; (c) has been advised by the Corporation to seek independent legal advice; (d) has sought such independent legal advice or deliberately decided not to do so; and (e) is executing this Agreement voluntarily.

 

10.7 Assignment

 

Except as otherwise provided herein, no party may assign any of its rights or obligations under this Agreement, except, for certainty, to an Eligible Transferee, without the prior written consent of the Board.

 

10.8 No Third-party Beneficiaries

 

Other than as provided in Section 8.5(b), this Agreement is for the sole benefit of the parties (and their respective heirs, executors, administrators, other personal representatives, successors and permitted assigns) and nothing herein, express or implied, is intended to or shall confer upon any other person, including any creditor of the Corporation, any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

10.9 Counterparts

 

This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. A copy of this Agreement executed by any party and transmitted by email shall be binding upon the parties in the same manner as an original executed copy that was delivered in person.

 

[The remainder of this page is intentionally left blank.]

 

-21-

 

 

IN WITNESS WHEREOF this Agreement has been executed by the parties pursuant to Section 3.4 of the Original Shareholders’ Agreement.

 

  CORPORATION
       
  TRIAGE TECHNOLOGIES INC.
       
  by  
    Name:  Tory Jarmain
    Title: Chief Executive Officer
       
  SHAREHOLDERS
       
  by  
  Tory Jarmain

 

Signature Page – Triage Shareholders’ Agreement

 

 

 

 

  ADVANCED HUMAN IMAGING LIMITED
       
  by  
    Name:  Vlado Bosanac
    Title: Chief Executive Officer
       
     
    Name: Steven Richards
    Title: Chief Financial Officer

 

Signature Page – Triage Shareholders’ Agreement

 

 

 

 

  by  
    Eric Lau

 

Signature Page – Triage Shareholders’ Agreement

 

 

 

 

SCHEDULE A FORM OF COUNTERPART

 

TO: TRIAGE TECHNOLOGIES INC.

 

AND TO: THE OTHER PARTIES TO THE SHAREHOLDERS’ AGREEMENT REFERRED TO BELOW

 

The undersigned hereby acknowledges and confirms that the undersigned has (i) received a copy of the amended and restated unanimous shareholders’ agreement dated March 31, 2021 between Triage Technologies Inc. (the “Corporation”) and its shareholders, as amended to the date hereof (the “Shareholders’ Agreement”), a copy of which is attached hereto, and (ii) read and understood fully the provisions of the Shareholders’ Agreement.

 

The undersigned hereby covenants and agrees to be bound by the Shareholders’ Agreement, as the same may be amended from time to time in accordance with the provisions thereof, as a Shareholder in the same manner and to the same extent as if the undersigned had been an original party to the Shareholders’ Agreement.

 

The undersigned acknowledges and confirms that prior to executing this Counterpart, the Corporation requested that the undersigned obtain legal advice with respect to the undersigned’s rights and obligations under the Shareholders’ Agreement, and, furthermore, the undersigned confirms and agrees that:

 

(a) the undersigned has executed this Counterpart on the undersigned’s own volition and without any duress whatsoever from the Corporation, the Shareholders or any other person; and

 

(b) if the undersigned did not obtain legal advice prior to executing this Counterpart, the undersigned will not in any proceeding relating to the enforcement of rights or obligations under the Shareholders’ Agreement raise that fact as a defence or otherwise.

 

Unless otherwise defined in this Counterpart, all terms used above that are defined in the Shareholders’ Agreement have the respective meanings given to them in the Shareholders’ Agreement.

 

  Signature:  
     
  Name:  
    (please print)
     
  Address:  
     
  Email:  
     
  Number and Class of Shares:  
     
  Name of Principal:  

 

 

 

 

Exhibit 10.16

 

Execution Version

 

TRIAGE TECHNOLOGIES INC.

(a company incorporated under the federal laws of Canada)

(Company)

 

and

 

ADVANCED HUMAN IMAGING LIMITED ACN 602 111 115

(Investor)

 

 

 

SUBSCRIPTION AGREEMENT

 

 

 

 

 

 

TABLE OF CONTENTS

  

1. DEFINITIONS AND INTERPRETATION 3
       
  1.1 Definitions 3
  1.2 Interpretation 8
  1.3 Business Day 9
  1.4 References to the calculation of time 9
  1.5 Fractional entitlements 10
  1.6 Time is of the Essence 10
       
2. SUBSCRIPTION FOR SUBSCRIPTION SHARES 10
       
  2.1 Application 10
  2.2 Subscription 10
  2.3 Issue 12
  2.4 Conditions of Issuance of Company Shares 12
       
3. REQUEST FOR FURTHER INVESTMENT 12
       
4. SHAREHOLDER APPROVAL 13
       
5. WARRANTIES 13
       
  5.1 Mutual Warranties 13
  5.2 Investor Warranties 14
  5.3 Company Warranty 15
       
6. RIGHT OF FIRST OFFER 15
       
  6.1 Right of First Offer 15
  6.2 Permitted Offering 16
  6.3 Termination of Right of First Offer 16
       
7. UNDERTAKINGS BY THE COMPANY 17
       
  7.1 Company Undertakings 17
  7.2 Investor Undertakings 17
       
8. DEFAULT 17
       
  8.1 Event of Default 17
  8.2 Non-Defaulting Party’s Powers on an Event of Default 18
       
9. CONFIDENTIALITY 18
       
  9.1 Confidential Information 18
  9.2 Reasonable endeavours 19
  9.3 Survival on termination 20
       
10. NOTICES 20
       
  10.1 Form of notice 20
  10.2 Means of giving notices 20
  10.3 Specified address for service 20
  10.4 Change of Address 20
  10.5 Receipt of notices 21
       
11. NOVATION 21
       
  11.1 AHI USA 21
  11.2 References 21
  11.3 Release by the Company 21
  11.4 Release by the Investor 22

 

i

 

 

12. MISCELLANEOUS 22
       
  12.1 Termination 22
  12.2 Effect of Termination 22
  12.3 Amendments and Waivers 22
  12.4 Taxes and withholdings 22
  12.5 Further assurance 22
  12.6 Governing law 23
  12.7 Costs 23
  12.8 Severance 23
  12.9 Entire Agreement 23
  12.10 Conflicts 23
  12.11 Counterparts 23
       
SCHEDULE A 25
       
SCHEDULE B 26

 

ii

 

 

THIS AGREEMENT is made the 31st day of March, 2021

 

 

BE TWE E N

 

 

TRIAGE TECHNOLOGIES INC. (a company incorporated under the federal laws of Canada) of 1 Adelaide Street East, Suite 3001 Toronto, Ontario M5C 2V9 Canada (Company);

 

AND

 

ADVANCED HUMAN IMAGING LIMITED (ACN 602 111 115) of Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 Australia (Investor).

 

 

RE CI T A LS

 

 

A. The Investor hereby irrevocably subscribes for and agrees to purchase 4,466,748 Subscription Shares for aggregate consideration of $6,000,000, payable in cash and AHI USA Shares or AHI ASX Shares (each as defined below) (the Aggregate Subscription Amount), in tranches on the terms and conditions contained in this Agreement.

 

B. On 3 December 2020 (Toronto time), the Investor advanced $500,000 to the Company as a prepayment of a portion of the Aggregate Subscription Amount.

 

C. On 16 March 2021 (Toronto time), the Investor advanced a further $100,000 to the Company as a prepayment of a portion of the Aggregate Subscription Amount.

 

D. The Company hereby agrees to issue a total of 4,466,748 Subscription Shares to the Investor in tranches on the terms and conditions contained in this Agreement.

 

E. The Investor and the Company will enter into a software reseller agreement (the Reseller Agreement) in connection with the entering into of this Agreement, pursuant to which, among other things, the Company will grant a non-exclusive license to the Investor to integrate the Triage Platform into the MyFiziq Platform (each as defined in the Reseller Agreement) and the Investor will grant a non- exclusive license to the Company to commercialise the Triage Platform, as an add-on to the MyFiziq Platform, or as a combined application.

 

IT IS AGREED as follows:

 

 
1. DEFINITIONS AND INTERPRETATION

 

1.1 Definitions

 

For the purposes of this Agreement, unless the context otherwise requires, the following capitalized terms shall have the respective meanings set out below:

 

Acceptance Period has the meaning given to it in clause 6.1(c). Aggregate Subscription Amount has the meaning set out in the recitals. Agreement means this agreement, including its recitals. AHI ASX Share means a fully paid ordinary Share in the Investor.

 

AHI USA means a holding company incorporated in the USA for the purpose of acquiring the Investor in connection with a listing on NASDAQ.

 

1

 

 

AHI USA Shares means shares in the common stock of AHI USA listed on NASDAQ.

 

ASX means the Australian Securities Exchange.

 

Business Day means a day that is not a Saturday, Sunday or public holiday in Toronto, Ontario, or Perth, Western Australia.

 

Change of Control means, with respect to the Company or the Investor (the “relevant entity”) (a) any transaction or series of related transactions to which the relevant entity is party in which in excess of fifty percent (50%) of the total voting power is transferred; (b) any merger, amalgamation or consolidation of the relevant entity with or into any other entity or person, or any other corporate reorganization, other than any such merger, amalgamation, consolidation or reorganization in which the shareholders of the relevant entity outstanding immediately prior to such transaction continue to retain at least fifty percent (50%) of the total voting power of the relevant entity or such surviving entity outstanding immediately after such transaction; or (c) a sale, transfer or other conveyance of all or substantially all of the relevant entitys assets, or the exclusive license of all or substantially all of the relevant entitys material intellectual property.

 

Claim means any allegation, debt, cause of action, liability, claim, proceeding, suit or demand of any nature howsoever arising and whether present or future, fixed or unascertained, actual or contingent whether at law, in equity, under statute or otherwise and which any party may have against another in connection with this Agreement.

 

Company Shares means any authorized shares in the capital of the Company, including the Subscription Shares.

 

Confidential Information has the meaning given to it in clause 9.1.

 

Corporations Act means the Corporations Act 2001 (Cth).

 

Deemed Issue Price means:

 

(a) for Subscription Shares, $1.34 per Subscription Share;

 

(b) for the first $500,000 of AHI ASX Shares issued to the Company, A$0.95 per AHI ASX Share, and for any subsequent AHI ASX Shares issued to the Company, the VWAP of AHI ASX Shares for the 5 trading days prior to the relevant Subscription Date; and

 

(c) for AHI USA Shares:

 

(i) where clause 2.2(f) applies: the price at which AHI USA Shares are listed on the NASDAQ; or

 

(ii) in all other cases: the VWAP of AHI USA Shares for the 5 trading days prior to the relevant Subscription Date.

 

Defaulting Party has the meaning given to it in clause 8.1.

 

Event of Default means any of the events set out in clause 8.1.

 

Exercise Notice has the meaning given to it in clause 6.1(c).

 

Further Investment Notice has the meaning given to it in clause 3(a).

 

2

 

 

Listing Rules means the Listing Rules of the ASX.

 

Material Adverse Effect means a material adverse effect on the Companys ability to perform and comply with its obligations under the Company Shares or on a shareholder of the Company’s rights under them.

 

NASDAQ means the NASDAQ Stock Market.

 

Non-Defaulting Party has the meaning given to it in clause 8.1(a).

 

Notice of Election has the meaning given to it in clause 2.2(f).

 

Novation Date means the date on which AHI USA completes the acquisition of the Investor.

 

Offer Notice has the meaning given to it in clause 6.1(b).

 

Offered Shares has the meaning given to it in clause 6.1(a).

 

Professional Investor means a professional investor for the purposes of section 708(11) of the Corporations Act.

 

Reseller Agreement has the meaning set out in the recitals.

 

Shareholder Approval means the Investor obtaining the required approvals from its shareholders at a General Meeting to issue AHI ASX Shares to the Company.

 

Shareholders’ Agreement means the shareholders’ agreement of the Company dated April 5, 2016 and attached as Schedule A hereto.

 

Sophisticated Investor means a sophisticated investor for the purposes of section 708(8) of the Corporations Act.

 

Subscription Amounts means the:

 

(a) Tranche 1 Subscription Amount;

 

(b) Tranche 2 Subscription Amount;

 

(c) Tranche 3 Subscription Amount;

 

(d) Tranche 4 Subscription Amount;

 

(e) Tranche 5 Subscription Amount; and

 

(f) Tranche 6 Subscription Amount,

 

(each being a Subscription Amount).

 

Subscription Date means:

 

(a) for the Tranche 1 Subscription Amount: the Tranche 1 Subscription Date;

 

(b) for the Tranche 2 Subscription Amount: the Tranche 2 Subscription Date;

 

(c) for the Tranche 3 Subscription Amount: the Tranche 3 Subscription Date;

 

3

 

 

(d) for the Tranche 4 Subscription Amount: the Tranche 4 Subscription Date;

 

(e) for the Tranche 5 Subscription Amount: the Tranche 5 Subscription Date; and

 

(f) for the Tranche 6 Subscription Amount: the Tranche 6 Subscription Date.

 

Subscription Shares means Series C Common Shares in the capital of the Company.

 

Third Party has the meaning given to it in clause 6.1(e).

 

Tranche 1 Subscription Amount means $500,000. Tranche 1 Subscription Date means the date hereof. Tranche 2 Subscription Amount means:

 

(a) $500,000, payable in immediately available funds to an account nominated by the Company ($100,000 of which has already been advanced as acknowledged under Recital C); and

 

(b) subject to Section 2.2(f), if the Novation Date:

 

(i) occurs by the Tranche 2 Subscription Date, $1,000,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(ii) does not occur by the Tranche 2 Subscription Date, the Company will, at its sole discretion, elect to (x) receive $1,000,000 worth of AHI ASX Shares at the Deemed Issue Price, or (y) not receive any additional consideration under this tranche.

 

Tranche 2 Subscription Date means the earlier of May 27, 2021 and the Novation Date.

 

Tranche 3 Further Investment Notice means the Further Investment Notice requesting the advance of the Tranche 3 Subscription Amount.

 

Tranche 3 Subscription Amount means:

 

(a) $500,000, payable in immediately available funds to an account nominated by the Company; and

 

(b) subject to Section 2.2(f), if the Novation Date:

 

(i) occurs:

 

(A) by the Tranche 2 Subscription Date, $500,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(B) by the Tranche 3 Subscription Date, but after the Tranche 2 Subscription Date, $1,500,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(ii) does not occur by the Tranche 3 Subscription Date, the Company will, at its sole discretion, elect to (x) receive $1,500,000, less the dollar value at the time of issuance of any AHI ASX Shares previously received by the Company pursuant to any prior Subscription Amount, worth of AHI ASX Shares at the Deemed Issue Price, or (y) not receive any additional consideration under this tranche.

 

4

 

 

Tranche 3 Subscription Date means the date that is 60 days after the Investor receives the Tranche 3 Further Investment Notice or such earlier date as the parties may mutually agree in writing.

 

Tranche 4 Further Investment Notice means the Further Investment Notice requesting the advance of the Tranche 4 Subscription Amount.

 

Tranche 4 Subscription Amount means:

 

(a) $500,000, payable in immediately available funds to an account nominated by the Company; and

 

(b) subject to Section 2.2(f), if the Novation Date:

 

(i) occurs:

 

(A) by the Tranche 3 Subscription Date, $500,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(B) by the Tranche 4 Subscription Date, but after the Tranche 3 Subscription Date, $2,000,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(ii) does not occur by the Tranche 4 Subscription Date, the Company will, at its sole discretion, elect to (x) receive $2,000,000, less the dollar value at the time of issuance of any AHI ASX Shares previously received by the Company pursuant to any prior Subscription Amount, worth of AHI ASX Shares at the Deemed Issue Price, or (y) not receive any additional consideration under this tranche.

 

Tranche 4 Subscription Date means the date that is 60 days after the Investor receives the Tranche 4 Further Investment Notice or such earlier date as the parties may mutually agree in writing.

 

Tranche 5 Further Investment Notice means the Further Investment Notice requesting the advance of the Tranche 5 Subscription Amount.

 

Tranche 5 Subscription Amount means:

 

(a) $500,000, payable in immediately available funds to an account nominated by the Company; and

 

(b) subject to Section 2.2(f), if the Novation Date:

 

(i) occurs:

 

(A) by the Tranche 4 Subscription Date, the number of AHI USA Shares that equals $500,000 when calculated at the Deemed Issue Price; or

 

5

 

 

  (B) by the Tranche 5 Subscription Date, but after the Tranche 4 Subscription Date, $2,500,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(ii) does not occur by the Tranche 5 Subscription Date, the Company will, at its sole discretion, elect to (x) receive $2,500,000, less the dollar value at the time of issuance of any AHI ASX Shares previously received by the Company pursuant to any prior Subscription Amount, worth of AHI ASX Shares at the Deemed Issue Price, or (y) not receive any additional consideration under this tranche.

 

Tranche 5 Subscription Date means the date that is 60 days after the Investor receives the Tranche 5 Further Investment Notice or such earlier date as the parties may mutually agree in writing.

 

Tranche 6 Further Investment Notice means the Further Investment Notice requesting the advance of the Tranche 6 Subscription Amount.

 

Tranche 6 Subscription Amount means:

 

(a) $500,000, payable in immediately available funds to an account nominated by the Company; and

 

(b) subject to Section 2.2(f), if the Novation Date:

 

(i) occurs:

 

(A) by the Tranche 5 Subscription Date, $500,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(B) by the Tranche 6 Subscription Date, but after the Tranche 5 Subscription Date, $3,000,000 worth of AHI USA Shares at the Deemed Issue Price; or

 

(ii) does not occur by the Tranche 6 Subscription Date, $3,000,000, less the dollar value at the time of issuance of any AHI ASX Shares previously received by the Company pursuant to any prior Subscription Amount, worth of AHI ASX Shares at the Deemed Issue Price.

 

Tranche 6 Subscription Date means the date that is 60 days after the Investor receives the Tranche 6 Further Investment Notice or such earlier date as the parties may mutually agree in writing.

 

Treasury Offer has the meaning given to it in clause 6.1.

 

VWAP means volume weighted average price.

 

Warrantor has the meaning given to it in clause 5.1.

 

1.2 Interpretation

 

In this Agreement:

 

(a) headings are for convenience only and do not affect its interpretation;

 

6

 

 

(b) specifying anything after the words “include” or “for example” or similar expressions does not limit what else is included,

 

and, unless the context otherwise requires:

 

(c) the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;

 

(d) a reference to any party includes that party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;

 

(e) a reference to any document (including this Agreement) is to that document as varied, novated, ratified or replaced from time to time;

 

(f) a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;

 

(g) words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;

 

(h) reference to parties, clauses or Articles are references to parties, clauses and Articles of this Agreement;

 

(i) where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning;

 

(j) other parts of speech and grammatical forms of a word or phrase defined in this Agreement have a corresponding meaning;

 

(k) a reference to $ or dollars is to the currency of the United States of America; and

 

(l) any amount computed or determined in whole or in part in a currency other than the U.S. dollar shall be converted to an amount expressed in U.S. dollars by the payor using the indicative exchange rate provided by the Bank of Canada for the day on which the particular amount is paid or, if no indicative rate is provided for that day, at the most recent indicative rate preceding that day, and paid in U.S. dollars.

 

1.3 Business Day

 

Where the day on or by which any thing is to be done is not a Business Day, that thing must be done on or by the immediately preceding Business Day.

 

1.4 References to the calculation of time

 

(a) Unless otherwise indicated, a reference to a time of day means that time of day in Toronto, Ontario.

 

7

 

 

(b) For the purposes of determining the length of a period (but not its commencement) a reference to:

 

(i) a day means a period of time commencing at midnight and ending 24 hours later; and

 

(ii) a month means a calendar month.

 

(c) Any time period within which a payment is to be made or any other action is to be taken hereunder shall be calculated excluding the day on which the period commences and including the day on which the period ends.

 

1.5 Fractional entitlements

 

Fractional entitlements to any Subscription Shares, AHI USA Shares or AHI ASX Shares that are to be issued pursuant to this Agreement will be rounded to the nearest whole number.

 

1.6 Time is of the Essence

 

Time shall be of the essence of this Agreement.

 

 
2. SUBSCRIPTION FOR SUBSCRIPTION SHARES

 

2.1 Application

 

The Investor agrees to subscribe for, and the Company agrees to issue to the Investor, the 4,466,748 Subscription Shares in tranches in accordance with this Agreement, in consideration for the Subscription Amounts.

 

2.2 Subscription

 

(a) On the Tranche 1 Subscription Date, the payment referenced in Recital B shall be fully set-off against the Tranche 1 Subscription Amount.

 

(b) The Investor must advance the cash component of the Tranche 2 Subscription Amount and each subsequent Subscription Amount to the Company on the relevant Subscription Date, provided that, on the Tranche 2 Subscription Date, the payment referenced in Recital C shall be set-off in part against the cash component of the Tranche 2 Subscription Amount.

 

(c) Subject to clauses 2.2(d) and (e), the Investor must issue any share component of the Tranche 2 Subscription Amount and each subsequent Subscription Amount to the Company on the earlier of:

 

(i) the relevant Subscription Date; and

 

(ii) the date specified under clause 2.2(f) (if applicable).

 

(d) Where the Investor is required to issue any AHI ASX Shares under this Agreement it must:

 

(i) allot and issue the relevant AHI ASX Shares to the Company;

 

8

 

 

(ii) enter the Company in the Investor’s register of members as the holder of the relevant AHI ASX Shares; and

 

(iii) following the issue of the relevant AHI ASX Shares:

 

(A) send holding statements in respect of the relevant AHI ASX Shares to the Company in accordance with applicable law;

 

(B) apply to ASX for official quotation of the relevant AHI ASX Shares in the same class and on the same terms as all other AHI ASX Shares quoted on ASX on the date of issue; and

 

(C) shall lodge with ASX a notice in accordance with section 708A(5)(e) of the Corporations Act.

 

(e) If the Investor is unable to comply with the requirements of section 708A(5) of the Corporations Act for any reason:

 

(i) the Investor shall use reasonable endeavours to ensure the relevant AHI ASX Shares are able to be freely traded on ASX in compliance with the requirements of the ASX Listing Rules and the Corporations Act as soon as reasonably practicable after the relevant issue date; and

 

(ii) the Company agrees that the Investor may place a holding lock on such AHI ASX Shares until those requirements have been met.

 

(f) Where the Novation Date occurs prior to a Subscription Date, the Company may, within 21 days after the Novation Date, elect by providing notice in writing to the Investor (the Notice of Election) to immediately receive the share component of all of the Subscription Amounts, in which case:

 

(i) the Investor must issue to the Company $3,000,000, less the dollar value at the time of issuance of any AHI ASX Shares previously received by the Company pursuant to any prior Subscription Amount, worth of AHI USA Shares at the Deemed Issue Price in respect thereof on the date which is 60 days after the Investor receives the Company’s Notice of Election; and

 

(ii) subject to clause 2.4 and the Companys receipt of the AHI USA Shares referred to in clause 2.2(f)(i), the Company must issue to the Investor $3,000,000, less the dollar value at the time of issuance of any AHI ASX Shares previously received by the Company pursuant to any prior Subscription Amount, worth of Subscription Shares at the Deemed Issue Price on the date which is 5 Business Days after the Investor receives the Company’s Notice of Election.

 

Notwithstanding any election by the Company pursuant to clause 2.2(f), the cash component of each Subscription Amount will continue to be paid at the times provided for under clause 2.2(b) in all cases. The Investor shall provide the Company with reasonable advance notice of the occurrence of the Novation Date.

 

9

 

 

2.3 Issue

 

Subject to clause 2.2(f), 2.4 and the receipt by the Company of the applicable Subscription Amount in accordance with clause 2.2, the Company must do each of the following on each applicable Subscription Date:

 

(a) issue to the Investor the amount of Subscription Shares that, when multiplied by the Deemed Issue Price, equals the applicable Subscription Amount;

 

(b) deliver a share certificate or notice of uncertificated shares for the relevant Subscription Shares to the Investor; and

 

(c) ensure the Investor is registered as the holder of the relevant Subscription Shares in the Companys share register.

 

The representations and warranties of the Investor set out in Section 5.2 shall be deemed to be made again on each date the Investor is issued Subscription Shares under this Agreement.

 

2.4 Conditions of Issuance of Company Shares

 

(a) The Company and the Investor shall use commercially reasonable efforts to enter into an amended and restated shareholders’ agreement with the other shareholders of the Company on the Tranche 1 Subscription Date, pursuant to which the Shareholders’ Agreement will be amended and restated in its entirety. Notwithstanding anything to the contrary in this Agreement, any issuance of Company Shares (including Subscription Shares) by the Company to the Investor under this Agreement shall be conditional upon (i) the Investor executing and being bound by such amended and restated shareholdersagreement (or such other shareholders’ agreement of the Company in effect at the time of issuance) and (ii) the satisfaction of all requirements under applicable securities laws in respect of the private placement of such Company Shares.

 

(b) The Investor acknowledges that (i) the Company is not a reporting issuer or the equivalent in any jurisdiction, (ii) the Company Shares are not listed on any stock exchange, (iii) no public market exists for the Company Shares, and (iv) the Company Shares are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under applicable securities laws, the Companys constating documents and the shareholders’ agreement of the Company in effect at the relevant time.

 

 

3. REQUEST FOR FURTHER INVESTMENT

 

(a) Any time after:

 

(i) in respect of the Tranche 3 Subscription Amount, the Tranche 2 Subscription Date;

 

10

 

 

(ii) in respect of the Tranche 4 Subscription Amount, the Tranche 3 Subscription Date;

 

(iii) in respect of the Tranche 5 Subscription Amount, the Tranche 4 Subscription Date; and

 

(iv) in respect of the Tranche 6 Subscription Amount, the Tranche 5 Subscription Date;

 

the Company may demand in writing that the Investor advance the next Subscription Amount (a Further Investment Notice) and the Investor shall advance such Subscription Amount to the Company on the relevant Subscription Date.

 

(b) For the avoidance of doubt:

 

(i) a Further Investment Notice can only request the advance of one Subscription Amount at a time; and

 

(ii) each Subscription Amount can only be advanced once.

 

 

4. SHAREHOLDER APPROVAL

 

(a) The issue of AHI ASX Shares that is contemplated in this Agreement is subject to and conditional on Shareholder Approval.

 

(b) If the Novation Date has not occurred by 27 May 2021, the Investor must seek Shareholder Approval for the issue of the AHI ASX Shares component of the Tranche 2 Subscription Amount at a General Meeting to be held prior to the Tranche 2 Subscription Date.

 

(c) Upon the receipt of a Further Investment Notice, if the Novation Date has not occurred prior to receipt of such notice, the Investor must use reasonable endeavours to convene a General Meeting prior to the relevant Subscription Date to obtain the required Shareholder Approval for the issue of the amount of AHI ASX Shares contemplated in the Further Investment Notice.

 

(d) If a Shareholder Approval is required and not obtained by the applicable Subscription Date in accordance with Section 4(c), the Investor must instead pay on such Subscription Date an amount equal to the value of the relevant AHI ASX Shares contemplated in the Further Investment Notice in immediately available funds to an account nominated by the Company.

 

 

5. WARRANTIES

 

5.1 Mutual Warranties

 

Each of the Company and the Investor (each, a Warrantor) represents and warrants to the other, as an inducement to the other to enter into this Agreement that, at the date of this Agreement:

 

(a) the execution and delivery of this Agreement has been properly authorised by all necessary corporate action of the Warrantor;

 

11

 

 

(b) the Warrantor is duly incorporated, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated and has full power and lawful authority to execute and deliver this Agreement and to consummate and perform or cause to be performed its obligations under this Agreement;

 

(c) the execution and delivery by the Warrantor of this Agreement, the performance by it of its obligations hereunder and compliance with the terms, conditions and provisions hereof will not conflict with or result in a breach of any of the terms, conditions or provisions of (i) its articles or other constating documents; (ii) any law, rule or regulation having the force of law; (iii) any indenture, mortgage, lease, agreement or instrument binding or affecting it or its properties, including any shareholders’ agreement or partnership agreement; or (iv) any judgment, injunction, determination or award which is binding upon it or its properties; and

 

(d) this Agreement constitutes a legal, valid and binding obligation of the Warrantor enforceable against it in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application relating to or affecting the enforcement of creditors’ rights and as limited by rules or laws concerning equitable remedies.

 

5.2 Investor Warranties

 

In addition to the warranties given under clause 5.1, the Investor represents and warrants to the Company as an inducement to the Company to enter into this Agreement that, at the date of this Agreement:

 

(a) the decision of the Investor to enter into this Agreement and subscribe for the Subscription Shares was made in Perth, Western Australia;

 

(b) it is a Sophisticated Investor or Professional Investor, or is otherwise a person who is able to be offered the Subscription Shares without disclosure under Chapter 6D of the Corporations Act, and will, on the request of the Company, promptly provide written evidence sufficient to satisfy the Company of the same;

 

(c) it is an “accredited investor” as defined in Section 1.1 of National Instrument 45-106 – Prospectus and Registration Exemption or under Section 73.3 of the Securities Act (Ontario), provided that the Investor has (i) reviewed the substance of each category of such definition, (ii) consulted its financial, accounting or tax advisors regarding the Investor’s compliance with such definition, and (iii) communicated in writing prior to the date hereof any exchange, valuation or other risks that might reasonably be expected to result in the Investor’s failure to satisfy such definition, and provided further that the Investor shall, upon reasonable request of the Company, provide such additional financial or other information reasonably required to support such representations and warranties;

 

(d) it is a person to whom it is lawful to offer or issue the Subscription Shares without a disclosure document (and is not a “U.S. Person” as defined under the U.S. Securities Act of 1933, or resident in the United States of America or in any other place in which it would not be lawful to offer or issue the Subscription Shares);

 

12

 

 

(e) the issuance of the Subscription Shares to the Investor does not require registration, qualification, disclosure or any other action by the Company in the jurisdiction in which the Investor is located or in which the offer of the Subscription Shares is received, and the Investor has satisfied itself as to the full observance of the laws of its jurisdiction in connection with the offer of and subscription for Subscription Shares;

 

(f) it is aware of and accepts the risks relating to its subscription for the Subscription Shares under this Agreement; and

 

(g) in deciding to subscribe for the Subscription Shares, it has:

 

(i) made and relied on its own enquiries and assessment of the Company, its business, operations and prospects;

 

(ii) made and relied on its own assessment of, and risks relating to, the Subscription Shares and an investment in the Company; and

 

(iii) not relied on any representations or warranties made or given by or on behalf of the Company (or any of its directors, officers, employees, agents or advisers), other than as set out in this Agreement.

 

5.3 Company Warranty

 

In addition to the warranties given under clause 5.1, the Company represents and warrants to the Investor as an inducement to the Investor to enter into this Agreement that, at the date of this Agreement, the copy of the Company’s articles of incorporation that has been provided to the Investor is a true and correct copy of the Company’s current articles of incorporation.

 

 

6. RIGHT OF FIRST OFFER

 

6.1 Right of First Offer

 

Subject to clauses 6.2 and 6.3, each time the Company proposes to issue any Company Shares on a date following the date on which the Tranche 6 Subscription Amount has been received by the Company, the Company shall first offer (the Treasury Offer) such Company Shares to the Investor on the following terms:

 

(a) The number of Company Shares the Investor shall be offered and may purchase shall be equal to the total number of Company Shares being offered pursuant to the Treasury Offer (the Offered Shares).

 

(b) Each Treasury Offer shall be made by written notice (an Offer Notice) to the Investor specifying (A) the total number and class of Offered Shares and (B) the price and terms upon which the Company proposes to offer the Offered Shares.

 

(c) The Investor shall have 10 days (the Acceptance Period) following receipt of the Offer Notice to accept the Treasury Offer. Acceptance of a Treasury Offer shall be made by notice in writing (an Exercise Notice) to the Company within the Acceptance Period specifying that the Investor accepts the Treasury Offer and wishes to purchase all, but not less than all, of the Offered Shares, at the price and on the terms set out in the Offer Notice. An Exercise Notice shall be irrevocable and unconditional. If the Investor does not accept the Treasury Offer before expiration of the Acceptance Period, then the Investor shall be deemed to have refused the Treasury Offer.

 

13

 

 

(d) If the Investor accepts the Treasury Offer in accordance with clause (c) above, the closing of the purchase and sale of the Offered Shares shall occur within 20 days of the date of the Exercise Notice, and the Investor shall pay the aggregate purchase price for the Offered Shares to the Company (or as the Company otherwise directs) by wire transfer in immediately available funds. If the closing does not occur within such 20 day period, the Company shall be entitled to offer and sell the Offered Shares to any other person in accordance with clause (e) below.

 

(e) If the Investor does not accept the Treasury Offer in accordance with the foregoing, the Company shall be entitled to offer and sell the Offered Shares to any other person (a Third Party), provided that such sale shall not be effected at an effective price which is less than the price set forth in the Treasury Offer. For greater certainty, where the consideration to be received by the Company in connection with any proposed sale to a Third Party includes shares in the capital of such Third Party, the effective price of the Offered Shares shall be equal to the sum of any cash consideration and the fair market value of the shares of the Third Party to be received as consideration for the Offered Shares.

 

6.2 Permitted Offering

 

The Company may issue Company Shares without complying with clause 6.1 in the following circumstances only:

 

(a) Company Shares, or options exercisable for Company Shares, issued or issuable to employees, officers, directors or consultants of the Company under any share option plan, employment agreement or consulting agreement, each on terms approved by the board of directors of the Company, provided that any such issuances of Company Shares shall be issued out of the Companys ESOP pool of 3,225,000 Series A Common Shares;

 

(b) any subdivision of Company Shares (by a split of any Company Shares or otherwise), payment of share dividend, reclassification, reorganization or any similar recapitalization; provided that AHI is not disproportionately affected relative to the other shareholders by any such subdivision of Company Shares, payment of share dividend, reclassification, reorganization or recapitalization; or

 

(c) Company Shares issued or issuable upon the exercise, conversion or exchange, in accordance with their terms, of options or convertible securities that are on issue on the date of this Agreement.

 

6.3 Termination of Right of First Offer

 

Unless otherwise provided below, the right of first offer set out in clause 6.1 shall terminate automatically and without further act or formality on the earliest of:

 

(a) the occurrence of a Change of Control of the Company or the Investor;

 

14

 

 

(b) a material breach by the Investor of any term of this Agreement or of any other agreement entered into between the Investor and the Company, unless the Company otherwise determines in its sole and absolute discretion;

 

(c) the occurrence of an Event of Default in respect of the Investor, unless the Company otherwise determines in its discretion;

 

(d) the date the Investor holds less than 50% of the Company Shares issued to it pursuant to this Agreement; and

 

(e) the termination of this Agreement for any reason.

 

 
7. UNDERTAKINGS BY THE COMPANY

 

7.1 Company Undertakings

 

The Company undertakes to the Investor to:

 

(a) maintain its status as a corporation validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; and

 

(b) notify the Investor immediately if any representation or warranty made by the Company in clauses 5.1 or 5.3 is found to be incorrect or misleading when made.

 

7.2 Investor Undertakings

 

The Investor undertakes to the Company to:

 

(a) maintain its status as a corporation validly existing and in good standing under the laws of the jurisdiction in which it is incorporated; and

 

(b) notify the Company immediately if any representation or warranty made by the Investor in clauses 5.1 or 5.2 is found to be incorrect or misleading when made.

 

 

8. DEFAULT

 

8.1 Event of Default

 

It is an Event of Default if, whether or not it is within the control of the Investor or the Company, as applicable (the Defaulting Party):

 

(a) non-remediable failure: the Defaulting Party fails to perform or observe any material undertaking, obligation or agreement set out in this Agreement, including any obligation to pay an amount or issue shares due to the other party (the Non-Defaulting Party) when due (other than, for certainty, any failure to issue shares arising pursuant to Section 2.4), and that failure is not, in the reasonable opinion of the Non-Defaulting Party, remediable;

 

(b) remediable failure: the failure described in clause 8.1(a) is, in the reasonable opinion of the Non-Defaulting Party, remediable, and the Defaulting Party does not remedy the failure within 10 days, or a longer period determined by the Non-Defaulting Party, after receipt by the Defaulting Party of a notice from the Non-Defaulting Party specifying the failure;

15

 

 

(c) misrepresentation: any warranty, representation or statement made by the Defaulting Party hereunder is or becomes false, misleading or incorrect in any material respect when made;

 

(d) receiver: a receiver, receiver and manager, official manager, trustee, administrator or similar official is appointed over the assets of the Defaulting Party and such appointment is not revoked or withdrawn within 30 days of the appointment;

 

(e) insolvency: the Defaulting Party is or becomes unable to pay its debts when they are due;

 

(f) arrangements: the Defaulting Party enters into or resolves to enter into any arrangement, composition or compromise with, or assignment for the benefit of, its creditors or any class of them otherwise than while solvent;

 

(g) winding up: an application or order is made for the winding-up or dissolution of the Defaulting Party or a resolution is passed, or any steps are taken to pass a resolution for the winding-up or dissolution of the Defaulting Party otherwise than for the purpose of an amalgamation or restructuring;

 

(h) de-listing: the Investors shares are de-listed from or suspended from trading on, any stock exchange, including the NASDAQ (other than any de-listing of shares of the Investor from the ASX in connection with the acquisition of the Investor by AHI USA);

 

(i) de-registration: a notice under section 601AB of the Corporations Act is given to, or an application under section 601AA is made by, or in respect of, the Investor;

 

(j) judgment: a judgment in an amount exceeding $500,000 is obtained against the Defaulting Party and is not set aside or satisfied within 7 days; and

 

(k) execution: any distress, attachment, execution or other process of a government agency in an amount exceeding $500,000 is issued against, levied or enforced upon any of the assets of the Defaulting Party.

 

8.2 Non-Defaulting Party’s Powers on an Event of Default

 

The Defaulting Party shall promptly notify the Non-Defaulting Party of the occurrence of an Event of Default in respect of the Defaulting Party. If an Event of Default occurs, the Non-Defaulting Party may, at any time within 90 days of the date it has actual notice of the Event of Default, terminate this Agreement by written notice to the Defaulting Party.

 

 

9. CONFIDENTIALITY

 

9.1 Confidential Information

 

Each party is to keep confidential the content and existence of this Agreement and any other information obtained from each other during the negotiations preceding the execution of this Agreement or in the course of furthering the transactions contemplated by this Agreement whether in the course of conducting due diligence or otherwise (Confidential Information), and is not to use it for any purpose other than for the purpose of furthering the transactions contemplated by this Agreement nor disclose it to any person except:

 

(a) to employees, shareholders, legal advisers, auditors and other consultants who have a need to know such information for the purpose of furthering the transactions contemplated by this Agreement and who have an obligation of confidentiality in respect of such information at least equal to or better than the obligations of the parties hereunder;

 

(b) with the consent of the party which owns the Confidential Information or to which the Confidential Information relates;

 

(c) if the information is, at the date of this Agreement, lawfully in the possession of the recipient of the information through sources other than the other party and the recipient has made inquiry reasonable in the circumstances to satisfy itself that such sources, at the time of their disclosure of such information to the recipient, were not prohibited from making such disclosure by a confidentiality obligation, whether contractual, fiduciary or otherwise, owed to the other party or its affiliates;

 

(d) if required by a regulatory agency, court or a stock exchange rule, provided that prior to such required disclosure (to the extent legally permissible) the recipient shall give the other party reasonable advance notice of such a requirement to enable the other party to seek a protective order or other appropriate remedy;

 

(e) if strictly and necessarily required in connection with legal proceedings relating to this Agreement;

 

(f) if the information is generally and publicly available other than as a result of a breach of confidence or disclosure in violation of this Agreement; or

 

(g) to a financier, prospective financier or prospective acquirer (or their advisers) of a party, provided that such party shall advise such financier, prospective financier or prospective acquirer (and their advisers) that such information is confidential and require that such financier, prospective financier or prospective acquirer (and their advisers) abide by the confidentiality obligations in this Agreement as if such person were a party hereto.

 

9.2 Reasonable endeavours

 

A party disclosing Confidential Information must use all reasonable endeavours to ensure that persons receiving the Confidential Information from it do not disclose or use the Confidential Information except in the circumstances permitted in this Article 9. A party disclosing Confidential Information shall be responsible for any disclosure or use of Confidential Information by its employees, shareholders, legal advisers, auditors and other consultants in contravention of this Agreement and the other party will not be required to first assert a claim against any of such persons as a condition of seeking or obtaining a remedy against the disclosing party.

 

16

 

 

9.3 Survival on termination

 

The obligations under this clause 9 contain obligations separate and independent from the other obligations of the parties and remain in existence for a period of five years from the date of this Agreement, regardless of any termination of this Agreement.

 

 

10. NOTICES

 

10.1 Form of notice

 

A notice:

 

(a) must be in the English language; and

 

(b) may be given on behalf of a person by a solicitor, director, officer or company secretary of the person.

 

10.2 Means of giving notices

 

A notice may be given to the addressee by:

 

(a) delivering it in writing to the street address of the addressee which includes placing it in a postal receptacle provided for the address or leaving it at the address with a person apparently of or over the age of 16 years;

 

(b) sending it by registered mail (charges prepaid) to the street address of the addressee; or

 

(c) sending it by email to the email address of the addressee.

 

10.3 Specified address for service

 

(a) Until the Company gives notice of a change, its street address and email address is:

 

Address: 1 Adelaide Street East, Suite 3001 Toronto, Ontario M5C 2V9, Canada

 

  Email: tory@triage.com

 

  Attention: Tory Jarmain

 

(b) Until the Investor gives notice of a change, its street address and email address is:

 

Address: Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 Australia

 

  Email: vlado@advancedhumanimaging.com

 

  Attention: Vlado Bosanac

 

17

 

 

10.4 Change of Address

 

A party may from time to time change its address by giving notice pursuant to clause 10.1 to the other party.

 

10.5 Receipt of notices

 

Any notice given pursuant to clause 10.1 will be conclusively deemed to have been received:

 

(a) in the case of personal delivery, on the actual day of delivery if delivered prior to 5 pm (in the recipient’s local time) on a Business Day or on the next following Business Day if delivered after 5 pm (in the recipients local time) on a Business Day or on a day other than a Business Day;

 

(b) if sent by mail, on the second Business Day after the day of posting; or

 

(c) if sent by email, on the day the email was sent if sent prior to 5 pm (in the recipient’s local time) on a Business Day or on the next following Business Day if delivered after 5 pm (in the recipient’s local time) on a Business Day or on a day other than a Business Day.

 

 
11. NOVATION

 

11.1 AHI USA

 

The parties acknowledge and agree that, on the Novation Date, AHI USA will replace the Investor in all its capacities under this Agreement, will be deemed to have made all of the representations and warranties of the Investor under this Agreement and will assume all of the Investor’s obligations and liabilities under this Agreement, both those arising on or before the Novation Date and those arising thereafter. In addition, on or prior to the Novation Date, the Investor shall cause AHI USA to (a) make any additional representations and warranties to the Company that the Company reasonably determines are required in order to confirm AHI USAs suitability to subscribe for Company Shares under applicable securities laws and (b) execute a joinder to the shareholders’ agreement of the Company in effect at such time. The Investor will cause AHI USA to execute any other documents (in a form reasonably acceptable to the Company) and do all other acts and things reasonably requested by the Company to give effect to the foregoing as of the Novation Date. In furtherance of the foregoing, the Investor, AHI USA and the Company shall enter into an assignment and assumption agreement on the Novation Date substantially in the form of the agreement attached as Schedule B hereto.

 

11.2 References

 

On and from the Novation Date but subject to compliance with clause 11.1, each reference in this Agreement to the Investor shall be deemed to be a reference to AHI USA.

 

11.3 Release by the Company

 

On and from the Novation Date but subject to compliance with clause 11.1, the Company releases the Investor from:

 

(a) any obligation and liability under or in respect of this Agreement; and

 

18

 

 

(b) any Claim which it may have or but for this release might have had against the Investor connected with this Agreement.

 

11.4 Release by the Investor

 

On and from the Novation Date but subject to compliance with clause 11.1, the Investor releases the Company from:

 

(a) any obligations and liability under or in respect of this Agreement; and

 

(b) any Claim which it may have or but for this release might have had against the Company connected with this Agreement.

 

 

12. MISCELLANEOUS

 

12.1 Termination

 

Unless earlier terminated in accordance with clause 8.2, this Agreement shall terminate (a) on the written agreement of the parties once all obligations under this Agreement have been satisfied, or (b) automatically upon a Change of Control of the Company.

 

12.2 Effect of Termination

 

On such termination, (a) subject to (b) below, any amounts or share issuances due from the Defaulting Party to the Non-Defaulting Party accrued to the date of termination shall be immediately due and payable or issuable, as applicable, and

(b) the Company is not obligated to accept any further subscription from the Investor, or to issue any Subscription Shares after the date of such Event of Default.

 

12.3 Amendments and Waivers

 

No amendment or waiver of any provision of this Agreement shall be binding on either party unless consented to in writing by such party. No waiver of any provision of this Agreement shall constitute a waiver of any other provision, nor shall any waiver of any provision of this Agreement constitute a continuing waiver unless otherwise expressly provided.

 

12.4 Taxes and withholdings

 

The Investor must make any payments to be made to the Company free of all withholdings and deductions. For greater certainty, in the event that the Investor is required under applicable law to withhold or deduct an amount from a payment to be made to the Company, the payment to the Company shall be increased to the extent necessary to ensure that the Company receives a sum net of any withholding or deduction equal to the amount which it would have received had no such withholding or deduction been made.

 

12.5 Further assurance

 

Each party shall sign, execute and do all deeds, acts, documents and things as may reasonably be required by the other party to effectively carry out and give effect to the terms and intentions of this Agreement.

 

19

 

 

12.6 Governing law

 

This Agreement shall be interpreted and enforced in accordance with, and the respective rights and obligations of the parties shall be governed by, the laws of the Province of Ontario and the federal laws of Canada applicable in that province and each party irrevocably and unconditionally (a) submits to the exclusive jurisdiction of the courts of the Province of Ontario over any action or proceeding arising out of or relating to this Agreement, (b) agrees to commence such an action or proceeding in Toronto, Ontario, and to cooperate and use its commercially reasonable efforts to bring the action or proceeding before the Ontario Superior Court of Justice (Commercial List), (c) waives any objection that it might otherwise be entitled to assert to the jurisdiction of such courts and (d) agrees not to assert that such courts are not a convenient forum for the determination of any such action or proceeding.

 

12.7 Costs

 

Each party shall bear its own legal costs of and incidental to the preparation, negotiation and execution of this Agreement.

 

12.8 Severance

 

If any provision of this Agreement is invalid and not enforceable in accordance with its terms, all other provisions which are self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and forceful in accordance with their terms.

 

12.9 Entire Agreement

 

This Agreement, together with (a) the shareholders’ agreement in respect of the Company to be entered into by the Investor, (b) the confidentiality agreement dated December 11, 2020 entered into between the Company and the Investor and (c) the Reseller Agreement, shall constitute the sole understanding of the parties with respect to the subject matter hereof and replaces all other agreements with respect thereto.

 

12.10 Conflicts

 

In the event of any conflict or inconsistency between the provisions of this Agreement and the shareholdersagreement of the Company to which the Investor is a party, the shareholders’ agreement shall prevail with respect to the Investor.

 

12.11 Counterparts

 

This Agreement may be executed in any number of counterparts (including by way of facsimile or other electronic means) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

20

 

 

EXECUTED by the parties as of the date first written above.

 

EXECUTED by ADVANCED HUMAN IMAGING   )
LIMITED   )
ACN 602 111 115   )
in accordance with section 127 of the Corporations Act 2001 (Cth):     )
   

   
Signature of authorized signatory   Signature of authorized signatory
     
     
Vlado Bosanac   Steven Richards  
Name of authorized signatory   Name of authorized signatory
     
EXECUTED BY   )
TRIAGE TECHNOLOGIES INC.   )
    )
    )
     
     
Signature of authorized signatory   Signature of authorized signatory
     
Tory Jarmain     Eric Lau  
Signature of authorized signatory   Signature of authorized signatory
     

 

21

 

 

 

SC HE DUL E A

 

 

Shareholders’ Agreement

 

(see attached)

 

22

 

 

 

SC HE DUL E B

 

 

Assignment and Assumption of the Subscription Agreement

 

THIS AGREEMENT is made the ■ day of ■, 2021

AMONG:

 

ADVANCED HUMAN IMAGING LIMITED (ACN 602 111 115) of Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 Australia (Investor)

 

- and -

 

[AHI USA] (a company incorporated under the laws of ■) of [address] (AHI USA)

 

- and -

 

TRIAGE TECHNOLOGIES INC. (a company incorporated under the federal laws of Canada) of 1 Adelaide Street East, Suite 3001 Toronto, Ontario M5C 2V9 Canada (Company);

 

WHEREAS the Investor entered into a subscription agreement (the Subscription Agreement) with Triage Technologies Inc. (the Company) on March 31, 2021 pursuant to which the Investor irrevocably agreed to, among other things, subscribe for 4,466,748 Subscription Shares for the Aggregate Subscription Price;

 

AND WHEREAS the Novation Date has occurred as of the date hereof;

 

AND WHEREAS, in accordance with the Subscription Agreement, the Investor wishes to transfer, assign, convey and set over to AHI USA, and AHI USA wishes to accept the conveyance of, all of the Investor’s obligations and liabilities under the Subscription Agreement;

 

NOW THEREFORE in consideration of the mutual covenants and agreements hereinafter contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby covenant and agree as follows:

 

1. Definitions and Interpretation

 

(a) Unless otherwise defined herein, all capitalized terms used in this Agreement, including in the recitals hereto, shall have the respective meanings ascribed to them in the Subscription Agreement.

 

(b) This Agreement shall be construed in accordance with the rules of interpretation in Section 1.2 of the Subscription Agreement.

 

2. Assignment and Assumption

 

(a) The Investor hereby transfers, assigns, conveys and sets over to AHI USA its entire right, title and interest in the Subscription Agreement. AHI USA hereby accepts and assumes the transfer, assignment and conveyance from the Investor of its entire right, title and interest in the Subscription Agreement.

 

(b) The Investor hereby assigns and transfers to AHI USA, and AHI USA hereby accepts and assumes, all liabilities of the Investor associated with the Subscription Agreement and agrees to pay, keep, observe and perform all of the terms, covenants, conditions and obligations of the Investor under the Subscription Agreement.

 

23

 

 

3. Representations and Warranties

 

AHI USA represents and warrants to the Company, as an inducement to the Company entering into the Agreement that:

 

(a) each of the representations and warranties of the Investor in Sections 5.1 and 5.2 of the Subscription Agreement are true and correct as of the date hereof as if such representations and warranties were made by AHI USA, except the representations and warranties in Sections 5.2(a), 5.2(b) and 5.2(d) of the Subscription Agreement;

 

(b) its decision to enter into this Agreement and subscribe for the Subscription Shares was made in the United States of America; and

 

(c) it is a person to whom it is lawful to offer or issue the Subscription Shares without a disclosure document and it is an “accredited investor” within the meaning of Rule 501(a)(1), (2), (3) or (7) of Regulation D, promulgated by the Securities and Exchange Commission under Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

4. Joinder

 

AHI USA shall execute a joinder to the shareholders’ agreement of the Company in effect on the date hereof and deliver same to the Company on the date hereof.

 

5. Further Assurances

 

The Investor and AHI USA shall execute and deliver such additional documents and instruments and shall perform such additional acts as may be necessary or appropriate in connection with this Agreement and all transactions contemplated by this Agreement to effectuate, carry out and perform all of the covenants, obligations and agreements of this Agreement and such transactions.

 

6. Governing Law

 

This Agreement shall be interpreted and enforced in accordance with, and the respective rights and obligations of the parties shall be governed by, the laws of the Province of Ontario and the federal laws of Canada applicable in that province and each party irrevocably and unconditionally (a) submits to the exclusive jurisdiction of the courts of the Province of Ontario over any action or proceeding arising out of or relating to this Agreement, (b) agrees to commence such an action or proceeding in Toronto, Ontario, and to cooperate and use its commercially reasonable efforts to bring the action or proceeding before the Ontario Superior Court of Justice (Commercial List), (c) waives any objection that it might otherwise be entitled to assert to the jurisdiction of such courts and

(d) agrees not to assert that such courts are not a convenient forum for the determination of any such action or proceeding.

 

7. Counterparts

 

This Agreement may be executed in any number of counterparts (including by way of facsimile or other electronic means) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

24

 

 

EXECUTED by the parties as of the date first written above.

 

EXECUTED by AHI USA   )
    )
    )
    )
     
     
     
Signature of authorized signatory   Signature of authorized signatory
     
     
Name of authorized signatory   Name of authorized signatory  
     
    )
EXECUTED by ADVANCED HUMAN IMAGING   )
LIMITED   )
ACN 602 111 115   )
in accordance with section 127 of the Corporations Act 2001 (Cth):    
     
     
Signature of authorized signatory   Signature of authorized signatory
     
     
     
Name of authorized signatory   Name of authorized signatory
     
     
EXECUTED BY   )
TRIAGE TECHNOLOGIES INC.   )
    )
    )
     
     
Signature of authorized signatory   Signature of authorized signatory
     
     
     
Name of authorized signatory   Name of authorized signatory

 

 

25

 

Exhibit 10.17

 

 

 

 

 

 

 

 

MYFIZIQ LIMITED

ACN 602 857 983

(Company)

 

and

 

THE PARTY IDENTIFIED IN ITEM 1 OF SCHEDULE 1

(Investor)

 

 

 

 

 

 

CONVERTIBLE NOTE SUBSCRIPTION DEED

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

T A B L E O F C O N T E N T S

 

1. DEFINITIONS AND INTERPRETATION 1
  1.1 Definitions 1
  1.2 Interpretation 5
  1.3 Business Day 6
  1.4 References to the calculation of time 6
  1.5 Fractional entitlements 6
       
2. SUBSCRIPTION FOR NOTES 6
  2.1 Application 6
  2.2 Subscription 6
  2.3 Issue 7
  2.4 Acknowledgements 7
       
3. GENERAL TERMS 7
  3.1 Status of Notes 7
  3.2 Acknowledgment of indebtedness 8
  3.3 Notes are unlisted 8
  3.4 Notes are unsecured 8
  3.5 Acknowledgment as to Terms 8
       
4. INTEREST 8
  4.1 Calculation of interest 8
  4.2 Payment of interest 8
       
5. REPAYMENT 9
  5.1 Repayment 9
  5.2 Payment arrangements 9
  5.3 Obligations cease 9
  5.4 Cancellation of Notes 9
       
6. CONVERSION 9
  6.1 Automatic conversion following a NASDAQ Listing 9
  6.2 Allotment, quotation and ranking of shares 10
  6.3 Satisfaction of Company’s obligations 11
       
7. WARRANTIES 11
  7.1 Mutual Warranties 11
  7.2 Investor Warranties 11
  7.3 Noteholder Warranties 12
       
8. ADDITIONAL ENTITLEMENTS: ANTI-DILUTION 12
  8.1 Reconstructions 12
  8.2 Calculation of adjustments 13
  8.3 General 13
       
9. TRANSFER OF NOTES 13
  9.1 Entitlements and restrictions 13
  9.2 Procedure 13
  9.3 Recognition of transferees 14
       
10. REGISTER OF NOTEHOLDERS 14
  10.1 Register of Noteholders 14
  10.2 Recognition of Registered Noteholder 14
  10.3 Issue and Replacement of Note Certificates 15

 

i

 

 

11. UNDERTAKINGS BY THE COMPANY 15
  11.1 General Undertakings 15
  11.2 Negative covenants 16
  11.3 General notices to Noteholder 16
  11.4 Attendance at shareholders meetings 16
       
12. DEFAULT 17
  12.1 Event of Default 17
  12.2 Noteholder’s powers on default 18
       
13. CONFIDENTIALITY 18
  13.1 Non-disclosure 18
  13.2 Permitted disclosure 18
       
14. NOTICES 19
  14.1 Form of notice 19
  14.2 Means of giving notices 19
  14.3 Specified address for service 19
  14.4 Change of Address 19
  14.5 Receipt of notices 20
       
15. MEETINGS OF NOTEHOLDERS 20
     
16. MISCELLANEOUS 20
  16.1 Amendments 20
  16.2 Taxes and withholdings 20
  16.3 Further assurance 20
  16.4 Governing law 20
  16.5 Costs and duty 21
  16.6 Severance 21
  16.7 Entire Agreement 21
  16.8 Counterparts 21
       
SCHEDULE 1 – INVESTOR PARTICULARS 23
   
SCHEDULE 2 – FORM OF NOTE CERTIFICATE 24

 

ii

 

 

THIS DEED is made the 28th day of May 2020

 

B E T WE E N

 

MYFIZIQ LIMITED (ACN 602 857 983) of Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 (Company);

 

AND

 

THE PARTY IDENTIFIED IN ITEM 1 OF SCHEDULE 1 (Investor).

 

R E CI TA LS

 

A. The Investor has agreed to advance the Subscription Funds to the Company upon the terms and conditions contained in this Deed.

 

B. The Company has agreed to issue the Notes with a face value of $1.00 per Note (Face Value) on the terms set out in this Deed.

 

C. The Company enters into this Deed in favour of the Investor and each Noteholder from time to time.

 

D. The Company intends to constitute and issue the Notes pursuant to this Deed and on the terms and conditions of this Deed.

 

IT IS AGREED as follows:

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 Definitions

 

In this Deed:

 

ADR means an American Depository Receipt.

 

Associated Capitalised Interest means, in relation to a Note, all interest (and interest on interest) accrued on the Note but, for the avoidance of doubt, does not include any interest which previously has been converted into Shares in accordance with clause 6.

 

ASX means ASX Limited or the Australian Securities Exchange, as the context requires.

 

Business Day means a day that is not a Saturday, Sunday or public holiday in Perth, Western Australia.

 

Conversion Date means the date determined by the Company, which date must be:

 

(a) where practicable: the date on which Shares (or ADRs representing a Share) are issued under the capital raising undertaken in connection with the NASDAQ Listing; or

 

(b) where it is not practicable for the Conversion Date to be the date specified in paragraph (a) above: as soon as reasonable practicable after the NASDAQ Listing has occurred or the Maturity Date (whichever comes first).

 

1

 

 

Conversion Price means the higher of:

 

(a) 75% of the issue price per Share (or the total issue price for the number ADRs representing a Share) under the capital raising undertaken in connection with the NASDAQ Listing; and

 

(b) US$1 per Share.

 

Conversion Shares has the meaning give in clause 6.1.

 

Deed means the deed constituted by this document and includes the recitals.

 

Event of Default means any of the events set out or referred to in this document as an Event of Default.

 

Face Value has the meaning in Recital B.

 

Financial Indebtedness means any indebtedness, present or future, actual or contingent, in respect of moneys borrowed or raised in any financial accommodation whatever including, without limitation, under or in respect of any overdraft facility, bill, bond, note, certificate of deposit, transferable or negotiable instrument, acceptance, Guarantee, redeemable or repurchasable share or stock, discounting arrangement, finance lease, swap, option, futures contract or analogous transaction, put option, hire purchase, deferred purchase price (for more than 90 days) of any asset or service, or any obligation to deliver goods or provide services paid for in advance by any financier or in connection with any other financing transaction.

 

Group means the Company and each of its related bodies corporate (as that term is defined in the Corporations Act).

 

Guarantee means any guarantee, indemnity, letter of credit or letter of comfort which gives rise to legal liabilities, whether of suretyship or otherwise, or any other obligation (whatever called and of whatever nature):

 

(a) to pay, to purchase, to provide funds (whether by way of advance of money, the purchase of or subscription for, shares or other securities, the purchase of assets, rights or services or otherwise) for the payment or discharge of;

 

(b) to indemnify against the consequences of default in the payment of; or

 

(c) otherwise to be responsible for,

 

any obligation or indebtedness, any dividend, capital or premium on shares or stock, or the insolvency or financial condition of any other person.

 

Interest Period means, in respect of a Note:

 

(a) in relation to the first Interest Period for a Note: the period commencing on the applicable Subscription Date for that Note and ending on the end of the Quarter in which that Subscription Date occurs;

 

(b) in relation to any subsequent Interest Period (other than the final Interest Period): a period ending on the end of each Quarter after the last mentioned date in (a) above; and

 

2

 

 

(c) in relation to the final Interest Period for a Note (being the Interest Period during which the Note is either converted or repaid in accordance with the Terms): a period which commences on the next day after the final day of the penultimate Interest Period and ending on the day prior to the date of conversion or repayment.

 

Interest Rate means 10% per annum.

 

Listing Rules means the Listing Rules of the ASX.

 

Material Adverse Change means any event or circumstance or series of events or circumstances which alone or together have a Material Adverse Effect.

 

Material Adverse Effect means a material adverse effect on the Company’s ability to perform and comply with its obligations under the Notes or on a Noteholder’s rights under them.

 

Maturity Date means 30 June 2021.

 

NASDAQ means the NASDAQ Stock Market.

 

NASDAQ Listing means the Company announcing that NASDAQ has provided confirmation to the Company that it has approved the Company’s application for admission to NASDAQ, subject only to conditions that the Company reasonably believes it can satisfy.

 

Note Certificate means a certificate in the form set out in Schedule 2 and issued to a Noteholder in respect of a Note held by it for the time being.

 

Noteholder means any person who is or, if more than one, the several persons who are, for the time being the holder or holders of a Note.

 

Notes means the Tranche 1 Notes, the Tranche 2 Notes, the Tranche 3 Notes and the Tranche 4 Notes.

 

PCAOB means the Public Company Accounting Oversight Board.

 

Professional Investor means a professional investor for the purposes of section 708(11) of the Corporations Act.

 

Quarter means each period of 3 months ending on either 31 March, 30 June, 30 September or 31 December.

 

Register of Noteholders means the Register of Noteholders maintained by the Company in accordance with clause 10.1(a).

 

Repayment Date means:

 

(a) where a NASDAQ Listing occurs prior to the Maturity Date: the Maturity Date; and

 

(b) where a NASDAQ Listing does not occur prior to the Maturity Date: 30 June 2021.

 

Share means a fully paid ordinary share in the capital of the Company.

 

Shareholder means a holder of Shares.

 

3

 

 

Sophisticated Investor means a sophisticated investor for the purposes of section 708(8) of the Corporations Act.

 

Subscription Date means:

 

(a) for the Tranche 1 Notes: the Tranche 1 Subscription Date;

 

(b) for the Tranche 2 Notes: the Tranche 2 Subscription Date;

 

(a) for the Tranche 3 Notes: the Tranche 3 Subscription Date; and

 

(b) for the Tranche 4 Notes: the Tranche 4 Subscription Date.

 

Subscription Funds means the amount specified in Schedule 1.

 

Terms means this Deed and includes any document executed in pursuance of it.

 

Tranche 1 Notes means the Notes:

 

(a) to be issued on the Tranche 1 Subscription Date in accordance with clause 2.3; and

 

(b) with an aggregate Face Value equal to the Tranche 1 Subscription Amount.

 

Tranche 2 Notes means the Notes:

 

(a) to be issued on the Tranche 2 Subscription Date in accordance with clause 2.3; and

 

(b) with an aggregate Face Value equal to the Tranche 2 Subscription Amount.

 

Tranche 3 Notes means the Notes:

 

(a) to be issued on the Tranche 3 Subscription Date in accordance with clause 2.3; and

 

(b) with an aggregate Face Value equal to the Tranche 3 Subscription Amount.

 

Tranche 4 Notes means the Notes:

 

(a) to be issued on the Tranche 4 Subscription Date in accordance with clause 2.3; and

 

(b) with an aggregate Face Value equal to the Tranche 4 Subscription Amount.

 

Tranche 1 Subscription Amount means $225,000.

 

Tranche 2 Subscription Amount means $450,000.

 

Tranche 3 Subscription Amount means $450,000.

 

Tranche 4 Subscription Amount means $375,000.

 

Tranche 1 Subscription Date means the date that is 14 days after the date of execution of this Deed.

 

4

 

 

Tranche 2 Subscription Date means the date that is 30 days from the date of commencement of the PCAOB audit by the Company by an PCAOB approved auditor.

 

Tranche 3 Subscription Date means the date that is two weeks from the date that the Company files a Registration Statement (Form F-1) with the Securities and Exchange Commission in relation to the NASDAQ Listing.

 

Tranche 4 Subscription Date means the date that is two weeks from the date that the Company engages an underwriter or an investment bank to provide services in connection with the NASDAQ Listing.

 

Transaction Documents means:

 

(a) these Terms;

 

(b) each Note;

 

(c) each document, agreement or instrument entered into under, pursuant to or for the purposes of anything in paragraphs (a) or (b).

 

1.2 Interpretation

 

In this Deed:

 

(a) headings are for convenience only and do not affect its interpretation;

 

(b) specifying anything after the words “include” or “for example” or similar expressions does not limit what else is included, and, unless the context otherwise requires:

 

(c) the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;

 

(d) a reference to any party includes that party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;

 

(e) a reference to any document (including this Deed) is to that document as varied, novated, ratified or replaced from time to time;

 

(f) a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;

 

(g) words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;

 

(h) reference to parties, clauses, Schedules or Annexures are references to parties, clauses, Schedules and Annexures to or of this Deed and a reference to this Deed includes any Schedule or Annexure to this Deed;

 

(i) where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning;

 

5

 

 

(j) other parts of speech and grammatical forms of a word or phrase defined in this deed have a corresponding meaning; and

 

(k) a reference to $ or dollar is to the currency of the United States of America.

 

1.3 Business Day

 

Where the day on or by which any thing is to be done is not a Business Day, that thing must be done on or by the preceding Business Day.

 

1.4 References to the calculation of time

 

(a) Unless the context otherwise requires a reference to a time of day means that time of day in Western Australia.

 

(b) For the purposes of determining the length of a period (but not its commencement) a reference to:

 

(i) a day means a period of time commencing at midnight and ending 24 hours later; and

 

(ii) a month means a calendar month.

 

(c) Where a period of time is specified and dates from a given day or the day of an act or event it must be calculated exclusive of that day.

 

1.5 Fractional entitlements

 

Fractional entitlements to Conversion Shares will be rounded up to the nearest whole number.

 

2. SUBSCRIPTION FOR NOTES

 

2.1 Application

 

The Investor agrees to purchase the Notes, and the Company agrees to issue the Notes to the Investor, in accordance with this Deed.

 

2.2 Subscription

 

The Investor must advance:

 

(a) the Tranche 1 Subscription Amount to the Company on the Tranche 1 Subscription Date;

 

(b) the Tranche 2 Subscription Amount to the Company on the Tranche 2 Subscription Date;

 

(c) the Tranche 3 Subscription Amount to the Company on the Tranche 3 Subscription Date; and

 

(d) the Tranche 4 Subscription Amount to the Company on the Tranche 4 Subscription Date,

 

in immediately available funds to an account nominated by the Company.

 

6

 

 

2.3 Issue

 

Subject to receipt of the applicable Subscription Amount in accordance with clause 2.2, the Company must do each of the following on the applicable Subscription Date:

 

(a) issue the relevant Notes to the Investor;

 

(b) deliver a Note Certificate for the relevant Notes to the Investor in accordance with clause 10.3(a); and

 

(c) ensure the Investor is registered as the holder of the relevant Notes in the applicable Register.

 

2.4 Acknowledgements

 

(a) The Investor acknowledges that no prospectus, offer information statement, product disclosure statement or other form of disclosure document (as defined in Chapter 6D of the Corporations Act) has been prepared for lodgement or will be lodged with the Australian Securities and Investments Commission or any other government agency in connection with the Deed or the issue of Notes.

 

(b) The Investor acknowledges and agrees that the Company may issue up to an additional $1,500,000 worth of convertible notes to other investors:

 

(i) on substantially the same terms and conditions as these Terms (including conversion rights and rights to interest); and

 

(ii) ranking equally with the Notes in terms of repayment.

 

3. GENERAL TERMS

 

3.1 Status of Notes

 

(a) Each Note is issued at the Face Value.

 

(b) Each Note may be:

 

(i) automatically converted into Conversion Shares pursuant to clause 6.1; or

 

(ii) repaid in cash pursuant to clause 5.

 

(c) A Note does not confer on the Noteholder any entitlement to:

 

(i) attend or vote at a general meeting of Shareholders;

 

(ii) receive dividends; or

 

(iii) participate in any rights issue, bonus issue or other equivalent offer or invitation of Shares or other securities to the holders of Shares,

 

other than after the issue of Conversion Shares pursuant to clause 6.

 

7

 

 

(d) The Notes may only be transferred with the prior written consent of the Company, which the Company can provide or withhold at its absolute discretion.

 

3.2 Acknowledgment of indebtedness

 

The Company acknowledges that on and from the relevant Subscription Date of each Note and at all times before the Note is converted or repaid in accordance with the Terms, it will be indebted to the relevant Noteholder to the extent of the Face Value of that Note.

 

3.3 Notes are unlisted

 

The Company does not intend to list the Notes for quotation on ASX, NASDAQ or any other stock exchange and it is not obliged to do so.

 

3.4 Notes are unsecured

 

The Notes are unsecured.

 

3.5 Acknowledgment as to Terms

 

(a) The Company acknowledges that the Investor at the date of these Terms applied for the issue of the Notes on the condition that the Notes would be issued on these Terms.

 

(b) The Investor by its subscription for, or subsequent purchase of, Notes is taken to have agreed to be bound by these Terms and must comply with all of its obligations under these Terms.

 

4. INTEREST

 

4.1 Calculation of interest

 

(a) Interest is payable from the date of issue of each Note until (and including):

 

(i) where (and to the extent that) the Note is converted in accordance with clause 6: of the Note; and

 

(ii) where (and to the extent that) the Note is not converted: the date on which the Note is repaid in full.

 

(b) The amount of interest payable on each Note in any period under these Terms:

 

(i) accrues daily; and

 

(ii) will be calculated at the Interest Rate on the Face Value for the number of days in the Interest Period.

 

4.2 Payment of interest

 

(a) Interest must be paid by the Company to the Noteholder in respect of each Note:

 

(i) where the Note is converted in accordance with clause 6: on the Conversion Date of the Note by way of the issue to the Noteholder of Shares in respect of the Associated Capitalised Interest; or

 

8

 

 

(ii) otherwise: on the Repayment Date.

 

(b) All accrued interest that has not been paid under this clause 4 or converted under clause 6 must be paid on the repayment of a Note, whether or not the Note is converted.

 

(c) Unless other arrangements are made between a Noteholder and the Company, interest will be paid by the Company to a bank account nominated by the Noteholder in writing to the Company (or such other means as the Noteholder and the Company may agree).

 

5. REPAYMENT

 

5.1 Repayment

 

In the event that a NASDAQ Listing has not occurred by the Maturity Date, on the Repayment Date the Company must pay to the Noteholder the Face Value of the Note and Associated Capitalised Interest.

 

5.2 Payment arrangements

 

(a) Unless other arrangements are made between the Noteholder and the Company, the Face Value and all Associated Capitalised Interest on each Note will be paid to a bank account nominated by the Noteholder in writing to the Company (or such other means as the Noteholder and the Company may agree).

 

(b) The Company need not make a payment to a Noteholder pursuant to this clause unless the Noteholder surrenders to the Company the Note Certificate for the relevant Note. The procedure set out in clause 10.3 for the replacement of lost Note Certificates may be followed in respect of any lost Note Certificates.

 

5.3 Obligations cease

 

Upon the payment of all amounts owing to a Noteholder the obligations in connection with a Note of the Company in respect of the relevant Note will be extinguished.

 

5.4 Cancellation of Notes

 

All Notes repaid by the Company must be cancelled and cannot be re-issued.

 

6. CONVERSION

 

6.1 Automatic conversion following a NASDAQ Listing

 

Where a NASDAQ Listing occurs prior to the Maturity Date, all of the Notes and Associated Capitalised Interest will be automatically converted into Shares (or ADRs representing Shares) at the applicable Conversion Price (Conversion Shares) in accordance with this clause 6.

 

9

 

 

6.2 Allotment, quotation and ranking of shares

 

(a) Each Share issued upon conversion of a Note and Associated Capitalised Interest under this clause 6 must:

 

(i) be allotted and issued within 5 Business Days after the Conversion Date; and

 

(ii) rank equally with, and have all rights, benefits and obligations identical with, the existing Shares.

 

(b) Promptly after each allotment the Company will apply to NASDAQ and ASX (if applicable) for the quotation of the Conversion Shares.

 

(c) Within 5 Business Days after the allotment and issue of any Shares under clause 6.2(a), the Company will (if required) give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with the Australian Securities and Investments Commission a prospectus prepared in accordance with the Corporations Act and do all things necessary to satisfy section 708A(11) of the Corporations Act to ensure that a sale of the Shares does not require disclosure to investors.

 

(d) Where Conversion Shares are to be held in certificated form, the Company must promptly after each allotment in accordance with its Constitution issue a share certificate to the Noteholder in the same manner as notices are to be given to it.

 

(e) Where:

 

(i) Conversion Shares are to be held in uncertificated mode; and

 

(ii) the Company and the Noteholder participate in any computerised or electronic system for market settlement, securities transfer and registration conducted in accordance with the law and the relevant rules of NASDAQ and ASX (if applicable),

 

the Company must within 10 Business Days of the Conversion Date effect the issue to the Noteholder of the Conversion Shares to which to the Noteholder is entitled in a manner required or permitted by the applicable law and rules applying in relation to that system.

 

(f) If a Noteholder incurs a liability (whether alone or together with others) to pay stamp duty on the issue to the Noteholder of Shares to which the Noteholder is entitled on conversion of the Note and Associated Capitalised Interest, the Company must at its own expense and without recourse to the Noteholder discharge that liability and pay that stamp duty (including any interest, penalty, fine, charge, fee or other amount in respect of stamp duty) provided that the Company will not in any event be liable in respect of any other tax to which the Noteholder or any other person is or may be liable as a result of conversion of Notes, issue of Shares to the Noteholder on such conversion or the payment by the Company of stamp duty under this clause 6.2(f).

 

10

 

 

6.3 Satisfaction of Company’s obligations

 

The issue of Conversion Shares in accordance with this clause 6 operates in satisfaction of the Company’s obligation to repay the Face Value of the Notes and Associated Capitalised Interest converted into those Conversion Shares.

 

7. WARRANTIES

 

7.1 Mutual Warranties

 

Each of the Company and the Investor (each, a Warrantor) represents and warrants to the other, as an inducement to the other to enter into this Deed that, at the date of this Deed:

 

(a) the execution and delivery of this Deed has been properly authorised by all necessary corporate action of the Warrantor;

 

(b) the Warrantor has full power and lawful authority to execute and deliver this Deed and to consummate and perform or cause to be performed its obligations under this Deed; and

 

(c) this Deed constitutes a legal, valid and binding obligation on the Warrantor enforceable in accordance with its terms by appropriate legal remedy.

 

7.2 Investor Warranties

 

In addition to the warranties given under clause 7.1, the Investor represents and warrants to the Company as an inducement to the Company to enter into this Deed that, at the date of this Deed:

 

(a) if a resident of Australia, it is a Sophisticated Investor or Professional Investor, or is otherwise a person who is able to be offered the Notes without disclosure under Chapter 6D of the Corporations Act, and will, on the request of the Company, promptly provide written evidence sufficient to satisfy the Company of the same;

 

(b) if a resident outside of Australia, it is a person to whom it is lawful to offer or issue the Notes and the Conversion Shares without a disclosure document (but who is not a “U.S. Person” under the Securities Act of 1933, or resident in the United States of America or in any other place in which it would not be lawful to offer or issue the Notes);

 

(c) the issue of Notes or the Conversion Shares does not require registration, qualification, disclosure or any other action by the Company in the jurisdiction in which the Investor is located or in which the offer of the Notes is received;

 

(d) it is aware of and accepts the risks relating to its subscription for the Notes under this Deed; and

 

(e) in deciding to subscribe for the Notes, it has:

 

(i) made and relies on its own enquiries and assessment of the Company, its business, operations and prospects;

 

(ii) made and relies on its own assessment of, and risks relating to, the Notes and an investment in the Company; and

 

11

 

 

(iii) not relied on any representations or warranties made or given by or on behalf of the Company (or any of its directors, officers, employees, agents or advisers), other than as set out in this Deed.

 

7.3 Noteholder Warranties

 

By accepting a transfer of Notes and agreeing to be entered onto the Register of Noteholders, each Noteholder represents and warrants to the Company that, at the date of transfer of the Notes and the date of issue of any Conversion Shares to the Noteholder:

 

(a) if a resident of Australia, it is a Sophisticated Investor or Professional Investor, or is otherwise a person who is able to be offered Shares without disclosure under Chapter 6D of the Corporations Act, and will, on the request of the Company, promptly provide written evidence sufficient to satisfy the Company of the same;

 

(b) if a resident outside of Australia, it is a person to whom it is lawful to offer or issue the Conversion Shares without a disclosure document (but who is not a “U.S. Person” under the Securities Act of 1933, or resident in the United States of America or in any other place in which it would not be lawful to offer or issue the Notes);

 

(c) the issue of Conversion Shares does not require registration, qualification, disclosure or any other action by the Company in the jurisdiction in which the Investor is located or in which the offer of the Notes is received;

 

(d) it is aware of and accepts the risks relating to its subscription for Conversion Shares under these Terms; and

 

(e) in deciding to acquire the Notes, it has:

 

(i) made and relies on its own enquiries and assessment of the Company, its business, operations and prospects;

 

(ii) made and relies on its own assessment of, and risks relating to, the Notes and an investment in the Company; and

 

(iii) not relied on any representations or warranties made or given by or on behalf of the Company (or any of its directors, officers, employees, agents or advisers), other than as set out in this Deed.

 

8. ADDITIONAL ENTITLEMENTS: ANTI-DILUTION

 

8.1 Reconstructions

 

(a) In the event of a reconstruction of the capital of the Company prior to the Conversion Date by way of consolidation, subdivision, reduction, return, scheme of arrangement or otherwise (but other than by way of a bonus issue, rights issue or other security issue), a proportionate adjustment will be made to the number and issue price of Ordinary Shares to which each Noteholder is entitled upon conversion of the Notes so that:

 

(i) the value of each Note is not adversely affected by the reconstruction;

 

12

 

 

(ii) the Noteholder is not conferred with any additional benefits which are not also conferred on the holders of Shares (subject to the same provisions with respect to rounding of entitlements as sanctioned by the meeting of holders of Shares approving the reconstruction of capital); and

 

(iii) subject to clause 8.1(b), in all other respects the terms for the conversion of the Notes shall remain unchanged.

 

(b) These Terms from time to time must be varied to the extent necessary to comply with the Listing Rules applying to a reorganisation of capital at the time of the reorganisation.

 

8.2 Calculation of adjustments

 

The adjustments in clause 8.1 will be calculated by the relevant Noteholder in accordance with any applicable Listing Rules, acting reasonably, which will be conclusive, in the absence of manifest error. The Noteholder must provide the Company with reasonable details of the manner in which the adjustment was calculated within a reasonable time after being requested to do so by the Company.

 

8.3 General

 

A Note does not confer any rights to participate in new issues of Shares or other securities without converting that Note.

 

9. TRANSFER OF NOTES

 

9.1 Entitlements and restrictions

 

Subject to these Terms, with the consent of the Company, the Notes may be freely transferred by an instrument in writing in common form or in such other form as the Company may approve.

 

9.2 Procedure

 

(a) Every instrument of transfer must be signed by the transferor and shall be signed also by the transferee unless complying with the provision of any law whereby such instrument is deemed to be so signed in the event of such compliance.

 

(b) Every instrument of transfer must be sent to the Company. The transfer must be accompanied by the relevant Note Certificate and evidence of the payment of any applicable stamp duty.

 

(c) Where an instrument of transfer is not accompanied by a Note Certificate because it is lost or destroyed, if the Company would be obliged to issue a replacement Note Certificate in accordance with these Terms, the instrument of transfer will be deemed to have been properly given on the date that it is received by the Company in accordance with these Terms.

 

(d) All instruments of transfer will be retained by the Company as will the surrendered Note Certificate.

 

(e) No transfer will be effected during the five Business Days (or such shorter period as the Company may decide) immediately preceding the Repayment Date of the relevant Note.

 

13

 

 

(f) Subject to any direction on an instrument of transfer, the Company may retain the amount owing and any interest payable upon any Note which is the subject of any transfer notice given to the Company within the period specified in the preceding clause until the specified transferee is registered as the holder of the Note and payment can be made to that transferee.

 

9.3 Recognition of transferees

 

Each Noteholder registered pursuant to a transfer will be recognised by the Company as entitled to its Notes free from any equity set off or cross claim on the part of the Company against the original or any intermediate holder of the Notes.

 

10. REGISTER OF NOTEHOLDERS

 

10.1 Register of Noteholders

 

(a) The Company must establish and maintain a Register of Noteholders at its registered office or at such other place permitted by the Corporations Act as the Company may determine. The Company may establish and maintain a branch Register of Noteholders at such places permitted by the Corporations Act as the Company may determine.

 

(b) There must be entered on the Register of Noteholders the names and addresses of each Noteholder and the number and tranche of Notes held by it.

 

(c) Each Noteholder must promptly notify the Company of any change of its name or registered address accompanied, in the case of change of name, by such evidence as the Company may reasonably require. The Register of Noteholders must be altered accordingly.

 

(d) Notes will be transferred by the Company between registered Noteholders without charge on the written request of a Noteholder subject to the payment by the Noteholder of any stamp duty involved.

 

(e) The Register of Noteholders will open during normal business hours for inspection by the Noteholders and as required by the Corporations Act.

 

10.2 Recognition of Registered Noteholder

 

(a) Subject to clause 9.2(e), the Company will only recognise the registered Noteholder as the owner of a Note referred to in the Note Certificate and is not bound to take notice or see to the execution of any trust whether express implied or constructive to which any Note may be subject.

 

(b) The payment to the registered Noteholder of the interest payable on a Note and of any other moneys payable upon a Note shall be a good discharge for the Company notwithstanding any notice it may have whether express or otherwise of the right title or interest of any other person to or in the Notes or such moneys.

 

(c) If several persons are entered in the Register as joint holders of any Notes then the payment to any one of such persons of any amount from time to time payable in respect of such Notes will be an effective discharge to the company for the moneys so paid.

 

14

 

 

10.3 Issue and Replacement of Note Certificates

 

(a) The Company must, subject to payment of the relevant Subscription Amount under clause 2.2, issue to the Investor a Note Certificate in respect of the Notes represented by the relevant Subscription Amount subscribed by the Investor on each Subscription Date.

 

(b) A Note Certificate must be executed by the Company, its attorney or such other person authorised by the directors of the Company. Such execution may be a facsimile applied by mechanical means. Certificates may be pre-printed or photocopies.

 

(c) If any Note Certificate becomes worn out or defaced then upon its production to the company it may cancel the same and issue a new Note Certificate in lieu thereof.

 

(d) If any Note Certificate is lost or destroyed then upon proof thereof to the satisfaction of the Company and upon such indemnity and/or advertisement (if any) as the Company may require being given or published, a new Note Certificate in lieu thereof shall be given to the Noteholder. An entry as to the issue of such new Certificate and indemnity (if any) must be made in the Register of Noteholders. The cost of any advertisement and indemnity must be paid by the Noteholder.

 

(e) Any Note Certificate that is returned to the Company in connection with the conversion or transfer of any Notes must be cancelled by the Company when the conversion or transfer is recorded in the Register of Noteholders. A new Note Certificate must be issued to the transferee within 10 Business Days of receipt of a valid transfer.

 

(f) Where the some but not all of the Notes specified in any Note Certificate that is cancelled in connection with the conversion of any Note, the Company must issue to the holder of the Note a Note Certificate in respect of the difference within ten Business Days from the date when the conversion is recorded in the Register of Noteholders.

 

11. UNDERTAKINGS BY THE COMPANY

 

11.1 General Undertakings

 

The Company undertakes to each Noteholder to:

 

(a) maintain status: maintain its status as a company limited by shares incorporated under the Corporations Act and not to transfer nor permit the transfer of its jurisdiction of incorporation outside Australia;

 

(b) comply with applicable laws: ensure that the Company and each member of the Group complies with all applicable laws (including without limitation all listing rules and requirements of any stock exchange);

 

(c) notify if representation and warranty is incorrect: notify the Noteholder immediately if any representation or warranty made or taken to be made by or on behalf of the Company in connection with the Transaction Documents or the Notes is found to be incorrect or misleading when made or taken to be made; and

 

15

 

 

(d) comply with consent: comply on time with any conditions attaching to any approval or consent given by the Noteholder in connection with the Transaction Documents.

 

11.2 Negative covenants

 

The Company undertakes to each Noteholder that it will not do any of the following until all of the Notes (together with [interest]) have been repaid in full or converted into Shares in accordance with the terms of this Deed:

 

(a) dispose of assets: sell or otherwise dispose of any assets or a series of related assets having an aggregate value of not less than $1,000,000 except with the prior written approval of the Noteholder(s);

 

(b) no dividends or distributions: pay, make or declare any dividend or other distribution without the prior written approval of the Noteholder(s);

 

(c) capital restructuring: purchase its own shares, reduce its share capital, return capital to shareholders or in any other way restructure its capital, if in each case to do so would be likely to have a Material Adverse Effect (for the avoidance of doubt, this does not prevent the Company from issuing any securities where permitted to do so in accordance with its constitution, the Corporations Act and the Listing Rules);

 

(d) mergers: enter into any merger or consolidation or make any acquisition of any other entity, company or business or do anything which would have the effect that the Company or any other member of the Group was operating business or activity which was not within the course of, or directly connected with, a business carried on by it as at the date of this Deed;

 

(e) incur indebtedness: incur any Financial Indebtedness without the prior written approval of the Noteholder(s);

 

(f) investments: deposit or invest money in or with any person except in the ordinary course of the Company’s business and on ordinary commercial terms;

 

(g) alteration of constitution: cause or permit its Constitution to be amended or replaced without the prior written approval of the Noteholder(s); or

 

(h) change in business: take any action which constitutes or results in any material alteration to the nature of the Company’s business.

 

11.3 General notices to Noteholder

 

The Company will send to the Noteholder a copy of all reports accounts, statements, notices and circulars issued to its members or any class thereof at the same time as the same are dispatched to the members.

 

11.4 Attendance at shareholders meetings

 

Without prejudice to the rights of Noteholder in their capacity as shareholders of the Company, the Company will permit the Noteholder to attend but not to speak or vote at any general meeting of its members.

 

16

 

 

12. DEFAULT

 

12.1 Event of Default

 

Notwithstanding any previous delay or waiver approved by the Noteholder(s), it is an Event of Default if, whether or not it is within the control of the Company:

 

(a) failure to pay: the Company fails to pay or repay any amount due by it under this Deed when due;

 

(b) non-remediable failure: the Company fails to perform or observe any other material undertaking, obligation or agreement expressed or implied in this Deed and that failure is not, in the reasonable opinion of the Investor, remediable;

 

(c) remediable failure: the failure described in clause 12.1(b) is, in the reasonable opinion of the Investor, remediable, and the Company does not remedy the failure within 21 days, or a longer period determined by the Investor, after receipt by the Company of a notice from the Investor specifying the failure;

 

(d) misrepresentation: any warranty, representation or statement by the Company is or becomes false, misleading or incorrect in a material respect when made or regarded as made by the Company under this Deed;

 

(e) judgment: a judgment in an amount exceeding $500,000 is obtained against the Company and is not set aside or satisfied within 7 days;

 

(f) execution: any distress, attachment, execution or other process of a government agency in an amount exceeding $500,000 is issued against, levied or enforced upon any of the assets of the Company;

 

(g) receiver: a receiver, receiver and manager, official manager, trustee, administrator or similar official is appointed, or steps taken for such appointment, over any of the assets or undertaking of the Company;

 

(h) insolvency: the Company is or becomes unable to pay its debts when they are due;

 

(i) arrangements: the Company enters into or resolves to enter into any arrangement, composition or compromise with, or assignment for the benefit of, its creditors or any class of them otherwise than while solvent and with the prior written consent of the Investor;

 

(j) administrator: an administrator is appointed, or a resolution is passed, or any steps are taken to appoint, or to pass a resolution to appoint, an administrator to the Company;

 

(k) winding up: an application or order is made for the winding-up or dissolution of the Company or a resolution is passed, or any steps are taken to pass a resolution for the winding-up or dissolution of the Company otherwise than for the purpose of an amalgamation or reconstruction which has the prior written consent of the Investor;

 

(l) deregistration: a notice under section 601AB of the Corporations Act is given to, or an application under section 601AA is made by, or in respect of the Company;

 

17

 

 

(m) suspends payment: the Company suspends payment of its debts generally; or

 

(n) vitiation of Deed:

 

(i) all or any part of any provision of this Deed is or becomes illegal, void, voidable, unenforceable or otherwise of limited force or effect; or

 

(ii) the execution, delivery and performance of this Deed by the Company violates, breaches or results in a contravention of any law, regulation or authorisation.

 

12.2 Noteholder’s powers on default

 

If an Event of Default occurs, the Noteholder, or if more than one, a 75% majority of such Noteholders by agreement in writing, may then or at any time subsequently by notice to the Company:

 

(a) declare all money owing under any of the Transaction Documents to be immediately due and payable, and the Company must immediately pay that money (including accrued interest and fees) and cash cover for the full amount of any money contingently owing under any of the Transaction Documents; and/or

 

(b) cancel their obligations (if any) under any of the Transaction Documents.

 

13. CONFIDENTIALITY

 

13.1 Non-disclosure

 

All information and other matters provided to or obtained by the Investor or any officer, employee, professional adviser or other consultant of the Investor on a confidential basis:

 

(a) under, in connection with or related to this Deed; or

 

(b) in the performance of any obligation, duty or power of the Investor under this Deed,

 

(collectively the "Information") is confidential to the Company and may not be disclosed to any person other than as set out in clause 13.2.

 

13.2 Permitted disclosure

 

Information which is in the public domain is not required to be kept confidential. The Investor may disclose Information of the Company:

 

(a) to a professional adviser, manager, banker, financial adviser, financier or insurer of the discloser or to a committee of any of them, if disclosed on a confidential basis;

 

(b) to comply with any applicable law or the listing rules or similar rules from time to time of a stock exchange, whether as a result of a voluntary or involuntary act or omission of the discloser or otherwise;

 

(c) to enforce, conduct or defend a claim or proceeding; or

 

(d) with the prior written consent of the Company.

 

18

 

 

14. NOTICES

 

14.1 Form of notice

 

A notice:

 

(a) must be in the English language; and

 

(b) may be given on behalf of a person by a solicitor, director or company secretary of the person.

 

14.2 Means of giving notices

 

A notice may be given to the addressee by:

 

(a) delivering it in writing to the street address of the addressee which includes placing it in a postal receptacle provided for the address or leaving it at the address with a person apparently of or over the age of 16 years;

 

(b) sending it by prepaid ordinary post (airmail if outside Australia) to the street address of the addressee; or

 

(c) sending it by email to the email address of the addressee.

 

Paragraphs (a) to (c) inclusive do not apply to the giving of notices under any other clause of these Terms which expressly specifies the method of giving notices under that other clause.

 

14.3 Specified address for service

 

(a) Until the Company gives notice of a change, its street address and email address is:

 

Address: Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 Email: vlado@myfiziq.com

 

Attention: Vlado Bosanac, Chief Executive Officer

 

(b) Until the Investor gives notice of a change, the Investor’s notice details are set out in Schedule 1.

 

(c) Until a Noteholder gives a notice of a change or an alternate address, their respective street addresses and email address will be as set out in the Register of Noteholders.

 

14.4 Change of Address

 

A party may from time to time change its address by giving notice pursuant to clause 14.1:

 

(a) for a Noteholder: to the Company; and

 

(b) for the Company: to each Noteholder.

 

19

 

 

14.5 Receipt of notices

 

Any notice given pursuant to clause 14.1 will be conclusively deemed to have been received:

 

(a) in the case of personal delivery, on the actual day of delivery if delivered prior to 5 pm (Perth time) on a Business Day or on the next following Business Day if delivered after 5 pm (Perth time) on a Business Day or on a day other than a Business Day;

 

(b) if sent by mail, on the second clear Business Day after the day of posting; or

 

(c) if sent by email, on the day the email was sent by clear email.

 

15. MEETINGS OF NOTEHOLDERS

 

The Company or a Noteholder may convene and conduct a meeting of Noteholders in accordance with normal meeting practice. A representative of the Company will chair the meeting unless the Noteholder (or if more than one, a majority of Noteholders) otherwise determines.

 

16. MISCELLANEOUS

 

16.1 Amendments

 

The Company may with the written authority of the Noteholder (or if more than one, the Noteholders by value) make any amendment or addition to these Terms provided that:

 

(a) such amendment or addition complies with the Listing Rules; and

 

(b) all necessary steps prescribed by the Listing Rules (including, without limitation, all necessary approvals and meetings) have been taken in the time period prescribed by the Listing Rules.

 

16.2 Taxes and withholdings

 

The Company must make any payments to be made to the Noteholder(s) free of all withholdings and deductions. [MYQ to confirm with tax advisers.]

 

16.3 Further assurance

 

Each party shall sign, execute and do all deeds, acts, documents and things as may reasonably be required by the other party to effectively carry out and give effect to the terms and intentions of this Deed.

 

16.4 Governing law

 

This Deed and performance by the parties hereunder shall be governed by and construed exclusively in accordance with the laws of Western Australia. Any and all actions, disputes or proceedings arising out of or relating to this Deed shall be subject to the exclusive and sole jurisdiction and venue of the courts of Western Australia, and the parties hereto hereby submit themselves to the jurisdiction of such courts.

 

20

 

 

16.5 Costs and duty

 

(a) All duty assessed on or in respect of this Deed shall be paid by the Company.

 

(b) The Company shall bear the legal costs of and incidental to the preparation, negotiation and execution of this Deed.

 

16.6 Severance

 

If any provision of this Deed is invalid and not enforceable in accordance with its terms, all other provisions which are self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and forceful in accordance with their terms.

 

16.7 Entire Agreement

 

This Deed shall constitute the sole understanding of the parties with respect to the subject matter and replaces all other agreements with respect thereto.

 

16.8 Counterparts

 

This Deed may be executed in any number of counterparts (including by way of facsimile) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

Signing page to follow

 

21

 

 

EXECUTED by the parties as a deed.

 

EXECUTED by MYFIZIQ LIMITED
ACN 602 857 983
in accordance with section 127 of the
Corporations Act 2001 (Cth):
  )
)
)
)
     
Vlado Bosanac   /s/ Vlado Bosanac
Name of director   Signature of Chief Executive Officer
     
Steven Richards   /s/ Steven Richards
Name of signatory   Signature of Chief Financial Officer

 

*please delete as applicable

 

EXECUTED BY
ASIA CORNERSTONE ASSET
MANAGEMENT Co. Ltd.
in accordance with its constituent
documents and place of incorporation:
  )
)
)
)
     
Dato Sri Marcus Liew   /s/ Dato Sri Marcus Liew
Signature of director   Signature of director/company secretary*
     
Ken Low   /s/ Ken Low
Name of director   Name of director/company secretary*

 

*please delete as applicable

 

22

 

 

S CH E D U LE 1 – IN VE S TO R P A R T IC UL AR S

 

ITEM 1 – INVESTOR
Name:

ASIA CORNERSTONE ASSET MANAGEMENT Co. Ltd.,

a company incorporated in Hong Kong

Address: Unit 1605, 16 th / Floor, Saxon Tower, Lai Chi Kok, Hong Kong
Email: ml@acam.com.hk or ken@acam.com.hk

 

23

 

 

S CH E D U LE 2 – FOR M O F NO TE CE R T I F IC A TE

 

MYFIZIQ LIMITED

ACN 602 857 983

(Company)

 

This is to certify that the following is the registered holder of the following convertible notes issued by the Company (Notes).

 

Name of Noteholder ASIA CORNERSTONE ASSET MANAGEMENT Co. Ltd.
Address of Noteholder Unit 1605, 16 th / Floor, Saxon Tower, Lai Chi Kok, Hong Kong
Terms The Notes are issued with the benefit of the rights and subject to the restrictions contained in the Convertible Note Subscription Deed between the Company and the Investor dated [insert] May 2020 (Deed).
Number of Notes [insert]
Face Value US$[1.00] per Note.
Conversion Securities To be determined in accordance with the Deed and the terms and conditions set out therein.

 

Dated:  
   
   
Signed for and on behalf of  
MYFIZIQ LIMITED ACN 602 857 983  

 

 

24

 

Exhibit 10.18

 

MYFIZIQ LIMITED

ACN 602 857 983

(Company)

 

and

 

THE PARTY IDENTIFIED IN ITEM 1 OF SCHEDULE 1

(Investor)

 

 

 

CONVERTIBLE NOTE SUBSCRIPTION DEED

 

 

 

 

 

 

TABLE OF CONTENTS 

 

 

1. DEFINITIONS AND INTERPRETATION 1
  1.1 Definitions 1
  1.2 Interpretation 4
  1.3 Business Day 5
  1.4 References to the calculation of time 5
  1.5 Fractional entitlements 5
2. SUBSCRIPTION FOR NOTES 5
  2.1 Application 5
  2.2 Subscription 5
  2.3 Issue 5
  2.4 Acknowledgements 5
3. GENERAL TERMS 6
  3.1 Status of Notes 6
  3.2 Acknowledgment of indebtedness 6
  3.3 Notes are unlisted 6
  3.4 Notes are unsecured 6
  3.5 Acknowledgment as to Terms 6
4. INTEREST 7
  4.1 Calculation of interest 7
  4.2 Payment of interest 7
5. REPAYMENT 7
  5.1 Repayment 7
  5.2 Payment arrangements 7
  5.3 Obligations cease 8
  5.4 Cancellation of Notes 8
6. CONVERSION 8
  6.1 Automatic conversion following a NASDAQ Listing 8
  6.2 Allotment, quotation and ranking of shares 8
  6.3 Satisfaction of Company’s obligations 9
7. WARRANTIES 9
  7.1 Mutual Warranties 9
  7.2 Investor Warranties 9
  7.3 Noteholder Warranties 10
8. ADDITIONAL ENTITLEMENTS: ANTI-DILUTION 11
  8.1 Reconstructions 11
  8.2 Calculation of adjustments 11
  8.3 General 11
9. TRANSFER OF NOTES 12
  9.1 Entitlements and restrictions 12
  9.2 Procedure 12
  9.3 Recognition of transferees 12
10. REGISTER OF NOTEHOLDERS 12
  10.1 Register of Noteholders 12
  10.2 Recognition of Registered Noteholder 13
  10.3 Issue and Replacement of Note Certificates 13

 

i

 

 

11. UNDERTAKINGS BY THE COMPANY 14
  11.1 General Undertakings 14
  11.2 Negative covenants 14
  11.3 General notices to Noteholder 15
  11.4 Attendance at shareholders meetings 15
12. DEFAULT 15
  12.1 Event of Default 15
  12.2 Noteholder’s powers on default 16
13. CONFIDENTIALITY 17
  13.1 Non-disclosure 17
  13.2 Permitted disclosure 17
14. NOTICES 17
  14.1 Form of notice 17
  14.2 Means of giving notices 17
  14.3 Specified address for service 18
  14.4 Change of Address 18
  14.5 Receipt of notices 18
15. MEETINGS OF NOTEHOLDERS 18
16. MISCELLANEOUS 19
  16.1 Amendments 19
  16.2 Taxes and withholdings 19
  16.3 Further assurance 19
  16.4 Governing law 19
  16.5 Costs and duty 19
  16.6 Severance 19
  16.7 Entire Agreement 19
  16.8 Counterparts 19

 

SCHEDULE 1 – INVESTOR PARTICULARS 21
SCHEDULE 2 – FORM OF NOTE CERTIFICATE 22

 

ii

 

 

THIS DEED is made the 15th day of October 2020

 

 

BETWEEN

 

 

MYFIZIQ LIMITED (ACN 602 857 983) of Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 (Company);

 

AND

 

THE PARTY IDENTIFIED IN ITEM 1 OF SCHEDULE 1 (Investor).

 

 

RECITALS

 

 

A. The Investor has agreed to advance the Subscription Amount to the Company upon the terms and conditions contained in this Deed.
   
B. The Company has agreed to issue the Notes with a face value of $1.00 per Note (Face Value) on the terms set out in this Deed.
   
C. The Company enters into this Deed in favour of the Investor and each Noteholder from time to time.
   
D. The Company intends to constitute and issue the Notes pursuant to this Deed and on the terms and conditions of this Deed.

 

IT IS AGREED as follows:

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 Definitions

 

In this Deed:

 

ADR means an American Depository Receipt.

 

Associated Capitalised Interest means, in relation to a Note, all interest (and interest on interest) accrued on the Note but, for the avoidance of doubt, does not include any interest which previously has been converted into Shares in accordance with clause 6.

 

ASX means ASX Limited or the Australian Securities Exchange, as the context requires.

 

Business Day means a day that is not a Saturday, Sunday or public holiday in Perth, Western Australia.

 

Conversion Date means the date determined by the Company, which date must be:

 

(a) where practicable: the date on which Shares (or ADRs representing a Share) are issued under the capital raising undertaken in connection with the NASDAQ Listing; or

 

(b) where it is not practicable for the Conversion Date to be the date specified in paragraph (a) above: as soon as reasonable practicable after the NASDAQ Listing has occurred or the Maturity Date (whichever comes first).

 

1

 

 

Conversion Price means the higher of:

 

(a) 75% of the issue price per Share (or the total issue price for the number ADRs representing a Share) under the capital raising undertaken in connection with the NASDAQ Listing; and

 

(b) $1 per Share.

 

Conversion Shares has the meaning give in clause 6.1.

 

Deed means the deed constituted by this document and includes the recitals.

 

Event of Default means any of the events set out or referred to in this document as an Event of Default.

 

Face Value has the meaning in Recital B.

 

Financial Indebtedness means any indebtedness, present or future, actual or contingent, in respect of moneys borrowed or raised in any financial accommodation whatever including, without limitation, under or in respect of any overdraft facility, bill, bond, note, certificate of deposit, transferable or negotiable instrument, acceptance, Guarantee, redeemable or repurchasable share or stock, discounting arrangement, finance lease, swap, option, futures contract or analogous transaction, put option, hire purchase, deferred purchase price (for more than 90 days) of any asset or service, or any obligation to deliver goods or provide services paid for in advance by any financier or in connection with any other financing transaction.

 

Group means the Company and each of its related bodies corporate (as that term is defined in the Corporations Act).

 

Guarantee means any guarantee, indemnity, letter of credit or letter of comfort which gives rise to legal liabilities, whether of suretyship or otherwise, or any other obligation (whatever called and of whatever nature):

 

(a) to pay, to purchase, to provide funds (whether by way of advance of money, the purchase of or subscription for, shares or other securities, the purchase of assets, rights or services or otherwise) for the payment or discharge of;

 

(b) to indemnify against the consequences of default in the payment of; or

 

(c) otherwise to be responsible for,

 

any obligation or indebtedness, any dividend, capital or premium on shares or stock, or the insolvency or financial condition of any other person.

 

Interest Period means, in respect of a Note:

 

(a) in relation to the first Interest Period for a Note: the period commencing on the Subscription Date for that Note and ending on the end of the Quarter in which the Subscription Date occurs;

 

(b) in relation to any subsequent Interest Period (other than the final Interest Period): a period ending on the end of each Quarter after the last mentioned date in (a) above; and

 

2

 

 

(c) in relation to the final Interest Period for a Note (being the Interest Period during which the Note is either converted or repaid in accordance with the Terms): a period which commences on the next day after the final day of the penultimate Interest Period and ending on the day prior to the date of conversion or repayment.

 

Interest Rate means 10% per annum.

 

Listing Rules means the Listing Rules of the ASX.

 

Material Adverse Effect means a material adverse effect on the Company’s ability to perform and comply with its obligations under the Notes or on a Noteholder’s rights under them.

 

Maturity Date means 30 June 2021.

 

NASDAQ means the NASDAQ Stock Market.

 

NASDAQ Listing means the Company announcing that NASDAQ has provided confirmation to the Company that it has approved the Company’s application for admission to NASDAQ, subject only to conditions that the Company reasonably believes it can satisfy.

 

Note Certificate means a certificate in the form set out in Schedule 2 and issued to a Noteholder in respect of a Note held by it for the time being.

 

Noteholder means any person who is or, if more than one, the several persons who are, for the time being the holder or holders of a Note.

 

Notes means a convertible note issued by the Company under this Deed.

 

PCAOB means the Public Company Accounting Oversight Board.

 

Professional Investor means a professional investor for the purposes of section 708(11) of the Corporations Act.

 

Quarter means each period of 3 months ending on either 31 March, 30 June, 30 September or 31 December.

 

Register of Noteholders means the Register of Noteholders maintained by the Company in accordance with clause 10.1(a).

 

Repayment Date means:

 

(a) where a NASDAQ Listing occurs prior to the Maturity Date: the Maturity Date; and

 

(b) where a NASDAQ Listing does not occur prior to the Maturity Date: 30 June 2021.

 

Share means a fully paid ordinary share in the capital of the Company.

 

Shareholder means a holder of Shares.

 

Sophisticated Investor means a sophisticated investor for the purposes of section 708(8) of the Corporations Act.

 

Subscription Amount means $375,000.

 

3

 

 

Subscription Date means the date that is two weeks from the date that the Company engages an underwriter or an investment bank to provide services in connection with the NASDAQ Listing.

 

Terms means this Deed and includes any document executed in pursuance of it.

 

Transaction Documents means:

 

(a) these Terms;

 

(b) each Note;

 

(c) each document, agreement or instrument entered into under, pursuant to or for the purposes of anything in paragraphs (a) or (b).

 

1.2 Interpretation

 

In this Deed:

 

(a) headings are for convenience only and do not affect its interpretation;
   
(b) specifying anything after the words “include” or “for example” or similar expressions does not limit what else is included,
   
  and, unless the context otherwise requires:
     
(c) the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;
   
(d) a reference to any party includes that party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;
   
(e) a reference to any document (including this Deed) is to that document as varied, novated, ratified or replaced from time to time;
   
(f) a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;
   
(g) words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;
   
(h) reference to parties, clauses, Schedules or Annexures are references to parties, clauses, Schedules and Annexures to or of this Deed and a reference to this Deed includes any Schedule or Annexure to this Deed;
   
(i) where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning;
   
(j) other parts of speech and grammatical forms of a word or phrase defined in this Deed have a corresponding meaning; and
   
(k) a reference to $ or dollar is to the currency of the United States of America.

 

4

 

 

1.3 Business Day

 

Where the day on or by which any thing is to be done is not a Business Day, that thing must be done on or by the preceding Business Day.

 

1.4 References to the calculation of time

 

(a) Unless the context otherwise requires a reference to a time of day means that time of day in Western Australia.

 

(b) For the purposes of determining the length of a period (but not its commencement) a reference to:

 

(i) a day means a period of time commencing at midnight and ending 24 hours later; and

 

(ii) a month means a calendar month.

 

(c) Where a period of time is specified and dates from a given day or the day of an act or event it must be calculated exclusive of that day.

 

1.5 Fractional entitlements

 

Fractional entitlements to Conversion Shares will be rounded up to the nearest whole number.

 

2. SUBSCRIPTION FOR NOTES

 

2.1 Application

 

The Investor agrees to purchase the Notes, and the Company agrees to issue the Notes to the Investor, in accordance with this Deed.

 

2.2 Subscription

 

The Investor must advance the Subscription Amount to the Company on the Subscription Date in immediately available funds to an account nominated by the Company.

 

2.3 Issue

 

Subject to receipt of the Subscription Amount in accordance with clause 2.2, the Company must do each of the following on the Subscription Date:

 

(a) issue the Notes to the Investor;

 

(b) deliver a Note Certificate for the Notes to the Investor in accordance with clause 10.3(a); and

 

(c) ensure the Investor is registered as the holder of the Notes in the Register.

 

2.4 Acknowledgements

 

The Investor acknowledges that no prospectus, offer information statement, product disclosure statement or other form of disclosure document (as defined in Chapter 6D of the Corporations Act) has been prepared for lodgement or will be lodged with the Australian Securities and Investments Commission or any other government agency in connection with the Deed or the issue of Notes.

 

5

 

 

3. GENERAL TERMS

 

3.1 Status of Notes

 

(a) Each Note is issued at the Face Value.

 

(b) Each Note may be:

 

(i) automatically converted into Conversion Shares pursuant to clause 6.1; or

 

(ii) repaid in cash pursuant to clause 5.

 

(c) A Note does not confer on the Noteholder any entitlement to:

 

(i) attend or vote at a general meeting of Shareholders;

 

(ii) receive dividends; or

 

(iii) participate in any rights issue, bonus issue or other equivalent offer or invitation of Shares or other securities to the holders of Shares,

 

other than after the issue of Conversion Shares pursuant to clause 6.

 

(d) The Notes may only be transferred with the prior written consent of the Company, which the Company can provide or withhold at its absolute discretion.

 

3.2 Acknowledgment of indebtedness

 

The Company acknowledges that on and from the Subscription Date of each Note and at all times before the Note is converted or repaid in accordance with the Terms, it will be indebted to the relevant Noteholder to the extent of the Face Value of that Note.

 

3.3 Notes are unlisted

 

The Company does not intend to list the Notes for quotation on ASX, NASDAQ or any other stock exchange and it is not obliged to do so.

 

3.4 Notes are unsecured

 

The Notes are unsecured.

 

3.5 Acknowledgment as to Terms

 

(a) The Company acknowledges that the Investor at the date of these Terms applied for the issue of the Notes on the condition that the Notes would be issued on these Terms.

 

(b) The Investor by its subscription for, or subsequent purchase of, Notes is taken to have agreed to be bound by these Terms and must comply with all of its obligations under these Terms.

 

6

 

 

4. INTEREST

 

4.1 Calculation of interest

 

(a) Interest is payable from the date of issue of each Note until (and including):

 

(i) where (and to the extent that) the Note is converted in accordance with clause 6: of the Note; and

 

(ii) where (and to the extent that) the Note is not converted: the date on which the Note is repaid in full.

 

(b) The amount of interest payable on each Note in any period under these Terms:

 

(i) accrues daily; and

 

(ii) will be calculated at the Interest Rate on the Face Value for the number of days in the Interest Period.

 

4.2 Payment of interest

 

(a) Interest must be paid by the Company to the Noteholder in respect of each Note:

 

(i) where the Note is converted in accordance with clause 6: on the Conversion Date of the Note by way of the issue to the Noteholder of Shares in respect of the Associated Capitalised Interest; or

 

(ii) otherwise: on the Repayment Date.

 

(b) All accrued interest that has not been paid under this clause 4 or converted under clause 6 must be paid on the repayment of a Note, whether or not the Note is converted.

 

(c) Unless other arrangements are made between a Noteholder and the Company, interest will be paid by the Company to a bank account nominated by the Noteholder in writing to the Company (or such other means as the Noteholder and the Company may agree).

 

5. REPAYMENT

 

5.1 Repayment

 

In the event that a NASDAQ Listing has not occurred by the Maturity Date, on the Repayment Date the Company must pay to the Noteholder the Face Value of the Note and Associated Capitalised Interest.

 

5.2 Payment arrangements

 

(a) Unless other arrangements are made between the Noteholder and the Company, the Face Value and all Associated Capitalised Interest on each Note will be paid to a bank account nominated by the Noteholder in writing to the Company (or such other means as the Noteholder and the Company may agree).

 

7

 

 

(b) The Company need not make a payment to a Noteholder pursuant to this clause unless the Noteholder surrenders to the Company the Note Certificate for the relevant Note. The procedure set out in clause 10.3 for the replacement of lost Note Certificates may be followed in respect of any lost Note Certificates.

 

5.3 Obligations cease

 

Upon the payment of all amounts owing to a Noteholder the obligations in connection with a Note of the Company in respect of the relevant Note will be extinguished.

 

5.4 Cancellation of Notes

 

All Notes repaid by the Company must be cancelled and cannot be re-issued.

 

6. CONVERSION

 

6.1 Automatic conversion following a NASDAQ Listing

 

Where a NASDAQ Listing occurs prior to the Maturity Date, all of the Notes and Associated Capitalised Interest will be automatically converted into Shares (or ADRs representing Shares) at the applicable Conversion Price (Conversion Shares) in accordance with this clause 6.

 

6.2 Allotment, quotation and ranking of shares

 

(a) Each Share issued upon conversion of a Note and Associated Capitalised Interest under this clause 6 must:

 

(i) be allotted and issued within 5 Business Days after the Conversion Date; and

 

(ii) rank equally with, and have all rights, benefits and obligations identical with, the existing Shares.

 

(b) Promptly after each allotment the Company will apply to NASDAQ and ASX (if applicable) for the quotation of the Conversion Shares.

 

(c) Within 5 Business Days after the allotment and issue of any Shares under clause 6.2(a), the Company will (if required) give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with the Australian Securities and Investments Commission a prospectus prepared in accordance with the Corporations Act and do all things necessary to satisfy section 708A(11) of the Corporations Act to ensure that a sale of the Shares does not require disclosure to investors.

 

(d) Where Conversion Shares are to be held in certificated form, the Company must promptly after each allotment in accordance with its Constitution issue a share certificate to the Noteholder in the same manner as notices are to be given to it.

 

(e) Where:

 

(i) Conversion Shares are to be held in uncertificated mode; and

 

8

 

 

(ii) the Company and the Noteholder participate in any computerised or electronic system for market settlement, securities transfer and registration conducted in accordance with the law and the relevant rules of NASDAQ and ASX (if applicable),

 

the Company must within 10 Business Days of the Conversion Date effect the issue to the Noteholder of the Conversion Shares to which to the Noteholder is entitled in a manner required or permitted by the applicable law and rules applying in relation to that system.

 

(f) If a Noteholder incurs a liability (whether alone or together with others) to pay stamp duty on the issue to the Noteholder of Shares to which the Noteholder is entitled on conversion of the Note and Associated Capitalised Interest, the Company must at its own expense and without recourse to the Noteholder discharge that liability and pay that stamp duty (including any interest, penalty, fine, charge, fee or other amount in respect of stamp duty) provided that the Company will not in any event be liable in respect of any other tax to which the Noteholder or any other person is or may be liable as a result of conversion of Notes, issue of Shares to the Noteholder on such conversion or the payment by the Company of stamp duty under this clause 6.2(f).

 

6.3 Satisfaction of Company’s obligations

 

The issue of Conversion Shares in accordance with this clause 6 operates in satisfaction of the Company’s obligation to repay the Face Value of the Notes and Associated Capitalised Interest converted into those Conversion Shares.

 

7. WARRANTIES

 

7.1 Mutual Warranties

 

Each of the Company and the Investor (each, a Warrantor) represents and warrants to the other, as an inducement to the other to enter into this Deed that, at the date of this Deed:

 

(a) the execution and delivery of this Deed has been properly authorised by all necessary corporate action of the Warrantor;

 

(b) the Warrantor has full power and lawful authority to execute and deliver this Deed and to consummate and perform or cause to be performed its obligations under this Deed; and

 

(c) this Deed constitutes a legal, valid and binding obligation on the Warrantor enforceable in accordance with its terms by appropriate legal remedy.

 

7.2 Investor Warranties

 

In addition to the warranties given under clause 7.1, the Investor represents and warrants to the Company as an inducement to the Company to enter into this Deed that, at the date of this Deed:

 

(a) if a resident of Australia, it is a Sophisticated Investor or Professional Investor, or is otherwise a person who is able to be offered the Notes without disclosure under Chapter 6D of the Corporations Act, and will, on the request of the Company, promptly provide written evidence sufficient to satisfy the Company of the same;

 

9

 

 

(b) if a resident outside of Australia, it is a person to whom it is lawful to offer or issue the Notes and the Conversion Shares without a disclosure document (but who is not a “U.S. Person” under the Securities Act of 1933, or resident in the United States of America or in any other place in which it would not be lawful to offer or issue the Notes);

 

(c) the issue of Notes or the Conversion Shares does not require registration, qualification, disclosure or any other action by the Company in the jurisdiction in which the Investor is located or in which the offer of the Notes is received;

 

(d) it is aware of and accepts the risks relating to its subscription for the Notes under this Deed; and

 

(e) in deciding to subscribe for the Notes, it has:

 

(i) made and relies on its own enquiries and assessment of the Company, its business, operations and prospects;

 

(ii) made and relies on its own assessment of, and risks relating to, the Notes and an investment in the Company; and

 

(iii) not relied on any representations or warranties made or given by or on behalf of the Company (or any of its directors, officers, employees, agents or advisers), other than as set out in this Deed.

 

7.3 Noteholder Warranties

 

By accepting a transfer of Notes and agreeing to be entered onto the Register of Noteholders, each Noteholder represents and warrants to the Company that, at the date of transfer of the Notes and the date of issue of any Conversion Shares to the Noteholder:

 

(a) if a resident of Australia, it is a Sophisticated Investor or Professional Investor, or is otherwise a person who is able to be offered Shares without disclosure under Chapter 6D of the Corporations Act, and will, on the request of the Company, promptly provide written evidence sufficient to satisfy the Company of the same;

 

(b) if a resident outside of Australia, it is a person to whom it is lawful to offer or issue the Conversion Shares without a disclosure document (but who is not a “U.S. Person” under the Securities Act of 1933, or resident in the United States of America or in any other place in which it would not be lawful to offer or issue the Notes);

 

(c) the issue of Conversion Shares does not require registration, qualification, disclosure or any other action by the Company in the jurisdiction in which the Investor is located or in which the offer of the Notes is received;

 

(d) it is aware of and accepts the risks relating to its subscription for Conversion Shares under these Terms; and

 

10

 

 

(e) in deciding to acquire the Notes, it has:

 

(i) made and relies on its own enquiries and assessment of the Company, its business, operations and prospects;

 

(ii) made and relies on its own assessment of, and risks relating to, the Notes and an investment in the Company; and

 

(iii) not relied on any representations or warranties made or given by or on behalf of the Company (or any of its directors, officers, employees, agents or advisers), other than as set out in this Deed.

 

8. ADDITIONAL ENTITLEMENTS: ANTI-DILUTION

 

8.1 Reconstructions

 

(a) In the event of a reconstruction of the capital of the Company prior to the Conversion Date by way of consolidation, subdivision, reduction, return, scheme of arrangement or otherwise (but other than by way of a bonus issue, rights issue or other security issue), a proportionate adjustment will be made to the number and issue price of Ordinary Shares to which each Noteholder is entitled upon conversion of the Notes so that:

 

(i) the value of each Note is not adversely affected by the reconstruction;

 

(ii) the Noteholder is not conferred with any additional benefits which are not also conferred on the holders of Shares (subject to the same provisions with respect to rounding of entitlements as sanctioned by the meeting of holders of Shares approving the reconstruction of capital); and

 

(iii) subject to clause 8.1(b), in all other respects the terms for the conversion of the Notes shall remain unchanged.

 

(b) These Terms from time to time must be varied to the extent necessary to comply with the Listing Rules applying to a reorganisation of capital at the time of the reorganisation.

 

8.2 Calculation of adjustments

 

The adjustments in clause 8.1 will be calculated by the relevant Noteholder in accordance with any applicable Listing Rules, acting reasonably, which will be conclusive, in the absence of manifest error. The Noteholder must provide the Company with reasonable details of the manner in which the adjustment was calculated within a reasonable time after being requested to do so by the Company.

 

8.3 General

 

A Note does not confer any rights to participate in new issues of Shares or other securities without converting that Note.

 

11

 

 

9. TRANSFER OF NOTES

 

9.1 Entitlements and restrictions

 

Subject to these Terms, with the consent of the Company, the Notes may be freely transferred by an instrument in writing in common form or in such other form as the Company may approve.

 

9.2 Procedure

 

(a) Every instrument of transfer must be signed by the transferor and shall be signed also by the transferee unless complying with the provision of any law whereby such instrument is deemed to be so signed in the event of such compliance.

 

(b) Every instrument of transfer must be sent to the Company. The transfer must be accompanied by the relevant Note Certificate and evidence of the payment of any applicable stamp duty.

 

(c) Where an instrument of transfer is not accompanied by a Note Certificate because it is lost or destroyed, if the Company would be obliged to issue a replacement Note Certificate in accordance with these Terms, the instrument of transfer will be deemed to have been properly given on the date that it is received by the Company in accordance with these Terms.

 

(d) All instruments of transfer will be retained by the Company as will the surrendered Note Certificate.

 

(e) No transfer will be effected during the five Business Days (or such shorter period as the Company may decide) immediately preceding the Repayment Date of the relevant Note.

 

(f) Subject to any direction on an instrument of transfer, the Company may retain the amount owing and any interest payable upon any Note which is the subject of any transfer notice given to the Company within the period specified in the preceding clause until the specified transferee is registered as the holder of the Note and payment can be made to that transferee.

 

9.3 Recognition of transferees

 

Each Noteholder registered pursuant to a transfer will be recognised by the Company as entitled to its Notes free from any equity set off or cross claim on the part of the Company against the original or any intermediate holder of the Notes.

 

10. REGISTER OF NOTEHOLDERS

 

10.1 Register of Noteholders

 

(a) The Company must establish and maintain a Register of Noteholders at its registered office or at such other place permitted by the Corporations Act as the Company may determine. The Company may establish and maintain a branch Register of Noteholders at such places permitted by the Corporations Act as the Company may determine.

 

(b) There must be entered on the Register of Noteholders the names and addresses of each Noteholder and the number of Notes held by it.

 

12

 

 

(c) Each Noteholder must promptly notify the Company of any change of its name or registered address accompanied, in the case of change of name, by such evidence as the Company may reasonably require. The Register of Noteholders must be altered accordingly.

 

(d) Notes will be transferred by the Company between registered Noteholders without charge on the written request of a Noteholder subject to the payment by the Noteholder of any stamp duty involved.

 

(e) The Register of Noteholders will open during normal business hours for inspection by the Noteholders and as required by the Corporations Act.

 

10.2 Recognition of Registered Noteholder

 

(a) Subject to clause 9.2(e), the Company will only recognise the registered Noteholder as the owner of a Note referred to in the Note Certificate and is not bound to take notice or see to the execution of any trust whether express implied or constructive to which any Note may be subject.

 

(b) The payment to the registered Noteholder of the interest payable on a Note and of any other moneys payable upon a Note shall be a good discharge for the Company notwithstanding any notice it may have whether express or otherwise of the right title or interest of any other person to or in the Notes or such moneys.

 

(c) If several persons are entered in the Register as joint holders of any Notes then the payment to any one of such persons of any amount from time to time payable in respect of such Notes will be an effective discharge to the company for the moneys so paid.

 

10.3 Issue and Replacement of Note Certificates

 

(a) The Company must, subject to payment of the Subscription Amount under clause 2.2, issue to the Investor a Note Certificate in respect of the Notes represented by the Subscription Amount subscribed by the Investor on the Subscription Date.

 

(b) A Note Certificate must be executed by the Company, its attorney or such other person authorised by the directors of the Company. Such execution may be a facsimile applied by mechanical means. Certificates may be pre-printed or photocopies.

 

(c) If any Note Certificate becomes worn out or defaced then upon its production to the company it may cancel the same and issue a new Note Certificate in lieu thereof.

 

(d) If any Note Certificate is lost or destroyed then upon proof thereof to the satisfaction of the Company and upon such indemnity and/or advertisement (if any) as the Company may require being given or published, a new Note Certificate in lieu thereof shall be given to the Noteholder. An entry as to the issue of such new Certificate and indemnity (if any) must be made in the Register of Noteholders. The cost of any advertisement and indemnity must be paid by the Noteholder.

 

(e) Any Note Certificate that is returned to the Company in connection with the conversion or transfer of any Notes must be cancelled by the Company when the conversion or transfer is recorded in the Register of Noteholders. A new Note Certificate must be issued to the transferee within 10 Business Days of receipt of a valid transfer.

 

13

 

 

(f) Where the some but not all of the Notes specified in any Note Certificate that is cancelled in connection with the conversion of any Note, the Company must issue to the holder of the Note a Note Certificate in respect of the difference within ten Business Days from the date when the conversion is recorded in the Register of Noteholders.

 

11. UNDERTAKINGS BY THE COMPANY

 

11.1 General Undertakings

 

The Company undertakes to each Noteholder to:

 

(a) maintain listing: (unless approved by the requisite majority of Shareholders and by the Noteholder, or if more than one, a 50% majority of such Noteholders by agreement in writing) maintain its listing and the official quotation of its securities on ASX, and must take or cause to be taken all action available to it to maintain such listing and official quotation;

 

(b) maintain status: maintain its status as a company limited by shares incorporated under the Corporations Act and not to transfer nor permit the transfer of its jurisdiction of incorporation outside Australia;

 

(c) comply with applicable laws: ensure that the Company and each member of the Group complies with all applicable laws (including without limitation all listing rules and requirements of any stock exchange);

 

(d) notify if representation and warranty is incorrect: notify the Noteholder immediately if any representation or warranty made or taken to be made by or on behalf of the Company in connection with the Transaction Documents or the Notes is found to be incorrect or misleading when made or taken to be made; and

 

(e) comply with consent: comply on time with any conditions attaching to any approval or consent given by the Noteholder in connection with the Transaction Documents.

 

11.2 Negative covenants

 

The Company undertakes to each Noteholder that it will not do any of the following until all of the Notes (together with [interest]) have been repaid in full or converted into Shares in accordance with the terms of this Deed:

 

(a) dispose of assets: sell or otherwise dispose of any assets or a series of related assets having an aggregate value of not less than $1,000,000 except with the prior written approval of the Noteholder(s);

 

(b) no dividends or distributions: pay, make or declare any dividend or other distribution without the prior written approval of the Noteholder(s);

 

(c) capital restructuring: purchase its own shares, reduce its share capital, return capital to shareholders or in any other way restructure its capital, if in each case to do so would be likely to have a Material Adverse Effect (for the avoidance of doubt, this does not prevent the Company from issuing any securities where permitted to do so in accordance with its constitution, the Corporations Act and the Listing Rules);

 

14

 

 

(d) mergers: enter into any merger or consolidation or make any acquisition of any other entity, company or business or do anything which would have the effect that the Company or any other member of the Group was operating business or activity which was not within the course of, or directly connected with, a business carried on by it as at the date of this Deed;

 

(e) incur indebtedness: incur any Financial Indebtedness without the prior written approval of the Noteholder(s);

 

(f) investments: deposit or invest money in or with any person except in the ordinary course of the Company’s business and on ordinary commercial terms;

 

(g) alteration of constitution: cause or permit its Constitution to be amended or replaced without the prior written approval of the Noteholder(s); or

 

(h) change in business: take any action which constitutes or results in any material alteration to the nature of the Company’s business.

 

11.3 General notices to Noteholder

 

The Company will send to the Noteholder a copy of all reports accounts, statements, notices and circulars issued to its members or any class thereof at the same time as the same are dispatched to the members.

 

11.4 Attendance at shareholders meetings

 

Without prejudice to the rights of Noteholder in their capacity as shareholders of the Company, the Company will permit the Noteholder to attend but not to speak or vote at any general meeting of its members.

 

12. DEFAULT

 

12.1 Event of Default

 

Notwithstanding any previous delay or waiver approved by the Noteholder(s), it is an Event of Default if, whether or not it is within the control of the Company:

 

(a) failure to pay: the Company fails to pay or repay any amount due by it under this Deed when due;

 

(b) non-remediable failure: the Company fails to perform or observe any other material undertaking, obligation or agreement expressed or implied in this Deed and that failure is not, in the reasonable opinion of the Investor, remediable;

 

(c) remediable failure: the failure described in clause 12.1(b) is, in the reasonable opinion of the Investor, remediable, and the Company does not remedy the failure within 21 days, or a longer period determined by the Investor, after receipt by the Company of a notice from the Investor specifying the failure;

 

(d) misrepresentation: any warranty, representation or statement by the Company is or becomes false, misleading or incorrect in a material respect when made or regarded as made by the Company under this Deed;
15

 

 

(e) judgment: a judgment in an amount exceeding $500,000 is obtained against the Company and is not set aside or satisfied within 7 days;

 

(f) execution: any distress, attachment, execution or other process of a government agency in an amount exceeding $500,000 is issued against, levied or enforced upon any of the assets of the Company;

 

(g) receiver: a receiver, receiver and manager, official manager, trustee, administrator or similar official is appointed, or steps taken for such appointment, over any of the assets or undertaking of the Company;

 

(h) insolvency: the Company is or becomes unable to pay its debts when they are due;

 

(i) arrangements: the Company enters into or resolves to enter into any arrangement, composition or compromise with, or assignment for the benefit of, its creditors or any class of them otherwise than while solvent and with the prior written consent of the Investor;

 

(j) administrator: an administrator is appointed, or a resolution is passed, or any steps are taken to appoint, or to pass a resolution to appoint, an administrator to the Company;

 

(k) winding up: an application or order is made for the winding-up or dissolution of the Company or a resolution is passed, or any steps are taken to pass a resolution for the winding-up or dissolution of the Company otherwise than for the purpose of an amalgamation or reconstruction which has the prior written consent of the Investor;

 

(l) deregistration: a notice under section 601AB of the Corporations Act is given to, or an application under section 601AA is made by, or in respect of the Company;

 

(m) suspends payment: the Company suspends payment of its debts generally; or

 

(n) vitiation of Deed:

 

(i) all or any part of any provision of this Deed is or becomes illegal, void, voidable, unenforceable or otherwise of limited force or effect; or

 

(ii) the execution, delivery and performance of this Deed by the Company violates, breaches or results in a contravention of any law, regulation or authorisation.

 

12.2 Noteholder’s powers on default

 

If an Event of Default occurs, the Noteholder, or if more than one, a 75% majority of such Noteholders by agreement in writing, may then or at any time subsequently by notice to the Company:

 

(a) declare all money owing under any of the Transaction Documents to be immediately due and payable, and the Company must immediately pay that money (including accrued interest and fees) and cash cover for the full amount of any money contingently owing under any of the Transaction Documents; and/or

 

16

 

 

(b) cancel their obligations (if any) under any of the Transaction Documents.

 

13. CONFIDENTIALITY

 

13.1 Non-disclosure

 

All information and other matters provided to or obtained by the Investor or any officer, employee, professional adviser or other consultant of the Investor on a confidential basis:

 

(a) under, in connection with or related to this Deed; or

 

(b) in the performance of any obligation, duty or power of the Investor under this Deed,

 

(collectively the “Information”) is confidential to the Company and may not be disclosed to any person other than as set out in clause 13.2.

 

13.2 Permitted disclosure

 

Information which is in the public domain is not required to be kept confidential. The Investor may disclose Information of the Company:

 

(a) to a professional adviser, manager, banker, financial adviser, financier or insurer of the discloser or to a committee of any of them, if disclosed on a confidential basis;

 

(b) to comply with any applicable law or the listing rules or similar rules from time to time of a stock exchange, whether as a result of a voluntary or involuntary act or omission of the discloser or otherwise;

 

(c) to enforce, conduct or defend a claim or proceeding; or

 

(d) with the prior written consent of the Company.

 

14. NOTICES

 

14.1 Form of notice

 

A notice:

 

(a) must be in the English language; and

 

(b) may be given on behalf of a person by a solicitor, director or company secretary of the person.

 

14.2 Means of giving notices

 

A notice may be given to the addressee by:

 

(a) delivering it in writing to the street address of the addressee which includes placing it in a postal receptacle provided for the address or leaving it at the address with a person apparently of or over the age of 16 years;

 

17

 

 

(b) sending it by prepaid ordinary post (airmail if outside Australia) to the street address of the addressee; or

 

(c) sending it by email to the email address of the addressee.

 

Paragraphs (a) to (c) inclusive do not apply to the giving of notices under any other clause of these Terms which expressly specifies the method of giving notices under that other clause.

 

14.3 Specified address for service

 

(a) Until the Company gives notice of a change, its street address and email address is:

 

Address: Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151
     
Email: vlado@myfiziq.com
     
Attention: Vlado Bosanac, Chief Executive Officer

 

(b) Until the Investor gives notice of a change, the Investor’s notice details are set out in Schedule 1.

 

(c) Until a Noteholder gives a notice of a change or an alternate address, their respective street addresses and email address will be as set out in the Register of Noteholders.

 

14.4 Change of Address

 

A party may from time to time change its address by giving notice pursuant to clause 14.1:

 

(a) for a Noteholder: to the Company; and

 

(b) for the Company: to each Noteholder.

 

14.5 Receipt of notices

 

Any notice given pursuant to clause 14.1 will be conclusively deemed to have been received:

 

(a) in the case of personal delivery, on the actual day of delivery if delivered prior to 5 pm (Perth time) on a Business Day or on the next following Business Day if delivered after 5 pm (Perth time) on a Business Day or on a day other than a Business Day;

 

(b) if sent by mail, on the second clear Business Day after the day of posting; or

 

(c) if sent by email, on the day the email was sent by clear email.

 

15. MEETINGS OF NOTEHOLDERS

 

The Company or a Noteholder may convene and conduct a meeting of Noteholders in accordance with normal meeting practice. A representative of the Company will chair the meeting unless the Noteholder (or if more than one, a majority of Noteholders) otherwise determines.

18

 

 

16. MISCELLANEOUS

 

16.1 Amendments

 

The Company may with the written authority of the Noteholder (or if more than one, the Noteholders by value) make any amendment or addition to these Terms provided that:

 

(a) such amendment or addition complies with the Listing Rules; and

 

(b) all necessary steps prescribed by the Listing Rules (including, without limitation, all necessary approvals and meetings) have been taken in the time period prescribed by the Listing Rules.

 

16.2 Taxes and withholdings

 

The Company must make any payments to be made to the Noteholder(s) free of all withholdings and deductions. [MYQ to confirm with tax advisers.]

 

16.3 Further assurance

 

Each party shall sign, execute and do all deeds, acts, documents and things as may reasonably be required by the other party to effectively carry out and give effect to the terms and intentions of this Deed.

 

16.4 Governing law

 

This Deed and performance by the parties hereunder shall be governed by and construed exclusively in accordance with the laws of Western Australia. Any and all actions, disputes or proceedings arising out of or relating to this Deed shall be subject to the exclusive and sole jurisdiction and venue of the courts of Western Australia, and the parties hereto hereby submit themselves to the jurisdiction of such courts.

 

16.5 Costs and duty

 

(a) All duty assessed on or in respect of this Deed shall be paid by the Company.

 

(b) The Company shall bear the legal costs of and incidental to the preparation, negotiation and execution of this Deed.

 

16.6 Severance

 

If any provision of this Deed is invalid and not enforceable in accordance with its terms, all other provisions which are self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and forceful in accordance with their terms.

 

16.7 Entire Agreement

 

This Deed shall constitute the sole understanding of the parties with respect to the subject matter and replaces all other agreements with respect thereto.

 

16.8 Counterparts

 

This Deed may be executed in any number of counterparts (including by way of facsimile) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

Signing page to follow

 

19

 

 

EXECUTED by the parties as a deed.

 

EXECUTED by MYFIZIQ LIMITED )  
ACN 602 857 983 )  
in accordance with section 127 of the )  
Corporations Act 2001 (Cth): )  
     
  /s/ Steven Richards
Signature of director   Signature of Chief Financial Officer
     
Vlado Bosanac   Steven Richards
Name of Chief Executive Officer   Name of Chief Financial Officer

 

EXECUTED BY )  
I CONCEPT GLOBAL GROWTH FUND )  
(Cayman Islands Company Registration )  
Number 328056) ))  
in accordance with its constituent ) )  
documents and place of incorporation: )  
     
/s/ Michael Marcus Liew   /s/ Chan Chi Yin, Stefanie
Signature of director   Signature of director
     
Michael Marcus Liew   Chan Chi Yin, Stefanie
Name of director   Name of director

 

20

 

 

 

SCHEDULE 1 – INVESTOR PARTICULARS

 

 

ITEM 1 – INVESTOR

 

Name: I CONCEPT GLOBAL GROWTH FUND (Cayman Islands Company Registration Number 328056)
   
Address: 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands
   
Email: stefanie.chan@asiacornerstone.com.hk and cw.li@asiacornerstone.com.hk
   
Attention: Ms Stefanie Chan and Mr Jacki Li

 

21

 

 

 

SCHEDULE 2 – FORM OF NOTE CERTIFICATE

 

 

MYFIZIQ LIMITED

ACN 602 857 983

(Company)

 

This is to certify that the following is the registered holder of the following convertible notes issued by the Company (Notes).

 

Name of Noteholder I CONCEPT GLOBAL GROWTH FUND (Company Registration Number 328056)
   
Address of Noteholder 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands
   
Terms The Notes are issued with the benefit of the rights and subject to the restrictions contained in the Convertible Note Subscription Deed between the Company and the Investor dated Thursday 15th October 2020 (Deed).
   
Number of Notes 375,000
   
Face Value US$1.00 per Note.
   
Conversion Securities To be determined in accordance with the Deed and the terms and conditions set out therein.

 

Dated: 15th October 2020

 

Signed for and on behalf of

MYFIZIQ LIMITED
ACN 602 857 983

 

 

22

 

 

 

Exhibit 10.19

 

NURALOGIX CORPORATION

(a company incorporated in Ontario, Canada)

 

and

 

MYFIZIQ LIMITED (ACN 602 111 115)

 

 

 

SOFTWARE RESELLER AGREEMENT

 

 

 

MyFiziq Contract Reference: MYQ010006

 

 

 

 

  21st day of August 2020
THIS AGREEMENT IS DATED        

 

 

 

P A R T I E S

 

 

 

NURALOGIX CORPORATION (a company incorporated in Ontario, Canada) of 250 Yonge St, Suite 1801, Toronto ON Canada M5B2L7 (NuraLogix);

 

AND

 

MYFIZIQ LIMITED (ACN 602 111 115) of Unit 5/71-73 South Perth Esplanade, South Perth, Western Australia 6151 (MyFiziq).

 

 

 

B A C K G R O U N D

 

A. MyFiziq owns, or has the right to licence, the MyFiziq Platform.

 

B. NuraLogix owns, or has the right to licence, the NuraLogix Platform.

 

C. NuraLogix seeks a licence to Commercialise the MyFiziq Platform, together, as an Add-on to the NuraLogix Platform, or as a Combined Application, to its Clients.

 

D. MyFiziq seeks a licence to Commercialise the NuraLogix Platform, together, as an Add-on to the MyFiziq Platform, or as a Combined Application, to its Clients.

 

E. The Parties wish to record the terms and conditions of their agreement on the terms and conditions of this Agreement.

 

It is agreed:

 

 

 

1. SUBSEQUENT AGREEMENTS

 

1.1 Data Processing Agreement and Software Development Kit EULA

 

Within thirty (30) days of the Commencement Date, the Parties agree to enter into:

 

(a) a Data Processing Agreement which documents both Parties’ requirements under data protection laws including the Privacy Act, the GDPR and all other applicable laws in relation to the processing of Active User data on the MyFiziq Platform, the NuraLogix Platform or the Combined Application; and

 

(b) a Software Development Kit EULA which documents the rights and both Parties’ obligations in relation to SDKs.

 

1.2 Commercial contracts

 

From time to time the Parties may enter into commercial contracts with Clients under which they agree to licence the Combined Application to Clients. These commercial contracts will document the terms, technical setup, pricing structure, liabilities, support requirements, representations, covenants, and warranties specific to the opportunity with the relevant Client.

 

2

 

 

Prior to entering into any such commercial contract, the Parties will separately agree their respective obligations to each other in relation to such commercial contract, including how revenues received from the commercial contract will be split between them on a case by case basis.

 

 

 

2. REFERENCE SCHEDULE, DEFINITIONS AND INTERPRETATION

 

2.1 Reference Schedule

 

Where a term used in this Agreement appears in bold type in the Reference Schedule, that term has the meaning shown opposite it in the Reference Schedule.

 

2.2 Definitions

 

In this Agreement:

 

Active User means a single user of the MyFiziq Platform, NuraLogix Platform or Combined Application who can be identified by a unique identification reference, email address or username who has either created or accessed an account in the MyFiziq Platform or the NuraLogix Platform via the Combined Application.

 

Add-on means a separate application which, although Commercialised concurrently with other application(s), is not integrated into a Combined Application with the other application(s) Commercialised concurrently.

 

Agreement means this agreement.

 

API means application program interface (in source and binary form).

 

Background IP means any Intellectual Property Rights created prior to, or independently of this Agreement, including any Intellectual Property Rights owned by third parties.

 

Business Day means:

 

(a) if determining when a notice, consent or other communication is given, a day that is not a Saturday, Sunday or public holiday in the place to which the notice, consent or other communication is sent; and

 

(b) for any other purpose, a day (other than a Saturday, Sunday or public holiday) on which banks are open for general banking business in Perth, Australia.

 

Business Hours means 9am to 5pm on Business Days.

 

Change of Control means a change in:

 

(a) control of the composition of the board of directors of the corporation;

 

(b) control of more than half the voting rights attaching to shares in the corporation; or

 

(c) control of more than half the issued shares of the corporation (not counting any share which carries no right to participate beyond a specified amount in the distribution of either profit or capital).

 

Clients means any individual, business or corporation which is granted a licence to use either Combined Application, or the MyFiziq Platform or NuraLogix Platform independently (separately, as an Add-on to any MyFiziq Platform or NuraLogix Platform or as a Combined Application) from NuraLogix or MyFiziq (or its Related parties), whether or not such licence covers additional subject matter.

 

3

 

 

Combined Application means the end product of combining the MyFiziq Platform, the NuraLogix Platform.

 

Commercialise and Commercialisation has the following meaning in relation to the Platforms: to use, reproduce, make available, publicise, advertise, market, promote, sub-license, sell, provide or distribute to Clients, the Platforms (as an Add- on to any NuraLogix Platform or MyFiziq Platform or as a Combined Application), or to keep it, maintain it, modify it (but only with the prior written consent of MyFiziq and/or NuraLogix as the context requires), and support it for the purpose of doing any of those things.

 

For clarity, for each commercial opportunity, the Parties will enter into a full commercial agreement as contemplated by clause 1.2.

 

Confidential Information means, in relation to each party (for the purposes of this definition, the “Discloser”), all information owned, disclosed or made available by or on behalf of the Discloser, relating to or comprised in:

 

(a) proprietary software tools, business processes, project management methodologies and tools, software testing and verification methods, solution architecture models and solutions, reports, plans, specifications, project documents, operational information and technical information;

 

(b) know-how, ideas, marketing strategies, operational information and financial information;

 

(d) the business affairs (including products, services, Clients, agreements and suppliers);

 

(e) strategic, financial and accounting information regarding the Discloser’s business, including information in relation to particular business opportunities;

 

(f) other information, which, by its nature or by the circumstances of its disclosure, is or could reasonably be expected to be regarded as confidential; and

 

(g) any Materials embodying any of the above information; but excluding any such information:

 

(h) which is publicly known;

 

(i) which is disclosed without restriction by a third party and without any breach of confidentiality by that third party; or

 

(j) which is developed or known independently by a party without reliance on any of the Discloser’s confidential information.

 

Consequential Loss means any of the following: loss of revenue; loss of profits; loss of opportunity to make profits; loss of business; loss of business opportunity; loss of use or amenity, or loss of anticipated savings; special, exemplary or punitive damages; and any loss which does not directly and naturally flow in the normal course of events from the occurrence of the event giving rise to the liability for such loss, whether or not such loss was in the contemplation of the Parties at the time of entry into this Agreement; including any of the above types of loss arising from an interruption to a business or activity.

 

4

 

 

Corporations Act means the Corporations Act 2001 (Cth).

 

Developed IP means any Intellectual Property Rights:

 

(a) which are created during the Term at the written request of a Party, in the course of this Agreement; or

 

(b) created, discovered or coming into existence as a result of utilising rights or carrying out tasks or obligations in connection with this Agreement (including the rights under the Licences).

 

For clarity, Intellectual Property Rights created during the Term that do not meet the criteria in Clauses (a) or (b) above are classified as Background IP.

 

Documentation means the user manuals or reference manuals supplied by a party for use of the MyFiziq Platform, the NuraLogix Platform and/or Combined Application, together with such Revisions to them, as that party may publish from time to time.

 

Exceptional Circumstance means a circumstance beyond the reasonable control of the Parties which results in a party being unable to observe or perform on time an obligation under the agreement. Such circumstances include, but are not limited to, the following:

 

(a) adverse changes in government regulations;

 

(b) any disaster or act of God, lightning strikes, atmospheric disturbances, earthquakes, floods, storms, explosions, fires and any natural disaster;

 

(c) acts of war, acts of public enemies, terrorism, riots, civil commotion, malicious damage, sabotage and revolution;

 

(d) strikes or industrial disputes; or

 

(e) acts or omissions of any third-party network providers (such as internet, telephony or power provider).

 

Further Term has the meaning given in clause 3.2.

 

GDPR means the General Data Protection Regulation (GDPR) required in the region or regions the platform will be distributed.

 

Government Body means:

 

(a) any person, body or other thing exercising an executive, legislative, judicial or other governmental function of any country or political subdivision of any country;

 

(b) any public authority constituted by or under a law of any country or political subdivision of any country; and

 

(c) any person deriving a power directly or indirectly from any other Government Body.

 

5

 

 

GST means GST as that term is defined in the GST Law, and any interest, penalties, fines or expenses relating to such GST. For payments which are subject to similar consumption taxes in other jurisdictions, references to GST are to be read as references to those consumption taxes as applicable with the necessary changes.

 

GST Law means the A New Tax System (Goods and Services Tax) Act 1999 (Cth) and/or associated Commonwealth legislation, regulations and publicly available rulings.

 

IAMA means The Institute of Arbitrators & Mediators Australia or, in the event that The Institute of Arbitrators & Mediators Australia ceases to exist or to provide mediation services, a professional dispute resolution organisation of equivalent standing.

 

Initial Term has the meaning given to it in clause 3.1.

 

Insolvency Event means: means an event of bankruptcy or insolvency, an assignment for the benefit of creditors, the appointment of a receiver, receiver and manager, provisional liquidator, liquidator and official manager or any similar person to any assets of a person, a failure to comply with a statutory demand, or anything else which occurs which is analogous or has a substantially similar effect, under the laws of any jurisdiction, or the person is otherwise insolvent or unable to pay its debts as and when they fall due.

 

Intellectual Property Rights means all current and future registered and unregistered rights in respect of copyright, circuit layouts, designs, trademarks, know-how, confidential information, patents, inventions, plant breeder’s rights and discoveries and all other intellectual property as defined in article 2 of the convention establishing the World Intellectual Property Organisation 1967.

 

Law means any statute, rule, regulation, proclamation, order in council, ordinance, local law or by-law, whether: present or future; or state, federal or otherwise.

 

Level 1 Support means direct contact with Active Users to field and manage support requests in respect of the NuraLogix Platform and/or MyFiziq Platform (as applicable) by personnel specifically designated and trained to perform such tasks.

 

Level 2 Support means the provision of NuraLogix or MyFiziq personnel (as applicable) acting as a point of contact for Level 1 Support staff with respect to the NuraLogix Platform and/or MyFiziq Platform (as applicable), and it will encompass handling inquiries, identification of component(s) involved in the problem and the obtaining of appropriate documentation of such inquiry or problem. Such personnel shall be specifically designated and trained to perform such support for Level 1 Support staff.

 

Level 3 Support means the provision of personnel of NuraLogix or MyFiziq personnel (as applicable) into direct contact with a primary point of contact provided by a client, and it will encompass handling inquiries or problems that cannot be resolved through the Level 1 Support or Level 2 Support.

 

Liability means a debt, liability or obligation, whether: actual, contingent or prospective; present or future; qualified or unqualified; or incurred jointly or severally with any other person.

 

Licences means the MyFiziq Platform Licence and the NuraLogix Platform Licence.

 

6

 

 

Loss means any loss (including Consequential Loss), diminution in value or deficiency of any kind whether direct, indirect, consequential or otherwise.

 

Material means property, information, software, firmware, documented methodology or process, documentation or other material in whatever form, including any reports, specifications, business rules or requirements, user manuals, user guides, operations manuals, training materials and instructions, and the subject matter of any category of Intellectual Property Rights.

 

MyFiziq Platform has the meaning given in the Reference Schedule.

 

MyFiziq Platform Licence has the meaning given in clause 4.1.

 

Nominated Application means the MyFiziq Platform or NuraLogix Platform (as the context requires).

 

NuraLogix Platform has the meaning given to it in the Reference Schedule.

 

NuraLogix Platform Licence has the meaning given in clause 5.1.

 

Parties means NuraLogix and MyFiziq.

 

Personnel means in relation to a party, any Related Body Corporate, associated entity, employee, officer, agent, contractor, or sub-contractor, professional adviser of that party.

 

Platforms means the MyFiziq Platform and the NuraLogix Platform.

 

Privacy Law means the Privacy Act 1988 (Cth).

 

Product Integration has its meaning given to it in clause 10 of the Reference Schedule.

 

Reference Schedule means Schedule 1.

 

Related Body Corporate has the meaning given to that term in section 9 of the

Corporations Act 2001 (Cth).

 

Revisions means modified or enhanced versions of either Nominated Application that may correct errors or provide minor performance or functionality enhancements to that application (Revised Application), along with natural successors to the specific Revised Application, but not new or different software that a party may market and licence for additional payments or as a new or separate.

 

SDK and Software Development Kit means a collection of software development tools in one installable package.

 

SDK EULA and Software Development Kit EULA means a Software Development Kit agreement with a Client which applies to its use or licence of the MyFiziq Platform or the NuraLogix Platform (whether or not as part of a broader licence in relation to a Combined Application), the terms of which must be satisfactory to both Parties.

 

Tax Invoice means a tax invoice compliant with the requirements of the GST Law or any other applicable law.

 

Term means the Initial Term and one or more Further Term.

 

7

 

 

2.3 Interpretation

 

(a) Unless the contrary intention appears, a reference in this Agreement to:

 

(i) this Agreement or another document includes any variation or replacement of it despite any change in the identity of the Parties;

 

(ii) one gender includes the others;

 

(iii) the singular includes the plural and the plural includes the singular;

 

(iv) a person, partnership, corporation, trust, association, joint venture, unincorporated body, Government Body or other entity includes any other of them;

 

(v) an item, recital, clause, subclause, paragraph, schedule or attachment is to an item, recital, clause, subclause, paragraph of, or schedule or attachment to, this Agreement and a reference to this Agreement includes any schedule or attachment;

 

(vi) a party includes the party’s executors, administrators, successors, substitutes (including a person who becomes a party by novation) and permitted assigns;

 

(vii) any statute, ordinance, code or other law includes regulations and other instruments under any of them and consolidations, amendments, re-enactments or replacements of any of them;

 

(viii) money is to US dollars, unless otherwise stated; and

 

(ix) a time is a reference to Perth, Australia time unless otherwise specified.

 

(b) The words include, including, such as, for example and similar expressions are not to be construed as words of limitation.

 

(c) Where a word or expression is given a particular meaning, other parts of speech and grammatical forms of that word or expression have a corresponding meaning.

 

(d) Headings and any table of contents or index are for convenience only and do not affect the interpretation of this Agreement.

 

(e) A provision of this Agreement must not be construed to the disadvantage of a party merely because that party or its advisers were responsible for the preparation of this Agreement or the inclusion of the provision in this Agreement.

 

2.4 Business Days

 

(a) If anything under this Agreement must be done on a day that is not a Business Day, it must be done instead on the next Business Day.

 

8

 

 

(b) If an act is required to be done on a particular day, it must be done before 5.00pm on that day or it will be considered to have been done on the following day.

 

 

 

3. TERM

 

3.1 Term

 

The initial term of this Agreement:

 

(a) commences on the Commencement Date; and

 

(b) unless renewed under clause 3.2, continues until the Expiry Date,

 

unless otherwise terminated earlier in accordance with this Agreement (Initial Term).

 

3.2 Rollover of Term

 

Unless:

 

(a) a party provides 60 days’ written notice to the other party of an intention to allow the Initial Term or the Further Term (as the case may be) to expire prior to the expiration of that period of time (Expiry Notice); or

 

(b) the agreement has been otherwise terminated earlier in accordance with clause 14 of this Agreement,

 

this Agreement shall automatically renew for a further term of 12 months (Further Term) commencing on the expiry date of the Initial Term or the Further Term (as the case may be) on the terms and conditions of this Agreement.

 

3.3 Expiry Notice

 

If a party provides an Expiry Notice to the other party in accordance with clause 3.2(a), the Initial Term or Further Term (as the case may be) shall expire on the Expiry Date of the Initial Term or the Further Term (as the case may be).

 

 

 

4. MYFIZIQ PLATFORM LICENCE

 

4.1 Grant of MyFiziq Platform Licence

 

(a) MyFiziq grants NuraLogix a non-exclusive licence to Commercialise the NuraLogix Platform, together, as an Add-on to the MyFiziq Platform, or as a Combined Application, to its Clients for the Term (MyFiziq Platform Licence).

 

(b) NuraLogix is licensed to integrate the MyFiziq Platform into the NuraLogix Platform for demonstration purposes only, where opportunities arise to Commercialise the MyFiziq Platform, the Parties agree to enter into a full commercial contract pursuant to clause 1.2.

 

4.2 Acknowledgements

 

NuraLogix acknowledges and agrees that:

 

(a) the MyFiziq Platform is licensed, and not sold, to NuraLogix by MyFiziq for use only under the terms of this Agreement;

 

9

 

 

(b) MyFiziq owns all intellectual property rights in the MyFiziq Platform and Documentation throughout the world;

 

(c) MyFiziq reserves all rights not expressly granted to NuraLogix;

 

(d) NuraLogix has no right to have access to the MyFiziq Platform in source code form or in unlocked coding or with comments (other than in accordance with this Agreement); and

 

(e) NuraLogix has no rights in, or to, the MyFiziq Platform or the Documentation other than the right to use them in accordance with this Agreement.

 

4.3 MyFiziq Platform upgrades

 

The terms of this Agreement will govern any MyFiziq Platform upgrades provided by MyFiziq.

 

 

 

5. NURALOGIX PLATFORM LICENCE

 

5.1 Grant of NuraLogix Platform Licence

 

(a) NuraLogix grants MyFiziq a non-exclusive licence to Commercialise the MyFiziq Platform, together, as an Add-on to the NuraLogix Platform, or as a Combined Application, to its Clients for the Term (NuraLogix Platform Licence).

 

(b) MyFiziq is licensed to integrate the NuraLogix Platform into the MyFiziq Platform for demonstration purposes only, where opportunities arise to Commercialise the NuraLogix Platform, the Parties agree to enter into a full commercial contract pursuant to clause 1.2.

 

5.2 Acknowledgements

 

MyFiziq acknowledges and agrees that:

 

(a) the NuraLogix Platform is licensed, and not sold, to MyFiziq by NuraLogix for use only under the terms of this Agreement;

 

(b) NuraLogix owns all intellectual property rights in the NuraLogix Platform and Documentation throughout the world;

 

(c) NuraLogix reserves all rights not expressly granted to MyFiziq;

 

(d) MyFiziq has no right to have access to the NuraLogix Platform in source code form or in unlocked coding or with comments (other than in accordance with this Agreement); and

 

(e) MyFiziq has no rights in, or to, the NuraLogix Platform or the Documentation other than the right to use them in accordance with this Agreement.

 

5.3 NuraLogix Platform upgrades

 

The terms of this Agreement will govern any NuraLogix Platform upgrades provided by NuraLogix.

 

10

 

 

6. REFERRALS

 

(a) Prior to marketing the Combined Application to a prospective Client, each Party (the first Party) must notify the other Party of its intention to market the Combined Application to the prospective Client. If the other Party:

 

(i) confirms that it has had prior contact with the prospective Client, the Parties must negotiate in good faith to agree how best to market the Combined Application to that Client, including how any revenue that generated from that Client is to be shared between the Parties; or

 

(ii) does not confirm that it has had prior contact with the prospective Client, the first Party may proceed to market the Combined Application to the prospective Client (and clauses 6(b) and (c) will apply (if applicable) to any commercial contract entered into with the prospective Client.

 

(b) In the circumstances where one Party (Marketing Party) marketed the Combined Application to a prospective Client, that did not have previous contact with the other Party, but that Client elects to only Commercialise the other Party’s Platform:

 

(i) the other Party may enter into a commercial contract with the Client in relation to the other Party’s Platform only; and

 

(ii) the Marketing Party shall be entitled to a referral fee of 20% of the revenue that is generated under the relevant commercial contract for a period of four (4) years from commencement of the commercial contract, payable 30 days from receipt of the relevant payment under the commercial contract.

 

(c) In the circumstances that one Party (Introducing Party) refers a prospective Client, that did not have previous contact with the other Party, to the other Party, which results in the other Party entering into a commercial contract with the Client in relation to the other Party’s Platform, the Introducing Party shall be entitled to a referral fee of 20% of the revenue that is generated under the relevant commercial contract for a period of 4 years from commencement of the commercial contract, payable 30 days from receipt of the relevant payment under the commercial contract.

 

(d) For clarity, this clause 6 survives termination of this Agreement to the extent that a referral or introduction has occurred, pursuant to this clause 6 prior to the termination of this Agreement, the associated payments payable under this clause 6 will continue to be payable following termination for the period specified under clause 6(b) or (c) (as applicable) or any period agreed under clause 6(a).

 

 

 

7. AMENDING THE SDK EULA

 

7.1 Proposed EULA Amendments Notice

 

A Party may at any time amend the SDK EULA (Amending Party) on providing at least fourteen (14) days prior written notice of the proposed amendments to the SDK EULA to the other Party (“Proposed EULA Amendments Notice”).

 

11

 

 

7.2 Objection Notice

 

(a) If the other Party does not wish to accept the Proposed EULA Amendments Notice, it must notify the Amending Party in writing within seven (7) days of the date of the Proposed EULA Amendments Notice that it objects to the Proposed EULA Amendments Notice and wishes to terminate this Agreement (“Objection Notice”).

 

(b) If an Objection Notice is issued by the other Party pursuant to clause (a), this Agreement will terminate seven (7) days after the date of the Objection Notice, unless the Amending Party notifies the other Party prior to the expiry of that seven (7) day period that it withdraws the Proposed EULA Amendments Notice.

 

(c) If an Objection Notice is not issued in accordance with clause (a), the other Party will be deemed to have irrevocably accepted the Proposed EULA Amendments Notice and the Proposed EULA Amendments Notice will become legally binding on the Parties to this Agreement on and from the fourteenth (14th) day following the Proposed EULA Amendments Notice.

 

 

 

8. SOFTWARE OBLIGATIONS

 

8.1 Integration of the Platforms (CompleteHealth)

 

(a) The Parties agree to work together to design, develop and integrate the NuraLogix Platform into the MyFiziq Platform according to the timeline and functional specifications set out in Reference Schedule, Clause 10 Product Integration.

 

(b) The Parties each agree to make available sufficient personnel and resources to prioritise the Product Integration.

 

(c) Other than as set out in Reference Schedule, Clause 10 Product Integration , each of the Parties will bear their own costs and expenses associated with the Product Integration.

 

(d) MyFiziq will undertake the iOS integration of the NuraLogix Platform as phase one for demonstration purposes.

 

(e) MyFiziq, will further undertake to develop the Android application upon commercial agreements being entered into by the Parties.

 

(f) The Combined solution will be called CompleteHealth.

 

(g) This clause specifically deals with the integration of the Nuralogix and MyFiziq platform to create the demonstration application called CompleteHealth.

 

8.2 MyFiziq Platform and NuraLogix Platform Obligations

 

(a) The Parties, agree that any updates or modifications to either the MyFiziq Platform or NuraLogix Platform pursuant to this Agreement at all times require the prior written approval of the Parties and will be undertaken by either Party at the upgrading Party’s expense, or as agreed in writing by both Parties.

 

12

 

 

(b) The Parties agree to provide all reasonable assistance, Materials and training to each other in order for it to make any updates to the Combined Application reasonably required as a result of any updates or modifications to the NuraLogix Platform for MyFiziq Platform, including but not limited to, providing access to and use of:

 

(i) all necessary Documentation; and

 

(ii) Personnel.

 

8.3 Support services

 

(a) Each party is responsible for supporting its own Nominated Application. For the avoidance of any doubt, both Parties agree that their obligations to provide support, including but not limited to any obligations to provide Level 1 Support, will be met if they make their best endeavours to be accessible via email and telephone communication channels during Eastern Standard Time Business Hours on each Business Day.

 

(b) NuraLogix will be responsible for the technical support of, to the extent applicable, the NuraLogix Platform.

 

(c) MyFiziq will be responsible for the technical support of, to the extent applicable, the MyFiziq Platform.

 

(d) For Active User support:

 

(i) the Party that is the key contact for the Active User and Client will be responsible for Level 1 Support; and

 

(ii) the Parties will share responsibility for Level 2 and 3 Support depending on the nature of the support required and the applicable Platform.

 

(e) The Parties will be responsible for the technical support of, to the extent applicable, the Combined Application.

 

(f) Nothing in this clause shall be taken to impose an obligation on either of the Parties to provide any support after completion of the Term.

 

 

 

9. CO-BRANDING AND PUBLICITY

 

(a) Each party agrees, in all cases, to include all trademarks owned by the other party and any trademarks adopted by the party from time to time (Trademarks) on all entire and partial copies of the Platforms in any form or on any Combined Application or on any related promotional and technical materials.

 

(b) Further, the Parties agree, in all cases, to include all copyright notices of the other on all entire and partial copies of the Platforms in any form.

 

(c) The Parties, (or its Related Bodies Corporate) owns the trademarks identified in the Reference Schedule.

 

(d) The Parties may use the Trademarks, and the Trademarks, in relation to the Platform or any Combined Application for the purpose of Commercialising the Platform in accordance with the terms of this Agreement.

 

13

 

 

(e) The Parties may produce and display promotional materials of any Combined Application and as otherwise may be reasonably required to carry out the terms of this Agreement, during the Term.

 

(f) A Party may produce and display technical materials of any Combined Application, provided it seeks and receives written permission from the other Party as technical materials may include Background IP and or Developed IP.

 

(g) The Parties, in all cases, unless otherwise mutually agreed by the Parties, the promotional and technical materials may be branded with the Trademarks, and the Parties’ Trademarks.

 

(h) All use of the Trademarks in accordance with this clause will be deemed use authorised by and attributable to NuraLogix or MyFiziq (as the case may be).

 

(i) Nothing in this clause grants any proprietary rights in or to the Trademarks to the Parties, or grants any proprietary rights in or to the Trademarks the Parties.

 

(j) All rights in and to the NuraLogix Trademarks remain unaltered by this Agreement and are retained by NuraLogix and all rights in and to the MyFiziq Trademarks remain unaltered by this Agreement and are retained by MyFiziq.

 

 

 

10. INTELLECTUAL PROPERTY RIGHTS

 

10.1 Ownership – Background IP

 

Ownership of Background IP is not altered by this Agreement. Without limitation:

 

(a) MyFiziq (or its Related Bodies Corporate) retains full ownership of the MyFiziq Platform; and

 

(b) NuraLogix (or its Related Bodies Corporate) retains full ownership of the NuraLogix Platform.

 

10.2 Ownership – Developed IP

 

(a) Where this IP is created by the combined use of the combined MyFiziq Platform and NuraLogix Platform, the IP will be owned by the Parties jointly in equal rights and standing. All decisions made in relation to such IP must be approved unanimously and jointly, including decisions in relation to protection of such IP and commercialisation outside of the commercialisation contemplated by this Agreement.

 

(b) Subject to clauses 10.2(c) and 10.2(d), ownership of any Intellectual Property Rights developed by each Party during the course of this Agreement remains with the party that developed those new Intellectual Property Rights.

 

(c) Both Parties agree that the Intellectual Property Rights in the Combined Application, excluding the MyFiziq Platform and the NuraLogix Platform, is vested in the Parties (or their respective nominated Related Bodies Corporate).

 

14

 

 

(d) Both Parties agree that any Intellectual Property Rights developed to the MyFiziq Platform or the Nuralogix Platform under clause 8.2 are vested in MyFiziq and Nuralogix respectively (or their respective nominated Related Bodies Corporate).

 

10.3 Party obligations

 

(a) The Parties will provide or procure all consents, waivers, permissions or other authorisations (including from unrelated third Parties or individuals) as may be necessary to give full effect to the ownership provisions in 10.1 and 10.2.

 

(b) The Parties will do all such further acts and execute and deliver all such further documents as may be necessary to give full effect to the ownership provisions in 10.1 and 10.2.

 

10.4 Prohibited activities

 

Each party (Obliged Party) must not (and must ensure that its Personnel do not), in relation to the Intellectual Property Rights of the other party:

 

(a) copy (except as expressly permitted by this Agreement), disassemble, attempt to derive the source code of, modify or create derivative works or reverse engineer or decompile the Intellectual Property Rights of the other Party (including the Nominated Application of the other party);

 

(b) use, or permit, the Intellectual Property Rights of the other party (including the Nominated Application of the other party) to be accessed or used in any way other than in a manner expressly permitted by this Agreement;

 

(c) merge any third-party source code (including open source code) with the Nominated Applications of the other party;

 

(d) challenge the validity of any Intellectual Property Rights of the other party;

 

(e) permit the Nominated Applications of the other party to be accessed in any unauthorised way, including via interfaces (including exposing or “passing through” a software API or otherwise making the application accessible as an API, (except as permitted under clauses 4, 5 and 8);

 

(f) disclose to any third party the results of any competitive analysis that the party may perform in relation to the Nominated Applications of the other party; or

 

(g) do or permit any other act which infringes the Intellectual Property Rights of the other party (or its licensors).

 

10.5 Notification of infringement claim

 

Each party must notify the other party promptly from the date it becomes aware of:

 

(a) any actual or suspected infringement by a third party of the other party’s Intellectual Property Rights; or

 

15

 

 

(b) any actual or threatened claim by a third party that its Intellectual Property Rights have or will be infringed by any act, omission or permission by a party in connection with this Agreement.

 

10.6 NuraLogix’s Undertakings

 

Except as expressly set out in this Agreement, NuraLogix undertakes:

 

(a) not to copy the MyFiziq Platform or Documentation expect where such copying is necessary to commercialise the MyFiziq Platform under this Agreement;

 

(b) not to make alterations to, or modifications of, the whole or any part of the MyFiziq Platform without the prior consent of MyFiziq;

 

(c) not to disassemble, de-compile, reverse engineer or create derivative works based on the whole or any part of the MyFiziq Platform nor attempt to do any such things except to the extent that such actions cannot be prohibited because they are essential for the purpose of achieving inter- operability of the MyFiziq Platform with another software program, and provided that the information obtained by NuraLogix during such activities:

 

(i) is used only for the purpose of achieving inter-operability of the MyFiziq Platform with another software program;

 

(ii) is not disclosed or communicated without MyFiziq’s prior written consent to any third party to whom it is not necessary to disclose or communicate it; and

 

(iii) is not used to create any software which is substantially similar to the MyFiziq Platform;

 

(d) to keep all copies of the MyFiziq Platform secure and to maintain accurate and up-to-date records of the number and locations of all copies of the MyFiziq Platform; and

 

(e) to supervise and control the use of the MyFiziq Platform and ensure that the MyFiziq Platform is used by any third party who is sub-licensed, sold, or provided the MyFiziq Platform in accordance with the terms of this Agreement.

 

10.7 MyFiziq’s Undertakings

 

Except as expressly set out in this Agreement, MyFiziq undertakes:

 

(a) not to copy the NuraLogix Platform or Documentation expect where such copying is necessary to commercialise the NuraLogix Platform under this Agreement;

 

(b) not to make alterations to, or modifications of, the whole or any part of the NuraLogix Platform without the prior consent of NuraLogix;

 

(c) not to disassemble, de-compile, reverse engineer or create derivative works based on the whole or any part of the NuraLogix Platform nor attempt to do any such things except to the extent that such actions cannot be prohibited because they are essential for the purpose of achieving inter-operability of the NuraLogix Platform with another

 

16

 

 

software program, and provided that the information obtained by MyFiziq during such activities:

 

(i) is used only for the purpose of achieving inter-operability of the NuraLogix Platform with another software program;

 

(ii) is not disclosed or communicated without NuraLogix’s prior written consent to any third party to whom it is not necessary to disclose or communicate it; and

 

(iii) is not used to create any software which is substantially similar to the NuraLogix Platform;

 

(d) to keep all copies of the NuraLogix Platform secure and to maintain accurate and up-to-date records of the number and locations of all copies of the NuraLogix Platform; and

 

(e) to supervise and control the use of the NuraLogix Platform and ensure that the NuraLogix Platform is used by any third party who is sub-licensed, sold, or provided the NuraLogix Platform in accordance with the terms of this Agreement.

 

10.8 Survival

 

This clause 10 survives the termination or expiration of this Agreement.

 

 

 

11. WARRANTIES AND INDEMNITY

 

11.1 Warranties

 

Each party warrants to the other party that:

 

(a) To the best of its knowledge, information and belief, at the date of this Agreement, no conflict of interest exists or is likely to arise in the performance of its obligations under this Agreement. Each party will inform the other party if any potential conflict of interest arises during the Term.

 

(b) It has the full right and title to enter into this Agreement and to grant the rights it sets out to the other party.

 

11.2 Indemnity NuraLogix

 

NuraLogix (and each of its Related Bodies Corporate) agrees to indemnify, defend and hold harmless MyFiziq, its directors, shareholders, officers, agents, employees, successors and assigns from and against any and all claims, demands, suits, actions, judgments, damages, costs, losses, expenses (including attorneys’ fees and expenses, payable as incurred) and other liabilities arising from, in connection with or related in any way to, directly or indirectly:

 

(a) any breach of this Agreement by NuraLogix; or

 

(b) NuraLogix’s activities under this Agreement, including without limitation, any unauthorised use by it or any of its Clients of any portion of MyFiziq Platform.

 

17

 

 

11.3 Indemnity MyFiziq

 

MyFiziq (and each of its Related Bodies Corporate) agrees to indemnify, defend and hold harmless NuraLogix, its directors, shareholders, officers, agents, employees, successors and assigns from and against any and all claims, demands, suits, actions, judgments, damages, costs, losses, expenses (including attorneys’ fees and expenses, payable as incurred) and other liabilities arising from, in connection with or related in any way to, directly or indirectly:

 

(a) any breach of this Agreement by MyFiziq; or

 

(b) MyFiziq’s activities under this Agreement, including without limitation, any unauthorised use by it or any of its Clients of any portion of NuraLogix Platform.

 

 

 

12. CONFIDENTIALITY

 

12.1 Non-disclosure

 

(a) A party must not, without the prior written approval of the other party, disclose the other party’s Confidential Information.

 

(b) Each party will:

 

(i) maintain absolute confidentiality in relation to the Confidential Information of the other party, in particular the know how in any Nominated Application, which is a trade secret; and

 

(ii) not use the Confidential Information for any other purpose other than to carry out the terms of this Agreement;

 

(c) Each party must take all reasonable steps to ensure that its employees and agents, and any sub-contractors engaged for the purposes of this Agreement, do not make public or disclose the other party’s Confidential Information.

 

(d) A party is not in breach of this clause 12.1 in circumstances where it is legally compelled to disclose the other party’s Confidential Information.

 

(e) Notwithstanding any other provision of this clause 12.1, the Parties may disclose the terms of this Agreement (other than Confidential Information of a technical nature) to its related companies, solicitors, auditors, insurers and accountants provided such parties themselves abide by the terms of this clause 12.1.

 

12.2 Return of Confidential Information

 

(a) Each party must on demand (Returning Party), return to the other party any Confidential Information supplied by the other party in connection with this Agreement.

 

(b) The Returning Party will confirm promptly, in writing, to the other party when it has complied with all obligations in this clause 12.2. If requested by the other party, the Returning Party will make that confirmation in the form of a statutory declaration.

 

18

 

 

(c) Notwithstanding the provisions of this clause 12, each party shall be entitled to retain on the terms of this clause 12 and not be required to destroy:

 

(i) any Confidential Information that the party is required to retain by any Law or regulation to which the party is subject;

 

(ii) electronic records on back-up storage tapes or a similar medium where to destroy such electronic records would be significantly impractical or prohibitively costly; or

 

(iii) any material which may be relevant to the defence of any litigation, administrative proceedings or investigations.

 

12.3 Security and unauthorised access

 

Each party must use commercially reasonable efforts to ensure that all information and Materials of the other party (or its agents or contractors) in the custody of that party for purposes connected with this Agreement are protected at all times from unauthorised access or use by a third party, and from misuse, damage or destruction by any person.

 

12.4 Acknowledgement as to types of remedy

 

Each party acknowledges and accepts that:

 

(a) the other party would suffer financial and other loss and damage if its Confidential Information was disclosed to any other person or used for any purpose other than as permitted by this Agreement and accordingly that monetary damages may be an insufficient remedy; and

 

(b) in addition to any other remedy, which may be available in law or equity, the other party is entitled to injunctive relief to prevent a breach of any of this clause 12 and to compel specific performance of this clause 12.

 

12.5 Survival

 

The obligations in this clause 12 survive the termination or expiration of this Agreement for as long as the information in question is Confidential Information.

 

 

 

13. DISPUTE RESOLUTION

 

13.1 Dispute Resolution Process

 

(a) A party claiming that a dispute or disagreement has arisen out of, or in connection with, this Agreement (Dispute) will, within five (5) Business Days of the Dispute arising, give written notice to the other Party providing particulars of the Dispute (Notice of Dispute) and, designating which of its authorised officers has authority to settle the Dispute.

 

(b) The Parties will meet at a location as agreed between the Parties in writing within five (5) Business Days of receipt of the Notice of Dispute in accordance with clause 13.1(a), to seek to resolve the Dispute amicably.

 

(c) If the Dispute has not been resolved within ten (10) Business Days of receipt of the Notice of Dispute in accordance with clause 13.1(a), the Parties agree to refer the Dispute to mediation administrated by a mediator recommended and accredited by IAMA in accordance with IAMA’s professional mediation rules.

 

19

 

 

(d) If the Dispute has not been resolved within thirty (30) Business Days of receipt of the Notice of Dispute in accordance with clause 13.1(a) then (on the basis that the exhaustion of the dispute resolution process set out in this clause 13.1 is a condition precedent to the right of either Party to commence court proceedings in relation to the Dispute) then the party who first served the Notice of Dispute may commence litigation.

 

(e) Any mediation discussions and proceedings undertaken in accordance with clause 13.1 constitute Confidential Information and will take place in a location agreed between the Parties in writing.

 

13.2 Urgent relief

 

Despite the condition precedent referred to in clause 13.1(d), nothing in this Agreement shall prevent either party seeking injunctive or urgent declaratory relief for any matter (including to protect Confidential Information) arising out of, or in connection with, this Agreement.

 

13.3 Obligations continue

 

Despite the existence of a Dispute, both Parties will at all times continue to fulfil all obligations under this Agreement, including in respect of confidentiality.

 

 

 

14. TERMINATION

 

14.1 Termination for cause

 

Either party (First Party) may terminate this Agreement immediately by written notice upon the occurrence of one of the following events:

 

(a) if the other party is in breach of this Agreement and that other party has failed to remedy the breach within thirty (30) days of a written notice to it from the First Party, specifying the breach and requiring it to be remedied;

 

(b) if the other party is in breach of this Agreement and that breach is not capable of remedy, as reasonably determined by the First Party; or

 

(c) an Insolvency Event occurs in respect of the other party.

 

14.2 Termination on notice

 

Either party may terminate the agreement for any reason, upon providing the other party with thirty 30 days’ prior written notice of such termination. The agreement (as is specified in the notice) terminates at the expiration of the period of notice.

 

14.3 Change of Control

 

Either party may terminate this Agreement immediately, if there has been a Change of Control in respect of the other party.

 

14.4 No prejudice of rights

 

Termination shall not prejudice or affect any right or action which shall have accrued or shall thereafter accrue to either party under this Agreement.

 

20

 

 

15. CONSEQUENCES OF TERMINATION OR EXPIRATION

 

Subject to clause 16 (which rights continue until the expiry of the Transition-Out Period, which is defined in the Reference Schedule), upon termination or expiration of this Agreement:

 

(a) the Transition-Out Period will commence;

 

(b) all rights granted to the Parties under this Agreement shall cease (subject to clause 16);

 

(c) the Parties must cease all activities authorised by this Agreement (subject to clause 16);

 

(d) all monies owing under the agreement become immediately payable and due;

 

(e) each party will cease using the brand and trademarks of the other party;

 

(f) each party (First Party) must immediately return or (if requested to do so by other party) destroy all Materials belonging to the other party in the First Party’s possession or control;

 

(g) the Parties may fulfil their obligations under any SDK EULA and Software Development Kit EULA which was executed prior to the Expiry Date; and

 

(h) subject to the terms of clause 12 each party must cease use of, destroy and (if requested by the other party) return all Confidential Information of the other party.

 

 

 

16. TRANSITION OUT

 

Irrespective of termination (other than where either Party has terminated this Agreement for cause pursuant to clause 14.1, in which case there will be no Transition Out Period) or expiration of this Agreement, the Parties agree that the Licences will continue for the Transition Out Period.

 

 

 

17. LIABILITY

 

As the Licences granted under this Agreement are for demonstration purposes only, the following Exclusions, Implied terms and Limitations of liability apply to the Licences in this Agreement.

 

As part of Commercialisation, where the Parties agree to into a full commercial contract, each commercial contract will include specific licence, warranties and liability’s pursuant to that commercial contract / opportunity / Client.

 

17.1 Exclusions

 

(a) To the extent permitted by Law, in no event will a party be liable to the other party for Consequential Loss even if a party has been made aware of the possibility of such Consequential Loss prior to entering into this Agreement.

 

(b) Each party agrees that the other party is not liable to third parties regarding, or arising out of or in connection with, this Agreement.

 

21

 

 

17.2 Implied terms

 

(a) To the full extent permitted by Law, any term which would otherwise be implied into this Agreement is excluded.

 

(b) In the event any statute implies terms into this Agreement which cannot be lawfully excluded, such terms will apply to this Agreement, save that the liability of each Party for breach of any such implied term will be limited in accordance with clause 17.3.

 

17.3 Limitation of liability

 

(a) To the full extent not prohibited by Law, in no event shall MyFiziq be liable for personal injury, or any incidental, special, indirect or consequential damages or Consequential Loss whatsoever, including, without limitation, damages for loss of data, business interruption or any other commercial damages or losses, arising out of or related to NuraLogix’s use or inability to use the MyFiziq Platform, however caused, regardless of the theory of liability (contract, tort or otherwise) and even if MyFiziq has been advised of the possibility of such damages. The foregoing limitations will apply even if the above stated remedy fails of its essential purpose.

 

(b) To the full extent not prohibited by Law, in no event shall NuraLogix be liable for personal injury, or any incidental, special, indirect or consequential damages or Consequential Loss whatsoever, including, without limitation, damages for loss of data, business interruption or any other commercial damages or losses, arising out of or related to MyFiziq’s use or inability to use the NuraLogix Platform, however caused, regardless of the theory of liability (contract, tort or otherwise) and even if NuraLogix has been advised of the possibility of such damages. The foregoing limitations will apply even if the above stated remedy fails of its essential purpose.

 

(c) Subject to clause 17.1, to the extent that a Party is Liable under (or in connection with) this Agreement (Liable Party), then the Liable Party’s cumulative Liability in the aggregate (to the fullest extent permitted by law) shall in no event exceed the lesser of the total amount paid to the Liable Party by the other Party under this Agreement during the 6 month period preceding the date of the event which gave rise to the Liability or an amount recovered under the other Party’s policies of insurance for such Liability.

 

 

 

18. FORCE MAJEURE

 

18.1 Suspension of obligations

 

If a party (Affected Party):

 

(a) is prevented from, or delayed in, performance of an obligation by an event of Exceptional Circumstance; and

 

(b) the Affected Party as soon as possible after the event of Exceptional Circumstance notifies the other party providing particulars of:

 

(i) the event of Exceptional Circumstance;

 

(ii) the anticipated period of delay; and

 

22

 

 

(iii) the action (if any action is reasonably possible) the Affected Party intends to take to mitigate the effect of the delay,

 

then those obligations of the Affected Party are suspended for the duration of the event of Exceptional Circumstance.

 

18.2 Obligation on other party

 

The party which is not the Affected Party must use all reasonable endeavours to remove or mitigate its Loss arising from, and the effects of, the event of Exceptional Circumstance.

 

 

 

19. PRIVACY

 

Each party agrees to comply with Privacy Law in relation to the exercise of its rights and obligations under this Agreement.

 

 

 

20. GOVERNING LAW AND JURISDICTION

 

This agreement is governed by and construed in accordance with the laws of California.

 

 

 

21. GOODS AND SERVICES TAX

 

21.1 GST exclusive

 

Unless expressly stated to the contrary all amounts expressed in this Agreement are exclusive of GST.

 

21.2 Recipient to pay Supplier

 

(a) If a party (Supplier) is obliged under the GST Law to pay an amount of GST for a taxable supply made by the Supplier to another party (Recipient) under this Agreement, the Recipient must pay the Supplier an amount equal to the GST payable on the supply by the Supplier.

 

(b) The Recipient must pay the amount referred to in (a) and any interest, penalties, fines or expenses relating to the GST, in addition to and at the same time as the consideration otherwise payable by the Recipient for the supply.

 

21.3 Tax Invoice

 

If requested by the Recipient, the Supplier must provide the Recipient with a Tax Invoice on or before payment of the amounts required by this clause 21.

 

 

 

22. MISCELLANEOUS

 

22.1 Exercise rights

 

A single or partial exercise or waiver by a party of any right under or relating to this Agreement will not prevent any other exercise of that right or exercise of any other right.

 

22.2 Merger

 

If the liability of a party to pay money under this Agreement becomes merged in any deed, judgment, order or other thing, the party liable must pay interest on the amount owing from time to time under that deed, judgment, order or other thing at the higher of the rate payable under this Agreement and that fixed by or payable under that deed, judgment, order or other thing.

 

23

 

 

22.3 No assignment

 

Neither party shall assign, transfer or novate all or any part of its rights or obligations under or relating to this Agreement or grant, declare, create or dispose of any right or interest in it, without the prior written consent of the other party.

 

22.4 Remedies cumulative

 

The rights and remedies under this Agreement are cumulative and not exclusive of any rights or remedies provided by law.

 

22.5 Severability

 

If a provision of this Agreement is illegal, invalid, unenforceable or void in a jurisdiction it is severed for that jurisdiction and the remainder of this Agreement has full force and effect and the validity or enforceability of that provision in any other jurisdiction is not affected.

 

22.6 Further assurance

 

Each party must promptly at its own cost do all things (including executing and delivering all documents) necessary or desirable to give full effect to this Agreement and the transactions contemplated by it.

 

22.7 Costs

 

Each party is responsible for its own costs in the negotiation and performance of this Agreement.

 

22.8 Variation

 

An amendment or variation to this Agreement is not effective unless it is in writing and signed by the Parties.

 

22.9 Waiver

 

(a) A party’s waiver of a right under or relating to this Agreement, whether prospectively or retrospectively, is not effective unless it is in writing and signed by that party.

 

(b) No other act, omission or delay by a party will constitute a waiver of a right.

 

22.10 Counterparts

 

This agreement may be executed in any number of counterparts each of which will be considered an original but all of which will constitute one and the same instrument. A party who has executed a counterpart of this Agreement may deliver it to, or exchange it with, another party by:

 

(a) faxing; or

 

(b) emailing a PDF (portable document format) copy of, the executed counterpart to that other party.

 

24

 

 

22.11 Whole agreement

 

This agreement:

 

(a) is the entire agreement and understanding between the Parties relating to the subject matter of this Agreement; and

 

(b) supersedes any prior agreement, representation (written or oral) or understanding on anything connected with that subject matter.

 

 

 

S CH E D U LE 1 – R E FE R E NC E S CH E D U LE

 

1. MyFiziq’s Address Details

 

Address:   Suite 5, 71–73 South Perth Esplanade
      South Perth, WA, 6151, Australia Electronic Mail:
      vlado@MyFiziq.com

 

Attention: Vlado Bosanac

 

2. NuraLogix’s Address Details

 

Address: 250 Yonge St, Suite 1801 Toronto ON Canada M5B2L7

 

Electronic   Mail: Marzio@NuraLogix.ai Attention: Marzio Pozzuoli

 

3. MyFiziq Platform

 

The MyFiziq Platform consists of the Licensed SDKs and MyFiziq Cloud Platform as documented below.

 

3.1 Licensed SDKs

 

MyFiziq will supply the following iOS & Android** SDKs:

 

- Image Capture SDK

 

- Input SDK

 

- Onboarding SDK

 

- Track SDK

 

- Profile SDK

 

- Billing SDK

 

- Support SDK.

 

iOS SDKs are provided as a LLVM bitcode binary framework.

 

As the iOS SDKs are distributed using Cocoapod, the iOS SDKs will work with projects using Objective C and multiple versions of Swift.

 

Android SDKs** are provided as set of Android Gradle modules (AAR).

 

The Android SDKs** are distributed in a private Maven repository. The modules contain Java bytecode and native submodules.

 

** Agreed functionality updates under development, will be made available when development completed.

 

25

 

 

3.2 MyFiziq Cloud Platform

 

In conjunction with the Licensed SDKs, MyFiziq will also supply the following:

 

Cloud based Anthropometric measurement inference utilizing the following services:

 

- AWS (Amazon Web Services) Lambda

 

- AWS S3

 

- AWS Cognito

 

- AWS CloudFront

 

- AWS DynamoDB

 

- AWS API Gateway**

 

Refer to the Data Processing Agreement for specific MyFiziq cloud services architecture information.

 

** Agreed functionality updates under development, will be made available when development completed.

 

4. NuraLogix Platform

 

The NuraLogix Platform consists of DeepAffex and Anura as documented below.

 

4.1 DeepAffex Cloud Account:

 

Setup of private ORG account and corresponding license

 

Creation of ORG ‘admin’ user and access credentials

 

Anura study set (points) configuration

 

DFX Dashboard access

 

4.2 Anura Core Package

 

Provided for both iOS and Android mobile platforms

 

Mobile Measurement libraries including

 

o camera source

 

o camera adapter

 

o face tracker pipe

 

o face tracker adapter

 

o DFX SDK pipe

 

o rendering sink

 

o UI shared objects

 

26

 

 

Documentation on how to use core interfaces

 

Ranges, scales and colour coding for all Anura results

 

Sample app (source code)

 

DeepAffex API client (source code)

 

Alibaba face tracker binary (as dependency of sample app)

 

5. Field of Use

 

This agreement, including the Licences, is only for use as a demonstrable product only. Where commercial opportunities arise to monetise the Combined Application, the Parties agree to enter into additional commercial contracts specific to the Commercialisation, or commercial opportunity.

 

Where NuraLogix would like to provide demonstration access to the MyFiziq Platform to a third party, the Parties agree that prior to providing access:

 

(i) NuraLogix will request permission in writing from MyFiziq to provide access to a specified third party.

 

(ii) MyFiziq will at its discretion either approve or deny permission in writing within 5 Business Days.

 

(iii) Unless otherwise agreed by the Parties in writing third party access will be limited to 4 Active Users from the third party, for a period of 2 weeks.

 

Where MyFiziq would like to provide demonstration access to the NuraLogix Platform to a third party, Parties agree that prior to providing access:

 

(i) MyFiziq will request permission in writing from NuraLogix to provide access to a specified third party.

 

(ii) NuraLogix will at its discretion either approve or deny permission in writing within 5 Business Days.

 

(iii) Unless otherwise agreed by the Parties in writing third party access will be limited to 4 Active Users from the third party, for a period of 2 weeks.

 

6. Commencement Date

 

The date the last party to this Agreement executes this Agreement.

 

7. Expiry Date

 

12 months from the Commencement Date.

 

8. Transition-Out Period

 

60 days.

 

9. Trademarks

 

NuraLogix:

 

“NuraLogix”

 

27

 

 

NuraLogix Logo

 

“TOI”

 

“DeepAffex”

 

DeepAffex Logo

 

“Anura”

 

Anura Logo

 

10. Product Integration

 

MyFiziq will undertake the integration of the NuraLogix Platform into the Combined Application at MyFiziq’s cost.

 

The Parties will work together with the aim of delivering a demonstrable product not later than 60 days after the date of this Agreement.

 

Product Integrations and potential associated cost of integration will be at the partners cost or if undertaken by MyFiziq the cost will be shared with NuraLogix. Any cost to NuraLogix will require approval from NuraLogix prior to commencement.

 

This clause is to deal with the integration of the combined technologies into a perspective partner.

 

For example, in the event Vitality / Discovery wish to integrate the CompleteHealth platform into one or more of the Vitality /Discovery platforms and require assistance from NuraLogix and MyFiziq. NuraLogix and MyFiziq will put forward the pricing to carry out such work and the parties will integrate their perspective technologies into the requested partner platform.

 

In the event NuraLogix and MyFiziq deem to value of the project to be of commercial substance, the parties may waive the integration costs. In such an event the parties will carry their own costs for such an integration.

 

28

 

 

EXECUTED AS A DEED

 

EXECUTED by NURALOGIX CORPORATION

in accordance with its constituent documents and place of incorporation:

 

/s/ Marzio Pozzuoli

)

)

)

)

 

Signature of director

8/21/2020

 

Marzio Pozzuoli

   
Name of director    

 

*please delete as applicable

 

EXECUTED by MYFIZIQ LIMITED ACN 602 111 115

in accordance with section 127 of the

Corporations Act 2001 (Cth):

 

 

 

/s/ Vlado Bosanac

)

)

)

)

 

 

/s/ Steven Richards

Signature of director 8/21/2020

 

Vlado Bosanac

Signature of director/company
secretary*     8/23/2020

 

Steven Richards

Name of director Name of director/company secretary*

 

*please delete as applicable

 

 

29

 

Exhibit 10.20

 

DATA PROCESSING AGREEMENT

 

THIS AGREEMENT is made in September 22nd, 2020

 

BETWEEN:

 

(1) MyFiziq Limited (ABN 85 602 111 115) of Unit 5, 71-73 South Perth Esplanade, South Perth Western Australia 6151 (“Data Controller” or “MyFiziq”)) and

 

(2) NuraLogix Corporation (GST Number: 800817272 RT0001) of 1801-250 Yonge St, Toronto, Ontario M5B 2L7, Canada (“Data Processor” or “NuraLogix”).

 

BACKGROUND:

 

(1) Under an agreement between the Data Controller and the Data Processor (“the Service Agreement”) the Data Processor provides to the Data Controller the Services described in Schedule 1.

 

(2) The provision of the Services by the Data Processor involves it in processing the Personal Data described in Schedule 2 on behalf of the Data Controller.

 

(3) The Personal Data may include information about individuals falling within scope of EU Regulation 2016/679 General Data Protection Regulation (“the GDPR”), the California Consumer Privacy Act, California Civil Code sections 1798.100 et seq (“the CCPA”), or equivalent data protection laws globally (collectively “the Data Protection Legislation”).

 

(4) The Data Protection Legislation requires that the Data Controller is required to put in place an agreement in writing between the Data Controller and any organisation which processes Personal Data on its behalf governing the processing of that data.

 

(5) The Parties have agreed to enter into this Agreement to ensure compliance with the said provisions of the Data Protection Legislation in relation to all processing of the Personal Data by the Data Processor for the Data Controller.

 

(6) The terms of this Agreement are to apply to all processing of Personal Data carried out for the Data Controller by the Data Processor and to all Personal Data held by the Data Processor in relation to all such processing.

 

IT IS AGREED as follows:

 

1. Definitions and Interpretation

 

1.1 In this Agreement, unless the context otherwise requires, the following expressions have the following meanings:

 

 

  “controller”, “processor”, “processing”, and “data subject” shall have the meanings given to the terms “controller”, “processor”, “processing”, and “data subject” respectively in Article 4 of the GDPR;

 

Page 1 of 12

 

 

  “Personal Data” means all such “personal data”, as defined in Article 4 of the GDPR, as is, or is to be, processed by the Data Processor on behalf of the Data Controller, as described in Schedule 2;
     
  “Services” means those services described in Schedule 1 which are provided by the Data Processor to the Data Controller and which the Data Controller uses for the purposes described in Schedule 1;
     
  “Sub-Processor” means a sub-processor appointed by the Data Processor to process the Personal Data; and
     
  “Sub-Processing Agreement” means an agreement between the Data Processor and a Sub-Processor governing the Personal Data processing carried out by the Sub-Processor, as described in Clause 7.

 

1.2 Unless the context otherwise requires, each reference in this Agreement to:

 

1.2.1 “writing”, and any cognate expression, includes a reference to any communication effected by electronic or facsimile transmission or similar means;

 

1.2.2 a statute or a provision of a statute is a reference to that statute or provision as amended or re-enacted at the relevant time;

 

1.2.3 “this Agreement” is a reference to this Agreement and each of the Schedules as amended or supplemented at the relevant time;

 

1.2.4 a Schedule is a schedule to this Agreement; and

 

1.2.5 a Clause or paragraph is a reference to a Clause of this Agreement (other than the Schedules) or a paragraph of the relevant Schedule.

 

1.2.6 a “Party” or the “Parties” refer to the parties to this Agreement.

 

1.3 The headings used in this Agreement are for convenience only and shall have no effect upon the interpretation of this Agreement.

 

1.4 Words imparting the singular number shall include the plural and vice versa.

 

1.5 References to any gender shall include all other genders.

 

1.6 References to persons shall include corporations.

 

2. Scope and Application of this Agreement

 

2.1 The provisions of this Agreement shall apply to the processing of the Personal Data described in Schedule 2, carried out for the Data Controller by the Data Processor, and to all Personal Data held or accessed by the Data Processor in relation to all such processing whether such Personal Data is held at the date of this Agreement or received afterwards.

 

2.2 The provisions of this Agreement supersede any other arrangement, understanding, or agreement including, but not limited to, the Service Agreement made between the Parties at any time relating to the Personal Data.

 

2.3 This Agreement shall continue in full force and effect for so long as the Data Processor is processing Personal Data on behalf of the Data Controller, and thereafter as provided in Clause 11.

 

Page 2 of 12

 

 

3. Provision of the Services and Processing Personal Data

 

3.1 The Data Processor is only to carry out the Services, and only to process the Personal Data received from the Data Controller:

 

3.1.1 for the purposes of those Services and not for any other purpose;

 

3.1.2 to the extent and in such a manner as is necessary for those purposes; and

 

3.1.3 strictly in accordance with the express written authorisation and instructions of the Data Controller (which may be specific instructions or instructions of a general nature or as otherwise notified by the Data Controller to the Data Processor).

 

4. Data Protection Compliance

 

4.1 All instructions given by the Data Controller to the Data Processor shall be made in writing and shall at all times be in compliance with the Data Protection Legislation. The Data Processor shall act only on such written instructions from the Data Controller unless the Data Processor is required by law to do otherwise.

 

4.2 The Data Processor shall promptly comply with any request from the Data Controller requiring the Data Processor to amend, transfer, delete, or otherwise dispose of the Personal Data.

 

4.3 The Data Processor shall transfer all Personal Data to the Data Controller on the Data Controller’s request in the formats, at the times, and in compliance with the Data Controller’s written instructions.

 

4.4 Both Parties shall comply at all times with the Data Protection Legislation and other applicable laws and shall not perform their obligations under this Agreement or any other agreement or arrangement between themselves in such way as to cause either Party to breach any of its applicable obligations under the Data Protection Legislation.

 

4.5 The Data Processor agrees to comply with any reasonable measures required by the Data Controller to ensure that its obligations under this Agreement are satisfactorily performed in accordance with any and all applicable legislation from time to time in force.

 

4.6 The Data Processor shall provide all reasonable assistance to the Data Controller in complying with its obligations under the Data Protection Legislation with respect to the security of processing, the notification of personal data breaches, the conduct of data protection impact assessments and equivalent risk assessments, and in dealings with any applicable data protection regulators.

 

4.7 When processing the Personal Data on behalf of the Data Controller, the Data Processor shall:

 

4.7.1 not process the Personal Data outside of Canada or the European Economic Area (all EU member states, plus Iceland, Liechtenstein, and Norway) (“EEA”) without the prior written consent of the Data Controller and, where the Data Controller consents to such a transfer to a country that is outside of Canada or EEA, to comply with the obligations of Data Processors under the provisions applicable to transfers of Personal Data to third countries set out in Chapter 5 of the GDPR by providing an adequate level of protection to any Personal Data that is transferred;

 

Page 3 of 12

 

 

4.7.2 not transfer any of the Personal Data to any third party without the written consent of the Data Controller and, in the event of such consent, the Personal Data shall be transferred strictly subject to the terms of a suitable agreement, as set out in Clause 7;

 

4.7.3 process the Personal Data only to the extent, and in such manner, as is necessary in order to comply with its obligations to the Data Controller or as may be required by law (in which case, the Data Processor shall inform the Data Controller of the legal requirement in question before processing the Personal Data for that purpose unless prohibited from doing so by law);

 

4.7.4 if so requested by the Data Controller (and within the timescales required by the Data Controller) supply further details of the technical and organisational systems in place to safeguard the security of the Personal Data held and to prevent unauthorised access;

 

4.7.5 keep detailed records of all processing activities carried out on the Personal Data;

 

4.7.6 make available to the Data Controller any and all such information as is reasonably required and necessary to demonstrate the Data Processor’s compliance with the Data Protection Legislation;

 

4.7.7 on reasonable prior notice, submit to audits and inspections and provide the Data Controller with any information reasonably required in order to assess and verify compliance with the provisions of this Agreement and both Parties’ compliance with the requirements of the Data Protection Legislation. The requirement to give notice will not apply if the Data Controller believes that the Data Processor is in breach of any of its obligations under this Agreement or under the law; and

 

4.7.8 inform the Data Controller immediately if it is asked to do anything that infringes the Data Protection Legislation.

 

5. Data Subject Access, Complaints, and Breaches

 

5.1 The Data Processor shall assist the Data Controller in complying with its obligations under the Data Protection Legislation. In particular, the following shall apply to data subject access requests, complaints, and data breaches.

 

5.2 The Data Processor shall notify the Data Controller without undue delay if it receives:

 

5.2.1 a subject access request from a data subject; or

 

5.2.2 any other complaint or request relating to the processing of the Personal Data.

 

5.3 The Data Processor shall cooperate fully with the Data Controller and assist as required in relation to any subject access request, complaint, or other request, including by:

 

5.3.1 providing the Data Controller with full details of the complaint or request;

 

5.3.2 providing the necessary information and assistance in order to comply with a subject access request;

 

5.3.3 providing the Data Controller with any Personal Data it holds in relation to a data subject (within the timescales required by the Data Controller); and

 

5.3.4 providing the Data Controller with any other information requested by the Data Controller.

 

Page 4 of 12

 

 

5.4 The Data Processor shall notify the Data Controller immediately if it becomes aware of any form of Personal Data breach, including any unauthorised or unlawful processing, loss of, damage to, or destruction of any of the Personal Data.

 

6. Security

 

The Data Processor shall implement suitable technical and organisational security measures in order to protect the Personal Data against unauthorised or unlawful access, processing, disclosure, copying, alteration, storage, reproduction, display, or distribution; and against loss, destruction, or damage, whether accidental or otherwise. Such measures shall include, but not be limited to, those set out in Schedule 3. Such measures shall be fully documented in writing by the Data Processor and be reviewed at least annually to ensure that they remain up-to- date, complete, and appropriate. The Data Processor shall inform the Data Controller in advance of any changes to such measures.

 

7. Appointment of Sub-Processors

 

7.1 The Data Processor shall not sub-contract any of its obligations or rights under this Agreement without the prior written authorisation of the Data Controller (such authorisation not to be unreasonably withheld).

 

7.2 The Controller authorises the Data Processor’s appointment of the Sub-Processors listed at Schedule 4.

 

7.3 Where the Data Processor appoints a Sub-Processor (with the written consent of the Data Controller), the Data Processor shall:

 

7.3.1 enter into a Sub-Processing Agreement with the Sub-Processor which shall impose upon the Sub-Processor the same obligations as are imposed upon the Data Processor by this Agreement and which shall permit both the Data Processor and the Data Controller to enforce those obligations; and

 

7.3.2 ensure that the Sub-Processor complies fully with its obligations under the Sub-Processing Agreement and the GDPR.

 

7.4 In the event that a Sub-Processor fails to meet its obligations under any Sub-Processing Agreement, the Data Processor shall remain fully liable to the Data Controller for failing to meet its obligations under this Agreement.

 

8. Deletion and/or Disposal of Personal Data

 

8.1 The Data Processor shall, at the written request of the Data Controller, delete (or otherwise dispose of) the Personal Data or return it to the Data Controller in the format(s) reasonably requested by the Data Controller within a reasonable time after the earlier of the following:

 

8.1.1 the end of the provision of the Services; or

 

8.1.2 the processing of that Personal Data by the Data Processor is no longer required for the performance of the Data Processor’s obligations under this Agreement or the Service Agreement.

 

8.2 Following the deletion, disposal, or return of the Personal Data under Clause 8.1, the Data Processor shall delete (or otherwise dispose of) all further copies of the Personal Data that it holds, unless retention of such copies is required by law, in which case the Data Processor shall inform the Data Controller of such requirement(s) in writing.

 

Page 5 of 12

 

 

9. Liability and Indemnity

 

The Data Processor shall indemnify, keep indemnified and defend the Data Controller, at the Data Processor’s own expense, against all claims, liabilities, costs, expenses, damages and losses (including all interest, penalties and legal costs (calculated on a full indemnity basis) and all other professional costs and expenses) suffered or incurred by the Data Controller arising out of the failure by the Data Processor or its employees or agents to comply with of its obligations under this Agreement (“Claims”). Each party acknowledges that Claims include any claim or action brought by a data subject arising from the Supplier’s breach of its obligations under this Agreement.

 

10. Intellectual Property Rights

 

All copyright, database rights, and other intellectual property rights subsisting in the Personal Data (including but not limited to any updates, amendments, or adaptations to the Personal Data made by either the Data Controller or the Data Processor) shall belong to the Data Controller or to any other applicable third party from whom the Data Controller has obtained the Personal Data under licence (including, but not limited to, data subjects, where applicable). The Data Processor is licensed to use such Personal Data under such rights only for the purposes of the Services, and in accordance with this Agreement.

 

11. Confidentiality

 

11.1 The Data Processor shall maintain the Personal Data in confidence, and in particular, unless the Data Controller has given written consent for the Data Processor to do so, the Data Processor shall not disclose any Personal Data supplied to the Data Processor by, for, or on behalf of, the Data Controller to any third party. The Data Processor shall not process or make any use of any Personal Data supplied to it by the Data Controller otherwise than in connection with the provision of the Services to the Data Controller.

 

11.2 The Data Processor shall ensure that all personnel who are to access and/or process any of the Personal Data are contractually obliged to keep the Personal Data confidential.

 

11.3 The obligations set out in in this Clause 11 shall continue for a period of six years after the cessation of the provision of Services by the Data Processor to the Data Controller.

 

11.4 Nothing in this Agreement shall prevent either Party from complying with any requirement to disclose Personal Data where such disclosure is required by law. In such cases, the Party required to disclose shall notify the other Party of the disclosure requirements prior to disclosure, unless such notification is prohibited by law.

 

12. Law and Jurisdiction

 

12.1 This Agreement (including any non-contractual matters and obligations arising therefrom or associated therewith) shall be governed by, and construed in accordance with, the laws of California.

 

12.2 Any dispute, controversy, proceedings or claim between the Parties relating to this Agreement (including any non-contractual matters and obligations arising therefrom or associated therewith) shall fall within the jurisdiction of the courts of the of California.

 

Page 6 of 12

 

 

SIGNED for and on behalf of the Data Controller by:  
MyFiziq CEO, Vlado Bosanac  
   
/s/ Vlado Bosanac  
Authorised Signature  
   
Date: September 22nd, 2020  
   
SIGNED for and on behalf of the Data Processor by:  
NuraLogix CEO, Marzio Pozzuoli  
   
/s/ Marzio Pozzuoli  
Authorised Signature  
   
Date: September 22nd, 2020  

 

Page 7 of 12

 

 

SCHEDULE 1

 

The Services

 

The provision, maintenance and improvement of the DeepAffex service, a cloud-based affective intelligence platform that utilizes innovative facial blood-flow imaging technology to detect, measure, analyze and access human physiology and psychological affects. The DeepAffex service is made of components including:

 

“DeepAffex Dashboard” (NuraLogix’s web portal used by the Processor for tasks such as Licensee Account configuration, viewing end user data, and billing).

 

“DeepAffex Platform SDK” (the Desktop SDK and/or the Mobile SDK).

 

“DeepAffex SaaS Engine” (NuraLogix’s cloud-based software-as-a-service affective intelligence engine that applies advanced signal processing and deep learning artificial intelligence models to predict physiological and psychological affects and stores end user data).

 

“Desktop SDK” (the APIs and software development tools for the Windows, Mac and Linux platforms made available by NuraLogix for the purpose of accelerating the integration of a desktop application with the APIs and the DeepAffex SaaS engine.)

 

“Mobile SDK” (the software development tools for the iOS and Android mobile platforms made available by NuraLogix for the purpose of accelerating the integration of a mobile application with the APIs and the DeepAffex SaaS Engine. The Mobile SDK also includes the measurement capabilities from NuraLogix’s Anura mobile application (including calibration, constraints, and interface) as well as a functional sample application.)

 

Page 8 of 12

 

 

SCHEDULE 2

 

Personal Data

 

Types of Personal Data   Email address, Name, Phone/Cell number, Photos, Facial Blood Flow data (FBF), measured biometric results e.g. Height, Weight, Age, Heart rate, Breathing rate, Blood pressure, Heart Rate Variability (HRV), Cardiac Workload (CW), Stress Index (MSI), Body Mass Index (BMI), Cardiovascular Disease Risk (CVD risk), Heart Attack Risk (HA risk), Stroke Risk (STK risk), computed results (e.g. General Wellness Score), IPs, usage data, device identification data.
Category of Data Subjects   Users (consumers) of MyFiziq’s products and services which incorporate NuraLogix’s DeepAffex SaaS Engine.
Nature of Processing   Using facial blood-flow imaging technology to detect, measure, analyze and access human physiology and psychological affects
Purpose of Processing   To incorporate physiological and psychological calculations and inferences generated about users in the MyFiziq products and services which incorporate NuraLogix’s DeepAffex SaaS Engine.

 

Page 9 of 12

 

 

SCHEDULE 3

 

Security Measures

 

1. The Data Processor shall ensure that, in respect of all Personal Data it receives from or processes on behalf of the Data Controller, it maintains security measures to a standard appropriate to:

 

1.1 the harm that might result from unlawful or unauthorised processing or accidental loss, damage, or destruction of the Personal Data; and

 

1.2 the nature of the Personal Data.

 

2. In particular, the Data Processor shall:

 

2.1 have in place, and comply with, a security policy which:

 

2.1.1 defines security needs based on a risk assessment;

 

2.1.2 allocates responsibility for implementing the policy to a specific individual or personnel;

 

2.1.3 is disseminated to all relevant staff; and

 

2.1.4 provides a mechanism for feedback and review.

 

2.2 ensure that appropriate security safeguards and anti-malware protection are in place to protect the hardware and software which is used in processing the Personal Data in accordance with best industry practice;

 

2.3 ensure that the effectiveness of all measures detailed in this Agreement and in any specific security policy are regularly tested, assessed, and evaluated;

 

2.4 prevent unauthorised access to the Personal Data;

 

2.5 protect the Personal Data using pseudonymisation, where it is practical to do so;

 

2.6 implement such measures as are necessary to ensure the ongoing confidentiality, integrity, availability, and resilience of systems and services used to process Personal Data;

 

2.7 ensure that its storage of Personal Data conforms with best industry practice such that the media on which Personal Data is recorded (including paper records and records stored electronically) are stored in secure locations and access by personnel to Personal Data is strictly monitored and controlled;

 

2.8 have secure methods in place for the transfer of Personal Data whether in physical form (for example, by using couriers rather than post) or electronic form (for example, by using encryption);

 

2.9 encrypting all Personal Data at rest and in transit using industry standard encryption ciphers;

 

2.10 utilising multi-factor authentication on all computers and other devices on which Personal Data is stored;

 

2.11 take reasonable steps to ensure the reliability of personnel who have access to the Personal Data;

 

Page 10 of 12

 

 

2.12 have in place methods for detecting and dealing with breaches of security (including loss, damage, or destruction of Personal Data) including, but not limited to:

 

2.12.1 the ability to identify which individuals have worked with specific Personal Data;

 

2.12.2 having a proper procedure in place for investigating and remedying personal data breaches and breaches of the Data Protection Legislation; and

 

2.12.3 notifying the Data Controller as soon as any such breach occurs.

 

2.13 have a secure procedure for backing up all Personal Data, whether stored electronically or otherwise, enabling Personal Data to be restored in a timely fashion, and storing back-ups separately from originals;

 

2.14 have a secure method of disposal of unwanted Personal Data including for back-ups, disks, print-outs, and redundant equipment; and

 

2.15 adopt such organisational, operational, and technological processes and procedures as are required to comply with the requirements of ISO/IEC 27001:2013, as appropriate to the Services provided to the Data Controller.

 

Page 11 of 12

 

 

SCHEDULE 4

 

Authorised Sub-Processors

 

Amazon Web Services (AWS) – provided the NuraLogix AWS hosting is located in Canada or the European Economic Area.

 

 

Page 12 of 12

 

 

Exhibit 10.21

 

 

 

10 December 2019

 

Prosser Enterprises Ltd ATF Prosser Family Trust 91 Hawkesbury Crescent, Farrer,

ACT, 2607

 

Dear Nick,

 

LETTER OF VARIATION – OPPORTUNITY FOR EARLIER CONVERSION

 

We refer to the converting note agreement which you (Investor) executed with MyFiziq Limited (ACN 602 111 115) (Company) on or about 10th April 2018 (Agreement).

 

As you would be aware, the converting note which you hold in accordance with the Agreement is currently due to mature on 31 December 2019 (Maturity Date).

 

This letter agreement is intended to vary your Agreement to:

 

(a) extend the Maturity Date to 30 June 2020; and

 

(b) capitalise any interest owing to you as at the date of this letter agreement and any future interest payments due to you prior to the Maturity Date.

 

Terms defined in the Agreement have the corresponding meaning where used in this letter agreement (unless otherwise specified).

 

By this letter agreement, the Agreement is varied as follows:

 

Maturity Date: 30 June 2020.

 

Interest Payment Dates: Interest will accrue to the Investor/s quarterly in arrears and the interest accrued to 31 December 2019 will be paid as follows:

 

i. $20,000 by 30 November 2019

 

ii. The balance of approximately $38,630.14 by 31 January 2019

 

iii. Interest will be paid on a monthly basis on the 1st of each calendar month at a rate of 8%pa being $3,333p,

 

All interest accrued from 1 January 2020 shall be capitalised (thereafter forming part of the Principal) and repaid on the Maturity Date.

 

Upon execution by all parties, this letter shall form a binding deed varying the Agreement on the terms and conditions above.

 

 

 

 

To record your agreement to the above variation of the Agreement, please execute this letter agreement where indicated below and return it to me.

 

For the avoidance of doubt, all remaining terms of the Agreement remain unaltered other than as varied by this deed.

 

Yours sincerely

 

/s/ Steven Richards

Mr Steven Richards Company Secretary MyFiziq Limited

 

2

 

 

EXECUTED by the Parties as a deed.

 

EXECUTED by MYFIZIQ LIMITED )    
ACN 602 111 115 )    
in accordance with section 127 of the )    
Corporations Act 2001 (Cth): )    

 

     
/s/ Vlado Bosanac   /s/ Steven Richards
Signature of director   Signature company secretary
     
Vlado Bosanac   Steven Richards
Name of director   Name of company secretary

 

EXECUTED by Prosser Enterprises Ltd ) ATF Prosser Family Trust)
ACN [123 704 405] )      
in accordance with section 127 of the )           
Corporations Act 2001 (Cth):        

 

/s/ Nicholas Prosser    
Signature of sole director   Signature of director/company secretary*

 

Nicholas Prosser    
Name of sole director   Name of director/company secretary*

 

 

3

 

Exhibit 10.22

 

  MYFIZIQ COMMERCIAL CONTRACT  

 

CONTRACT REFERENCE: MYQ010007

 

DATE OF AGREEMENT

 

This Commercial Contract is applicable from 01/04/2019.

 

PARTIES

 

MyFiziq Limited ABN 85 602 111 115 of Unit 5, 71-73 South Perth Esplanade, South Perth Western Australia 6151 (“MyFiziq”), (“Licensor”).

 

Body Composition Technologies Pty Limited ABN 17 620 646 531 of Unit 5, 71-73 South Perth Esplanade, South Perth Western Australia 6151 (“BCT”), (“Licensee”).

 

RECITALS

 

A. Intellectual Property Rights are documented in the IP Licence Agreement between MyFiziq and BCT dated 22/09/2017.
B. The Licensee sector (Field) rights are documented in the IP Licence Agreement between MyFiziq and BCT dated 22/09/2017 and in the shareholders Deed between MyFiziq and BCT dated on or about the 22nd of September, 2017 or as subsequently amended from time to time.
C. The Licensee has the right to exploit the Licensed SDKs from MyFiziq in the Licensee Field as documented in the IP Licence Agreement.
D. The Licensee wishes to engage the Licensor, and the Licensor wishes to accept the engagement, to perform the Services, on the following terms and conditions.

 

THE PARTIES AGREE AS FOLLOWS:

 

1. Subsequent agreements

 

Within thirty (30) days of the Commencement Date, the parties agree to enter into:

 

1. a Data Processing Agreement which documents both parties’ requirements under data protection laws including the Privacy Act and GDPR in relation to the processing of Active User data on the MyFiziq Services.

 

2. a Support Agreement which documents the support services to be provided by MyFiziq during the contract Term, the steps for reporting issues / incidents, as well as response and resolution time frames.

 

The Software Development Kit EULA shown in Schedule 4 will be used by the Licensee to document the rights and obligations in relation to any Software Development Kit EULA with third parties.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 1 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Definitions and Interpretation

 

Definitions

 

In this Commercial Contract, the following words have the following meanings, unless expressly agreed otherwise:

 

3D Model means a virtual 3D representation of a User's human body shape.

 

Active User means a single user of the Licensed SDKs who can be identified by a unique identification reference, email address or username who has either created or accessed an account in MyFiziq’s Platform via the Licensee Field.

 

Additional Commercial Contract means as specified in clause 3.1.

 

Australian Consumer Law means schedule 2 to the Competition and Consumer Act

2010 (Cth).

 

Avatar means 3D Model.

 

Business Day means Monday – Friday excluding public holidays In Western Australia.

 

Business Hours means 9:00am – 5:00pm on Business Days.

 

Commencement Date means the Commencement Date as set out in Schedule 1.

 

Commercial Contract means this MyFiziq Commercial Contract including Schedules 1, 2, 3 and 4.

 

Confidential Information means as defined in clause 0.

 

Documentation means as set out in Schedule 1.

 

EULA means the MyFiziq Software Development Kit End User Licence Agreement.

 

Fees means as set out in Schedule 1.

 

Force Majeure Event means war, strike, lockout, natural disaster, flood, earthquake, act of God, or other circumstances beyond the reasonable control of MyFiziq.

 

GDPR means the General Data Protection Regulation (GDPR) (EU) 2016/679.

 

GST has the meaning given by the A New Tax System (Goods and Services Tax) Act

1999 (Cth)).

 

Initial Term means the initial term set out in Schedule 1. The Initial Term commences on the Commencement Date.

 

Insolvency Event means: (a) where the party is an individual, that party commits an act of bankruptcy or is declared bankrupt or insolvent or that party's estate otherwise becomes liable to be dealt with under any law relating to bankruptcy or insolvency; or (b) where the party is a company, (b) the party ceases to (or is unable to) pay its creditors (or any class of them) in the ordinary course of business, (c) a receiver, receiver and manager, administrator, liquidator or similar officer is appointed to the party, (d) the party enters into, or resolves to, enter into, a scheme or arrangement, compromise or composition with any class of creditors; (e) a resolution is passed or an application to a court is taken for the winding up, dissolution or administration of the party, (f) any liquidator, receiver or manager enters into possession of any of the assets of the party, (g) the party applies for, consents to, or acquiesces in the appointment of a trustee or receiver, or (h) except to reconstruct or amalgamate while solvent on terms approved by the other party, the party enters into or resolves or proposes to enter into a scheme of arrangement, compromise or re-construction with any of its creditors or members.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 2 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Intellectual Property Rights means all copyright, trademark rights, patent rights, and design rights, whether registered or unregistered, and all other rights to intellectual property as defined under article 2 of the convention establishing the World Intellectual Property Organization, and all rights to enforce any of the foregoing rights.

 

Licensee means as set out on the first page of this Agreement.

 

Licensee Field means the medical, insurance and medical research sectors as documented in the IP Licence Agreement between MyFiziq and BCT dated 22/09/2017.

 

Licensee Materials means software, data, logos and other materials and information supplied by or on behalf of the Licensee to MyFiziq in connection with this Commercial Contract. For the avoidance of doubt, Licensee Materials do not include the Licensed SDKs or Platform or the Documentation.

 

Licensed SDKs means as specified in Schedule 1.

 

Licensor means as set out on the first page of this Agreement.

 

Moral Rights has the meaning given to that term in the Copyright Act 1968 (Cth).

 

Payment Terms means as set out in Schedule 1.

 

Personal Property Securities Register means the Personal Property Securities Register established under the Personal Property Securities Act 2009 (Cth).

 

Platform means as specified in Schedule 1. Privacy Act means the Privacy Act 1988 (Cth). Renewal Term means as set out in clause 2.2.

 

SDK has the meaning given to it in the EULA in Schedule 4.

 

SDK Documentation means as set out in Schedule 1.

 

SDK support means as set out in clause 3 of the EULA in Schedule 4.

 

Services means the Implementation Services in clause 4, and the Cloud Services in clause 5.

 

Silhouette means the image of a user represented as a solid shape or a single colour, with the interior of a silhouette being featureless.

 

Term means the Initial Term and any Renewal Terms.

 

User means Active User.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 3 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

1.1. Interpretation

 

In this Commercial Contract:

 

(a) Headings and underlining’s are for convenience only and do not affect the construction of this Commercial Contract.

 

(b) A provision of this Commercial Contract will not be interpreted against a party because the party prepared or was responsible for the preparation of the provision, or because the party's legal representative prepared the provision.

 

(c) A reference to a statute or regulation includes amendments thereto.

 

(d) A reference to a clause, subclause or paragraph is a reference to a clause, subclause or paragraph of this Commercial Contract.

 

(e) A reference to a subclause or paragraph is a reference to the subclause or paragraph in the clause in which the reference is made.

 

(f) The recitals are correct and form part of this Commercial Contract.

 

(g) A reference to time is to time in Western Australia.

 

(h) A reference to a person includes a reference to an individual, a partnership, a company, a joint venture, government body, government department, and any other legal entity.

 

(i) The words "includes", "including" and similar expressions are not words of limitation.

 

(j) To the extent of any inconsistency between the provisions of this Commercial Contract and the IP Licence Agreement between MyFiziq and BCT dated 22/09/2017 the IP Licence Agreement shall prevail.

 

(k) To the extent of any inconsistency between the provisions of this Commercial Contract and the Shareholders Deed between MyFiziq and BCT dated on or about the 22nd of September, 2017 or as subsequently amended from time to time the Shareholders Deed shall prevail.

 

(l) To the extent of any inconsistency between the provisions of the EULA, or Support Agreement and this Commercial Contract, this Commercial Contract will prevail.

 

(m) To the extent of any inconsistency between the provisions of the Data Processing Agreement, and this Commercial Contract, this Commercial Contract will prevail, except where inconsistent with the Privacy Act, the GDPR and any other applicable data protection laws (collectively, "Data Protection Laws") in which case the interpretation provisions of the relevant Data Protection Laws will prevail.

 

(n) Reference to A$ is to Australian currency, and US$ is to the currency of the United States of America.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 4 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

2. Term

 

2.1. The Contract commences on the Commencement Date and shall continue for the Initial Term.

 

2.2. Upon expiry of the Initial Term, the Contract shall automatically renew for subsequent terms each equivalent to the length of the Initial Term (each a "Renewal Term"), until and unless terminated earlier:

 

(a) by either party providing at least 90 days written notice prior to the expiry of the Initial Term or the then subsequent Renewal Term, in which case if such notice is provided this Commercial Contract will terminate at the expiry of the Initial Term or the then current Renewal Term; or

 

(b) otherwise in accordance with this Commercial Contract.

 

3. Additional Commercial Contracts

 

3.1. The Parties may enter into further commercial contracts (each an Additional Commercial Contract) by completing and executing an agreement in the form set out in Schedule 3.

 

3.2. Where the Parties enter into an Additional Commercial Contract, the terms of this Commercial Contract will be incorporated into the Additional Commercial Contract and apply with the necessary changes.

 

4. Implementation Services

 

4.1. MyFiziq will supply the Licensee with the Licensed SDKs, Documentation and setup the Platform free of charge to the Licensee.

 

4.2. MyFiziq will also provide services (“Implementation Services”) which will be charged as per the Ad Hoc rate for the specific level required to provide assistance in Schedule 2 – Additional Fees.

 

5. Cloud Services

 

5.1. Once the Platform has been setup, MyFiziq will also provide the following cloud monitoring services (“Cloud Services”):

 

(a) MyFiziq will provide 24/7 monitoring of the Platform through a third-party managed service from Itoc Pty Ltd (“Itoc”) ABN: 17 156 344 811 of 6D / 31 James Street, Fortitude Valley, Brisbane, Queensland, Australia, 4008.

 

(b) Cloud monitoring will be charged as per the Monitoring Fees in Schedule 1.

 

6. Fees

 

6.1. The Licensee must pay the Fees to MyFiziq in accordance with the Payment Terms.

 

6.2. The Fees are exclusive of all taxes, duties and customs including GST and the Licensee agrees to pay MyFiziq all taxes, duties and customs, including GST, in respect of any Supply (as that term is defined in the A New Tax System (Goods and Services Tax) Act 1999 (Cth)) made by MyFiziq under this Commercial Contract. The Licensee must pay all such taxes, duties and customs, including GST, at the same time as the Fees.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 5 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

7. Ownership of Intellectual Property

 

7.1. All Intellectual Property Rights owned by or proprietary to, a party as at the date of this Commercial Contract will at all times remain owned by that party.

 

7.2. The Licensee agrees and acknowledges that this Commercial Contract does not transfer or assign any Intellectual Property Rights to it.

 

8. Liability

 

8.1. Neither party is liable to the other party for any indirect, special or consequential loss or damage incurred by the other party, including liability for loss of profits, loss of business opportunity, loss of savings, or loss of data.

 

8.2. For any loss that is not otherwise excluded, MyFiziq is only liable for loss directly incurred by the Licensee as a result of one or more breaches by MyFiziq of its obligations under this Commercial Contract. However, MyFiziq's liability for all such direct loss (i.e. for any loss or damage which falls under the first limb of Hadley v Baxendale (1854) 9 ex 341 being that which arises naturally, according to the usual course of things) is capped, in the aggregate, at an amount equivalent to the Fees paid by the Licensee under this Commercial Contract, and which cap is reduced to the extent the Licensee or any Force Majeure Event caused or was responsible for such loss.

 

8.3. The goods and services supplied under this Commercial Contract may come with implied non-excludable guarantees which are regulated by the Australian Consumer Law. The extent of the implied guarantees depends on whether the Licensee is a 'consumer' of goods or services within the meaning of that term pursuant to the Australian Consumer Law as amended. Where the Licensee is a 'consumer' for the purposes of the Australian Consumer Law, MyFiziq is required to provide and shall be deemed to have provided the following mandatory statement to the Licensee: "Our goods come with guarantees that cannot be excluded under the Australian Consumer Law. You are entitled to a replacement or refund for a major failure and for compensation for any other reasonably foreseeable loss or damage. You are also entitled to have the goods repaired or replaced if the goods fail to be of acceptable quality and the failure does not amount to a major failure."

 

8.4. If the goods or services supplied by MyFiziq to the Licensee are supplied to the Licensee as a 'consumer' of goods or services within the meaning of that term in the Australian Consumer Law as amended the Licensee will have the benefit of certain non-excludable rights and remedies in respect of the goods or services and nothing in these terms and conditions excludes or restricts or modifies any condition, warranty, guarantee, right or remedy which pursuant to the Competition and Consumer Act 2010 (Cth) is so conferred. However,

 

8.5. If the goods or services are subject to a non-excludable condition, warranty, guarantee, right or remedy implied by the Australian Consumer Law and the goods or services are not ordinarily acquired for personal, domestic or household use or consumption, then pursuant to s 64A of the Australian Consumer Law, MyFiziq limits its liability for breach of any such non-excludable warranty, guarantee, right or remedy implied by the Australian Consumer Law (other than a guarantee implied by sections 51, 52 or 53 of the Australian Consumer Law) or expressly given by MyFiziq to the Licensee, in respect of each of the goods and services, where it is fair and reasonable to do so, at the option of MyFiziq, to one or more of the following:

 

(a) if the breach relates to goods:

 

(i) the replacement of the goods or the supply of equivalent goods;

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 6 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

(ii) the repair of such goods;

 

(iii) the payment of the cost of replacing the goods or of acquiring equivalent goods; or

 

(iv) the payment of the cost of having the goods repaired; and

 

(b) if the breach relates to services:

 

(i) the supplying of services again; or

 

(ii) the payment of the cost of having the services supplied again.

 

8.6. Where MyFiziq elects to repair goods, the Licensee agrees that the goods may be replaced by refurbished goods of the same type rather than being repaired and refurbished parts may be used to repair goods. The Licensee acknowledges that where the goods are repaired and are capable of retaining user-generated data, it is possible that the repair of the goods may result in loss of data.

 

8.7. Any warranty against defects provided by MyFiziq to the Licensee as a 'consumer' under the Australian Consumer Law is in addition to other rights and remedies of the Licensee under a law in relation to the goods or services to which the warranty relates.

 

8.8. All conditions, warranties and guarantees implied in this Commercial Contract are excluded, to the extent possible by law.

 

9. MyFiziq’s insurance obligations

 

9.1. For the duration of this Commercial Contract MyFiziq must:

 

(a) Take out and maintain appropriate public liability and indemnity insurance with a minimum limit of A$10,000,000. MyFiziq to provide copies of the relevant certificates of currency of insurance to the Licensee upon request.

 

10. Indemnity from MyFiziq for third party IP infringement claims

 

10.1. MyFiziq agrees to indemnify the Licensee against any loss and damage that may be incurred by the Licensee directly as a result of a claim that the Licensee's use of the Licensed SDKs in accordance with this Commercial Contract breaches the Intellectual Property Rights of any third party ("IP Claim"), provided that:

 

(b) the Licensee notifies MyFiziq immediately upon receipt by the Licensee of notice of any IP Claim or upon the Licensee suspecting or having reasonable cause to suspect that such an IP Claim may be made;

 

(c) the Licensee not making any admission or settlement of such IP Claim without MyFiziq's prior written consent;

 

(d) the Licensee giving MyFiziq sole control of the defence and any negotiations for compromise; and

 

(e) the Licensee providing such assistance as MyFiziq reasonably requires.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 7 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

10.2. If the Licensed SDKs become the subject of any such IP Claim referred to in sub- clause 10.1, the Licensee must permit MyFiziq if, and as MyFiziq considers appropriate:

 

(a) to replace all or part of the Licensed SDKs with functionally equivalent SDK; and/or

 

(b) to modify the Licensed SDKs as necessary to avoid such claim; and/or

 

(c) to procure a license from the relevant complainant to continue using the Licensed SDKs.

 

10.3. If in the above circumstances MyFiziq is unable to procure for the Licensee the right to continue using the Licensed SDKs, or to provide the Licensee with functionally equivalent non-infringing SDK, or to modify the Licensed SDKs as necessary to avoid the IP Claim, this Commercial Contract and the licenses granted by MyFiziq to the Licensee under this Commercial Contract may be terminated by MyFiziq at any time.

 

10.4. MyFiziq shall have no liability under this Commercial Contract or otherwise for any claim of Intellectual Property Rights infringement in respect of the Licensed SDKs to the extent such claim is caused by or arises out of:

 

(a) the Licensee's use of the Licensed SDKs in combination with Licensed SDKs or hardware not supplied or approved in writing by MyFiziq;

 

(b) any modification or enhancement of or to the Licensed SDKs made by the Licensee or any third party;

 

(c) use of any version of the Licensed SDKs other than specified in the Software Development Kit EULA clauses 3.1 SDK Versions and 3.2 SDK Support of the EULA, if such claim could have been avoided by the use of such latest supplied version;

 

(d) where the claim for infringement arises in respect of a feature of the Licensed SDKs which was requested by the Licensee or which is specified in any requirements specification provided to MyFiziq by the Licensee which sets out the Licensee's requirements for the Licensed SDKs;

 

(e) the Licensee Materials; or

 

(f) the Licensee's breach of this Commercial Contract.

 

11. Indemnity from Licensee

 

11.1. The Licensee indemnifies MyFiziq in respect of all and any loss and damage incurred by MyFiziq as a result of any breach by the Licensee of its obligations under this Commercial Contract or as a result of any Licensee Materials. The Licensee warrants that all Licensee Materials, and all use thereof by MyFiziq for the purposes of this Commercial Contract, will not infringe the rights of any person or breach any law or regulation.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 8 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Confidentiality

 

11.2. Each party agrees and acknowledges that it may receive confidential information of the other party during the Term of this Commercial Contract ("Confidential Information").

 

11.3. The Licensee agrees and acknowledges that the Licensed SDKs, Platform and Documentation constitutes and contains confidential and proprietary information of MyFiziq.

 

11.4. MyFiziq agrees and acknowledges that the Licensee Materials constitutes and contains confidential and proprietary information of the Licensee.

 

11.5. Each party (the first party) agrees and acknowledges to take all prudent steps to ensure that the Confidential Information of the other party will be received and held by the first party in strict confidence and will not be disclosed by the first party, except:

 

(a) with the prior written consent of the other party;

 

(b) where disclosed to the employees or professional advisors of the first party on a confidential basis;

 

(c) as required by the rules of any stock exchange; or

 

(d) as required by a court of competent jurisdiction, and then, only to the extent required, and provided that the first party must promptly notify the other party of such requirement of disclosure and provide full particulars to the other party of the disclosure.

 

11.6. Confidential Information does not include any information:

 

(a) that is independently developed, obtained or known by a party, without breaching any obligation of confidence to the other party; or

 

(b) that is in the public domain, except where due to a breach of this Commercial Contract or any breach of any obligation of confidence.

 

12. Termination

 

12.1. Either party may terminate this Commercial Contract if the other party (the "Defaulting Party") is in material breach of this Commercial Contract and the breach is not capable of remedy, or where the breach is capable of remedy and the Defaulting Party fails to remedy the breach within thirty (30) days of notice.

 

12.2. Either party may terminate this Commercial Contract by written notice to the other party if the other party suffers an Insolvency Event.

 

12.3. The Licensee may terminate this Commercial Contract by providing ninety (90) days written notice to MyFiziq in the event:

 

(a) Licensee sells its business, or

 

(b) if a majority of the shares in the Licensee are acquired by a third party.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 9 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

12.4. Upon termination of this Commercial Contract, Licensee shall pay all monies or Fees specified in Schedule 1 owed and due up to unpaid Fees specified in Schedule 1, up till the date of termination of this Commercial Contract. Any provisions of this Commercial Contract that, in order to fulfil the purposes of such provisions, need to survive the termination or expiration of this Commercial Contract, shall be deemed to survive for as long as necessary to fulfil such purposes.

 

12.5. Termination does not affect any accrued rights of either party.

 

13. Notices

 

13.1. A notice under this Commercial Contract shall be sent by hand delivery, post or email, using the address specified at the top of the first page of this Commercial Contract or the email address for the recipient’s Representative specified in Schedule 1.

 

13.2. Any notice issued by hand shall be deemed delivered upon delivery.

 

13.3. Any notice issued by post shall be deemed delivered five (5) Business Days after posting if posted domestically, or twenty (20) Business Days after posting if posted internationally.

 

13.4. Any notice issued via email shall be deemed to be delivered upon the email being successfully sent, provided that if an email is sent out of Business Hours, it shall be deemed to be delivered at 9am on the next business day.

 

14. Dispute Resolution

 

14.1. If a dispute arises between the parties out of or relating to this Commercial Contract ("Dispute"), any party to the Dispute must seek to resolve it strictly in accordance with the provisions of this clause. Compliance with the provisions of this clause is a condition precedent to seeking relief in any court in respect of the Dispute, except as otherwise provided in this clause.

 

14.2. A party seeking to resolve a Dispute must notify the existence and nature of the Dispute to the other party ("Notification"). Upon receipt of a Notification, each party must refer resolution of the Dispute to their chief executives (or nominees).

 

14.3. If the Dispute has not been resolved within one (1) calendar month of the Notification, then each party will be entitled to pursue such course of action as it determines.

 

14.4. Nothing in this clause shall limit either party's right to seek urgent interlocutory relief from any court of competent jurisdiction at any time.

 

15. General

 

15.1. Amendment: This Commercial Contract may only be amended by a written document signed by the parties.

 

15.2. Further Assurance: Each party shall sign and execute and do all deeds, acts, and things as may reasonably be required by the other party to carry out and give effect to the terms and conditions of this Commercial Contract.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 10 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

15.3. Assignment: Each party (the first party) may not assign, transfer, license or novate its rights or obligations under this Commercial Contract without the prior written consent of the other party.

 

15.4. Costs: Each party shall bear its own costs of and incidental to the preparation, negotiation and execution of this Commercial Contract.

 

15.5. Severability: If any provision of this Commercial Contract is deemed invalid by a court of competent jurisdiction, the remainder of this Commercial Contract shall remain enforceable.

 

15.6. Relationship: The parties are independent contractors and this Commercial Contract does not create any relationship of partnership, joint venture, or employer and employee or otherwise.

 

15.7. Australian Consumer Law: The exclusions and limitations of liability set out in this Commercial Contract shall apply to the fullest extent permissible at law, but the parties do not exclude or limit liability which may not be excluded or limited by law. Without limiting the foregoing provisions, MyFiziq does not exclude liability under the Australian Consumer Law which is prohibited from being excluded. The parties acknowledge and agree that the limitations and exclusions of liability contained in this Commercial Contract constitute an allocation of risks that form part of the negotiated commercial terms of this Commercial Contract.

 

15.8. Waiver: A provision of, or right under, this Commercial Contract may only be waived in writing signed by the party granting the waiver. A failure or delay in exercise, or partial exercise, of a power, right, authority or remedy arising from a default or breach under this Commercial Contract does not result in a waiver of that power, right, authority or remedy.

 

15.9. Counterparts: This Commercial Contract may be executed in counterparts and by electronic mail counterparts provided that no binding agreement shall be reached until the executed counterparts are exchanged.

 

15.10. Jurisdiction: This Commercial Contract will be interpreted in accordance with the laws in force in Western Australia. The parties irrevocably submit to the exclusive jurisdiction of the courts situated in Western Australia in relation to any dispute concerning this Commercial Contract.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 11 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

If the terms and conditions set out above are acceptable, please execute this Commercial Contract in the appropriate place below.

 

Signed as an agreement.

 

Signed for and on behalf of Body Composition Technologies Pty Limited by its authorised representative:

 

/s/ Martin Otway  
Martin Otway (Director)  

 

EXECUTED by MYFIZIQ LTD )
ACN 602 111 115 )
in accordance with section 127 of the )
Corporations Act 2001 (Cth): )

 

/s/ Vlado Bosanac   /s/ David Tabb
Signature of director   Signature
     
     
Vlado Bosanac (CEO)   David Tabb (COO)
Name of director   Name of Chief Operations Officer

 

Schedule 1

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 12 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Licensee Field The medical, insurance and medical research sectors

 

Licensed SDKs: MyFiziq will supply the following iOS & Android SDKs:

 

Image Capture SDK
Input SDK
Onboarding SDK
Track SDK
Profile SDK
Billing SDK
Support SDK.

 

Platform: In conjunction with the Licensed SDKs, MyFiziq will also supply the following:

 

Cloud based Anthropometric measurement inference utilizing the following services:

 

o AWS (Amazon Web Services) Lambda
o AWS S3
o AWS Cognito
o AWS CloudFront
o AWS DynamoDB
o AWS API Gateway**

 

Refer to the Data Processing Agreement for specific MyFiziq cloud services architecture information.

 

Data Protection: MyFiziq data is encrypted ‘in Flight’ and ‘At Rest’ and incorporates the following data protection:

 

Data sent using TLS 1.2 (TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256)

 

Data securely stored in AWS S3 using SSE-S3 encryption (AES256)
Data Residency
Monitoring and Logging: AWS CloudWatch, Datadog (via managed service)
Identity and Access Control: AWS IAM, AWS Cognito.

 

Documentation: Documentation includes:

 

SDK Documentation

 

iOS SDK documentation
Android SDK documentation.

 

Support Documentation as set out in Schedule 1 – Support & Service Levels of the Support Agreement.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 13 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Commencement Date:   01/04/2019
     
Initial Term   24 Months.
     
Fees:   The Fees are: the BCT re-imbursement charges that include but are not limited to: office rent, AWS tenancy monthly fees, backend managed services monthly fees, utilisation of MyFiziq staff for day to day business, research and technical capabilities as per the rate card in Schedule 2 – Additional Fees.
     
Fees Currency:   All Fees will be charged in A$ Dollars.
     
Payment Terms:   Submission of Invoices:
     
    MyFiziq will generate an invoice on the first day of each month for the previous month’s Fees.
     
    Invoice Delivery Method:
     
    On the first day of each month, invoices will be sent electronically to the Licensee’s Representative’s email address.
     
    Invoice Due Date
     
    Invoices shall be paid within fourteen (14) calendar days of the invoice date.
     
    Accepted Payment Methods:
     
    Electronic Funds Transfer. The Licensee is to bear all bank charges related to payment.
     
    Payment Disputes:
     
    Licensee shall notify MyFiziq in writing of any payment dispute, include detailed information on the basis of the dispute, prior to the due date of any invoice. Failure to provide such notification prior to the due date of an invoice shall constitute a waiver by the Licensee of any such dispute. If MyFiziq engages an attorney to enforce this Commercial Contract, and a court rules in MyFiziq’s favour, the Licensee agrees to pay MyFiziq’s reasonable attorneys’ fees, court costs, expert fees, and other litigation expenses.
     
    Late Payment Notices:
     
    A late payment notice will be issued by MyFiziq to the Licensee’s Representative’s email address in the event an invoice is unpaid by the Invoice Due Date.
     
    The first late payment notice will be issued by MyFiziq to the Licensee’s Representative’s email address seven (7) days after the Invoice Due Date in the event an invoice is unpaid.
     
    The second late payment notice will be issued by MyFiziq to the Licensee’s Representative’s email address fourteen (14) days after the Invoice Due Date in the event an invoice is unpaid.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 14 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

    Demand Notice:
     
    A Demand notice is a final reminder letter that an invoice has not been paid by the Licensee prior to MyFiziq taking legal action. A Demand Notice will be issued by MyFiziq to the Licensee’s Representative’s email address fourteen (14) days after the second Late Payment Notice in the event the invoice has not been paid.
     
    Right to Payment.
     
    Licensee shall reimburse MyFiziq for all costs, including reasonable attorney’s fees, court costs, and other fees, in the event MyFiziq incurs same in an effort to enforce its rights, including its right to payment, under this Commercial Contract.

 

MyFiziq's Representative   COO | David Tabb | +61 422 052 805 | david@myfiziq.com
     
Licensee's   Martin Otway
Representative   P: +65 9199 9278
    E: martin@bodycompositiontech.com
    81 Anson Road / Suite 8.22 / Singapore 079908

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 15 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Schedule 2

 

Additional Fees

 

Professional Services

 

 

Staff Name   Role  

MYQ
Base Rate

    Charge
Factor
    BCT Charge Rate  
Terence   CTO   $ 134.77       2     $ 269.54  
Amar   CSO   $ 134.77       2     $ 269.54  
Dave   COO   $ 98.27       1.5     $ 147.40  
Ryan   CDO   $ 67.38       2     $ 134.77  
Steve   CFO   $ 84.23       1.5     $ 134.76  
Phil   Senior iOS Engineer   $ 78.62       2     $ 157.23  
Sean   iOS Engineer   $ 56.15       1.75     $ 98.27  
Amita   iOS Engineer   $ 47.73       1.75     $ 83.53  
Tim   QA   $ 49.13       2     $ 98.27  
Luke   Cloud Developer   $ 67.38       2     $ 134.77  
Adam   Senior Android Engineer   $ 73.00       2     $ 146.00  
Nigel   Android Engineer   $ 61.77       2     $ 123.54  
Sam   Android Engineer   $ 47.73       2     $ 95.46  
Victoria   Android Developer   $ 47.73       2     $ 95.46  
Neeraj   MLCV Engineer   $ 70.19       1     $ 70.19  

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 16 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Schedule 3

 

THIS COMMERCIAL CONTRACT is made the                 day of                20[xx]

 

 

BETWEEN

 

 

MYFIZIQ LIMITED (ABN 85 602 111 115) of Unit 5, 71-73 South Perth Esplanade, South Perth Western Australia 6151 (Licensor);

 

AND

 

[Insert Licensee Company Name] [ABN] of [Insert Licensee Company Address] (“Licensee”).

 

 

RECITALS

 

 

A. The Parties have entered into a Commercial Contract dated on or about [XX] [month] 2019 (Original Commercial Contract).

 

B. Clause 3 of the Original Commercial Contract provides for the Parties to enter into Additional Commercial Contracts.

 

C. The Licensor has agreed to licence the Licensed SDKs to the Licensee on the terms of this Agreement, which is an Additional Commercial Contract for the purposes of the Original Commercial Contract.

 

IT IS AGREED as follows:

 

(a) This Agreement is an Additional Commercial Contract for the purposes of the Original Commercial Contract.

 

(b) The terms and conditions of the Original Commercial Contract are incorporated into and apply to this Additional Commercial Contract with the necessary changes.

 

(c) The key terms of the Licence granted under this Additional Commercial Contract are as follows (which shall apply as the Licence Schedule for the purposes of this Additional Commercial Contract):

 

1. Licensee Products

 

[insert]

 

2. Licensed SDKs

 

[insert]

 

3. Platform

 

[insert]

 

4. Data Protection

 

[insert]

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 17 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

5. Documentation

 

[insert]

 

6. Commencement Date

 

[insert]

 

7. Initial Term

 

[insert]

 

8. Fees

 

[insert]

 

9. Fees Currency

 

[insert]

 

10. Payment Terms

 

[insert]

 

11. Monthly Subscriber Fees

 

[insert]

 

12. Additional Fees

 

[insert]

 

EXECUTED by the Parties as an agreement.

 

[Note: Signing blocks from final Commercial Contract to be inserted for each Additional Commercial Contract entered into. Signing blocks have been removed from this Schedule in the final Commercial Contract to avoid confusion.]

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 18 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Schedule 4

 

COMMERCIAL CONTRACT REFERENCE: BCT010XX

 

This BCT Software Development Kit End User License Agreement(“EULA”) is made and entered into, by and between Body Composition Technologies Pty Ltd Limited ABN 17 620 646 531of Unit 5, 71 - 73 South Perth Esplanade, South Perth Western Australia 6151 Australia (“BCT”) and [Insert Licensee Company Name] [ABN] of [Insert Licensee Company Address] (“Licensee”).

 

By downloading and/or using the BCT Software Development Kit and/or any update and/or upgrade to the BCT Software Development Kit (the “SDK”), the Licensee will be deemed to have wholly and unconditionally agreed to be legally bound by the terms and conditions of this EULA. If the Licensee does not wish to accept the following terms and conditions, the Licensee must not and cannot download and/or use the SDK for any purpose and must immediately delete the SDK from all Licensee computer systems and electronic devices.

 

TERMS AND CONDITIONS:

 

(Note: please see clause 12 for definitions and interpretation provisions)

 

2. Licence

 

2.1. The SDK comprises a set of software development tools that allows the creation of applications (“Applications”) incorporating BCT’s image capture, avatar creation and circumference measurement production processes. The software development tools include libraries (including a binary library), documentation, sample code (including Example-ObjC, which is provided as source code for the sake of providing an example integration of the SDK into an Application; and Example-Swift (which is the same as Example-ObjC, just a Swift code version)) and other materials supplied to the Licensee via BCT in connection with those software development tools (collectively, “BCT Licensed IP”). For the avoidance of doubt, the SDK includes the BCT Licensed IP.

 

2.2. BCT hereby grants to the Licensee a non-exclusive, non-assignable, non-sublicensable licence for the Term for the Licensee to use the SDK to create Applications incorporating BCT Licensed IP in accordance with the Documentation (the "Licence").

 

2.3. The Licensee must not use the SDK or any BCT Licensed IP in any way other than pursuant to the License, except with respect to any parts of the BCT Licensed IP that BCT may elect to release to the Licensee as open source software under the Apache 2.0 license. If BCT so elects to release to the Licensee any parts of the BCT Licensed IP as open source software under the Apache 2.0 license, the Licensee must only use those parts of the BCT Licensed IP pursuant to the Apache 2.0 license. The Licensee agrees and acknowledges that certain parts of the SDK comprise of Open Source Software and the Licensee’s use of those parts of the SDK is governed by the applicable Open Source Licenses. Those applicable Open Source Licenses and the components of the SDK that are governed by those Open Source Licenses are as follows:

 

AFNetworking - [MIT - https://github.com/AFNetworking/AFNetworking
GBDeviceInfo - [Apache 2.0] -
PureLayout - [MIT] - https://github.com/PureLayout/PureLayout/blob/master/LICENSE
AWS-SDK-IOS - [Apache 2.0] - https://github.com/aws/aws-sdk-ios
InterfaCSS - [MIT] - https://github.com/tolo/InterfaCSS

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 19 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

SHEmailValidator - [Apache 2.0] - https://github.com/spothero/SpotHeroEmailValidator-iOS
Lottie - [Apache 2.0] - https://github.com/airbnb/lottie-ios
JBChartView - [Apache 2.0] - https://github.com/Jawbone/JBChartView
JWT - [MIT] - https://github.com/yourkarma/JWT
OpenCV - [BSD] - https://github.com/opencv/opencv
Tiny-AES-c - [Unlicense] - https://github.com/kokke/tiny-AES-c
Jsoncpp - [MIT] - https://github.com/open-source-parsers/jsoncpp
RCP Dev_Tones - https://rcptones.com/dev_tones/#tab-id-13

 

3. Licence Restrictions

 

3.1. Subject to clause 2.3, if the Licensee has entered into a Commercial Contract with BCT, the Licensee must not use the SDK except pursuant to the Commercial Contract.

 

3.2. Subject to clause 2.3, the Licensee must not do or authorise the commission of any act that would or might invalidate or be inconsistent with BCT's Intellectual Property Rights in the SDK. Without limiting the foregoing provisions, the Licensee agrees and acknowledges that the Licensee must not and shall not, and will not permit any person to (unless expressly permitted under any provision of the Commercial Contract or this EULA):

 

(a) license, sublicense, resell, on-sell, assign, transfer, distribute, or provide others with access to, the SDK;

 

(b) "frame", "mirror" or serve any of the SDK on any web server or other computer server over the Internet or any other network; or

 

(c) copy, alter, modify, create derivative works from, reproduce, distribute, resell, transfer to a third party, reverse assemble, disassemble, reverse engineer, decompile, reverse compile or enhance the SDK (except as expressly permitted by the Copyright Act 1968 (Cth)).

 

3.3. The Licensee must not use the SDK in any way which is in breach of any statute, regulation, law or legal right of any person.

 

4. SDKs

 

4.1. SDK versions

 

(a) BCT follow’s the Semantic Versioning 2.0.0 scheme where a version number comprises of: MAJOR.MINOR.PATCH.

 

(b) MAJOR indicates the year, eg: `Version 19.x.x` is a version released in year 2019.

 

(c) MINOR either indicates the Long-Term Support (LTS) (guaranteed 12-month support) version if it equals 1, anything else is variably supported. Eg: `Version 19.1.x` is the LTS, and anything else `Version 19.0.x` or `Version 19.2.x` only has latest as supported.

 

(d) PATCH is for interface non-breaking bug fixes, so throughout the year LTS will have updates, eg: `Version 19.0.1`, etc...

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 20 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

4.2. SDK support

 

(a) BCT will support LTS versions for 12 months unless BCT deem an update is required. In the event an update is required the Licensee will be notified and provided a 6- month grace period to update to the new LTS SDK version (“SDK Support”).

 

4.3. SDK implementation audit

 

(a) Once Product Integration is complete of either initial Licensed SDKs or SDK version update(s), the Licensee agrees to allow BCT access to a pre-release version of the Licensee Products integrated with the Licensed SDKs, for the purpose of conducting an implementation audit (“SDK Implementation Audit”) as documented in Schedule 1 - SDK Implementation Audit Checklist.

 

(b) In the event BCT deems an SDK implementation audit is not required, the Licensee has the option to request a SDK implementation audit.

 

(c) From the date the Licensee notifies BCT that the Licensee Products integrated with the Licensed SDKs are ready for implementation audit, BCT has 5 Business Days to conduct the audit and provide an audit report.

 

(d) From the date that BCT submits the audit report to the Licensee, the Licensee has 10 Business Days to either challenge or rectify any SDK audit Non-Conformance’s prior to releasing the Licensee Products integrated with the Licensed SDKs to Licensee users.

 

5. Ownership of Intellectual Property

 

5.1. If BCT has entered into a Commercial Contract with the Licensee, the ownership of Intellectual Property connected with this Agreement is as set out in the Commercial Contract.

 

5.2. If BCT has not entered into a Commercial Contract with the Licensee, the ownership of Intellectual Property in connection with this Agreement will be dealt with in accordance with the following clauses:

 

(a) The Licensee agrees and acknowledges that this EULA does not transfer or assign any Intellectual Property Rights to the Licensee.

 

(b) As between the Licensee and BCT, BCT owns all Intellectual Property Rights in the SDK and the Documentation.

 

(c) Subject to clause 2.3, the Licensee has no rights in the SDK or the Documentation or in any modification or enhancement thereof, other than the rights granted to the Licensee pursuant to the Licence.

 

(d) The Licensee must not take any step to invalidate or prejudice BCT's Intellectual Property Rights in the SDK or the Documentation or otherwise. Without limiting the foregoing provisions, the Licensee must not register any security interest or purchase money security interest on the Personal Property Securities Register, or otherwise encumber or charge the Licensee’s rights in respect of the SDK or the Documentation or under any licence granted by BCT to the Licensee.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 21 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

6. Liability

 

6.1. Neither party is liable to the other party for any indirect, incidental, special or consequential loss or damage incurred by the other party, including liability for loss of profits, loss of business opportunity, loss of savings, or loss of data, even if the party has been advised of the possibility thereof.

 

6.2. To the maximum extent possible by law, we shall also have no liability for any direct loss or damage (i.e for any loss which falls under the first limb of Hadley v Baxendale (1854) 9 ex 341 being that which arises naturally, according to the usual course of things).

 

6.3. The SDK may come with implied non-excludable guarantees which are regulated by the Australian Consumer Law. The extent of the implied guarantees depend on whether the Licensee is a ‘consumer’ of goods or services within the meaning of that term pursuant to the Australian Consumer Law as amended. Where the Licensee is a ‘consumer’ for the purposes of the Australian Consumer Law, BCT is required to provide and shall be deemed to have provided the following mandatory statement to the Licensee: “Our goods come with guarantees that cannot be excluded under the Australian Consumer Law. The Licensee is entitled to a replacement or refund for a major failure and for compensation for any other reasonably foreseeable loss or damage. The Licensee is also entitled to have the goods repaired or replaced if the goods fail to be of acceptable quality and the failure does not amount to a major failure.”

 

6.4. If the SDK is supplied to the Licensee in the Licensee’s capacity as a 'consumer' within the meaning of that term in the Australian Consumer Law as amended the Licensee will have the benefit of certain non-excludable rights and remedies in respect of the SDK and nothing in this EULA excludes or restricts or modifies any condition, warranty, guarantee, right or remedy which pursuant to the Competition and Consumer Act 2010 (Cth) is so conferred. However, if the SDK is subject to a non-excludable condition, warranty, guarantee, right or remedy implied by the Australian Consumer Law and the SDK is not ordinarily acquired for personal, domestic or household use or consumption, then pursuant to s 64A of the Australian Consumer Law, BCT limits its liability for its breach of any such non-excludable warranty, guarantee, right or remedy implied by the Australian Consumer Law (other than a guarantee implied by sections 51, 52 or 53 of the Australian Consumer Law) or expressly given by BCT to the Licensee, in respect of the SDK, at BCT’s option, to one or more of the following:

 

(a) if the breach relates to goods:

 

(v) the replacement of the goods or the supply of equivalent goods;

 

(vi) the repair of such goods;

 

(vii) the payment of the cost of replacing the goods or of acquiring equivalent goods; or

 

(viii) the payment of the cost of having the goods repaired; and

 

(b) if the breach relates to services:

 

(iii) the supplying of the services again; or

 

(iv) the payment of the cost of having the services supplied again.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 22 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

6.5. If BCT elects to repair goods, the goods may be replaced by refurbished goods of the same type rather than being repaired. Refurbished parts may be used to repair goods. The Licensee acknowledges that where the goods are repaired and are capable of retaining user-generated data, it is possible that the repair of the goods may result in loss of data.

 

6.6. Any warranty against defects provided by BCT to the Licensee as a ‘consumer’ under the Australian Consumer Law is in addition to other of the Licensee’s rights and remedies under a law in relation to the goods or services to which the warranty relates.

 

6.7. Except with respect to any non-excludable warranty, guarantee, right or remedy that may be implied by the Australian Consumer Law into this EULA, all conditions, warranties and guarantees implied in this EULA are excluded, to the extent possible by law.

 

7. Indemnity

 

7.1. Each party must indemnify, defend and hold the other party and its affiliates, officers, directors, personnel, staff, suppliers, licensees, and other customers harmless from and against any and all liability, loss and costs, including reasonable attorneys' fees incurred by such parties, in connection with or arising out of:

 

(a) the first party’s violation of this EULA; and/or

 

(b) the first party’s breach of any applicable laws or regulations.

 

8. Confidentiality

 

8.1. Each party to this EULA agrees and acknowledges that it may receive confidential information of the other party during the Term of this EULA ("Confidential Information").

 

8.2. The Licensee agrees and acknowledges that the Documentation and the SDK constitutes and contains confidential and proprietary information of BCT.

 

8.3. Each party (the “first party”) agrees and acknowledges to take all prudent steps to ensure that the Confidential Information of the other party will be received and held by the first party in strict confidence and will not be disclosed by the first party, except:

 

(a) with the prior written consent of the other party;

 

(b) where disclosed to the employees or professional advisors of the first party on a confidential basis;

 

(c) as required by the rules of any stock exchange; or

 

(d) as required by a court of competent jurisdiction, and then, only to the extent required, and provided that the first party must promptly notify the other party of such requirement of disclosure and provide full particulars to the other party of the disclosure.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 23 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

8.4. Confidential Information does not include any information:

 

(a) that is independently developed, obtained or known by a party, without breaching any obligation of confidence to the other party; or

 

(b) that is in the public domain, except where due to a breach of this EULA or any breach of any obligation of confidence.

 

9. Term and Termination

 

9.1. If BCT has entered into a Commercial Contract with the Licensee, the Licensee and BCT each have the right to terminate this EULA pursuant to the Commercial Contract.

 

9.2. The Licensee and BCT each may terminate this EULA at any time without notice for any reason or no reason.

 

9.3. Irrespective of whether BCT has or has not entered into a Commercial Contract with the Licensee, BCT may terminate this EULA at any time without notice for the Licensee’s breach of this EULA if the Licensee fails to comply with any term or condition of this EULA at any time.

 

9.4. This EULA will automatically and immediately terminate upon expiry of the Term.

 

9.5. Upon termination, the Licensee must immediately uninstall and cease use of the SDK, and destroy all copies of it that are in the Licensee’s possession or control. Further, the Licensee must ensure that all copies of the SDK that the Licensee have provided to any person at any time are also uninstalled and no longer used at any time upon termination of this EULA.

 

9.6. Termination of this EULA does not affect any of the Licensee’s or BCT’s accrued rights.

 

10. Dispute Resolution

 

10.1. If BCT has entered into a Commercial Contract with the Licensee, any dispute in connection with this Agreement will be dealt with in accordance with the dispute resolution clauses as set out in the Commercial Contract.

 

10.2. If BCT has not entered into a Commercial Contract with the Licensee, any dispute in connection with this Agreement will be dealt with in accordance with the following dispute resolution clauses:

 

(a) If a dispute arises between the Licensee and BCT out of or relating to this EULA ("Dispute"), any party to the Dispute must seek to resolve it strictly in accordance with the provisions of this clause. Compliance with the provisions of this clause is a condition precedent to seeking relief in any court in respect of the Dispute, except as otherwise provided in this clause.

 

(b) A party seeking to resolve a Dispute must provide written notice of the existence and nature of the Dispute to the other party ("Notification"). Upon receipt of a Notification, each party must refer resolution of the Dispute to their chief executives (or nominees).

 

(c) If the Dispute has not been resolved within one (1) calendar month of the Notification, then each party will be entitled to pursue such course of action as it determines.

 

(d) Nothing in this clause shall limit either party's right to seek urgent interlocutory relief from any court of competent jurisdiction at any time.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 24 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

11. General

 

11.1. Amendment: The Licensee may not amend this EULA. BCT may amend this EULA at any time. Any such amendments will take effect 3 Business Days after BCT notifies the Licensee of them. If the Licensee is not satisfied with the amendments made by BCT to this EULA the Licensee the Licensee must terminate this EULA by written notice to BCT within 2 Business Days after the Licensee is notified of the amendments.

 

11.2. Assignment: The Licensee may not assign, transfer, license or novate the Licensee’s rights or obligations under this EULA without BCT’s prior written consent. BCT may assign or novate its rights or obligations at any time in connection with the sale or merger of BCT’s business, shares, Intellectual Property Rights or other assets.

 

11.3. Severability: If any provision of this EULA is deemed invalid by a court of competent jurisdiction, the remainder of this EULA shall remain enforceable.

 

11.4. Relationship: The Licensee and BCT are independent contracting entities and this EULA does not create any relationship of partnership, joint venture, or employer and employee or otherwise.

 

11.5. Australian Consumer Law: The exclusions and limitations of liability set out in this EULA shall apply to the fullest extent permissible at law, but the parties do not exclude or limit liability which may not be excluded or limited by law. Without limiting the foregoing provisions, BCT does not exclude liability under the Australian Consumer Law which is prohibited from being excluded. The parties acknowledge and agree that the limitations and exclusions of liability contained in this EULA constitute an allocation of risks that form part of the commercial terms of this EULA.

 

11.6. Entire agreement: This EULA (and the Commercial Contract, if any) constitutes the entire agreement between the parties and to the extent possible by law, supersedes all prior understandings, representations, arrangements and licences between the parties regarding its subject matter.

 

11.7. Jurisdiction: This EULA will be interpreted in accordance with the laws in force in Western Australia. The parties irrevocably submit to the non-exclusive jurisdiction of the courts situated in Western Australia.

 

12. Definitions and Interpretation

 

12.1. Definitions

 

In this EULA, the following words have the following meanings, unless expressly agreed in writing to the contrary by the Licensee and BCT:

 

Applications means as defined in clause 2.1.

 

Australian Consumer Law means schedule 2 to the Competition and Consumer Act 2010 (Cth).

 

Business Day means Monday – Friday excluding public holidays in Western Australia.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 25 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Business Hours means 9:00am – 5:00pm on Business Days.

 

Commencement Date means the date that the Licensee first uses, executes or accesses the SDK or if there is a Commercial Contract, the commencement date set out in that Commercial Contract.

 

Confidential Information means as defined in clause 0.

 

Documentation means any documents, user guides and/or explanatory materials supplied by BCT with or in connection to the SDK.

 

Force Majeure Event means war, strike, lockout, natural disaster, flood, earthquake, act of God, or other circumstances beyond the reasonable control of BCT.

 

Insolvency Event means: (a) where the party is an individual, that party commits an act of bankruptcy or is declared bankrupt or insolvent or that party's estate otherwise becomes liable to be dealt with under any law relating to bankruptcy or insolvency; or (b) where the party is a company, (b) the party ceases to (or is unable to) pay its creditors (or any class of them) in the ordinary course of business, (c) a receiver, receiver and manager, administrator, liquidator or similar officer is appointed to the party, (d) the party enters into, or resolves to, enter into, a scheme or arrangement, compromise or composition with any class of creditors; (e) a resolution is passed or an application to a court is taken for the winding up, dissolution or administration of the party, (f) any liquidator, receiver or manager enters into possession of any of the assets of the party, (g) the party applies for, consents to, or acquiesces in the appointment of a trustee or receiver, or (h) except to reconstruct or amalgamate while solvent on terms approved by the other party, the party enters into or resolves or proposes to enter into a scheme of arrangement, compromise or re-construction with any of its creditors or members.

 

Intellectual Property Rights means all copyright, trademark rights, patent rights, and design rights, whether registered or unregistered, and all other rights to intellectual property as defined under article 2 of the convention establishing the World Intellectual Property Organization, and all rights to enforce any of the foregoing rights.

 

Licence means as set out in clause 2.2.

 

Licensee Products means as set out in Schedule 1 of the Commercial Contract. Licensed SDKs means as specified in Schedule 1 of the Commercial Contract. BCT Licensed IP means as defined in clause 2.1.

Personal Property Securities Register means the Personal Property Securities Register established under the Personal Property Securities Act 2009 (Cth).

 

Product Integration means the integration of the Licensed SDKs into the Licensee Products, including all associated design, development, testing and implementation under a Commercial Contract between the parties.

 

Term means twelve (12) months from the Commencement Date, unless there is a Commercial Contract in place, in which case the Term shall be as defined in the Commercial Contract.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 26 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

12.2. Interpretation

 

In this EULA:

 

(a) Headings and underlining’s are for convenience only and do not affect the construction of this EULA.

 

(b) A provision of this EULA will not be interpreted against a party because the party prepared or was responsible for the preparation of the provision, or because the party's legal representative prepared the provision.

 

(c) Currency refers to Australian Dollars.

 

(d) A reference to a statute or regulation includes amendments thereto.

 

(e) A reference to a clause, subclause or paragraph is a reference to a clause, subclause or paragraph of this EULA.

 

(f) A reference to a subclause or paragraph is a reference to the subclause or paragraph in the clause in which the reference is made.

 

(g) The recitals are correct and form part of this EULA.

 

(h) A reference to time is to time in Western Australia.

 

(i) A reference to a person includes a reference to an individual, a partnership, a company, a joint venture, government body, government department, and any other legal entity.

 

(j) The words "includes", "including" and similar expressions are not words of limitation.

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

Page 27 of 28

  MYFIZIQ COMMERCIAL CONTRACT  

 

Schedule 1

 

SDK Implementation Audit Checklist

 

Auditor name: ___________________________________________________________

 

Licensee Company Name: ________________ Audit Date:_________________________

 

Licensed SDK(s) audited (include version numbering):

 

 

 

 

 

Within the implemented BCT Licensed SDKs there are no bugs or UX/UI blockers (eg all buttons work)
No offensive language
No unreadable text
New User - Able to create a new account
New User - Able to create first avatar
Returning user – Able to create second avatar
6 avatar accuracy test - minimum 97% average accuracy in comparison to ISAK physical measurements
6 avatar repeatability test – minimum 97% average repeatability test

 

Note: This checklist is to be used for initial Product Integration and, at the discretion of BCT may be used on any subsequent SDK version updates.

 

There were _____ Non-Conformance’s in this audit.

 

Description of Non-Conformance’s (write N/A if 0)

 

 

 

 

 

 

 

Comments (if applicable)

 

 

 

 

 

Auditor Signature: ________________________________________________________

 

Licensee Representative Name: ______________________________________________

 

Licensee Representative Signature: ___________________________________________

 

Unit 5, 71-73 South Perth Esplanade | South Perth | 6151 | Western Australia

ABN 85 602 111 115 | www.MyFiziq.com 

 

Page 28 of 28

 

 

Exhibit 10.23

 

MY FIZIQ LTD
ACN 602 111 115

(MyFiziq)

 

and

 

BODY COMPOSITION TECHNOLOGIES PTY LIMITED
ACN 620 646 531

(Company)

 

 

IP LICENCE AGREEMENT

 

 

 

 

THIS AGREEMENT is made the 22 day of September 2017

 

 

BETWEEN

 

 

MYFIZIQ LTD (ACN 602 111 115) of Suite 5, 71-73 South Perth Esplanade South Perth, Western Australia (MyFiziq);

 

AND

 

BODY COMPOSITION TECHNOLOGIES PTY LIMITED (ACN 620 646 531) of Suite 5, 71-73 South

Perth Esplanade, South Perth, Western Australia (Company).

 

 

RECITALS

 

 

A. MyFiziq is the owner of the MyFiziq IP.

 

B. MyFiziq agrees to grant the Company an exclusive licence to use and Exploit the MyFiziq IP, including using, reproducing and adapting the MyFiziq Materials, solely in the Company Field, and related matters, on the terms and conditions of this Agreement.

 

IT IS AGREED as follows:

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 Definitions

 

The following definitions apply in this Agreement.

 

Additional Licence Fee has the meaning given in the Shareholders’ Deed.

 

Authorisation means:

 

(a) an authorisation, consent, declaration, exemption, notarisation or waiver, however it is described; and

 

(b) in relation to anything that could be prohibited or restricted by law if a Government Agency acts in any way within a specified period, the expiry of that period without that action being taken,

 

including any renewal or amendment.

 

Business means the business of engaging in the Development Activities, and such other activities as the shareholders of The Company may from time to time determine.

 

Business Day means a day that is not a Saturday, Sunday or public holiday in Perth, Western Australia or Singapore.

 

Claim means any claim, action, proceeding, demand or cause of action (whether based in contract, tort or statute, or otherwise arising).

 

2

 

Company Field means the medical, insurance and medical research sectors. For the avoidance of doubt, a list of examples of companies that fall into each sector are provided in schedule 4 of the Shareholders’ Deed.

 

Company Improvements means all Intellectual Property created or developed by Company in respect of the MyFiziq Platform or based on or using any MyFiziq IP to the extent for use or Exploitation in the Company Field.

 

Company Improvement IP means all Intellectual Property Rights in and in relation to all Company Improvements.

 

Company Licence has the meaning given in clause 3.1.

 

Computer Data means computer-readable information or data stored in electronic form.

 

Computer Software means computer programs and all related manuals and documentation.

 

Condition mean the condition precedent set out in clause 2.1.

 

Confidential Information means the MyFiziq Platform, the MyFiziq Materials, the MyFiziq Know How, the terms of this Agreement and all other information disclosed by a Party to another Party under this Agreement or in negotiations in relation to the subject matter of this Agreement, other than information that the recipient can establish:

 

(a) is already in the public domain;

 

(b) is independently developed by the recipient; or

 

(c) is lawfully received by the recipient from another person having the unrestricted legal right to disclose that information without requiring the maintenance of confidentiality.

 

Consideration means the sum of the Initial Licence Fee and any Additional Licence Fee.

 

Development Activities means engaging in research and development activities with a view to commercialising the MyFiziq Platform in the Field, the initial phases of which are expected to be as follows:

 

(a) Phase 1: advance the MyFiziq Avatar technology, for the use in estimating trunk circumferences for comparison to a healthy trunk circumference benchmark. Using these circumference measures and additional anthropometric variables, predict whole body fat and trunk fat with regression;

 

(b) Phase 2: Estimate whole body fat, trunk fat and buttock/thigh fat using DXA scans and machine/deep learning; and

 

(c) Phase 3: Estimate whole body fat, trunk fat, buttock/thigh fat and visceral fat using iDXA scans and machine/deep learning.

 

3

 

All applications will be integrated into the MyFiziq Platform and are aimed at the global healthcare, insurance industries and medical research and will be white labelled as a separate application.

 

DXA means Dual-energy X-ray absorptiometry.

 

Effective Date means the date that is 5 Business Days after the satisfaction (or waiver) of the Conditions, or such other date agreed to by the Parties in writing.

 

Encumbrance means any royalty, mortgage, lien, charge, pledge, caveat, contract, assignment by way of security, security interest, title retention, preferential right or trust arrangement, Claim, covenant, profit à prendre, lease, pre-emptive right or any other right or interest of any third party or any agreement or arrangement having the same effect and Encumber has a corresponding meaning.

 

End Date has the meaning given in the Shareholders’ Deed.

 

Excluded Company Improvements and IP means Company Improvements and Company Improvements IP that comprise Intellectual Property and Intellectual Property Rights directly associated with DXA scans acquired by the Company and calculating segment fat and visceral fat percentages

 

Execution Date means the date the last of the Parties execute this Agreement.

 

Exploit means:

 

(a) in relation to a product – to make, sell, hire or otherwise dispose of the product, offer to make, sell, hire or otherwise dispose of it, use or import it, or keep it for the purpose of doing any of those things; and

 

(b) in relation to a method or process – to use the method or process or do any of the actions in paragraph (a) in respect of a product resulting from such use.

 

Force Majeure Event means any occurrence or omission as a direct or indirect result of which the Party relying on it is prevented from or delayed in performing any of its obligations (other than a payment obligation) under this Agreement and that is beyond the reasonable control of that Party including forces of nature, industrial action and action or inaction by a Government Agency.

 

Government Agency means:

 

(a) a government or government department or other body;

 

(b) a governmental, semi-governmental or judicial person; or

 

(c) a person (whether autonomous or not) who is charged with the administration of a law.

 

GST has the meaning given to it in the GST Act.

 

GST Act means the A New Tax System (Goods and Services Tax) Act 1999 and any regulations thereto or such other act or regulations of equivalent effect.

 

4

 

Insolvency Event means being in liquidation or provisional liquidation or under administration, having a controller or analogous person appointed to it or any of its property, being taken to have failed to comply with a statutory demand, being unable to pay its debts or otherwise insolvent, taking any step that could result in the person becoming an insolvent under administration, entering into a compromise or arrangement with, or assignment for the benefit of, any of its members or creditors, or any analogous event.

 

Intellectual Property means copyrights, trade and service marks, including the trademarks, trade names, rights in logos and get-up, inventions, confidential information, trade secrets and Know How, registered designs, design rights, patents, utility models, semi-conductor topographies, all rights of whatsoever nature in Computer Software and Computer Data, all rights of privacy and all intangible rights and privileges of a nature similar or allied to any of the foregoing, in every case in any part of the world and whether or not registered; and including all granted registrations and all applications for registration in respect of any of the same.

 

Intellectual Property Rights means any and all existing and future intellectual and industrial property rights throughout the world, including rights in relation to copyright, trade marks, designs, circuit layouts, business and domain names, trade secrets and other Intellectual Property (including the right to apply for registration of any such rights), and other results of intellectual activity in the industrial, commercial, scientific, literary or artistic fields.

 

Know How means scientific, technical and other information which is not in the public domain including inventions, discoveries, concepts, data, ideas, specifications, procedures for experiments and tests and results of experiments, experimentation and testing, results of research and development and information in laboratory records, case reports, data analyses and summaries and submissions to and information from Government Agencies.

 

MyFiziq Field means everything outside of the COMPANY Field and includes, without limitation, the fitness, sports, fitness research, the non-medical weight loss/weight gain and non-medical health sectors.

 

MyFiziq IP means all Intellectual Property Rights in and in relation to MyFiziq Platform, the MyFiziq Materials and the MyFiziq Know How, including any modifications and improvements, owned by MyFiziq now and in the future.

 

MyFiziq Know How means Know How in relation to the MyFiziq Platform.

 

MyFiziq Licence has the meaning given in clause 4.2(b).

 

MyFiziq Materials means:

 

(a) all technical documentation and research records (whether in written form or stored in electronic form); and

 

(b) all computer software and technical data and other physical things,

 

which comprise, contain or embody the MyFiziq Platform.

 

5

 

MyFiziq Platform means the fitness tracking software platform which provides users with a simple means of tracking circumference change via an application on their smartphone.

 

Party means a party to this Agreement and Parties means all of them.

 

Shareholders’ Deed means a shareholders’ deed between MyFiziq and the remaining shareholders in the Company dated on or around the date of this Agreement.

 

Term means from the date of satisfaction of the Condition until this Agreement is validly terminated in accordance with its terms.

 

Territory means the World.

 

The Group has the meaning given in the Shareholders’ Deed.

 

1.2 Interpretation

 

In this Agreement unless the context otherwise requires:

 

(a) headings are for convenience only and do not affect its interpretation;

 

(b) an obligation or liability assumed by, or a right conferred on, 2 or more Parties binds or benefits all of them jointly and each of them severally;

 

(c) the expression person includes an individual, the estate of an individual, a corporation, an authority, an association or joint venture (whether incorporated or unincorporated), a partnership and a trust;

 

(d) a reference to any party includes that party’s executors, administrators, successors and permitted assigns, including any person taking by way of novation;

 

(e) a reference to any document (including this Agreement) is to that document as varied, novated, ratified or replaced from time to time;

 

(f) a reference to any statute or to any statutory provision includes any statutory modification or re-enactment of it or any statutory provision substituted for it, and all ordinances, by-laws, regulations, rules and statutory instruments (however described) issued under it;

 

(g) words importing the singular include the plural (and vice versa) and words indicating a gender include every other gender;

 

(h) reference to parties, clauses, schedules, exhibits or annexures are references to parties, clauses, schedules, exhibits and annexures to or of this Agreement and a reference to this Agreement includes any schedule, exhibit or annexure to this Agreement;

 

(i) where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning; and

 

(j) a reference to $ or dollar is to Australian currency.

 

6

 

2. CONDITION PRECEDENT

 

2.1 Condition

 

Clause 3 of this Agreement is subject to and conditional upon the Shareholders Deed becoming unconditional.

 

2.2 Benefit of MyFiziq

 

The Condition is inserted in this Agreement for the benefit of MyFiziq and MyFiziq may, by notice in writing to the Company on or before the End Date, waive the Condition or grant an extension of time for satisfaction of the Condition.

 

2.3 Satisfaction or waiver of Conditions

 

Subject to clause 2.2, if the Condition is not satisfied, or waived by MyFiziq, in accordance with the provisions of this Agreement on or before the End Date, either Party may terminate this Agreement by written notice to the other Party.

 

3. LICENCE

 

3.1 Grant of Company Licence

 

On and from the Effective Date and for the Term, for the Consideration and on the terms and conditions contained in this Agreement, MyFiziq grants to the Company an exclusive, royalty-free, perpetual licence of the MyFiziq IP, including a licence to use, reproduce and adapt the MyFiziq Materials, solely for use in the Company Field in the Territory (Company Licence).

 

3.2 Consideration

 

(a) On the Effective Date, The Company must pay MyFiziq A$350,000, in cleared funds to a bank account nominated by MyFiziq.

 

(b) The Company must pay MyFiziq an additional A$1,150,000, in cleared funds to a bank account nominated by MyFiziq. The Company will pay the additional A$1,150,000 within 60 Business Days from the Effective Date.

 

(c) In the event the Company does not pay this amount within 60 Business Days, the Company may request an extension to the terms of this payment which will not be unreasonably withheld by MyFiziq.

 

(d) The Company must pay MyFiziq the Additional Licence Fee in accordance with the Shareholders’ Deed.

 

3.3 Sub-licensing

 

The Company can only grant sub-licenses of the Company Licence with the prior written consent of MyFiziq, which may not be unreasonably withheld by MyFiziq.

 

7

  

4. INTELLECTUAL PROPERTY RIGHTS

 

4.1 Acknowledgment

 

The Parties acknowledges that:

 

(a) all Intellectual Property owned by, or proprietary to, a Party as at the Execution Date will at all times remain owned by that Party exclusively;

 

(b) other than as expressly set out in this Agreement, nothing in this Agreement confers on a Party any right or interest in, or licence to use (or permit or cause to be used) any of the other Party’s, or any third party’s, Intellectual Property; and

 

(c) other than as expressly set out in this Agreement, MyFiziq is exclusively entitled to ownership of all Intellectual Property and Intellectual Property Rights arising from, or in relation to, any modifications or improvements to the MyFiziq Platform.

 

4.2 Company Improvements and Company Improvements IP

 

The Parties acknowledge and agree that:

 

(a) all Company Improvements and all Company Improvement IP are legally and beneficially owned by The Company, including ownership of, and the right to licence solely within the Company Field;

 

(i) any new or unique algorithms developed by The Company;

 

(ii) patents applied for by The Company;

 

(iii) all data collected or acquired by The Company; and

 

(iv) all data derived from data collected or acquired by The Company;

 

(b) The Company grants MyFiziq a royalty free, perpetual, exclusive licence in the Territory to use and Exploit all Company Improvements and all Company Improvement IP (excluding the Excluded Company Improvements and IP) outside the Field (MyFiziq Licence);

 

(c) The Company has the exclusive right to use and Exploit all Excluded Company Improvements and IP outside the MyFiziq Field; and

 

(d) in the event The Company wishes to Exploit the Excluded Company Improvements and IP within the MyFiziq Field, it may only do so in conjunction with MyFiziq, based on a commercial arm’s length licensing arrangement to be negotiated with MyFiziq.

 

4.3 Notification

 

Each Party must notify the other as soon as practicable upon becoming aware of:

 

(a) any actual or apparent infringement by any person of MyFiziq IP or Company Improvements IP; or

 

(b) any assertion or claim by any person that the Exploitation of MyFiziq IP or Company Improvements IP infringes the Intellectual Property Rights of a third person (Third Party Claim).

 

8

 

4.4 Conduct of proceedings

 

(a) A Party that owns Intellectual Property Rights the subject of this Agreement (IP Owner) may, but is not obliged to, take sole conduct at its cost of any claim, demand or proceedings, including negotiations for settlement or compromise before or after the commencement of legal proceedings:

 

(i) against a person for infringement of the IP Owner’s Intellectual Property Rights (Infringement Claim); or

 

(ii) in defence of any Third Party Claim in respect of the IP Owner’s Intellectual Property Rights.

 

(b) If an IP Owner exercises its right under clause 4.4(a), then:

 

(i) the other Party must at its cost join any relevant proceedings in the manner directed by the IP Owner; and

 

(ii) the other Party must at its cost provide the IP Owner with all reasonable assistance in relation to the proceedings; and

 

(iii) if an amount is awarded or paid to the IP Owner in settlement of any Infringement Claim or Third Party Claim (including any damages, account of profits or costs awarded in any proceedings) (Award), then:

 

(A) the IP Owner must reimburse the other Party from the amount of the Award, the costs reasonably incurred by the other Party in assisting the IP Owner pursuant to paragraph (ii); and

 

(B) the IP Owner shall be entitled to retain the balance of the Award, if any.

 

5. CONFIDENTIAL INFORMATION

 

5.1 Obligation of confidentiality

 

Subject to clause 5.2:

 

(a) each Party must keep the Confidential Information of the other Party confidential;

 

(b) except as expressly envisaged by this Agreement, each Party must not use the other Party's Confidential Information other than for the purpose of exercising its rights and performing its obligations under this Agreement; and

 

(c) each Party must use at least the same degree of care to avoid disclosure of the other Party's Confidential Information as it uses to protect its own Confidential Information.

 

9

 

5.2 Right to disclose

 

A Party may disclose the Confidential Information of another Party (other than any trade secret):

 

(a) to its officers, employees, professional advisers or agents, its related bodies corporate, and the officers, employees or agents of a related body corporate who have a need to know the Confidential Information; or

 

(b) to the extent required by law, or under the rules of any stock exchange, so long as the Party gives the other Party reasonable advance notice and opportunity to object to the requirement to disclose such information or obtain an appropriate order to protect its Confidential Information.

 

5.3 Public domain

 

No piece or body of information shall be deemed to be in the public domain merely because it contains information which is in the public domain or is embraced by a general disclosure which is in the public domain.

 

6. REPRESENTATIONS AND WARRANTIES

 

6.1 Warranties by each Party

 

On the Execution Date, each Party represents and warrants to the other Party that:

 

(a) (power) it has full legal capacity and power to:

 

(i) own its property and to carry on its business; and

 

(ii) enter into this Agreement and to carry out the transactions that this Agreement contemplates;

 

(b) (corporate authority) it has taken all corporate action that is necessary or desirable to authorise its entry into this Agreement and its carrying out the transactions that this Agreement contemplates;

 

(c) (Authorisations) it holds each Authorisation that is necessary or desirable to:

 

(i) enable it to properly execute this Agreement and to carry out the transactions that this Agreement contemplates;

 

(ii) ensure that this Agreement is legal, valid, binding and admissible in evidence; or

 

(iii) enable it to properly carry on its business, and it is complying with any conditions to which any of these Authorisations is subject;

 

10

 

(d) (documents effective) this Agreement constitutes its legal, valid and binding obligations, enforceable against it in accordance with its terms (except to the extent limited by equitable principles and laws affecting creditors’ rights generally), subject to any necessary stamping or registration; and

 

(e) (no contravention) neither its execution of this Agreement nor the carrying out by it of the transactions that this Agreement contemplates, does or will:

 

(i) contravene any law to which it or any of its property is subject or any order of any Government Agency that is binding on it or any of its property;

 

(ii) contravene any undertaking or instrument binding on it or any of its property;

 

(iii) contravene its constitution; or

 

(iv) require it to make any payment or delivery in respect of any financial indebtedness before it would otherwise be obliged to do so.

 

6.2 Additional representations and warranties by MyFiziq

 

On the Execution Date, MyFiziq represents and warrants that:

 

(a) (no Encumbrance) there is no Encumbrance over any of the MyFiziq IP;

 

(b) (ownership) to the best of its knowledge it owns all right, title and interest in and in relation to the MyFiziq IP;

 

(c) (right to licence) it has the right to grant the licence granted in clause 3;

 

(d) (no dealings) it has not granted a licence under the MyFiziq IP and has not assigned or in any way disposed of or otherwise encumbered any right, title or interest in or to any of the MyFiziq IP, and is not aware that any other person has done so;

 

(e) (right to practice) to the best of its knowledge the Exploitation of the MyFiziq Platform does not infringe, nor is it alleged to infringe, any Intellectual Property Rights of any third person; and

 

(f) (no infringement) to the best of its knowledge, there has not been:

 

(i) any infringement of any of the MyFiziq IP; or

 

(ii) any misuse or unauthorised disclosure of Confidential Information in the MyFiziq IP, the MyFiziq Know How or the MyFiziq Materials; or

 

11

 

(iii) any other act which may affect the ability to protect the Confidential Information in the MyFiziq IP, the MyFiziq Know How or the MyFiziq Materials.

 

6.3 Repetition of representations and warranties

 

The representations and warranties in this clause 6 are taken to be repeated on the Effective Date, on the basis of the facts and circumstances as at that date.

 

6.4 Reliance on representations and warranties

 

Each Party acknowledges that the other Party has executed this Agreement and agreed to take part in the transactions that this Agreement contemplates in reliance on the representations and warranties that are made or repeated in this Agreement.

 

7. FORCE MAJEURE

 

7.1 Notice and suspension of obligations

 

If a Party to this Agreement is affected, or likely to be affected, by a Force Majeure Event:

 

(a) that Party shall immediately give the other prompt notice of that fact including:

 

(i) full particulars of the Force Majeure Event;

 

(ii) an estimate of its likely duration;

 

(iii) the obligations affected by it and the extent of its effect on those obligations; and

 

(iv) the steps taken to rectify it; and

 

(b) the obligations under this Agreement of the Party giving the notice are suspended to the extent to which they are affected by the relevant Force Majeure Event as long as the Force Majeure Event continues.

 

7.2 Effort to overcome

 

A Party claiming a Force Majeure Event shall use its best endeavours to remove, overcome or minimise the effects of that Force Majeure Event as quickly as possible. However, this does not require a Party to settle any industrial dispute in any way it does not want to.

 

8. DISPUTES

 

8.1 Dispute resolution

 

If a dispute arises out of or in relation to this Agreement (including any dispute as to breach or termination of this Agreement or as to any claim in tort, in equity or pursuant to any statute) (Dispute), a Party may not commence any court or arbitration proceedings relating to the Dispute unless it has complied with this clause 8, except if the Party seeks urgent interlocutory relief.

 

12

 

8.2 Dispute Notice

 

A Party claiming that a Dispute has arisen must give written notice to the other Party specifying the nature of the Dispute (Dispute Notice).

 

8.3 Negotiation

 

Upon receipt of a Dispute Notice, the parties must procure that representatives of The Company and MyFiziq meet to endeavour to resolve the Dispute expeditiously by negotiation.

 

8.4 Resolution of Disputes

 

If the parties have not resolved the Dispute under clause 8.3 within 14 days of receipt of a Dispute Notice, the parties shall endeavour to resolve the Dispute expeditiously using informal dispute resolution techniques such as mediation, expert evaluation or determination or similar techniques agreed by the parties.

 

8.5 Mediation

 

If the parties do not agree within 30 days of receipt of a Dispute Notice (or such further period as the parties agree in writing) as to:

 

(a) the dispute resolution technique and procedures to be adopted;

 

(b) the timetable for all steps in those procedures; and

 

(c) the selection and compensation of the independent person required for such technique,

 

the parties shall mediate the Dispute in accordance with the Mediation Rules of the Law Society of Western Australia, and the President of the Law Society of Western Australia (or the President's nominee) will select the mediator and determine the mediator's remuneration.

 

9. TERM AND TERMINATION

 

9.1 Termination by a Party

 

A Party may, by giving notice to the other Party in writing, terminate this Agreement with immediate effect if:

 

(a) the other Party commits a breach of its material obligations under this Agreement and fails to remedy that breach within 20 Business Days of receiving written notice from the other Party of the breach requesting that the breach be remedied; or

 

(b) an Insolvency Event occurs in relation to the other Party.

 

9.2 Escrow Deed

 

As soon as practicable after the date of this Agreement, the Parties agree to:

 

(a) enter into an escrow deed, on standard commercial terms, pursuant which the source code for the MyFiziq Platform (Source Code) will be held in escrow by an escrow agent (the Escrow Agent) on terms that ensure that the Company can continue to have access to the Source Code in the event that an Insolvency Event occurs in relation to MyFiziq; and

 

(b) appoint a mutually agreed independent Escrow Agent to hold the Source Code.

 

13

 

9.3 Survival

 

(a) Termination or expiry of this Agreement does not affect any rights and obligations of the parties that may have accrued before the effective date of termination or expiry.

 

(b) Clauses 1, 5, 8 and 9 survive termination or expiry of this Agreement.

 

10. GST

 

10.1 Definitions

 

Words defined in A New Tax System (Goods and Services Tax) Act 1999 (Cth) have the same meaning in this clause 10.

 

10.2 Payment of GST

 

If a Party makes a supply to another Party under or in connection with this Agreement, then (unless the consideration is expressly stated to be inclusive of GST) the consideration for that supply is exclusive of GST, and in addition to paying or providing that consideration the recipient must:

 

(a) pay to the supplier an amount equal to any GST for which the supplier is liable on that supply, without deduction or set-off of any other amount; and

 

(b) make that payment as and when the consideration or part of it must be paid or provided, except that the recipient need not pay unless the supplier has issued to the recipient a tax invoice (or an adjustment note) for that supply.

 

10.3 Refunds and claims

 

(a) The supplier must refund to the recipient any overpayment by the recipient for GST.

 

(b) If a Party provides a payment for or any satisfaction of a claim or a right to claim under or in connection with this Agreement that gives rise to a liability for GST, the provider must pay, and indemnify the recipient on demand against, the amount of that GST.

 

(c) If a Party has a claim under or in connection with this Agreement for a cost on which that Party must pay an amount for GST, the claim is for the cost plus the amount for GST (except any amount for GST for which that Party is entitled to an input tax credit).

 

14

 

11. NOTICES

 

11.1 Requirements for Notice

 

Each notice authorised or required to be given to a Party shall be in writing and may be delivered personally or sent by properly addressed and prepaid mail or facsimile in each case addressed to the Party at its address set out in clause 11.2, or as the case may be to such other address as it may from time to time notify to the other parties pursuant to clause 11.3.

 

11.2 Address of parties

 

The initial address of the parties shall be as follows:

 

In the case of The Company:

 

Suite 5, 71-73 South Perth Esplanade

South Perth WA 6151

Email: cyril.donnelly@uwa.edu.au

Attention: Cyril Jon Donnelly

 

In the case of MyFiziq:

 

Suite 5, 71-73 South Perth Esplanade

South Perth WA 6151

Email: vlado@myfiziq.com

Attention: Vlado Bosanac

 

11.3 Change of Address

 

Each Party may from time to time change its address by giving notice pursuant to clause 11.1 to the other parties.

 

11.4 Receipt of Notice

 

Any notice given pursuant to clause 11.1 will be conclusively deemed to have been received:

 

(a) in the case of personal delivery, on the actual day of delivery if delivered prior to 5 pm (Perth time) on a Business Day or on the next following Business Day if delivered after 5 pm (Perth time) on a Business Day or on a day other than a Business Day;

 

(b) if sent by mail, on the second clear Business Day after the day of posting; or

 

(c) if sent by facsimile, on the day the facsimile was sent by clear transmission.

 

12. FURTHER ASSURANCE

 

Each Party shall sign, execute and do all deeds, acts, documents and things as may reasonably be required by the other Party to effectively carry out and give effect to the terms and intentions of this Agreement.

 

15

 

13. GOVERNING LAW

 

This Agreement shall be governed by and construed in accordance with the law from time to time in the State of Western Australia and the parties agree to submit to the non-exclusive jurisdiction of the courts of Western Australia and the courts which hear appeals therefrom.

 

14. VARIATION

 

No modification or alteration of the terms of this Agreement shall be binding unless made in writing dated subsequent to the date of this Agreement and duly executed by the parties.

 

15. COSTS

 

15.1 Stamp Duty

 

All stamp duty (if any) assessed on or in respect of this Agreement shall be paid by The Company.

 

15.2 Legal Costs

 

Each Party shall bear their own legal costs of and incidental to the preparation, negotiation and execution of this Agreement.

 

16. MISCELLANEOUS

 

16.1 Severance

 

If any provision of this Agreement is invalid and not enforceable in accordance with its terms, all other provisions which are self-sustaining and capable of separate enforcement without regard to the invalid provision, shall be and continue to be valid and forceful in accordance with their terms.

 

16.2 Assignment

 

No Party may assign or transfer its rights or interests under this Agreement, the Company Licence or the MyFiziq Licence other than with the prior written consent of the other Party, such consent not to be unreasonably withheld.

 

16.3 Entire Agreement

 

This Agreement shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other agreements with respect thereto.

 

16.4 Counterparts

 

This Agreement may be executed in any number of counterparts (including by way of facsimile) each of which shall be deemed for all purposes to be an original and all such counterparts taken together shall be deemed to constitute one and the same instrument.

 

16.5 Time

 

Time shall be of the essence in this Agreement in all respects.

 

16

 

EXECUTED by the Parties as an Agreement.

 

EXECUTED BY )
MYFIZIQ LTD )
Australian Company Number 602 111 115 )
in accordance with its constituent )
documents and place of formation: )

 

 
Director – Vlado Bosanac  
   
 
Company Secretary – Kevin Hart  

 

EXECUTED BY )
BODY COMPOSITION TECHNOLOGIES PTY )
LIMITED )
Australian Company Number 620 646 531 )
in accordance with its constituent )
documents and place of formation:  

 

 
Director  
   
 
Director/Director & Company Secretary  

 

 

17

 

 

Exhibit 10.24

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

Exhibit 10.25

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 10.26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 10.27

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit 10.28

 

US$500,000 Issue Date: January 20, 2021

 

New York, New York

 

PROMISSORY NOTE

 

FOR VALUE RECEIVED, the undersigned, BEARN, LLC, a limited liability company organized and existing under the laws of the State of Maryland (the “Borrower”), hereby promises to pay to the order of MYFIZIQ LIMITED, a company organized under the laws of Australia (the “Lender” and collectively with the Borrower, the “Parties”) on the Termination Date (as defined below), the unpaid principal amount of the loan (the “Loan”) made by the Lender to the Borrower, as evidenced hereby, in the principal amount of Five Hundred Thousand United States Dollars (US$500,000). The Borrower hereby promises to pay interest on the unpaid principal amount of the Loan on the dates and at the rate provided for herein. The principal amount shall be advanced in multiple tranches pursuant to the terms and conditions herein provided. The principal amount of the initial tranche to be advanced on the date hereof shall equal Two Hundred Thousand United States Dollars (US$200,000).

 

Section 1. Certain Terms Defined. The following terms for all purposes of this Promissory Note shall have the respective meanings specified below.

 

Bearn App” means downloadable application software designed to run on mobile platforms including Android and iOS operating systems and which, inter alia, in combination with a fitness tracker, captures, processes, stores and transmits biometric data.

 

Business Day” means any day except a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized by law to close.

 

Default” means any event which, with the giving of notice, lapse of time, determination of materiality or fulfillment of any other applicable condition (or any combination of the foregoing), would constitute an Event of Default.

 

Event of Default” has the meaning given to it in Section 9.

 

Funding Completion Date” means the date that is three (3) months from the Issue Date of this Note.

 

GAAP” means generally accepted accounting principles in the United States, in effect from time to time, consistently applied.

 

Material Adverse Effect” means a material adverse effect on (a) the business, operations, prospects, condition (financial or otherwise) or property of the Borrower, (b) the validity or enforceability of any provision of any Transaction Document, (c) the ability of any party to any Transaction Document to timely perform its obligations thereunder, or (d) the rights and remedies of the Lender under any Transaction Document.

 

 

 

 

Obligations” means all of the liabilities and obligations (primary, secondary, direct, contingent, sole, joint or several) due or to become due, or that are now or may be hereafter contracted or acquired, or owing to, of the Borrower to the Lender, including, without limitation, all obligations under this Promissory Note and any other instruments, agreements or other documents executed and/or delivered in connection herewith or therewith, in each case, whether now or hereafter existing, voluntary or involuntary, direct or indirect, absolute or contingent, liquidated or unliquidated, whether or not jointly owed with others, and whether or not from time to time decreased or extinguished and later increased, created or incurred, and all or any portion of such obligations or liabilities that are paid, to the extent all or any part of such payment is avoided or recovered directly or indirectly from the Lender as a preference, fraudulent transfer or otherwise as such obligations may be amended, supplemented, converted, extended or modified from time to time. Without limiting the generality of the foregoing, the term “Obligations” shall include, without limitation: (i) principal of, and interest on the loans; (ii) any and all other fees, indemnities, costs, obligations and liabilities of the Borrower from time to time under or in connection with this Promissory Note and any other instruments, agreements or other documents executed and/or delivered in connection herewith or therewith and (iii) all amounts (including but not limited to post petition interest) in respect of the foregoing that would be payable but for the fact that the obligations to pay such amounts are unenforceable or not allowable due to the existence of a bankruptcy, reorganization or similar proceeding involving the Borrower.

 

Permitted Liens” means liens in favor of the Lender, statutory liens created by operation of applicable law, liens arising in the ordinary course of business and securing obligations that are not overdue or are being contested in good faith by appropriate proceedings, or liens for taxes not yet due and payable or that are being contested in good faith by appropriate proceedings, provided that adequate reserves with respect thereto are maintained on the books of the Borrower in accordance with GAAP.

 

Person” means and includes any natural person, individual, partnership, joint venture, corporation, trust, limited liability company, limited company, joint stock company, unincorporated organization, government entity or any political subdivision or agency thereof, or any other entity.

 

Pledge and Escrow Agreement” means the Pledge And Escrow Agreement dated of even date herewith made by the Pledgor, in favor of the Lender.

 

Pledgor” means Aaron Drew.

 

Security Agreement” means the Security Agreement dated of even date herewith made by the Borrower, in favor of the Lender.

 

Software” shall mean software developed by the Borrower, including the Bearn App and related back end operating software used in connection with the operation of the Borrower’s business, including, but not limited to IOS and Android downloadable mobile applications for, inter alia, the measurement of calories burned by a user.

 

  2  

 

 

“Termination Date” means the maturity date as defined in Section 2.

 

“Transaction Documents” means this Promissory Note, the Security Agreement, and any Pledge and/or Escrow Agreement.

 

Unique Users” and “Unique Monthly Users” means any person who establishes an account with Bearn having an identification reference, email address or username, a Unique Monthly User is a Unique User that engages the MyFizIq Technology through the Bearn Application in a given month.

 

Section 2. Advances. The Lender may make principal advances to the Borrower, as follows: (i) Two Hundred Thousand United States Dollars (US$200,000) shall be advanced promptly following the execution of this Note and (ii) Three Hundred Thousand United States Dollars (US$300,000) (the Subsequent Advances”) may be advanced in three equal installments of One Hundred Thousand United States Dollars (US$100,000) each on those dates which are thirty (30) calendar days following the Issue Date, sixty (60) calendar days following the Issue Date, and ninety (90) calendar days following the Issue Date. Notwithstanding the foregoing, in the event that the Lender does not fund the Subsequent Advances, the Unique Users target shall be reduced from 1,000,000 Unique Users on a proportional basis. The initial $200,000 principal advance shall result in a Unique Users requirement of 400,000, and each additional $100,000 Subsequent Advance tranche funded shall result in an additional 200,000 Unique Users requirement (the “Unique Users Requirement Reduction”).

 

Section 3. Maturity Of the Loan. The Loan shall mature, and the principal amount thereof shall be due and payable (together with accrued but unpaid interest thereon), on the occurrence of any of the following (collectively, the “Maturity Date”): (i) if the Borrower does not increase its number of Unique Users to one million (1,000,000) or more unique monthly users using the MyFiziq Technology, subject to the Unique Users Requirement Reduction, in the first twelve (12) months immediately following the Funding Completion Date, the principal amount outstanding (together with accrued but unpaid interest thereon), shall be due and payable on the date that is twelve (12) months following the Funding Completion Date; (ii) if the Borrower successfully increases its number of Unique Users to one million (1,000,000) unique monthly users using the MyFiziq Technology, subject to the Unique Users Requirement Reduction, in the first twelve (12) months after the Funding Completion Date, the principal amount (together with accrued but unpaid interest thereon), shall be due and payable on the date that is twenty-four (24) months after the Funding Completion Date, subject to Section 11 herein.

 

Notwithstanding the foregoing, the Loan shall mature, and the principal amount thereof shall be due and payable (together with accrued but unpaid interest thereon), on the earlier of: (i) the date on which the Borrower completes a capital raise in an amount that exceeds $2,000,000 in a single transaction; or (ii) March 20, 2022.

 

  3  

 

 

In the event that the Borrower completes one or more capital raises of less than $2,000,000, the Borrower shall, upon each such capital raise, repay a pro rata amount of the Loan (plus accrued but unpaid Interest) equal to the percentage: (A) the amount of the capital raise divided by (B) $2,000,000. For the avoidance of doubt and by way of example, in the event that the Borrower raises $1,000,000, then 50% of the Loan and accrued but unpaid Interest is repayable on completion of the capital raise.

 

Section 4. Interest Payments. The unpaid principal amount of the Loan shall bear interest at the following interest rates per annum (the “Interest Rate”):

 

(i) During the period beginning on the Issue Date and ending on the date which is 12 months from the Funding Completion Date, interest shall accrue at a rate of eight percent (8%) per annum;

 

(ii) During the period from (but not including) the date which is 12 months after the Funding Completion Date until the Maturity Date, following such date interest shall accrue pursuant to the following:

 

(A) In the event that the Borrower achieved less than five hundred thousand (500,000) unique monthly active users using the MyFiziq platform, subject to the Unique Users Requirement Reduction, by such date, interest shall accrue at a rate of fifteen percent (15%) per annum;

 

(B) In the event that the Borrower achieved five hundred thousand (500,000) or more unique month active users but less than seven hundred fifty thousand (750,000) unique monthly active users using the MyFiziq Technology, subject to the Unique Users Requirement Reduction, by such date, interest shall accrue at a rate of twelve percent (12%) per annum;

 

(C) In the event that the Borrower achieved seven hundred fifty thousand (750,000) or more unique monthly active users but less than one million (1,000,000) unique monthly active users using the MyFiziq Technology, subject to the Unique Users Requirement Reduction, by such date, interest shall accrue at a rate of ten percent (10%) per annum; and

 

(D) In the event that the Borrower achieved one million (1,000,000) unique monthly active users or more using the MyFiziq Technology, subject to the Unique Users Requirement Reduction, by such date, the interest rate shall be zero percent (0%).

 

One month of interest shall be due and payable on the twelve (12) month anniversary of the Issue Date and shall continue monthly thereafter. Interest which is outstanding as of the Maturity Date shall be paid in full on the Maturity Date.

 

Notwithstanding the foregoing, following an Event of Default, any balance outstanding on the Loan shall bear interest, payable on demand, for each day until paid at a rate per annum equal to the lesser of (i) the maximum interest rate permitted by applicable law and (ii) eighteen percent (18%) (the “Default Rate”).

 

  4  

 

 

Interest shall be computed on the basis of a year of 360 days and paid for the actual number of days elapsed (including the first day but excluding the last day).

 

Section 5. Optional Prepayments. The Borrower may prepay the Loan in whole or in part at any time prior to the Maturity Date without penalty by paying the principal amount to be prepaid together with interest accrued thereon and any other amount which may be outstanding to the date of prepayment.

 

Section 6. General Provisions As To Payments. All payments of principal of and interest on the Loan by the Borrower hereunder shall be made not later than 12:00 Noon (New York City time) on the date when due by cashier’s check or by wire transfer of immediately available funds to the Lender’s account at a bank specified by the Lender in writing to the Borrower without reduction by reason of any set-off or counterclaim. In the event that any required payment date is not a Business Day, then said payment date shall be the next succeeding Business Day.

 

Section 7. Representations and Warranties of the Borrower. The Borrower represents and warrants to the Lender that:

 

a. it is duly organized, validly existing and in good standing under the laws of the state of its incorporation;
     
b. it is duly authorized to do business in all jurisdictions material to the conduct of its business;
     
c. it has full power and authority and holds all requisite governmental licenses, permits and other approvals to enter into and perform its obligations under this Promissory Note and to conduct its business substantially as currently conducted by it;
     
d. the execution, delivery and performance of this Promissory Note are within the Borrower’s limited liability company powers and have been duly authorized by all necessary limited liability company action;
     
e. this Promissory Note has been duly executed by an authorized officer of the Borrower and constitutes a legal, valid and binding obligation enforceable against the Borrower;
     
  f. this Promissory Note does not violate any of the Borrower’s organizational documents, any law, court order or material agreement by which the Borrower is bound; and
     
g. the Borrower’s performance under this Promissory Note is not threatened by any pending or threatened litigation.

 

  5  

 

 

Section 8. Affirmative Covenants. Unless the Lender shall otherwise agree, the Borrower shall:

 

a. (i) maintain its limited liability company existence and qualify and remain qualified to conduct business as currently conducted; (ii) maintain all approvals necessary for the Loan and the Transaction Documents; and (iii) operate its business with due diligence, efficiency and in conformity with sound business practices;
     
b. (i) keep its properties and business insured with financially sound and reputable insurers against loss or damage in such manner and to the same extent as shall be no less than that generally accepted as customary in regard to property and business of like character; (ii) punctually pay any premium, commission and any other amount necessary for effectuating and maintaining in force each insurance policy required pursuant hereto and (iii) upon the request of the Lender cause the Lender to be a named insured (without recourse for premiums) and a loss payee of the Borrower’s insurances;
     
c. comply in all material respects with all applicable laws, rules, regulations and orders of any government authority;
     
d. take all necessary action to permit the Lender’s representatives to (i) visit (with prior notice to the Borrower) the premises of the Borrower, its facilities, plants and equipment, (ii) meet with the Borrower’s directors, officers, employees, and agents, and (iii) have reasonable access to the Borrower’s books and the Borrower’s auditors during working hours and on working days, provided that, so long as no Event of Default has occurred and is continuing, the Lender gives the Borrower notice two (2) Business Days in advance of such visit;
     
e. maintain records, books, management information systems and financial control procedures which together are adequate to: (i) support the accounting practices and tax elections of the Borrower; (ii) record and monitor the use of the Loan proceeds; and (iii) accurately, adequately and fairly reflect the financial condition of the Borrower and the results of its operations in conformity with GAAP;
     
f. pay and discharge all taxes, assessments and governmental charges upon it, its income and its properties prior to the date on which penalties are attached thereto, unless and only to the extent that (i) such taxes, assessments and governmental charges shall be contested in good faith and by appropriate proceedings by the Borrower, (ii) reserves which are adequate under GAAP are maintained by the Borrower with respect thereto, and (iii) any failure to pay and discharge such taxes, assessments and governmental charges would not have and could not reasonably be expected to have a Material Adverse Effect;

 

  6  

 

 

g. promptly inform the Lender, in writing, of any proposed material change in the nature or scope of the business or operations of the Borrower, or any event or condition which has or could reasonably be expected to have a Material Adverse Effect;
     
h. comply with the requirements of all applicable laws, rules, regulations, and orders of any government authority, a breach of which would or would reasonably be expected to result in a Material Adverse Effect;
     
i. obtain, make and keep in full force and effect all licenses, contracts, consents, approvals and authorizations from and registrations with government authorities that may be required to conduct its business, to maintain compliance with all applicable laws and regulations, and remit monies payable pursuant to this Promissory Note;
     
j. promptly notify the Lender of the occurrence of (i) any Default or Event of Default; (ii) any event, development or circumstance whereby the Borrower’s financial statements fail in any material respect to present fairly and accurately, in accordance with GAAP, the financial condition and operating results of the Borrower as of the date of such financial statements; (iii) any material litigation or proceedings that are instituted or, to the knowledge of the Borrower, threatened against the Borrower or any of their respective assets; (iv) each and every event which, at the giving of notice, lapse of time, determination of materiality or fulfillment of any other applicable condition (or any combination of the foregoing), would constitute an event of default (however described) under either of the Transaction Documents; and (v) any other development in the business or affairs of the Borrower if the effect thereof might have a Material Adverse Effect;
     
k. comply with the Transaction Documents and use its best efforts to cause every other party to the Transaction Documents (other than the Lender) or any other document executed in connection with the transactions contemplated hereby;
     
l. inform the Lender, as soon as they are made, of any judicial or non-judicial claims against the Borrower of more than $25,000 or the equivalent thereof in any other currency for each claim;
     
m. execute such other and further documents and instruments as the Lender may reasonably request to implement the provisions of this Promissory Note;
     
n. supply the Lender with (i) annual financial statements of the Borrower as soon as they are available and, in any event, within 180 days after the end of the Borrower’s financial year; and (ii) quarterly financial statements of the Borrower and its activities as soon as they are available;

 

  7  

 

 

o. provide to the Lender statement or statements, lists of property and accounts, budgets, forecasts, reports and financial information (including a listing of all outstanding indebtedness of the Borrower and any subsidiaries for borrowed monies) with respect to the business, operations and management of the Borrower and any subsidiaries and the employment of the assets owned or operated directly or indirectly by the Borrower or any of its subsidiaries as the Lender may from time to time reasonably request in writing;

 

p. the Borrower shall use the Loan for the purpose of finalizing the Bearn SDK, API, MYQ enhancements and product roadmap to complete integrations with complimentary partners in order to increase the number of single users of the Borrower’s Software to one million (1,000,000) unique monthly active users, using the MyFiziq Technology, subject to the Unique Users Requirement Reduction, within the twelve (12) months after the Funding Completion Date, wherein Unique Users can be identified by a unique identification reference, email address or username.

 

Section 9. Negative Covenants. Unless the Lender shall otherwise agree, the Borrower shall not:

 

a. enter into any transaction except on an arm’s length basis or otherwise agreed in writing by the Lender;

 

b. undertake or permit, without the agreement of the Lender, any (i) merger, consolidation or transfer of shares in the Borrower resulting in the creation of a wholly-owned subsidiary, or vice versa, (ii) any conversion of the Borrower into another corporate form, or (iii) any sale, transfer, lease or exchange or other action with respect to the disposal of, or disposition of rights to, any assets or business lines of the Borrower in a single transaction or series of transactions outside of the Borrower’s ordinary course of business other than the sale, transfer, lease or exchange or other action with respect to the disposal of, or disposition of rights;

 

c. liquidate or dissolve or enter into any consolidation, merger, spin-off, consolidation or reorganization, or acquire the assets or stock of any other business or company or enter into any partnership, joint venture, syndicate, pool, profit-sharing or royalty agreement or other combination, or engage in any transaction with an affiliate, whereby its income or profits are, or might be shared with any other Person, or enter into any management contract or similar arrangement whereby its business or operations are managed by another Person, provided that Bearn shall be permitted to license the Software to third parties in arms-length transactions;

 

d. make any change to the scope or nature of its respective business activities as carried on at the date hereof or undertake any operations not permitted by the Transaction Documents;

 

  8  

 

 

e. establish a subsidiary or acquire any equity interests in any other entity or enter into any agreement to acquire any stock obligations or securities of or any other interest in or make any capital contribution to any other Person without the prior written consent of the Lender;

 

f. (i) enter into any agreement or arrangement to guarantee or, in any way or under any condition, to become obligated for all or any part of any financial or other obligation of another Person; (ii) create, incur or suffer any lien upon any of its assets, now owned or hereafter acquired, except Permitted Liens; or (iii) assign, sell, transfer or otherwise dispose of, or terminate, waive or amend any of the rights and obligations hereunder;

 

g. make or permit to exist, loans or advances to, or deposits (except commercial bank deposits in the ordinary course of business) with, other Persons or investments in any Person or enterprise;

 

h. (i) violate any laws, ordinances, government rules or regulations to which it is subject or (ii) fail to obtain or maintain any patents, trademarks, service marks, trade names, copyrights, design patents, licenses, permits, franchises or other governmental authorizations necessary to ownership of its property or the conduct of its respective business, in either case where such failure would have or could reasonably be expected to have a Material Adverse Effect;

 

i. except as otherwise approved by the Lender, create, incur, assume, or suffer to exist any lease obligation other than lease obligations in the ordinary course of business of the Borrower;

 

j. except as required by applicable law, declare or pay any dividends, issue or sell any securities, or distribute or otherwise transfer to its members or other equity stakeholders or subordinated lenders any money in cash or kind on any shares, including, without limitation, any payments under any agreements between the Borrower and its members , whether in writing or otherwise; provided, however, that so long as no Default or Event of Default shall have occurred, the Borrower may make distributions to its members in sufficient amounts to enable such shareholder to pay federal, state and local income taxes attributable to their equity interest;

 

k. assign or otherwise transfer, terminate, waive or amend either of the Transaction Documents without the prior consent of the Lender, except for amendment in the ordinary course of business;

 

l. permit any modification to the accounting practices followed by the Borrower, other than as contemplated herein and except in accordance with applicable generally accepted accounting principles, or change its external auditors, without consent from the Lender; and

 

  9  

 

 

m. grant any liens (other than Permitted Liens) or incur any debt other than in the ordinary course of business unless such debt is raised for the purposes of repaying in full this Promissory Note or unless such debt is subordinated to the indebtedness created under this Promissory Note and does not begin to amortize and interest thereon is not payable until this Promissory Note is repaid in full.

 

Section 10. Events Of Default. Each of the following events shall constitute an “Event of Default”:

 

a. the principal of the Loan shall not be paid when due;

 

b. any interest on the Loan shall not be paid within five (5) Business Days of the date that such interest was due;

 

c. any warranty, representation or statement by the Borrower is or becomes false, misleading or incorrect in a material respect when made or regarded as made by the Borrower under this Promissory Note or the Transaction Documents;

 

d. the Borrower fails to perform or observe any material undertaking, obligation or agreement expressed or implied in this Promissory Note or the Transaction Documents and such default is not cured within thirty (30) days, or such longer period as is determined by the Lender, after receipt by the Borrower of a notice from the Lender specifying the failure;

 

e. the Borrower fails to register a copyright in the Software following written demand by the Lender, provided, however that the application for such a registration shall be construed as complete performance hereof;

 

f. a judgment in an amount exceeding Twenty Five Thousand United States Dollars (US$25,000) is obtained against the Borrower, and such judgment amount is not set aside or satisfied within seven (7) days of the judgment being entered;

 

g. a receiver, receiver and manager, official manager, trustee, administrator or similar official is appointed, or steps are taken for such appointment, over any of the assets or undertaking of the Borrower;

 

h. the Borrower is, or becomes, unable to pay its debts when they are due or is, or becomes, unable to pay its debts within the meaning of the US Bankruptcy Code or is presumed to be insolvent under the US Bankruptcy Code;

 

i. the Borrower enters into, or resolves to enter into, any arrangement, composition or compromise with, or assignment for the benefit of, its creditors or any class of them otherwise than while solvent and with the prior written consent of the Lender;

 

  10  

 

 

j. an application or order is made for the winding up or dissolution of the Borrower, which application or order is not dismissed or withdrawn within twenty on (21) days, or a resolution is passed or any steps are taken to pass a resolution for the winding up or dissolution of the Borrower otherwise than for the purpose of an amalgamation or reconstruction which has the prior written consent of the Lender; or

 

k. the Borrower suspends payment of its debts generally.

 

If an Event of Default described above shall occur, the unpaid principal and accrued interest on the Loan shall become due and payable within thirty (30) days of the Lender’s issuance of a formal demand notice to the Borrower. Immediately upon the occurrence of any Event of Default described above, or upon failure to pay this Promissory Note on the Termination Date, the Lender, without any notice to the Borrower, which notice is expressly waived by the Borrower, may proceed to protect, enforce, exercise and pursue any and all rights and remedies available to the Lender under this Promissory Note and any other agreement or instrument, and any and all rights and remedies available to the Lender at law or in equity.

 

In addition to the foregoing, in the event that any Event of Default described above shall occur for any reason, whether voluntary or involuntary, and be continuing for thirty (30) days following the Lender’s issuance of a formal demand letter to the Borrower: (i) the non-exclusive license of the Software shall be, and hereby is, automatically converted to an irrevocable exclusive license to the Software in favor of the Lender in all countries worldwide, excluding the United States and Canada, and/or (ii) the Lender may convert the outstanding balance of the Loan (or any portion thereof in a pro-rata amount) to limited liability company interests in the Borrower equal to twenty five percent (25%) ownership of all of the then issued and outstanding limited liability company interests on a fully diluted basis as of the date of the Event of Default, provided the loan is fully funded at $500,000.00 In the event that the loan is partially funded the ownership interest in the event of default shall be pro-rated based upon the actual amount funded: E.g. if Borrower lends $250,000.00, in the event of the default, the ownership interest would be twelve and one-half percent (12.5%). The Borrower shall, upon demand, take any and all actions which are necessary or advisable to affect the foregoing. The forgoing rights shall be in addition to any and all rights provided by any other Transaction Document.

 

All sums paid or advanced by the Lender in connection with the foregoing and all out-of-pocket costs and reasonable expenses (including, with limitation, reasonable attorneys’ fees and expenses) incurred in connection therewith, together with interest thereon at the Default Rate from the date of payment until repaid in full, shall be paid by the Borrower to the Lender on demand and shall constitute and become a part of the obligations of the Borrower secured hereby.

 

Section 11. Forgiveness. The Parties acknowledge and agree that in the event that the Borrower increases the number of Unique Users using the MyFiziq Technology to no less than two million (2,000,000) unique active user per month at any time prior to the Maturity Date, the Loan and any and all principal and accrued and outstanding interest shall be immediately forgiven and this Promissory Note shall be cancelled.

 

  11  

 

 

Section 12. Further Assurances. The Borrower hereby agrees that, from time to time upon the written request of the Lender, the Borrower will execute and deliver such further documents and do such other acts and things as the Lender may reasonably request in order to fully effect the purposes of this Promissory Note and to protect and preserve the priority and validity of the security interests granted hereunder.

 

Section 13. Powers And Remedies Cumulative; Delay Or Omission Not Waiver Of Event Of Default. No right or remedy herein conferred upon or reserved to the Lender is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy.

 

No delay or omission of the Lender to exercise any right or power accruing upon any Event of Default occurring and continuing as aforesaid shall impair any such right or power or shall be construed to be a waiver of any Event of Default or an acquiescence therein; and every power and remedy given by this Promissory Note or by law may be exercised from time to time, and as often as shall be deemed expedient, by the Lender.

 

Section 14. Transfers. The Parties may not transfer or assign this Promissory Note nor any right or obligation hereunder to any person or entity without the prior written consent of the other Party.

 

Section 15. Modification. This Promissory Note may be modified only with the written consent of both the Borrower and the Lender.

 

Section 16. Expenses. The Borrower agrees to pay to the Lender legal fees relating to the preparation of this Promissory Note and the Transaction Documents, in an amount to not exceed US$15,000.00 plus all out-of-pocket cost and expenses.

 

Section 17. Notices. Each notice authorized or required to be given to a party shall be in writing and may be delivered personally or sent by properly addressed prepaid mail in each case addressed to the party at its address set out in below:

 

In the case of the Lender:

 

Suite 5, 71-73 South Perth Esplanade

South Perth WA 6151

Email: vlado@MyFiziq.com

 

  12  

 

 

In the case of the Borrower:

 

314 Law St.

San Diego, CA

 

814 Law

Street

San Diego, CA

92109

Email: aaron@bearncorp.com

 

Section 18. Miscellaneous. This Promissory Note shall be deemed to be a contract under the laws of the State of New York, and for all purposes shall be construed in accordance with the laws of said state. The parties hereto hereby waive presentment, demand, notice, protest and all other demands and notices in connection with the delivery, acceptance, performance and enforcement of or any default under this Promissory Note, except as specifically provided herein, and assent to extensions of the time of payment, or forbearance or other indulgence without notice. The Section headings herein are for convenience only and shall not affect the construction hereof. Any provision of this Promissory Note which is illegal, invalid, prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity, prohibition or unenforceability without invalidating or impairing the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction. This Promissory Note shall bind the Borrower and his or her heirs, administrators, executors, personal representatives and permitted assigns. The rights under and benefits of this Promissory Note shall inure to the Lender and its permitted successors and assigns. This Promissory Note may be executed in any number of counterparts, each of which when executed and delivered to the other parties shall constitute an original, but all counterparts together shall constitute one and the same Promissory Note.

 

[Signature Page Follows]

 

  13  

 

 

IN WITNESS WHEREOF, the Borrower has caused this instrument to be duly executed on the date indicated below.

 

Date: January ___, 2021  
   
  BEARN LLC
   
  By: /s/ aaron Drew
  Name: aaron Drew
  Title: CEO
   
  Secured Party:
   
  MYFIZIQ LIMITED
   
  By: /s/ Vlado Bosanac
  Name: Vlado Bosanac
  Title: Chief Executive Officer

 

 

 

 

Exhibit 10.29

 

PLEDGE AND ESCROW AGREEMENT

 

THIS PLEDGE AND ESCROW AGREEMENT (“Agreement”) is made and entered into as of January 20, 2021 by and between AARON DREW, an individual, (the “Pledgor”), and MYFIZIQ LIMITED, a company organized under the laws of Australia (the “Secured Party”), with the joinder of LUCOSKY BROOKMAN LLP (“Escrow Agent”).

 

RECITALS

 

WHEREAS, the Secured Party has made certain financial accommodations for the benefit of Bearn, LLC (the “Company”), in which Pledgor owns a majority interest, and the Company has issued a Promissory Note of even date herewith in favor of the Secured Party (the “Note”); and

 

WHEREAS, in order to secure the full and prompt payment when due (whether at the stated maturity, by acceleration or otherwise) of all of the Pledgor’s Obligations to the Secured Party, or any successor to the Secured Party, under the Note and all other Transaction Documents, Pledgor has agreed to pledge to the Secured Party 95 units representing 95% of the issued and outstanding Membership Interests (representing 100% of the Membership Interest owned by the Pledgor) (the “Pledged Securities”) of Bearn, LLC, a Maryland limited liability company (the “Company”); and

 

NOW, THEREFORE, in consideration of the mutual covenants, agreements, warranties, and representations herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

1. Recitals, Construction and Defined Terms. The recitations set forth in the preamble of this Agreement are true and correct and incorporated herein by this reference. In this Agreement, unless the express context otherwise requires: (i) the words “herein,” “hereof” and “hereunder” and words of similar import refer to this Agreement as a whole and not to any particular provision of this Agreement; (ii) references to the words “Section” or “Subsection” refer to the respective Sections and Subsections of this Agreement, and references to “Exhibit” or “Schedule” refer to the respective Exhibits and Schedules attached hereto; and (iii) wherever the word “include,” “includes,” “including” or words of similar import are used in this Agreement, such words will be deemed to be followed by the words “without limitation.” All capitalized terms used in this Agreement that are defined in the Note shall have the meanings assigned to them in the Note, unless the context of this Agreement requires otherwise (provided that if a capitalized term used herein is defined in the Note and separately defined in this Agreement, the meaning of such term as defined in this Agreement shall control for purposes of this Agreement).

 

2. Pledge. In order to secure the full and timely payment and performance of all of the Company’s Obligations to the Secured Party under the Transaction Documents, the Pledgor hereby transfers, pledges, assigns, sets over, delivers and grants to the Secured Party a continuing lien and security interest in and to all of the following property of Pledgor, both now owned and existing and hereafter created, acquired and arising (all being collectively hereinafter referred to as the “Collateral”) and all right, title and interest of Pledgor in and to the Collateral, to-wit:

 

(a) the Pledged Securities owned by Pledgor;

  

1

 

 

(b) any certificates representing or evidencing the Pledged Securities, if any;

 

(c) any and all distributions thereon, and cash and non-cash proceeds and products thereof, including all dividends, cash, distributions, income, profits, instruments, securities, stock dividends, distributions of capital stock or other securities held by Pledger in the Company and all other property from time to time received, receivable or otherwise distributed in respect of, in exchange for or upon conversion of the Pledged Securities, whether in connection with stock splits, recapitalizations, merger, conversions, combinations, reclassifications, exchanges of securities or otherwise; and

 

(d) any and all voting, management, and other rights, powers and privileges accruing or incidental to an owner of the Pledged Securities and the other property referred to in subsections 2(a) through 2(c) above.

 

3. Transfer of Pledged Securities. Simultaneously with the execution of this Agreement, Pledgor shall deliver to the Escrow Agent: (i) the Pledged Securities, together with undated, irrevocably and duly executed assignments and proxies thereof in form and substance acceptable to Secured Party (together with medallion guaranteed signatures, if required by Secured Party), executed in blank by Pledgor; (ii) all other property, instruments, documents and papers comprising, representing or evidencing the Collateral, or any part thereof, together with proper instruments of assignment or endorsement, as Secured Party may request or require, duly executed by Pledgor (collectively, items (i) and (ii), the “Transfer Documents”); and (iii) an irrevocable proxy in favor of the Secured Party in respect of the Pledged Securities (the “Irrevocable Proxies”). The Pledged Securities, the Irrevocable Proxies and other Transfer Documents (collectively, the “Pledged Materials”) shall be held by the Escrow Agent pursuant to this Agreement until the full payment and performance of all of the Obligations, the termination or expiration of this Agreement, the delivery of the Pledged Materials in accordance with this Agreement or the selection and exercise by the Secured Party of alternative security interest as set forth in the Transfer Documents In addition, all non-cash dividends, dividends paid or payable in cash or otherwise in connection with a partial or total liquidation or dissolution of the Company, instruments, securities and any other distributions, whether paid or payable in cash or otherwise, made on or in respect of the Pledged Securities, whether resulting from a subdivision, combination, or reclassification of the outstanding capital stock or other securities of the Company, or received in exchange for the Pledged Securities or any part thereof, or in redemption thereof, as a result of any merger, consolidation, acquisition, or other exchange of assets to which the Company may be a party or otherwise, or any other property that constitutes part of the Collateral from time to time, including any additional certificates representing any portion of the Collateral hereafter acquired by the Pledgor, shall be immediately delivered or cause to be delivered by Pledgor to the Escrow Agent in the same form as so received, together with proper instruments of assignment or endorsement duly executed by Pledgor.

 

4. Security Interest Only. The security interests in the Collateral granted to Secured Party hereunder are granted as security only and shall not subject the Secured Party to, or transfer or in any way affect or modify, any obligation or liability of the Pledgor with respect to any of the Collateral or any transaction in connection therewith.

 

2

 

 

 

5. Record Owner of Collateral. Until an “Event of Default” (as hereinafter defined) under this Agreement which has not been cured or waived by the Secured Party shall occur, the Pledged Securities shall remain registered in the name of the Pledgor. Pledgor will promptly give to the Secured Party copies of any notices or other communications received by it and with respect to Collateral registered in the name of Pledgor.

 

6. Rights Related to Pledged Securities. Subject to the terms of this Agreement:

 

(a) Unless and until an Event of Default under this Agreement which has not been cured or waived by the Secured Party shall occur, Pledgor shall be entitled to exercise any and all voting, management, and other rights, powers and privileges accruing to an owner of the Pledged Securities, or any part thereof, for any purpose consistent with the terms of this Agreement; provided, however, such action would not materially and adversely affect the rights inuring to Secured Party under any of the Transaction Documents, or adversely affect the remedies of the Secured Party under any of the Transaction Documents, or the ability of the Secured Party to exercise same.

 

(b) Upon the occurrence of an Event of Default which has not been cured or waived by the Secured Party, all rights of the Pledgor in and to the Pledged Securities and all other Collateral shall cease and all such rights shall immediately vest in Secured Party, as may be determined by Secured Party, although Secured Party shall not have any duty to exercise such rights or be required to sell or to otherwise realize upon the Collateral, as hereinafter authorized, or to preserve the same, and Secured Party shall not be responsible for any failure to do so or delay in doing so. To effectuate the foregoing, Pledgor hereby grants to Secured Party a proxy to vote the Pledged Securities for and on behalf of Pledgor, which proxy is irrevocable and coupled with an interest and which proxy shall be effective upon the occurrence of any Event of Default which has not been cured or waived by the Secured Party. Such proxy shall remain in effect so long as the Obligations remain outstanding. The Company hereby agrees that any vote by Pledgor in violation of this Section 6 shall be null, void and of no force or effect. Furthermore, all dividends or other distributions received by the Pledgor shall be subject to delivery to Escrow Agent in accordance with Section 3 above, and until such delivery, any of such dividends and other distributions shall be received in trust for the benefit of the Secured Party, shall be segregated from other property or funds of the Pledgor and shall be forthwith delivered to Escrow Agent in accordance with Section 3 above.

 

7. Release of Pledged Securities. Upon the timely payment in full of all of the Obligations in accordance with the terms thereof, Secured Party shall timely notify the Escrow Agent in writing to such effect. Upon receipt of such written notice, the Escrow Agent shall return all of the Pledged Materials in Escrow Agent’s possession to the Pledgor, whereupon any and all rights of Secured Party in and to the Pledged Materials and all other Collateral shall be terminated.

 

3

 

 

8. Representations, Warranties, and Covenants of the Pledgor and the Company. The Pledgor and the Company hereby covenant, warrant and represent, for the benefit of the Secured Party, as follows (the following representations and warranties shall be made as of the date of this Agreement and as of each date when Pledged Securities are delivered to Escrow Agent hereunder, as applicable):

 

(a) The Pledged Securities are free and clear of any and all Liens, other than as created by this Agreement.

 

(b) The Pledged Securities have been duly authorized and are validly issued, fully paid and non-assessable, and are subject to no options to purchase, or any similar rights or to any restrictions on transferability.

 

(c) Each certificate or document of title constituting the Pledged Securities is genuine in all respects and represents what it purports to be.

 

(d) By virtue of the execution and delivery of this Agreement and upon delivery to Escrow Agent of the Pledged Securities in accordance with this Agreement, Secured Party will have a valid and perfected, first priority security interest in the Collateral, subject to no prior or other Liens of any nature whatsoever.

 

(e) Pledgor covenants, that for so long as this Agreement is in effect, Pledgor will defend the Collateral and the priority of Secured Party’s security interests therein, at its sole cost and expense, against the claims and demands of all Persons at any time claiming the same or any interest therein.

 

(f) At its option, Secured Party may pay, for Pledgor’s account, any taxes (including documentary stamp taxes), Liens, security interests, or other encumbrances at any time levied or placed on the Collateral. Pledgor agrees to reimburse Secured Party on demand for any payment made or expense incurred by Secured Party pursuant to the foregoing authorization. Any such amount, if not promptly paid upon demand therefor, shall accrue interest at the highest non- usurious rate permitted by applicable law from the date of outlay, until paid, and shall constitute an Obligation secured hereby.

 

(g) The Pledged Securities constitute all of the securities owned, legally or beneficially, by the Pledgor of the Company, and such securities represent 100% of the issued and outstanding membership interests of the Company. At all times while this Agreement remains in effect, the Pledged Securities shall constitute and represent 100% of the issued and outstanding membership interests of the Company.

 

(h) The Company and the Pledgor hereby authorize Secured Party to prepare and file such financing statements, amendments and other documents and do such acts as Secured Party deems necessary in order to establish and maintain valid, attached and perfected, first priority security interests in the Collateral in favor of Secured Party, for its own benefit and as agent for its Affiliates, free and clear of all Liens and claims and rights of third parties whatsoever. The Company and Pledgor hereby irrevocably authorize Secured Party at any time, and from time to time, to file in any jurisdiction any initial financing statements, amendments, continuations and other documents in furtherance of the foregoing.

 

4

 

  

9. Events of Default. The occurrence of any one or more of the following events shall constitute an “Event of Default” hereunder:

 

(a) Default. The occurrence of any breach, default or “Event of Default” (as such term may be defined in any Transaction Documents), after applicable notice and cure periods, under any of the Transaction Documents.

 

(b) Covenants and Agreements. The failure of Pledgor or the Company to perform, observe or comply with any and all of the covenants, promises and agreements of the Pledgor and the Company in this Agreement, which such failure is not cured by the Pledgor or the Company within ten (10) days after receipt of written notice thereof from Secured Party, except that there shall be no notice or cure period with respect to any failure to pay any sums due under or as part of the Obligations (provided that if the failure to perform or default in performance is not capable of being cured, in Secured Party’s sole discretion, then the cure period set forth herein shall not be applicable and the failure or default shall be an immediate Event of Default hereunder).

 

(c) Information, Representations and Warranties. If any representation or warranty made herein or in any other Transaction Documents, or if any information contained in any financial statement, application, schedule, report or any other document given by the Company to Secured Party in connection with the Obligations, with the Collateral, or with the Transaction Documents, is not in all material respects true, accurate and complete, or if the Pledgor or the Company omitted to state any material fact or any fact necessary to make such information not misleading.

 

10. Rights and Remedies. Subject at all times to the Uniform Commercial Code as then in effect in the State governing this Agreement, the Secured Party shall have the following rights and remedies upon the occurrence and continuation of an Event of Default:

 

(a) Upon and anytime after the occurrence and continuation of an Event of Default which has not been cured or waived by the Secured Party, the Secured Party shall have the right to acquire the Pledged Securities and all other Collateral in accordance with the following procedure: (i) the Secured Party shall provide written notice of such Event of Default (the “Default Notice”) to the Escrow Agent, with a copy to the Pledgor and the Company; (ii) not less than five (5) days following receipt of a Default Notice, the Escrow Agent shall deliver the Pledged Securities and all other Collateral, along with the applicable Transfer Documents, to the Secured Party.

 

5

 

 

 

(b) Upon receipt of the Pledged Securities and other Collateral issued to the Secured Party, the Secured Party shall have the right to, without notice or demand to Pledgor or the Company: (i) sell the Collateral and to apply the proceeds of such sales, net of any selling commissions, to the Obligations owed to the Secured Party by the Company under the Transaction Documents, including outstanding principal, interest, legal fees, and any other amounts owed to the Secured Party; and (ii) exercise in any jurisdiction in which enforcement hereof is sought, any rights and remedies available to Secured Party under the provisions of any of the Transaction Documents, the rights and remedies of a secured party under the Uniform Commercial Code as then in effect in the State governing this Agreement, and all other rights and remedies available to the Secured Party, under equity or applicable law, all such rights and remedies being cumulative and enforceable alternatively, successively or concurrently. In furtherance of the foregoing rights and remedies:

 

(i) Secured Party may sell the Pledged Securities, or any part thereof, or any other portion of the Collateral, in one or more sales, at public or private sale, conducted by any agent of, or auctioneer or attorney for Secured Party, at Secured Party’s place of business or elsewhere, or at any broker’s board or on any securities exchange, for cash, upon credit or for future delivery, and at such price or prices, all as Secured Party may deem appropriate. Secured Party may be a purchaser at any such sale of any or all of the Collateral so sold. In the event Secured Party is a purchaser at any such sale, Secured Party may apply to such purchase all or any portion of the sums then due and owing by the Company to Secured Party under any of the Transaction Documents or otherwise, and the Secured Party may, upon compliance with the terms of the sale, hold, retain and dispose of such property without further accountability to the Pledgor or the Company therefore. Secured Party is authorized, in its absolute discretion, to restrict the prospective bidders or purchasers of any of the Collateral at any public or private sale as to their number, nature of business and investment intention, including the restricting of bidders or purchasers to one or more persons who represent and agree, to the satisfaction of Secured Party, that they are purchasing the Collateral, or any part thereof, for their own account, for investment, and not with a view to the distribution or resale of any of such Collateral.

 

(ii) Upon any such sale, Secured Party shall have the right to deliver, assign and transfer to each purchaser thereof the Collateral so sold to such purchaser. Each purchaser (including Secured Party) at any such sale shall, to the full extent permitted by law, hold the Collateral so purchased absolutely free from any claim or right whatsoever, including, without limitation, any equity or right of redemption of the Pledgor, who, to the full extent that it may lawfully do so, hereby specifically waives all rights of redemption, stay, valuation or appraisal which she now has or may have under any rule of law or statute now existing or hereafter adopted.

 

(iii) At any such sale, the Collateral may be sold in one lot as an entirety, in separate blocks or individually as Secured Party may determine, in its sole and absolute discretion. Secured Party shall not be obligated to make any sale of any Collateral if it shall determine in its sole and absolute discretion, not to do so, regardless of the fact that notice of sale of such Collateral shall have been given. Secured Party may, without notice or publication, adjourn any public or private sale from time to time by announcement at the time and place fixed for such sale, or any adjournment thereof, and any such sale may be made at any time or place to which the same may be so adjourned without further notice or publication.

 

6

 

 

(iv) The Pledgor and the Company acknowledge that compliance with applicable federal and state securities laws (including, without limitation, the Securities Act of 1933, as amended, blue sky or other state securities laws or similar laws now or hereafter existing analogous in purpose or effect) might very strictly limit or restrict the course of conduct of Secured Party if Secured Party were to attempt to sell or otherwise dispose of all or any part of the Collateral, and might also limit or restrict the extent to which or the manner in which any subsequent transferee of any such securities could sell or dispose of the same. The Pledgor and the Company further acknowledge that under applicable laws, Secured Party may be held to have certain general duties and obligations to the Pledgor, as pledgors of the Collateral, or the Company, to make some effort toward obtaining a fair price for the Collateral even though the obligations of the Pledgor and the Company may be discharged or reduced by the proceeds of sale at a lesser price. The Pledgor and the Company understand and agree that, to the extent allowable under applicable law, Secured Party is not to have any such general duty or obligation to the Pledgor or the Company, and neither the Pledgor nor the Company will attempt to hold Secured Party responsible for selling all or any part of the Collateral at an inadequate price even if Secured Party shall accept the first offer received or does not approach more than one possible purchaser. Without limiting their generality, the foregoing provisions would apply if, for example, Secured Party were to place all or any part of such securities for private placement by an investment banking firm, or if such investment banking firm purchased all or any part of such securities for its own account, or if Secured Party placed all or any part of such securities privately with a purchaser or purchasers.

 

(c) To the extent that the net proceeds received by the Secured Party are insufficient to satisfy the Obligations in full, the Secured Party shall be entitled to a deficiency judgment against the Company and any other Person obligated for the Obligations for such deficiency amount. The Secured Party shall have the absolute right to sell or dispose of the Collateral, or any part thereof, in any manner it sees fit and shall have no liability to the Pledgor, the Company, or any other party for selling or disposing of such Collateral even if other methods of sales or dispositions would or allegedly would result in greater proceeds than the method actually used. The Company and any other Person obligated for the Obligations shall remain liable for all deficiencies and shortfalls, if any, that may exist after the Secured Party has exhausted all remedies hereunder.

 

(d) Each right, power and remedy of the Secured Party provided for in this Agreement or any other Transaction Document shall be cumulative and concurrent and shall be in addition to every other such right, power or remedy. The exercise or beginning of the exercise by the Secured Party of any one or more of the rights, powers or remedies provided for in this Agreement or any other Transaction Documents, or now or hereafter existing at law or in equity or by statute or otherwise, shall not preclude the simultaneous or later exercise by the Secured Party of all such other rights, powers or remedies, and no failure or delay on the part of the Secured Party to exercise any such right, power or remedy shall operate as a waiver thereof. No notice to or demand on the Pledgor in any case shall entitle it to any other or further notice or demand in similar or other circumstances or constitute a waiver of any of the rights of the Secured Party to any other further action in any circumstances without demand or notice. The Secured Party shall have the full power to enforce or to assign or contract its rights under this Agreement to a third party.

 

(e) In addition to all other remedies available to the Secured Party, upon the issuance of the Pledged Securities to the Secured Party hereunder, Pledgor and the Company each agree to: (i) take such action and prepare, distribute and/or file such documents and papers, as are required or advisable in the opinion of Secured Party and/or its counsel, to permit the sale of the Pledged Securities, whether at public sale, private sale or otherwise, including, without limitation, issuing, or causing its counsel to issue, any opinion of counsel for Pledgor or the Company required to allow the Secured Party to sell the Pledged Securities or any other Collateral under Rule 144; (ii) to bear all costs and expenses of carrying out its obligations under this Section 8(e), which shall be a part of the Obligations secured hereby; and (iv) that there is no adequate remedy at law for the failure by the Pledgor and the Company to comply with the provisions of this Section 8(e) and that such failure would not be adequately compensable in damages, and therefore agrees that its agreements contained in this subsection may be specifically enforced.

 

7

 

 

11. Concerning the Escrow Agent.

 

(a) The Escrow Agent undertakes to perform only such duties as are expressly set forth herein and no implied duties or obligations shall be read into this Agreement against the Escrow Agent. Escrow Agent agrees to release any property held by it hereunder (the “Escrowed Property”) in accordance with the terms and conditions set forth in this Agreement.

 

(b) The Escrow Agent may act in reliance upon any writing or instrument or signature which it, in good faith, believes to be genuine, may assume the validity and accuracy of any statement or assertion contained in such a writing or instrument, and may assume that any person purporting to give any writing, notice, advice or instructions in connection with the provisions hereof has been duly authorized to do so. The Escrow Agent shall not be liable in any manner for the sufficiency or correctness as to form, manner, and execution, or validity of any instrument deposited in this escrow, nor as to the identity, authority, or right of any person executing the same; and its duties hereunder shall be limited to the safekeeping of the Escrowed Property, and for the disposition of the same in accordance with this Agreement. Escrow Agent shall not be deemed to have knowledge of any matter or thing unless and until Escrow Agent has actually received written notice of such matter or thing and Escrow Agent shall not be charged with any constructive notice whatsoever.

 

(c) Escrow Agent shall hold in escrow, pursuant to this Agreement, the Escrowed Property actually delivered and received by Escrow Agent hereunder, but Escrow Agent shall not be obligated to ascertain the existence of (or initiate recovery of) any other property that may be part or portion of the Collateral, or to become or remain informed with respect to the possibility or probability of additional Collateral being realized upon or collected at any time in the future, or to inform any parties to this Agreement or any third party with respect to the nature and extent of any Collateral realized and received by Escrow Agent (except upon the written request of such party), or to monitor current market values of the Collateral. Further, Escrow Agent shall not be obligated to proceed with any action or inaction based on information with respect to market values of the Collateral which Escrow Agent may in any manner learn, nor shall Escrow Agent be obligated to inform the parties hereto or any third party with respect to market values of any of the Collateral at any time, Escrow Agent having no duties with respect to investment management or information, all parties hereto understanding and intending that Escrow Agent’s responsibilities are purely ministerial in nature. Any reduction in the market value or other value of the Collateral while deposited with Escrow Agent shall be at the sole risk of Pledgor and Secured Party. If all or any portion of the Escrowed Property is in the form of a check or in any other form other than cash, Escrow Agent shall deposit same as required but shall not be liable for the nonpayment thereof, nor responsible to enforce collection thereof.

 

8

 

  

(d) In the event instructions from Secured Party, Pledgor, or any other Person would require Escrow Agent to expend any monies or to incur any cost, Escrow Agent shall be entitled to refrain from taking any action until it receives payment for such costs. It is agreed that the duties of Escrow Agent are purely ministerial in nature and shall be expressly limited to the safekeeping of the Escrowed Property and for the disposition of same in accordance with this Agreement. Secured Party, Pledgor and the Company, jointly and severally, each hereby indemnifies Escrow Agent and holds it harmless from and against any and all claims, liabilities, damages, costs, penalties, losses, actions, suits or proceedings at law or in equity, or any other expenses, fees or charges of any character or nature (collectively, the “Claims”), which it may incur or with which it may be threatened, directly or indirectly, arising from or in any way connected with this Agreement or which may result from Escrow Agent’s following of instructions from Secured Party, Pledgor or the Company, and in connection therewith, indemnifies Escrow Agent against any and all expenses, including attorneys’ fees and the cost of defending any action, suit, or proceeding or resisting any Claim, whether or not litigation is instituted, unless any such Claims arise as a result of Escrow Agent’s gross negligence or willful misconduct. Escrow Agent shall be vested with a lien on all Escrowed Property under the terms of this Agreement, for indemnification, attorneys’ fees, court costs and all other costs and expenses arising from any suit, interpleader or otherwise, or other expenses, fees or charges of any character or nature, which may be incurred by Escrow Agent by reason of disputes arising between Pledgor, the Company, Secured Party, or any third party as to the correct interpretation of this Agreement, and instructions given to Escrow Agent hereunder, or otherwise, with the right of Escrow Agent, regardless of the instruments aforesaid and without the necessity of instituting any action, suit or proceeding, to hold any property hereunder until and unless said additional expenses, fees and charges shall be fully paid. Any fees and costs charged by the Escrow Agent for serving hereunder shall be paid by the Pledgor and the Company, jointly and severally.

 

(e) In the event Escrow Agent shall be uncertain as to its duties or rights hereunder or shall receive instructions, claims or demands from Secured Party, the Company, Pledgor or from third persons with respect to the Escrowed Property, which, in Escrow Agent’s sole opinion, are in conflict with each other or with any provision of this Agreement, Escrow Agent shall be entitled to refrain from taking any action until it shall be directed otherwise in writing by Pledgor, the Company and Secured Party and said third persons, if any, or by a final order or judgment of a court of competent jurisdiction. If any of the parties shall be in disagreement about the interpretation of this Agreement, or about the rights and obligations, or the propriety of any action contemplated by the Escrow Agent hereunder, the Escrow Agent may, at its sole discretion, deposit the Escrowed Property with a court having jurisdiction over this Agreement, and, upon notifying all parties concerned of such action, all liability on the part of the Escrow Agent shall fully cease and terminate. The Escrow Agent shall be indemnified by the Pledgor, the Company and Secured Party for all costs, including reasonable attorneys’ fees, in connection with the aforesaid proceeding, and shall be fully protected in suspending all or a part of its activities under this Agreement until a final decision or other settlement in the proceeding is received. In the event Escrow Agent is joined as a party to a lawsuit by virtue of the fact that it is holding the Escrowed Property, Escrow Agent shall, at its sole option, either: (i) tender the Collateral in its possession to the registry of the appropriate court; or (ii) disburse the Collateral in its possession in accordance with the court’s ultimate disposition of the case, and Secured Party, the Company and Pledgor hereby, jointly and severally, indemnify and hold Escrow Agent harmless from and against any damages or losses in connection therewith including, but not limited to, reasonable attorneys’ fees and court costs at all trial and appellate levels.

 

9

 

 

(f) The Escrow Agent may consult with counsel of its own choice (and the costs of such counsel shall be paid by the Pledgor, the Company and Secured Party, jointly and severally) and shall have full and complete authorization and protection for any action taken or suffered by it hereunder in good faith and in accordance with the opinion of such counsel. The Escrow Agent shall not be liable for any mistakes of fact or error of judgment, or for any actions or omissions of any kind, unless caused by its willful misconduct or gross negligence.

 

(g) The Escrow Agent may resign upon ten (10) days’ written notice to the parties in this Agreement. If a successor Escrow Agent is not appointed by Secured Party and Pledgor within this ten (10) day period, the Escrow Agent may petition a court of competent jurisdiction to name a successor.

 

(h) Conflict Waiver. The Pledgor and the Company hereby acknowledge that the Escrow Agent is counsel to the Secured Party in connection with the transactions contemplated and referred herein. The Pledgor and the Company agree that in the event of any dispute arising in connection with this Agreement or otherwise in connection with any transaction or agreement contemplated and referred herein, the Escrow Agent shall be permitted to continue to represent the Secured Party and neither the Pledgor, nor the Company, will seek to disqualify such counsel and each of them waives any objection Pledgor or the Company might have with respect to the Escrow Agent acting as the Escrow Agent pursuant to this Agreement. Pledgor, the Company and Secured Party acknowledge and agree that nothing in this Agreement shall prohibit Escrow Agent from: (i) serving in a similar capacity on behalf of others; or (ii) acting in the capacity of attorneys for one or more of the parties hereto in connection with any matter.

 

12. Increase in Obligations. It is the intent of the parties to secure payment of the Obligations, as the amount of such Obligations may increase from time to time in accordance with the terms and provisions of the Transaction Documents, and all of the Obligations, as so increased from time to time, shall be and are secured hereby. Upon the execution hereof, Pledgor and the Company shall pay any and all documentary stamp taxes and/or other charges required to be paid in connection with the execution and enforcement of the Transaction Documents, and if, as and to the extent the Obligations are increased from time to time in accordance with the terms and provisions of the Transaction Documents, then Pledgor and the Company shall immediately pay any additional documentary stamp taxes or other charges in connection therewith.

 

13. Irrevocable Authorization and Instruction. If applicable, Pledgor and the Company hereby authorize and instruct the transfer agent for such Company (or transfer agents if there is more than one) to comply with any instruction received by it from Secured Party in writing that:

 

(i) states that an Event of Default hereunder exists or has occurred; and (b) is otherwise in accordance with the terms of this Agreement, without any other or further instructions from Pledgor or the Company, and Pledgor and such Company agree that such transfer agents shall be fully protected in so complying with any such instruction from Secured Party.

 

10

 

 

14. Appointment as Attorney-in-Fact. The Company and Pledgor hereby irrevocably constitutes and appoints Secured Party and any officer or agent of Secured Party, with full power of substitution, as its true and lawful attorney-in-fact, with full irrevocable power and authority in the place and stead of Pledgor or such Company, as applicable, and in the name of Pledgor, such Company, or in the name of Secured Party, as applicable, from time to time in the discretion of Secured Party, so long as an Event of Default hereunder exists, for the purpose of carrying out the terms of this Agreement, to take any and all appropriate action and to execute any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Agreement, including any financing statements, endorsements, assignments or other instruments of transfer. Pledgor and the Company each hereby ratify all that said attorneys shall lawfully do or cause to be done pursuant to the power of attorney granted in this Section 14. All powers, authorizations and agencies contained in this Agreement are coupled with an interest and are irrevocable until the Obligations are paid and performed in full.

 

15. Continuing Obligation of Pledgor and the Company. The obligations, covenants, agreements and duties of the Pledgor and the Company under this Agreement shall in no way be affected or impaired by: (i) the modification or amendment (whether material or otherwise) of any of the obligations of the Pledgor or the Company or any other Person, as applicable; (ii) the voluntary or involuntary bankruptcy, assignment for the benefit of creditors, reorganization, or other similar proceedings affecting the Company, Pledgor or any other Person, as applicable; (iii) the release of the Company, Pledgor or any other Person from the performance or observance of any of the agreements, covenants, terms or conditions contained in any Transaction Documents, by the operation of law or otherwise, including the release of the Company’s obligation to pay interest or attorney’s fees.

 

Pledgor and the Company further agree that Secured Party may take other guaranties or collateral or security to further secure the Obligations, and consent that any of the terms, covenants and conditions contained in any of the Transaction Documents may be renewed, altered, extended, changed or modified by Secured Party or may be released by Secured Party, without in any manner affecting this Agreement or releasing Pledgor herefrom, and Pledgor shall continue to be liable hereunder to pay and perform pursuant hereto, notwithstanding any such release or the taking of such other guaranties, collateral or security. This Agreement is additional and supplemental to any and all other guarantees, security agreements or collateral heretofore and hereafter executed by Pledgor and the Company for the benefit of Secured Party, whether relating to the indebtedness evidenced by any of the Transaction Documents or not, and shall not supersede or be superseded by any other document or guaranty executed by Pledgor, the Company or any other Person for any purpose. Pledgor and the Company hereby agree that Pledgor, the Company, and any additional parties who may become liable for repayment of the sums due under the Transaction Documents, may hereafter be released from their liability hereunder and thereunder; and Secured Party may take, or delay in taking or refuse to take, any and all action with reference to any of the Transaction Documents (regardless of whether same might vary the risk or alter the rights, remedies or recourses of Pledgor), including specifically the settlement or compromise of any amount allegedly due thereunder, all without notice to, consideration to or the consent of the Pledgor, and without in any way releasing, diminishing or affecting in any way the absolute nature of Pledgor’s obligations and liabilities hereunder.

 

11

 

 

No delay on the part of the Secured Party in exercising any rights hereunder or failure to exercise the same shall operate as a waiver of such rights. Pledgor and the Company hereby waive any and all legal requirements, statutory or otherwise, that Secured Party shall institute any action or proceeding at law or in equity or exhaust its rights, remedies and recourses against Pledgor, the Company or anyone else with respect to the Transaction Documents, as a condition precedent to bringing an action against Pledgor or the Company upon this Agreement or as a condition precedent to Secured Party’s rights to sell the Pledged Securities or any other Collateral. Pledgor and the Company agree that Secured Party may simultaneously maintain an action upon this Agreement and an action or proceeding upon the Transaction Documents. All remedies afforded by reason of this Agreement are separate and cumulative remedies and may be exercised serially, simultaneously and in any order, and the exercise of any of such remedies shall not be deemed an exclusion of the other remedies and shall in no way limit or prejudice any other contractual, legal, equitable or statutory remedies which Secured Party may have in the Pledged Securities, any other Collateral, or under the Transaction Documents. Until the Obligations, and all extensions, renewals and modifications thereof, are paid in full, and until each and all of the terms, covenants and conditions of this Agreement are fully performed, Pledgor shall not be released by any act or thing which might, but for this provision of this Agreement, be deemed a legal or equitable discharge of a surety, or by reason of any waiver, extension, modification, forbearance or delay of Secured Party or any obligation or agreement between the Company or their successors or assigns, and the then holder of the Transaction Documents, relating to the payment of any sums evidenced or secured thereby or to any of the other terms, covenants and conditions contained therein, and Pledgor hereby expressly waive and surrender any defense to liability hereunder based upon any of the foregoing acts, things, agreements or waivers, or any of them. Pledgor and the Company also waive any defense arising by virtue of any disability, insolvency, bankruptcy, lack of authority or power or dissolution of Pledgor or the Company, even though rendering the Transaction Documents void, unenforceable or otherwise uncollectible, it being agreed that Pledgor and the Company shall remain liable hereunder, regardless of any claim which Pledgor or the Company might otherwise have against Secured Party by virtue of Secured Party’s invocation of any right, remedy or recourse given to it hereunder or under the Transaction Documents. In addition, Pledgor waives and renounces any right of subrogation, reimbursement or indemnity whatsoever, and any right of recourse to security for the Obligations of the Company to Secured Party, unless and until all of said Obligations have been paid in full to Secured Party.

 

Pledgor agrees and understands that Secured Party’s right to exercise its rights hereunder, in the Event of a Default, is a non-judicial remedy. Accordingly, Pledgor waives and release any and all claims or defenses that they may have or come to have in connection with Secured Party’s enforcement of such rights other than as to proof of repayment. Pledgor further stipulates that as a condition precedent to its filing or taking any action that would delay or impair the recognition or enforcement of Secured Party’s rights pursuant to its enforcement of its rights hereunder, Pledgor shall be required to post a bond in the amount of 20% of the remaining principal and interest due to Secured Party under the Note at the time of Secured Party’s enforcement of its rights hereunder.

  

12

 

 

16. Miscellaneous.

 

(a) Performance for Pledgor or the Company. The Pledgor and the Company agree and hereby acknowledge that Secured Party may, in Secured Party’s sole discretion, but Secured Party shall not be obligated to, whether or not an Event of Default shall have occurred, advance funds on behalf of the Company or Pledgor, without prior notice to the Pledgor or the Company, in order to insure the Company’s and Pledgor’s compliance with any covenant, warranty, representation or agreement of the Pledgor or the Company made in or pursuant to this Agreement or the other Transaction Documents, to continue or complete, or cause to be continued or completed, performance of the Pledgor’s and the Company’s obligations under any contracts of the Pledgor or the Company, or to preserve or protect any right or interest of Secured Party in the Collateral or under or pursuant to this Agreement or the other Transaction Documents; provided, however, that the making of any such advance by Secured Party shall not constitute a waiver by Secured Party of any Event of Default with respect to which such advance is made, nor relieve the Pledgor or the Company of any such Event of Default. The Pledgor and the Company, respectively and as applicable, shall pay to Secured Party upon demand all such advances made by Secured Party with interest thereon at the highest rate permitted by applicable law. All such advances shall be deemed to be included in the Obligations and secured by the security interest granted Secured Party hereunder; provided, however, that the provisions of this Subsection shall survive the termination of this Agreement and Secured Party’s security interest hereunder and the payment of all other Obligations.

 

(b) Applications of Payments and Collateral. Except as may be otherwise specifically provided in this Agreement or the other Transaction Documents, all Collateral and proceeds of Collateral coming into Secured Party’s possession may be applied by Secured Party (after payment of any costs, fees and other amounts incurred by Secured Party in connection therewith) to any of the Obligations, whether matured or unmatured, as Secured Party shall determine in its sole discretion. Any surplus held by the Secured Party and remaining after the indefeasible payment in full in cash of all of the Obligations shall be paid over to whomsoever shall be lawfully entitled to receive the same or as a court of competent jurisdiction shall direct. In the event that the proceeds of any such sale, collection or realization are insufficient to pay all amounts to which the Secured Party is legally entitled, the Company shall be liable for the deficiency, together with interest thereon at the highest rate permitted by applicable law, together with the costs of collection and the reasonable fees, costs, expenses and other client charges of any attorneys employed by the Secured Party to collect such deficiency.

 

(c) Waivers by Pledgor and the Company. The Company and the Pledgor hereby waive, to the extent the same may be waived under applicable law: (i) notice of acceptance of this Agreement; (ii) all claims and rights of the Pledgor and the Company against Secured Party on account of actions taken or not taken by Secured Party in the exercise of Secured Party’s rights or remedies hereunder, under any other Transaction Documents or under applicable law; (iii) all claims of the Pledgor and the Company for failure of Secured Party to comply with any requirement of applicable law relating to enforcement of Secured Party’s rights or remedies hereunder, under the other Transaction Documents or under applicable law; (iv) all rights of redemption of the Pledgor with respect to the Collateral; (v) in the event Secured Party seeks to repossess any or all of the Collateral by judicial proceedings, any bond(s) or demand(s) for possession which otherwise may be necessary or required; (vi) presentment, demand for payment, protest and notice of non-payment and all exemptions applicable to any of the Collateral or the Pledgor or the Company; (vii) any and all other notices or demands which by applicable law must be given to or made upon the Pledgor or the Company by Secured Party; (viii) settlement, compromise or release of the obligations of any person or entity primarily or secondarily liable upon any of the Obligations; (ix) all rights of the Pledgor or the Company to demand that Secured Party release account debtors or other persons or entities liable on any of the Collateral from further obligation to Secured Party; and (x) substitution, impairment, exchange or release of any Collateral for any of the Obligations. The Pledgor and the Company agree that Secured Party may exercise any or all of its rights and/or remedies hereunder and under any other Transaction Documents and under applicable law without resorting to and without regard to any Collateral or sources of liability with respect to any of the Obligations.

 

13

 

  

(d) Waivers by Secured Party. No failure or any delay on the part of Secured Party in exercising any right, power or remedy hereunder or under any other Transaction Documents or under applicable law, shall operate as a waiver thereof.

 

(e) Secured Party’s Setoff. Secured Party shall have the right, in addition to all other rights and remedies available to it, following an Event of Default, to set off against any Obligations due Secured Party, any debt owing to the Pledgor or the Company by Secured Party.

 

(f) Modifications, Waivers and Consents. No modifications or waiver of any provision of this Agreement or any other Transaction Documents, and no consent by Secured Party to any departure by the Pledgor or the Company therefrom, shall in any event be effective unless the same shall be in writing, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given, and any single or partial written waiver by Secured Party of any term, provision or right of Secured Party hereunder shall only be applicable to the specific instance to which it relates and shall not be deemed to be a continuing or future waiver of any other right, power or remedy. No notice to or demand upon the Pledgor or the Company in any case shall entitle Pledgor or the Company to any other or further notice or demand in the same, similar or other circumstances.

 

(g) Notices. All notices of request, demand and other communications hereunder shall be addressed, sent and deemed delivered in accordance with the Note, including delivery of any such notices or communications to the Pledgor on behalf of the Company, which the Company hereby agrees and acknowledges shall be valid and effective notice to the Company hereunder.

 

(h) APPLICABLE LAW AND CONSENT TO JURISDICTION. THE PLEDGOR, THE COMPANY AND THE SECURED PARTY EACH IRREVOCABLY AGREES THAT ANY DISPUTE ARISING UNDER, RELATING TO, OR IN CONNECTION WITH, DIRECTLY OR INDIRECTLY, THIS AGREEMENT OR RELATED TO ANY MATTER WHICH IS THE SUBJECT OF OR INCIDENTAL TO THIS AGREEMENT (WHETHER OR NOT SUCH CLAIM IS BASED UPON BREACH OF CONTRACT OR TORT) SHALL BE SUBJECT TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE STATE AND/OR FEDERAL COURTS LOCATED IN NEW YORK; PROVIDED, HOWEVER, SECURED PARTY MAY, AT SECURED PARTY’S SOLE OPTION, ELECT TO BRING ANY ACTION IN ANY OTHER JURISDICTION. THIS PROVISION IS INTENDED TO BE A “MANDATORY” FORUM SELECTION CLAUSE AND GOVERNED BY AND INTERPRETED CONSISTENT WITH NEW YORK LAW. THE PLEDGOR, THE COMPANY AND SECURED PARTY EACH HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION AND VENUE OF ANY STATE OR FEDERAL COURT HAVING ITS SITUS IN SAID COUNTY (OR TO ANY OTHER JURISDICTION OR VENUE, IF SECURED PARTY SO ELECTS), AND EACH WAIVES ANY OBJECTION BASED ON FORUM NON CONVENIENS. THE PLEDGOR AND THE COMPANY EACH HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS AND CONSENT THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, DIRECTED TO THE PLEDGOR OR THE COMPANY, AS APPLICABLE, AS SET FORTH HEREIN AND IN THE MANNER PROVIDED BY APPLICABLE STATUTE, LAW, RULE OF COURT OR OTHERWISE. EXCEPT FOR THE FOREGOING MANDATORY FORUM SELECTION CLAUSE, THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS.

 

14

 

 

(i) Survival: Successors and Assigns. All covenants, agreements, representations and warranties made herein shall survive the execution and delivery hereof, and shall continue in full force and effect until all Obligations have been paid in full, there exists no commitment by Secured Party which could give rise to any Obligations. Whenever in this Agreement any of the parties hereto is referred to, such reference shall be deemed to include the successors and assigns of such party. In the event that Secured Party assigns this Agreement and/or its security interest in the Collateral, such assignment shall be binding upon and recognized by the Pledgor. All covenants, agreements, representations and warranties by or on behalf of the Pledgor or the Company which are contained in this Agreement shall inure to the benefit of Secured Party, its successors and assigns. Neither the Pledgor, nor the Company, may assign this Agreement or delegate any of their respective rights or obligations hereunder, without the prior written consent of Secured Party, which consent may be withheld in Secured Party’s sole and absolute discretion.

 

(j) Severability. If any term, provision or condition, or any part thereof, of this Agreement shall for any reason be found or held invalid or unenforceable by any court or governmental authority of competent jurisdiction, such invalidity or unenforceability shall not affect the remainder of such term, provision or condition nor any other term, provision or condition, and this Agreement shall survive and be construed as if such invalid or unenforceable term, provision or condition had not been contained therein.

 

(k) Merger, Integration and Non-Reliance. This Agreement and the other Transaction Documents contain the entire agreement of the parties hereto with respect to the matters covered and the transactions contemplated hereby, and no other agreement, statement or promise made by any party hereto, or by any employee, officer, agent or attorney of any party hereto, which is not contained herein shall be valid or binding. Further, Pledgor understands and acknowledges that the agents and representatives of the Secured Party do not have authority to make any statements, promises or representations in conflict with or in addition to the information contained in this Agreement or any other loan document, and Secured Party hereby specifically disclaims any responsibility for any such statements, promises or representations. by execution of this Agreement, Pledgor acknowledges that he has not relied upon such statements, promises or representations, if any, and waives any rights, defenses, or claims arising from any such statements, promises or representations.

  

15

 

 

(l) WAIVER OF JURY TRIAL. THE PLEDGOR AND THE COMPANY EACH HEREBY: (i) COVENANTS AND AGREES NOT TO ELECT A TRIAL BY JURY OF ANY ISSUE TRIABLE OF RIGHT BY A JURY; AND (ii) WAIVES TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO WHICH THE PLEDGOR, THE COMPANY AND SECURED PARTY MAY BE PARTIES, ARISING OUT OF, IN CONNECTION WITH OR IN ANY WAY PERTAINING TO THIS AGREEMENT, AND/OR ANY TRANSACTIONS, OCCURRENCES, COMMUNICATIONS, OR UNDERSTANDINGS (OR THE LACK OF ANY OF THE FOREGOING) RELATING IN ANY WAY TO DEBTOR-CREDITOR RELATIONSHIP BETWEEN THE PARTIES. IT IS UNDERSTOOD AND AGREED THAT THIS WAIVER CONSTITUTES A WAIVER OF TRIAL BY JURY OF ALL CLAIMS AGAINST ALL PARTIES TO SUCH ACTIONS OR PROCEEDINGS, INCLUDING CLAIMS AGAINST PARTIES WHO ARE NOT PARTIES TO THIS AGREEMENT. THIS WAIVER OF JURY TRIAL IS SEPARATELY GIVEN, KNOWINGLY, WILLINGLY AND VOLUNTARILY MADE BY THE PLEDGOR AND THE COMPANY AND THE PLEDGOR AND THE COMPANY HEREBY AGREE THAT NO REPRESENTATIONS OF FACT OR OPINION HAVE BEEN MADE BY ANY INDIVIDUAL TO INDUCE THIS WAIVER OF TRIAL BY JURY OR TO IN ANY WAY MODIFY OR NULLIFY ITS EFFECT. SECURED PARTY IS HEREBY AUTHORIZED TO SUBMIT THIS AGREEMENT TO ANY COURT HAVING JURISDICTION OVER THE SUBJECT MATTER AND THE PLEDGOR, THE COMPANY AND SECURED PARTY, SO AS TO SERVE AS CONCLUSIVE EVIDENCE OF SUCH WAIVER OF RIGHT TO TRIAL BY JURY. THE PLEDGOR AND THE COMPANY REPRESENT AND WARRANT THAT EACH OF THEM HAS BEEN REPRESENTED IN THE SIGNING OF THIS AGREEMENT AND IN THE MAKING OF THIS WAIVER BY INDEPENDENT LEGAL COUNSEL, SELECTED OF ITS OWN FREE WILL, AND/OR THAT IT HAS HAD THE OPPORTUNITY TO DISCUSS THIS WAIVER WITH COUNSEL.

 

(m) Execution. This Agreement may be executed in one or more counterparts, all of which taken together shall be deemed and considered one and the same Agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format file or other similar format file, such signature shall be deemed an original for all purposes and shall create a valid and binding obligation of the party executing same with the same force and effect as if such facsimile or “.pdf” signature page was an original thereof.

 

(n) Headings. The headings and sub-headings contained in the titling of this Agreement are intended to be used for convenience only and shall not be used or deemed to limit or diminish any of the provisions hereof.

 

(o) Gender and Use of Singular and Plural. All pronouns shall be deemed to refer to the masculine, feminine, neuter, singular or plural, as the identity of the party or parties or their personal representatives, successors and assigns may require.

 

16

 

 

(p) Further Assurances. The parties hereto will execute and deliver such further instruments and do such further acts and things as may be reasonably required to carry out the intent and purposes of this Agreement, including the execution and filing of UCC-1 Financing Statements in any jurisdiction as Secured Party may require.

 

(q) Time is of the Essence. The parties hereby agree that time is of the essence with respect to performance of each of the parties’ obligations under this Agreement. The parties agree that in the event that any date on which performance is to occur falls on a Saturday, Sunday or state or national holiday, then the time for such performance shall be extended until the next business day thereafter occurring.

 

(r) Joint Preparation. The preparation of this Agreement has been a joint effort of the parties and the resulting documents shall not, solely as a matter of judicial construction, be construed more severely against one of the parties than the other.

 

(s) Prevailing Party. If any legal action or other proceeding is brought for the enforcement of this Agreement or any other Transaction Documents, or because of an alleged dispute, breach, default or misrepresentation in connection with any provisions of this Agreement or any other Transaction Documents, the successful or prevailing party or parties shall be entitled to recover from the non-prevailing party, reasonable attorneys’ fees, court costs and all expenses, even if not taxable as court costs (including, without limitation, all such fees, costs and expenses incident to appeals), incurred in that action or proceeding, in addition to any other relief to which such party or parties may be entitled.

 

(t) Costs and Expenses. The Pledgor and the Company, jointly and severally, agree to pay to the Secured Party, upon demand, the amount of any and all costs and expenses, including the reasonable fees, costs, expenses and disbursements of counsel for the Secured Party and of any experts and agents, which the Secured Party may incur in connection with: (i) the preparation, negotiation, execution, delivery, recordation, administration, amendment, waiver or other modification or termination of this Agreement, (ii) the custody, preservation, use or operation of, or the sale of, collection from, or other realization upon, any Collateral; (iii) the exercise, enforcement or defense of any of the rights of the Secured Party hereunder, including at all levels of litigation; or (iv) the failure by the Pledgor or the Company to perform or observe any of the provisions hereof. Included in the foregoing shall be the amount of all expenses paid or incurred by Secured Party in consulting with counsel concerning any of its rights hereunder, under any Transaction Documents or under applicable law, as well as such portion of Secured Party’s overhead as Secured Party shall allocate to collection and enforcement of the Obligations in Secured Party’s sole but reasonable discretion. All such costs and expenses shall bear interest from the date of outlay until paid, at the highest rate allowed by law. The provisions of this Subsection shall survive the termination of this Agreement and Secured Party’s security interest hereunder and the payment of all Obligations.

 

(u) Non-Recourse Guarantee. The Pledgor hereby absolutely, unconditionally and irrevocably guarantees to the Secured Party, for the ratable benefit of the Secured Party and its respective successors, indorsees, transferees and assigns, the prompt and complete payment and performance by the Borrower when due (whether at the stated maturity, by acceleration or otherwise) of the Obligations, provided, however, if and to the extent required in order for the Obligations of the Pledgor to be enforceable under applicable federal, state and other laws, the maximum liability of the Pledgor hereunder shall be limited to the amount which is received pursuant to the excise of any and all rights to foreclose upon the Pledged Securities and the rights pertaining thereto contained herein.

 

[Signatures on the following page]

 

17

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.

 

PLEDGOR:  
   
/s/ Aaron Drew  
AARON DREW  

 

[Signature Page – BEARN, LLC. –Pledge and Escrow Agreement]

 

 

 

 

COMPANY:  
     
BEARN, LLC  
     
  /s/ Aaron Drew  
Name:   Aaron Drew  
Title: CEO  

 

[Signature Page – BEARN, LLC. –Pledge and Escrow Agreement]

 

 

 

 

SECURED PARTY:  
     
MYFIZIQ LIMITED  
     
By: /s/ Vlado Bosanac  
Name:   Vlado Bosanac  
Title: CEO  

 

[Signature Page – BEARN, LLC. –Pledge and Escrow Agreement]

 

 

 

 

 

Exhibit 10.30

 

SECURITY AGREEMENT

 

This SECURITY AGREEMENT (the “Security Agreement”) dated and made effective as of January 20, 2021 is executed by Bearn LLC, a limited liability company organized and existing under the laws of the State of Maryland, including any successors or assigns (the “Debtor”) and MyFizIQ Limited, a limited corporation incorporated under the laws of Australia (the “Secured Party”).

 

R E C I T A L S:

 

WHEREAS, pursuant to Promissory Note dated as of the date hereof (the “Loan Agreement”), issued by the Debtor, as borrower, in favor of the Secured Party, as lender, the Secured Party has agreed to advance certain loan proceeds to the Debtor; and

 

WHEREAS, in order to induce the Secured Party to made the loan advances to the Debtor the Debtor has agreed to execute and deliver to the Secured Party this Agreement for the benefit of the Secured Party and to grant to Secured Party an unconditional and continuing, first priority security interest in the Software of the Debtor to secure the prompt payment, performance and discharge in full of all of Debtor’s obligation under the Loan Agreement and the other transaction documents executed in connection therewith (the “Transaction Documents”).

 

A G R E E M E N T S:

 

1 DEFINITIONS.

 

1.1 Defined Terms. Capitalized terms used but not otherwise defined in this Security Agreement (including the Recitals) shall have the meanings ascribed to them in the Loan Agreement. For the purposes of this Security Agreement, the following capitalized words and phrases shall have the meanings set forth below.

 

(a) Bearn App” means means downloadable application software designed to run on mobile platforms including Android and iOS operating systems and which, inter alia, in combination with a fitness tracker, captures, processes, stores and transmits biometric data..

 

(b) “Capital Securities” shall mean, with respect to any Person, all shares, interests, participations or other equivalents (however designated, whether voting or non-voting) of such Person’s capital, whether now outstanding or issued or acquired after the date hereof, including common shares, preferred shares, membership interests in a limited liability company, limited or general partnership interests in a partnership or any other equivalent of such ownership interest.

 

(c) “Collateral” shall have the meaning set forth in Section 2.1 hereof.

 

(d) “Obligor” shall mean Debtor, or any other party liable with respect to the Obligations.

 

1

 

 

(e) “Organizational Identification Number” means, with respect to Debtor, the organizational identification number assigned to Debtor by the applicable governmental unit or agency of the jurisdiction of organization of Debtor, if any.

 

(f) “Software” shall mean software developed by the Debtor, including the Bearn App and related back end operating software used in connection with the operation of the Debtor’s business, including, but not limited to IOS and Android downloadable mobile applications for, inter alia, the measurement of calories burned by a user.

 

(g) “Taxes” shall mean any and all present and future taxes, duties, levies, imposts, deductions, assessments, charges or withholdings, and any and all liabilities (including interest and penalties and other additions to taxes) with respect to the foregoing.

 

(h) “Unmatured Event of Default” shall mean any event which, with the giving of notice, the passage of time or both, would constitute an Event of Default.

 

1.2 Other Terms Defined in UCC. All other capitalized words and phrases used herein and not otherwise specifically defined herein or in the Loan Agreement shall have the respective meanings assigned to such terms in the UCC, to the extent the same are used or defined therein.

 

1.3 Other Interpretive Provisions.

 

(a) The meanings of defined terms are equally applicable to the singular and plural forms of the defined terms. Whenever the context so requires, the neutral gender includes the masculine and feminine, the single number includes the plural, and vice versa, and in particular the word “Debtor” shall be so construed.

 

(b) Section and Schedule references are to this Security Agreement unless otherwise specified. The words “hereof”, “herein” and “hereunder” and words of similar import when used in this Security Agreement shall refer to this Security Agreement as a whole and not to any particular provision of this Security Agreement

 

(c) The term “including” (or words of similar import) is not limiting, and means “including, without limitation”.

 

(d) In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including”; the words “to” and “until” each mean “to but excluding”, and the word “through” means “to and including”.

 

(e) Unless otherwise expressly provided herein: (i) references to agreements (including this Security Agreement and the other Transaction Documents) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, supplements and other modifications thereto, but only to the extent such amendments, restatements, supplements and other modifications are not prohibited by the terms of any Transaction Document; and (ii) references to any statute or regulation shall be construed as including all statutory and regulatory provisions amending, replacing, supplementing or interpreting such statute or regulation.

 

2

 

 

(f) To the extent any of the provisions of the other Transaction Documents are inconsistent with the terms of this Security Agreement, the provisions of this Security Agreement shall govern.

 

(g) This Security Agreement and the other Transaction Documents may use several different limitations, tests or measurements to regulate the same or similar matters. All such limitations, tests and measurements are cumulative and each shall be performed in accordance with its terms.

 

2 SECURITY FOR THE OBLIGATIONS.

 

2.1 Security for Obligations. As security for the payment and performance of the Obligations, Debtor does hereby pledge, assign, transfer, deliver and grant to Secured Party, for its own benefit and as agent for its Affiliates, the Software (“Collateral”).

 

2.2 Possession and Transfer of Collateral. Until an Event of Default has occurred, Debtor shall be entitled to possession and use of the Collateral. The cancellation or surrender of any promissory note evidencing an Obligation, upon payment or otherwise, shall not affect the right of Secured Party to retain the Collateral for any other of the Obligations, except upon payment in full of the Obligations. Debtor shall not sell, assign (by operation of law or otherwise), license, lease or otherwise dispose of, or grant any option with respect to any of the Collateral, except as permitted pursuant to the Loan Agreement.

 

2.3 Financing Statements. Debtor authorizes Secured Party to prepare and file such financing statements, amendments and other documents and do such acts as Secured Party deems necessary in order to establish and maintain valid, attached and perfected, first priority security interests in the Collateral in favor of Secured Party, for its own benefit and as agent for its Affiliates, free and clear of all Liens and claims and rights of third parties whatsoever, except Permitted Liens. Debtor hereby irrevocably authorizes Secured Party at any time, and from time to time, to file in any jurisdiction any initial financing statements and amendments thereto that: (a) indicate the Collateral: (i) is comprised of all assets of Debtor (or words of similar effect), regardless of whether any particular asset comprising a part of the Collateral falls within the scope of Article 9 of the UCC of the jurisdiction wherein such financing statement or amendment is filed; or (ii) as being of an equal or lesser scope or within greater detail as the grant of the security interest set forth herein; and (b) contain any other information required by Section 5 of Article 9 of the UCC of the jurisdiction wherein such financing statement or amendment is filed regarding the sufficiency or filing office acceptance of any financing statement or amendment, including: (A) whether Debtor is an organization, the type of organization and any Organizational Identification Number issued to each Debtor; and (B) in the case of a financing statement filed as a fixture filing or indicating Collateral as as-extracted collateral or timber to be cut, a sufficient description of the real property to which the Collateral relates. Debtor agrees to furnish any such information to Secured Party promptly upon request. In addition, Debtor shall make appropriate entries on their books and records disclosing the security interests of Secured Party, for its own benefit and as agent for its Affiliates, in the Collateral. Debtor hereby agrees that a photogenic or other reproduction of this Security Agreement is sufficient for filing as a financing statement and Debtor authorizes Secured Party to file this Security Agreement as a financing statement in any jurisdiction.

 

3

 

 

2.4 Preservation of the Collateral. Secured Party may, but is not required to, take such actions from time to time as Secured Party deems appropriate to maintain or protect the Collateral. Secured Party shall have exercised reasonable care in the custody and preservation of the Collateral if Secured Party takes such action as Debtor shall reasonably request in writing which is not inconsistent with Secured Party’s status as a secured party, but the failure of Secured Party to comply with any such request shall not be deemed a failure to exercise reasonable care; provided, however, Secured Party’s responsibility for the safekeeping of the Collateral shall: (i) be deemed reasonable if such Collateral is accorded treatment substantially equal to that which Secured Party accords its own property; and (ii) not extend to matters beyond the control of Secured Party, including acts of God, war, insurrection, riot or governmental actions. In addition, any failure of Secured Party to preserve or protect any rights with respect to the Collateral against prior or third parties, or to do any act with respect to preservation of the Collateral, not so requested by Debtor, shall not be deemed a failure to exercise reasonable care in the custody or preservation of the Collateral. Debtor shall have the sole responsibility for taking such action as may be necessary, from time to time, to preserve all rights of Debtor and Secured Party in the applicable Collateral against prior or third parties.

 

2.5 Other Actions as to any and all Collateral. Debtor further agrees to take any other action reasonably requested by Secured Party to ensure the attachment, perfection and first priority of, and the ability of Secured Party to enforce, the security interest of Secured Party, for its own benefit and as agent for its Affiliates, in any and all of the Collateral, including: (i) causing Secured Party’s name to be noted as secured party on any certificate of title for a titled good if such notation is a condition to attachment, perfection or priority of, or ability of the bank to enforce, the security interest of Secured Party, for its own benefit and as agent for its Affiliates, in such Collateral; (ii) complying with any provision of any statute, regulation or treaty of the United States as to any material portion of the Collateral as soon as possible but not more than forty-five (45) days after such request if compliance with such provision is a condition to attachment, perfection or priority of, or ability of Secured Party to enforce, the security interest of Secured Party, for its own benefit and as agent for its Affiliates, in such Collateral; (iii) obtaining governmental and other third party consents and approvals, including, without limitation, any consent of any licensor, lessor or other Person with authority or control over or an interest in any material portion of the Collateral as soon as possible but not more than forty-five (45) days after such request; (iv) obtaining waivers from mortgagees and landlords in form and substance reasonably satisfactory to Secured Party which affect any material portion of the Collateral as soon as possible but not more than forty- five (45) days after such request; and (v) taking all actions required by the UCC in effect from time to time or by other law, as applicable in any relevant UCC jurisdiction, or by other law as applicable in any foreign jurisdiction. Debtor further agrees to indemnify and hold Secured Party harmless against claims of any Persons not a party to this Security Agreement concerning disputes arising over the Collateral, except to the extent resulting from the gross negligence or willful misconduct of Secured Party or its Affiliates.

 

4

 

 

2.6 Letter-of-Credit Rights. If Debtor at any time is a beneficiary under a letter of credit now or hereafter issued in favor of Debtor, Debtor shall promptly notify Secured Party thereof and, at the request and option of Secured Party, Debtor shall, pursuant to an agreement in form and substance reasonably satisfactory to Secured Party, either: (i) arrange for the issuer and any confirmer of such letter of credit to consent to an assignment to Secured Party, for its own benefit and as agent for its Affiliates, of the proceeds of any drawing under the letter of credit; or (ii) arrange for Secured Party, for its own benefit and as agent for its Affiliates, to become the transferee beneficiary of the letter of credit, with Secured Party agreeing, in each case, that the proceeds of any drawing under the letter to credit are to be applied as provided in the Loan Agreement.

 

2.7 Commercial Tort Claims. If Debtor shall at any time hold or acquire a Commercial Tort Claim, Debtor shall promptly notify Secured Party in writing signed by Debtor of the details thereof and grant to Secured Party, for its own benefit and as agent for its Affiliates, in such written notice or other written instrument, a security interest therein and in the proceeds thereof, all upon the terms of this Security Agreement, in each case in form and substance reasonably satisfactory to Secured Party, and shall execute any amendments hereto deemed reasonably necessary by Secured Party to perfect the security interest of Secured Party, for its own benefit and as agent for its Affiliates, in such Commercial Tort Claim.

 

2.8 Additional Requirements on Collateral. Debtor, at the Debtor’ expense, shall promptly: (A) execute all notices of security interest for each relevant type of Software in forms suitable for filing with any United States or foreign office handling the registration or filing of copyrights and other intellectual property and any successor office or agency thereto; and (B) take all commercially reasonable steps in any hearing, suit, action, or other proceeding before any such office or any similar office or agency in any other country or any political subdivision thereof, to diligently prosecute or maintain, as applicable, each application and registration of any Software or any other intellectual property rights and assets that are part of the Collateral, including filing of renewals, affidavits of use, affidavits of incontestability and opposition, interference and cancellation proceedings.

 

3 REPRESENTATIONS AND WARRANTIES.

 

Debtor make the following representations and warranties to Secured Party:

 

3.1 Debtor Organization and Name. Debtor is a limited liability company, duly organized, existing and in good standing under the laws of its State of organization, with full and adequate power to carry on and conduct its business as presently conducted. Debtor is duly licensed or qualified in all foreign jurisdictions wherein the nature of their activities requires such qualification or licensing. Debtor’s Organizational Identification Number, if applicable, is set forth in the Loan Agreement. The exact legal name of Debtor is as set forth in the first paragraph of this Security Agreement, and Debtor currently do not conduct, nor has it during the last five (5) years conducted, business under any other name or trade name.

 

5

 

 

3.2 Authorization. Debtor has full right, power and authority to enter into this Security Agreement and to perform all of their duties and obligations under this Security Agreement. The execution and delivery of this Security Agreement and the other Transaction Documents will not, nor will the observance or performance of any of the matters and things herein or therein set forth, violate or contravene any provision of law or of the articles of incorporation, bylaws, operating agreement, or other governing documents of Debtor. All necessary and appropriate action has been taken on the part of Debtor to authorize the execution and delivery of this Security Agreement.

 

3.3 Validity and Binding Nature. This Security Agreement is the legal, valid and binding obligation of Debtor, enforceable against Debtor in accordance with its terms, subject to bankruptcy, insolvency and similar laws affecting the enforceability of creditors’ rights generally and to general principles of equity.

 

3.4 Consent; Absence of Breach. The execution, delivery and performance of this Security Agreement and any other documents or instruments to be executed and delivered by Debtor in connection herewith, do not and will not: (a) require any consent, approval, authorization, or filings with, notice to or other act by or in respect of, any governmental authority or any other Person (other than filings or notices pursuant to federal or state securities laws or other than any consent or approval which has been obtained and is in full force and effect); (b) conflict with: (i) any provision of law or any applicable regulation, order, writ, injunction or decree of any court or governmental authority; (ii) the articles of incorporation, bylaws, or other organic or governance document of Debtor; or (iii) any agreement, indenture, instrument or other document, or any judgment, order or decree, which is binding upon Debtor or any of their properties or assets; or (c) require, or result in, the creation or imposition of any Lien on any asset of Debtor, other than Liens in favor of Secured Party created pursuant to this Security Agreement and Permitted Liens.

 

3.5 Ownership of Collateral; Liens. Debtor is the sole owners of all the Collateral, free and clear of all Liens, charges and claims (including infringement claims with respect to patents, trademarks, service marks, copyrights and other intellectual property rights), other than Permitted Liens.

 

3.6 Adverse Circumstances. No condition, circumstance, event, agreement, document, instrument, restriction, litigation or proceeding (or threatened litigation or proceeding or basis therefor) exists which: (i) would have a Material Adverse Effect upon Debtor; or (ii) would constitute an Event of Default or an Unmatured Event of Default.

 

3.7 Security Interest. This Security Agreement creates a valid security interest in favor of Secured Party in the Collateral and, when properly perfected by filing in the appropriate jurisdictions and or agency, shall constitute a valid, perfected, first-priority security interest in such Collateral.

 

6

 

 

3.8 Place of Business. The principal place of business and books and records of Debtor and location of all Collateral is set forth in the preamble to this Security Agreement, and Debtor shall promptly notify Secured Party of any change in such location. Debtor will not remove or permit the Collateral to be removed from such locations without the prior written consent of Secured Party, except as permitted pursuant to the Loan Agreement.

 

3.9 Complete Information. This Security Agreement and all financial statements, schedules, certificates, confirmations, agreements, contracts, and other materials and information heretofore or contemporaneously herewith furnished in writing by Debtor to Secured Party for purposes of, or in connection with, this Security Agreement and the transactions contemplated hereby is, and all written information hereafter furnished by or on behalf of Debtor to Secured Party pursuant hereto or in connection herewith will be, true and accurate in every material respect on the date as of which such information is dated or certified, and none of such information is or will be incomplete by omitting to state any material fact necessary to make such information not misleading in light of the circumstances under which made (it being recognized by Secured Party that any projections and forecasts provided by Debtor are based on good faith estimates and assumptions believed by Debtor to be reasonable as of the date of the applicable projections or assumptions and that actual results during the period or periods covered by any such projections and forecasts may differ from projected or forecasted results).

 

4 REMEDIES.

 

Upon the occurrence of any default in the payment or performance of any of the covenants, conditions and agreements contained in this Security Agreement or any other Event of Default, Secured Party shall have all rights, powers and remedies set forth in this Security Agreement or the other Transaction Documents or in any other written agreement or instrument relating to any of the Obligations or any security therefor, as a secured party under the UCC or as otherwise provided at law or in equity. Without limiting the generality of the foregoing, Secured Party may, at its option upon the occurrence of an Event of Default, declare its commitments to Debtor to be terminated and all Obligations to be immediately due and payable, or, if provided in the Transaction Documents, all commitments of Secured Party to Debtor shall immediately terminate and all Obligations shall be automatically due and payable, all without demand, notice or further action of any kind required on the part of Secured Party. Debtor hereby waives any and all presentment, demand, notice of dishonor, protest, and all other notices and demands in connection with the enforcement of Secured Party’s rights under the Transaction Documents, and hereby consent to, and waives notice of release, with or without consideration, of any Collateral, notwithstanding anything contained herein or in the Transaction Documents to the contrary. In addition to the foregoing:

 

4.1 Possession and Assembly of Collateral. Secured Party may, without notice, demand or the initiation of legal process of any kind, take possession of any or all of the Collateral (in addition to Collateral of which Secured Party already has possession), wherever it may be found, and for that purpose may pursue the same wherever it may be found, and may at any time enter into any of Debtor’ premises where any of the Collateral may be or is supposed to be, and search for, take possession of, remove, keep and store any of the Collateral until the same shall be sold or otherwise disposed of and Secured Party shall have the right to store and conduct a sale of the same in any of Debtor’ premises without cost to Secured Party. At Secured Party’s request, Debtor will, at Debtor’ sole expense, assemble the Collateral and make it available to Secured Party at a place or places to be designated by Secured Party which is reasonably convenient to Secured Party and Debtor.

 

7

 

 

4.2 Sale of Collateral. Secured Party may sell any or all of the Collateral at public or private sale, upon such terms and conditions as Secured Party may deem proper, and Secured Party may purchase any or all of the Collateral at any such sale. Debtor acknowledges that Secured Party may be unable to effect a public sale of all or any portion of the Collateral because of certain legal and/or practical restrictions and provisions which may be applicable to the Collateral and, therefore, may be compelled to resort to one or more private sales to a restricted group of offerees and purchasers. Debtor consents to any such private sale so made even though at places and upon terms less favorable than if the Collateral were sold at public sale. Secured Party shall have no obligation to clean-up or otherwise prepare the Collateral for sale. Secured Party may apply the net proceeds, after deducting all costs, expenses, attorneys’ and paralegals’ fees incurred or paid at any time in the collection, protection and sale of the Collateral and the Obligations, to the payment of the Obligations, returning the excess proceeds, if any, to Debtor. Debtor shall remain liable for any amount remaining unpaid after such application, with interest at the default rate under the Loan Agreement. Any notification of intended disposition of the Collateral required by law shall be conclusively deemed reasonably and properly given if given by Secured Party at least ten (10) calendar days before the date of such disposition. Debtor hereby confirm, approve and ratify all acts and deeds of Secured Party relating to the foregoing, and each part thereof, and expressly waives any and all claims of any nature, kind or description which it has or may hereafter have against Secured Party or its representatives, by reason of taking, selling or collecting any portion of the Collateral. Debtor consents to releases of the Collateral at any time (including prior to default) and to sales of the Collateral in groups, parcels or portions, or as an entirety, as Secured Party shall deem appropriate. Debtor expressly absolves Secured Party from any loss or decline in market value of any Collateral by reason of delay in the enforcement or assertion or non-enforcement of any rights or remedies under this Security Agreement.

 

4.3 Standards for Exercising Remedies. To the extent that applicable law imposes duties on Secured Party to exercise remedies in a commercially reasonable manner, Debtor acknowledge and agree that it is not commercially unreasonable for Secured Party: (i) to incur expenses deemed necessary by Secured Party to prepare Collateral for disposition or otherwise to complete raw material or work-in-process into finished goods or other finished products for disposition; (ii) to fail to obtain third party consents for access to Collateral to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third party consents for the collection or disposition of Collateral to be collected or disposed of; (iii) to fail to exercise collection remedies against any of their customers or other Persons obligated on Collateral or to remove liens or encumbrances on or any adverse claims against Collateral; (iv) to exercise collection remedies against any of their customers and other Persons obligated on Collateral directly or through the use of collection agencies and other collection specialists; (v) to advertise dispositions of Collateral through publications or media of general circulation, whether or not the Collateral is of a specialized nature; (vi) to contact other Persons, whether or not in the same business as Debtor, for expressions of interest in acquiring all or any portion of the Collateral; (vii) to hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the Collateral is of a specialized nature; (viii) to dispose of Collateral by utilizing internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match buyers and sellers of assets; (ix) to dispose of assets in wholesale rather than retail markets; (x) to disclaim disposition warranties, including any warranties of title; (xi) to purchase insurance or credit enhancements to insure Secured Party against risks of loss, collection or disposition of Collateral or to provide to Secured Party a guaranteed return from the collection or disposition of Collateral; or (xii) to the extent deemed appropriate by Secured Party, to obtain the services of other brokers, investment bankers, consultants and other professionals to assist Secured Party in the collection or disposition of any of the Collateral. Debtor acknowledges that the purpose of this section is to provide non-exhaustive indications of what actions or omissions by Secured Party would not be commercially unreasonable in Secured Party’s exercise of remedies against the Collateral and that other actions or omissions by Secured Party shall not be deemed commercially unreasonable solely on account of not being indicated in this Section. Without limitation upon the foregoing, nothing contained in this Section shall be construed to grant any rights to Debtor or to impose any duties on Secured Party that would not have been granted or imposed by this Security Agreement or by applicable law in the absence of this Section.

 

8

 

 

4.4 UCC and Offset Rights. Secured Party may exercise, from time to time, any and all rights and remedies available to it under the UCC or under any other applicable law in addition to, and not in lieu of, any rights and remedies expressly granted in this Security Agreement or in any other agreements between any Obligor and Secured Party, and may, without demand or notice of any kind, appropriate and apply toward the payment of such of the Obligations, whether matured or unmatured, including costs of collection and attorneys’ and paralegals’ fees and costs, and in such order of application as Secured Party may, from time to time, elect, any indebtedness of Secured Party to any Obligor, however created or arising, including balances, credits, deposits, accounts or moneys of such Obligor in the possession, control or custody of, or in transit to Secured Party. Each Debtor, on behalf of itself and any Obligor, hereby waive the benefit of any law that would otherwise restrict or limit Secured Party in the exercise of its right, which is hereby acknowledged, to appropriate at any time hereafter any such indebtedness owing from Secured Party to any Obligor.

 

4.5 Additional Remedies. Upon the occurrence of an Event of Default, Secured Party shall have the right and power to:

 

(a) extend, renew or modify for one or more periods (whether or not longer than the original period) the Obligations or any obligation of any nature of any other obligor with respect to the Obligations;

 

(b) grant releases, compromises or indulgences with respect to the Obligations, any extension or renewal of any of the Obligations, any security therefor, or to any other obligor with respect to the Obligations;

 

(c) at any time, and from time to time, accept additions to, releases, reductions, exchanges or substitution of the Collateral, without in any way altering, impairing, diminishing or affecting the provisions of this Security Agreement, the Transaction Documents, or any of the other Obligations, or Secured Party’s rights hereunder, under the Obligations.

 

Debtor hereby ratifies and confirms whatever Secured Party may do with respect to the Collateral and agrees that Secured Party shall not be liable for any error of judgment or mistakes of fact or law with respect to actions taken in connection with the Collateral.

 

9

 

 

4.6 Attorney-in-Fact. Debtor hereby irrevocably make, constitute and appoint Secured Party (and any officer of Secured Party or any Person designated by Secured Party for that purpose) as each Debtor’s true and lawful proxy and attorney-in-fact (and agent-in- fact) in each Debtor’s name, place and stead, with full power of substitution, to: (i) take such actions as are permitted in this Security Agreement; (ii) execute such financing statements and other documents and to do such other acts as Secured Party may require to perfect and preserve Secured Party’s security interest in, and to enforce such interests in the Collateral; and (iii) upon the occurrence of an Event of Default, carry out any remedy provided for in this Security Agreement, the Loan Agreement, or otherwise at law or in equity. Debtor hereby acknowledge that the constitution and appointment of such proxy and attorney-in-fact are coupled with an interest and are irrevocable. Debtor hereby ratifies and confirms all that such attorney-in-fact may do or cause to be done by virtue of any provision of this Security Agreement.

 

4.7 No Marshaling. Secured Party shall not be required to marshal any present or future collateral security (including this Security Agreement and the Collateral) for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral security or other assurances of payment in any particular order. To the extent that it lawfully may, Debtor hereby agrees that it will not invoke any law relating to the marshaling of collateral which might cause delay in or impede the enforcement of Secured Party’s rights under this Security Agreement or under any other instrument creating or evidencing any of the Obligations or under which any of the Obligations is outstanding or by which any of the Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, Debtor hereby irrevocably waive the benefits of all such laws.

 

4.8 No Waiver. No Event of Default shall be waived by Secured Party except in writing. No failure or delay on the part of Secured Party in exercising any right, power or remedy hereunder shall operate as a waiver of the exercise of the same or any other right at any other time; nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. There shall be no obligation on the part of Secured Party to exercise any remedy available to Secured Party in any order. The remedies provided for herein are cumulative and not exclusive of any remedies provided at law or in equity. Debtor agrees that in the event that it fails to perform, observe or discharge any of its Obligations or liabilities under this Security Agreement or any other agreements with Secured Party, no remedy of law will provide adequate relief to Secured Party, and further agrees that Secured Party shall be entitled to temporary and permanent injunctive relief in any such case without the necessity of proving actual damages.

10

 

 

4.9 Application of Proceeds. Secured Party will, within three (3) Business Days after receipt of cash or solvent credits from collection of items of payment, proceeds of Collateral or any other source, apply the whole or any part thereof against the Obligations secured hereby. Secured Party shall further have the exclusive right to determine how, when and what application of such payments and such credits shall be made on the Obligations, and such determination shall be conclusive upon Debtor. Any proceeds of any disposition by Secured Party of all or any part of the Collateral may be first applied by Secured Party to the payment of expenses incurred by Secured Party in connection with the Collateral, including reasonable attorneys’ fees and legal expenses and costs as provided for in Section 5.14 hereof.

 

5 MISCELLANEOUS.

 

5.1 Entire Agreement. This Security Agreement and the other Transaction Documents: (i) are valid, binding and enforceable against Debtor and Secured Party in accordance with their respective provisions and no conditions exist as to their legal effectiveness; (ii) constitute the entire agreement between the parties with respect to the subject matter hereof and thereof; and (iii) are the final expression of the intentions of Debtor and Secured Party. No promises, either expressed or implied, exist between Debtor and Secured Party, unless contained herein or therein. This Security Agreement, together with the other Transaction Documents, supersedes all negotiations, representations, warranties, commitments, term sheets, discussions, negotiations, offers or contracts (of any kind or nature, whether oral or written) prior to or contemporaneous with the execution hereof with respect to any matter, directly or indirectly related to the terms of this Security Agreement and the other Transaction Documents. This Security Agreement and the other Transaction Documents are the result of negotiations between Secured Party and Debtor and have been reviewed (or have had the opportunity to be reviewed) by counsel to all such parties and are the products of all parties. Accordingly, this Security Agreement and the other Transaction Documents shall not be construed more strictly against Secured Party merely because of Secured Party’s involvement in their preparation. DEBTOR ACKNOWLEDGE THAT IT HAS NOT RELIED UPON ANY STATEMENTS, PROMISES OR REPRESENTATIONS, IF ANY, THAT ARE NOT CONTAINED WITHIN THIS SECURITY AGREEMENT OR IN ANY OTHER THE TRANSACTION DOCUMENT AND WAIVES ANY RIGHTS, DEFENSES, OR CLAIMS ARISING FROM ANY SUCH STATEMENTS, PROMISES OR REPRESENTATIONS.

 

5.2 Amendments; Waivers. No delay on the part of Secured Party in the exercise of any right, power or remedy shall operate as a waiver thereof, nor shall any single or partial exercise by Secured Party of any right, power or remedy preclude other or further exercise thereof, or the exercise of any other right, power or remedy. No amendment, modification or waiver of, or consent with respect to, any provision of this Security Agreement or the other Transaction Documents shall in any event be effective unless the same shall be in writing and acknowledged by Secured Party, and then any such amendment, modification, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

11

 

 

5.3 WAIVER OF CLAIMS AND DEFENSES. THE DEBTOR WAIVE EVERY PRESENT AND FUTURE DEFENSE, CAUSE OF ACTION, COUNTERCLAIM OR SETOFF WHICH THE DEBTOR MAY NOW HAVE AS OF THE DATE HEREOF, OR AS THEY MAY IN THE FUTURE COME TO HAVE, TO ANY ACTION BY SECURED PARTY IN ENFORCING THIS SECURITY AGREEMENT OR ANY OTHER TRANSACTION DOCUMENTS -- OTHER THAN FOR SET OFF TO ESTABLISH THE AMOUNTS DUE AND PAID IN RESPECT OF THE LOAN AGREEMENT. THE DEBTOR UNDERSTANDS AND AGREES THAT IT IS WAIVING DEFENSES AND CLAIMS WHICH MAY NOT YET HAVE ACCRUED OR OF WHICH IT MAY NOT YET BE AWARE AS MATERIAL INDUCEMENT FOR SECURED PARTY ENTERING THIS SECURITY AGREEMENT AND GRANTING ANY FINANCIAL ACCOMMODATION TO THE DEBTOR. THIS PROVISION IS INTENDED TO BE CONSTRUED AS BROADLY AS PERMISSIBLE UNDER APPLICABLE LAW. FURTHER, THE DEBTOR UNDERSTAND AND ACKNOWLEDGE THAT THE AGENTS AND REPRESENTATIVES OF THE SECURED PARTY DO NOT HAVE AUTHORITY TO MAKE ANY STATEMENTS, PROMISES OR REPRESENTATIONS IN CONFLICT WITH OR IN ADDITION TO THE INFORMATION CONTAINED IN THIS SECURITY AGREEMENT OR ANY OTHER TRANSACTION DOCUMENT, AND SECURED PARTY HEREBY SPECIFICALLY DISCLAIMS ANY RESPONSIBILITY FOR ANY SUCH STATEMENTS, PROMISES OR REPRESENTATIONS. BY EXECUTION OF THIS AGREEMENT, THE DEBTOR ACKNOWLEDGE THAT THEY HAVE NOT RELIED UPON SUCH STATEMENTS, PROMISES OR REPRESENTATIONS, IF ANY, AND WAIVES ANY RIGHTS, DEFENSES, OR CLAIMS ARISING FROM ANY SUCH STATEMENTS, PROMISES OR REPRESENTATIONS.

 

5.4 MANDATORY FORUM SELECTION. TO INDUCE SECURED PARTY TO MAKE CERTAIN FINANCIAL ACCOMODATIONS TO DEBTOR, DEBTOR IRREVOCABLY AGREES THAT ANY DISPUTE ARISING UNDER, RELATING TO, OR IN CONNECTION WITH, DIRECTLY OR INDIRECTLY, THIS SECURITY AGREEMENT OR RELATED TO ANY MATTER WHICH IS THE SUBJECT OF OR INCIDENTAL TO THIS SECURITY AGREEMENT ANY OTHER TRANSACTION DOCUMENT, OR THE COLLATERAL (WHETHER OR NOT SUCH CLAIM IS BASED UPON BREACH OF CONTRACT OR TORT) SHALL, EXCEPT AS HEREINAFTER PROVIDED, BE SUBJECT TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE STATE AND/OR FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK; PROVIDED, HOWEVER, SECURED PARTY MAY, AT SECURED PARTY’S SOLE OPTION, ELECT TO BRING ANY ACTION IN ANY OTHER JURISDICTION. THIS PROVISION IS INTENDED TO BE A “MANDATORY” FORUM SELECTION CLAUSE AND GOVERNED BY AND INTERPRETED CONSISTENT WITH NEW YORK LAW. DEBTOR HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION AND VENUE OF ANY STATE OR FEDERAL COURT HAVING IT SITUS IN SUCH COUNTY (OR TO ANY JURISDICTION OR VENUE, IF SECURED PARTY SO ELECTS), AND DEBTOR HEREBY WAIVE ANY OBJECTION BASED ON FORUM NON CONVENIENS.

 

12

 

 

5.5 WAIVER OF PERSONAL SERVICE. DEBTOR HEREBY WAIVES PERSONAL SERVICE OF ANY AND ALL PROCESS AND CONSENTS THAT ALL SUCH SERVICE OF PROCESS MAY BE MADE BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, OR BY FEDERAL EXPRESS, DIRECTED TO THE DEBTOR, AS SET FORTH AND ACCORDING TO THE TERMS IN THE NOTICE PROVISIONS HEREIN. DEBTOR AGREE THAT NO ACKNOWLEDGMENT OF ACTUAL RECEIPT OF PROCESS IS REQUIRED AND SERVICE WILL BE DEEMED EFFECTIVE PURSUANT TO TERMS OF NOTICE PROVISIONS CONTAINED HEREIN. SERVICE MAY ALSO BE MADE IN ANY MANNER PROVIDED BY APPLICABLE STATUTE, LAW, RULE OF COURT OR OTHERWISE.

 

5.6 WAIVER OF JURY TRIAL. DEBTOR AND SECURED PARTY, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, EACH KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE IRREVOCABLY, ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS UNDER THIS SECURITY AGREEMENT, ANY NOTE, ANY OTHER TRANSACTION DOCUMENT, ANY OF THE OTHER OBLIGATIONS, THE COLLATERAL, OR ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED OR WHICH MAY IN THE FUTURE BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH OR ARISING FROM ANY LENDING RELATIONSHIP EXISTING IN CONNECTION WITH ANY OF THE FOREGOING, OR ANY COURSE OF CONDUCT OR COURSE OF DEALING IN WHICH SECURED PARTY AND DEBTOR ARE ADVERSE PARTIES, AND EACH AGREE THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. THIS PROVISION IS A MATERIAL INDUCEMENT FOR SECURED PARTY GRANTING ANY FINANCIAL ACCOMMODATION TO DEBTOR.

 

5.7 Assignability. Secured Party, without consent from or notice to anyone, may at any time assign Secured Party’s rights in this Security Agreement, the other Transaction Documents, the Obligations, or any part thereof and transfer Secured Party’s rights in any or all of the Collateral, and Secured Party thereafter shall be relieved from all liability with respect to such Collateral. This Security Agreement shall be binding upon Secured Party and Debtor and their respective legal representatives and successors. All references herein to Debtor shall be deemed to include any successors, whether immediate or remote. In the case of a joint venture or partnership, the term “Debtor” shall be deemed to include all joint venturers or partners thereof, who shall be jointly and severally liable hereunder.

 

5.8 Binding Effect. This Security Agreement shall become effective upon execution by Debtor and Secured Party and shall bind the Debtor and Secured Party, and their respective successors and permitted assigns.

 

13

 

 

5.9 Governing Law. This Security Agreement shall be delivered and accepted in and shall be deemed to be a contract made under and governed by the internal laws of the State of New York, and for all purposes shall be construed in accordance with the laws of such State, without giving effect to the choice of law provisions of such State.

 

5.10 Enforceability. Wherever possible, each provision of this Security Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Security Agreement shall be prohibited by, unenforceable or invalid under any jurisdiction, such provision shall as to such jurisdiction, be severable and be ineffective to the extent of such prohibition or invalidity, without invalidating the remaining provisions of this Security Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

5.11 Time of Essence. Time is of the essence in making payments of all amounts due Secured Party under the Transaction Documents and in the performance and observance by Debtor of each covenant, agreement, provision and term of this Security Agreement and the other Transaction Documents.

 

5.12 Counterparts; Facsimile Signatures. This Security Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Security Agreement. Receipt of an executed signature page to this Security Agreement by facsimile or other electronic transmission shall constitute effective delivery thereof. Electronic records of executed Transaction Documents maintained by Secured Party shall be deemed to be originals thereof.

 

5.13 Notices. Except as otherwise provided herein, Debtor waives all notices and demands in connection with the enforcement of Secured Party’s rights hereunder. All notices, requests, demands and other communications provided for hereunder shall be made in accordance with the terms of the Loan Agreement.

 

5.14 Costs, Fees and Expenses. Debtor shall pay or reimburse Secured Party for all reasonable costs, fees and expenses incurred by Secured Party or for which Secured Party becomes obligated in connection with the enforcement or defense of this Security Agreement, including search fees, costs and expenses and attorneys’ fees, costs and time charges of counsel to Secured Party and all taxes payable in connection with this Security Agreement. In furtherance of the foregoing, Debtor shall pay any and all stamp and other taxes, UCC search fees, filing fees and other costs and expenses in connection with the execution and delivery of this Security Agreement and the other Transaction Documents to be delivered hereunder, and agrees to save and hold Secured Party harmless from and against any and all liabilities with respect to or resulting from any delay in paying or omission to pay such costs and expenses. That portion of the Obligations consisting of costs, expenses or advances to be reimbursed by Debtor to Secured Party pursuant to this Security Agreement or the other Transaction Documents which are not paid on or prior to the date hereof shall be payable by Debtor to Secured Party on demand. If at any time or times hereafter Secured Party: (a) employs counsel for advice or other representation: (i) with respect to this Security Agreement or the other Transaction Documents; (ii) to represent Secured Party in any litigation, contest, dispute, suit or proceeding or to commence, defend, or intervene or to take any other action in or with respect to any litigation, contest, dispute, suit, or proceeding (whether instituted by Secured Party, Debtor, or any other Person) in any way or respect relating to this Security Agreement; or (iii) to enforce any rights of Secured Party against Debtor or any other Person under of this Security Agreement; (b) takes any action to protect, collect, sell, liquidate, or otherwise dispose of any of the Collateral; and/or (c) attempts to or enforces any of Secured Party’s rights or remedies under this Security Agreement, the costs and expenses incurred by Secured Party in any manner or way with respect to the foregoing, shall be part of the Obligations, payable by Debtor to Secured Party on demand.

 

14

 

 

5.15 Termination. This Security Agreement and the Liens and security interests granted hereunder shall not terminate until the termination of the Loan Agreement and the commitments to make Loans thereunder and the full and complete performance and satisfaction and payment in full of all the Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted). Upon termination of this Security Agreement, Secured Party shall also deliver to Debtor (at the sole expense of Debtor) such UCC termination statements, and such other documentation, without recourse, warranty or representation whatsoever, as shall be reasonably requested by Debtor to effect the termination and release of the Liens and security interests in favor of Secured Party affecting the Collateral; provided, however, to the extent any such terminations or releases require Secured Party to expend any sums in terminating or releasing any such Liens, Secured Party may refrain from terminating or releasing such Liens unless and until Debtor pay to Secured Party the estimated cost, as reasonably determined by Secured Party, of effectuating such terminations or releases.

 

5.16 Reinstatement. This Security Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against Debtor for liquidation or reorganization, should Debtor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of Debtor’s assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

 

5.17 Increase in Obligations. It is the intent of the parties to secure payment of the Obligations, as the amount of such Obligations may increase from time to time in accordance with the terms and provisions of the Transaction Documents, and all of the Obligations, as so increased from time to time, shall be and are secured hereby. Upon the execution hereof, Debtor shall pay any and all documentary stamp taxes and/or other charges required to be paid in connection with the execution and enforcement of the Transaction Documents, and if, as and to the extent the Obligations are increased from time to time in accordance with the terms and provisions of the Transaction Documents, then Debtor shall immediately pay any additional documentary stamp taxes or other charges in connection therewith.

 

[SIGNATURE PAGE FOLLOWS]

 

15

 

 

IN WITNESS WHEREOF, Debtor and Secured Party have executed this Security Agreement as of the date first above written.

 

  Debtor:
     
  BEARN LLC
     
  By: /s/ aaron Drew
  Name: aaron Drew
  Title: CEO
     
  Secured Party:
     
  MYFIZIQ LIMITED
     
  By: /s/ Vlado Bosanac
  Name: Vlado Bosanac
  Title: CEO

 

16

 

 

ANNEX A

to

SECURITY

AGREEMENT

 

FORM OF ADDITIONAL DEBTOR JOINDER

 

Security Agreement dated as of November       , 2020 made by

BEARN LLC and its subsidiaries party thereto from time to time, as Debtor

to and in favor of the Secured Parties identified therein (the “Security Agreement”)

 

Reference is made to the Security Agreement as defined above; capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in, or by reference in, the Security Agreement.

 

The undersigned hereby agrees that upon delivery of this Additional Debtor Joinder to the Secured Parties referred to above, the undersigned shall (a) be an Additional Debtor under the Security Agreement, (b) have all the rights and obligations of the Debtor under the Security Agreement as fully and to the same extent as if the undersigned was an original signatory thereto and (c) be deemed to have made the representations and warranties set forth therein as of the date of execution and delivery of this Additional Debtor Joinder. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE UNDERSIGNED SPECIFICALLY GRANTS TO THE SECURED PARTIES A SECURITY INTEREST IN THE COLLATERAL AS MORE FULLY SET FORTH IN THE SECURITY AGREEMENT AND ACKNOWLEDGES AND AGREES TO THE WAIVER OF JURY TRIAL PROVISIONS SET FORTH THEREIN.

 

Attached hereto are supplemental and/or replacement Schedules to the Security Agreement, as applicable.

 

An executed copy of this Joinder shall be delivered to the Secured Parties, and the Secured Parties may rely on the matters set forth herein on or after the date hereof. This Joinder shall not be modified, amended or terminated without the prior written consent of the Secured Parties.

 

17

 

 

IN WITNESS WHEREOF, the undersigned has caused this Joinder to be executed in the name and on behalf of the undersigned.

 

  [Name of Additional Debtor]
     
  By:                                                        
  Name:   
  Title:  
     
  Address:

 

Dated:

 

 

18

 

 

Exhibit 14.1

 

Code of Conduct

 

Introduction

 

This Code of Conduct sets out the standards which the Board, management and employees of the Company are encouraged to comply with when dealing with each other, the Company’s security holders and the broader community.

 

Responsibilities to Security Holders

 

The Company aims:

 

to increase shareholder value within an appropriate framework which safeguards the rights and interests of security holders; and

 

to comply with systems of control and accountability which the Company has in place as part of its corporate governance with openness and integrity.

 

The Board, management and employees of the Company shall act in the best interests of the Company.

 

Responsibilities to Clients, Employees, Suppliers, Creditors, Customers and Consumers

 

The Company is to comply with all legislative and common law requirements which affect its business.

 

Employment Practices

 

The Company will employ the best available staff with skills required to carry out the role for which they are employed. The Company will ensure a safe workplace and maintain proper occupational health and safety practices.

 

Responsibility to the Community

 

The Company will recognise, consider and respect environmental, native title and cultural heritage issues which arise in relation to the Company’s activities and comply with all applicable legal requirements.

 

Responsibility to the Individual

 

The Company recognises and respects the rights of individuals and will comply with the applicable legal rules regarding privacy and confidential information.

 

Obligations Relative to Fair Trading and Dealing

 

The Company will deal with others in a way that is fair and will not engage in deceptive practices.

 

 

 

 

Business Courtesies, Bribes, Facilitation Payments, Inducements and Commissions

 

Corrupt practices are unacceptable to the Company. It is prohibited for the Company or its directors, managers, or employees to directly or indirectly offer, pay, solicit, or accept bribes or any other corrupt arrangements.

 

Conflicts of Interest

 

The Board, management and employees (each being an “Insider”) shall report any situations where there is a real or apparent conflict of interest between them as individuals and the interest of the Company. Where a real or apparent conflict of interest arises, the matter should be brought to the attention of the Chairperson in the case of a Board member or the Chief Executive Officer, the Chief Executive Officer in the case of a member of management and a supervisor in the case of an employee, so that it may be considered and dealt with in an appropriate manner.

 

A conflict of interest arises any time such a person has a duty or interest that may conflict with the proper and impartial fulfillment of such person’s duties, responsibilities or obligations to the Company, such as:

 

making an investment that may affect his/her business decisions;

 

owning a meaningful financial interest in, or being employed by, an organization that competes with or whose interests could reasonably be expected to conflict with those of the Company;

 

owning a meaningful interest in, or being employed by, an organization that does, or seeks to do, business with the Company;

 

making a decision on a matter where such person’s self-interests may reasonably call into question the appropriateness of the decision; and

 

being employed by or accepting compensation from any other person as a result of business activity or prospective business activity affecting the Company.

 

No Insider shall direct, or seek to direct, any Company business to any business enterprise in which the Insider or his or her family has a meaningful ownership position or serves in a leadership capacity.

 

2

 

 

No Insider shall seek or accept for his or her self or for any family member any favors, preferential treatment, special benefits, gifts, loans or other consideration as a result of such Insider’s association with a business associate or with the company, except those customary and usual benefits directly provided by a business associate of the Company.

 

If requested by the Chairperson, a Board member who has a conflict of interest (or in the case of the Chairperson, if requested by the Deputy Chairperson) shall leave a Board meeting but only for such period as the Board meeting is addressing the specific matter in relation to which the Board member has a conflict of interest.

 

Corporate Opportunities and Transactions with Business Associates

 

Insiders and their family members must not profit, directly or indirectly, due to their position in the Company to the detriment, or at the expense, of the Company or any of its business associates. No Insider shall take for his or her own advantage any business opportunity for profit, which he or she learns about as a result of his or her position with the Company.

 

Confidentiality

 

No Insider or a family member of an Insider:

 

shall discuss with, or inform others about, any actual or contemplated business transaction by the Company or any business associate except as required in the performance of the Insider’s employment duties and then only for the benefit of the Company or the business associate, as appropriate, and in no event for personal gain or for the benefit of any other third party;

 

shall give any information to any third party about any pending or proposed business transaction of the Company or its business associates unless expressly authorized to do so by the Company’s CEO; or

 

other than the Company’s CEO, CFO or Chairman of the Board may discuss the Company or its business associates with any member of the press or media except with the prior authorization of the Company’s CEO, CFO or Chairman of the Board.

 

Document Retention

 

The Company will comply fully with all applicable laws and regulations concerning the retention and preservation of records. All Insiders shall comply fully with the Company’s policies regarding the retention and preservation of records. Under no circumstances may Company records be destroyed selectively or maintained outside Company premises or designated storage facilities.

 

If the existence of a subpoena or impending government investigation becomes known to an Insider, he or she must immediately contact the CEO and Chair of the Company’s Audit Committee of the Board, if such Audit Committee is in place. If there is not an Audit Committee in place, he or she must immediately contact the Company’s CFO. Insiders must retain all records and documents that may be responsive to a subpoena or pertain to an investigation.

 

3

 

 

Reporting and Treatment of Violations

 

Persons who become aware of or suspect violations of this Code of Conduct should report such suspected violations promptly to the Chair of the Company’s Audit Committee of the Board if such Audit Committee is in place. If there is not an Audit Committee in place, he or she must immediately contact the Chairman of the Board if such person is different than the Company’s CEO, if such person is not, than the person should immediately contact another member of the Company’s Board. To assist in the response to or investigation of the alleged violation, the report should contain as much specific information as possible to allow for proper assessment of the nature, extent and urgency of the alleged violation. Without limiting the foregoing, the report should, to the extent possible, contain the following information:

 

the alleged event, matter or issue that is subject of the alleged violation;

 

the name of each person involved;

 

if the alleged violation involves a specific event or events, the approximate date and location of each event; and

 

any additional information, documentation or other evidence available relating to the alleged violation.

 

the Audit Committee of the Board, if one is in place, if not, the entire Board, shall have the power to monitor, investigate, make determinations and take action with respect to violations of this Code of Conduct. In determining whether a violation of this Code has occurred, the Audit Committee of the Board, if one is in place, if not, the entire Board, may take into account:

 

the nature and severity of the violation;

 

whether the violation was a single occurrence or involved repeated occurrences;

 

whether the violation appears to have been intentional or inadvertent;

 

whether the person in question had been advised prior to the violation as to the proper course of action;

 

whether the person in question had committed other violations in the past; and

 

such other facts and circumstances as the Audit Committee of the Board shall deem advisable in the context of the alleged violation.

 

4

 

 

Consequences of Violations

 

If a violation is substantiated, the Board, upon recommendation of the Audit Committee of the Board, may impose such sanctions or take such actions as it deems appropriate, including, but not limited to, the following:

 

disciplinary action (including censure, re-assignment, demotion, suspension or termination);

 

pursuit of any and all remedies available to the Company in equity or at law for any damages or harm resulting from a violation, including injunctive relief; and

 

referral of matters to appropriate legal or regulatory authorities for investigation and prosecution.

 

Requests for Waivers and Changes in Code of Conduct

 

A waiver of a provision of this Code of Conduct shall be requested whenever there is reasonable likelihood that a contemplated action will violate the Code of Conduct. Any waiver (including an implicit waiver) that constitutes a material departure from a provision of this Code of Conduct shall be publicly disclosed on a timely basis, to the extent required by applicable rules and regulations of the SEC and the ASX Listing Rules. In addition, any amendments to this Code of Conduct (other than technical, administrative or other non-substantive amendments) shall be publicly disclosed on a timely basis, to the extent required by applicable rules and regulations of the SEC and the ASX Listing Rules.

 

Compliance with the Code of Conduct

 

Any breach of compliance with this Code of Conduct is to be reported directly to the Chairperson.

 

Periodic Review of Code

 

The Company will monitor compliance with this Code of Conduct periodically by liaising with the Board, management, and staff. Suggestions for improvements or amendments to this Code of Conduct can be made at any time to the Chairperson.

 

Every director and employee is required to sign this Code of Conduct.

 

I have received, read and understand this Code of Conduct:

 

 

Signed:          
         
Name:        
         
Date:        
         
Employee Director    

 

 

5

 

Exhibit 23.1

 

PKF Perth  

 

26 August 2021

 

The Directors

Advanced Human Imaging Limited.

By email to Chief Financial Officer: steven.richards@advancedhumanimaging.com

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Registration Statement Form F-1 for Advanced Human Imaging Limited, our report dated 18th December 2020 relating to the financial statements for the year ended 30 June 2020 with 30 June 2019 comparatives, as well as our report dated 26th February 2021 relating to the half year financial statements ended 31 December 2020 with 31 December 2019 comparatives.

 

We also consent to the reference to us under the caption “Experts” in the Registration Statement.

 

Yours sincerely,

 

 

 

SImon FErmanis

Partner

PErth, WEstern AUstralia

 

Level 4, 35 Havelock Street, West Perth, WA 6005
PO Box 609, West Perth, WA 6872
T: +61 8 9426 8999 F: +61 8 9426 8900 www.pkfperth.com.au

 

PKF Perth is a member firm of the PKF International Limited family of legally independent firms and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm or firms.

 

Liability limited by a scheme approved under Professional Standards Legislation.

Exhibit 99.1

 

CONSENT OF Edward Greissing Jr

 

Advanced Human Imaging Limited (the “Company”) intends to file a Registration Statement on Form F-l (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration Statement as a Director Nominee.

 

Dated: July 20, 2021

 

By: /s/ Edward Greissing Jr  
Name:  Edward Greissing Jr  

Exhibit 99.2

 

Audit and Risk Management Committee Charter

 

Responsibilities of the Audit and Risk Management Committee

 

1 The Audit and Risk Management Committee is entrusted by the Board to provide appropriate quality assurance regarding procedures and processes in relation to the following responsibilities:

 

1.1 external audit function:

 

1.1.1 review and oversee the planning process for external audits;

 

1.1.2 review the overall conduct of the external audit process including the independence of all parties to the process;

 

1.1.3 review the performance of the external auditors;

 

1.1.4 consider the reappointment and proposed fees of the external auditor;

 

1.1.5 here appropriate seek tenders for the audit and where a change of external auditor is recommended this will be reported to the Board for submission to security holders for shareholder approval;

 

1.2 reviewing the quality and accuracy of published financial reports (including ensuring that the Chief Executive Officer and Chief Financial Officer have made a declaration in relation to the maintenance and compliance of the financial statements);

 

1.3 reviewing the accounting function and ongoing application of appropriate accounting and business policies and procedures;

 

1.4 review the Company’s risk management framework including in relation to economic, environmental, and social sustainability risk at least annually; and

 

1.5 any other matters that the Board may refer to the Audit and Risk Management Committee from time to time.

 

Authority

 

2 The Company’s Audit and Risk Management Committee has the following authority:

 

2.1 to request management to attend meetings and to provide advice or information in the form required by the Audit and Risk Management Committee, and to request attendance by or information from a Company director with prior authority of the Chairperson;

 

2.2 through the Chairperson of the Audit and Risk Management Committee to contact external regulatory agencies directly in circumstances where the Audit and Risk Management Committee considers it is appropriate with all such contact documented clearly by the Audit and Risk Management Committee Chairperson; and

 

 

 

 

2.3 for the Audit and Risk Management Committee Chairperson on behalf of the Audit and Risk Management Committee to seek independent legal advice at the expense of the Company in circumstances where the Audit and Risk Management Committee Chairperson considers it is appropriate.

 

Composition of the Audit and Risk Management Committee

 

3 The Committee shall be compromised of three (3) or more directors as determined by the Board. Each member must be independent of the management of the Company and are free of any relationship that, in the opinion of the Board, would interfere with their exercise of independent judgment as a Committee member. Further, each member of the Committee shall meet the independence and experience requirements of the listing rules of any securities exchange or association in which the Company’s securities are traded and the rules and regulations of the Securities and Exchange Commission (the “SEC”), including Rule 10A-3, and the Listing Rules of the Australian Securities Exchange (the “ASX”. All members of the Committee shall have a basic understanding of finance and accounting and be able to read and understand fundamental financial statements, including a company’s balance sheet, income statement, and cash flow statement. At least one member of the Committee must have past employment experience in finance or accounting, professional certification in accounting, or any other comparable experience or background that results in the member’s financial sophistication, including being or having been a Chief Executive Officer (“CEO”) or Chief Financial Officer (“CFO”) or other senior officer with financial oversight responsibilities.

 

4 Committee members shall be appointed by the Board after due consideration of recommendations of the Nominating and Corporate Governance Committee, and the Board may designate a Chair of the Committee. If an Audit Committee Chair is not designated or present, the members of the Committee may designate a Chair by majority vote of the Committee membership. The Board may, at any time and at its complete discretion, replace a Committee member.

 

5 The Secretary to the Board shall be the Secretary to the Audit and Risk Management Committee.

 

Conduct of Meetings

 

6 Committee members shall meet (either in person or telephonically) at least four times each fiscal year and more often if the Committee, at its discretion, deems this desirable. The Committee shall meet, at its discretion, with management, the Company’s principal accounting officer, the independent auditors, and as a committee to discuss any matters that the Committee or each of these groups believes should be discussed. The Committee may request any officer or employee of the Company or the Company’s outside counsel or independent auditors to attend a meeting of the Committee or to meet with any members of, or consultants to, the Committee.

 

2

 

 

  7  

 

8 The quorum for an Audit and Risk Management Committee meeting shall be a minimum of two members.

 

9 Audit and Risk Management Committee meeting agendas will be sent to Audit and Risk Management Committee members in advance of meetings wherever practicable.

 

10 The Secretary shall maintain minutes of all meetings of the Audit and Risk Management Committee and these minutes shall be signed by the Chairperson of the Audit and Risk Management Committee and approved by the Audit and Risk Management Committee at the next Audit and Risk Management Committee meeting or sooner if required.

 

11 The minutes of each Audit and Risk Management Committee meeting will be tabled at the next Board meeting.

 

12 The Secretary shall assist the Audit and Risk Management Committee Chairperson in dealing with the meeting agenda, providing documentation to Audit and Risk Management Committee members and any communications with Audit and Risk Management Committee members.

 

Voting

 

13 Each member of the Audit and Risk Management Committee shall have one vote.

 

14 In the case of equality of voting, the Audit and Risk Management Committee Chairperson shall have a casting vote in addition to his deliberative vote.

 

Who Attends Audit and Risk Management Committee Meetings?

 

15 All Audit and Risk Management Committee members are expected to attend Audit and Risk Management Committee meetings.

 

16 Any members of the Board may attend Audit and Risk Management Committee meetings.

 

17 The Audit and Risk Management Committee Chairperson may request the Audit and Risk Management Committee to meet with only non-executive directors present and may require that only Audit and Risk Management Committee members be present at all or part of a meeting.

 

18 The Audit and Risk Management Committee Chairperson may invite representatives of the external auditor and the Company management to attend all or part of any Audit and Risk Management Committee meeting. The external auditor shall attend an Audit and Risk Management Committee meeting at least once in each annual reporting cycle.

 

3

 

 

Audit and Risk Management Committee Review and Reporting

 

19 The Audit and Risk Management Committee is required to undertake an annual performance review of its own activities and the Chairperson of the Audit and Risk Management Committee shall report to the Board on the Audit and Risk Management Committee’s performance annually. This review will assess the performance of the Audit and Risk Management Committee against the objectives contained in this document and other relevant criteria as approved by the Board.

 

20 The Audit and Risk Management Committee activities and functions shall be reviewed annually by the Board and its activities and functions may be revised in the interests of better meeting the needs of the security holders as owners of the Company as a whole.

 

21 The Audit and Risk Management Committee will report to security holders through the Annual Report. Information to be provided will include:

 

21.1 full description of the Audit and Risk Management Committee’s composition;

 

21.2 an outline of Audit and Risk Management Committee responsibilities; and

 

21.3 any other information required by law, the rules and regulations of the SEC or the ASX Listing Rules.

 

Independent Auditors

 

22 The Committee shall have the sole authority to appoint or replace the independent auditor. The Committee shall be directly responsible for the compensation and oversight of the work of the independent auditor (including resolutions of disagreements between management and the independent auditor regarding final reporting) for the purpose of preparing or issuing an audit report or related work. The independent auditor shall report directly to the Committee. The Committee shall approve in advance the provision by the independent auditors of all services to the Company whether or not related to the audit. However, neither the Committee nor any person with authority delegated from the Committee may approve an auditor providing the services that are described in Section 10A(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as “prohibited activities.”

 

23 The Committee shall obtain, review and discuss reports from the independent auditor regarding (1) all critical accounting policies and practices to be used; (2) all alternative treatments of financial information within generally accepted accounting principles that have been discussed with management officials of the Company, ramifications of the use of these alternative disclosures and treatments, and the treatment preferred by the independent auditor and the reasons for favoring that treatment; and (3) other material written communications between the independent auditor and Company management, such as any management letter or schedule of unadjusted differences.

 

4

 

 

24 The Committee shall assure the regular rotation of the lead audit partner as required by Section 10A(j) of the Exchange Act.

 

25 The Committee shall assure that hiring policies for employees or former employees of the independent auditor are consistent with Section 10A(l) of the Exchange Act.

 

26 The Committee shall discuss with the independent auditor and then disclose the matters required to be discussed and disclosed by applicable accounting and auditing guidance, including any difficulties the independent auditor encountered in the course of the audit work, any restrictions on the scope of the independent auditor’s activities or on access to requested information, and any significant disagreements with management.

 

27 The Committee shall ascertain annually from the independent auditor whether the Company has issues under Section 10A(b) of the Exchange Act.

 

28 The Committee shall determine the independence of the auditors and receive from the independent auditors a formal written statement delineating all relationships between the auditor and the company (consistent with PCAOB Independence Standards Board Standard 1 or any other applicable standards), and thereafter actively engaging in a dialogue with the auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the auditor and for taking, or recommending that the full Board take, appropriate action to oversee the independence of the outside auditor.

 

Accounting Department and Legal Compliance

 

29 The Committee shall:

 

29.1 review the personnel activities and qualifications of the Company’s accounting personnel, as needed;

 

29.2 review the appointment and performance of the principal accounting officer, and review financial and accounting personnel succession planning with the Company;

 

29.3 review significant reports prepared by the Company’s principal accounting officer together with management’s response and follow-up to these reports;

 

29.4 on at least an annual basis, review with the Company’s counsel any legal matters that could have a significant impact on the Company’s financial statements, the Company’s compliance with applicable laws and regulations, and inquiries received from regulators or governmental agencies.

 

29.5 establish procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters and the confidential, anonymous submission by employees of the Company of concerns regarding questionable accounting or auditing matters.

 

29.6 the Committee shall review the CEO’s and CFO’s disclosure and certifications under Sections 302 and 906 of the Sarbanes-Oxley Act.

 

5

 

 

29.7 conduct an appropriate review of and approve all related party transactions on an ongoing basis and the Committee shall review potential conflict of interest situations where appropriate.

 

29.8 conduct an annual risk review with respect to the matters within the role and the responsibilities of the Committee.

 

30 The Committee shall:

 

30.1 Report regularly to the Board on its activities;

 

30.2 Maintain minutes of its meetings and records relating to those meetings and the Committee’s activities;

 

30.3 Have authority to obtain, at the expense of the Company, advice and assistance from internal or external legal, consulting or other advisors;

 

30.4 Form and delegate authority to subcommittees of one or more Committee members when desired and appropriate;

 

30.5 Review and reassess the adequacy of this Charter annually and recommend to the Board any proposed changes to this Charter; and

 

30.6 Periodically review the Committee’s own performance.

 

General

 

31 In performing their responsibilities, Committee members are entitled to rely in good faith on information, opinions, reports or statements prepared or presented by:

 

31.1 One of more officers or employees of the Company whom the Committee member reasonably believes to be reliable and competent in the matters presented;

 

31.2 Counsel, independent auditors, or other persons as to matters which the Committee member reasonably believes to be within the professional or expert competence of such person; and

 

31.3 Other committees of the Board as to matters within their respective designated authority which the Committee member reasonably believes to merit confidence.

 

32 The Committee has the powers and responsibilities delineated in this Charter. It is not, however, the Committee’s responsibility to prepare and certify the Company’s financial statements, to guarantee the independent auditor’s report, or to guarantee other disclosures by the Company. These are fundamental responsibilities of management and the independent auditor. Committee members are not full-time Company employees and are not performing the functions of auditors or accountants.

 

 

6

 

Exhibit 99.3

 

Advanced Human Imaging Limited.

 

Charter of the Nominating and Corporate Governance Committee of the Board of Directors

 

The purpose of the Nominating and Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Advanced Human Imaging Limited. (the “Company”) shall be as set forth in this charter (the “Charter”). The Committee has been delegated authority by the Board to: (1) identify qualified individuals to become Board members; (2) determine the composition of the Board and its committees; (3) monitor the self-assessment practices of the Board and its committees; and (4) develop and implement the Company’s corporate governance guidelines.

 

Authority and Responsibilities

 

In furtherance of these purposes, the Committee has the following authority and responsibilities:

 

1. To oversee the administration of the Company’s Code of Conduct and related policies.

 

2. To lead the search for individuals qualified to become members of the Board and to select director nominees to be presented for election by the shareholders at each annual meeting. The Committee shall select individuals as director nominees who shall have the highest personal and professional integrity, who have demonstrated exceptional ability and judgment and who shall be most effective, in conjunction with the other nominees to the Board, in collectively serving the long-term interests of the shareholders.

 

3. To ensure, in cooperation with the Compensation Committee, that no agreements or arrangements are made with directors or relatives of directors for providing professional or consulting services to the Company or an affiliate or an individual officer of the Company or one of their affiliated, without appropriate review and evaluation for conflicts of interest.

 

4. To ensure that Board members do not serve on more than three other for-profit public company boards that have a class of securities registered under the Securities Exchange Act of 1934, as amended, in addition to the Company’s Board. Newly appointed or elected directors shall have a grace period of nine (9) months to gain compliance with this condition.

 

5. To review the Board’s committee structure and to recommend to the Board for its approval, directors to serve as members of each committee as well as recommendations for committee chairs. The Committee shall review and recommend committee positions, including chairs of suck committees, annually and shall recommend additional committee members to fill vacancies.

 

6. To review recommendations received from shareholders for persons to be considered for nomination to the Board, and to designate a member of the Committee to receive such communications directly from shareholders, and to publish the name and contact information of such person in the Company’s proxy statement for each of its annual meeting of shareholders.

 

7. To monitor compliance with the Company’s corporate governance guidelines. The Committee shall review the guidelines at least annually, and recommend changes as necessary to the Board.

 

8. To develop and implement an annual self-evaluation of the Board, both individually and as a Board, and of its committees. The Committee shall oversee the annual self-evaluations, with a focus on the effectiveness of the directors, Board, and committees as representative of the shareholders.

 

9. To review and recommend changes to procedures whereby shareholders may communicate with the Board.

 

10. To assess the independence of directors annually and report to the Board.

 

11. To recommend to the Board for its approval, the leadership structure of the Board, including whether the Board should have an executive or non-executive Chair, whether the roles of Chair and CEO should combine, and whether a Lead Director of the Board should be appointed.

 

 

 

 

Actions and Recommendations

 

In carrying out its responsibilities under its charter, the Committee is required to:

 

(a) Establish criteria for selection of potential directors, taking into consideration the following desired attributes: leadership, independence; interpersonal skills; financial acumen; business experiences; industry knowledge; diversity of viewpoints, and any other experiences as the Committee deems important to the effectiveness of the Board. The Committee will periodically assess the criteria to ensure it is consistent with the best practices and the goals of the Company.

 

(b) Identify individuals who satisfy the criteria for selection to the Board and make recommendations to the Board on new candidates for Board membership.

 

(c) Receive and evaluate nominations for Board membership which are recommended by existing directors, officers, or shareholders in accordance with procedures established by the Committee in accordance with the Company’s corporate governance guidelines and applicable law.

 

(d) Oversee the process for conducting background checks on new candidates for Board membership, including the process of validating candidate credentials.

 

(e) Review any potential conflicts of interest for Board members in the event of a particular member’s change of employment and recommend to the Board the Committee’s belief as to whether that director should continue his or her board service or resign from the Board.

 

(f) Establish criteria for the evaluation of existing directors and the reelection or removal of directors based on the needs of the Company.

 

(g) Monitor the requirement that Board members shall not serve on more than three other for-profit public company boards in addition to the Company’s Board. Determinations regarding the definition of “for-profit public company board” shall be made by the Committee.

 

(h) Review the qualifications, performance and independence of existing Board members and make recommendations to the Board whether they should stand for reelection.

 

(i) Recommend to the Board the removal of a director where appropriate.

 

(j) Recommend to the Board a slate of nominees for the next annual meeting of shareholders.

 

(k) Oversee the orientation process for new directors.

 

Shareholder Recommendations

 

The Committee will consider all recommendations for nominations to the Board from any person (or group) who has (or collectively if a group have) held more than 3% of the Company’s voting securities for longer than one year. Shareholders desiring to submit recommendations to the Committee should submit information regarding such recommendation in writing or by electronic mail to the person designated in the proxy statement circulated in advance of each annual meeting of shareholders. Each proxy statement shall set forth the information to be provided either directly in the proxy statement or by reference to the Company’s website. When the required information has been received, the Committee will evaluate the proposed nominee based on the criteria described above, with the principal criteria being the needs of the Company and the qualifications of such proposed nominee to fulfill those needs.

 

2

 

 

The Committee shall:

 

(a) Report regularly to the Board on its activities;

 

(b) Maintain minutes of its meetings and records relating to those meetings and the Committee’s activities;

 

(c) Have authority to obtain, at the expense of the Company, advice and assistance from search firms and internal or external legal, consulting, or other advisors;

 

(d) Form and delegate authority to subcommittees of one or more Committee members when desired and appropriate;

 

(e) Review and reassess the adequacy of this Charter annually and recommend to the Board any proposed changes to this Charter; and

 

(f) Periodically review the Committee’s own performance.

 

In performing their responsibilities, Committee members are entitled to rely in good faith on information, opinions, reports or statements prepared or presented by:

 

(a) One or more officers or employees of the Company whom the Committee member reasonably believes to be reliable and competent in the matters presented;

 

(b) Counsel, independent auditors, or other persons as to matters which the Committee member reasonably believes to be within the professional or expert competence of such person; and

 

(c) Other committees of the Board as to matters within their respective designated authority which committee the Committee member reasonably believes to merit confidence.

 

 

3

 

Exhibit 99.4

 

Advanced Human Imaging Limited.

 

Charter of the Compensation Committee of the Board of Directors

 

I. Authority and Composition

 

The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Advanced Human Imaging Limited. (the “Company”) members are appointed annually by the Board on the recommendation of the Nominating and Corporate Governance Committee, and may be replaced by the Board. The Committee must consist of at least three (3) directors. Each member of the Committee shall be independent in accordance with the rules of The NASDAQ Stock Market and the Australian Securities Exchange (ASX). At least two (2) members of the Committee must qualify as “non-employee directors” for the purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Without limiting the foregoing, to be considered as independent, the Board will consider all relevant factors, including (a) the source of compensation of the director, including any consulting, advisory or other compensatory fee paid by, or on behalf of, the Company, and (b) whether the director is affiliated with the Company, any subsidiary of the Company or any affiliate of a subsidiary of the Company.

 

The Board shall appoint an independent director to act as the Chairperson of the Committee upon the recommendation of the Nominating and Corporate Governance Committee.

 

This Charter may be amended only by the Board.

 

II. Purposes of the Committee

 

The primary purposes of the Committee are to: (i) develop recommendations for the Board with respect to the compensation of the Company’s Chief Executive Officer (the “CEO”) and non-employee directors; (ii) discharge the responsibilities of the Board relating to the approval of the compensation of the Company’s executive officers, other than the CEO; (iii) make determinations with respect to the compensation programs and policies of the Company; (iv) review and discuss with the Company’s management, the Compensation Discussion and Analysis (the “CD&A”) and other Committee or executive compensation disclosures to be included in the Company’s annual proxy statement and/or annual report on Form 10-K, and determine whether to recommend to the Board that the CD&A be included in the proxy statement and/or annual report on Form 10-K; and (v) provide the Compensation Committee Report for inclusion in the Company’s annual proxy statement and/or annual report on Form 10-K that complies with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and ASX.

 

III. Duties and Responsibilities of the Committee

 

The following activities are set forth as a guide with the understanding that the Committee may diverge from this guide as it considers appropriate, subject to compliance with applicable securities exchange, securities, tax and other legal and self-regulatory requirements. Although the Board may consider other duties from time to time, the Committee, to the extent it deems necessary or appropriate, will have the following responsibilities:

 

A. The Committee shall annually review goals and objectives relevant to the CEO’s compensation, evaluate the CEO’s performance in light of those goals and objectives, determine the CEO’s cash and equity-based compensation based on this evaluation, and recommend such goals, objectives and compensation to the Board for its approval. In determining any incentive component of the CEO’s compensation, the Committee will consider appropriate factors, which may include the Company’s performance and relative shareholder return, the achievement of the CEO’s performance milestones, the value of similar incentive grants or awards to chief executive officers at comparable companies, and the grants or awards given to the CEO in past years. The CEO may not be present for such discussions and determinations.

 

B. The Committee shall annually review and approve the compensation of the Company’s “executive officers,” (as that term is defined in the regulations promulgated by the SEC, the NASDAQ rules and the ASX Listing Rules) other than the CEO. In making such compensation decisions, the Committee will take into account peer group practices and other appropriate factors, such as corporate and individual performance and historical compensation practices for such officers. The Committee will solicit the recommendations of the CEO in connection with the foregoing. The Committee will also provide general oversight of the Company’s compensation and benefits plans, policies and programs that pertain to employees other than executive officers.

 

 

 

 

C. The Committee shall annually review and recommend to the Board for its approval, the fees and equity compensation paid to the Company’s non-employee directors, based on appropriate factors as determined by the Committee. Such review and recommendations shall ensure that no agreements or arrangements for providing professional or consulting services to the Company or an affiliate or an individual officer of the Company or one of their affiliates are made with any director, immediate family members of a director or persons (including entities) with an existing business or personal relationship with any director, without a full review and evaluation of potential conflicts of interest.

 

D. The Committee shall have the sole authority to retain and terminate any compensation consultant to be used by the Committee or the Company to assist in the evaluation of the compensation of non-employee directors, the CEO or the other executive officers, shall have sole authority to approve such compensation consultant’s fees and other retention terms, and shall have sole authority to oversee the work of such compensation consultant. In determining whether to engage a compensation consultant, the Committee shall consider the independence factors set forth in the NASDAQ rules and the ASX Corporate Governance Principles and Recommendations (4th Edition) pertaining to corporate governance. Management will advise the Committee of any compensation consultant to be retained with respect to other compensation matters in advance of such retention.

 

E. The Committee shall periodically review and make recommendations to the Board with respect to incentive-compensation programs and equity-based plans, and shall periodically review and make recommendations to the Board with respect to the adoption of or material changes in material employee benefit, bonus, severance and other compensation plans of the Company. The Committee will manage and disclose the policy (if any) under which participants to a equity-based plan may be permitted (at the discretion of the Company) to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the equity-based plan. As appropriate in connection with this process, the Committee shall seek appropriate input from internal or external advisors.

 

F. The Committee shall determine the need for and the appropriateness of employment agreements and change in control agreements for each of the Company’s executive officers and any other officers recommended by the CEO or the Board.

 

G. The Committee shall determine and approve the options and other equity-based compensation to be granted to executive officers, other than the CEO; and shall recommend to the Board for approval options and other equity-based compensation to be granted to the CEO and non-employee directors. The Committee shall, in conjunction with the CEO, determine the issuance of options and other equity-based compensation under the Company’s incentive compensation and other stock-based plans to all other officers and employees of the Company. The Committee may delegate the determination with respect to persons other than officers to the CEO but will approve the aggregate amount granted to all employees and all new hire grants. Any equity awards to the CEO shall be determined by the Committee and recommended to the Board for its review and approval.

 

H. The Committee shall perform such duties and responsibilities as may be assigned to the Committee by the Board and/or under the terms of any compensation plan of the Company.

 

2

 

 

The Committee shall:

 

(a) Report regularly to the Board on its activities;

 

(b) Maintain minutes of its meetings and records relating to those meetings and the Committee’s activities;

 

(c) Have authority to obtain, at the expense of the Company, advice and assistance from internal or external legal, consulting or other advisors;

 

(d) Form and delegate authority to subcommittees of one or more Committee members when desired and appropriate;

 

(e) Review and reassess the adequacy of this Charter annually and recommend to the Board any proposed changes to this Charter; and

 

(f) Periodically review the Committee’s own performance.

 

IV. General

 

In performing their responsibilities, Committee members are entitled to rely in good faith on information, opinions, reports or statements prepared or presented by:

 

(a) One or more officers or employees of the Company whom the Committee member reasonably believes to be reliable and competent in the matters presented;

 

(b) Counsel, independent auditors, or other persons as to matters which the Committee member reasonably believes to be within the professional or expert competence of such person; and

 

(c) Other committees of the Board as to matters within their respective designated authority which committee the Committee member reasonably believes to merit confidence.

 

 

3